Unnamed: 0,N1,N2,sentence,relation,add_closeness_centrality,add_average_degree_connectivity,add_avg_neighbor_deg,add_eigenvector_centrality_numpy,add_katz_centrality_numpy,avg_clustering,common_neighbors,deg_cent,degree,degree_assortativity_coefficient,density,group_degree_centrality,large_clique_size,len_local_bridges,len_min_edge_dominating_set,len_min_maximal_matching,len_min_weighted_dominating_set,len_min_weighted_vertex_cover,ramsey_R2,local_node_connectivity,mean_degree_mixing_matrix,nb_edges,nb_nodes,node_connectivity,resource_allocation_index,treewidth_min_degree
0,614989,HP:0002664,"The SNP rs11102001, which encodes a nonsynonymous amino acid change P356S in EPS8L3, is a potential candidate modifier of the effect of HCAs on prostate cancer risk.",0,1.4423570997499784,214611.74275540764,196.85898994811933,0.29241778980322664,0.3836026713502433,0.0,0.0,0.9987562189054726,803.0,-0.6983854148566222,0.02098204629028769,1.0,2.0,41.0,33.0,33.0,33.0,66.0,1544,31.0,1.67789739321861e-06,6790.0,805.0,1.0,0,28.0
1,603848,HP:0003128,Our study further emphasizes that NDUFS6 sequence should be analyzed in patients presenting with lethal neonatal lactic acidemia due to isolated complex I deficiency,1,1.3348382242287435,699315.1857142857,141.76591692363502,0.18848404019879367,0.00015942895366449623,0.0,0.0,1.0033783783783785,297.0,-0.3412950823508661,0.23946673946673944,1.0,2.0,2.0,134.0,134.0,2.0,268.0,296,134.0,4.444444444444445e-05,10526.0,297.0,1.0,0,163.0
2,613012,HP:0001251,"This report describes the first putative mutations, p.L70P and p.R450C, in the coding region of the UROC1 gene in a girl with urocanic aciduria presenting with mental retardation and intermittent ataxia.",1,1.4450686851970829,1093215.5189898692,313.56339483394834,0.20253355435509068,0.08554010841339707,0.0,0.0,1.0011273957158962,888.0,-0.7167817615199091,0.054671074682348636,1.0,2.0,3.0,73.0,73.0,73.0,146.0,1626,72.0,1.5092152684290281e-06,21531.0,888.0,1.0,0,60.0
6,605210,HP:0100753,"In a large Scottish pedigree, a balanced translocation t (1;11)(q42.1;q14.3) disrupting the DISC1 and DISC2 genes segregates with major mental illness, including schizophrenia and depression.",0,1.295564516129032,17818.979761904757,31.939285714285717,0.3441342230996482,0.011407350805438685,0.0,0.0,0.9901960784313726,101.0,-0.4820955509932641,0.1614315629164287,1.0,2.0,3.0,35.0,35.0,3.0,70.0,114,33.0,0.0002972651605231866,848.0,103.0,1.0,0,31.0
4,605210,HP:0100753,"A frame-shift carboxyl-terminal deletion was reported in DISC1 in an American family with schizophrenia, but subsequently found in two controls.",0,1.295564516129032,17818.979761904757,31.939285714285717,0.3441342230996482,0.011407350805438685,0.0,0.0,0.9901960784313726,101.0,-0.4820955509932641,0.1614315629164287,1.0,2.0,3.0,35.0,35.0,3.0,70.0,114,33.0,0.0002972651605231866,848.0,103.0,1.0,0,31.0
8,602117,HP:0001513,"These three CNVs are close to two known PWS genes, NDN (necdin homolog) and C15orf2 (chromosome 15 open reading frame 2), and partially overlap with another obesity gene PWRN1 (Prader-Willi region nonprotein-coding RNA 1).",1,1.3340610612762012,3739932.601945277,186.8859577922078,0.16382419752004818,0.21295574081773253,0.0,0.0,1.0014556040756917,688.0,-0.3733407928980257,0.13594241901086626,1.0,2.0,0.0,275.0,275.0,5.0,550.0,704,275.0,8.025102520684701e-06,32127.0,688.0,2.0,0,342.0
17,191170,HP:0002664,Data on the relationship between ribosome biogenesis and p53 function indicate that the tumour suppressor can be activated by either nucleolar disruption or ribosomal protein defects.,1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
201,616404,HP:0002664,"We found that a downregulation of rRNA synthesis, induced by silencing the POLR1A gene coding for the RNA polymerase I catalytic subunit, stabilised p53 without altering the nucleolar integrity in human cancer cells.",0,1.4035709491839143,3154603.398384072,304.5643074981597,0.16209639772125378,0.21646108517810025,0.0,0.0,0.9988674971687428,882.0,-0.7019512329253574,0.07748164166790507,1.0,2.0,24.0,112.0,112.0,109.0,224.0,1544,110.0,1.677897393218609e-06,30240.0,884.0,1.0,0,133.0
169,191170,HP:0002664,"We found that a downregulation of rRNA synthesis, induced by silencing the POLR1A gene coding for the RNA polymerase I catalytic subunit, stabilised p53 without altering the nucleolar integrity in human cancer cells.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
205,164785,HP:0002664,"Furthermore, we demonstrated that in three different experimental models characterised by an upregulation of rRNA synthesis, cancer cells treated with insulin or exposed to the insulin-like growth factor 1, rat liver stimulated by cortisol and regenerating rat liver after partial hepatectomy, the p53 protein level was reduced due to a lowered ribosomal protein availability for MDM2 binding.",1,1.391410468595884,3660844.478079444,241.1528468479716,0.1733730375837963,0.17860145508336964,0.0,0.0,1.001044932079415,958.0,-0.6026291737214196,0.07917269302338772,1.0,2.0,2.0,186.0,186.0,112.0,372.0,1542,185.0,1.6778973932186097e-06,36293.0,958.0,1.0,0,185.0
25,191170,HP:0002664,"Furthermore, we demonstrated that in three different experimental models characterised by an upregulation of rRNA synthesis, cancer cells treated with insulin or exposed to the insulin-like growth factor 1, rat liver stimulated by cortisol and regenerating rat liver after partial hepatectomy, the p53 protein level was reduced due to a lowered ribosomal protein availability for MDM2 binding.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
221,613900,HP:0001251,"Exome and targeted sequencing has recently identified four new genes causing ataxia: TGM6, ANO10, SYT14, and rundataxin.",1,1.4438772681720289,1795769.4004353052,386.6604367342375,0.1776976367762186,-0.01800110934048061,0.0,0.0,1.001124859392576,890.0,-0.7437085751561233,0.06874786719075845,1.0,2.0,1.0,77.0,77.0,77.0,154.0,1626,76.0,1.5092152684290275e-06,27197.0,890.0,1.0,0,77.0
225,610949,HP:0001251,"Exome and targeted sequencing has recently identified four new genes causing ataxia: TGM6, ANO10, SYT14, and rundataxin.",1,1.4632347057870532,919705.8571934195,457.0641961738767,0.19211990436093274,0.17806850516633327,0.0,0.0,1.0011641443539,860.0,-0.8280549881083588,0.05498010125348567,1.0,2.0,1.0,47.0,47.0,47.0,94.0,1626,46.0,1.5092152684290275e-06,20308.0,860.0,1.0,0,49.0
228,609144,HP:0001251,Mutations of SLC49A1 encoding FLVCR1 are noted in patients with a rare neurodegenerative disorder: posterior column ataxia with retinitis pigmentosa.,1,1.4038800339200108,3598751.13586837,288.2122649797927,0.16890308909656404,0.06338047303717034,0.0,0.0,1.001027749229188,974.0,-0.6222014495487379,0.08173877442487196,1.0,2.0,2.0,158.0,158.0,137.0,316.0,1626,157.0,1.5092152684290275e-06,38732.0,974.0,1.0,0,149.0
229,173321,HP:0000365,"A homozygous mutation of SERPINB6, a gene encoding an intracellular protease inhibitor, has recently been associated with post-lingual, autosomal-recessive, nonsyndromic hearing loss in humans (DFNB91).",1,1.4966080165463551,32149.372093023256,829.0938907495092,0.3564763313182762,0.41095839137106055,0.0,0.0,1.000804505229284,1244.0,-0.9546556349968668,0.007464308164305319,1.0,2.0,1.0,7.0,7.0,7.0,14.0,2474,6.0,6.524672396198987e-07,5771.0,1244.0,1.0,0,6.0
231,173321,HP:0000365,These findings establish these mutant mice as a suitable model system to elucidate how SERPINB6 deficiency causes deafness in humans,1,1.4966080165463551,32149.372093023256,829.0938907495092,0.3564763313182762,0.41095839137106055,0.0,0.0,1.000804505229284,1244.0,-0.9546556349968668,0.007464308164305319,1.0,2.0,1.0,7.0,7.0,7.0,14.0,2474,6.0,6.524672396198987e-07,5771.0,1244.0,1.0,0,6.0
235,179617,HP:0002664,"The RAD51 recombinase plays a central role in homologous recombination (HR), which is critical for repair of DNA double-strand breaks, maintenance of genomic stability, and prevention of developmental disorders and cancer.",1,1.347529020406903,13693843.446212115,291.753931975873,0.14026292918403013,0.0743855024881839,0.0,0.0,1.0008460236886632,1183.0,-0.43154997044693855,0.11204986605220887,1.0,2.0,2.0,410.0,410.0,67.0,820.0,1542,409.0,1.67789739321861e-06,78340.0,1183.0,1.0,0,539.0
262,164757,HP:0002664,We extended our findings to BRAF WT tumor cell lines that are intrinsically resistant to vemurafenib and dabrafenib.,1,1.3343717616163435,16381827.818362188,267.1583928605997,0.14243558102353174,0.0178111227871734,0.0,0.0,1.0006944444444446,1441.0,-0.2821765440487228,0.0923076181663968,1.0,2.0,9.0,611.0,611.0,3.0,1222.0,1542,610.0,1.6778973932186103e-06,95771.0,1441.0,1.0,0,790.0
247,164757,HP:0002664,"The novel aspects of this study are the direct identification of serine biosynthesis as a critical mechanism of BRAF V600E inhibitor resistance and the first successful example of using gemcitabine + BRAFis in combination to kill previously drug-resistant cancer cells, creating the translational potential of pretreatment with gemcitabine prior to BRAFi treatment of tumor cells to reverse resistance within the mutational profile and the WT.",1,1.3343717616163435,16381827.818362188,267.1583928605997,0.14243558102353174,0.0178111227871734,0.0,0.0,1.0006944444444446,1441.0,-0.2821765440487228,0.0923076181663968,1.0,2.0,9.0,611.0,611.0,3.0,1222.0,1542,610.0,1.6778973932186103e-06,95771.0,1441.0,1.0,0,790.0
335,601231,HP:0002664,"These experiments suggest that excessive phosphorylation of eIF2a decreases survival of cancer cells; making eIF2a a worthy target for drug development, with the potential to enhance the cytotoxic effects of established anti-neoplastic therapies and circumvent resistance to rapalogues and possibly to other drugs that inhibit upstream components of the mTOR pathway",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
377,615585,HP:0001022,"Here, we report that these defects can occur independently of albinism in people with recessive mutations in the putative glutamine transporter gene SLC38A8.",0,1.2628205128205128,5823.722222222222,29.421409214092144,0.3637030244977573,0.2428811294651711,0.0,0.0,0.9833333333333334,59.0,-0.6038320262019695,0.2196721311475409,1.0,2.0,7.0,19.0,19.0,19.0,38.0,50,17.0,0.0005668934240362813,402.0,61.0,1.0,0,24.0
378,172471,HP:0001425,Increasing evidence shows that patients with PHKG2 mutations have a severe hepatic phenotype within the heterogeneous GSD IX disorder.,0,1.3218134830413233,597478.6467532467,96.66059379217272,0.2308438988843657,0.08214262444705367,0.0,0.0,0.997560975609756,409.0,-0.39331570996036097,0.11477063675746245,1.0,2.0,6.0,147.0,147.0,11.0,294.0,496,145.0,1.6259105098855364e-05,9670.0,411.0,1.0,0,167.0
379,609607,HP:0002664,"However, because nectin4 and CD46 have substantially overlapping receptor binding surfaces on H, disruption of nectin4 binding compromised CD46 binding and greatly diminished the oncolytic potency of these viruses on human cancer cells.",0,1.3926442906235714,1165656.198048503,216.4869001297017,0.20301617410718967,0.2021777893220361,0.0,0.0,0.9988399071925754,861.0,-0.6704255149912047,0.04878842219312656,1.0,2.0,59.0,90.0,90.0,89.0,180.0,1544,88.0,1.6778973932186103e-06,18147.0,863.0,1.0,0,92.0
380,615762,HP:0000365,Exome sequencing revealed an insertion mutation in GRXCR2 as the cause of moderate-to-severe and likely progressive hearing loss in the affected individuals of the family.,1,1.4942596129415908,104137.28730636543,835.4546924377161,0.2970274876523589,-0.034704652142484804,0.0,0.0,1.0008019246190858,1248.0,-0.9110838170590588,0.011706300248802254,1.0,2.0,1.0,11.0,11.0,11.0,22.0,2474,10.0,6.524672396198987e-07,9109.0,1248.0,1.0,0,10.0
389,615762,HP:0003676,Exome sequencing revealed an insertion mutation in GRXCR2 as the cause of moderate-to-severe and likely progressive hearing loss in the affected individuals of the family.,0,1.4032463874742782,15466.197427766036,86.02185981956974,0.4038649247978009,0.39218919072500735,0.0,0.0,0.9963503649635036,273.0,-0.652093568105185,0.030789648307896482,1.0,2.0,33.0,12.0,12.0,12.0,24.0,526,10.0,1.4457343607685525e-05,1160.0,275.0,1.0,0,17.0
386,615762,HP:0000365,Targeted disruption of Grxcr2 is concurrently reported to cause hearing loss in mice.,1,1.4942596129415908,104137.28730636543,835.4546924377161,0.2970274876523589,-0.034704652142484804,0.0,0.0,1.0008019246190858,1248.0,-0.9110838170590588,0.011706300248802254,1.0,2.0,1.0,11.0,11.0,11.0,22.0,2474,10.0,6.524672396198987e-07,9109.0,1248.0,1.0,0,10.0
383,615762,HP:0000365,"Our results indicate that GRXCR2 should be considered in differential genetic diagnosis for individuals with early onset, moderate-to-severe and progressive hearing loss.",1,1.4942596129415908,104137.28730636543,835.4546924377161,0.2970274876523589,-0.034704652142484804,0.0,0.0,1.0008019246190858,1248.0,-0.9110838170590588,0.011706300248802254,1.0,2.0,1.0,11.0,11.0,11.0,22.0,2474,10.0,6.524672396198987e-07,9109.0,1248.0,1.0,0,10.0
391,615762,HP:0003676,"Our results indicate that GRXCR2 should be considered in differential genetic diagnosis for individuals with early onset, moderate-to-severe and progressive hearing loss.",0,1.4032463874742782,15466.197427766036,86.02185981956974,0.4038649247978009,0.39218919072500735,0.0,0.0,0.9963503649635036,273.0,-0.652093568105185,0.030789648307896482,1.0,2.0,33.0,12.0,12.0,12.0,24.0,526,10.0,1.4457343607685525e-05,1160.0,275.0,1.0,0,17.0
393,615720,HP:0000478,"In zebrafish, downregulation of slc7a14 expression leads to an abnormal eye phenotype and defective light-induced locomotor response.",1,1.4700137714229575,8377394.249676587,816.6280608985107,0.17271116835873854,0.15622350422312944,0.0,0.0,1.0003818251240932,2620.0,-0.649358739237922,0.025736470711681225,1.0,2.0,1.0,113.0,113.0,113.0,226.0,5014,112.0,1.5898089431204514e-07,88299.0,2620.0,1.0,0,112.0
394,615720,HP:0000546,"Furthermore, targeted knockout of Slc7a14 in mice results in retinal degeneration with abnormal ERG response.",1,1.3500927193707415,845020.1834609836,159.6744655917889,0.18176299489559544,0.050017653462554816,0.0,0.0,1.003021148036254,332.0,-0.5497496403937413,0.2166126742620027,1.0,2.0,1.0,113.0,113.0,113.0,226.0,438,112.0,2.06611570247934e-05,11902.0,332.0,1.0,0,139.0
395,606800,HP:0001251,"Friedreich ataxia (FRDA) is the most frequent progressive autosomal recessive disorder associated with unstable expansion of GAA trinucleotide repeats in the first intron of the FXN gene, which encodes for the mitochondrial frataxin protein.",0,1.3920959108394837,3366919.8915416193,267.98297444999764,0.1698433868334385,0.09059038692246574,0.0,0.0,0.998971193415638,971.0,-0.6419820802441675,0.07646369676745376,1.0,2.0,7.0,152.0,152.0,108.0,304.0,1628,150.0,1.5055139448229137e-06,36158.0,973.0,1.0,0,138.0
396,606829,HP:0001251,"Friedreich ataxia (FRDA) is the most frequent progressive autosomal recessive disorder associated with unstable expansion of GAA trinucleotide repeats in the first intron of the FXN gene, which encodes for the mitochondrial frataxin protein.",1,1.4023815810809952,4311237.858529254,305.76853404897685,0.16432710239269194,0.09577822841222207,0.0,0.0,1.0010235414534288,978.0,-0.6358103352348582,0.08778594796892955,1.0,2.0,4.0,160.0,160.0,135.0,320.0,1626,159.0,1.5092152684290285e-06,41940.0,978.0,1.0,0,162.0
397,607245,HP:0001258,The AP4B1-associated phenotype has previously been assigned to spastic paraplegia-47.,1,1.3389162023380312,504481.45000000007,121.67425149700598,0.19780115881012827,0.0737059304718148,0.0,0.0,1.0034965034965035,287.0,-0.331542020394292,0.20701249969542654,1.0,2.0,1.0,120.0,120.0,8.0,240.0,240,120.0,3.5430839002267575e-05,8496.0,287.0,1.0,0,143.0
398,600037,HP:0000568,"In severe bilateral cases (anophthalmia or severe microphthalmia) the genetic cause is now identifiable in approximately 80 percent of cases, with de novo heterozygous loss-of-function mutations in SOX2 or OTX2 being the most common.",1,1.3364531751646078,2341949.324603175,197.14875,0.1511851019029072,0.1234921042944323,0.0,0.0,1.001953125,513.0,-0.2260444447974175,0.18962445175438605,1.0,2.0,3.0,217.0,217.0,3.0,434.0,450,217.0,1.1973036721303628e-05,24903.0,513.0,1.0,0,313.0
399,184429,HP:0000528,"In severe bilateral cases (anophthalmia or severe microphthalmia) the genetic cause is now identifiable in approximately 80 percent of cases, with de novo heterozygous loss-of-function mutations in SOX2 or OTX2 being the most common.",1,1.3869094428649205,466262.380830281,145.053125,0.2006512703292613,0.19923134437618595,0.0,0.0,1.0033003300330037,304.0,-0.7609317257964744,0.1591323606044815,1.0,2.0,2.0,64.0,64.0,64.0,128.0,224,64.0,1.7217334412286292e-05,7329.0,304.0,1.0,0,70.0
400,600037,HP:0000528,"In severe bilateral cases (anophthalmia or severe microphthalmia) the genetic cause is now identifiable in approximately 80 percent of cases, with de novo heterozygous loss-of-function mutations in SOX2 or OTX2 being the most common.",0,1.397982826768434,543083.2644841268,153.63715277777774,0.20089807988357605,0.1564977985585734,0.0,0.0,1.002849002849003,352.0,-0.7498604370155172,0.13022856772856772,1.0,2.0,5.0,64.0,64.0,64.0,128.0,256,64.0,1.1973036721303622e-05,8045.0,352.0,1.0,0,71.0
401,604773,HP:0002751,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.3165442807155878,149286.95753968257,76.3264614789005,0.2513178477744382,0.14710555411546286,0.0,0.0,0.9956140350877192,227.0,-0.6717651866416144,0.13828238719068414,1.0,2.0,8.0,55.0,55.0,34.0,110.0,330,53.0,3.6289737262302225e-05,3610.0,229.0,1.0,0,50.0
403,600529,HP:0002751,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.3220016857883743,461133.2865079365,106.13333333333333,0.20715314985549527,0.12876969245879405,0.0,0.0,0.9964912280701754,284.0,-0.4860409960740589,0.1840264998159735,1.0,2.0,3.0,104.0,104.0,43.0,208.0,330,102.0,3.6289737262302225e-05,7500.0,286.0,1.0,0,137.0
404,602858,HP:0002751,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.3627868475606424,2598650.2130785887,192.35528127458699,0.17577243377766022,0.04433233987181925,0.0,0.0,0.9984871406959152,660.0,-0.5074810913780502,0.11024676517772668,1.0,2.0,7.0,165.0,165.0,165.0,330.0,422,164.0,4.04843548210794e-06,24121.0,662.0,1.0,0,175.0
405,300256,HP:0002751,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.3189640187728142,758839.4265873015,115.98602642276423,0.1949423097139404,0.02876283560148945,0.0,0.0,0.9971988795518208,356.0,-0.3292370669877495,0.163341314179303,1.0,2.0,5.0,142.0,142.0,6.0,284.0,330,140.0,2.6846358291497765e-05,10438.0,358.0,1.0,0,188.0
406,614574,HP:0002751,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.3362883248432458,328780.1833333333,107.33658536585371,0.21058960292935414,0.028551454394153537,0.0,0.0,0.9959183673469388,244.0,-0.6311779263831261,0.19605110336817647,1.0,2.0,2.0,78.0,78.0,62.0,156.0,330,76.0,3.6289737262302225e-05,5908.0,246.0,1.0,0,88.0
407,604773,HP:0003198,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.3810281009549554,265622.26963869465,111.05389442598744,0.2404134522381856,0.06607668760343835,0.0,0.0,0.996894409937888,321.0,-0.6871526729555524,0.11235890237101706,1.0,2.0,1.0,63.0,63.0,49.0,126.0,518,61.0,1.4792899408284022e-05,5843.0,323.0,1.0,0,50.0
408,600301,HP:0003198,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.3776884991305658,449150.5453823954,150.97724431107775,0.20763246498549004,0.029510324833784775,0.0,0.0,0.9968847352024922,320.0,-0.7224040340260401,0.1502873396412608,1.0,2.0,2.0,62.0,62.0,59.0,124.0,518,60.0,1.4792899408284024e-05,7767.0,322.0,1.0,0,60.0
411,600234,HP:0003198,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.4328048422025064,61430.816143117285,104.65680056377731,0.3285319214506629,0.02586646012761977,0.0,0.0,0.99644128113879,280.0,-0.6886735224396999,0.059589611569622176,1.0,2.0,2.0,23.0,23.0,23.0,46.0,518,21.0,1.490735081468672e-05,2361.0,282.0,1.0,0,22.0
412,300256,HP:0003198,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.3270982001075915,1224297.1873015878,130.98800872093022,0.19479315688090407,0.11113769009989907,0.0,0.0,0.9977827050997784,450.0,-0.4476623398390058,0.14372191589977046,1.0,2.0,3.0,175.0,175.0,23.0,350.0,518,173.0,1.4792899408284024e-05,14649.0,452.0,1.0,0,191.0
413,614505,HP:0003198,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",1,1.3468353861620808,975257.7766594515,136.12305523933432,0.19603097703768865,0.18487577311201533,0.0,0.0,1.0025,401.0,-0.58831611369429,0.15615960099750625,1.0,2.0,3.0,127.0,127.0,68.0,254.0,516,127.0,1.490735081468672e-05,12524.0,401.0,1.0,0,138.0
414,614574,HP:0003198,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.3598542457569798,376832.7873376624,111.16220930232558,0.2279046497606612,0.04449992443068161,0.0,0.0,0.9970501474926252,338.0,-0.6219713611924029,0.1215339233038348,1.0,2.0,3.0,77.0,77.0,62.0,154.0,518,75.0,1.4792899408284022e-05,7004.0,340.0,1.0,0,76.0
415,604773,HP:0000365,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.4548963585053518,1220350.9413655684,380.16786644595857,0.21646108620325646,0.2234453111366782,0.0,0.0,0.9992313604919292,1300.0,-0.7157352683275544,0.028301519214216638,1.0,2.0,22.0,62.0,62.0,57.0,124.0,2476,60.0,6.524672396198986e-07,23970.0,1302.0,1.0,0,51.0
416,600301,HP:0000365,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.4569305417959564,2206570.048271508,559.5466398936031,0.17580252356235646,0.024362793764859485,0.0,0.0,0.9992307692307691,1299.0,-0.7939483750069251,0.04046236622716254,1.0,2.0,18.0,63.0,63.0,63.0,126.0,2476,61.0,6.524672396198984e-07,34217.0,1301.0,1.0,0,58.0
417,600529,HP:0000365,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.4328755000413227,4824125.992937803,439.76139854486667,0.1641449102420568,0.0885261959275768,0.0,0.0,0.9992636229749632,1357.0,-0.6803599074642754,0.05336484745237391,1.0,2.0,17.0,121.0,121.0,121.0,242.0,2476,119.0,6.524672396198988e-07,49243.0,1359.0,1.0,0,120.0
419,600234,HP:0000365,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.4729329555380386,268923.3960575341,423.22418608069376,0.3100862847806534,0.2572119700912034,0.0,0.0,0.9992063492063492,1259.0,-0.6842190391452692,0.013045831602532634,1.0,2.0,29.0,23.0,23.0,23.0,46.0,2476,21.0,6.524672396198986e-07,10364.0,1261.0,1.0,0,22.0
420,300256,HP:0000365,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",1,1.4180619779755048,8787388.911746427,423.06712729048775,0.14745551388397046,0.037956306697980696,0.0,0.0,1.0007002801120448,1429.0,-0.6578613876202081,0.06891559982985497,1.0,2.0,2.0,190.0,190.0,159.0,380.0,2474,189.0,6.524672396198988e-07,70315.0,1429.0,1.0,0,225.0
421,614505,HP:0000365,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",1,1.4339826243929792,6008262.669452728,446.6465789667083,0.1572544079793019,0.10106120215875572,0.0,0.0,1.0007251631617111,1380.0,-0.6717424334393561,0.06016962512217424,1.0,2.0,2.0,142.0,142.0,135.0,284.0,2474,141.0,6.524672396198988e-07,57252.0,1380.0,1.0,0,147.0
422,614574,HP:0000365,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.447594255854308,2572670.3136101705,461.6457760711399,0.17868567082767448,0.11399177559083964,0.0,0.0,0.9992412746585736,1317.0,-0.7285969784481463,0.0412495786457069,1.0,2.0,21.0,80.0,80.0,80.0,160.0,2476,78.0,6.524672396198987e-07,35855.0,1319.0,1.0,0,83.0
423,312180,HP:0001249,"Intragenic mutations of the UBE2A gene, as well as larger deletions of Xq24 encompassing UBE2A have in recent years been associated with a syndromic form of X-linked intellectual disability called UBE2A deficiency syndrome or X-linked intellectual disability type Nascimento (OMIM#300860).",1,1.4047502102900298,20325405.834221072,470.1963261357387,0.13480476145421205,0.015724674082425227,0.0,0.0,1.0005230125523012,1913.0,-0.5805852183174497,0.06695982344977221,1.0,2.0,2.0,307.0,307.0,249.0,614.0,3204,306.0,3.8916426584744994e-07,122458.0,1913.0,1.0,0,351.0
424,605031,HP:0003510,"Here we identify mutations in the genes encoding PLK4 kinase, a master regulator of centriole duplication, and its substrate TUBGCP6 in individuals with microcephalic primordial dwarfism and additional congenital anomalies, including retinopathy, thereby extending the human phenotypic spectrum associated with centriole dysfunction.",0,1.3440753955457545,526540.1404761904,127.94676827233286,0.2006952667749272,0.0748159477175604,0.0,0.0,0.9965753424657534,291.0,-0.5479245054430442,0.18869512366169527,1.0,2.0,3.0,90.0,90.0,90.0,180.0,180,89.0,2.426654371617851e-05,8072.0,293.0,1.0,0,98.0
425,610053,HP:0003510,"Here we identify mutations in the genes encoding PLK4 kinase, a master regulator of centriole duplication, and its substrate TUBGCP6 in individuals with microcephalic primordial dwarfism and additional congenital anomalies, including retinopathy, thereby extending the human phenotypic spectrum associated with centriole dysfunction.",0,1.327128482972136,259586.01666666672,98.17173654882616,0.2155303215787122,0.07052375910372738,0.0,0.0,0.9953051643192488,212.0,-0.3367085332799343,0.2271949453731736,1.0,2.0,1.0,90.0,90.0,90.0,180.0,180,88.0,6.503642039542144e-05,5178.0,214.0,1.0,0,117.0
426,605031,HP:0000252,"Furthermore, we establish that different levels of impaired PLK4 activity result in growth and cilia phenotypes, providing a mechanism by which microcephaly disorders can occur with or without ciliopathic features.",1,1.4045022465102976,11880985.901099065,493.1039316419541,0.1298529367047867,0.08845477081250662,0.0,0.0,1.0008103727714748,1235.0,-0.6518117000021789,0.10933798778207206,1.0,2.0,1.0,202.0,202.0,202.0,404.0,2066,201.0,9.353172034763872e-07,83315.0,1235.0,1.0,0,275.0
427,606227,HP:0000568,"Mutations in the membrane frizzled-related protein (MFRP/Mfrp) gene, specifically expressed in the retinal pigment epithelium (RPE) and ciliary body, cause nanophthalmia or posterior microphthalmia with retinitis pigmentosa in humans, and photoreceptor degeneration in mice.",1,1.3811037430810544,221553.57575333168,104.64242424242424,0.23566474303178164,0.2369147575698116,0.0,0.0,1.0034482758620689,291.0,-0.7154874493232254,0.1265552790615002,1.0,2.0,3.0,60.0,60.0,39.0,120.0,450,59.0,1.957866708434489e-05,5340.0,291.0,1.0,0,64.0
431,606227,HP:0000546,"In Mfrprd6 eyes, a significant 1.5- to 2.0-fold decrease was observed among transcripts of genes linked to retinal degeneration, including those involved in visual cycle (Rpe65, Lrat, Rgr), phototransduction (Pde6a, Guca1b, Rgs9), and photoreceptor disc morphogenesis (Rpgrip1 and Fscn2).",1,1.3794906334547201,253631.45094627593,112.39103362391032,0.2345608526142308,0.03284596465931083,0.0,0.0,1.0035211267605633,285.0,-0.6444084831416447,0.14084507042253522,1.0,2.0,4.0,63.0,63.0,59.0,126.0,438,62.0,2.066115702479339e-05,5700.0,285.0,1.0,0,63.0
432,180069,HP:0000546,"In Mfrprd6 eyes, a significant 1.5- to 2.0-fold decrease was observed among transcripts of genes linked to retinal degeneration, including those involved in visual cycle (Rpe65, Lrat, Rgr), phototransduction (Pde6a, Guca1b, Rgs9), and photoreceptor disc morphogenesis (Rpgrip1 and Fscn2).",0,1.3253582258160417,1303239.9151260508,159.89845751197237,0.17741304443032346,0.09926865126882237,0.0,0.0,0.9973958333333331,383.0,-0.4207411991227773,0.20549242424242425,1.0,2.0,3.0,157.0,157.0,61.0,314.0,440,155.0,2.0474601257140522e-05,15190.0,385.0,1.0,0,184.0
434,604863,HP:0000546,"In Mfrprd6 eyes, a significant 1.5- to 2.0-fold decrease was observed among transcripts of genes linked to retinal degeneration, including those involved in visual cycle (Rpe65, Lrat, Rgr), phototransduction (Pde6a, Guca1b, Rgs9), and photoreceptor disc morphogenesis (Rpgrip1 and Fscn2).",0,1.3287005037579471,1298230.4265873018,162.76132771338249,0.17676875778822435,0.10123466382493417,0.0,0.0,0.9973404255319148,375.0,-0.4396072935331152,0.21193351769287205,1.0,2.0,2.0,151.0,151.0,155.0,302.0,440,150.0,2.0474601257140515e-05,15021.0,377.0,1.0,0,176.0
435,600342,HP:0000546,"In Mfrprd6 eyes, a significant 1.5- to 2.0-fold decrease was observed among transcripts of genes linked to retinal degeneration, including those involved in visual cycle (Rpe65, Lrat, Rgr), phototransduction (Pde6a, Guca1b, Rgs9), and photoreceptor disc morphogenesis (Rpgrip1 and Fscn2).",1,1.3397505125917581,912688.7310800308,156.81465870506966,0.17956180676386035,0.04866779617782111,0.0,0.0,0.9970326409495548,336.0,-0.537034089635196,0.21319333485505595,1.0,2.0,1.0,118.0,118.0,118.0,236.0,440,116.0,2.0474601257140522e-05,12142.0,338.0,1.0,0,142.0
437,602275,HP:0000546,"In Mfrprd6 eyes, a significant 1.5- to 2.0-fold decrease was observed among transcripts of genes linked to retinal degeneration, including those involved in visual cycle (Rpe65, Lrat, Rgr), phototransduction (Pde6a, Guca1b, Rgs9), and photoreceptor disc morphogenesis (Rpgrip1 and Fscn2).",0,1.3500927193707415,829736.1586385837,159.41956600800097,0.1822466743628096,0.04626038348847602,0.0,0.0,1.003021148036254,332.0,-0.5442888143688127,0.2162668802096604,1.0,2.0,1.0,113.0,113.0,113.0,226.0,438,112.0,2.0661157024793387e-05,11883.0,332.0,1.0,0,139.0
438,607814,HP:0000546,"In Mfrprd6 eyes, a significant 1.5- to 2.0-fold decrease was observed among transcripts of genes linked to retinal degeneration, including those involved in visual cycle (Rpe65, Lrat, Rgr), phototransduction (Pde6a, Guca1b, Rgs9), and photoreceptor disc morphogenesis (Rpgrip1 and Fscn2).",0,1.4500863371465569,27648.114430344634,155.4288086342881,0.3023898096565463,0.17453711844022393,0.0,0.0,0.9956709956709956,230.0,-0.9385251269600006,0.06855500821018062,1.0,2.0,1.0,12.0,12.0,11.0,24.0,440,10.0,2.0474601257140515e-05,1837.0,232.0,1.0,0,10.0
439,605446,HP:0000546,"In Mfrprd6 eyes, a significant 1.5- to 2.0-fold decrease was observed among transcripts of genes linked to retinal degeneration, including those involved in visual cycle (Rpe65, Lrat, Rgr), phototransduction (Pde6a, Guca1b, Rgs9), and photoreceptor disc morphogenesis (Rpgrip1 and Fscn2).",1,1.3353569144871256,1273775.0710317462,136.41489286968738,0.1889180605963812,0.1270121729315754,0.0,0.0,1.002092050209205,479.0,-0.3102686191086078,0.14164795904997335,1.0,2.0,2.0,197.0,197.0,3.0,394.0,438,196.0,1.4679761013490698e-05,16216.0,479.0,1.0,0,204.0
440,607643,HP:0000546,"In Mfrprd6 eyes, a significant 1.5- to 2.0-fold decrease was observed among transcripts of genes linked to retinal degeneration, including those involved in visual cycle (Rpe65, Lrat, Rgr), phototransduction (Pde6a, Guca1b, Rgs9), and photoreceptor disc morphogenesis (Rpgrip1 and Fscn2).",0,1.3394337714863498,929852.9326923076,154.72064855661327,0.18018553673842824,0.0440984964368134,0.0,0.0,0.9970414201183432,337.0,-0.5285033577605787,0.21029481070325184,1.0,2.0,1.0,118.0,118.0,119.0,236.0,440,116.0,2.0474601257140515e-05,12048.0,339.0,1.0,0,147.0
429,606227,HP:0000568,"Transcripts of Prss56, a gene associated with angle-closure glaucoma, posterior microphthalmia and myopia, were increased in Mfrprd6 eyes by 17-fold.",1,1.3811037430810544,221553.57575333168,104.64242424242424,0.23566474303178164,0.2369147575698116,0.0,0.0,1.0034482758620689,291.0,-0.7154874493232254,0.1265552790615002,1.0,2.0,3.0,60.0,60.0,39.0,120.0,450,59.0,1.957866708434489e-05,5340.0,291.0,1.0,0,64.0
442,606227,HP:0000501,"Transcripts of Prss56, a gene associated with angle-closure glaucoma, posterior microphthalmia and myopia, were increased in Mfrprd6 eyes by 17-fold.",1,1.3993375576036868,390162.59596132615,144.4851475279107,0.22162938848130712,0.12043147022972815,0.0,0.0,1.0027100271002711,370.0,-0.7004490998056915,0.11477330989526112,1.0,2.0,3.0,64.0,64.0,59.0,128.0,608,63.0,1.0749798441279223e-05,7835.0,370.0,1.0,0,68.0
443,613858,HP:0000501,"Transcripts of Prss56, a gene associated with angle-closure glaucoma, posterior microphthalmia and myopia, were increased in Mfrprd6 eyes by 17-fold.",1,1.4419152276295133,98593.79115118882,136.46699915110358,0.2852660392088776,0.06553242350124103,0.0,0.0,1.002994011976048,335.0,-0.7268360424293995,0.06862096702118152,1.0,2.0,1.0,31.0,31.0,30.0,62.0,608,30.0,1.0749798441279223e-05,3839.0,335.0,1.0,0,27.0
444,606227,HP:0000545,"Transcripts of Prss56, a gene associated with angle-closure glaucoma, posterior microphthalmia and myopia, were increased in Mfrprd6 eyes by 17-fold.",0,1.3790164538931171,324908.0460458616,126.51038159371492,0.24027938950686165,0.07595873218563401,0.0,0.0,0.9974424552429668,390.0,-0.6548466992068891,0.09417245158933138,1.0,2.0,5.0,62.0,62.0,53.0,124.0,650,60.0,9.409462155143213e-06,7217.0,392.0,1.0,0,60.0
451,613858,HP:0000545,"Transcripts of Prss56, a gene associated with angle-closure glaucoma, posterior microphthalmia and myopia, were increased in Mfrprd6 eyes by 17-fold.",0,1.4278465522001595,113951.11678760506,135.63749502190362,0.2797798303701744,-0.048049277364645086,0.0,0.0,0.9971910112359548,355.0,-0.7208163814202093,0.06508670884083971,1.0,2.0,2.0,31.0,31.0,30.0,62.0,650,29.0,9.409462155143213e-06,4136.0,357.0,1.0,0,26.0
457,610299,HP:0001249,"In summary, our genetic findings implicate homozygous SLC6A17 mutations in autosomal-recessive intellectual disability, and their pathogenic role is strengthened by genetic evidence and in silico and in vitro functional analyses",1,1.451758665789324,5839817.041861213,553.2523196004994,0.16130525015204786,0.038761558706722515,0.0,0.0,1.0005793742757825,1727.0,-0.6696120849655289,0.04304277842003595,1.0,2.0,1.0,125.0,125.0,125.0,250.0,3204,124.0,3.891642658474503e-07,64151.0,1727.0,1.0,0,119.0
458,605896,HP:0001371,The finding expands the molecular basis of congenital contractures and the phenotypic spectrum of ECEL1 mutations.,1,1.407383147418538,3499927.9805125436,343.6130208333333,0.1532483010235865,0.11080814933243703,0.0,0.0,1.0013175230566536,760.0,-0.7036907466735859,0.12039040288468204,1.0,2.0,1.0,120.0,120.0,120.0,240.0,1280,119.0,2.433794699681904e-06,34723.0,760.0,1.0,0,121.0
459,601728,HP:0002664,"Here we developed a novel whole-body insertional mutagenesis screen in mice, which was designed for the discovery of Pten-cooperating tumor suppressors.",1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
519,606025,HP:0002664,"We validated ZBTB20, CELF2, PARD3, AKAP13 and WAC, which were identified by our screens in multiple cancer types, as new tumor suppressor genes in prostate cancer.",0,1.3595110490539537,7139069.830532509,254.38413234466395,0.14957192667225255,0.059501671056314785,0.0,0.0,0.9990356798457088,1036.0,-0.5481837314661832,0.09440675730161296,1.0,2.0,11.0,261.0,261.0,144.0,522.0,1544,259.0,1.6778973932186097e-06,50810.0,1038.0,1.0,0,353.0
520,615049,HP:0002664,"We validated ZBTB20, CELF2, PARD3, AKAP13 and WAC, which were identified by our screens in multiple cancer types, as new tumor suppressor genes in prostate cancer.",0,1.350522229411221,9084524.745866634,264.1147073207034,0.1459839875740244,0.08094448571055704,0.0,0.0,0.999071494893222,1076.0,-0.5341383494691474,0.10053350284150124,1.0,2.0,11.0,299.0,299.0,122.0,598.0,1544,297.0,1.6778973932186103e-06,58360.0,1078.0,1.0,0,428.0
483,601728,HP:0002664,"Our study identified complex PTEN-cooperating tumor suppressor networks in different cancer types, with potential clinical implications",1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
521,613036,HP:0001251,"We report the identification of mutations in PMPCA in 17 patients from four families affected with cerebellar ataxia, including the large Lebanese family previously described with autosomal recessive cerebellar ataxia and short stature of Norman type and localized to chromosome 9q34 (OMIM #213200).",1,1.421178170200508,3543276.8328182567,385.02029520295196,0.15796264961494716,0.09515102693777024,0.0,0.0,1.0010729613733906,933.0,-0.7128665629141346,0.0925989815492044,1.0,2.0,1.0,120.0,120.0,120.0,240.0,1626,119.0,1.5092152684290268e-06,40260.0,933.0,1.0,0,116.0
522,613036,HP:0000007,"We report the identification of mutations in PMPCA in 17 patients from four families affected with cerebellar ataxia, including the large Lebanese family previously described with autosomal recessive cerebellar ataxia and short stature of Norman type and localized to chromosome 9q34 (OMIM #213200).",1,1.4691394115294656,6635154.172072514,657.8372093023256,0.17721334413802636,0.12229519506031145,0.0,0.0,1.0003705075954057,2700.0,-0.6456802996450703,0.020702317730846808,1.0,2.0,123.0,120.0,120.0,120.0,240.0,5160,119.0,1.5011496554636375e-07,75432.0,2700.0,1.0,0,123.0
523,613036,HP:0004322,"We report the identification of mutations in PMPCA in 17 patients from four families affected with cerebellar ataxia, including the large Lebanese family previously described with autosomal recessive cerebellar ataxia and short stature of Norman type and localized to chromosome 9q34 (OMIM #213200).",1,1.4379022015241318,3998093.769356112,419.6085561497326,0.16275569657962136,0.05750221684931867,0.0,0.0,1.0008058017727641,1242.0,-0.6822780214309799,0.059024655458106735,1.0,2.0,1.0,120.0,120.0,109.0,240.0,2244,119.0,7.929402939746843e-07,45488.0,1242.0,1.0,0,121.0
530,609610,HP:0000252,We have identified TUBGCP4 variants in individuals with autosomal-recessive microcephaly and chorioretinopathy.,1,1.438168692277089,5762207.181407934,602.8638475754642,0.1387145674078511,0.07655708278311246,0.0,0.0,1.000875656742557,1143.0,-0.7430778164214717,0.0918298084893504,1.0,2.0,1.0,110.0,110.0,110.0,220.0,2066,109.0,9.353172034763868e-07,59933.0,1143.0,1.0,0,124.0
527,609610,HP:0000252,"Subsequent Sanger sequencing was performed on a panel of individuals from 12 French families affected by microcephaly and ophthalmic manifestations, and one other individual was identified with compound-heterozygous mutations in TUBGCP4.",1,1.438168692277089,5762207.181407934,602.8638475754642,0.1387145674078511,0.07655708278311246,0.0,0.0,1.000875656742557,1143.0,-0.7430778164214717,0.0918298084893504,1.0,2.0,1.0,110.0,110.0,110.0,220.0,2066,109.0,9.353172034763868e-07,59933.0,1143.0,1.0,0,124.0
533,609610,HP:0007731,"Moreover, zebrafish treated with morpholinos against tubgcp4 were found to have reduced head volume and eye developmental anomalies with chorioretinal dysplasia.",1,1.410599721059972,37197.13921568627,89.77186147186147,0.27475555906714016,0.18713788538471496,0.0,0.0,1.007692307692308,131.0,-0.9048405411617628,0.1859072225484439,1.0,2.0,1.0,21.0,21.0,21.0,42.0,130,21.0,8.11622433244055e-05,1583.0,131.0,1.0,0,21.0
524,609610,HP:0000252,"In summary, the identification of TUBGCP4 mutations in individuals with microcephaly and a spectrum of anomalies in eye development, particularly photoreceptor anomalies, provides evidence of an important role for the y-TuRC in brain and eye development",1,1.438168692277089,5762207.181407934,602.8638475754642,0.1387145674078511,0.07655708278311246,0.0,0.0,1.000875656742557,1143.0,-0.7430778164214717,0.0918298084893504,1.0,2.0,1.0,110.0,110.0,110.0,220.0,2066,109.0,9.353172034763868e-07,59933.0,1143.0,1.0,0,124.0
534,609653,HP:0001425,"A third proband was doubly heterozygous for inherited rare variants in additional components of complex I, NDUFAF2 and NDUFB9, confirming that Histiocytoid CM is genetically heterogeneous.",1,1.314358083356011,960414.311904762,113.18006367674226,0.2059924173906855,0.12092223459012227,0.0,0.0,0.997797356828194,453.0,-0.3179532455787348,0.12529408917074114,1.0,2.0,9.0,177.0,177.0,3.0,354.0,496,175.0,1.6259105098855364e-05,12941.0,455.0,1.0,0,214.0
535,601445,HP:0001425,"A third proband was doubly heterozygous for inherited rare variants in additional components of complex I, NDUFAF2 and NDUFB9, confirming that Histiocytoid CM is genetically heterogeneous.",0,1.3168874938758808,762326.0900793652,112.04807692307692,0.208399877433685,0.13639936269184078,0.0,0.0,0.9975,399.0,-0.4347251611495962,0.13408977556109725,1.0,2.0,10.0,136.0,136.0,22.0,272.0,496,134.0,1.625910509885536e-05,10754.0,401.0,1.0,0,132.0
536,603474,HP:0000365,"We previously mapped a locus (ahl8) contributing to the progressive hearing loss of DBA/2J (D2) mice and later showed that a missense variant of the Fscn2 gene, unique to the D2 inbred strain, was responsible for the ahl8 effect.",0,1.3790434870346078,17776002.779866453,374.6853545162371,0.13309761784367266,0.060930894883191325,0.0,0.0,0.9993614303959132,1565.0,-0.5823275154241083,0.08002373343570007,1.0,2.0,6.0,314.0,314.0,188.0,628.0,2476,312.0,6.514144487633225e-07,98186.0,1567.0,1.0,0,380.0
537,607643,HP:0000365,"We previously mapped a locus (ahl8) contributing to the progressive hearing loss of DBA/2J (D2) mice and later showed that a missense variant of the Fscn2 gene, unique to the D2 inbred strain, was responsible for the ahl8 effect.",1,1.4432421933441648,5877411.564759431,503.6018661880163,0.15916208424486752,0.11416548282900055,0.0,0.0,1.0007385524372232,1355.0,-0.6727326910518148,0.05913870069276764,1.0,2.0,1.0,118.0,118.0,118.0,236.0,2474,117.0,6.52467239619899e-07,54250.0,1355.0,1.0,0,140.0
622,600960,HP:0002664,"We used a set of previously uncharacterized antibodies against the cancer/testis antigens ADAM2, CALR3 and SAGE1 to investigate their expression in a large panel of normal tissues as well as breast and lung cancers.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
634,300096,HP:0001249,"Three patients presented with cognitive impairment, reinforcing the association between the disrupted genes (TSPAN7-MRX58, KIAA2022-MRX98, and IL1RAPL1-MRX21/34) and intellectual disability.",1,1.434457265387511,10962266.552390363,542.3753607171363,0.14717487984749025,0.02426814970937337,0.0,0.0,1.0005605381165918,1785.0,-0.6288540502727588,0.05594641444021555,1.0,2.0,1.0,183.0,183.0,183.0,366.0,3204,182.0,3.8916426584744994e-07,89079.0,1785.0,1.0,0,195.0
641,300206,HP:0001249,"Three patients presented with cognitive impairment, reinforcing the association between the disrupted genes (TSPAN7-MRX58, KIAA2022-MRX98, and IL1RAPL1-MRX21/34) and intellectual disability.",1,1.4223431099644692,17128730.753005758,546.2090647560117,0.1370541621987404,0.07628525953094104,0.0,0.0,1.0005461496450028,1832.0,-0.6191787745128313,0.06549979847316592,1.0,2.0,1.0,230.0,230.0,230.0,460.0,3204,229.0,3.8916426584744994e-07,109856.0,1832.0,1.0,0,243.0
644,616013,HP:0001249,"Two recent reports describe a new syndrome of intellectual disability, short stature, microcephaly, and young onset diabetes or disturbed glucose metabolism in association with inactivating mutations in the TRMT10A gene.",1,1.4178686825968019,19274967.352595747,565.4464449558534,0.1317148705872636,0.083285787789215,0.0,0.0,1.0005405405405403,1851.0,-0.6393662685649211,0.07117029509249931,1.0,2.0,2.0,248.0,248.0,246.0,496.0,3204,247.0,3.8916426584744994e-07,121856.0,1851.0,1.0,0,258.0
645,616013,HP:0004322,"Two recent reports describe a new syndrome of intellectual disability, short stature, microcephaly, and young onset diabetes or disturbed glucose metabolism in association with inactivating mutations in the TRMT10A gene.",1,1.3967042787905433,15006382.463739127,456.2001052337693,0.13080541780896385,0.020427536841349472,0.0,0.0,1.0007299270072991,1371.0,-0.640765750174072,0.09898789843845666,1.0,2.0,1.0,248.0,248.0,242.0,496.0,2244,247.0,7.929402939746845e-07,92963.0,1371.0,1.0,0,261.0
646,616013,HP:0000252,"Two recent reports describe a new syndrome of intellectual disability, short stature, microcephaly, and young onset diabetes or disturbed glucose metabolism in association with inactivating mutations in the TRMT10A gene.",1,1.3916286850250963,12750899.17610319,439.4995665138774,0.12963284161305005,0.0936684245501928,0.0,0.0,1.0007806401249024,1282.0,-0.6216426419036928,0.1073897756847042,1.0,2.0,1.0,248.0,248.0,235.0,496.0,2066,247.0,9.353172034763868e-07,88180.0,1282.0,1.0,0,331.0
647,300499,HP:0001249,"Yeast trm7D mutants grow poorly due to lack of 2*-O-methylated C32 (Cm32 ) and Gm34 on tRNA(Phe) , catalyzed by Trm7-Trm732 and Trm7-Trm734, respectively, which in turn results in loss of wybutosine at G37 . Mutations in human FTSJ1, the likely TRM7 homolog, cause nonsyndromic X-linked intellectual disability (NSXLID), but the role of FTSJ1 in tRNA modification is unknown.",1,1.432822385073914,11791993.65929302,539.1786754651923,0.1464649382359954,0.034886854456008067,0.0,0.0,1.000558659217877,1791.0,-0.6227637937558256,0.05686470839610841,1.0,2.0,1.0,189.0,189.0,189.0,378.0,3204,188.0,3.8916426584745004e-07,91151.0,1791.0,1.0,0,201.0
648,616735,HP:0003006,"Moreover, overexpression of mutant but not normal CCDC174 in neuroblastoma cells caused rapid apoptosis.",0,1.2817445996803631,55410.91666666667,62.45631678189818,0.2633242926534842,-0.1214719944277192,0.0,0.0,0.9919354838709676,123.0,-0.6054334614912296,0.2176774193548387,1.0,2.0,13.0,38.0,38.0,38.0,76.0,100,37.0,0.0001321178491214163,1687.0,125.0,1.0,0,53.0
544,600960,HP:0002664,"Furthermore, parallel immunohistochemical analysis of three PP2A inhibitors demonstrated that two PP2A inhibitors, CIP2A and SET, are highly expressed in both dysplastic and adenocarcinomatous tumors of the Smgb-Tag mice.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
669,614759,HP:0001651,"Here, we identify new patients with dextrocardia who have mutations in CFAP53, a coiled-coil domain containing protein.",1,1.4074519531935152,31390.648862765138,78.4695652173913,0.29044994929697265,0.1770660090480732,0.0,0.0,1.0072992700729926,138.0,-0.8374991955902289,0.1591029302866815,1.0,2.0,1.0,23.0,23.0,23.0,46.0,230,22.0,7.431629013079665e-05,1504.0,138.0,1.0,0,23.0
671,614759,HP:0001651,"We show that cfap53 is required for cilia rotation specifically in Kupffer*s vesicle, the zebrafish laterality organ, providing a mechanism by which patients with CFAP53 mutations develop dextrocardia and heterotaxy, and confirming previous evidence that left-right asymmetry in humans is regulated through cilia-driven fluid flow in a laterality organ.",1,1.4074519531935152,31390.648862765138,78.4695652173913,0.29044994929697265,0.1770660090480732,0.0,0.0,1.0072992700729926,138.0,-0.8374991955902289,0.1591029302866815,1.0,2.0,1.0,23.0,23.0,23.0,46.0,230,22.0,7.431629013079665e-05,1504.0,138.0,1.0,0,23.0
673,123670,HP:0000518,This paper shows the significant difference in distribution of CRYGB promoter (G(-47)--&gt;A) genotypes in patients with cataract compared to the control group.,1,1.491418200674099,26165.78572096066,434.4985447697312,0.3362175537637867,0.3975575462511973,0.0,0.0,1.0015220700152208,658.0,-0.872722371642205,0.017843842093332042,1.0,2.0,1.0,9.0,9.0,9.0,18.0,1298,8.0,2.366863905325444e-06,3857.0,658.0,1.0,0,8.0
674,610844,HP:0000007,"Mutations in the ALS5/SPG11/KIAA1840 gene are a frequent cause of autosomal recessive hereditary spastic paraplegia with thin corpus callosum and peripheral axonal neuropathy, and account for a 40% of autosomal recessive juvenile amyotrophic lateral sclerosis.",1,1.4422172191655998,13892410.417601885,482.91207751938,0.16311624441598274,0.08353705572325364,0.0,0.0,1.0003534817956876,2830.0,-0.5754734534231797,0.027494888253537627,1.0,2.0,81.0,248.0,248.0,177.0,496.0,5160,247.0,1.5011496554636367e-07,110063.0,2830.0,1.0,0,275.0
683,610844,HP:0009830,"Mutations in the ALS5/SPG11/KIAA1840 gene are a frequent cause of autosomal recessive hereditary spastic paraplegia with thin corpus callosum and peripheral axonal neuropathy, and account for a 40% of autosomal recessive juvenile amyotrophic lateral sclerosis.",1,1.3545100648523,4632666.73524531,231.79550644567212,0.16246898444000926,0.1529226403945032,0.0,0.0,1.0012626262626263,793.0,-0.5242819363081007,0.1263581591450444,1.0,2.0,3.0,246.0,246.0,127.0,492.0,1086,245.0,3.3791089965397925e-06,39680.0,793.0,1.0,0,351.0
680,610844,HP:0000007,"The overlap of axonal Charcot-Marie-Tooth disease with both diseases, as well as the common autosomal recessive inheritance pattern of thin corpus callosum and axonal Charcot-Marie-Tooth disease in three related patients, prompted us to analyse the ALS5/SPG11/KIAA1840 gene in affected individuals with autosomal recessive axonal Charcot-Marie-Tooth disease.",1,1.4422172191655998,13892410.417601885,482.91207751938,0.16311624441598274,0.08353705572325364,0.0,0.0,1.0003534817956876,2830.0,-0.5754734534231797,0.027494888253537627,1.0,2.0,81.0,248.0,248.0,177.0,496.0,5160,247.0,1.5011496554636367e-07,110063.0,2830.0,1.0,0,275.0
684,608507,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4429563575780515,11317613.551168924,446.1364719228588,0.1733276231410587,0.1323803680916019,0.0,0.0,1.0003539823008851,2826.0,-0.5721521084425386,0.025100927543856358,1.0,2.0,68.0,241.0,241.0,147.0,482.0,5160,240.0,1.5011496554636375e-07,100196.0,2826.0,1.0,0,259.0
685,150330,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.365368562050469,35709349.87344581,295.2055072745222,0.1535144973853284,0.09184789289855357,0.0,0.0,1.0002827254735651,3538.0,-0.4111674920349413,0.032960132511783286,1.0,2.0,23.0,875.0,875.0,52.0,1750.0,5160,874.0,1.5011496554636367e-07,206230.0,3538.0,1.0,0,1064.0
686,162280,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4424015201601352,12202749.793138465,441.5991407490426,0.17181369295425325,-0.006398265505636727,0.0,0.0,1.0003536067892504,2829.0,-0.5711122920147219,0.025068708961488485,1.0,2.0,45.0,241.0,241.0,154.0,482.0,5160,240.0,1.5011496554636367e-07,100280.0,2829.0,1.0,0,278.0
687,602195,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",0,1.4274908491003764,2692293.526351468,417.5018537243006,0.2368481144788836,0.17454428410701087,0.0,0.0,0.9996258885147772,2672.0,-0.5680019383996506,0.011075602698639348,1.0,2.0,262.0,92.0,92.0,89.0,184.0,5162,90.0,1.5011496554636367e-07,39582.0,2674.0,1.0,0,87.0
688,606598,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4684443885370235,4250304.7585182255,458.608829646436,0.21063312961709832,0.2335036398640973,0.0,0.0,1.0003700962250186,2703.0,-0.5808365344725325,0.0147441516444294,1.0,2.0,212.0,120.0,120.0,111.0,240.0,5160,119.0,1.5011496554636367e-07,53842.0,2703.0,1.0,0,120.0
689,610933,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4828463238847074,2055822.6650266724,548.0471414728682,0.2474884381481436,0.5147461420294756,0.0,0.0,1.0003783579265986,2644.0,-0.6040973882795357,0.009795520722967013,1.0,2.0,258.0,64.0,64.0,64.0,128.0,5160,63.0,1.5011496554636367e-07,34226.0,2644.0,1.0,0,61.0
690,614141,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4823317586162081,2388064.3706766968,643.0861522198733,0.2254165585839245,0.11070684080233847,0.0,0.0,1.0003780718336486,2646.0,-0.6287459407476131,0.011826532755509262,1.0,2.0,315.0,66.0,66.0,66.0,132.0,5160,65.0,1.5011496554636372e-07,41385.0,2646.0,1.0,0,62.0
691,600502,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4648013065902217,5358855.434036773,494.2981568233785,0.19988528848050824,0.03252343799927096,0.0,0.0,1.0003679175864606,2719.0,-0.5825838849594001,0.017643535895035645,1.0,2.0,101.0,137.0,137.0,134.0,274.0,5160,136.0,1.501149655463636e-07,65195.0,2719.0,1.0,0,123.0
692,604139,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4902579899884485,1068343.6891355934,748.8891472868218,0.2661596316006479,0.2976297150911058,0.0,0.0,1.0003824091778202,2616.0,-0.6537969644517557,0.007773606750048239,1.0,2.0,302.0,36.0,36.0,36.0,72.0,5160,35.0,1.5011496554636372e-07,26589.0,2616.0,1.0,0,35.0
693,602072,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4908026127759784,932425.345233136,716.6150478796169,0.27851748597682396,0.2383644914933405,0.0,0.0,1.0003827018752391,2614.0,-0.6493387004483899,0.007041480256887536,1.0,2.0,303.0,34.0,34.0,34.0,68.0,5160,33.0,1.5011496554636367e-07,24048.0,2614.0,1.0,0,44.0
694,601314,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4584621459173488,4960339.8047736725,382.9663621262459,0.2071577385924182,0.05574164125687287,0.0,0.0,1.0003640334910813,2748.0,-0.5453353695493744,0.016003961447422596,1.0,2.0,157.0,164.0,164.0,112.0,328.0,5160,163.0,1.5011496554636367e-07,60405.0,2748.0,1.0,0,172.0
695,605379,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4648013065902217,6723037.480074292,573.240290558251,0.1829830803267348,0.25319959917587026,0.0,0.0,1.0003679175864606,2719.0,-0.5999831624114653,0.020461305597299792,1.0,2.0,167.0,139.0,139.0,138.0,278.0,5160,138.0,1.5011496554636367e-07,75607.0,2719.0,1.0,0,129.0
696,612012,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4632405495031031,7323430.885939947,543.7815652543271,0.18607495318676054,0.001292004729533382,0.0,0.0,1.000366972477064,2726.0,-0.5990699705500211,0.020230603027590246,1.0,2.0,81.0,145.0,145.0,144.0,290.0,5160,144.0,1.501149655463636e-07,75140.0,2726.0,1.0,0,147.0
697,608181,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4750829143599749,4461196.4928527335,605.8094655242759,0.1995795969800016,0.35150006372994524,0.0,0.0,1.00037397157816,2675.0,-0.5973348055944002,0.01552030980224942,1.0,2.0,239.0,94.0,94.0,93.0,188.0,5160,93.0,1.5011496554636367e-07,55508.0,2675.0,1.0,0,89.0
698,611026,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4512386649083615,9968979.492917733,477.6277122236224,0.17270962390893188,0.027954024772819525,0.0,0.0,1.0003594536304816,2783.0,-0.5827997937864975,0.023219438756360185,1.0,2.0,96.0,203.0,203.0,159.0,406.0,5160,202.0,1.5011496554636375e-07,89886.0,2783.0,1.0,0,192.0
699,609471,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4569810459465191,9402367.437117305,541.151561461794,0.17721581796237296,0.03968062297147498,0.0,0.0,1.0003631082062454,2755.0,-0.5806781508167201,0.02337757849661341,1.0,2.0,74.0,173.0,173.0,171.0,346.0,5160,172.0,1.5011496554636367e-07,88686.0,2755.0,1.0,0,169.0
700,613541,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4482779518990745,12314252.62641753,513.1308335111298,0.16656375811518528,0.016776442224010056,0.0,0.0,1.0003575259206292,2798.0,-0.5829251019822189,0.02636006156908134,1.0,2.0,114.0,217.0,217.0,211.0,434.0,5160,216.0,1.5011496554636386e-07,103147.0,2798.0,1.0,0,210.0
701,604878,HP:0000007,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4524451682871444,12947918.312791953,593.7390567819623,0.15901538929605435,0.17253492997328862,0.0,0.0,1.0003602305475503,2777.0,-0.6053085948112443,0.02819293725009573,1.0,2.0,117.0,197.0,197.0,197.0,394.0,5160,196.0,1.5011496554636375e-07,108669.0,2777.0,1.0,0,193.0
702,608507,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3553079213037431,3894082.7423687405,215.41593675605262,0.1692397247467166,0.07249873854724039,0.0,0.0,1.001269035532995,789.0,-0.5217052527493385,0.11731742937471452,1.0,2.0,3.0,236.0,236.0,106.0,472.0,1086,235.0,3.379108996539793e-06,36470.0,789.0,1.0,0,326.0
703,150330,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3450745576112864,8213203.635954223,181.7408216934452,0.17172129244296336,0.0562557674644531,0.0,0.0,1.0006666666666666,1501.0,-0.2698398011331476,0.055949367088607586,1.0,2.0,64.0,510.0,510.0,2.0,1020.0,1086,510.0,1.087333542826262e-06,62985.0,1501.0,1.0,0,569.0
704,162280,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3547073005017376,4074536.842912642,216.125141449777,0.16843218326637674,0.04838417987303978,0.0,0.0,1.0012642225031607,792.0,-0.525231116166032,0.11778978150659565,1.0,2.0,7.0,239.0,239.0,106.0,478.0,1086,238.0,3.379108996539793e-06,36896.0,792.0,1.0,0,283.0
705,602195,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4135984048791932,1104120.6236357396,201.63754103611168,0.20952603732396627,0.011636430316531374,0.0,0.0,1.001577287066246,635.0,-0.6140880335962504,0.07880473931294865,1.0,2.0,2.0,91.0,91.0,89.0,182.0,1086,90.0,3.3791089965397912e-06,15863.0,635.0,1.0,0,87.0
706,606598,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3959337157559304,1589326.1231172334,203.2133135695998,0.19520086785818952,0.06983768211995188,0.0,0.0,1.0015037593984963,666.0,-0.6099272698113856,0.09202736571157624,1.0,2.0,3.0,121.0,121.0,99.0,242.0,1086,120.0,3.379108996539792e-06,20379.0,666.0,1.0,0,126.0
707,610933,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4337041608724863,857207.041758211,243.4846915285451,0.2120902503582585,0.08392363470610573,0.0,0.0,1.0016501650165015,607.0,-0.6734542572555499,0.07579341130159144,1.0,2.0,1.0,64.0,64.0,64.0,128.0,1086,63.0,3.3791089965397938e-06,13940.0,607.0,1.0,0,62.0
708,614141,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4321131856063052,838562.0428744046,248.7965009208104,0.2044405565993292,0.11403048473902395,0.0,0.0,1.0016447368421053,609.0,-0.7143142450989742,0.07908240428657852,1.0,2.0,1.0,66.0,66.0,66.0,132.0,1086,65.0,3.3791089965397925e-06,14641.0,609.0,1.0,0,62.0
709,600502,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3883293049278331,1932582.2178014924,211.79164513692916,0.18868819681506568,0.029864143954205107,0.0,0.0,1.001468428781204,682.0,-0.5990230557523999,0.10093402405467206,1.0,2.0,3.0,136.0,136.0,120.0,272.0,1086,135.0,3.3791089965397925e-06,23439.0,682.0,1.0,0,141.0
710,604139,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4589751806105804,426566.51109121507,314.05448127685696,0.22093824378838006,0.11381417079074024,0.0,0.0,1.0017301038062283,579.0,-0.7891707103338643,0.06336542541429861,1.0,2.0,1.0,36.0,36.0,36.0,72.0,1086,35.0,3.379108996539792e-06,10603.0,579.0,1.0,0,40.0
711,602072,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4610185323898237,380457.0116896263,305.345574693966,0.2280654109911613,0.037240687434370236,0.0,0.0,1.001736111111111,577.0,-0.7783485810714595,0.05879308684767956,1.0,2.0,1.0,34.0,34.0,34.0,68.0,1086,33.0,3.3791089965397912e-06,9770.0,577.0,1.0,0,33.0
712,601314,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3766707589407687,1728544.2765091076,173.53344514601415,0.19492331073820665,0.13747026121581202,0.0,0.0,1.0014084507042256,711.0,-0.5656736155828679,0.08821140627166657,1.0,2.0,6.0,161.0,161.0,70.0,322.0,1086,160.0,3.3791089965397925e-06,22265.0,711.0,1.0,0,161.0
713,605379,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3883293049278331,2431180.257574778,246.1188971474754,0.1754072558265493,0.08143588239606522,0.0,0.0,1.001468428781204,682.0,-0.6205237687158104,0.11729344030040348,1.0,2.0,2.0,137.0,137.0,135.0,274.0,1086,136.0,3.379108996539792e-06,27238.0,682.0,1.0,0,134.0
714,612012,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3852799656447945,2762600.805733156,244.29351144075284,0.17306216290340026,0.05501048633687981,0.0,0.0,1.001453488372093,689.0,-0.6289319842589735,0.11859536908900666,1.0,2.0,3.0,144.0,144.0,143.0,288.0,1086,143.0,3.379108996539793e-06,28109.0,689.0,1.0,0,154.0
718,608181,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.4116974087108067,1669139.7800518922,256.6223126877968,0.1874544093941175,0.0880017664433041,0.0,0.0,1.001569858712716,638.0,-0.6558665349547251,0.10210971294715138,1.0,2.0,2.0,94.0,94.0,92.0,188.0,1086,93.0,3.3791089965397925e-06,20749.0,638.0,1.0,0,110.0
719,611026,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",0,1.3655604046311542,3442928.42987568,219.2405809723394,0.16749418588633708,0.07195249688800265,0.0,0.0,1.0013422818791946,746.0,-0.5783534868930172,0.11657700127750688,1.0,2.0,1.0,201.0,201.0,114.0,402.0,1086,200.0,3.3791089965397925e-06,32395.0,746.0,1.0,0,262.0
720,609471,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.374213407573217,3323904.037745098,241.16941857405945,0.1692825783397648,0.12299463845178185,0.0,0.0,1.00139470013947,718.0,-0.5869909946623292,0.12400010877884095,1.0,2.0,8.0,168.0,168.0,147.0,336.0,1086,167.0,3.379108996539793e-06,31918.0,718.0,1.0,0,204.0
721,613541,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3616088625168428,4110742.2192834937,238.15402875631474,0.16402874683101598,0.04965068972839514,0.0,0.0,1.0013157894736842,761.0,-0.5464933568583916,0.1281036032920672,1.0,2.0,3.0,215.0,215.0,159.0,430.0,1086,214.0,3.379108996539792e-06,37045.0,761.0,1.0,0,257.0
722,604878,HP:0009830,"Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).",1,1.3672673838536906,3974916.4769674763,240.17780519954,0.1660681857014908,0.07918683414226528,0.0,0.0,1.0013531799729365,740.0,-0.5558355700440896,0.12697582562264564,1.0,2.0,1.0,197.0,197.0,195.0,394.0,1086,196.0,3.3791089965397925e-06,34719.0,740.0,1.0,0,225.0
677,610844,HP:0000007,"Our results indicate that ALS5/SPG11/KIAA1840 is the causative gene of a wide spectrum of clinical features, including autosomal recessive axonal Charcot-Marie-Tooth disease",1,1.4422172191655998,13892410.417601885,482.91207751938,0.16311624441598274,0.08353705572325364,0.0,0.0,1.0003534817956876,2830.0,-0.5754734534231797,0.027494888253537627,1.0,2.0,81.0,248.0,248.0,177.0,496.0,5160,247.0,1.5011496554636367e-07,110063.0,2830.0,1.0,0,275.0
723,612988,HP:0000648,"Autosomal-recessive optic neuropathies are rare blinding conditions related to retinal ganglion cell (RGC) and optic-nerve degeneration, for which only mutations in TMEM126A and ACO2 are known.",1,1.4459330513719828,463769.78019291407,272.1489693400312,0.20926321725985889,-0.03531179382683156,0.0,0.0,1.0018281535648994,548.0,-0.7779524143025149,0.07651556599367486,1.0,2.0,1.0,46.0,46.0,46.0,92.0,1004,45.0,3.952428569734674e-06,11468.0,548.0,1.0,0,46.0
724,100850,HP:0000648,"Autosomal-recessive optic neuropathies are rare blinding conditions related to retinal ganglion cell (RGC) and optic-nerve degeneration, for which only mutations in TMEM126A and ACO2 are known.",1,1.3975106584733932,2734620.7222320084,325.60880801119845,0.15137610956292824,0.043748708431425816,0.0,0.0,1.0016339869281046,613.0,-0.7611121163853983,0.1577903592105684,1.0,2.0,2.0,110.0,110.0,108.0,220.0,1004,109.0,3.952428569734674e-06,29598.0,613.0,1.0,0,130.0
725,610502,HP:0009830,"In four families with early-onset recessive optic neuropathy, we identified mutations in RTN4IP1, which encodes a mitochondrial ubiquinol oxydo-reductase.",0,1.439712852733686,399072.1156095985,218.4783302639656,0.2355250787514304,0.1250476779783216,0.0,0.0,0.99830220713073,588.0,-0.7439242508547159,0.05515812494604472,1.0,2.0,2.0,44.0,44.0,43.0,88.0,1088,42.0,3.36671997306624e-06,9584.0,590.0,1.0,0,44.0
726,187270,HP:0002664,"Using CRC and EC genome-wide association series, totalling 13,265 cancer cases and 40,245 controls, we found that the protective allele [G] at one previously-identified CRC polymorphism, rs2736100 near TERT, was associated with EC risk (odds ratio (OR) = 1.08, P = 0.000167); this polymorphism influences the risk of several other cancers.",1,1.3359106102315903,13308465.81815717,248.90731500273625,0.14821247890763742,0.07673672570581681,0.0,0.0,1.000728862973761,1373.0,-0.34113106850631714,0.0893353491641168,1.0,2.0,4.0,539.0,539.0,8.0,1078.0,1542,538.0,1.6778973932186097e-06,84143.0,1373.0,1.0,0,761.0
727,614427,HP:0002664,"Another polymorphism, rs12970291 near gene TSHZ1, was associated with both CRC and EC (OR = 1.26, P = 4.82 x 10(-8)), with the alleles showing opposite effects on the risks of the two cancers",0,1.45356463693872,183431.23611625767,309.53529738743754,0.2761366411231755,0.32318269268991856,0.0,0.0,0.9987389659520808,792.0,-0.8046029237377654,0.022485793514409776,1.0,2.0,37.0,22.0,22.0,22.0,44.0,1544,20.0,1.6778973932186097e-06,7079.0,794.0,1.0,0,20.0
728,601445,HP:0002664,"In this study, we used quantitative proteomic analyses to compare a highly metastatic cancer cell line and a parental breast cancer cell line; and observed that NDUFB9, an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (complex I), was down-regulated in highly metastatic breast cancer cells.",0,1.3775665926748055,3470506.9437554074,264.34836848931667,0.1666981102255112,0.09648619947944047,0.0,0.0,0.9989177489177488,923.0,-0.66780091015097,0.0801053001053001,1.0,2.0,31.0,144.0,144.0,120.0,288.0,1544,142.0,1.6778973932186097e-06,34233.0,925.0,1.0,0,150.0
729,610957,HP:0000618,"Thus, mutated YARS2 aggravates mitochondrial dysfunctions associated with the m.11778G&gt;A mutation, exceeding the threshold for the expression of blindness phenotype.",0,1.3324831470159064,951531.1731282944,141.49598393574297,0.1929580734652556,0.08262506129159564,0.0,0.0,0.9973821989528796,381.0,-0.5468692539552885,0.16971279373368145,1.0,2.0,4.0,127.0,127.0,89.0,254.0,500,125.0,1.587276392438215e-05,12415.0,383.0,1.0,0,170.0
730,615684,HP:0008209,"More recently, evidence has indicated that variations in HFM1 gene could be causative for primary ovarian insufficiency (POI), also known as premature ovarian failure.",1,1.3593810444874277,19434.36349206349,59.70625798212005,0.28476155091177296,0.15595541384021047,0.0,0.0,1.011904761904762,85.0,-0.7451839297935939,0.3081232492997199,1.0,2.0,1.0,27.0,27.0,27.0,54.0,116,26.0,0.0002872737719046251,1100.0,85.0,1.0,0,37.0
731,615684,HP:0003745,The aim of this study was to investigate the association between HFM1 gene variants and sporadic POI in Chinese women.,0,1.3275881555153708,25248.134343434347,44.569200779727105,0.3395244589773393,0.12438384241987502,0.0,0.0,0.9918699186991872,122.0,-0.6681076135379582,0.13335955940204566,1.0,2.0,5.0,25.0,25.0,23.0,50.0,196,23.0,0.00010850694444444445,1017.0,124.0,1.0,0,30.0
732,300579,HP:0000750,"Our data, with previously published reports, suggest that duplications involving SHROOM4 and DGKK may represent a new syndromic X-linked ID critical region associated with mild to severe ID, speech delay +/- dysarthria, attention deficit disorder, precocious puberty, constipation, and motor delay.",0,1.412931282793466,4629063.736041736,385.6107175989086,0.14915626783131689,0.011832059386555259,0.0,0.0,1.0011668611435238,858.0,-0.6964470453537406,0.11200506999806883,1.0,2.0,1.0,125.0,125.0,125.0,250.0,1466,124.0,1.8561278203862235e-06,41179.0,858.0,1.0,0,127.0
733,300579,HP:0001270,"Our data, with previously published reports, suggest that duplications involving SHROOM4 and DGKK may represent a new syndromic X-linked ID critical region associated with mild to severe ID, speech delay +/- dysarthria, attention deficit disorder, precocious puberty, constipation, and motor delay.",0,1.39612711126954,3595954.980045118,308.8272504145937,0.1594201054292647,0.04681346343622075,0.0,0.0,0.9986282578875172,728.0,-0.6731144271028352,0.12212638818422684,1.0,2.0,1.0,125.0,125.0,126.0,250.0,1208,123.0,2.7320538214602825e-06,32496.0,730.0,1.0,0,143.0
736,600734,HP:0003745,"Somatic mutations in four genes (KCNJ5, ATP1A1, ATP2B3 and CACNA1D), differently implicated in intracellular ion homeostasis, have been identified in nearly 60% of the sporadic APAs.",0,1.2704447632711622,144477.20454545456,59.925925925925924,0.249038468443406,0.058829802181857835,0.0,0.0,0.9956709956709956,230.0,-0.4067635559712982,0.129123749813405,1.0,2.0,20.0,74.0,74.0,2.0,148.0,192,73.0,5.406574394463668e-05,3460.0,232.0,1.0,0,83.0
740,300014,HP:0003745,"Somatic mutations in four genes (KCNJ5, ATP1A1, ATP2B3 and CACNA1D), differently implicated in intracellular ion homeostasis, have been identified in nearly 60% of the sporadic APAs.",0,1.2718270808578058,87161.9142857143,57.30555155010815,0.2638046929237242,-0.057228530812730015,0.0,0.0,0.9940828402366864,168.0,-0.4786106382749185,0.1706230421162548,1.0,2.0,11.0,62.0,62.0,20.0,124.0,192,60.0,0.00010850694444444445,2451.0,170.0,1.0,0,65.0
744,114206,HP:0003745,"Somatic mutations in four genes (KCNJ5, ATP1A1, ATP2B3 and CACNA1D), differently implicated in intracellular ion homeostasis, have been identified in nearly 60% of the sporadic APAs.",0,1.29046319126453,194690.26666666672,73.8835386338186,0.23299679842736384,0.22671571385613884,0.0,0.0,0.9957805907172996,236.0,-0.31189723174840456,0.1530333652448321,1.0,2.0,14.0,88.0,88.0,2.0,176.0,192,87.0,4.959333465582226e-05,4316.0,238.0,1.0,0,105.0
746,600734,HP:0001250,"Germline mutations in KCNJ5 and CACNA1H cause FH-III and FH-IV, respectively, while germline mutations in CACNA1D cause the rare PASNA syndrome, featuring primary aldosteronism seizures and neurological abnormalities.",0,1.447171070339326,2991464.060165789,340.21297491039434,0.1958663669659084,0.09221851217170564,0.0,0.0,1.0005938242280286,1685.0,-0.6368220458831,0.029778611050416917,1.0,2.0,3.0,132.0,132.0,72.0,264.0,3100,131.0,4.156965348783943e-07,42249.0,1685.0,1.0,0,113.0
747,114206,HP:0001250,"Germline mutations in KCNJ5 and CACNA1H cause FH-III and FH-IV, respectively, while germline mutations in CACNA1D cause the rare PASNA syndrome, featuring primary aldosteronism seizures and neurological abnormalities.",1,1.4452632449130052,5131509.341572771,465.6111050102951,0.16666915673369906,0.0456015717639894,0.0,0.0,1.0005917159763311,1691.0,-0.6884046587977308,0.042114361097211485,1.0,2.0,2.0,139.0,139.0,132.0,278.0,3100,138.0,4.156965348783941e-07,60177.0,1691.0,1.0,0,126.0
748,182465,HP:0003745,"Here we describe four additional individuals from three families, comprising two sporadic subjects (one of whom had no limb malformation) and a mildly affected female with a severely affected son.",0,1.3477930424869269,851003.3673520923,140.28254847645428,0.20193620822776,0.05262584921542986,0.0,0.0,0.99781181619256,456.0,-0.6236374836537921,0.10373329001557527,1.0,2.0,27.0,96.0,96.0,96.0,192.0,240,95.0,7.631024693995909e-06,10856.0,458.0,1.0,0,109.0
826,171834,HP:0002664,"We find mutually exclusive associations between EECTGs and somatic mutations in mutated genes, such as PIK3CA in breast cancer.",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
840,617670,HP:0030078,We show that the meiosis-related EECTG (MEIOB) and its nearby CT-ncRNA have a role in tumorigenesis in lung adenocarcinoma.,0,1.1794871794871795,2292.157575757576,14.322689075630253,0.468264263303505,0.4380534926817831,0.0,0.0,0.981132075471698,52.0,-0.6329465644548712,0.13487071977638015,1.0,2.0,11.0,13.0,13.0,9.0,26.0,50,11.0,0.0007716049382716049,193.0,54.0,1.0,0,15.0
843,616101,HP:0001251,"Recently, mutations in transmembrane protein 240 (TMEM240) were identified as the cause of spinocerebellar ataxia type 21 (SCA21) in several French families.",1,1.4474916967687816,1225680.9043659184,337.5320063059785,0.19417590730314285,0.15365892074814386,0.0,0.0,1.0011325028312572,884.0,-0.7358277735728745,0.05647140814684616,1.0,2.0,2.0,70.0,70.0,69.0,140.0,1626,69.0,1.5092152684290275e-06,22040.0,884.0,1.0,0,66.0
841,616101,HP:0001251,Here we used Sanger sequencing to detect mutations in exons of TMEM240 in 340 unrelated probands with spinocerebellar ataxia for whom commonly known causative mutations have been excluded (96 probands of autosomal dominant spinocerebellar ataxia families and 244 patients with sporadic spinocerebellar ataxia).,1,1.4474916967687816,1225680.9043659184,337.5320063059785,0.19417590730314285,0.15365892074814386,0.0,0.0,1.0011325028312572,884.0,-0.7358277735728745,0.05647140814684616,1.0,2.0,2.0,70.0,70.0,69.0,140.0,1626,69.0,1.5092152684290275e-06,22040.0,884.0,1.0,0,66.0
845,616101,HP:0003745,Here we used Sanger sequencing to detect mutations in exons of TMEM240 in 340 unrelated probands with spinocerebellar ataxia for whom commonly known causative mutations have been excluded (96 probands of autosomal dominant spinocerebellar ataxia families and 244 patients with sporadic spinocerebellar ataxia).,0,1.2819705882352939,76482.00952380952,53.855003706449224,0.2736120175943953,-0.03298918807995856,0.0,0.0,0.9940119760479044,166.0,-0.5157347113400761,0.16203307670373535,1.0,2.0,9.0,55.0,55.0,18.0,110.0,200,54.0,0.00010850694444444445,2273.0,168.0,1.0,0,56.0
846,612641,HP:0004839,"Genotype-phenotype correlation was clarified after combined analysis of the cases and the literature review; anemia was most severe in HS patients with mutations on the ANK1 spectrin-binding domain (p &lt; 0.05), and SPTB mutations in HS patients spared the tetramerization domain in which mutations of hereditary elliptocytosis and pyropoikilocytosis are located.",0,1.3050639788239915,1971.0,103.37012987012987,0.5597263124966748,-0.0521598458217791,0.0,0.0,0.9957264957264956,233.0,-0.7756651455690159,0.015784688125113657,1.0,2.0,130.0,3.0,3.0,3.0,6.0,264,2.0,1.8579072532699166e-05,434.0,235.0,1.0,0,3.0
847,182870,HP:0004839,"Genotype-phenotype correlation was clarified after combined analysis of the cases and the literature review; anemia was most severe in HS patients with mutations on the ANK1 spectrin-binding domain (p &lt; 0.05), and SPTB mutations in HS patients spared the tetramerization domain in which mutations of hereditary elliptocytosis and pyropoikilocytosis are located.",0,1.4960650406504064,833.0,121.4430894308943,0.5726324760021334,0.6257065140695361,0.0,0.0,1.0080645161290325,125.0,-0.9982586782040264,0.030838709677419363,1.0,2.0,7.0,2.0,2.0,2.0,4.0,232,2.0,6.503642039542144e-05,239.0,125.0,1.0,0,2.0
848,615302,HP:0001249,ADAT3-related intellectual disability has been recently described in 24 individuals from eight Saudi families who had cognitive impairment and strabismus.,1,1.4095745255887673,27820052.429844294,599.5058724503778,0.12446931825453905,0.07284992928468242,0.0,0.0,1.0005296610169492,1889.0,-0.6318204533107074,0.08182800064602383,1.0,2.0,2.0,286.0,286.0,279.0,572.0,3204,285.0,3.891642658474498e-07,145917.0,1889.0,1.0,0,289.0
852,615302,HP:0000486,ADAT3-related intellectual disability has been recently described in 24 individuals from eight Saudi families who had cognitive impairment and strabismus.,1,1.370062762252915,16595761.060064932,416.98775892178236,0.12302053686356115,0.11552038327366056,0.0,0.0,1.000892857142857,1121.0,-0.6101490339200247,0.14183127309799926,1.0,2.0,2.0,284.0,284.0,272.0,568.0,1668,283.0,1.434257234034924e-06,89036.0,1121.0,1.0,0,352.0
850,615302,HP:0001249,ADAT3-related intellectual disability is an important recognizable cause of intellectual disability in Arabia,1,1.4095745255887673,27820052.429844294,599.5058724503778,0.12446931825453905,0.07284992928468242,0.0,0.0,1.0005296610169492,1889.0,-0.6318204533107074,0.08182800064602383,1.0,2.0,2.0,286.0,286.0,279.0,572.0,3204,285.0,3.891642658474498e-07,145917.0,1889.0,1.0,0,289.0
853,607444,HP:0000007,The human Shwachman-Diamond syndrome (SDS) is an autosomal recessive disease caused by mutations in a highly conserved ribosome assembly factor SBDS.,1,1.4354458637068714,14840273.456671508,453.10416666666674,0.16425939762051428,0.1918041588367784,0.0,0.0,1.000348796651552,2868.0,-0.5821828464040778,0.028553165220157817,1.0,2.0,4.0,284.0,284.0,171.0,568.0,5160,283.0,1.5011496554636367e-07,117390.0,2868.0,1.0,0,246.0
854,156845,HP:0000568,"Here we show that the microphthalmia-associated transcription factor, MITF, which plays a central role in the development and function of RPE cells, regulates the expression of two visual cycle genes, Rlbp1 which encodes retinaldehyde binding protein-1 (RLBP1), and Rdh5, which encodes retinol dehydrogenase-5 (RDH5).",0,1.3348988367714958,1528330.9464285714,157.64666666666662,0.1681262711069704,0.023169264425948813,0.0,0.0,1.0023584905660377,425.0,-0.4145555313342822,0.18526082130965602,1.0,2.0,10.0,165.0,165.0,26.0,330.0,450,164.0,1.957866708434489e-05,16692.0,425.0,1.0,0,239.0
858,180090,HP:0000568,"Here we show that the microphthalmia-associated transcription factor, MITF, which plays a central role in the development and function of RPE cells, regulates the expression of two visual cycle genes, Rlbp1 which encodes retinaldehyde binding protein-1 (RLBP1), and Rdh5, which encodes retinol dehydrogenase-5 (RDH5).",0,1.2718579807289483,896371.8309523809,121.28484364604124,0.18484646457488435,0.2460210348299787,0.0,0.0,0.9974554707379136,392.0,-0.5692472066154929,0.15274925407835085,1.0,2.0,27.0,121.0,121.0,48.0,242.0,504,119.0,1.9406547769217335e-05,11826.0,394.0,1.0,0,133.0
859,601617,HP:0000568,"Here we show that the microphthalmia-associated transcription factor, MITF, which plays a central role in the development and function of RPE cells, regulates the expression of two visual cycle genes, Rlbp1 which encodes retinaldehyde binding protein-1 (RLBP1), and Rdh5, which encodes retinol dehydrogenase-5 (RDH5).",0,1.3283323546682326,181468.27942612945,82.50829420970265,0.244704648187446,0.12083549205821212,0.0,0.0,0.9966329966329966,296.0,-0.7079217558200539,0.10487424581384312,1.0,2.0,10.0,58.0,58.0,30.0,116.0,470,56.0,1.9406547769217335e-05,4641.0,298.0,1.0,0,54.0
860,156845,HP:0000546,"Third, the retinal degeneration associated with the disruption of the visual cycle in Mitf-deficient mice can be partially corrected both structurally and functionally by an exogenous supply of 9-cis-retinal.",0,1.301380055202208,772614.4537545787,105.59248858447486,0.2024371145771036,0.14705376658817168,0.0,0.0,0.9976190476190476,419.0,-0.4469169512048803,0.1272254269878973,1.0,2.0,14.0,155.0,155.0,11.0,310.0,440,153.0,2.0474601257140515e-05,11248.0,421.0,1.0,0,164.0
864,615949,HP:0002664,"Recently, TMEM98 is supposed to be of great value for the discoveries of anti-tumor drugs.",0,1.4079176881958122,144935.04491366702,171.52457623328414,0.3376912605368474,0.4255999306236871,0.0,0.0,0.9987515605493134,800.0,-0.5725351438718203,0.017241540343896813,1.0,2.0,109.0,29.0,29.0,28.0,58.0,1544,27.0,1.67789739321861e-06,5538.0,802.0,1.0,0,27.0
861,615949,HP:0002664,"Clinical lung cancer tissue and normal tissue were collected, and the mRNA expression of TMEM98 in cancer tissue was significantly higher than that in normal tissue.",0,1.4079176881958122,144935.04491366702,171.52457623328414,0.3376912605368474,0.4255999306236871,0.0,0.0,0.9987515605493134,800.0,-0.5725351438718203,0.017241540343896813,1.0,2.0,109.0,29.0,29.0,28.0,58.0,1544,27.0,1.67789739321861e-06,5538.0,802.0,1.0,0,27.0
867,615949,HP:0002664,"To conclude, our results indicated that siRNA-TMEM98 inhibited the invasion and migration of lung cancer cells, which can be considered as a novel target for NSCLC treatment.",0,1.4079176881958122,144935.04491366702,171.52457623328414,0.3376912605368474,0.4255999306236871,0.0,0.0,0.9987515605493134,800.0,-0.5725351438718203,0.017241540343896813,1.0,2.0,109.0,29.0,29.0,28.0,58.0,1544,27.0,1.67789739321861e-06,5538.0,802.0,1.0,0,27.0
870,604061,HP:0002664,"Among them four novel fusion genes SEPT9/CYHR, IGF1R/TTC23, SYT8/TNNI2 and CASZ1/DFFA were validated and characterized in 48 formalin-fixed paraffin-embedded (FFPE) specimens of bladder cancer.",0,1.401169031996131,2150343.770653287,278.95674947620466,0.17441469573484886,0.0037803444929031256,0.0,0.0,0.9988584474885844,875.0,-0.7085486973439081,0.0683499684999193,1.0,2.0,24.0,100.0,100.0,99.0,200.0,1544,98.0,1.6778973932186097e-06,26255.0,877.0,1.0,0,96.0
879,147370,HP:0002664,"Among them four novel fusion genes SEPT9/CYHR, IGF1R/TTC23, SYT8/TNNI2 and CASZ1/DFFA were validated and characterized in 48 formalin-fixed paraffin-embedded (FFPE) specimens of bladder cancer.",0,1.3712605042016808,6458880.601129428,276.9840442454054,0.14996118780434278,0.13345480149572236,0.0,0.0,0.9989837398373984,983.0,-0.5900672374890614,0.09637860591803887,1.0,2.0,15.0,212.0,212.0,212.0,424.0,1544,210.0,1.6778973932186097e-06,46707.0,985.0,1.0,0,268.0
880,191043,HP:0002664,"Among them four novel fusion genes SEPT9/CYHR, IGF1R/TTC23, SYT8/TNNI2 and CASZ1/DFFA were validated and characterized in 48 formalin-fixed paraffin-embedded (FFPE) specimens of bladder cancer.",0,1.384680696093315,3418974.5619484223,228.6154980799064,0.16914510631820304,0.21383736947671755,0.0,0.0,0.9989189189189188,924.0,-0.619457180166429,0.06970988266884595,1.0,2.0,25.0,150.0,150.0,128.0,300.0,1544,148.0,1.6778973932186106e-06,29855.0,926.0,1.0,0,164.0
882,191043,HP:0002664,"In contrast, the SYT8/TNNI2 fusion transcript resulting from transcription-induced chimerism by read-through mechanisms was a rather common and tumor-specific event occurring in 37.5% (18/48) of the UC specimens.",0,1.384680696093315,3418974.5619484223,228.6154980799064,0.16914510631820304,0.21383736947671755,0.0,0.0,0.9989189189189188,924.0,-0.619457180166429,0.06970988266884595,1.0,2.0,25.0,150.0,150.0,128.0,300.0,1544,148.0,1.6778973932186106e-06,29855.0,926.0,1.0,0,164.0
909,164870,HP:0002664,"We found evidence for at least five independent causal variants, each associated with different phenotype sets, including estrogen receptor (ER(+) or ER(-)) and human ERBB2 (HER2(+) or HER2(-)) tumor subtypes, mammographic density and tumor grade.",1,1.4721661571960971,183488.34663624788,198.3850960971584,0.3314920934853949,0.09201373930954154,0.0,0.0,1.0012453300124533,804.0,-0.6686948012217765,0.019448213478064226,1.0,2.0,1.0,33.0,33.0,33.0,66.0,1542,33.0,1.6778973932186097e-06,6278.0,804.0,1.0,0,33.0
925,133430,HP:0002664,"The best candidate causal variants for ER(-) tumors lie in four separate enhancer elements, and their risk alleles reduce expression of ESR1, RMND1 and CCDC170, whereas the risk alleles of the strongest candidates for the remaining independent causal variant disrupt a silencer element and putatively increase ESR1 and RMND1 expression.",0,1.4122127220908376,2151868.453707986,232.6757750407146,0.1890807510997476,0.016727864277858145,0.0,0.0,1.0011074197120708,904.0,-0.6512926783478565,0.06466400101921814,1.0,2.0,3.0,131.0,131.0,86.0,262.0,1506,130.0,1.6778973932186103e-06,26393.0,904.0,1.0,0,119.0
926,614917,HP:0002664,"The best candidate causal variants for ER(-) tumors lie in four separate enhancer elements, and their risk alleles reduce expression of ESR1, RMND1 and CCDC170, whereas the risk alleles of the strongest candidates for the remaining independent causal variant disrupt a silencer element and putatively increase ESR1 and RMND1 expression.",0,1.392023699165693,2193517.7085225703,239.08428583009083,0.18360106134098966,0.1807059649475568,0.0,0.0,0.9988888888888888,899.0,-0.6489233274418056,0.0664076951535331,1.0,2.0,30.0,127.0,127.0,110.0,254.0,1544,125.0,1.6778973932186097e-06,26925.0,901.0,1.0,0,121.0
927,616174,HP:0001159,"As the striking syndactyly observed in the present case is typical for FLPIS, we suggest CREBBP analysis in saliva samples for FLPIS syndrome cases in which no causal CKAP2L variant is detected",1,1.3444872225931768,3747306.738888888,243.98352136649143,0.14389292832829798,-0.02759842414396416,0.0,0.0,1.0018761726078798,534.0,-0.5590159739761833,0.21314585660981933,1.0,2.0,1.0,190.0,190.0,178.0,380.0,674,189.0,8.753194916144393e-06,30333.0,534.0,1.0,0,327.0
928,600140,HP:0001159,"As the striking syndactyly observed in the present case is typical for FLPIS, we suggest CREBBP analysis in saliva samples for FLPIS syndrome cases in which no causal CKAP2L variant is detected",1,1.3485670229542666,8626148.859126983,272.2123064890852,0.13998261086004224,0.12442621206150392,0.0,0.0,1.001019367991845,982.0,-0.2590926556640164,0.12509368427827292,1.0,2.0,5.0,336.0,336.0,8.0,672.0,674,336.0,2.3962656595960853e-06,60254.0,982.0,1.0,0,354.0
884,164870,HP:0002664,80.5 % of luminal-type tumours developed bone metastasis as opposed to 41.7 % of basal and 55.6 % of HER2-like tumours.,1,1.4721661571960971,183488.34663624788,198.3850960971584,0.3314920934853949,0.09201373930954154,0.0,0.0,1.0012453300124533,804.0,-0.6686948012217765,0.019448213478064226,1.0,2.0,1.0,33.0,33.0,33.0,66.0,1542,33.0,1.6778973932186097e-06,6278.0,804.0,1.0,0,33.0
538,600960,HP:0002664,"A novel 15-gene signature identified 82.4 % of the tumours with bone metastasis, 85.2 % of the tumours which had bone metastasis as first site of metastasis and 100 % of the ones with bone metastasis only (p 9.99e-09), in the training set.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
929,209901,HP:0002664,"The expression levels of the up-regulated genes (NAT1, BBS1 and PH-4) were also found to be correlated to epithelial to mesenchymal transition status of the tumour.",0,1.3663354700854702,7086855.540839718,281.32691999889613,0.14858939866306706,0.11642759725587072,0.0,0.0,0.9990069513406156,1006.0,-0.5874615261186367,0.10110575180088588,1.0,2.0,12.0,235.0,235.0,224.0,470.0,1544,233.0,1.67789739321861e-06,51314.0,1008.0,1.0,0,272.0
932,300828,HP:0000718,"Individuals with PTCHD1 deletion show symptoms of ADHD, sleep disruption, hypotonia, aggression, ASD, and ID.",0,1.3346465542738837,1043135.2952380951,135.13292579654916,0.19151049032412548,0.07152284963290073,0.0,0.0,1.0025773195876289,389.0,-0.3397205945195329,0.17394588291416002,1.0,2.0,1.0,171.0,171.0,8.0,342.0,376,170.0,2.450740123517302e-05,13127.0,389.0,1.0,0,194.0
934,300828,HP:0000752,"TRN-restricted deletion of Ptchd1 leads to attention deficits and hyperactivity, both of which are rescued by pharmacological augmentation of SK channel activity.",0,1.3487172360854691,3221753.184343435,224.85172050972287,0.15632943844874328,0.06266964016343797,0.0,0.0,1.0017152658662094,584.0,-0.533561022424736,0.17411123381658405,1.0,2.0,1.0,191.0,191.0,201.0,382.0,766,190.0,6.781684027777778e-06,29640.0,584.0,1.0,0,228.0
930,300828,HP:0000718,"Global Ptchd1 deletion recapitulates learning impairment, hyper-aggression, and motor defects, all of which are insensitive to SK pharmacological targeting and not found in the TRN-restricted deletion mouse.",0,1.3346465542738837,1043135.2952380951,135.13292579654916,0.19151049032412548,0.07152284963290073,0.0,0.0,1.0025773195876289,389.0,-0.3397205945195329,0.17394588291416002,1.0,2.0,1.0,171.0,171.0,8.0,342.0,376,170.0,2.450740123517302e-05,13127.0,389.0,1.0,0,194.0
935,606151,HP:0001425,"Bardet Biedl syndrome (BBS) is a multisystem genetically heterogeneous ciliopathy that most commonly leads to obesity, photoreceptor degeneration, digit anomalies, genito-urinary abnormalities, as well as cognitive impairment with autism, among other features.",0,1.3163163281373012,1064593.6309523808,115.29840438199571,0.2067306802427935,0.09903095912423,0.0,0.0,0.997867803837953,468.0,-0.3132181558851957,0.12414825568207595,1.0,2.0,8.0,191.0,191.0,2.0,382.0,496,189.0,1.6259105098855357e-05,13683.0,470.0,1.0,0,221.0
951,606151,HP:0001513,"Bardet Biedl syndrome (BBS) is a multisystem genetically heterogeneous ciliopathy that most commonly leads to obesity, photoreceptor degeneration, digit anomalies, genito-urinary abnormalities, as well as cognitive impairment with autism, among other features.",1,1.3419405320813769,3568875.757199088,233.41470845331142,0.15398705607858534,0.07816370434918507,0.0,0.0,1.0017482517482517,573.0,-0.43657230252937135,0.1933694577673636,1.0,2.0,2.0,219.0,219.0,218.0,438.0,704,218.0,8.025102520684701e-06,31689.0,573.0,1.0,0,274.0
955,606151,HP:0000717,"Bardet Biedl syndrome (BBS) is a multisystem genetically heterogeneous ciliopathy that most commonly leads to obesity, photoreceptor degeneration, digit anomalies, genito-urinary abnormalities, as well as cognitive impairment with autism, among other features.",0,1.3275355566771494,890112.5420634922,136.1245893510197,0.1838644820143844,0.040327869175239735,0.0,0.0,0.997282608695652,367.0,-0.33227061080608217,0.17908271474019088,1.0,2.0,4.0,142.0,142.0,31.0,284.0,294,140.0,2.029056083110137e-05,12159.0,369.0,1.0,0,168.0
956,614477,HP:0000007,Mutations in C8ORF37 were previously associated with severe autosomal recessive retinal dystrophies (retinitis pigmentosa RP64 and cone-rod dystrophy CORD16) but not BBS.,1,1.4427710886910268,16310866.648598265,518.6648448043185,0.1654228737304111,0.2607271819824889,0.0,0.0,1.0003538570417552,2827.0,-0.5585460486564398,0.029269121861255493,1.0,2.0,19.0,244.0,244.0,243.0,488.0,5160,243.0,1.5011496554636367e-07,116917.0,2827.0,1.0,0,235.0
963,606151,HP:0000007,Mutations in C8ORF37 were previously associated with severe autosomal recessive retinal dystrophies (retinitis pigmentosa RP64 and cone-rod dystrophy CORD16) but not BBS.,1,1.4476951697119902,16529860.326488595,570.2214669051879,0.16530792190000526,0.13343289512387654,0.0,0.0,1.0003571428571427,2801.0,-0.5644242727269968,0.029600652828071606,1.0,2.0,19.0,220.0,220.0,219.0,440.0,5160,219.0,1.5011496554636367e-07,116076.0,2801.0,1.0,0,212.0
968,616120,HP:0001251,We identified a homozygous frameshift mutation in CWF19L1 (c.467delC; p.(P156Hfs*33)) by a combination of linkage analysis and Whole Exome Sequencing in a consanguineous Turkish family with a 9-year-old boy affected by early onset cerebellar ataxia and mild ID.,1,1.4202450557265625,3772942.9883968974,379.3977476660013,0.15716480090809593,0.02204074576895265,0.0,0.0,1.0010706638115632,935.0,-0.7067567662304521,0.0921732757732254,1.0,2.0,1.0,122.0,122.0,119.0,244.0,1626,121.0,1.5092152684290268e-06,40247.0,935.0,1.0,0,111.0
966,616120,HP:0001251,"So far, homozygous or compound heterozygous mutations in CWF19L1 have been identified in two Turkish siblings and a Dutch girl, respectively, affected by cerebellar ataxia and ID.",1,1.4202450557265625,3772942.9883968974,379.3977476660013,0.15716480090809593,0.02204074576895265,0.0,0.0,1.0010706638115632,935.0,-0.7067567662304521,0.0921732757732254,1.0,2.0,1.0,122.0,122.0,119.0,244.0,1626,121.0,1.5092152684290268e-06,40247.0,935.0,1.0,0,111.0
970,606025,HP:0001249,We report a boy with intellectual disability carrying two de novo missense mutations in the last exon of ZBTB20 (Ser616Phe and Gly741Arg; both previously unreported).,1,1.4142738171167184,18553298.580871306,519.8820766494712,0.13400700655418768,0.04301347630209966,0.0,0.0,1.0005359056806002,1867.0,-0.6139481478766079,0.0678645464664957,1.0,2.0,2.0,260.0,260.0,240.0,520.0,3204,259.0,3.8916426584745004e-07,118214.0,1867.0,1.0,0,280.0
976,121011,HP:0000365,"Although there are nearly 100 different causative genes identified for nonsyndromic hearing loss (NSHL), Sanger sequencing-based DNA diagnostics usually only analyses three, namely, GJB2, SLC26A4, and OTOF.",1,1.395883254657124,11360890.773559922,359.9890516043107,0.1442161069048109,0.0490995817099891,0.0,0.0,1.000660501981506,1515.0,-0.6063388048985573,0.07124963487101682,1.0,2.0,7.0,266.0,266.0,150.0,532.0,2474,265.0,6.524672396198986e-07,81713.0,1515.0,1.0,0,305.0
1019,605646,HP:0000365,"Although there are nearly 100 different causative genes identified for nonsyndromic hearing loss (NSHL), Sanger sequencing-based DNA diagnostics usually only analyses three, namely, GJB2, SLC26A4, and OTOF.",1,1.4413226495142712,4479611.427125419,456.96235976102685,0.15949329773347126,0.021256166761706764,0.0,0.0,1.0007358351729212,1360.0,-0.7348599879376381,0.0553207375665498,1.0,2.0,1.0,121.0,121.0,109.0,242.0,2474,120.0,6.524672396198984e-07,51123.0,1360.0,1.0,0,110.0
1027,603681,HP:0000365,"Although there are nearly 100 different causative genes identified for nonsyndromic hearing loss (NSHL), Sanger sequencing-based DNA diagnostics usually only analyses three, namely, GJB2, SLC26A4, and OTOF.",1,1.4852314859225304,328260.8637490036,515.1521901853348,0.2651210704097913,0.0955538076383784,0.0,0.0,1.0007917656373713,1264.0,-0.7858008079976947,0.0170530282530042,1.0,2.0,1.0,26.0,26.0,24.0,52.0,2474,25.0,6.524672396198987e-07,13612.0,1264.0,1.0,0,24.0
1028,606151,HP:0000556,"Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder characterized by retinal dystrophy, polydactyly, obesity, developmental delay, and renal defects.",1,1.3390830838956251,2478853.171987661,198.38579270627952,0.16573883982257498,0.056413130734765976,0.0,0.0,1.0018552875695732,540.0,-0.3999985735777312,0.17797017797017795,1.0,2.0,2.0,216.0,216.0,43.0,432.0,638,215.0,9.765625000000004e-06,25900.0,540.0,1.0,0,247.0
1029,606151,HP:0010442,"Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder characterized by retinal dystrophy, polydactyly, obesity, developmental delay, and renal defects.",1,1.3343968161687203,1959323.2726190481,196.8049858332981,0.15705520720144334,0.04905760041618376,0.0,0.0,1.0023041474654375,435.0,-0.2918283991701828,0.2266751416918269,1.0,2.0,4.0,189.0,189.0,2.0,378.0,428,188.0,2.0290560831101375e-05,21397.0,435.0,1.0,0,280.0
953,606151,HP:0001513,"Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder characterized by retinal dystrophy, polydactyly, obesity, developmental delay, and renal defects.",1,1.3419405320813769,3568875.757199088,233.41470845331142,0.15398705607858534,0.07816370434918507,0.0,0.0,1.0017482517482517,573.0,-0.43657230252937135,0.1933694577673636,1.0,2.0,2.0,219.0,219.0,218.0,438.0,704,218.0,8.025102520684701e-06,31689.0,573.0,1.0,0,274.0
1031,611140,HP:0001249,Here we report six affected individuals from four families with intellectual disability (ID) and neurological and other congenital abnormalities associated with compound heterozygous variants in TELO2.,0,1.4194905713795278,21157404.24974563,606.623507805326,0.1286047419421027,0.03199633863124608,0.0,0.0,1.0005425935973955,1844.0,-0.6614826109296869,0.07505505382975744,1.0,2.0,1.0,242.0,242.0,237.0,484.0,3204,241.0,3.8916426584744994e-07,127537.0,1844.0,1.0,0,284.0
1032,300975,HP:0002664,"Like USP22, USP51 and USP27X are required for normal cell proliferation, and their depletion suppresses tumor growth.",0,1.3627130491198058,3851123.893426212,233.84499585379857,0.16574888198356905,0.15544149012120148,0.0,0.0,0.998952879581152,954.0,-0.6051793592771035,0.07720431991938488,1.0,2.0,44.0,180.0,180.0,127.0,360.0,1544,178.0,1.6778973932186103e-06,35243.0,956.0,1.0,0,222.0
1033,603550,HP:0000365,"Only four genetic midfrequency deafness genes, namely, DFNA10 (EYA4), DFNA8/12 (TECTA), DFNA13 (COL11A2), DFNA44 (CCDC50), have been reported to date.",1,1.4819903620890424,433397.476556911,456.1870115871732,0.2707641577816607,0.10606823910475316,0.0,0.0,1.000788022064618,1270.0,-0.7079162321030428,0.018196484304710138,1.0,2.0,3.0,31.0,31.0,31.0,62.0,2474,30.0,6.524672396198988e-07,14663.0,1270.0,1.0,0,30.0
1034,602574,HP:0000365,"Only four genetic midfrequency deafness genes, namely, DFNA10 (EYA4), DFNA8/12 (TECTA), DFNA13 (COL11A2), DFNA44 (CCDC50), have been reported to date.",1,1.4936783660063004,110406.28956058373,807.5924279170035,0.2939545190951088,-0.01346974284845828,0.0,0.0,1.000801282051282,1249.0,-0.8977674066389171,0.012314980189279628,1.0,2.0,2.0,11.0,11.0,11.0,22.0,2474,10.0,6.524672396198988e-07,9598.0,1249.0,1.0,0,10.0
1035,120290,HP:0000365,"Only four genetic midfrequency deafness genes, namely, DFNA10 (EYA4), DFNA8/12 (TECTA), DFNA13 (COL11A2), DFNA44 (CCDC50), have been reported to date.",1,1.3956614265704324,13298334.249677874,362.33543403366343,0.14396858112237332,0.0644524087677076,0.0,0.0,1.0006600660066007,1516.0,-0.5762750077024534,0.07182963678953648,1.0,2.0,6.0,272.0,272.0,189.0,544.0,2474,271.0,6.52467239619899e-07,82487.0,1516.0,1.0,0,363.0
1036,611051,HP:0000365,"Only four genetic midfrequency deafness genes, namely, DFNA10 (EYA4), DFNA8/12 (TECTA), DFNA13 (COL11A2), DFNA44 (CCDC50), have been reported to date.",1,1.4948431896908738,90764.48704761176,888.222877930477,0.3009770723765981,-0.035380237489050635,0.0,0.0,1.0008025682182986,1247.0,-0.9025263906168108,0.011341505327070685,1.0,2.0,1.0,10.0,10.0,10.0,20.0,2474,9.0,6.524672396198987e-07,8811.0,1247.0,1.0,0,9.0
1037,608752,HP:0000546,"The gene that encodes C1q/TNF-related protein 5 (CTRP5), a secreted protein of the C1q family, is mutated in individuals with late-onset retinal degeneration.",1,1.443557697133966,48901.54500931413,127.30282274802823,0.2860052786582958,0.14924376407423498,0.0,0.0,1.0041666666666669,241.0,-0.7872197448546628,0.08800138312586446,1.0,2.0,2.0,21.0,21.0,20.0,42.0,438,20.0,2.066115702479339e-05,2545.0,241.0,1.0,0,19.0
1040,608752,HP:0001513,Inhibition of CTRP5 action may result in the alleviation of insulin resistance associated with obesity and diabetes,0,1.4010355209205738,77341.3030199359,133.5568181818182,0.3013984158400057,0.2481768524115038,0.0,0.0,0.9973333333333332,374.0,-0.7353261473647883,0.043943262411347515,1.0,2.0,36.0,22.0,22.0,21.0,44.0,706,20.0,8.025102520684701e-06,3098.0,376.0,1.0,0,30.0
1042,121011,HP:0001427,"The variants GJB2 c.235delC, SLC26A4 c.919-2A&gt;G, and mitochondrial variants m.1555A&gt;G and m.1494C&gt;T were assayed using real time PCR.",0,1.2768584655843749,4812.535256410257,47.63069544364507,0.6335475555390582,0.4376510969726404,0.0,0.0,0.9964912280701754,284.0,-0.5111477190468955,0.013544350386455649,1.0,2.0,186.0,7.0,7.0,7.0,14.0,556,6.0,1.2846700325021518e-05,552.0,286.0,1.0,0,7.0
1043,605646,HP:0001427,"The variants GJB2 c.235delC, SLC26A4 c.919-2A&gt;G, and mitochondrial variants m.1555A&gt;G and m.1494C&gt;T were assayed using real time PCR.",0,1.3145218221834645,3380.8797036297033,48.14634146341464,0.4934717696649621,0.2283137742800292,0.0,0.0,0.9923076923076924,129.0,-0.6525586500306579,0.04615384615384616,1.0,2.0,47.0,7.0,7.0,7.0,14.0,116,6.0,6.503642039542144e-05,393.0,131.0,1.0,0,7.0
1006,121011,HP:0000365,The most frequent hearing loss associated allele detected in this population was the 235delC variant in GJB2 gene.,1,1.395883254657124,11360890.773559922,359.9890516043107,0.1442161069048109,0.0490995817099891,0.0,0.0,1.000660501981506,1515.0,-0.6063388048985573,0.07124963487101682,1.0,2.0,7.0,266.0,266.0,150.0,532.0,2474,265.0,6.524672396198986e-07,81713.0,1515.0,1.0,0,305.0
1044,608296,HP:0002664,"Taken all together, these findings provide convincing evidence implicating FIBP aberrations in the newly recognized overgrowth syndrome and expand the associated phenotypes to include possible Wilms tumor predisposition.",1,1.3863180381098863,5267874.97775419,267.33301387105223,0.15662623240053247,0.09236697424932692,0.0,0.0,1.001027749229188,974.0,-0.5960670235552136,0.09065718970731304,1.0,2.0,2.0,202.0,202.0,181.0,404.0,1542,201.0,1.6778973932186103e-06,42958.0,974.0,1.0,0,239.0
1046,611223,HP:0001287,"Here, we have performed a prospective nationwide genetic association study using the Human Exome BeadChip and identified gene variants in encoding dynactin 4 (DCTN4), retinoic acid early transcript 1E (RAET1E), and V-akt murine thymoma viral oncogene homolog 3 (AKT3) to be associated with unfavourable outcome in patients with pneumococcal meningitis.",0,1.256103004770806,65215.1619047619,45.15769230769231,0.30194319564604555,0.4106779758190163,0.0,0.0,0.9956521739130436,229.0,-0.4226944386190192,0.08055712403538491,1.0,2.0,45.0,55.0,55.0,16.0,110.0,210,53.0,3.460207612456747e-05,2140.0,231.0,1.0,0,56.0
1048,611223,HP:0001287,"No clinical replication cohort is available, so we validated the role of one of these targets, AKT3, in a pneumococcal meningitis mouse model.",0,1.256103004770806,65215.1619047619,45.15769230769231,0.30194319564604555,0.4106779758190163,0.0,0.0,0.9956521739130436,229.0,-0.4226944386190192,0.08055712403538491,1.0,2.0,45.0,55.0,55.0,16.0,110.0,210,53.0,3.460207612456747e-05,2140.0,231.0,1.0,0,56.0
1050,613622,HP:0001250,"We identified a homozygous missense mutation, c.1308 G-A (p.V421M) in FOXRED1 in a patient who presented with epilepsy and severe psychomotor retardation.",1,1.4237491876359332,16082413.193530798,560.1865437788018,0.13905344152518476,0.012057839724158937,0.0,0.0,1.0005662514156286,1767.0,-0.6420731573778296,0.0683424119426173,1.0,2.0,1.0,217.0,217.0,217.0,434.0,3100,216.0,4.156965348783941e-07,106632.0,1767.0,1.0,0,238.0
1051,612012,HP:0001258,"Complex recessive spastic paraplegias have in the past been frequently associated with mutations in SPG11 (spatacsin), ZFYVE26/SPG15, SPG7 (paraplegin) and a handful of other rare genes, but many cases remain genetically undefined.",1,1.3364456300813008,431481.7178571428,123.28310502283104,0.19619109822108946,0.2026562167625728,0.0,0.0,1.0037735849056604,266.0,-0.2245420647893024,0.2303872889771599,1.0,2.0,5.0,117.0,117.0,2.0,234.0,240,117.0,4.627701420704336e-05,8120.0,266.0,1.0,0,150.0
1053,602783,HP:0001258,"Complex recessive spastic paraplegias have in the past been frequently associated with mutations in SPG11 (spatacsin), ZFYVE26/SPG15, SPG7 (paraplegin) and a handful of other rare genes, but many cases remain genetically undefined.",1,1.3391956549851285,457745.8119047621,122.11247534516764,0.19556328431644945,0.2298701050106133,0.0,0.0,1.003472222222222,289.0,-0.2377118670310493,0.20590638216070745,1.0,2.0,3.0,120.0,120.0,4.0,240.0,240,120.0,3.4602076124567484e-05,8569.0,289.0,1.0,0,166.0
1059,610844,HP:0001258,"The SPG11 gene was first analysed, revealing homozygous or compound heterozygous mutations in 30/97 (30.9%) of probands, the largest SPG11 series reported to date, and by far the most common cause of complex spastic paraplegia in the UK, with severe and progressive clinical features and other neurological manifestations, linked with magnetic resonance imaging defects.",1,1.3532349196243834,686474.1261904761,134.98833333333334,0.1963293848500352,0.11323700453192065,0.0,0.0,1.002710027100271,370.0,-0.3530058694085728,0.16033106277008716,1.0,2.0,3.0,120.0,120.0,120.0,240.0,240,120.0,1.5872763924382153e-05,10945.0,370.0,1.0,0,138.0
1052,612012,HP:0001258,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",1,1.3364456300813008,431481.7178571428,123.28310502283104,0.19619109822108946,0.2026562167625728,0.0,0.0,1.0037735849056604,266.0,-0.2245420647893024,0.2303872889771599,1.0,2.0,5.0,117.0,117.0,2.0,234.0,240,117.0,4.627701420704336e-05,8120.0,266.0,1.0,0,150.0
1055,602783,HP:0001258,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",1,1.3391956549851285,457745.8119047621,122.11247534516764,0.19556328431644945,0.2298701050106133,0.0,0.0,1.003472222222222,289.0,-0.2377118670310493,0.20590638216070745,1.0,2.0,3.0,120.0,120.0,4.0,240.0,240,120.0,3.4602076124567484e-05,8569.0,289.0,1.0,0,166.0
1061,610513,HP:0001258,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",1,1.350270434430497,529638.1059523809,118.18910256410255,0.1997383177972868,0.2264550187256149,0.0,0.0,1.002832861189802,354.0,-0.29369195047839297,0.15004561386661544,1.0,2.0,13.0,120.0,120.0,10.0,240.0,240,120.0,1.810774105930285e-05,9375.0,354.0,1.0,0,137.0
1062,126375,HP:0001258,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",0,1.3060222025739268,329811.54047619045,105.10062189054726,0.2074724414520201,0.12119880148413298,0.0,0.0,0.996078431372549,254.0,-0.2750650062094168,0.2077512254901961,1.0,2.0,7.0,110.0,110.0,11.0,220.0,242,108.0,5.486968449931413e-05,6781.0,256.0,1.0,0,144.0
1063,602783,HP:0009830,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",1,1.3763118685802538,3123655.9256279664,236.70487212178668,0.16890008287873895,0.14293798768439442,0.0,0.0,1.0014064697609002,712.0,-0.6179218977186303,0.12052971759983565,1.0,2.0,1.0,168.0,168.0,125.0,336.0,1086,167.0,3.3791089965397925e-06,30508.0,712.0,1.0,0,206.0
1064,610513,HP:0009830,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",1,1.357849160288812,3668466.654129205,210.16461255135292,0.16846016755622245,0.0958946154416598,0.0,0.0,1.0012886597938144,777.0,-0.5486877730568404,0.11399912430840264,1.0,2.0,3.0,228.0,228.0,99.0,456.0,1086,227.0,3.379108996539792e-06,34368.0,777.0,1.0,0,275.0
1065,607998,HP:0009830,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",1,1.4050955840503532,1451582.9734809091,225.59058688627124,0.18809514752755974,0.0810567687076939,0.0,0.0,1.0015432098765429,649.0,-0.658580568303073,0.09514637904468412,1.0,2.0,3.0,101.0,101.0,97.0,202.0,1086,100.0,3.3791089965397925e-06,20007.0,649.0,1.0,0,109.0
1066,126375,HP:0009830,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",1,1.3906077157430468,2208583.3185633807,237.1388774360244,0.1803686309954731,-0.003226126253853777,0.0,0.0,1.0014792899408282,677.0,-0.6118641366142539,0.1113815737722112,1.0,2.0,3.0,132.0,132.0,128.0,264.0,1086,131.0,3.379108996539792e-06,25487.0,677.0,1.0,0,128.0
1067,612012,HP:0001425,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",0,1.3127180532973242,505584.9956709957,93.15001941101437,0.2313941857125111,0.2344825914227409,0.0,0.0,0.99746192893401,393.0,-0.4470987993744042,0.11253614341707896,1.0,2.0,12.0,127.0,127.0,23.0,254.0,498,125.0,1.6259105098855357e-05,8757.0,395.0,1.0,0,146.0
1068,602783,HP:0001425,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",0,1.3142449380073142,621086.6444444443,94.12332606664593,0.221919818412745,0.20949584515578834,0.0,0.0,0.9976019184652278,416.0,-0.4581747419312499,0.11083955801865683,1.0,2.0,9.0,136.0,136.0,9.0,272.0,496,134.0,1.625910509885536e-05,9660.0,418.0,1.0,0,137.0
1069,610513,HP:0001425,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",0,1.2948340002670142,759598.4042207792,91.3126405757985,0.2181646638455544,0.14216936572675715,0.0,0.0,0.9979253112033196,481.0,-0.3822395876731256,0.0963291324106767,1.0,2.0,20.0,167.0,167.0,2.0,334.0,504,165.0,1.625910509885536e-05,11213.0,483.0,1.0,0,189.0
1070,607998,HP:0001425,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",0,1.3020933014354066,328323.84362026857,78.526926896341,0.2522046018943155,0.19548087179128704,0.0,0.0,0.9971751412429378,353.0,-0.5295625558470837,0.09594970955677568,1.0,2.0,21.0,94.0,94.0,33.0,188.0,496,92.0,1.6259105098855364e-05,6029.0,355.0,1.0,0,105.0
1071,126375,HP:0001425,"In the remaining cases, next generation sequencing was carried out revealing variants in a number of other known complex spastic paraplegia genes, including five in SPG7 (5/97), four in FA2H (also known as SPG35) (4/97) and two in ZFYVE26/SPG15 Variants were identified in genes usually associated with pure spastic paraplegia and also in the Parkinson*s disease-associated gene ATP13A2, neuronal ceroid lipofuscinosis gene TPP1 and the hereditary motor and sensory neuropathy DNMT1 gene, highlighting the genetic heterogeneity of spastic paraplegia.",0,1.324230230409252,520668.029151404,93.90597619191492,0.2377730158922912,0.16443629753301947,0.0,0.0,0.9973821989528796,381.0,-0.4504500814929667,0.11434937733244024,1.0,2.0,7.0,123.0,123.0,26.0,246.0,496,121.0,1.625910509885536e-05,8365.0,383.0,1.0,0,135.0
1072,616585,HP:0002652,"Because RSPRY1 was been discovered as the cause of progressive skeletal dysplasia, a loss of this gene might explain the skeletal defects observed in the patient",0,1.3429643929643929,1472793.2000000004,164.71539582321515,0.1791685102531858,0.15807921209466602,0.0,0.0,1.0021881838074398,458.0,-0.2585529434857383,0.1698183520778191,1.0,2.0,12.0,173.0,173.0,11.0,346.0,362,173.0,1.2311480455524776e-05,17772.0,458.0,1.0,0,209.0
1073,604574,HP:0001250,"We describe a neurological disorder with epilepsy and prominent choreoathetosis caused by biallelic pathogenic variants in FRRS1L, which encodes an AMPA receptor outer-core protein.",0,1.44033586269822,9553022.57039795,550.1892130675981,0.14740572978994015,0.05271786361268155,0.0,0.0,1.0005861664712778,1707.0,-0.6777690417895583,0.05386756552393393,1.0,2.0,1.0,153.0,153.0,150.0,306.0,3100,152.0,4.156965348783943e-07,78435.0,1707.0,1.0,0,150.0
1074,604392,HP:0000618,"Its dysfunction, caused by mutations in either the enzyme itself or AIPL1 (aryl hydrocarbon receptor-interacting protein-like 1), leads to retinal diseases culminating in blindness.",0,1.3624161073825505,936373.2729979171,175.62128514056224,0.18081524482452405,0.21210600941709126,0.0,0.0,1.0028735632183907,349.0,-0.6585463758684754,0.20633665975035406,1.0,2.0,1.0,100.0,100.0,100.0,200.0,498,99.0,1.6e-05,12530.0,349.0,1.0,0,115.0
1075,612804,HP:0002149,"Missense mutations in the mitochondrial seryl-tRNA synthetase gene, SARS2, have been identified in HUPRA syndrome (hyperuricemia, pulmonary hypertension, renal failure in infancy, and alkalosis).",1,1.3889579020013805,17275.639926739932,43.9004347826087,0.3794467220521568,-0.06390761769212591,0.0,0.0,1.0086206896551724,117.0,-0.5524383677962622,0.12717359269083406,1.0,2.0,11.0,25.0,25.0,25.0,50.0,66,25.0,0.00011562030292519366,863.0,117.0,1.0,0,25.0
1076,612804,HP:0000083,"Missense mutations in the mitochondrial seryl-tRNA synthetase gene, SARS2, have been identified in HUPRA syndrome (hyperuricemia, pulmonary hypertension, renal failure in infancy, and alkalosis).",1,1.3796357025325925,431755.96643467643,126.75481919234558,0.23338248664629074,0.09339308843723984,0.0,0.0,1.0025,401.0,-0.5679246364690286,0.11204488778054862,1.0,2.0,1.0,90.0,90.0,73.0,180.0,618,89.0,1.0405827263267434e-05,8986.0,401.0,1.0,0,84.0
1077,615054,HP:0000501,Evidence is accumulating to suggest that mutations in the Ankyrin and SOCS Box-containing protein-10 (ASB10) gene are associated with glaucoma.,1,1.4622588235294116,47638.32907390339,146.8486842105263,0.30907604920936915,0.21830226967159333,0.0,0.0,1.0031055900621118,323.0,-0.8196322954377904,0.05049708670653616,1.0,2.0,1.0,19.0,19.0,19.0,38.0,608,18.0,1.0749798441279228e-05,2626.0,323.0,1.0,0,18.0
1083,615054,HP:0000501,"Since its identification in a large Oregon family with primary open-angle glaucoma (POAG), ASB10 variants have been associated with disease in US, German and Pakistani cohorts.",1,1.4622588235294116,47638.32907390339,146.8486842105263,0.30907604920936915,0.21830226967159333,0.0,0.0,1.0031055900621118,323.0,-0.8196322954377904,0.05049708670653616,1.0,2.0,1.0,19.0,19.0,19.0,38.0,608,18.0,1.0749798441279228e-05,2626.0,323.0,1.0,0,18.0
1080,615054,HP:0000501,"In this publication, we will review the literature that supports identification of ASB10 as a glaucoma-associated gene and the current knowledge of the function of the ASB10 protein.",1,1.4622588235294116,47638.32907390339,146.8486842105263,0.30907604920936915,0.21830226967159333,0.0,0.0,1.0031055900621118,323.0,-0.8196322954377904,0.05049708670653616,1.0,2.0,1.0,19.0,19.0,19.0,38.0,608,18.0,1.0749798441279228e-05,2626.0,323.0,1.0,0,18.0
1086,615054,HP:0002664,"In addition, we present new data that indicates ASB10 expression is up-regulated by the inflammatory cytokines tumor necrosis factor-a and interleukin-1a.",0,1.4137447675699493,80512.14989357974,168.58543245272713,0.3787113520482268,0.4428125783128724,0.0,0.0,0.9987357774968396,790.0,-0.6766515079538176,0.012383634065049994,1.0,2.0,110.0,18.0,18.0,14.0,36.0,1544,16.0,1.67789739321861e-06,3879.0,792.0,1.0,0,16.0
1087,609826,HP:0002148,"Similar findings were observed in a patient with chronic hypophosphatemia as a result of a mutation in SLC34A3 who had a 50% reduction in both serum Pi content and muscle VATP After oral Pi repletion and normalization of serum Pi levels, muscle VATP completely normalized in the patient.",1,1.3873529707449483,100847.02023809524,83.46197047496791,0.2828780993113416,0.15652992698505164,0.0,0.0,1.0052083333333333,193.0,-0.6604335455248002,0.1454555267702936,1.0,2.0,7.0,41.0,41.0,41.0,82.0,82,41.0,4.2718612499466016e-05,2695.0,193.0,1.0,0,45.0
1113,614145,HP:0002664,"Previous studies have implicated coiled-coil domain-containing protein 8 (CCDC8) as a tumor suppressor in several types of cancer, such as breast and prostate cancers.",0,1.3681522748375117,4650204.596083682,247.23480144603585,0.15974390279770112,0.02092904663222362,0.0,0.0,0.9989583333333332,959.0,-0.5993650426887176,0.08243366285119667,1.0,2.0,32.0,187.0,187.0,172.0,374.0,1544,185.0,1.6778973932186106e-06,38025.0,961.0,1.0,0,222.0
1108,614145,HP:0002664,"However, the expression levels or functions of CCDC8 in lung cancer have not been elucidated.",0,1.3681522748375117,4650204.596083682,247.23480144603585,0.15974390279770112,0.02092904663222362,0.0,0.0,0.9989583333333332,959.0,-0.5993650426887176,0.08243366285119667,1.0,2.0,32.0,187.0,187.0,172.0,374.0,1544,185.0,1.6778973932186106e-06,38025.0,961.0,1.0,0,222.0
1103,614145,HP:0002664,"Here, we used immunohistochemical staining to measure CCDC8 expression in 147 samples from tumors and 30 samples from the adjacent normal lung tissues of patients with non-small cell lung cancer.",0,1.3681522748375117,4650204.596083682,247.23480144603585,0.15974390279770112,0.02092904663222362,0.0,0.0,0.9989583333333332,959.0,-0.5993650426887176,0.08243366285119667,1.0,2.0,32.0,187.0,187.0,172.0,374.0,1544,185.0,1.6778973932186106e-06,38025.0,961.0,1.0,0,222.0
1093,614145,HP:0002664,"CCDC8 was shown to be located predominantly in the cytoplasm and partially on the cell membrane, and its expression level was significantly lower in lung cancer samples than that in the adjacent normal lung tissues (P=.001).",0,1.3681522748375117,4650204.596083682,247.23480144603585,0.15974390279770112,0.02092904663222362,0.0,0.0,0.9989583333333332,959.0,-0.5993650426887176,0.08243366285119667,1.0,2.0,32.0,187.0,187.0,172.0,374.0,1544,185.0,1.6778973932186106e-06,38025.0,961.0,1.0,0,222.0
1088,614145,HP:0002664,"CCDC8 expression was closely related to tumor differentiation (P=.039), tumor-node-metastasis stage (P=.009), lymph node metastasis (P=.038), and prognosis (P=.043) of lung cancer.",0,1.3681522748375117,4650204.596083682,247.23480144603585,0.15974390279770112,0.02092904663222362,0.0,0.0,0.9989583333333332,959.0,-0.5993650426887176,0.08243366285119667,1.0,2.0,32.0,187.0,187.0,172.0,374.0,1544,185.0,1.6778973932186106e-06,38025.0,961.0,1.0,0,222.0
1098,614145,HP:0002664,"Collectively, CCDC8 may suppress the invasion and metastasis of lung cancer cells, and it may represent a promising therapeutic target for non-small cell lung cancer",0,1.3681522748375117,4650204.596083682,247.23480144603585,0.15974390279770112,0.02092904663222362,0.0,0.0,0.9989583333333332,959.0,-0.5993650426887176,0.08243366285119667,1.0,2.0,32.0,187.0,187.0,172.0,374.0,1544,185.0,1.6778973932186106e-06,38025.0,961.0,1.0,0,222.0
1118,617048,HP:0002664,"Collectively, these findings demonstrate that mutations in DNAJC21 cause a cancer-prone BMF syndrome due to corruption of early nuclear rRNA biogenesis and late cytoplasmic maturation of the 60S subunit",1,1.3555888955907682,9883476.743217893,270.9321465254193,0.14418742299576254,0.06489535749035218,0.0,0.0,1.0008960573476702,1117.0,-0.5141789404547529,0.10381269593733856,1.0,2.0,5.0,326.0,326.0,127.0,652.0,1542,325.0,1.6778973932186097e-06,64705.0,1117.0,1.0,0,408.0
1119,608429,HP:0001371,"Marden-Walker syndrome is challenging to diagnose, as there is significant overlap with other multi-system congenital contracture syndromes including Beals congenital contractural arachnodactyly, D4ST1-Deficient Ehlers-Danlos syndrome (adducted thumb-clubfoot syndrome), Schwartz-Jampel syndrome, Freeman-Sheldon syndrome, Cerebro-oculo-facio-skeletal syndrome, and Van den Ende-Gupta syndrome.",1,1.3558950349812942,8958347.521264847,306.8690340909091,0.1369868272219976,0.03021394432982695,0.0,0.0,1.0010810810810808,926.0,-0.5573276817284399,0.14163329636331795,1.0,2.0,1.0,279.0,279.0,168.0,558.0,1280,278.0,2.4337946996819024e-06,60658.0,926.0,1.0,0,400.0
1120,608429,HP:0001166,"Marden-Walker syndrome is challenging to diagnose, as there is significant overlap with other multi-system congenital contracture syndromes including Beals congenital contractural arachnodactyly, D4ST1-Deficient Ehlers-Danlos syndrome (adducted thumb-clubfoot syndrome), Schwartz-Jampel syndrome, Freeman-Sheldon syndrome, Cerebro-oculo-facio-skeletal syndrome, and Van den Ende-Gupta syndrome.",1,1.3777388661292451,808726.3027777781,156.53671328671328,0.19592844445431407,-0.0018472931555711168,0.0,0.0,1.0026809651474529,374.0,-0.6394559286841506,0.15102292440251752,1.0,2.0,2.0,88.0,88.0,88.0,176.0,284,88.0,1.2140489747356407e-05,10534.0,374.0,1.0,0,88.0
1121,613619,HP:0001249,"SNP microarray and whole exome sequencing identified a homozygous frameshift mutation (p.L870V) in SCARF2 and predicted damaging mutations in several genes, most notably DGCR2 (p.P75L) and NCAM2 (p.S147G), both possible candidates for this child*s intellectual disability.",0,1.4245183517359148,8163105.128950184,389.4519221439522,0.1579561091766808,0.08681925374641172,0.0,0.0,0.9994432071269488,1795.0,-0.6160052507729428,0.042469322168970064,1.0,2.0,11.0,190.0,190.0,162.0,380.0,3206,188.0,3.8916426584745004e-07,68533.0,1797.0,1.0,0,213.0
1122,603024,HP:0002664,"Co-mutations of ARID1A, GPRC5A and MLL2 introduced by CRISPR/Cas9 significantly enhance the capabilities of self-renewal and tumor-initiating of BCNSCs.",0,1.3546281035100065,9858656.371040234,272.6693282973591,0.1422430853524375,0.011701026400070123,0.0,0.0,0.999073215940686,1078.0,-0.5409422080924086,0.10384958637970686,1.0,2.0,7.0,296.0,296.0,138.0,592.0,1544,294.0,1.6778973932186103e-06,60509.0,1080.0,1.0,0,396.0
1126,113810,HP:0002664,"Developmental exposure to endocrine-disrupting chemicals (EDCs), 17b-estradiol-3-benzoate (EB) and bisphenol A (BPA), increases susceptibility to prostate cancer (PCa) in rodent models.",0,1.3963389357853482,2202676.196498029,285.332518065592,0.17459616642363676,0.1091586850513506,0.0,0.0,0.998859749144812,876.0,-0.7133099326630891,0.07028516660909136,1.0,2.0,35.0,102.0,102.0,98.0,204.0,1544,100.0,1.67789739321861e-06,27060.0,878.0,1.0,0,102.0
1132,616658,HP:0001427,"We conclude that QIL1/MIC13 deficiency in human, is associated with disassembly of the MICOS complex, with the associated aberration of cristae morphology and mitochondrial respiratory dysfunction.",0,1.4028806084880852,5356.015927761851,75.19544364508393,0.44052256126415423,0.3154062145453069,0.0,0.0,0.9931506849315068,145.0,-0.7909857050487406,0.05274438542540304,1.0,2.0,17.0,7.0,7.0,7.0,14.0,206,6.0,5.102040816326531e-05,566.0,147.0,1.0,0,7.0
1130,616658,HP:0001427,"3-Methylglutaconic aciduria is associated with variants in genes encoding mitochondrial inner membrane organizing determinants, including TAZ, DNAJC19, SERAC1 and QIL1/MIC13",0,1.4028806084880852,5356.015927761851,75.19544364508393,0.44052256126415423,0.3154062145453069,0.0,0.0,0.9931506849315068,145.0,-0.7909857050487406,0.05274438542540304,1.0,2.0,17.0,7.0,7.0,7.0,14.0,206,6.0,5.102040816326531e-05,566.0,147.0,1.0,0,7.0
1134,608977,HP:0001427,"3-Methylglutaconic aciduria is associated with variants in genes encoding mitochondrial inner membrane organizing determinants, including TAZ, DNAJC19, SERAC1 and QIL1/MIC13",0,1.334805299076676,5191.089987789987,67.18497109826589,0.478311588297333,-0.02415369184823471,0.0,0.0,0.9944444444444444,179.0,-0.6719416527215801,0.034192756292203814,1.0,2.0,61.0,7.0,7.0,7.0,14.0,182,6.0,3.302946228035407e-05,557.0,181.0,1.0,0,7.0
1135,614725,HP:0001427,"3-Methylglutaconic aciduria is associated with variants in genes encoding mitochondrial inner membrane organizing determinants, including TAZ, DNAJC19, SERAC1 and QIL1/MIC13",0,1.3903858317520557,4074.738095238095,61.25840978593272,0.4441497077925673,0.3593953611719,0.0,0.0,0.9913793103448276,115.0,-0.8017121692033565,0.06660772178013558,1.0,2.0,14.0,7.0,7.0,7.0,14.0,152,6.0,8.264462809917356e-05,452.0,117.0,1.0,0,7.0
1136,611663,HP:0000078,"In humans, loss of TBC1D20 (TBC1 domain family, member 20) protein function causes Warburg Micro syndrome 4 (WARBM4), an autosomal recessive disorder characterized by congenital eye, brain, and genital abnormalities.",1,1.4161729917351074,15009220.58038154,504.88215198291863,0.1351304143328554,0.052175496152051686,0.0,0.0,1.0006459948320414,1549.0,-0.6401049367123313,0.07766784605555305,1.0,2.0,2.0,213.0,213.0,213.0,426.0,2670,212.0,5.60256732044892e-07,93118.0,1549.0,1.0,0,214.0
1137,604447,HP:0001250,"Here, we report mutations in GNB5 that are associated with heart-rate disturbance, eye disease, intellectual disability, gastric problems, hypotonia, and seizures in nine individuals from six families.",1,1.4626108032436451,2951328.3910458954,520.4854480286738,0.18757096779489565,0.04967638782311512,0.0,0.0,1.0006101281269066,1640.0,-0.6891802655945853,0.03294171044211966,1.0,2.0,2.0,88.0,88.0,86.0,176.0,3100,87.0,4.156965348783941e-07,44273.0,1640.0,1.0,0,75.0
1138,605906,HP:0001638,"Mutations in the LDB3 gene have been identified in patients with Z-disc-associated, alternatively spliced, PDZ motif-containing protein (ZASP)-related myofibrillar myopathy (ZASP-MFM) characterized by late-onset distal myopathy with signs of cardiomyopathy and neuropathy.",1,1.3761711138853558,1109540.3709400077,154.92432696331426,0.20637067371662915,0.18853862849236752,0.0,0.0,1.0017825311942958,562.0,-0.5809757001122826,0.10029116790682628,1.0,2.0,3.0,127.0,127.0,71.0,254.0,856,126.0,5.4335718671383015e-06,15810.0,562.0,1.0,0,123.0
1142,605906,HP:0009830,"Mutations in the LDB3 gene have been identified in patients with Z-disc-associated, alternatively spliced, PDZ motif-containing protein (ZASP)-related myofibrillar myopathy (ZASP-MFM) characterized by late-onset distal myopathy with signs of cardiomyopathy and neuropathy.",1,1.3906077157430468,1083497.7015806395,161.0761661306726,0.21328295101598524,0.04386730532065558,0.0,0.0,1.0014792899408282,677.0,-0.5928692112132411,0.07565573842133325,1.0,2.0,3.0,128.0,128.0,56.0,256.0,1086,127.0,3.379108996539792e-06,17312.0,677.0,1.0,0,111.0
1140,605906,HP:0001638,"We describe an autosomal dominant inherited pedigree with ZASP-MFM that is in line with the typical phenotype of distal myopathy without cardiomyopathy and neuropathy, while mild asymmetrical muscle atrophy can be observed in some affected members.",1,1.3761711138853558,1109540.3709400077,154.92432696331426,0.20637067371662915,0.18853862849236752,0.0,0.0,1.0017825311942958,562.0,-0.5809757001122826,0.10029116790682628,1.0,2.0,3.0,127.0,127.0,71.0,254.0,856,126.0,5.4335718671383015e-06,15810.0,562.0,1.0,0,123.0
1144,605906,HP:0009830,"We describe an autosomal dominant inherited pedigree with ZASP-MFM that is in line with the typical phenotype of distal myopathy without cardiomyopathy and neuropathy, while mild asymmetrical muscle atrophy can be observed in some affected members.",1,1.3906077157430468,1083497.7015806395,161.0761661306726,0.21328295101598524,0.04386730532065558,0.0,0.0,1.0014792899408282,677.0,-0.5928692112132411,0.07565573842133325,1.0,2.0,3.0,128.0,128.0,56.0,256.0,1086,127.0,3.379108996539792e-06,17312.0,677.0,1.0,0,111.0
1146,616404,HP:0005321,"Of those, POLR1C is also implicated in a mandibulofacial dysostosis syndrome without leukodystrophy as POLR1A is.",0,1.3695922353080427,2811.271043771044,71.1554054054054,0.4517202572823851,0.3260635774733534,0.0,0.0,0.9913793103448276,115.0,-0.8803473430451302,0.056292366637194224,1.0,2.0,24.0,5.0,5.0,5.0,10.0,94,4.0,7.971938775510202e-05,382.0,117.0,1.0,0,5.0
1147,610060,HP:0005321,"Of those, POLR1C is also implicated in a mandibulofacial dysostosis syndrome without leukodystrophy as POLR1A is.",1,1.4930208491089911,3262.8568694986607,145.3111510791367,0.5987825738221723,0.09964561841199172,0.0,0.0,1.0035587188612098,282.0,-0.6871794234026333,0.014462027712576663,1.0,2.0,122.0,4.0,4.0,4.0,8.0,250,4.0,1.2846700325021518e-05,573.0,282.0,1.0,0,4.0
1150,601663,HP:0002664,"On these bases, we investigated whether the ligation of ERb by a selective agonist, the 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), could impact HL tumor growth.",0,1.4389491766874765,519236.99298413505,231.73165549024483,0.2466300544757412,0.1638049788210631,0.0,0.0,0.9987789987789988,818.0,-0.7193249843816057,0.0327436790851425,1.0,2.0,28.0,48.0,48.0,48.0,96.0,1544,46.0,1.6778973932186097e-06,10995.0,820.0,1.0,0,53.0
1148,601663,HP:0002664,"After ERb activation, both DRAM2 and protein 1 light chain 3 (LC3), a key actor in the autophagosome formation, strictly interacted each other and localized at mitochondrial level.Altogether these results suggest that targeting ERb with selective agonists might affect HL cell proliferation and tumor growth via a mechanism that brings into play DRAM2-dependent autophagic cascade",0,1.4389491766874765,519236.99298413505,231.73165549024483,0.2466300544757412,0.1638049788210631,0.0,0.0,0.9987789987789988,818.0,-0.7193249843816057,0.0327436790851425,1.0,2.0,28.0,48.0,48.0,48.0,96.0,1544,46.0,1.6778973932186097e-06,10995.0,820.0,1.0,0,53.0
1152,179605,HP:0000546,"Mutations in peripherin 2 (PRPH2), also known as retinal degeneration slow/RDS, lead to various retinal degenerations including retinitis pigmentosa (RP) and macular/pattern dystrophy (MD/PD).",1,1.3347811096072992,1076634.6022588522,128.29659609796596,0.1867067107804668,0.14714682978290408,0.0,0.0,1.0024038461538465,417.0,-0.4088706436424821,0.15381156613171,1.0,2.0,7.0,161.0,161.0,11.0,322.0,438,160.0,2.0661157024793387e-05,13341.0,417.0,1.0,0,179.0
1153,179605,HP:0001425,We asked whether ROM1 could modify the phenotype of a PRPH2 mutation associated with a high degree of intrafamilial phenotypic heterogeneity: Y141C.,0,1.2697824087020309,553145.3852209065,76.32135116345644,0.2344892930200679,0.09481804745878956,0.0,0.0,0.9977578475336324,445.0,-0.4587961964453561,0.08640563397237187,1.0,2.0,32.0,138.0,138.0,5.0,276.0,496,136.0,1.6259105098855364e-05,8613.0,447.0,1.0,0,143.0
1161,604365,HP:0009733,CD133 has been shown to be an important stem cell factor that promotes glioma progression.,0,1.3022774327122153,52708.7515873016,52.757929592192404,0.3130947652635654,0.09172413314927673,0.0,0.0,0.9947368421052633,189.0,-0.5245958213092985,0.09534306971617526,1.0,2.0,28.0,39.0,39.0,39.0,78.0,140,38.0,4.3282548476454294e-05,1730.0,191.0,1.0,0,43.0
1191,604365,HP:0009733,"In this study, we found that CD133 mRNA expression was a prognostic marker in three independent glioma patient cohorts, corroborating a putative role for CD133 in glioma progression.",0,1.3022774327122153,52708.7515873016,52.757929592192404,0.3130947652635654,0.09172413314927673,0.0,0.0,0.9947368421052633,189.0,-0.5245958213092985,0.09534306971617526,1.0,2.0,28.0,39.0,39.0,39.0,78.0,140,38.0,4.3282548476454294e-05,1730.0,191.0,1.0,0,43.0
1179,604365,HP:0009733,"Importantly, we found that CD133 expression in glioma was highly correlated with the expression of HOX gene stem cell factors (HOXA5, HOXA7, HOXA10, HOXC4 and HOXC6).",0,1.3022774327122153,52708.7515873016,52.757929592192404,0.3130947652635654,0.09172413314927673,0.0,0.0,0.9947368421052633,189.0,-0.5245958213092985,0.09534306971617526,1.0,2.0,28.0,39.0,39.0,39.0,78.0,140,38.0,4.3282548476454294e-05,1730.0,191.0,1.0,0,43.0
1155,604365,HP:0009733,CD133 (p = 0.021) and HOXA7 (p = 0.001) were independent prognostic markers when the three glioma patient cohorts were combined (n = 231).,0,1.3022774327122153,52708.7515873016,52.757929592192404,0.3130947652635654,0.09172413314927673,0.0,0.0,0.9947368421052633,189.0,-0.5245958213092985,0.09534306971617526,1.0,2.0,28.0,39.0,39.0,39.0,78.0,140,38.0,4.3282548476454294e-05,1730.0,191.0,1.0,0,43.0
1197,604365,HP:0009733,Our results suggest that HOX genes may play a more important role in progression of glioma when CD133 expression is low.,0,1.3022774327122153,52708.7515873016,52.757929592192404,0.3130947652635654,0.09172413314927673,0.0,0.0,0.9947368421052633,189.0,-0.5245958213092985,0.09534306971617526,1.0,2.0,28.0,39.0,39.0,39.0,78.0,140,38.0,4.3282548476454294e-05,1730.0,191.0,1.0,0,43.0
1173,604365,HP:0009733,"Furthermore, we showed that low-level expression of LIM2 in CD133-high glioma was associated with poorer survival, suggesting that LIM2 could be a therapeutic target for glioma expressing a high level of CD133.",0,1.3022774327122153,52708.7515873016,52.757929592192404,0.3130947652635654,0.09172413314927673,0.0,0.0,0.9947368421052633,189.0,-0.5245958213092985,0.09534306971617526,1.0,2.0,28.0,39.0,39.0,39.0,78.0,140,38.0,4.3282548476454294e-05,1730.0,191.0,1.0,0,43.0
1205,154045,HP:0009733,"Furthermore, we showed that low-level expression of LIM2 in CD133-high glioma was associated with poorer survival, suggesting that LIM2 could be a therapeutic target for glioma expressing a high level of CD133.",0,1.2037037037037035,3580.129365079365,18.657894736842106,0.4421573395048686,0.3992303104935357,0.0,0.0,0.9827586206896552,57.0,-0.6214214734687736,0.15663354763296314,1.0,2.0,9.0,16.0,16.0,10.0,32.0,78,14.0,0.0006574621959237344,268.0,59.0,1.0,0,17.0
1167,604365,HP:0009733,"Connectivity mapping identified vinblastine and vincristine as agents that could reverse the CD133/HOX genes/LIM2-signature, and we confirmed this by in vitro analysis in glioma cell lines, demonstrating that CD133 and HOX genes were co-expressed and could be downregulated by vincristine.",0,1.3022774327122153,52708.7515873016,52.757929592192404,0.3130947652635654,0.09172413314927673,0.0,0.0,0.9947368421052633,189.0,-0.5245958213092985,0.09534306971617526,1.0,2.0,28.0,39.0,39.0,39.0,78.0,140,38.0,4.3282548476454294e-05,1730.0,191.0,1.0,0,43.0
1185,604365,HP:0009733,"In conclusion, our data show that CD133 and HOX genes are important prognostic markers in glioma and shed light on possible treatment strategies for glioma expressing a high level of CD133",0,1.3022774327122153,52708.7515873016,52.757929592192404,0.3130947652635654,0.09172413314927673,0.0,0.0,0.9947368421052633,189.0,-0.5245958213092985,0.09534306971617526,1.0,2.0,28.0,39.0,39.0,39.0,78.0,140,38.0,4.3282548476454294e-05,1730.0,191.0,1.0,0,43.0
1207,191044,HP:0001638,Objective: To investigate the genotype-phenotype correlation in Chinese familial hypertrophic cardiomyopathy (HCM )focusing on the cardiac troponin C gene TNNC1 c.,1,1.3775439735568409,1306437.659362868,181.41478205036742,0.19644668737694201,0.19071100823931264,0.0,0.0,1.0017921146953406,559.0,-0.5974962342161788,0.11667019318932295,1.0,2.0,4.0,124.0,124.0,111.0,248.0,856,123.0,5.4335718671383015e-06,18196.0,559.0,1.0,0,118.0
1208,600770,HP:0001425,"Idiopathic pulmonary fibrosis (IPF) is a complex, heterogeneous genetic disorder that is associated with rare and common sequence variants in many genes (MUC5B, SFTPC, SFTPA2, RTEL1, TERT, and hTR), 11 novel loci, and multiple emerging epigenetic and transcriptional profiles.",0,1.3368284665402979,202666.6436374084,68.50172805371778,0.27008280418776603,0.2687349400752096,0.0,0.0,0.9969696969696972,329.0,-0.6281936637920006,0.08098507735969973,1.0,2.0,10.0,66.0,66.0,33.0,132.0,506,64.0,1.625910509885536e-05,4423.0,331.0,1.0,0,62.0
1209,178620,HP:0001425,"Idiopathic pulmonary fibrosis (IPF) is a complex, heterogeneous genetic disorder that is associated with rare and common sequence variants in many genes (MUC5B, SFTPC, SFTPA2, RTEL1, TERT, and hTR), 11 novel loci, and multiple emerging epigenetic and transcriptional profiles.",1,1.3163919413919414,350692.8347041847,74.9901495106634,0.248155909851166,0.15749666108300742,0.0,0.0,0.9973333333333332,374.0,-0.5406267903856987,0.0921418439716312,1.0,2.0,11.0,104.0,104.0,26.0,208.0,496,102.0,1.6259105098855357e-05,6496.0,376.0,1.0,0,100.0
1210,178642,HP:0001425,"Idiopathic pulmonary fibrosis (IPF) is a complex, heterogeneous genetic disorder that is associated with rare and common sequence variants in many genes (MUC5B, SFTPC, SFTPA2, RTEL1, TERT, and hTR), 11 novel loci, and multiple emerging epigenetic and transcriptional profiles.",0,1.3368284665402979,202666.6436374084,68.50172805371778,0.27008280418776603,0.2687349400752098,0.0,0.0,0.9969696969696972,329.0,-0.6281936637920005,0.08098507735969973,1.0,2.0,10.0,66.0,66.0,33.0,132.0,496,64.0,1.625910509885536e-05,4423.0,331.0,1.0,0,62.0
1211,608833,HP:0001425,"Idiopathic pulmonary fibrosis (IPF) is a complex, heterogeneous genetic disorder that is associated with rare and common sequence variants in many genes (MUC5B, SFTPC, SFTPA2, RTEL1, TERT, and hTR), 11 novel loci, and multiple emerging epigenetic and transcriptional profiles.",0,1.3206231289213548,1389098.43510101,120.15260231208237,0.20168607135912808,0.181023871311408,0.0,0.0,0.9982758620689656,579.0,-0.27043915675473634,0.10275387263339072,1.0,2.0,10.0,213.0,213.0,2.0,426.0,496,211.0,9.018027036045053e-06,17313.0,581.0,1.0,0,257.0
1212,187270,HP:0001425,"Idiopathic pulmonary fibrosis (IPF) is a complex, heterogeneous genetic disorder that is associated with rare and common sequence variants in many genes (MUC5B, SFTPC, SFTPA2, RTEL1, TERT, and hTR), 11 novel loci, and multiple emerging epigenetic and transcriptional profiles.",0,1.3446669504045712,1997669.629839941,131.59905577898235,0.2076584150538465,0.07746686686516116,0.0,0.0,0.9988235294117648,849.0,-0.3408452681711032,0.06510541231768853,1.0,2.0,17.0,237.0,237.0,10.0,474.0,532,235.0,2.7502069530732184e-06,23547.0,851.0,1.0,0,235.0
1213,600770,HP:0003745,"In the past 5 years, we have found that: 1) genetic risk variants play major and similar roles in the development of both familial and sporadic fibrotic idiopathic interstitial pneumonia, accounting for up to 35% of the risk of idiopathic interstitial pneumonia (a disease that was previously thought to be idiopathic); 2) a promoter variant in MUC5B rs35705950 is the strongest risk factor for the development of IIP and IPF; however, rs35705950 has a low penetrance; and 3) IPF is a complex genetic disease with 11 independent loci contributing to the development of this disease, pronounced changes in DNA methylation, and transcriptional subtypes.",0,1.2603704539188412,86280.93214285716,48.306290115532725,0.2766754921461124,0.11699769434064655,0.0,0.0,0.99438202247191,177.0,-0.5586107573772641,0.13903709748289494,1.0,2.0,14.0,55.0,55.0,5.0,110.0,214,53.0,0.00010850694444444445,2215.0,179.0,1.0,0,50.0
1214,600770,HP:0002090,"In the past 5 years, we have found that: 1) genetic risk variants play major and similar roles in the development of both familial and sporadic fibrotic idiopathic interstitial pneumonia, accounting for up to 35% of the risk of idiopathic interstitial pneumonia (a disease that was previously thought to be idiopathic); 2) a promoter variant in MUC5B rs35705950 is the strongest risk factor for the development of IIP and IPF; however, rs35705950 has a low penetrance; and 3) IPF is a complex genetic disease with 11 independent loci contributing to the development of this disease, pronounced changes in DNA methylation, and transcriptional subtypes.",0,1.3489994216310004,218984.9528235653,91.82145090681676,0.2338527157157149,0.09655757630379813,0.0,0.0,0.9964028776978416,277.0,-0.6194742103052611,0.14084216497769525,1.0,2.0,1.0,68.0,68.0,44.0,136.0,392,66.0,2.5767218944059367e-05,5462.0,279.0,1.0,0,69.0
1245,601607,HP:0002664,"The aim of the study was detailed clinicopathological investigation of SMARCB1/INI1-deficient sinonasal carcinomas, including molecular genetic analysis of mutational status and DNA methylation of selected protooncogenes and tumor suppressor genes by means of next generation sequencing (NGS) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA).",1,1.3396459207409952,12225578.24190254,245.38261997405968,0.14557418044513382,0.12700196151807008,0.0,0.0,1.000778816199377,1285.0,-0.4059447124260791,0.09173182055105034,1.0,2.0,2.0,465.0,465.0,24.0,930.0,1542,464.0,1.677897393218609e-06,75676.0,1285.0,1.0,0,609.0
1240,601607,HP:0002664,"Regarding DNA methylation, all four SMARCB1/INI1-deficient tumors showed methylation of RASSF1 gene by means of MS-MLPA.",1,1.3396459207409952,12225578.24190254,245.38261997405968,0.14557418044513382,0.12700196151807008,0.0,0.0,1.000778816199377,1285.0,-0.4059447124260791,0.09173182055105034,1.0,2.0,2.0,465.0,465.0,24.0,930.0,1542,464.0,1.677897393218609e-06,75676.0,1285.0,1.0,0,609.0
1250,601607,HP:0002664,There was a statistically significant difference in RASSF1 gene methylation between SMARCB1/INI1-deficient and SMARCB1/INI1-positive tumors (p=0.0095).,1,1.3396459207409952,12225578.24190254,245.38261997405968,0.14557418044513382,0.12700196151807008,0.0,0.0,1.000778816199377,1285.0,-0.4059447124260791,0.09173182055105034,1.0,2.0,2.0,465.0,465.0,24.0,930.0,1542,464.0,1.677897393218609e-06,75676.0,1285.0,1.0,0,609.0
1255,612036,HP:0001250,"Biallelic PARS2 or NARS2 mutations are reported to cause Alpers* syndrome, which is an autosomal recessive neurodegenerative disorder characterized by psychomotor regression and epilepsy with variable degree of liver involvement.",0,1.4276347491306507,16656586.296995224,608.785027147876,0.13547113106492806,0.10488724649666054,0.0,0.0,1.0005711022272987,1752.0,-0.6517214853024399,0.07092881041231494,1.0,2.0,1.0,202.0,202.0,202.0,404.0,3100,201.0,4.156965348783941e-07,108796.0,1752.0,1.0,0,213.0
1259,612803,HP:0001250,"Biallelic PARS2 or NARS2 mutations are reported to cause Alpers* syndrome, which is an autosomal recessive neurodegenerative disorder characterized by psychomotor regression and epilepsy with variable degree of liver involvement.",1,1.444634701851987,9216410.2172692,631.1571215880892,0.14410810646493422,0.04838208672534874,0.0,0.0,1.0005910165484633,1693.0,-0.7146598967454456,0.057692710493353935,1.0,2.0,2.0,142.0,142.0,142.0,284.0,3100,141.0,4.156965348783942e-07,82632.0,1693.0,1.0,0,135.0
1262,612803,HP:0001250,"Moreover, it is known that NARS2 mutations cause various clinical phenotypes, including non-syndromic hearing loss, Leigh syndrome, intellectual disability with epilepsy and severe myopathy.",1,1.444634701851987,9216410.2172692,631.1571215880892,0.14410810646493422,0.04838208672534874,0.0,0.0,1.0005910165484633,1693.0,-0.7146598967454456,0.057692710493353935,1.0,2.0,2.0,142.0,142.0,142.0,284.0,3100,141.0,4.156965348783942e-07,82632.0,1693.0,1.0,0,135.0
1268,612803,HP:0000365,"Moreover, it is known that NARS2 mutations cause various clinical phenotypes, including non-syndromic hearing loss, Leigh syndrome, intellectual disability with epilepsy and severe myopathy.",0,1.4339826243929792,6987889.877413535,488.9458480080954,0.1505485141397017,0.08970407714272427,0.0,0.0,1.0007251631617111,1380.0,-0.6866915025930675,0.06586793622768021,1.0,2.0,2.0,142.0,142.0,142.0,284.0,2474,141.0,6.524672396198988e-07,62674.0,1380.0,1.0,0,150.0
1272,612803,HP:0001249,"Moreover, it is known that NARS2 mutations cause various clinical phenotypes, including non-syndromic hearing loss, Leigh syndrome, intellectual disability with epilepsy and severe myopathy.",1,1.4460835643645966,9227339.49095876,643.6785093807566,0.14565421698035494,0.1054014412190139,0.0,0.0,1.000573394495413,1745.0,-0.7098659043706452,0.05553416051102757,1.0,2.0,2.0,142.0,142.0,142.0,284.0,3204,141.0,3.8916426584744994e-07,84503.0,1745.0,1.0,0,137.0
1273,612036,HP:0000365,"The individuals with PARS2 and NARS2 mutations, we have reported here demonstrate similar neurological features as those previously reported, with diversity in clinical presentation such as hearing loss and seizure type.",0,1.4040653162054009,11310629.097109985,445.9710694189872,0.14244437604615026,0.03731851693238044,0.0,0.0,0.9993055555555556,1439.0,-0.6491300164054529,0.07569203485234019,1.0,2.0,22.0,203.0,203.0,203.0,406.0,2476,201.0,6.524672396198984e-07,78532.0,1441.0,1.0,0,229.0
1270,612803,HP:0000365,"The individuals with PARS2 and NARS2 mutations, we have reported here demonstrate similar neurological features as those previously reported, with diversity in clinical presentation such as hearing loss and seizure type.",0,1.4339826243929792,6987889.877413535,488.9458480080954,0.1505485141397017,0.08970407714272427,0.0,0.0,1.0007251631617111,1380.0,-0.6866915025930675,0.06586793622768021,1.0,2.0,2.0,142.0,142.0,142.0,284.0,2474,141.0,6.524672396198988e-07,62674.0,1380.0,1.0,0,150.0
1257,612036,HP:0001250,"The individuals with PARS2 and NARS2 mutations, we have reported here demonstrate similar neurological features as those previously reported, with diversity in clinical presentation such as hearing loss and seizure type.",0,1.4276347491306507,16656586.296995224,608.785027147876,0.13547113106492806,0.10488724649666054,0.0,0.0,1.0005711022272987,1752.0,-0.6517214853024399,0.07092881041231494,1.0,2.0,1.0,202.0,202.0,202.0,404.0,3100,201.0,4.156965348783941e-07,108796.0,1752.0,1.0,0,213.0
1265,612803,HP:0001250,"The individuals with PARS2 and NARS2 mutations, we have reported here demonstrate similar neurological features as those previously reported, with diversity in clinical presentation such as hearing loss and seizure type.",1,1.444634701851987,9216410.2172692,631.1571215880892,0.14410810646493422,0.04838208672534874,0.0,0.0,1.0005910165484633,1693.0,-0.7146598967454456,0.057692710493353935,1.0,2.0,2.0,142.0,142.0,142.0,284.0,3100,141.0,4.156965348783942e-07,82632.0,1693.0,1.0,0,135.0
1286,601019,HP:0002664,"The present study identified a functional long non-coding RNA, SLC6A9-5:2, which was involved in the radioactive therapy resistance of thyroid cancer.",0,1.374779982564656,4179007.870885555,272.1017363290239,0.16199785419787502,0.21815219745855474,0.0,0.0,0.9989212513484356,926.0,-0.6355470098074862,0.08319383997321728,1.0,2.0,37.0,154.0,154.0,149.0,308.0,1544,152.0,1.6778973932186097e-06,35784.0,928.0,1.0,0,164.0
1290,601019,HP:0002664,We demonstrated that SLC6A9-5:2 was remarkably downregulated in 131I-resistant thyroid cancer cell lines and 131I-insensitive patients and was positively correlated with Poly (ADP-ribose) polymerase 1 (PARP-1) expression and its activation.,0,1.374779982564656,4179007.870885555,272.1017363290239,0.16199785419787502,0.21815219745855474,0.0,0.0,0.9989212513484356,926.0,-0.6355470098074862,0.08319383997321728,1.0,2.0,37.0,154.0,154.0,149.0,308.0,1544,152.0,1.6778973932186097e-06,35784.0,928.0,1.0,0,164.0
1274,601019,HP:0002664,"After downregulating SLC6A9 or blocking PARP-1 artificially, the sensitive thyroid cancer cells mostly displayed a tolerant phenotype under 131I exposure.",0,1.374779982564656,4179007.870885555,272.1017363290239,0.16199785419787502,0.21815219745855474,0.0,0.0,0.9989212513484356,926.0,-0.6355470098074862,0.08319383997321728,1.0,2.0,37.0,154.0,154.0,149.0,308.0,1544,152.0,1.6778973932186097e-06,35784.0,928.0,1.0,0,164.0
1278,601019,HP:0002664,"Furthermore, SLC6A9-5:2 overexpression was positively correlated with PARP-1 mRNA and protein levels, which restored the sensitivity of resistant thyroid cancer cells.",0,1.374779982564656,4179007.870885555,272.1017363290239,0.16199785419787502,0.21815219745855474,0.0,0.0,0.9989212513484356,926.0,-0.6355470098074862,0.08319383997321728,1.0,2.0,37.0,154.0,154.0,149.0,308.0,1544,152.0,1.6778973932186097e-06,35784.0,928.0,1.0,0,164.0
1282,601019,HP:0002664,"In patients with thyroid cancer, a positive correlation between SLC6A9-5:2 and PARP-1 was identified, and low SLC6A9-5:2 expression was associated with a worse prognosis of papillary thyroid carcinoma.",0,1.374779982564656,4179007.870885555,272.1017363290239,0.16199785419787502,0.21815219745855474,0.0,0.0,0.9989212513484356,926.0,-0.6355470098074862,0.08319383997321728,1.0,2.0,37.0,154.0,154.0,149.0,308.0,1544,152.0,1.6778973932186097e-06,35784.0,928.0,1.0,0,164.0
1294,601019,HP:0002895,"In patients with thyroid cancer, a positive correlation between SLC6A9-5:2 and PARP-1 was identified, and low SLC6A9-5:2 expression was associated with a worse prognosis of papillary thyroid carcinoma.",0,1.3641064817535409,9179.337860713991,51.65395894428153,0.44374767398799386,0.05979753248321591,0.0,0.0,0.9940119760479044,166.0,-0.6648320673826572,0.04818933561448532,1.0,2.0,26.0,12.0,12.0,12.0,24.0,184,10.0,4.10913872452334e-05,676.0,168.0,1.0,0,11.0
1304,605131,HP:0002664,"In this mini-review, we update the current knowledge for the functional roles of WWOX under physiological and pathological settings, and provide new insights regarding pS14-WWOX in T leukemia cell maturation, and switching the anticancer pY33-WWOX to pS14-WWOX for cancer promotion and disease progression.",1,1.3555888955907682,8197196.577404298,243.4432423922089,0.15156926192774967,0.17795094962722313,0.0,0.0,1.0008960573476702,1117.0,-0.5011928936683259,0.09327981055245907,1.0,2.0,3.0,335.0,335.0,87.0,670.0,1542,334.0,1.67789739321861e-06,58140.0,1117.0,1.0,0,436.0
1301,605131,HP:0002664,Impact statement WWOX was originally designated as a tumor suppressor.,1,1.3555888955907682,8197196.577404298,243.4432423922089,0.15156926192774967,0.17795094962722313,0.0,0.0,1.0008960573476702,1117.0,-0.5011928936683259,0.09327981055245907,1.0,2.0,3.0,335.0,335.0,87.0,670.0,1542,334.0,1.67789739321861e-06,58140.0,1117.0,1.0,0,436.0
1298,605131,HP:0002664,"However, human newborns deficient in WWOX do not spontaneously develop tumors.",1,1.3555888955907682,8197196.577404298,243.4432423922089,0.15156926192774967,0.17795094962722313,0.0,0.0,1.0008960573476702,1117.0,-0.5011928936683259,0.09327981055245907,1.0,2.0,3.0,335.0,335.0,87.0,670.0,1542,334.0,1.67789739321861e-06,58140.0,1117.0,1.0,0,436.0
1307,605131,HP:0002664,"Suppression of pS14-WWOX by Zfra reduces cancer growth and mitigates Alzheimer*s disease progression, suggesting that pS14-WWOX facilitates disease progression.",1,1.3555888955907682,8197196.577404298,243.4432423922089,0.15156926192774967,0.17795094962722313,0.0,0.0,1.0008960573476702,1117.0,-0.5011928936683259,0.09327981055245907,1.0,2.0,3.0,335.0,335.0,87.0,670.0,1542,334.0,1.67789739321861e-06,58140.0,1117.0,1.0,0,436.0
1310,609317,HP:0000007,"In this study, we employed whole-exome sequencing and identified a homozygous missense mutation c.1522C &gt; A (p.Pro508Thr) in the TRIM36 gene as the cause of autosomal recessive APH in an Indian family.",0,1.4949543056532688,351661.4763023741,823.2287433700529,0.31278682766175325,0.7522009555032618,0.0,0.0,1.0003849114703618,2599.0,-0.7167021099482099,0.004599092266493212,1.0,2.0,449.0,19.0,19.0,19.0,38.0,5160,18.0,1.5011496554636367e-07,15527.0,2599.0,1.0,0,18.0
1311,610219,HP:0000007,Mutations in the Pejvakin (Pjvk) gene cause autosomal recessive hearing loss DFNB59 with audiological features of auditory neuropathy spectrum disorder (ANSD) or cochlear dysfunction.,1,1.4975032890268056,106548.64260516301,869.1558139534883,0.3884992877857744,0.9491928174908972,0.0,0.0,1.000386249517188,2590.0,-0.578884686282511,0.002582353914914749,1.0,2.0,1389.0,10.0,10.0,10.0,20.0,5160,9.0,1.5011496554636367e-07,8658.0,2590.0,1.0,0,9.0
1316,610219,HP:0000365,Mutations in the Pejvakin (Pjvk) gene cause autosomal recessive hearing loss DFNB59 with audiological features of auditory neuropathy spectrum disorder (ANSD) or cochlear dysfunction.,1,1.4948431896908738,94178.11782672227,912.9209377526273,0.29694567137794764,-0.02667228908045613,0.0,0.0,1.0008025682182986,1247.0,-0.9204129225613982,0.011656868941317913,1.0,2.0,1.0,10.0,10.0,10.0,20.0,2474,9.0,6.524672396198986e-07,9056.0,1247.0,1.0,0,9.0
1318,610219,HP:0009830,Mutations in the Pejvakin (Pjvk) gene cause autosomal recessive hearing loss DFNB59 with audiological features of auditory neuropathy spectrum disorder (ANSD) or cochlear dysfunction.,0,1.4160840140284827,35303.547752661965,224.82946593001842,0.3483153983152817,0.10385283440599194,0.0,0.0,0.9981949458483756,553.0,-0.7536972104645663,0.017829381728298697,1.0,2.0,80.0,11.0,11.0,11.0,22.0,1088,9.0,3.3791089965397925e-06,2741.0,555.0,1.0,0,10.0
1312,610219,HP:0000365,"By contrast, loss of Pjvk in adult OHCs causes a slowly progressive hearing loss associated with OHC degeneration and delayed loss of inner hair cells (IHCs), indicating a primary role for pejvakin in regulating OHC function and survival.",1,1.4948431896908738,94178.11782672227,912.9209377526273,0.29694567137794764,-0.02667228908045613,0.0,0.0,1.0008025682182986,1247.0,-0.9204129225613982,0.011656868941317913,1.0,2.0,1.0,10.0,10.0,10.0,20.0,2474,9.0,6.524672396198986e-07,9056.0,1247.0,1.0,0,9.0
1321,300195,HP:0011800,"In this study, we report a family with X-linked recessive syndrome caused by mutated AMMECR1 and characterized by elliptocytosis with or without anemia, midface hypoplasia, proportionate short stature and hearing loss.",0,1.3342644320297952,2342211.6047619046,197.6125523012552,0.15690908818239194,0.10222939968094892,0.0,0.0,1.002092050209205,479.0,-0.28329069326690925,0.20670678977297546,1.0,2.0,2.0,216.0,216.0,12.0,432.0,480,216.0,1.7217334412286292e-05,23664.0,479.0,1.0,0,310.0
1325,300195,HP:0004322,"In this study, we report a family with X-linked recessive syndrome caused by mutated AMMECR1 and characterized by elliptocytosis with or without anemia, midface hypoplasia, proportionate short stature and hearing loss.",0,1.3992298918589792,13875030.045162056,438.7095630188173,0.13475361250219542,0.07004914644239005,0.0,0.0,1.000735294117647,1361.0,-0.6151771729228633,0.093399101007045,1.0,2.0,1.0,239.0,239.0,239.0,478.0,2244,238.0,7.929402939746843e-07,86439.0,1361.0,1.0,0,249.0
1326,300195,HP:0000365,"In this study, we report a family with X-linked recessive syndrome caused by mutated AMMECR1 and characterized by elliptocytosis with or without anemia, midface hypoplasia, proportionate short stature and hearing loss.",1,1.4051421389108352,13237258.302589806,428.52192678331636,0.13921046953109845,0.03988990340023967,0.0,0.0,1.0006779661016951,1476.0,-0.6009191452077968,0.07885076477883422,1.0,2.0,1.0,239.0,239.0,239.0,478.0,2474,238.0,6.524672396198985e-07,85833.0,1476.0,1.0,0,250.0
1332,300195,HP:0004445,"In this study, we report a family with X-linked recessive syndrome caused by mutated AMMECR1 and characterized by elliptocytosis with or without anemia, midface hypoplasia, proportionate short stature and hearing loss.",1,1.4752686105907031,8165.765002344115,73.76234309623429,0.5541361587622691,0.09602745897730393,0.0,0.0,1.004032258064516,249.0,-0.596698484870502,0.02293043140303148,1.0,2.0,55.0,10.0,10.0,10.0,20.0,218,10.0,1.736111111111111e-05,708.0,249.0,1.0,0,10.0
1323,300195,HP:0011800,"Recently, mutations in AMMECR1 were reported in two maternal half-brothers, presenting with nephrocalcinosis, midface hypoplasia and, in one of the siblings, deafness and elliptocytosis.",0,1.3342644320297952,2342211.6047619046,197.6125523012552,0.15690908818239194,0.10222939968094892,0.0,0.0,1.002092050209205,479.0,-0.28329069326690925,0.20670678977297546,1.0,2.0,2.0,216.0,216.0,12.0,432.0,480,216.0,1.7217334412286292e-05,23664.0,479.0,1.0,0,310.0
1336,300195,HP:0000121,"Recently, mutations in AMMECR1 were reported in two maternal half-brothers, presenting with nephrocalcinosis, midface hypoplasia and, in one of the siblings, deafness and elliptocytosis.",0,1.3837967168520695,161173.64112831609,78.99856366702055,0.2900107495535249,0.10916908313159,0.0,0.0,1.00327868852459,306.0,-0.4890557779109672,0.08858887817422051,1.0,2.0,17.0,67.0,67.0,67.0,134.0,172,67.0,1.7361111111111114e-05,4134.0,306.0,1.0,0,76.0
1319,300195,HP:0011800,"AMMECR1 gene is localized in the critical region of contiguous deletion syndrome on Xq22.3 implicated in Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis (AMME complex).",0,1.3342644320297952,2342211.6047619046,197.6125523012552,0.15690908818239194,0.10222939968094892,0.0,0.0,1.002092050209205,479.0,-0.28329069326690925,0.20670678977297546,1.0,2.0,2.0,216.0,216.0,12.0,432.0,480,216.0,1.7217334412286292e-05,23664.0,479.0,1.0,0,310.0
1330,300195,HP:0004445,"AMMECR1 gene is localized in the critical region of contiguous deletion syndrome on Xq22.3 implicated in Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis (AMME complex).",1,1.4752686105907031,8165.765002344115,73.76234309623429,0.5541361587622691,0.09602745897730393,0.0,0.0,1.004032258064516,249.0,-0.596698484870502,0.02293043140303148,1.0,2.0,55.0,10.0,10.0,10.0,20.0,218,10.0,1.736111111111111e-05,708.0,249.0,1.0,0,10.0
1339,300724,HP:0001250,"Mutations in the X-linked gene CNKSR2 have been described in patients with seizures and neurodevelopmental deficits, especially those affecting language.",0,1.411033046876886,20699913.35853201,530.3378002618737,0.13385322485594198,0.04100739135158926,0.0,0.0,1.0005494505494503,1821.0,-0.5943372148659655,0.07382310166494681,1.0,2.0,1.0,271.0,271.0,271.0,542.0,3100,270.0,4.156965348783936e-07,122333.0,1821.0,1.0,0,283.0
1337,300724,HP:0001250,"In this study, we sequenced 112 patients with phenotypes within the epilepsy-aphasia spectrum (EAS) to determine the frequency of CNKSR2 mutation within this complex set of disorders.",0,1.411033046876886,20699913.35853201,530.3378002618737,0.13385322485594198,0.04100739135158926,0.0,0.0,1.0005494505494503,1821.0,-0.5943372148659655,0.07382310166494681,1.0,2.0,1.0,271.0,271.0,271.0,542.0,3100,270.0,4.156965348783936e-07,122333.0,1821.0,1.0,0,283.0
1341,600960,HP:0001250,"In this study, we sequenced 112 patients with phenotypes within the epilepsy-aphasia spectrum (EAS) to determine the frequency of CNKSR2 mutation within this complex set of disorders.",0,1.436787295169634,12779579.29530456,597.591204428326,0.14014269076327318,0.05895903701234965,0.0,0.0,1.0005820721769498,1719.0,-0.6780666266371862,0.06167053021730017,1.0,2.0,1.0,169.0,169.0,169.0,338.0,3100,168.0,4.1569653487839437e-07,91064.0,1719.0,1.0,0,189.0
1342,611037,HP:0002664,"The SLC25A26 gene encodes the mitochondrial carrier that catalyzes the import of S-adenosylmethionine (SAM) into the mitochondrial matrix, required for mitochondrial methylation processes, and is down-regulated in cervical cancer cells.",0,1.4138001533350368,560831.4875095808,211.6702230032216,0.2438772381669712,0.09279537168129028,0.0,0.0,0.9988009592326138,833.0,-0.6740547749502804,0.03694768735909476,1.0,2.0,41.0,56.0,56.0,50.0,112.0,1544,54.0,1.6778973932186097e-06,12865.0,835.0,1.0,0,48.0
1343,601556,HP:0001251,"While polyglutamine ataxias, linked to CAG repeat expansions in genes such as ATXN1, ATXN2, ATXN3, ATXN7, CACNA1A and TBP, have been extensively characterized in large cohorts, there is a need for comprehensive assessment of frequency and phenotype of more *conventional* ataxias.",1,1.4027533080747074,3682574.22840373,285.10122101221015,0.1666384436939733,0.07866691749434697,0.0,0.0,1.0010245901639343,977.0,-0.6467967467027029,0.08160645670084064,1.0,2.0,1.0,162.0,162.0,102.0,324.0,1626,161.0,1.5092152684290281e-06,38908.0,977.0,1.0,0,175.0
1344,601517,HP:0001251,"While polyglutamine ataxias, linked to CAG repeat expansions in genes such as ATXN1, ATXN2, ATXN3, ATXN7, CACNA1A and TBP, have been extensively characterized in large cohorts, there is a need for comprehensive assessment of frequency and phenotype of more *conventional* ataxias.",1,1.386592582454698,4768410.782196509,270.0367964243024,0.16235357994864247,0.004434432617291793,0.0,0.0,1.0009756097560976,1026.0,-0.5953385678312604,0.08667712642038701,1.0,2.0,1.0,210.0,210.0,121.0,420.0,1624,209.0,1.5092152684290275e-06,45577.0,1026.0,1.0,0,236.0
1347,607047,HP:0001251,"While polyglutamine ataxias, linked to CAG repeat expansions in genes such as ATXN1, ATXN2, ATXN3, ATXN7, CACNA1A and TBP, have been extensively characterized in large cohorts, there is a need for comprehensive assessment of frequency and phenotype of more *conventional* ataxias.",1,1.401643832944441,3824637.9065303686,289.8691178528552,0.1652493812053885,0.05242686260558007,0.0,0.0,1.0010214504596526,980.0,-0.6413500434466297,0.08371516124325114,1.0,2.0,3.0,165.0,165.0,121.0,330.0,1626,164.0,1.5092152684290275e-06,40159.0,980.0,1.0,0,166.0
1349,607640,HP:0001251,"While polyglutamine ataxias, linked to CAG repeat expansions in genes such as ATXN1, ATXN2, ATXN3, ATXN7, CACNA1A and TBP, have been extensively characterized in large cohorts, there is a need for comprehensive assessment of frequency and phenotype of more *conventional* ataxias.",1,1.425011687704535,3196588.8538221377,381.9830653663679,0.16195166232792113,0.06037330153985735,0.0,0.0,1.0010822510822512,925.0,-0.7146211386412202,0.087988767988768,1.0,2.0,1.0,111.0,111.0,106.0,222.0,1626,110.0,1.5092152684290275e-06,37602.0,925.0,1.0,0,103.0
1354,601011,HP:0001251,"While polyglutamine ataxias, linked to CAG repeat expansions in genes such as ATXN1, ATXN2, ATXN3, ATXN7, CACNA1A and TBP, have been extensively characterized in large cohorts, there is a need for comprehensive assessment of frequency and phenotype of more *conventional* ataxias.",1,1.362285281582118,9830012.739163063,297.48201538090143,0.1441587870275142,-0.00664436106837899,0.0,0.0,1.000882612533098,1134.0,-0.552798588541349,0.1065688476691713,1.0,2.0,5.0,308.0,308.0,142.0,616.0,1626,307.0,1.5092152684290285e-06,68461.0,1134.0,1.0,0,367.0
1356,600075,HP:0001251,"While polyglutamine ataxias, linked to CAG repeat expansions in genes such as ATXN1, ATXN2, ATXN3, ATXN7, CACNA1A and TBP, have been extensively characterized in large cohorts, there is a need for comprehensive assessment of frequency and phenotype of more *conventional* ataxias.",1,1.4069713019589312,3572721.909728093,291.1458408701734,0.16640834490242173,0.07906352178967388,0.0,0.0,1.0010362694300516,966.0,-0.6595894177423071,0.08043424623735504,1.0,2.0,2.0,150.0,150.0,107.0,300.0,1626,150.0,1.5092152684290262e-06,37490.0,966.0,1.0,0,158.0
1357,602783,HP:0001251,"Clinical comparisons showed that ataxias due to channelopathies had a significantly earlier age at onset with an average of 24.6 years, versus 40.9 years for polyglutamine expansion spinocerebellar ataxias and 37.8 years for SPG7-related forms (P = 0.001).",1,1.40091361969015,4668265.3592918115,318.3707795657838,0.15773481803780304,0.04555472551204043,0.0,0.0,1.001019367991845,982.0,-0.6616122772509242,0.09248013685690024,1.0,2.0,1.0,169.0,169.0,130.0,338.0,1626,168.0,1.5092152684290268e-06,44545.0,982.0,1.0,0,204.0
1352,601011,HP:0001251,"Similar differences were found among a single gene group, comparing 23 patients with CACNA1A expansions (spinocerebellar ataxia 6) to 22 patients with CACNA1A point mutations, which had lower average age at onset (25.2 versus 47.3 years) with longer disease duration (18.7 versus 10.9), but lower severity indexes (0.39 versus 0.44), indicating slower progression of the disease.",1,1.362285281582118,9830012.739163063,297.48201538090143,0.1441587870275142,-0.00664436106837899,0.0,0.0,1.000882612533098,1134.0,-0.552798588541349,0.1065688476691713,1.0,2.0,5.0,308.0,308.0,142.0,616.0,1626,307.0,1.5092152684290285e-06,68461.0,1134.0,1.0,0,367.0
1350,601011,HP:0001251,"In conclusion, we identified relevant genetic variations in up to 15% of cases after exclusion of polyglutamine expansion spinocerebellar ataxias, and confirmed CACNA1A and SPG7 as major ataxia genes.",1,1.362285281582118,9830012.739163063,297.48201538090143,0.1441587870275142,-0.00664436106837899,0.0,0.0,1.000882612533098,1134.0,-0.552798588541349,0.1065688476691713,1.0,2.0,5.0,308.0,308.0,142.0,616.0,1626,307.0,1.5092152684290285e-06,68461.0,1134.0,1.0,0,367.0
1360,602783,HP:0001251,"In conclusion, we identified relevant genetic variations in up to 15% of cases after exclusion of polyglutamine expansion spinocerebellar ataxias, and confirmed CACNA1A and SPG7 as major ataxia genes.",1,1.40091361969015,4668265.3592918115,318.3707795657838,0.15773481803780304,0.04555472551204043,0.0,0.0,1.001019367991845,982.0,-0.6616122772509242,0.09248013685690024,1.0,2.0,1.0,169.0,169.0,130.0,338.0,1626,168.0,1.5092152684290268e-06,44545.0,982.0,1.0,0,204.0
1366,607108,HP:0000518,This included identification of: complex ocular phenotypes due to two novel PAX6 mutations; progressive cortical cataract and lamellar cataract with lens subluxation due to two novel CRYGS mutations.,1,1.359782154460037,6390467.862545787,259.3816280122121,0.1467365531831829,0.07759423025326513,0.0,0.0,1.0010905125408942,918.0,-0.5791343234629271,0.1171956484035514,1.0,2.0,11.0,247.0,247.0,143.0,494.0,1298,246.0,2.3668639053254427e-06,49328.0,918.0,1.0,0,329.0
1367,123730,HP:0000518,This included identification of: complex ocular phenotypes due to two novel PAX6 mutations; progressive cortical cataract and lamellar cataract with lens subluxation due to two novel CRYGS mutations.,1,1.4925094152809781,15640.0,448.0810862865948,0.3384366262316747,0.3701746187186526,0.0,0.0,1.0015243902439024,657.0,-0.9506354979604524,0.01643185952407469,1.0,2.0,2.0,7.0,7.0,7.0,14.0,1298,6.0,2.366863905325444e-06,3541.0,657.0,1.0,0,6.0
1368,610035,HP:0001875,"VPS45-associated severe congenital neutropenia (SCN) is a rare disorder characterized by life-threating infections, neutropenia, neutrophil and platelet dysfunction, poor response to filgrastim, and myelofibrosis with extramedullary hematopoiesis.",1,1.369098462494176,266475.82391562685,135.2633620689655,0.20673750014653464,-0.033253025995600045,0.0,0.0,1.0046082949308757,218.0,-0.7179043211609109,0.24343635056863824,1.0,2.0,1.0,58.0,58.0,58.0,116.0,320,57.0,3.857875853555033e-05,5758.0,218.0,1.0,0,66.0
1369,610621,HP:0002671,"Here, we report that the expression of the INTU gene is aberrantly elevated in human basal cell carcinoma (BCC), coinciding with increased primary cilia formation and activated hedgehog (Hh) signaling.",0,1.3417945955651316,170600.4664862915,91.59609250398724,0.2772949727405431,0.11745344004819015,0.0,0.0,0.9969696969696972,329.0,-0.6053092451962245,0.06855259544081296,1.0,2.0,47.0,45.0,45.0,45.0,90.0,174,44.0,1.2225536701061176e-05,3744.0,331.0,1.0,0,49.0
1371,613842,HP:0000545,"Independently, the same approach identified a second homozygous truncating GZF1 variant in another multiplex consanguineous family affected by severe myopia, retinal detachment, and milder skeletal involvement.",0,1.407014010286033,455363.9225126181,162.3321385902031,0.22194490309588533,0.020769771156155244,0.0,0.0,1.0025974025974025,386.0,-0.6731809828601054,0.11369356032568467,1.0,2.0,1.0,62.0,62.0,62.0,124.0,648,61.0,9.467455621301773e-06,8448.0,386.0,1.0,0,62.0
1373,613842,HP:0000541,"Independently, the same approach identified a second homozygous truncating GZF1 variant in another multiplex consanguineous family affected by severe myopia, retinal detachment, and milder skeletal involvement.",0,1.3398484074263328,82093.325,64.42165898617512,0.27360323791538754,-0.07440282569404774,0.0,0.0,1.006896551724138,146.0,-0.4727666916839436,0.2170996693434105,1.0,2.0,1.0,61.0,61.0,39.0,122.0,168,60.0,0.0001384083044982699,2298.0,146.0,1.0,0,62.0
1372,613842,HP:0000545,Our results suggest that GZF1 mutations cause a phenotype of severe myopia and significant articular involvement not previously described in Larsen syndrome,0,1.407014010286033,455363.9225126181,162.3321385902031,0.22194490309588533,0.020769771156155244,0.0,0.0,1.0025974025974025,386.0,-0.6731809828601054,0.11369356032568467,1.0,2.0,1.0,62.0,62.0,62.0,124.0,648,61.0,9.467455621301773e-06,8448.0,386.0,1.0,0,62.0
1374,165240,HP:0010442,"To date variants in four genes GLI3, ZNF141, MIPOL1 and PITX1 have been implicated in developing non-syndromic form of polydactyly.",1,1.368745100600993,4174246.6206654455,224.78486166373642,0.15847147626784525,0.11945640105525525,0.0,0.0,1.0012210012210012,820.0,-0.4315290064073228,0.10586974001608147,1.0,2.0,33.0,214.0,214.0,214.0,428.0,428,214.0,2.714079831944177e-06,35550.0,820.0,1.0,0,242.0
1375,194648,HP:0010442,"To date variants in four genes GLI3, ZNF141, MIPOL1 and PITX1 have been implicated in developing non-syndromic form of polydactyly.",1,1.426277089783282,105963.36009244456,155.14143302180685,0.2292600071215436,0.1345823759422162,0.0,0.0,1.0041152263374489,244.0,-0.8636445367546031,0.1376914254874182,1.0,2.0,2.0,29.0,29.0,29.0,58.0,428,28.0,2.1633315305570567e-05,4082.0,244.0,1.0,0,30.0
1376,602149,HP:0010442,"To date variants in four genes GLI3, ZNF141, MIPOL1 and PITX1 have been implicated in developing non-syndromic form of polydactyly.",1,1.335505054273889,1390601.833333333,163.68423090824595,0.16782324142890465,-0.014309430137687531,0.0,0.0,1.0025380710659901,395.0,-0.4370871372086653,0.20627128445672427,1.0,2.0,4.0,158.0,158.0,59.0,316.0,428,157.0,2.1633315305570567e-05,16051.0,395.0,1.0,0,216.0
1377,617631,HP:0010442,"A homozygous splice acceptor site variant (c.395-1G&gt;A) was identified in the IQCE gene, which completely co-segregated with post-axial polydactyly phenotype within the family.",0,1.4670884606454608,13492.028571428571,193.34968847352025,0.27596743150670344,0.2856613265209462,0.0,0.0,1.0044444444444445,226.0,-0.9649356393672248,0.0864110127826942,1.0,2.0,1.0,12.0,12.0,12.0,24.0,428,11.0,2.1633315305570567e-05,2197.0,226.0,1.0,0,11.0
1378,602122,HP:0002664,"Knockdown of SRP72 resulted in significant radiosensitization of HeLa (cervical), PSN-1 (pancreatic), and T24 (bladder), BT-549 (breast) and MCF7 (breast) tumor lines as measured by colony formation assays.",1,1.4864147964145076,84020.06283385049,286.00202658884564,0.3784667195759255,0.3630164855189469,0.0,0.0,1.0012722646310432,787.0,-0.6927020830783429,0.014494440510716447,1.0,2.0,10.0,16.0,16.0,16.0,32.0,1542,15.0,1.67789739321861e-06,4483.0,787.0,1.0,0,15.0
1380,602122,HP:0002664,"SRP72 depletion also resulted in the radiosensitization of normal lung fibroblast cell lines (HFL1 and MRC-5), demonstrating that the effect is not restricted to tumor cells.",1,1.4864147964145076,84020.06283385049,286.00202658884564,0.3784667195759255,0.3630164855189469,0.0,0.0,1.0012722646310432,787.0,-0.6927020830783429,0.014494440510716447,1.0,2.0,10.0,16.0,16.0,16.0,32.0,1542,15.0,1.67789739321861e-06,4483.0,787.0,1.0,0,15.0
1383,179410,HP:0002664,"Protein kinase A (PKA) signaling pathway including AKAP12, RDX, and RAB13 genes were identified as potential mechanisms for the activity of garlic extract in cancer prevention.",0,1.3995878586243116,72805.19450473202,215.20963035019454,0.364413870009368,0.5362308433168721,0.0,0.0,0.9987309644670048,787.0,-0.6433096293646773,0.013282250230002636,1.0,2.0,149.0,17.0,17.0,15.0,34.0,1544,15.0,1.6778973932186097e-06,4129.0,789.0,1.0,0,14.0
1385,614901,HP:0002664,"Mechanistically, BCKDK promotes colorectal cancer by enhancing the MAPK signaling pathway through direct MEK phosphorylation, rather than by branched-chain amino acids catabolism.",0,1.4238984643869208,75944.21407327749,248.1288910505837,0.3353621901125077,0.2231120917922796,0.0,0.0,0.9987309644670048,787.0,-0.7817547415501288,0.014942129406239344,1.0,2.0,95.0,16.0,16.0,16.0,32.0,1544,14.0,1.67789739321861e-06,4645.0,789.0,1.0,0,14.0
1386,607512,HP:0002664,ADAMTS18 dysregulation plays an important role in many disease processes including cancer.,0,1.402759614405751,401247.5225322275,234.7779570402708,0.2512851780001406,0.3817855659822065,0.0,0.0,0.998769987699877,812.0,-0.6759420972665277,0.02984064238676785,1.0,2.0,101.0,42.0,42.0,42.0,84.0,1544,40.0,1.6778973932186097e-06,9874.0,814.0,1.0,0,39.0
1426,607512,HP:0002664,"We previously found ADAMTS18 as frequently methylated tumor suppressor gene (TSG) for multiple carcinomas, however, its biological functions and underlying molecular mechanisms in breast carcinogenesis remain unknown.",0,1.402759614405751,401247.5225322275,234.7779570402708,0.2512851780001406,0.3817855659822065,0.0,0.0,0.998769987699877,812.0,-0.6759420972665277,0.02984064238676785,1.0,2.0,101.0,42.0,42.0,42.0,84.0,1544,40.0,1.6778973932186097e-06,9874.0,814.0,1.0,0,39.0
1411,607512,HP:0002664,"Here, we found that ADAMTS18 was silenced or downregulated in breast cancer cell lines.",0,1.402759614405751,401247.5225322275,234.7779570402708,0.2512851780001406,0.3817855659822065,0.0,0.0,0.998769987699877,812.0,-0.6759420972665277,0.02984064238676785,1.0,2.0,101.0,42.0,42.0,42.0,84.0,1544,40.0,1.6778973932186097e-06,9874.0,814.0,1.0,0,39.0
1396,607512,HP:0002664,ADAMTS18 was reduced in primary breast tumor tissues as compared with their adjacent noncancer tissues.,0,1.402759614405751,401247.5225322275,234.7779570402708,0.2512851780001406,0.3817855659822065,0.0,0.0,0.998769987699877,812.0,-0.6759420972665277,0.02984064238676785,1.0,2.0,101.0,42.0,42.0,42.0,84.0,1544,40.0,1.6778973932186097e-06,9874.0,814.0,1.0,0,39.0
1391,607512,HP:0002664,"ADAMTS18 promoter methylation was detected in 70.8% of tumor tissues by methylation-specific PCR, but none of the normal tissues.",0,1.402759614405751,401247.5225322275,234.7779570402708,0.2512851780001406,0.3817855659822065,0.0,0.0,0.998769987699877,812.0,-0.6759420972665277,0.02984064238676785,1.0,2.0,101.0,42.0,42.0,42.0,84.0,1544,40.0,1.6778973932186097e-06,9874.0,814.0,1.0,0,39.0
1401,607512,HP:0002664,Ectopic expression of ADAMTS18 in breast tumor cells resulted in inhibition of cell migration and invasion.,0,1.402759614405751,401247.5225322275,234.7779570402708,0.2512851780001406,0.3817855659822065,0.0,0.0,0.998769987699877,812.0,-0.6759420972665277,0.02984064238676785,1.0,2.0,101.0,42.0,42.0,42.0,84.0,1544,40.0,1.6778973932186097e-06,9874.0,814.0,1.0,0,39.0
1416,607512,HP:0002664,Nude mouse model further confirmed that ADAMTS18 suppressed breast cancer metastasis in vivo.,0,1.402759614405751,401247.5225322275,234.7779570402708,0.2512851780001406,0.3817855659822065,0.0,0.0,0.998769987699877,812.0,-0.6759420972665277,0.02984064238676785,1.0,2.0,101.0,42.0,42.0,42.0,84.0,1544,40.0,1.6778973932186097e-06,9874.0,814.0,1.0,0,39.0
1406,607512,HP:0002664,"Further mechanistic studies showed that ADAMTS18 suppressed epithelial-mesenchymal transition (EMT), further inhibited migration and invasion of breast cancer cells.",0,1.402759614405751,401247.5225322275,234.7779570402708,0.2512851780001406,0.3817855659822065,0.0,0.0,0.998769987699877,812.0,-0.6759420972665277,0.02984064238676785,1.0,2.0,101.0,42.0,42.0,42.0,84.0,1544,40.0,1.6778973932186097e-06,9874.0,814.0,1.0,0,39.0
1421,607512,HP:0002664,"Thus, ADAMTS18 as an antimetastatic tumor suppressor antagonizes AKT and NF-kB signaling in breast tumorigenesis.",0,1.402759614405751,401247.5225322275,234.7779570402708,0.2512851780001406,0.3817855659822065,0.0,0.0,0.998769987699877,812.0,-0.6759420972665277,0.02984064238676785,1.0,2.0,101.0,42.0,42.0,42.0,84.0,1544,40.0,1.6778973932186097e-06,9874.0,814.0,1.0,0,39.0
1473,609145,HP:0002664,"Thus, ADAMTS18 as an antimetastatic tumor suppressor antagonizes AKT and NF-kB signaling in breast tumorigenesis.",0,1.3822965008126258,3042852.2095307475,270.7389414793736,0.16620742155098553,0.2396575150870838,0.0,0.0,0.998896247240618,905.0,-0.6703174021911298,0.07687084267324781,1.0,2.0,42.0,135.0,135.0,117.0,270.0,1544,133.0,1.6778973932186086e-06,31584.0,907.0,1.0,0,134.0
1489,601652,HP:0000501,"Recent studies have suggested possible therapeutic targets for some patients with early-onset glaucoma based on the molecular and cellular events caused by MYOC, OPTN and TBK1 mutations.",1,1.4073110624315444,262094.4453319627,131.62329854809437,0.2349117592840757,0.14654407766116162,0.0,0.0,1.002770083102493,362.0,-0.7238762608840974,0.09811603740377403,1.0,2.0,1.0,56.0,56.0,38.0,112.0,608,55.0,1.0749798441279228e-05,6411.0,362.0,1.0,0,44.0
1491,602432,HP:0000501,"Recent studies have suggested possible therapeutic targets for some patients with early-onset glaucoma based on the molecular and cellular events caused by MYOC, OPTN and TBK1 mutations.",1,1.3793293572216228,380212.7599206349,106.06058415268942,0.2299727434611773,0.18334624241124653,0.0,0.0,1.0025380710659901,395.0,-0.6442384622336976,0.09545717406669664,1.0,2.0,14.0,76.0,76.0,41.0,152.0,608,75.0,1.0749798441279228e-05,7428.0,395.0,1.0,0,69.0
1492,600046,HP:0000501,"Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).",0,1.3103661001971596,815528.9351037849,115.93078678839956,0.20188563183294253,0.17201845364388565,0.0,0.0,0.9977876106194692,451.0,-0.5935984179289474,0.1146730742933052,1.0,2.0,16.0,122.0,122.0,47.0,244.0,610,120.0,1.0679653124866504e-05,11740.0,453.0,1.0,0,125.0
1493,601785,HP:0000501,"Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).",0,1.3023546881814598,3389676.54534632,180.4579790823212,0.1597355989158531,0.027492173260655388,0.0,0.0,0.9985611510791368,694.0,-0.2815660064922809,0.12892169023401967,1.0,2.0,28.0,277.0,277.0,4.0,554.0,610,275.0,6.5410351842282545e-06,31181.0,696.0,1.0,0,279.0
1500,601090,HP:0000501,"Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).",1,1.3449478714501355,1848308.656592573,175.79246411483246,0.16838298798222354,0.10480122820613094,0.0,0.0,1.0020876826722338,480.0,-0.5582393625798304,0.17045059151009045,1.0,2.0,3.0,166.0,166.0,95.0,332.0,608,165.0,1.0749798441279223e-05,19595.0,480.0,1.0,0,204.0
1503,601517,HP:0000501,"Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).",0,1.3039993164643486,915543.9321506271,98.68200210032124,0.20931089009365755,0.2169528533432888,0.0,0.0,0.9980694980694982,517.0,-0.5102218406647646,0.09392877600970087,1.0,2.0,17.0,156.0,156.0,16.0,312.0,642,154.0,1.0679653124866504e-05,12626.0,519.0,1.0,0,184.0
1504,606448,HP:0000501,"Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).",0,1.2863028501958669,914645.2585931028,114.98022279625444,0.19379281224373104,0.04015489289116048,0.0,0.0,0.997863247863248,467.0,-0.6051639225873671,0.11348932990724035,1.0,2.0,29.0,129.0,129.0,45.0,258.0,610,127.0,1.0749798441279228e-05,12455.0,469.0,1.0,0,139.0
1505,118490,HP:0000501,"Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).",0,1.3041615658187278,1656563.964087617,137.9333184656557,0.18037579060006267,0.2025536586301505,0.0,0.0,0.99815157116451,540.0,-0.4776416740704144,0.12686633335834285,1.0,2.0,17.0,199.0,199.0,18.0,398.0,610,197.0,1.0679653124866504e-05,18600.0,542.0,1.0,0,240.0
1506,610192,HP:0000501,"Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).",1,1.354305451625267,1345151.9264957265,161.60887694588584,0.18110414684125514,0.05526589727613256,0.0,0.0,1.002247191011236,446.0,-0.5800322953441758,0.15762583765808436,1.0,2.0,5.0,134.0,134.0,89.0,268.0,608,133.0,1.0749798441279228e-05,15642.0,446.0,1.0,0,173.0
1510,603564,HP:0000501,"Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).",0,1.3057532298210264,1890092.6427960924,155.46673635022137,0.17279473865662015,0.13476948130160887,0.0,0.0,0.9980732177263968,518.0,-0.4826791909379437,0.14667259522750853,1.0,2.0,16.0,187.0,187.0,39.0,374.0,610,185.0,1.0679653124866504e-05,19792.0,520.0,1.0,0,268.0
1511,601011,HP:0000501,"Recent GWAS completed for three types of common adult-onset glaucoma have identified novel loci for POAG (primary-open-angle glaucoma) (ABCA1, AFAP1, GMDS, PMM2, TGFBR3, FNDC3B, ARHGEF12, GAS7, FOXC1, ATXN2, TXNRD2); PACG (primary angle-closure glaucoma (EPDR1, CHAT, GLIS3, FERMT2, DPM2-FAM102); and exfoliation syndrome (XFS) glaucoma (CACNA1A).",0,1.2896402560702287,2189137.5335470084,138.18395433677654,0.17250574849672906,0.09676902569842674,0.0,0.0,0.9984025559105428,625.0,-0.4507328093506239,0.11153064188207958,1.0,2.0,32.0,216.0,216.0,4.0,432.0,610,214.0,9.64468963388758e-06,21888.0,627.0,1.0,0,265.0
1512,610661,HP:0001263,"NGLY1 patients produce little or no N-glycanase (Ngly1), and the symptoms include global developmental delay, frequent seizures, complex hyperkinetic movement disorder, difficulty in swallowing/aspiration, liver dysfunction, and a lack of tears.",1,1.3827732494663092,21309221.344397053,408.2039628983425,0.1332739438573378,0.0118329026554868,0.0,0.0,1.0005224660397076,1915.0,-0.5595040518848446,0.0725308364094715,1.0,2.0,16.0,393.0,393.0,170.0,786.0,2998,392.0,4.4444444444444454e-07,132924.0,1915.0,1.0,0,462.0
1513,610661,HP:0001250,"NGLY1 patients produce little or no N-glycanase (Ngly1), and the symptoms include global developmental delay, frequent seizures, complex hyperkinetic movement disorder, difficulty in swallowing/aspiration, liver dysfunction, and a lack of tears.",1,1.3848220563125648,20937893.665909376,398.4534398263027,0.13638617695169006,0.11201640376379307,0.0,0.0,1.0005089058524173,1966.0,-0.550405055687184,0.06765548678682642,1.0,2.0,16.0,393.0,393.0,172.0,786.0,3100,392.0,4.156965348783943e-07,130683.0,1966.0,1.0,0,445.0
1514,610661,HP:0100022,"NGLY1 patients produce little or no N-glycanase (Ngly1), and the symptoms include global developmental delay, frequent seizures, complex hyperkinetic movement disorder, difficulty in swallowing/aspiration, liver dysfunction, and a lack of tears.",1,1.3905405259892634,22083617.485769544,416.10255844978064,0.14023595220680432,0.16524873593812198,0.0,0.0,1.0004725897920606,2117.0,-0.5456552408529914,0.06209700391019499,1.0,2.0,16.0,394.0,394.0,182.0,788.0,3402,393.0,3.45208029262594e-07,139084.0,2117.0,1.0,0,437.0
1515,610661,HP:0001410,"NGLY1 patients produce little or no N-glycanase (Ngly1), and the symptoms include global developmental delay, frequent seizures, complex hyperkinetic movement disorder, difficulty in swallowing/aspiration, liver dysfunction, and a lack of tears.",0,1.3016905351566703,989652.3471756312,120.00647742975588,0.2059490991000793,0.2854236255754674,0.0,0.0,0.9982876712328766,583.0,-0.3102397694242106,0.08573352066502751,1.0,2.0,54.0,166.0,166.0,8.0,332.0,384,165.0,5.750795047415306e-06,14645.0,585.0,1.0,0,190.0
1520,300304,HP:0002664,The major aim of the present study was to explore the effects of cullin 4B (CUL4B) on the proliferation and invasion of human gastric cancer cells.,0,1.3557164561010715,8204945.1297566015,259.70930553107644,0.14797956514842658,0.08419058053742229,0.0,0.0,0.9990557129367328,1058.0,-0.5072358122263935,0.09791544176599498,1.0,2.0,11.0,287.0,287.0,117.0,574.0,1544,285.0,1.6778973932186103e-06,54957.0,1060.0,1.0,0,441.0
1532,600900,HP:0002664,"Gastric tumor tissues and paired adjacent non-tumor tissues were obtained from 21 gastric cancer patients, and gastric cancer cell lines (AGS, MGC-803, KATO-III, MKN-45, SGC-7901, BGC-823 and MKN-74) were cultured.",0,1.400561161703175,941457.6872488172,204.979171435111,0.21034037305605727,0.11542276431943975,0.0,0.0,0.998833138856476,856.0,-0.7101797965956365,0.04459639932218695,1.0,2.0,41.0,78.0,78.0,53.0,156.0,1544,76.0,1.6778973932186103e-06,16396.0,858.0,1.0,0,67.0
1516,300304,HP:0002664,"Knockdown of CUL4B in gastric cancer cells suppressed cell proliferation, caused G1 arrest and inhibited cell invasion.",0,1.3557164561010715,8204945.1297566015,259.70930553107644,0.14797956514842658,0.08419058053742229,0.0,0.0,0.9990557129367328,1058.0,-0.5072358122263935,0.09791544176599498,1.0,2.0,11.0,287.0,287.0,117.0,574.0,1544,285.0,1.6778973932186103e-06,54957.0,1060.0,1.0,0,441.0
1528,300304,HP:0002664,"These results indirectly demonstrate that CUL4B enhances the proliferation and invasion abilities of gastric cancer cells by upregulating the constituent factors Wnt and b-catenin, as well as by negatively regulating the mRNA and protein expression of GSK-3b, caspase-3 and cyclin E.",0,1.3557164561010715,8204945.1297566015,259.70930553107644,0.14797956514842658,0.08419058053742229,0.0,0.0,0.9990557129367328,1058.0,-0.5072358122263935,0.09791544176599498,1.0,2.0,11.0,287.0,287.0,117.0,574.0,1544,285.0,1.6778973932186103e-06,54957.0,1060.0,1.0,0,441.0
1547,600300,HP:0100753,"Gene-based tests highlighted 20 additional genes of which 5 had previously been associated to schizophrenia and/or bipolar disorder: CSMD1, CCDC141, SLC1A2, CACNA1C, and SNAP25.",0,1.341005291005291,98057.47976190476,63.68387445887446,0.29916963148847997,0.13462787035950702,0.0,0.0,0.9954954954954954,221.0,-0.5427932462437881,0.11311760190683955,1.0,2.0,8.0,57.0,57.0,57.0,114.0,144,55.0,3.6289737262302225e-05,2800.0,223.0,1.0,0,58.0
1548,114205,HP:0100753,"Gene-based tests highlighted 20 additional genes of which 5 had previously been associated to schizophrenia and/or bipolar disorder: CSMD1, CCDC141, SLC1A2, CACNA1C, and SNAP25.",0,1.2701922192587145,52470.980377302425,40.247448979591844,0.3358742237061129,0.34729816885035514,0.0,0.0,0.9950980392156864,203.0,-0.4908898367324305,0.0838833094213295,1.0,2.0,31.0,49.0,49.0,16.0,98.0,266,47.0,4.565376186997809e-05,1754.0,205.0,1.0,0,48.0
1549,600322,HP:0100753,"Gene-based tests highlighted 20 additional genes of which 5 had previously been associated to schizophrenia and/or bipolar disorder: CSMD1, CCDC141, SLC1A2, CACNA1C, and SNAP25.",0,1.3158624514697728,93778.60391830392,56.35361741263029,0.32346098408582596,0.30248615750898045,0.0,0.0,0.9965517241379308,289.0,-0.4635103990221865,0.06500770233439981,1.0,2.0,38.0,55.0,55.0,57.0,110.0,154,53.0,1.826283877565929e-05,2743.0,291.0,1.0,0,49.0
1550,600300,HP:0007302,"Gene-based tests highlighted 20 additional genes of which 5 had previously been associated to schizophrenia and/or bipolar disorder: CSMD1, CCDC141, SLC1A2, CACNA1C, and SNAP25.",0,1.390079529022929,39474.99002247753,93.67719298245615,0.3090025230177396,0.21082543967012307,0.0,0.0,0.9945945945945946,184.0,-0.8307913015508783,0.1014821272885789,1.0,2.0,12.0,20.0,20.0,20.0,40.0,140,19.0,3.6289737262302225e-05,1746.0,186.0,1.0,0,20.0
1551,114205,HP:0007302,"Gene-based tests highlighted 20 additional genes of which 5 had previously been associated to schizophrenia and/or bipolar disorder: CSMD1, CCDC141, SLC1A2, CACNA1C, and SNAP25.",0,1.3372226035232213,27402.32124819625,60.1267454350161,0.3497438414906236,-0.00913644274418636,0.0,0.0,0.9940119760479044,166.0,-0.6446837931319311,0.08155118334759054,1.0,2.0,28.0,20.0,20.0,20.0,40.0,208,19.0,4.565376186997809e-05,1144.0,168.0,1.0,0,20.0
1552,600322,HP:0007302,"Gene-based tests highlighted 20 additional genes of which 5 had previously been associated to schizophrenia and/or bipolar disorder: CSMD1, CCDC141, SLC1A2, CACNA1C, and SNAP25.",0,1.3703541306646725,41818.60670228464,94.84210526315788,0.3339942489065341,0.456799656236912,0.0,0.0,0.9960474308300394,252.0,-0.6856545171082622,0.058603840527839166,1.0,2.0,39.0,20.0,20.0,20.0,40.0,184,19.0,1.826283877565929e-05,1883.0,254.0,1.0,0,20.0
1553,612418,HP:0001987,"Our findings are both important for the differential diagnosis of patients with urea cycle disorders and also broaden the differential diagnosis of hyperammonemia associated with 3-methylglutaconic aciduria, which was earlier only reported in TMEM70 and SERAC1 defect",1,1.3938429242072967,135717.1327858416,77.63715415019762,0.2800405723224467,0.3382417755668869,0.0,0.0,1.0035211267605637,285.0,-0.4796655314959269,0.08514949345193971,1.0,2.0,25.0,55.0,55.0,55.0,110.0,150,55.0,1.874027848053822e-05,3446.0,285.0,1.0,0,63.0
1554,614725,HP:0001987,"Our findings are both important for the differential diagnosis of patients with urea cycle disorders and also broaden the differential diagnosis of hyperammonemia associated with 3-methylglutaconic aciduria, which was earlier only reported in TMEM70 and SERAC1 defect",1,1.3526280884928663,96886.91190476187,73.15029190992493,0.2670009052081465,-0.03633614112662946,0.0,0.0,1.0061349693251531,164.0,-0.4792120891482699,0.2000598533592698,1.0,2.0,2.0,55.0,55.0,55.0,110.0,110,55.0,8.264462809917356e-05,2674.0,164.0,1.0,0,73.0
1573,610966,HP:0001513,"In 2007, FTO (fat mass and obesity associated) was the first gene identified through a genome-wide association study (GWAS) associated with obesity in humans.",1,1.3551840203056889,2205350.7880762005,190.34733201581028,0.16843673176063007,0.09191852693852773,0.0,0.0,1.001953125,513.0,-0.5941046245150907,0.16011817738791426,1.0,2.0,3.0,159.0,159.0,128.0,318.0,704,158.0,8.025102520684701e-06,21028.0,513.0,1.0,0,202.0
1579,610966,HP:0001513,"Recent prevalent research topic concentrated in the three neighboring genes of FTO: RPGRIP1L, IRX3 and IRX5, as having a functional link between obesity-associated common variants within FTO and the observed human phenotypes.",1,1.3551840203056889,2205350.7880762005,190.34733201581028,0.16843673176063007,0.09191852693852773,0.0,0.0,1.001953125,513.0,-0.5941046245150907,0.16011817738791426,1.0,2.0,3.0,159.0,159.0,128.0,318.0,704,158.0,8.025102520684701e-06,21028.0,513.0,1.0,0,202.0
1605,610937,HP:0001513,"Recent prevalent research topic concentrated in the three neighboring genes of FTO: RPGRIP1L, IRX3 and IRX5, as having a functional link between obesity-associated common variants within FTO and the observed human phenotypes.",0,1.3231238044210782,4157055.6676368318,186.81292997543,0.16112279451678652,0.0792281031068982,0.0,0.0,0.9986168741355465,722.0,-0.3510607481652902,0.1301360965284305,1.0,2.0,7.0,289.0,289.0,3.0,578.0,706,287.0,7.265277061340734e-06,34060.0,724.0,1.0,0,350.0
1607,606195,HP:0001513,"Recent prevalent research topic concentrated in the three neighboring genes of FTO: RPGRIP1L, IRX3 and IRX5, as having a functional link between obesity-associated common variants within FTO and the observed human phenotypes.",0,1.3364245407465312,2355144.7416666667,179.53490479115482,0.16799313943790073,-0.0057507630021639035,0.0,0.0,0.9981412639405204,537.0,-0.549261653816592,0.1521887565435096,1.0,2.0,5.0,179.0,179.0,89.0,358.0,706,177.0,8.025102520684701e-06,22066.0,539.0,1.0,0,219.0
1608,606883,HP:0002664,"Genes with DMRs were involved in inflammatory response (IRAK4 and ESM1), cancer (BRCA1 and LASP1), endocrine function (CNPY1), and male fertility (IFT140, TESC, and PRDM8).",0,1.4308806562905605,389457.67534518905,198.9501080847384,0.2755809934307896,0.13297015993980213,0.0,0.0,0.9987760097919216,816.0,-0.6225444334238913,0.02750237166806822,1.0,2.0,36.0,43.0,43.0,40.0,86.0,1550,41.0,1.6778973932186097e-06,9190.0,818.0,1.0,0,40.0
1623,113705,HP:0002664,"Genes with DMRs were involved in inflammatory response (IRAK4 and ESM1), cancer (BRCA1 and LASP1), endocrine function (CNPY1), and male fertility (IFT140, TESC, and PRDM8).",1,1.342124294666095,14779870.286244314,292.6232998839511,0.14059513390679754,0.0363653511393512,0.0,0.0,1.0008032128514055,1246.0,-0.37767621403519097,0.11088720854525648,1.0,2.0,3.0,471.0,471.0,37.0,942.0,1542,470.0,1.6778973932186097e-06,86008.0,1246.0,1.0,0,633.0
1687,160740,HP:0000303,"On the other hand, MYH1, MYH2, MYH3, MYH7, MYH8, FOXO3, NFATC1, PTGS2, KAT6B, HDAC4, and RUNX2 expression is suspected to be involved in the epigenetic regulations behind the mandibular prognathism phenotype",0,1.3529115341545352,227998.6271645021,109.15254237288136,0.21079625607989927,0.020892957476330368,0.0,0.0,0.9954337899543381,218.0,-0.7509613898078513,0.2004566210045662,1.0,2.0,1.0,59.0,59.0,40.0,118.0,320,57.0,3.857875853555033e-05,4829.0,220.0,1.0,0,62.0
1688,160720,HP:0000303,"On the other hand, MYH1, MYH2, MYH3, MYH7, MYH8, FOXO3, NFATC1, PTGS2, KAT6B, HDAC4, and RUNX2 expression is suspected to be involved in the epigenetic regulations behind the mandibular prognathism phenotype",1,1.3649335110928793,2095457.336309524,188.54559373170625,0.1727625489602424,0.10138476557435076,0.0,0.0,1.001733102253033,578.0,-0.4528355323445161,0.13032449191318896,1.0,2.0,22.0,159.0,159.0,159.0,318.0,318,159.0,5.668934240362811e-06,21732.0,578.0,1.0,0,159.0
1689,160760,HP:0000303,"On the other hand, MYH1, MYH2, MYH3, MYH7, MYH8, FOXO3, NFATC1, PTGS2, KAT6B, HDAC4, and RUNX2 expression is suspected to be involved in the epigenetic regulations behind the mandibular prognathism phenotype",1,1.3602316602316602,1080085.3245493784,130.0048152515723,0.18687618003348272,0.16029165559658606,0.0,0.0,1.0018450184501844,543.0,-0.33431072283106256,0.09933878344308306,1.0,2.0,38.0,159.0,159.0,5.0,318.0,318,159.0,6.7465002529937596e-06,14618.0,543.0,1.0,0,196.0
1690,160741,HP:0000303,"On the other hand, MYH1, MYH2, MYH3, MYH7, MYH8, FOXO3, NFATC1, PTGS2, KAT6B, HDAC4, and RUNX2 expression is suspected to be involved in the epigenetic regulations behind the mandibular prognathism phenotype",1,1.3419199589735498,543494.0452380952,136.25535812419858,0.18542072987862107,-0.028838104910818764,0.0,0.0,1.0038314176245209,262.0,-0.5695861973415586,0.2491006405194349,1.0,2.0,3.0,99.0,99.0,87.0,198.0,318,98.0,3.90625e-05,8517.0,262.0,1.0,0,103.0
1691,605880,HP:0000303,"On the other hand, MYH1, MYH2, MYH3, MYH7, MYH8, FOXO3, NFATC1, PTGS2, KAT6B, HDAC4, and RUNX2 expression is suspected to be involved in the epigenetic regulations behind the mandibular prognathism phenotype",0,1.3386507635700124,1976224.404365079,182.40396297884502,0.16998795986985946,0.05705337892151593,0.0,0.0,0.998046875,511.0,-0.4097785790017077,0.1543463693957115,1.0,2.0,10.0,160.0,160.0,160.0,320.0,320,159.0,8.025102520684701e-06,20270.0,513.0,1.0,0,173.0
1692,600211,HP:0000303,"On the other hand, MYH1, MYH2, MYH3, MYH7, MYH8, FOXO3, NFATC1, PTGS2, KAT6B, HDAC4, and RUNX2 expression is suspected to be involved in the epigenetic regulations behind the mandibular prognathism phenotype",1,1.3516020335082717,1035294.61537556,131.64131411383258,0.1885878797987615,0.42143678781964017,0.0,0.0,1.0020833333333332,481.0,-0.3054117887775631,0.12137907137907138,1.0,2.0,23.0,158.0,158.0,5.0,316.0,318,158.0,9.585062638384345e-06,14012.0,481.0,1.0,0,206.0
1693,603214,HP:0012120,"We report a new (fifth) patient with the cblJ disorder who presented at 7 days of age with poor feeding, hypotonia, methylmalonic aciduria, and elevated plasma homocysteine and harbored the mutations c.1667_1668delAG [p.Glu556Glyfs*27] and c.1295G&gt;A [p.Arg432Gln] in the ABCD4 gene.",1,1.4433229813664596,22011.65912698413,74.09902597402598,0.3564180982571381,0.3289025582968741,0.0,0.0,1.0059171597633136,170.0,-0.7050776414741681,0.07476505395057431,1.0,2.0,42.0,16.0,16.0,16.0,32.0,188,16.0,4.162330905306972e-05,1074.0,170.0,1.0,0,24.0
1694,615288,HP:0012265,"Mutations in three subunits (DRC1, DRC2/CCDC65, DRC4/GAS8) have been linked to defects in ciliary motility in humans and lead to a ciliopathy known as primary ciliary dyskinesia (PCD).",1,1.4082284634830682,14017.0,183.84623655913967,0.18610654497178747,0.144541421639989,0.0,0.0,1.0054347826086956,185.0,-0.9999737113122958,0.27150411280846065,1.0,2.0,1.0,30.0,30.0,30.0,60.0,308,30.0,4.10913872452334e-05,4621.0,185.0,1.0,0,30.0
1494,601090,HP:0000501,"Alterations in FOXC1 levels cause ocular malformations and disrupt stress response in ocular tissues, thereby contributing to glaucoma progression.",1,1.3449478714501355,1848308.656592573,175.79246411483246,0.16838298798222354,0.10480122820613094,0.0,0.0,1.0020876826722338,480.0,-0.5582393625798304,0.17045059151009045,1.0,2.0,3.0,166.0,166.0,95.0,332.0,608,165.0,1.0749798441279223e-05,19595.0,480.0,1.0,0,204.0
1497,601090,HP:0000501,"In addition, we found that FOXC1 regulation of RAB3GAP1, RAB3GAP2 and SNAP25 affects secretion of Myocilin (MYOC), a protein associated with juvenile onset glaucoma and steroid-induced glaucoma.",1,1.3449478714501355,1848308.656592573,175.79246411483246,0.16838298798222354,0.10480122820613094,0.0,0.0,1.0020876826722338,480.0,-0.5582393625798304,0.17045059151009045,1.0,2.0,3.0,166.0,166.0,95.0,332.0,608,165.0,1.0749798441279223e-05,19595.0,480.0,1.0,0,204.0
1696,609275,HP:0000501,"In addition, we found that FOXC1 regulation of RAB3GAP1, RAB3GAP2 and SNAP25 affects secretion of Myocilin (MYOC), a protein associated with juvenile onset glaucoma and steroid-induced glaucoma.",0,1.3230686908265512,4003919.842277992,199.46618065433853,0.1570241186054051,1.9181867186537915e-05,0.0,0.0,0.9985185185185186,674.0,-0.3066402940269958,0.14739425816348894,1.0,2.0,8.0,280.0,280.0,4.0,560.0,610,278.0,7.2652770613407345e-06,33628.0,676.0,1.0,0,272.0
1487,601652,HP:0000501,"In addition, we found that FOXC1 regulation of RAB3GAP1, RAB3GAP2 and SNAP25 affects secretion of Myocilin (MYOC), a protein associated with juvenile onset glaucoma and steroid-induced glaucoma.",1,1.4073110624315444,262094.4453319627,131.62329854809437,0.2349117592840757,0.14654407766116162,0.0,0.0,1.002770083102493,362.0,-0.7238762608840974,0.09811603740377403,1.0,2.0,1.0,56.0,56.0,38.0,112.0,608,55.0,1.0749798441279228e-05,6411.0,362.0,1.0,0,44.0
1698,601090,HP:0003621,"In addition, we found that FOXC1 regulation of RAB3GAP1, RAB3GAP2 and SNAP25 affects secretion of Myocilin (MYOC), a protein associated with juvenile onset glaucoma and steroid-induced glaucoma.",0,1.2818274159639054,149144.19385964915,53.5748432601881,0.2901926109154853,-0.021751642530098158,0.0,0.0,0.9965870307167236,292.0,-0.34747464833278063,0.09050172970211977,1.0,2.0,22.0,91.0,91.0,2.0,182.0,234,89.0,3.1919307989402804e-05,3898.0,294.0,1.0,0,101.0
1699,602536,HP:0003621,"In addition, we found that FOXC1 regulation of RAB3GAP1, RAB3GAP2 and SNAP25 affects secretion of Myocilin (MYOC), a protein associated with juvenile onset glaucoma and steroid-induced glaucoma.",0,1.322398200131364,324045.51887556893,77.79402474335352,0.2629580907515335,0.049192014721752206,0.0,0.0,0.9973614775725592,378.0,-0.39180903589959204,0.08987640605471463,1.0,2.0,17.0,112.0,112.0,14.0,224.0,234,110.0,1.4457343607685525e-05,6472.0,380.0,1.0,0,128.0
1700,609275,HP:0003621,"In addition, we found that FOXC1 regulation of RAB3GAP1, RAB3GAP2 and SNAP25 affects secretion of Myocilin (MYOC), a protein associated with juvenile onset glaucoma and steroid-induced glaucoma.",0,1.3348825079362223,416223.3982961926,86.54044734389562,0.2655704964934376,0.12158354152842052,0.0,0.0,0.9979466119096508,486.0,-0.3923447772887005,0.0669202544854748,1.0,2.0,30.0,117.0,117.0,41.0,234.0,254,115.0,7.2652770613407345e-06,7952.0,488.0,1.0,0,120.0
1701,600322,HP:0003621,"In addition, we found that FOXC1 regulation of RAB3GAP1, RAB3GAP2 and SNAP25 affects secretion of Myocilin (MYOC), a protein associated with juvenile onset glaucoma and steroid-induced glaucoma.",0,1.3151241878956628,332380.53888888896,82.96159538256623,0.2541651806221773,0.2916157960619057,0.0,0.0,0.9971428571428572,349.0,-0.3825581458059592,0.10775742775742776,1.0,2.0,16.0,115.0,115.0,9.0,230.0,234,113.0,1.8262838775659286e-05,6619.0,351.0,1.0,0,122.0
1702,601652,HP:0003621,"In addition, we found that FOXC1 regulation of RAB3GAP1, RAB3GAP2 and SNAP25 affects secretion of Myocilin (MYOC), a protein associated with juvenile onset glaucoma and steroid-induced glaucoma.",0,1.2494461674789543,36451.497258297255,32.33620689655173,0.3604185234322541,0.1562568035291063,0.0,0.0,0.9942857142857142,174.0,-0.5729959867321532,0.08746753246753247,1.0,2.0,18.0,41.0,41.0,11.0,82.0,234,39.0,7.305135510263716e-05,1347.0,176.0,1.0,0,35.0
638,300206,HP:0001249,"Mutations and deletions of the interleukin-1 receptor accessory protein like 1 (IL1RAPL1) gene, located on the X chromosome, are associated with intellectual disability (ID) and autism spectrum disorder (ASD).",1,1.4223431099644692,17128730.753005758,546.2090647560117,0.1370541621987404,0.07628525953094104,0.0,0.0,1.0005461496450028,1832.0,-0.6191787745128313,0.06549979847316592,1.0,2.0,1.0,230.0,230.0,230.0,460.0,3204,229.0,3.8916426584744994e-07,109856.0,1832.0,1.0,0,243.0
635,300206,HP:0001249,Here we show that the X-linked intellectual disability protein interleukin-1 receptor accessory protein like 1 (IL1RAPL1) regulates dendrite morphology of mice hippocampal neurons and induced pluripotent stem cell-derived neurons from a patient carrying a null mutation of IL1RAPL1 gene.,1,1.4223431099644692,17128730.753005758,546.2090647560117,0.1370541621987404,0.07628525953094104,0.0,0.0,1.0005461496450028,1832.0,-0.6191787745128313,0.06549979847316592,1.0,2.0,1.0,230.0,230.0,230.0,460.0,3204,229.0,3.8916426584744994e-07,109856.0,1832.0,1.0,0,243.0
279,601231,HP:0002664,"Functional studies have elucidated the role of the mammalian target of rapamycin (mTOR) pathway in breast carcinogenesis, but to date, there is a paucity of data on its contribution to breast cancer risk in women of African ancestry.",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
349,601231,HP:0002664,"We examined 47628 SNPs in 61 mTOR pathway genes in the genome wide association study of breast cancer in the African Diaspora study (The Root consortium), which included 3686 participants (1657 cases).",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
314,601231,HP:0002664,"The mTOR pathway was significantly associated with overall and estrogen receptor-negative (ER-) breast cancer risk (P = 0.003 and 0.03, respectively).",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
1703,300075,HP:0002664,"PRKAG3 (Padj = 0.0018) and RPS6KA3 (Padj = 0.061) were the leading genes for the associations with overall breast cancer risk and ER- breast cancer risk, respectively.",0,1.3243032598849451,11207282.236518174,241.17242711965642,0.1445073966251573,0.21678231226253453,0.0,0.0,0.9991769547325102,1214.0,-0.4330318196871185,0.0927333766515053,1.0,2.0,29.0,418.0,418.0,41.0,836.0,1544,417.0,1.67789739321861e-06,68504.0,1216.0,1.0,0,569.0
1704,115441,HP:0001250,"This study adds knowledge to the increasingly growing list of causative and candidate genes in ID and epilepsy, and highlights CSNK2B as a new gene for neurodevelopmental disorders",0,1.4421568382787218,9943151.38641057,584.364904934843,0.145658622565944,0.04850272760050287,0.0,0.0,1.0005882352941176,1701.0,-0.6827079524636769,0.05561157796451914,1.0,2.0,1.0,151.0,151.0,151.0,302.0,3100,150.0,4.156965348783943e-07,80406.0,1701.0,1.0,0,170.0
1707,138890,HP:0002664,"Moreover, ZNF131 and HAUS5 kd phenocopied each other in GSCs, each causing: mitotic arrest, centrosome fragmentation, loss of Augmin/HAUS complex on the mitotic spindle, and loss of GSC self-renewal and tumor formation capacity.",0,1.3814234091422386,3773499.9491447625,262.3012784880489,0.16372186382625006,0.1558280732019673,0.0,0.0,0.9989118607181721,918.0,-0.6628627428106406,0.07819226948005867,1.0,2.0,31.0,145.0,145.0,140.0,290.0,1544,143.0,1.6778973932186097e-06,33055.0,920.0,1.0,0,158.0
1739,131550,HP:0002664,"Tumor growth in xenografts as well as EGFR signaling were assessed in HCT116 cells expressing IL17RD with either a mutant 3* untranslated region (UTR) or wild-type (WT) 3*UTR.Results: miR-31, miR-34a, miR-106b, and miR-193a-3p were significantly dysregulated in ulcerative colitis-neoplasia and adjacent tissue.",1,1.4135577242017423,2148700.9990685256,249.19306594831886,0.18304335818682368,0.03828770954761315,0.0,0.0,1.0011111111111108,901.0,-0.6842090355364789,0.06837094586262177,1.0,2.0,6.0,124.0,124.0,94.0,248.0,1542,123.0,1.6778973932186097e-06,27721.0,901.0,1.0,0,105.0
1714,131550,HP:0002664,"IL17RD expression was increased in ulcerative colitis cancers, and miR-193a-3p treatment decreased growth and EGFR signaling of HCT116 cells in xenografts expressing both IL17RD with WT 3*UTR compared with cells expressing IL17RD with mutant 3*UTR.Conclusions: miR-193a-3p is downregulated in ulcerative colitis neoplasia, and its loss promotes carcinogenesis through upregulation of IL17RD.",1,1.4135577242017423,2148700.9990685256,249.19306594831886,0.18304335818682368,0.03828770954761315,0.0,0.0,1.0011111111111108,901.0,-0.6842090355364789,0.06837094586262177,1.0,2.0,6.0,124.0,124.0,94.0,248.0,1542,123.0,1.6778973932186097e-06,27721.0,901.0,1.0,0,105.0
1749,600922,HP:0001425,"In aggregate, our findings implicate MYLK as a gene involved in the recessive form of MMIHS, confirming that this disease of the visceral organs is heterogeneous with a myopathic origin",0,1.3273683056792125,904958.7306277056,102.76996687523004,0.208049978288726,0.0959829392457182,0.0,0.0,0.99781181619256,456.0,-0.4038518601452025,0.11336512092343268,1.0,2.0,2.0,164.0,164.0,3.0,328.0,496,162.0,1.625910509885536e-05,11864.0,458.0,1.0,0,185.0
1752,600536,HP:0009733,We identified integrin a7 (ITGA7) as a major laminin receptor in GSCs and in primary high-grade glioma specimens.,0,1.3101412608053975,89063.25793650791,68.2642105263158,0.29782718870673136,0.3512523736113214,0.0,0.0,0.99581589958159,238.0,-0.5760197149853058,0.08207810320781032,1.0,2.0,43.0,39.0,39.0,39.0,78.0,148,38.0,2.475186257765897e-05,2354.0,240.0,1.0,0,40.0
1750,600536,HP:0009733,Analyses of mRNA profiles in comprehensive datasets revealed that high ITGA7 expression negatively correlated with survival of patients with both low- and high-grade glioma.,0,1.3101412608053975,89063.25793650791,68.2642105263158,0.29782718870673136,0.3512523736113214,0.0,0.0,0.99581589958159,238.0,-0.5760197149853058,0.08207810320781032,1.0,2.0,43.0,39.0,39.0,39.0,78.0,148,38.0,2.475186257765897e-05,2354.0,240.0,1.0,0,40.0
1754,600536,HP:0002664,"We also found that targeting of ITGA7 by RNAi or blocking mAbs impaired laminin-induced signaling, and it led to a significant delay in tumor engraftment plus a strong reduction in tumor size and invasion.",0,1.3721166422873674,4565220.049983414,244.05732814526587,0.16051055687969873,0.05724341662222272,0.0,0.0,0.9989711934156379,971.0,-0.6199170489034792,0.08334284952989987,1.0,2.0,18.0,197.0,197.0,132.0,394.0,1544,195.0,1.67789739321861e-06,39411.0,973.0,1.0,0,243.0
1755,600536,HP:0012174,"Our data, therefore, highlight ITGA7 as a glioblastoma biomarker and candidate therapeutic target",0,1.317967793219385,30752.849153297684,59.75,0.3648338919882317,0.06696885545014461,0.0,0.0,0.995475113122172,220.0,-0.5496032116984165,0.05177122824181648,1.0,2.0,59.0,21.0,21.0,21.0,42.0,148,20.0,2.475186257765897e-05,1270.0,222.0,1.0,0,21.0
1756,138295,HP:0000252,"Mutations in the glutaminyl-tRNA synthetase (QARS) gene have been reported in patients with progressive microcephaly, cerebral-cerebellar atrophy, and intractable seizures.",0,1.438168692277089,5372850.291325454,584.8080084484733,0.1399254667854432,0.0375956746793432,0.0,0.0,1.000875656742557,1143.0,-0.7426017054702915,0.08907949553591266,1.0,2.0,1.0,110.0,110.0,110.0,220.0,2066,109.0,9.353172034763874e-07,58138.0,1143.0,1.0,0,115.0
1757,138295,HP:0001272,"Mutations in the glutaminyl-tRNA synthetase (QARS) gene have been reported in patients with progressive microcephaly, cerebral-cerebellar atrophy, and intractable seizures.",0,1.372885766328389,1702503.386507937,237.14196649272185,0.16354520163229458,0.07085429432088991,0.0,0.0,1.0022727272727272,441.0,-0.6870555350282567,0.2018037518037518,1.0,2.0,1.0,110.0,110.0,110.0,220.0,662,109.0,9.072434315575554e-06,19579.0,441.0,1.0,0,111.0
1758,138295,HP:0001250,"Mutations in the glutaminyl-tRNA synthetase (QARS) gene have been reported in patients with progressive microcephaly, cerebral-cerebellar atrophy, and intractable seizures.",0,1.4554930546935827,7986193.991361617,745.062521994135,0.14539020688293353,0.13454124758220942,0.0,0.0,1.0006027727546716,1660.0,-0.7462323495066985,0.05557564798071128,1.0,2.0,1.0,110.0,110.0,110.0,220.0,3100,109.0,4.156965348783941e-07,76526.0,1660.0,1.0,0,108.0
1760,138295,HP:0001250,"The clinical presentation of our patients differs from the original QARS-associated syndrome in the severe postnatal growth failure, absence of epilepsy, and minor MRI findings, thus further expanding the phenotypic spectrum of the glutaminyl-tRNA synthetase deficiency syndromes",0,1.4554930546935827,7986193.991361617,745.062521994135,0.14539020688293353,0.13454124758220942,0.0,0.0,1.0006027727546716,1660.0,-0.7462323495066985,0.05557564798071128,1.0,2.0,1.0,110.0,110.0,110.0,220.0,3100,109.0,4.156965348783941e-07,76526.0,1660.0,1.0,0,108.0
1762,608151,HP:0000556,"Patients with WDR19 mutations can show various extrarenal manifestations such as skeletal disorders, Caroli disease, and retinal dystrophy, and typically display nephronophthisis as a renal phenotype.",1,1.3340623152380529,2049042.2172790973,135.68150470219436,0.18842044125217908,0.012162795205348728,0.0,0.0,1.0015432098765429,649.0,-0.4145641115173013,0.1046624436454945,1.0,2.0,6.0,226.0,226.0,2.0,452.0,638,225.0,9.127335456960047e-06,22008.0,649.0,1.0,0,234.0
1763,608151,HP:0001425,"In addition, differences in pathology of the kidneys from WDR19 mutations may result in heterogeneous features in renal ultrasound findings.",0,1.3120669056152927,1247710.9288045291,107.29842964053488,0.21152643632154755,0.1292395260556912,0.0,0.0,0.9982698961937716,577.0,-0.30794519759843314,0.09234391714625503,1.0,2.0,15.0,201.0,201.0,2.0,402.0,496,199.0,9.127335456960047e-06,15452.0,579.0,1.0,0,239.0
1764,600571,HP:0001425,"Silver-Russell Syndrome (SRS) is clinically heterogeneous disorder characterized by low birth weight, postnatal growth restriction, and variable dysmorphic features.",0,1.3456207737582333,463180.5611111111,103.07860664608972,0.2293233573691272,0.0759866589520874,0.0,0.0,0.997134670487106,348.0,-0.5556904606153734,0.1243389275480966,1.0,2.0,3.0,98.0,98.0,74.0,196.0,496,96.0,1.6259105098855357e-05,7594.0,350.0,1.0,0,95.0
939,606151,HP:0001425,"Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder characterized by retinal dystrophy, polydactyly, obesity, developmental delay, and renal defects.",0,1.3163163281373012,1064593.6309523808,115.29840438199571,0.2067306802427935,0.09903095912423,0.0,0.0,0.997867803837953,468.0,-0.3132181558851957,0.12414825568207595,1.0,2.0,8.0,191.0,191.0,2.0,382.0,496,189.0,1.6259105098855357e-05,13683.0,470.0,1.0,0,221.0
1765,300120,HP:0000135,"Although three patients with MAMLD1 mutations were reported to have hypergonadotropic hypogonadism in their teens, the functional significance of MAMLD1 in the postnatal testis remains unclear.",0,1.3647014908987112,1160772.6571966293,173.7149748210973,0.1839015380257408,0.1739922761911535,0.0,0.0,0.997797356828194,453.0,-0.64336505003763,0.14285714285714285,1.0,2.0,2.0,105.0,105.0,99.0,210.0,688,103.0,8.401596303297626e-06,14755.0,455.0,1.0,0,129.0
1766,602445,HP:0001250,"We present two pediatric cases of progressive myoclonic epilepsy with SERPINI1 pathogenic variants that lead to a severe presentation; we highlight the importance of including this gene, previously known as causing an adult-onset dementia-epilepsy syndrome, in the genetic work-up of childhood-onset progressive myoclonic epilepsies",1,1.4815653490695642,1192399.0175600993,673.1641167434716,0.21480100333017907,0.09823910591824413,0.0,0.0,1.0006285355122566,1592.0,-0.7559758644222956,0.021735800308898358,1.0,2.0,1.0,42.0,42.0,42.0,84.0,3100,41.0,4.156965348783941e-07,27527.0,1592.0,1.0,0,41.0
1767,601489,HP:0002180,Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with strong genetic components.,0,1.2312140383018924,15830.209340659341,26.843253968253972,0.3761122708051058,0.06020204220731215,0.0,0.0,0.991304347826087,114.0,-0.5804491572794277,0.1158920539730135,1.0,2.0,13.0,30.0,30.0,9.0,60.0,146,28.0,0.00018765246762994932,773.0,116.0,1.0,0,25.0
1774,604982,HP:0001022,"Hermansky-Pudlak syndrome (HPS), first described in 1959, is a rare form of syndromic oculocutaneous albinism associated with bleeding diathesis and in some cases pulmonary fibrosis and granulomatous colitis.",1,1.4175208505761765,17581.58452380952,54.66666666666666,0.3573475676206121,0.20552329952719994,0.0,0.0,1.0081967213114755,123.0,-0.7007423014363683,0.11195521791283487,1.0,2.0,12.0,18.0,18.0,18.0,36.0,66,18.0,8.8999644001424e-05,840.0,123.0,1.0,0,18.0
1768,604982,HP:0001022,"HPS-5 therefore appears as a mild form of HPS, which is often clinically undistinguishable from mild oculocutaneous or ocular forms of albinism.",1,1.4175208505761765,17581.58452380952,54.66666666666666,0.3573475676206121,0.20552329952719994,0.0,0.0,1.0081967213114755,123.0,-0.7007423014363683,0.11195521791283487,1.0,2.0,12.0,18.0,18.0,18.0,36.0,66,18.0,8.8999644001424e-05,840.0,123.0,1.0,0,18.0
1777,608537,HP:0002668,"Alterations of von Hippel-Lindau (VHL), succinate dehydrogenase (SDHX), and TMEM127 have been associated with the development of pheochromocytomas (PCs) and paragangliomas (PGLs) and are also associated with the development of renal neoplasms.",1,1.4625773334010987,90510.15396136123,209.9746271215498,0.24386159720173306,0.05400843809842333,0.0,0.0,1.0030769230769232,326.0,-0.9141690766446048,0.07092024539877301,1.0,2.0,28.0,19.0,19.0,19.0,38.0,358,19.0,1.0541406645302749e-05,3757.0,326.0,1.0,0,19.0
1778,613403,HP:0002668,"Alterations of von Hippel-Lindau (VHL), succinate dehydrogenase (SDHX), and TMEM127 have been associated with the development of pheochromocytomas (PCs) and paragangliomas (PGLs) and are also associated with the development of renal neoplasms.",1,1.4462958215842092,54728.43504273504,190.84369214493518,0.2315692637192729,-0.039416079074662665,0.0,0.0,1.0046082949308757,218.0,-0.9498978968991858,0.1399399653320932,1.0,2.0,0.0,19.0,19.0,19.0,38.0,358,19.0,2.5e-05,3310.0,218.0,7.0,0,19.0
1779,604455,HP:0002668,"Alterations of von Hippel-Lindau (VHL), succinate dehydrogenase (SDHX), and TMEM127 have been associated with the development of pheochromocytomas (PCs) and paragangliomas (PGLs) and are also associated with the development of renal neoplasms.",0,1.3196002805049092,19512.302380952387,54.30385241454151,0.3149717259999279,0.19905366377608869,0.0,0.0,0.9914529914529916,116.0,-0.736683234501452,0.13718673040706938,1.0,2.0,16.0,20.0,20.0,20.0,40.0,74,19.0,0.00010412328196584755,947.0,118.0,1.0,0,20.0
1787,602690,HP:0002664,This study involved 2 primary renal PGL and 12 cases of PC/PGL with associated renal neoplasia with a mean follow up of 74 months.,1,1.3362913929618414,12107845.650814038,238.5258040405373,0.14801864264586315,0.06774311571033638,0.0,0.0,1.000735294117647,1361.0,-0.3764887027914669,0.08614232614427109,1.0,2.0,2.0,521.0,521.0,12.0,1042.0,1542,520.0,1.67789739321861e-06,79723.0,1361.0,1.0,0,697.0
1785,602690,HP:0002664,Primary renal PGL and neoplasia was associated with about 2% of 710 cases of PC/PGL.,1,1.3362913929618414,12107845.650814038,238.5258040405373,0.14801864264586315,0.06774311571033638,0.0,0.0,1.000735294117647,1361.0,-0.3764887027914669,0.08614232614427109,1.0,2.0,2.0,521.0,521.0,12.0,1042.0,1542,520.0,1.67789739321861e-06,79723.0,1361.0,1.0,0,697.0
1790,608537,HP:0002664,"Up to half of patients with PC/PGL and renal neoplasia had VHL syndrome, SDH deficiency, or alterations in TMEM127.",1,1.3618496077945474,6027068.07461144,219.1824484467484,0.16311609695858187,0.09506203626881264,0.0,0.0,1.000928505106778,1078.0,-0.5463102846795095,0.08290396432059782,1.0,2.0,3.0,276.0,276.0,77.0,552.0,1542,275.0,1.6778973932186097e-06,48126.0,1078.0,1.0,0,314.0
1791,613403,HP:0002664,"Up to half of patients with PC/PGL and renal neoplasia had VHL syndrome, SDH deficiency, or alterations in TMEM127.",1,1.387550981490707,3464018.6162630967,218.87889512412914,0.1809378796726584,0.07666722113530704,0.0,0.0,1.001031991744066,970.0,-0.5767724851097398,0.07366718798208377,1.0,2.0,0.0,189.0,189.0,115.0,378.0,1542,188.0,1.67789739321861e-06,34621.0,970.0,2.0,0,175.0
1794,604455,HP:0002664,"Up to half of patients with PC/PGL and renal neoplasia had VHL syndrome, SDH deficiency, or alterations in TMEM127.",0,1.391441575778232,1397593.9794546377,222.38033348041768,0.20177468366301074,0.05518921018156783,0.0,0.0,0.998849252013809,868.0,-0.657776812368828,0.0525270161236988,1.0,2.0,48.0,92.0,92.0,81.0,184.0,1544,90.0,1.677897393218609e-06,19856.0,870.0,1.0,0,88.0
1796,104614,HP:0001425,"Cystinuria is a heterogeneous, rare but important cause of inherited kidney stone disease due to mutations in 2 genes: SLC3A1 and SLC7A9.",0,1.320407722007722,561447.5434676434,101.96764346764346,0.2234233472724753,0.1567384542997204,0.0,0.0,0.997326203208556,373.0,-0.4972207480801026,0.1242638146167558,1.0,2.0,9.0,117.0,117.0,45.0,234.0,496,115.0,1.625910509885536e-05,8714.0,375.0,1.0,0,137.0
1797,604144,HP:0001425,"Cystinuria is a heterogeneous, rare but important cause of inherited kidney stone disease due to mutations in 2 genes: SLC3A1 and SLC7A9.",0,1.3757688828584351,48738.710674625945,66.8214942951785,0.3480882129209711,0.11530536246724304,0.0,0.0,0.99644128113879,280.0,-0.6557437417431323,0.05469321824285101,1.0,2.0,10.0,28.0,28.0,22.0,56.0,508,26.0,1.625910509885536e-05,2167.0,282.0,1.0,0,26.0
1798,600917,HP:0002664,"Mammographic density and PAM50 molecular subtypes were considered.Results: In the univariate analyses, TP53, PPP1R3A, and KMT2B were significantly more frequently mutated in interval cancers than in screen-detected cancers.",0,1.4526500317034057,82679.6739006938,209.45503674881112,0.3714071812170807,0.31271604232369743,0.0,0.0,0.99873417721519,789.0,-0.6995600284271578,0.0142040999215862,1.0,2.0,46.0,19.0,19.0,19.0,38.0,1544,18.0,1.67789739321861e-06,4438.0,791.0,1.0,0,26.0
1799,606834,HP:0002664,"Mammographic density and PAM50 molecular subtypes were considered.Results: In the univariate analyses, TP53, PPP1R3A, and KMT2B were significantly more frequently mutated in interval cancers than in screen-detected cancers.",0,1.4149530515832809,1455629.8155514703,287.60917681540246,0.1846845495801145,0.13945080512892347,0.0,0.0,0.9988221436984688,848.0,-0.7314674876005997,0.057764844453682525,1.0,2.0,31.0,75.0,75.0,72.0,150.0,1544,73.0,1.67789739321861e-06,20843.0,850.0,1.0,0,68.0
1800,607875,HP:0000568,"We show that morpholino-mediated inpp5k loss of function in the zebrafish results in shortened body axis, microphthalmia with disorganized lens, microcephaly, reduced touch-evoked motility, and highly disorganized myofibers.",0,1.3203199712575358,1509902.3781385282,164.6,0.16398248753522174,0.1620510989418524,0.0,0.0,0.997536945812808,405.0,-0.4441201375076093,0.2017041672214086,1.0,2.0,5.0,166.0,166.0,81.0,332.0,452,164.0,1.9406547769217335e-05,16665.0,407.0,1.0,0,211.0
1801,607875,HP:0000252,"We show that morpholino-mediated inpp5k loss of function in the zebrafish results in shortened body axis, microphthalmia with disorganized lens, microcephaly, reduced touch-evoked motility, and highly disorganized myofibers.",1,1.4114225521592207,7919791.594252135,450.3508766268689,0.1381401223402126,0.10796983085615172,0.0,0.0,1.0008250825082508,1213.0,-0.6599367585897611,0.09391384315678064,1.0,2.0,3.0,178.0,178.0,178.0,356.0,2066,177.0,9.353172034763868e-07,69034.0,1213.0,1.0,0,181.0
1803,607875,HP:0000518,"Altogether these data demonstrate that mutations in INPP5K cause a congenital muscular dystrophy syndrome with short stature, cataracts, and intellectual disability",1,1.3832198997263059,4552826.975920813,280.76147919876735,0.15425793888667247,0.04131570866884071,0.0,0.0,1.001207729468599,829.0,-0.6285983581007365,0.1152777049352284,1.0,2.0,1.0,179.0,179.0,177.0,358.0,1298,178.0,2.366863905325444e-06,39564.0,829.0,1.0,0,201.0
1363,602783,HP:0001251,"Various genes (eg, SPG7, SYNE1, PNPLA6) traditionally rooted in either the ataxia or hereditary spastic paraplegia classification system have now been shown to cause ataxia on the one end of the disease continuum and hereditary spastic paraplegia on the other.",1,1.40091361969015,4668265.3592918115,318.3707795657838,0.15773481803780304,0.04555472551204043,0.0,0.0,1.001019367991845,982.0,-0.6616122772509242,0.09248013685690024,1.0,2.0,1.0,169.0,169.0,130.0,338.0,1626,168.0,1.5092152684290268e-06,44545.0,982.0,1.0,0,204.0
1804,608441,HP:0001251,"Various genes (eg, SPG7, SYNE1, PNPLA6) traditionally rooted in either the ataxia or hereditary spastic paraplegia classification system have now been shown to cause ataxia on the one end of the disease continuum and hereditary spastic paraplegia on the other.",1,1.3687953572361469,6582459.310121204,262.4114305129065,0.15463804893158115,0.10404507456172893,0.0,0.0,1.000910746812386,1099.0,-0.5653258916264681,0.0920177475466188,1.0,2.0,12.0,270.0,270.0,109.0,540.0,1626,269.0,1.5092152684290275e-06,55519.0,1099.0,1.0,0,329.0
1805,603197,HP:0001251,"Various genes (eg, SPG7, SYNE1, PNPLA6) traditionally rooted in either the ataxia or hereditary spastic paraplegia classification system have now been shown to cause ataxia on the one end of the disease continuum and hereditary spastic paraplegia on the other.",1,1.3706585891751597,8593322.985927036,298.8435664140035,0.1508201762710944,0.15701250468275213,0.0,0.0,1.0009182736455464,1090.0,-0.551632846304266,0.10403113705866,1.0,2.0,6.0,270.0,270.0,146.0,540.0,1626,269.0,1.5092152684290275e-06,61743.0,1090.0,1.0,0,372.0
1806,609471,HP:0001251,Other genes such as GBA2 and KIF1C were almost simultaneously published as both a hereditary spastic paraplegia and an ataxia gene.,1,1.3987673312621285,5247581.012100925,328.6736250219645,0.15733644252411053,0.06072438339947817,0.0,0.0,1.0010131712259371,988.0,-0.6285818928096152,0.09707164802349573,1.0,2.0,7.0,169.0,169.0,162.0,338.0,1626,168.0,1.5092152684290275e-06,47330.0,988.0,1.0,0,186.0
1827,191160,HP:0002664,"Before and after eight weeks daily treatment with six capsules of F&amp;amp;V juice concentrate or placebo, peripheral blood gene expression (microarray, quantitative polymerase chain reaction (qPCR)), plasma tumour necrosis factor (TNF)a (enzyme-linked immunosorbent assay (ELISA)), body composition (Dual-energy X-ray absorptiometry (DEXA)) and lipid profiles were assessed.",0,1.4602670579691517,200974.08525960872,239.91050583657588,0.2850613192309647,0.15408425189867206,0.0,0.0,0.9987531172069826,801.0,-0.7836891500894245,0.02382275941528495,1.0,2.0,14.0,31.0,31.0,25.0,62.0,1544,29.0,1.6778973932186097e-06,7671.0,803.0,1.0,0,23.0
1869,613293,HP:0001085,"We report a sibling pair with FTHS caused by a homozygous, novel mutation pLys133Glnfs*13 in the SH3PXD2B gene: one sibling had bilateral ocular hypertension and unilateral colobomas of iris, choroid and retina; the other, unilateral myelinated nerve fiber layer of the optic disk and papilledema due to idiopathic intracranial hypertension.",0,1.370269586890299,168096.55090187592,102.89616110761484,0.24081574867389074,0.23319091500297706,0.0,0.0,0.9962962962962963,269.0,-0.6978307618539943,0.10509771764384312,1.0,2.0,15.0,43.0,43.0,43.0,86.0,176,42.0,1.9236688211757463e-05,3845.0,271.0,1.0,0,43.0
1870,613293,HP:0002516,"We report a sibling pair with FTHS caused by a homozygous, novel mutation pLys133Glnfs*13 in the SH3PXD2B gene: one sibling had bilateral ocular hypertension and unilateral colobomas of iris, choroid and retina; the other, unilateral myelinated nerve fiber layer of the optic disk and papilledema due to idiopathic intracranial hypertension.",0,1.3564814814814814,229575.1695144724,91.11392748220942,0.2516447020860044,0.1502604732169358,0.0,0.0,0.9965870307167236,292.0,-0.5736706510892144,0.11132780757354137,1.0,2.0,9.0,65.0,65.0,66.0,130.0,180,63.0,1.9236688211757467e-05,4795.0,294.0,1.0,0,75.0
1891,604242,HP:0002664,"Ring finger protein 6 (RNF6) is a key oncogene in both prostate cancer and leukemia, but its role is elusive in breast cancer.",1,1.4579124143052034,644016.6164598943,302.6206225680934,0.22432755059894632,0.033092519281105015,0.0,0.0,1.0012165450121655,823.0,-0.7319058768441029,0.0435827620154145,1.0,2.0,1.0,52.0,52.0,52.0,104.0,1542,51.0,1.67789739321861e-06,14742.0,823.0,1.0,0,46.0
1881,604242,HP:0002664,"In the present study, we found that RNF6 was overexpressed in more than 70% of breast cancer tissues and it was associated with overall survival.",1,1.4579124143052034,644016.6164598943,302.6206225680934,0.22432755059894632,0.033092519281105015,0.0,0.0,1.0012165450121655,823.0,-0.7319058768441029,0.0435827620154145,1.0,2.0,1.0,52.0,52.0,52.0,104.0,1542,51.0,1.67789739321861e-06,14742.0,823.0,1.0,0,46.0
1886,604242,HP:0002664,"RNF6 increased breast cancer cell proliferation, migration and reduced cell sensitivity to doxorubicin.",1,1.4579124143052034,644016.6164598943,302.6206225680934,0.22432755059894632,0.033092519281105015,0.0,0.0,1.0012165450121655,823.0,-0.7319058768441029,0.0435827620154145,1.0,2.0,1.0,52.0,52.0,52.0,104.0,1542,51.0,1.67789739321861e-06,14742.0,823.0,1.0,0,46.0
1871,604242,HP:0002664,"Further studies showed that RNF6 was closely associated with increased expression of estrogen receptor, a critical factor in the development of breast cancers.",1,1.4579124143052034,644016.6164598943,302.6206225680934,0.22432755059894632,0.033092519281105015,0.0,0.0,1.0012165450121655,823.0,-0.7319058768441029,0.0435827620154145,1.0,2.0,1.0,52.0,52.0,52.0,104.0,1542,51.0,1.67789739321861e-06,14742.0,823.0,1.0,0,46.0
1876,604242,HP:0002664,"In doxorubicin-resistant breast cancer cells, RNF6 was found to be elevated in association with increased ERa and anti-apoptotic Bcl-xL, but not pro-apoptotic Bim-1.",1,1.4579124143052034,644016.6164598943,302.6206225680934,0.22432755059894632,0.033092519281105015,0.0,0.0,1.0012165450121655,823.0,-0.7319058768441029,0.0435827620154145,1.0,2.0,1.0,52.0,52.0,52.0,104.0,1542,51.0,1.67789739321861e-06,14742.0,823.0,1.0,0,46.0
1896,604242,HP:0002664,"Therefore, this study demonstrated that there exists an RNF6/ERa/Bcl-xL axle in breast cancer which promotes cancer cell proliferation and survival.",1,1.4579124143052034,644016.6164598943,302.6206225680934,0.22432755059894632,0.033092519281105015,0.0,0.0,1.0012165450121655,823.0,-0.7319058768441029,0.0435827620154145,1.0,2.0,1.0,52.0,52.0,52.0,104.0,1542,51.0,1.67789739321861e-06,14742.0,823.0,1.0,0,46.0
1901,613289,HP:0001251,"Spinocerebellar ataxia type 8 (SCA8) is a progressive neurological disorder caused by the expanded repeat CTA/CTG of two overlapping genes, ATXN8OS and ATXN8, expressed bidirectionally.",1,1.4321295645925676,2388735.2100091088,356.2863669453021,0.17275805353083093,0.1707474986440331,0.0,0.0,1.0010989010989009,911.0,-0.7112933352834169,0.07517400272614322,1.0,2.0,0.0,98.0,98.0,98.0,196.0,1626,98.0,1.5092152684290281e-06,31160.0,911.0,2.0,0,93.0
1902,109270,HP:0008341,"Here, we applied next-generation sequencing in 89 patients with a clinical diagnosis of distal renal tubular acidosis, analyzing the prevalence of genetic defects in SLC4A1, ATP6V0A4, and ATP6V1B1 genes and the clinical phenotype.",1,1.4864599483204133,2437.4367015098724,75.92708333333333,0.6707058791577571,0.5682147029118384,0.0,0.0,1.0051020408163265,197.0,-0.5816153014120314,0.01916502641665804,1.0,2.0,103.0,5.0,5.0,5.0,10.0,384,5.0,2.684635829149776e-05,370.0,197.0,1.0,0,5.0
1906,605239,HP:0008341,"Here, we applied next-generation sequencing in 89 patients with a clinical diagnosis of distal renal tubular acidosis, analyzing the prevalence of genetic defects in SLC4A1, ATP6V0A4, and ATP6V1B1 genes and the clinical phenotype.",1,1.4630418167922263,1320.635714285714,40.15238095238095,0.5596808911335436,0.5601856330860475,0.0,0.0,1.0149253731343282,68.0,-0.7726272591860734,0.08165057067603161,1.0,2.0,13.0,5.0,5.0,5.0,10.0,80,5.0,0.000244140625,186.0,68.0,1.0,0,5.0
1908,192150,HP:0100753,"With this data-driven weighting procedure the LRT detected significant signal in genes located in regions already confirmed as associated with schizophrenia - the PRRC2A (p = 1.020e-06) and the VARS2 (p = 2.383e-06) - in the Swedish schizophrenia case-control cohort of 11,040 individuals with exome-sequencing data.",0,1.320076893502499,65509.861111111124,52.904870129870126,0.3035622522818077,0.05456246441497376,0.0,0.0,0.9940119760479044,166.0,-0.4923967632827032,0.14649272882805814,1.0,2.0,5.0,50.0,50.0,47.0,100.0,114,48.0,8.11622433244055e-05,2055.0,168.0,1.0,0,52.0
1909,603357,HP:0000972,"Nagashima-type palmoplantar keratosis (NPPK) is an autosomal recessive skin disorder with a high, unmet medical need that is caused by mutations in SERPINB7.",0,1.2736633663366337,9430.52380952381,44.10714285714286,0.2854897245311074,0.14235999515411496,0.0,0.0,0.984375,63.0,-0.6080006267746798,0.3451923076923077,1.0,2.0,3.0,25.0,25.0,24.0,50.0,72,23.0,0.0007304601899196494,718.0,65.0,1.0,0,33.0
1911,602346,HP:0002804,"Recently mutations in the CASPR/CNTN1 complex have been associated with similar severe phenotypes and CNTNAP1 gene mutations, causing loss of the CASPR protein, were shown to cause severe, prenatal onset arthrogryposis multiplex congenita in four unrelated families.",1,1.3404510218463708,469419.8444444445,133.95827922077922,0.1956428766660736,-0.046239041318063855,0.0,0.0,1.0036231884057971,277.0,-0.2363617957019319,0.2337937529430231,1.0,2.0,3.0,112.0,112.0,112.0,224.0,224,112.0,3.6289737262302225e-05,8937.0,277.0,1.0,0,149.0
1912,600016,HP:0002804,"Recently mutations in the CASPR/CNTN1 complex have been associated with similar severe phenotypes and CNTNAP1 gene mutations, causing loss of the CASPR protein, were shown to cause severe, prenatal onset arthrogryposis multiplex congenita in four unrelated families.",0,1.3191269140613109,298996.42142857146,111.80927051671732,0.2006629977636997,-0.10903488939955117,0.0,0.0,0.9951690821256038,206.0,-0.3922144590484985,0.2702526941657377,1.0,2.0,2.0,91.0,91.0,85.0,182.0,226,89.0,7.694675284702985e-05,5818.0,208.0,1.0,0,122.0
1913,602346,HP:0003577,"Recently mutations in the CASPR/CNTN1 complex have been associated with similar severe phenotypes and CNTNAP1 gene mutations, causing loss of the CASPR protein, were shown to cause severe, prenatal onset arthrogryposis multiplex congenita in four unrelated families.",0,1.3476433092381297,1594725.327777778,172.63686040735215,0.18106564080337728,-0.0012622993924053874,0.0,0.0,1.0021321961620469,470.0,-0.4851489228668645,0.16771764278909404,1.0,2.0,2.0,164.0,164.0,153.0,328.0,610,163.0,1.0679653124866502e-05,18485.0,470.0,1.0,0,215.0
1914,600016,HP:0003577,"Recently mutations in the CASPR/CNTN1 complex have been associated with similar severe phenotypes and CNTNAP1 gene mutations, causing loss of the CASPR protein, were shown to cause severe, prenatal onset arthrogryposis multiplex congenita in four unrelated families.",0,1.3689837142061885,805188.9357864356,152.10861527729332,0.19775145785681306,-0.007803978723733159,0.0,0.0,0.9975,399.0,-0.6537230512644435,0.1394638403990025,1.0,2.0,1.0,95.0,95.0,90.0,190.0,612,93.0,1.0610192150579848e-05,11185.0,401.0,1.0,0,103.0
1910,602346,HP:0002804,Here we report a consanguineous Arab family from Qatar with three children having an early lethal form of arthrogryposis multiplex congenita and a novel frameshift mutation in CNTNAP1.,1,1.3404510218463708,469419.8444444445,133.95827922077922,0.1956428766660736,-0.046239041318063855,0.0,0.0,1.0036231884057971,277.0,-0.2363617957019319,0.2337937529430231,1.0,2.0,3.0,112.0,112.0,112.0,224.0,224,112.0,3.6289737262302225e-05,8937.0,277.0,1.0,0,149.0
1915,609302,HP:0001298,Mutations in SLC25A22 are known to cause neonatal epileptic encephalopathy and migrating partial seizures in infancy.,1,1.3342651876116736,1899837.520238096,161.50176619568114,0.17587545262187831,0.0556329886900882,0.0,0.0,1.0020449897750512,490.0,-0.3724463970575722,0.1651099703685155,1.0,2.0,1.0,213.0,213.0,2.0,426.0,484,212.0,1.6128772116578765e-05,19781.0,490.0,1.0,0,237.0
1916,609302,HP:0001250,Mutations in SLC25A22 are known to cause neonatal epileptic encephalopathy and migrating partial seizures in infancy.,1,1.4162176878546455,18415198.272726886,541.2475806451613,0.13547229687439838,0.023561042484031663,0.0,0.0,1.0005564830272675,1798.0,-0.614063461419849,0.07162784594024275,1.0,2.0,1.0,248.0,248.0,248.0,496.0,3100,247.0,4.156965348783943e-07,115715.0,1798.0,1.0,0,249.0
1917,109091,HP:0002664,"Our objective was to identify the CpG loci that are persistently hyper-methylated during serrated carcinogenesis, from the early SSA/P lesion through the later cancer phases of neoplasia development.",1,1.4149252260984753,1932252.858155896,222.49842213303106,0.199183559543726,0.1309441430554232,0.0,0.0,1.0011148272017838,898.0,-0.6267051452353637,0.060237912566759276,1.0,2.0,0.0,126.0,126.0,90.0,252.0,1542,126.0,1.677897393218609e-06,24261.0,898.0,2.0,0,113.0
1920,109091,HP:0002664,"We identified CpG loci and regions consistently hyper-methylated throughout the serrated carcinogenesis spectrum, in both our SSA/P specimens and in serrated cancers.",1,1.4149252260984753,1932252.858155896,222.49842213303106,0.199183559543726,0.1309441430554232,0.0,0.0,1.0011148272017838,898.0,-0.6267051452353637,0.060237912566759276,1.0,2.0,0.0,126.0,126.0,90.0,252.0,1542,126.0,1.677897393218609e-06,24261.0,898.0,2.0,0,113.0
1930,164761,HP:0002664,"Hyper-methylated CpG loci included the known the tumor suppressor gene RET (p = 5.72 x 10-10), as well as loci in differentially methylated regions for GSG1L, MIR4493, NTNG1, MCIDAS, ZNF568, and RERG.",1,1.3454208312212703,10532873.130266957,248.6928072346046,0.14679757854877915,0.02628547516165559,0.0,0.0,1.0008305647840532,1205.0,-0.4632247979281744,0.09519995588701564,1.0,2.0,7.0,395.0,395.0,52.0,790.0,1542,394.0,1.677897393218609e-06,69059.0,1205.0,1.0,0,548.0
1942,618689,HP:0002664,"Hyper-methylated CpG loci included the known the tumor suppressor gene RET (p = 5.72 x 10-10), as well as loci in differentially methylated regions for GSG1L, MIR4493, NTNG1, MCIDAS, ZNF568, and RERG.",0,1.3828459607148131,2044138.450142857,266.7533702786621,0.1779667381956053,0.1503351048351826,0.0,0.0,0.9988518943742823,870.0,-0.6829191846183598,0.06345653524894933,1.0,2.0,68.0,98.0,98.0,98.0,196.0,1546,96.0,1.6778973932186097e-06,24098.0,872.0,1.0,0,101.0
1943,614086,HP:0002664,"Hyper-methylated CpG loci included the known the tumor suppressor gene RET (p = 5.72 x 10-10), as well as loci in differentially methylated regions for GSG1L, MIR4493, NTNG1, MCIDAS, ZNF568, and RERG.",0,1.3841736171625378,2686091.3659705203,222.3460912628228,0.17231952273752,0.11640830969700525,0.0,0.0,0.9989327641408752,936.0,-0.6721005055713264,0.07027827776804345,1.0,2.0,17.0,154.0,154.0,87.0,308.0,1544,152.0,1.67789739321861e-06,30884.0,938.0,1.0,0,147.0
1944,603683,HP:0000252,"Here de novo missense mutations in the RPS23 gene, which codes for uS12, are reported in two unrelated individuals with microcephaly, hearing loss, and overlapping dysmorphic features.",1,1.4440759663421128,4675102.642344291,586.2972425424896,0.14268951379771272,0.021982024353501595,0.0,0.0,1.00088573959256,1130.0,-0.7618746390227964,0.0815021516417536,1.0,2.0,1.0,97.0,97.0,97.0,194.0,2066,96.0,9.353172034763872e-07,51989.0,1130.0,1.0,0,104.0
1945,107400,HP:0000252,"Here de novo missense mutations in the RPS23 gene, which codes for uS12, are reported in two unrelated individuals with microcephaly, hearing loss, and overlapping dysmorphic features.",0,1.4498013108986911,607736.7027736976,238.56374721896708,0.27158773370067385,0.06069338412320601,0.0,0.0,0.9990834097158572,1090.0,-0.6315983850473114,0.023282400459302386,1.0,2.0,18.0,56.0,56.0,48.0,112.0,2068,54.0,9.353172034763872e-07,13869.0,1092.0,1.0,0,52.0
1946,603683,HP:0000365,"Here de novo missense mutations in the RPS23 gene, which codes for uS12, are reported in two unrelated individuals with microcephaly, hearing loss, and overlapping dysmorphic features.",1,1.4516990951760795,5351150.063192457,587.7809299185759,0.1518029719050256,0.05420022885305043,0.0,0.0,1.0007501875468867,1334.0,-0.7453321102816992,0.05946276674116055,1.0,2.0,1.0,97.0,97.0,97.0,194.0,2474,96.0,6.524672396198986e-07,52869.0,1334.0,1.0,0,106.0
1947,107400,HP:0000365,"Here de novo missense mutations in the RPS23 gene, which codes for uS12, are reported in two unrelated individuals with microcephaly, hearing loss, and overlapping dysmorphic features.",0,1.4539946461862043,755412.569673727,300.3344537576764,0.26076743994753204,0.06562150637987349,0.0,0.0,0.9992277992277993,1294.0,-0.6489768006174185,0.020913770913770915,1.0,2.0,29.0,57.0,57.0,57.0,114.0,2476,55.0,6.524672396198987e-07,17550.0,1296.0,1.0,0,53.0
1948,606628,HP:0001627,"Single nucleotide polymorphism in infant genes in the folate (MTHFS rs12438477), homocysteine (TRDMT1 rs6602178 and GNMT rs11752813) and transsulfuration (GSTP1 rs7941395 and MGST1 rs7294985) pathways were also associated with an increased risk of congenital heart defects.Conclusions Common maternal or infant genetic variants in folate, homocysteine, or transsulfuration pathways are associated with an increased risk of certain congenital heart defects among children of women taking SSRIs during cardiogenesis",0,1.4660457044666213,144172.1715975036,274.51064204045736,0.3571742641353312,0.2332823917113991,0.0,0.0,0.9991364421416234,1157.0,-0.664190453166576,0.009705526025204863,1.0,2.0,43.0,21.0,21.0,21.0,42.0,2276,19.0,7.721745361547558e-07,6513.0,1159.0,1.0,0,19.0
1949,612498,HP:0003198,"This study showed that ADSSL1 myopathy was not rare among distal myopathy patients of Korean origin, and expanded the clinical and genetic spectrum.",0,1.3730685358255452,543883.4015873015,130.88372093023256,0.21083278490598176,0.20966795133320787,0.0,0.0,1.0029154518950436,344.0,-0.6636414705064667,0.14309444708115804,1.0,2.0,1.0,84.0,84.0,68.0,168.0,516,84.0,1.490735081468672e-05,8442.0,344.0,1.0,0,87.0
1955,300226,HP:0000365,"Mutations in one of our candidate genes, Smpx, have been reported as the cause of X-linked deafness in humans.",1,1.4908066730810208,158048.05518060905,573.2418089305245,0.3006045477381612,-0.026439552448905168,0.0,0.0,1.0007980845969673,1254.0,-0.8059367870514993,0.01223602429130215,1.0,2.0,1.0,17.0,17.0,17.0,34.0,2474,16.0,6.524672396198987e-07,9613.0,1254.0,1.0,0,15.0
1972,609520,HP:0001332,"We here review the current knowledge and recent findings in the known genes for isolated dystonia TOR1A, THAP1, and GNAL as well as for the combined dystonias due to mutations in GCH1, ATP1A3, and SGCE.",1,1.4478135650774089,240116.1505671264,195.15686274509804,0.2451008234036936,-0.006949444589638083,0.0,0.0,1.0020833333333332,481.0,-0.7518606575889373,0.060585585585585584,1.0,2.0,1.0,39.0,39.0,39.0,78.0,884,38.0,5.095567365948362e-06,6994.0,481.0,1.0,0,38.0
1974,139312,HP:0001332,"We here review the current knowledge and recent findings in the known genes for isolated dystonia TOR1A, THAP1, and GNAL as well as for the combined dystonias due to mutations in GCH1, ATP1A3, and SGCE.",1,1.4661138855715992,122728.39217821414,225.0488310708899,0.2661852098455625,-0.029655823158546507,0.0,0.0,1.0021505376344086,466.0,-0.8203956005033156,0.04728413863122433,1.0,2.0,1.0,24.0,24.0,24.0,48.0,884,23.0,5.095567365948362e-06,5123.0,466.0,1.0,0,27.0
1977,600225,HP:0001332,"We here review the current knowledge and recent findings in the known genes for isolated dystonia TOR1A, THAP1, and GNAL as well as for the combined dystonias due to mutations in GCH1, ATP1A3, and SGCE.",1,1.3595311650294468,2574343.2247114,209.8690228690228,0.1662247764459072,0.14841700849448067,0.0,0.0,1.0015974440894568,627.0,-0.5751768970835153,0.13946425750696811,1.0,2.0,4.0,179.0,179.0,112.0,358.0,884,178.0,5.095567365948361e-06,27370.0,627.0,1.0,0,242.0
1981,182350,HP:0001332,"We here review the current knowledge and recent findings in the known genes for isolated dystonia TOR1A, THAP1, and GNAL as well as for the combined dystonias due to mutations in GCH1, ATP1A3, and SGCE.",1,1.375009138837215,2029170.005620111,216.96221238086068,0.17391535924654716,0.12443608399048756,0.0,0.0,1.0017182130584192,583.0,-0.6119384562462932,0.1367084578522042,1.0,2.0,4.0,137.0,137.0,134.0,274.0,884,136.0,5.095567365948361e-06,23193.0,583.0,1.0,0,162.0
1983,604149,HP:0001332,"We here review the current knowledge and recent findings in the known genes for isolated dystonia TOR1A, THAP1, and GNAL as well as for the combined dystonias due to mutations in GCH1, ATP1A3, and SGCE.",1,1.4444829979181124,266578.3886762744,203.25705666882138,0.2391945714527095,0.06627760486399101,0.0,0.0,1.0020703933747412,484.0,-0.7435451813464891,0.06669746590695208,1.0,2.0,2.0,41.0,41.0,39.0,82.0,884,40.0,5.095567365948359e-06,7796.0,484.0,1.0,0,40.0
1984,603424,HP:0001332,"We present confirmatory evidence for a role of dystonia genes that had not yet been unequivocally established including PRKRA, TUBB4A, ANO3, and TAF1.",1,1.4229111455200547,669751.5243614218,226.06151018099547,0.202702182000347,0.08318791231531897,0.0,0.0,1.001980198019802,506.0,-0.7275043462457899,0.09891597855437716,1.0,2.0,1.0,64.0,64.0,64.0,128.0,884,63.0,5.095567365948361e-06,12638.0,506.0,1.0,0,66.0
1986,602662,HP:0001332,"We present confirmatory evidence for a role of dystonia genes that had not yet been unequivocally established including PRKRA, TUBB4A, ANO3, and TAF1.",1,1.3709317587013985,2616178.4864898995,237.3883611518984,0.1610990987881749,-0.021579899986396384,0.0,0.0,1.0016891891891893,593.0,-0.6385717455872966,0.15221503122009025,1.0,2.0,2.0,149.0,149.0,127.0,298.0,884,148.0,5.095567365948359e-06,26718.0,593.0,1.0,0,173.0
1987,610110,HP:0001332,"We present confirmatory evidence for a role of dystonia genes that had not yet been unequivocally established including PRKRA, TUBB4A, ANO3, and TAF1.",1,1.4444829979181124,208809.3609788359,171.94462400344753,0.2574701255302115,0.11545595361607798,0.0,0.0,1.0020703933747412,484.0,-0.7056849089470132,0.056422497133959575,1.0,2.0,2.0,41.0,41.0,41.0,82.0,884,40.0,5.095567365948362e-06,6595.0,484.0,1.0,0,36.0
1988,313650,HP:0001332,"We present confirmatory evidence for a role of dystonia genes that had not yet been unequivocally established including PRKRA, TUBB4A, ANO3, and TAF1.",1,1.337246700931315,4231923.321933622,196.727240649259,0.16070403360066415,0.04407417864211128,0.0,0.0,1.0013020833333333,769.0,-0.4484241368951776,0.12521334525357608,1.0,2.0,6.0,293.0,293.0,41.0,586.0,884,292.0,5.095567365948362e-06,36975.0,769.0,1.0,0,357.0
1998,606834,HP:0001332,We finally discuss selected novel genes for dystonia such as KMT2B and VAC14 along with the challenges for gene identification in the NGS era and the translational importance of dystonia genetics in clinical practice,1,1.4121998574553318,1204186.8746064436,268.7259211376859,0.17045817767333776,0.10249176005385784,0.0,0.0,1.001930501930502,519.0,-0.7879028526585078,0.13109558774298655,1.0,2.0,1.0,77.0,77.0,77.0,154.0,884,76.0,5.095567365948359e-06,17622.0,519.0,1.0,0,85.0
2001,604632,HP:0001332,We finally discuss selected novel genes for dystonia such as KMT2B and VAC14 along with the challenges for gene identification in the NGS era and the translational importance of dystonia genetics in clinical practice,1,1.333850353857657,4288637.067780188,162.9202995787174,0.16823039721153876,-0.004355748485114757,0.0,0.0,1.0011415525114151,877.0,-0.4556343425101166,0.09298511425938363,1.0,2.0,26.0,304.0,304.0,5.0,608.0,884,303.0,5.095567365948362e-06,35718.0,877.0,1.0,0,320.0
2002,608921,HP:0002664,"In human breast cancer xenografts in humanized mice, blocking the recruitment of naive CD4+ T cells into tumor by knocking down the expression of PITPNM3, a CCL18 receptor, significantly reduces intratumoral Tregs and inhibits tumor progression.",0,1.4434875001277059,128655.75007635301,202.1248378728924,0.3247568360005997,0.2318205548742429,0.0,0.0,0.9987437185929648,795.0,-0.7233271334359425,0.017190721486983224,1.0,2.0,47.0,24.0,24.0,23.0,48.0,1544,22.0,1.67789739321861e-06,5453.0,797.0,1.0,0,26.0
2004,608921,HP:0002664,Inhibiting naive CD4+ T cell recruitment into tumors by interfering with PITPNM3 recognition of CCL18 may be an attractive strategy for anticancer immunotherapy,0,1.4434875001277059,128655.75007635301,202.1248378728924,0.3247568360005997,0.2318205548742429,0.0,0.0,0.9987437185929648,795.0,-0.7233271334359425,0.017190721486983224,1.0,2.0,47.0,24.0,24.0,23.0,48.0,1544,22.0,1.67789739321861e-06,5453.0,797.0,1.0,0,26.0
2006,613940,HP:0001298,"Biallelic mutations in the SPATA5 gene, encoding ATPase family protein, are an important cause of newly recognized epileptic encephalopathy classified as epilepsy, hearing loss, and mental retardation syndrome (EHLMRS, OMIM: 616577).",0,1.3109054139943377,1561064.3404761902,163.1271320555653,0.17036915649967893,0.1122392403975038,0.0,0.0,0.9976798143851509,430.0,-0.4130979375352002,0.1877416860015468,1.0,2.0,10.0,173.0,173.0,55.0,346.0,486,171.0,1.6796560064498793e-05,17478.0,432.0,1.0,0,229.0
2007,613940,HP:0001250,"Biallelic mutations in the SPATA5 gene, encoding ATPase family protein, are an important cause of newly recognized epileptic encephalopathy classified as epilepsy, hearing loss, and mental retardation syndrome (EHLMRS, OMIM: 616577).",1,1.4314128609624652,13285512.331853801,588.3970967741935,0.13844709057865054,0.07546319927125017,0.0,0.0,1.0005757052389177,1738.0,-0.674606632141686,0.06535678818750898,1.0,2.0,4.0,185.0,185.0,179.0,370.0,3100,184.0,4.156965348783941e-07,98653.0,1738.0,1.0,0,182.0
2008,613940,HP:0000365,"Biallelic mutations in the SPATA5 gene, encoding ATPase family protein, are an important cause of newly recognized epileptic encephalopathy classified as epilepsy, hearing loss, and mental retardation syndrome (EHLMRS, OMIM: 616577).",1,1.4192613750390874,9799820.400937082,448.0898149262973,0.14360137118016802,0.0628450336256635,0.0,0.0,1.0007022471910112,1425.0,-0.6746149063369653,0.07207470924502267,1.0,2.0,5.0,183.0,183.0,177.0,366.0,2474,182.0,6.524672396198988e-07,73127.0,1425.0,1.0,0,230.0
2009,146738,HP:0000028,"In two different patients with unilateral cryptorchidism, we found the variants rs121912556 and p.R105R of INSL3 gene in a heterozygous form associated with cryptorchidism, so we could considered them as risk factors for cryptorchidism.",1,1.4820156507702564,87597.60605202155,415.88725490196083,0.2560172180457776,0.10315686029702642,0.0,0.0,1.001592356687898,629.0,-0.8777881157214983,0.03482932164086154,1.0,2.0,1.0,17.0,17.0,17.0,34.0,1224,16.0,2.661209413229937e-06,6879.0,629.0,1.0,0,15.0
2010,123680,HP:0000518,"Six novel CRYGC mutations (p.Asp65ThrfsX38, p.Arg142GlyfsX5, p.Arg142AlafsX22, p.Tyr144X, p.Arg169X, and p.Tyr46Asp) were identified in other six families with congenital nuclear cataracts, respectively.",1,1.466628108733372,305235.44544486795,302.74734886250343,0.2493024125273481,-0.07670488187758492,0.0,0.0,1.0014662756598245,683.0,-0.7173861253951921,0.04199602409586824,1.0,2.0,1.0,34.0,34.0,34.0,68.0,1298,33.0,2.366863905325444e-06,9781.0,683.0,1.0,0,32.0
2011,608303,HP:0009733,"Through genetic mapping of disease loci and whole-exome sequencing in four unrelated multiplex families presenting with severe AMC, we identified biallelic loss-of-function mutations in LGI4 (leucine-rich glioma-inactivated 4).",0,1.2900794626034242,42534.72380952381,46.96324863883847,0.3198897786043171,-0.09556041731218053,0.0,0.0,0.9935483870967742,154.0,-0.5615097705179297,0.11918941273779984,1.0,2.0,20.0,39.0,39.0,39.0,78.0,110,38.0,7.305135510263716e-05,1441.0,156.0,1.0,0,49.0
2012,608303,HP:0002804,This is consistent with previous studies reporting arthrogryposis in Lgi4-deficient mice due to peripheral hypomyelination.,1,1.3353403231945742,357573.2178571429,118.77339901477829,0.19817182916811674,-0.04566005836122308,0.0,0.0,1.0044052863436126,228.0,-0.2740027895219126,0.2615348945049849,1.0,2.0,2.0,99.0,99.0,2.0,198.0,224,98.0,7.305135510263716e-05,6768.0,228.0,1.0,0,145.0
2013,609739,HP:0000365,"Segregation analysis of heterozygous variants, related to hearing loss, identified by whole exome sequencing in the child (ILDR1: c.1159T&gt;C, SYNE4: c.313G&gt;C, and GPR98: c.18746T&gt;G) excluded them from being responsible for the hearing loss in the proposita.",1,1.4913764443440591,173443.6334125995,656.0650262732418,0.2928783960025632,0.10998494103691736,0.0,0.0,1.0007987220447283,1253.0,-0.8168353373270323,0.013211742297718702,1.0,2.0,1.0,16.0,16.0,16.0,32.0,2474,15.0,6.524672396198987e-07,10363.0,1253.0,1.0,0,15.0
2014,615535,HP:0000365,"Segregation analysis of heterozygous variants, related to hearing loss, identified by whole exome sequencing in the child (ILDR1: c.1159T&gt;C, SYNE4: c.313G&gt;C, and GPR98: c.18746T&gt;G) excluded them from being responsible for the hearing loss in the proposita.",1,1.4936783660063004,112916.09692890749,767.3726758286175,0.2970773649301514,-0.052002687120809986,0.0,0.0,1.000801282051282,1249.0,-0.9087217991893988,0.011701669027529716,1.0,2.0,1.0,12.0,12.0,12.0,24.0,2474,11.0,6.524672396198986e-07,9120.0,1249.0,1.0,0,11.0
2015,608461,HP:0000365,"Therefore, we conclude that the novel splice-site variant identified in COL27A1 is the most likely cause for Steel syndrome in this family and that the hearing loss is part of this syndrome*s phenotype",0,1.4697570451114002,2256981.1655473933,642.5312229644443,0.17558869203688646,0.07817308218770838,0.0,0.0,1.0007733952049498,1294.0,-0.8041212181491263,0.0418506020409505,1.0,2.0,1.0,57.0,57.0,57.0,114.0,2474,56.0,6.524672396198987e-07,35011.0,1294.0,1.0,0,70.0
2016,608625,HP:0001425,Our findings expand the clinical phenotype and further demonstrate the clinical heterogeneity related to PTRH2 variants,0,1.304175523038277,1020065.7136321194,116.94522798168181,0.20117202169370546,0.053859005461075984,0.0,0.0,0.9979674796747968,491.0,-0.2599187267620335,0.12038457098566928,1.0,2.0,15.0,206.0,206.0,2.0,412.0,496,204.0,1.625910509885536e-05,14600.0,493.0,1.0,0,230.0
2018,606810,HP:0100753,"Mutations in the proline dehydrogenase gene PRODH are linked to behavioral alterations in schizophrenia and as part of DiGeorge and velo-cardio-facial syndromes, but the role of PRODH in their etiology remains unclear.",1,1.3377541998231657,19801.74761904762,33.984375,0.3673240817292292,-0.022004887483131425,0.0,0.0,1.0084033613445378,120.0,-0.4410723951404332,0.14215686274509806,1.0,2.0,10.0,39.0,39.0,2.0,78.0,112,38.0,0.00023668639053254435,1015.0,120.0,1.0,0,37.0
2019,102579,HP:0001263,"Furthermore, despite the otolith*s developmental delay until well after postural behaviors normally appear, downstream circuits can drive righting reflexes within a1-2 days of its arrival, indicating that vestibular circuit wiring is not impaired by a delay in patterned activity.",0,1.4538573129559291,4103243.811157782,532.8907038349191,0.17138315694975367,0.08110444348374353,0.0,0.0,0.9993761696818464,1602.0,-0.6913601275076221,0.04104523469865573,1.0,2.0,1.0,104.0,104.0,100.0,208.0,3000,102.0,4.43852443918134e-07,52768.0,1604.0,1.0,0,110.0
2020,300808,HP:0001022,The aim of the present study was to evaluate mutations of the G protein-coupled receptor 143 (GPR143) gene for ocular albinism type 1 (OA1) in Chinese patients.,0,1.3011645113555943,12804.092857142856,41.72222222222222,0.33921021282005903,0.134814738967531,0.0,0.0,0.9873417721518988,78.0,-0.7276629131918888,0.19873417721518988,1.0,2.0,8.0,19.0,19.0,19.0,38.0,42,18.0,0.0002687449610319806,628.0,80.0,1.0,0,19.0
489,601728,HP:0002664,"PTEN, KRAS and PIK3R1 were the most frequently mutated canonical cancer-related genes.",1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
2084,171833,HP:0002664,"PTEN, KRAS and PIK3R1 were the most frequently mutated canonical cancer-related genes.",1,1.3606302301356197,8671978.428571425,272.0410253868332,0.1500307407205458,0.07878600103357282,0.0,0.0,1.0009225092250922,1085.0,-0.4971223745138521,0.1032190045402758,1.0,2.0,7.0,311.0,311.0,119.0,622.0,1542,310.0,1.6778973932186097e-06,60700.0,1085.0,1.0,0,427.0
2085,238331,HP:0002664,"In the present study, we performed three-dimensional fluorescence in situ hybridization experiments in the colorectal cancer cell lines DLD-1 and LoVo using whole chromosome painting probes for chromosomes 8 and 11 and BAC clones targeting four genes with different expression levels assessed by gene expression arrays and RT-PCR.",0,1.3956644880174292,2228940.68395352,255.3409653664341,0.17834961296859925,0.2584640845512909,0.0,0.0,0.9988801791713324,892.0,-0.6867955362211999,0.06861219878197565,1.0,2.0,22.0,115.0,115.0,96.0,230.0,1544,113.0,1.67789739321861e-06,27388.0,894.0,1.0,0,109.0
2086,612021,HP:0002664,OTUD6B encodes a member of the ovarian tumor domain (OTU)-containing subfamily of deubiquitinating enzymes.,0,1.3625593410298231,7317981.685146674,287.6517420072083,0.146118695635266,0.023633482997146158,0.0,0.0,0.9989888776541962,988.0,-0.6031468123767598,0.10082626058359123,1.0,2.0,27.0,218.0,218.0,218.0,436.0,1544,216.0,1.677897393218609e-06,49360.0,990.0,1.0,0,316.0
2087,612021,HP:0001249,"Herein, we report biallelic pathogenic variants in OTUD6B in 12 individuals from 6 independent families with an intellectual disability syndrome associated with seizures and dysmorphic features.",1,1.42553973500506,21019435.8685427,652.3532997347785,0.12841779424626032,0.1051885941305752,0.0,0.0,1.0005500550055006,1819.0,-0.6785317019095362,0.07540077812069278,1.0,2.0,1.0,217.0,217.0,217.0,434.0,3204,216.0,3.8916426584744967e-07,124673.0,1819.0,1.0,0,227.0
2088,612021,HP:0001250,"Herein, we report biallelic pathogenic variants in OTUD6B in 12 individuals from 6 independent families with an intellectual disability syndrome associated with seizures and dysmorphic features.",0,1.4237491876359332,18848564.38496838,594.1028571428571,0.13180720267593488,0.0820201841046769,0.0,0.0,1.0005662514156286,1767.0,-0.6618355511395211,0.072480181200453,1.0,2.0,1.0,217.0,217.0,217.0,434.0,3100,216.0,4.156965348783942e-07,113088.0,1767.0,1.0,0,249.0
2089,612021,HP:0001627,"Homozygous Otud6b knockout mice were subviable, smaller in size, and had congenital heart defects, consistent with the severity of loss-of-function variants in humans.",0,1.4059244999220282,15150986.75237818,485.9942933339818,0.1310626943753027,0.03758443054398535,0.0,0.0,1.0007390983000741,1354.0,-0.6673728997023287,0.09668213641986023,1.0,2.0,1.0,217.0,217.0,217.0,434.0,2274,216.0,7.721745361547563e-07,88559.0,1354.0,1.0,0,253.0
2090,612661,HP:0002664,Our study revealed that the expression of WD repeat containing antisense to P53 (WRAP53) is higher in lung-adenocarcinoma specimens than in specimens from adjacent non-tumor tissues.,1,1.3791735155600702,6951010.075907426,295.0319987712472,0.15155155968750428,0.15622810048119973,0.0,0.0,1.001002004008016,999.0,-0.5888512259554399,0.10414221837067528,1.0,2.0,5.0,228.0,228.0,228.0,456.0,1542,227.0,1.6778973932186097e-06,51915.0,999.0,1.0,0,233.0
2092,612661,HP:0002664,The prevalence of WRAP53 overexpression was significantly higher in patients with tumor larger than 3.0 cm than in patients with tumor smaller than 3.0 cm.,1,1.3791735155600702,6951010.075907426,295.0319987712472,0.15155155968750428,0.15622810048119973,0.0,0.0,1.001002004008016,999.0,-0.5888512259554399,0.10414221837067528,1.0,2.0,5.0,228.0,228.0,228.0,456.0,1542,227.0,1.6778973932186097e-06,51915.0,999.0,1.0,0,233.0
2094,605906,HP:0003198,"Mutations, A147T and A165V, within the ZM of ZASP-LDex10 cause myofibrillar myopathy, but the mechanism is unknown.",1,1.3495782678352652,765357.71984127,128.92051371051718,0.2121385372951664,0.07789330697586251,0.0,0.0,1.0025575447570332,392.0,-0.5381053188980728,0.14836369330340832,1.0,2.0,2.0,129.0,129.0,62.0,258.0,516,128.0,1.4907350814686725e-05,11370.0,392.0,1.0,0,142.0
2095,609317,HP:0002664,We found that hypermethylation of TRIM36 and reduced gene expression was prevalent in several types of human cancers.,0,1.4242616342158676,122242.42197963904,251.79725578537784,0.3202449745811503,0.4830856013553414,0.0,0.0,0.9987357774968396,790.0,-0.6951219157181133,0.017309632353880142,1.0,2.0,93.0,20.0,20.0,20.0,40.0,1544,18.0,1.67789739321861e-06,5422.0,792.0,1.0,0,19.0
2096,614041,HP:0009919,"In childhood tumors, including retinoblastoma, osteosarcoma, and neuroblastoma, the RB-E2F1 pathway is inactivated, as a rule.",1,1.4946156061042326,2021.0,145.91150442477874,0.5913106216173709,0.16146134101556453,0.0,0.0,1.0043859649122806,229.0,-0.7900369565345464,0.016547920018386578,1.0,2.0,107.0,3.0,3.0,3.0,6.0,240,3.0,1.9406547769217335e-05,432.0,229.0,1.0,0,3.0
2097,614041,HP:0002669,"In childhood tumors, including retinoblastoma, osteosarcoma, and neuroblastoma, the RB-E2F1 pathway is inactivated, as a rule.",1,1.425556131857999,92648.15010987614,127.46598451327436,0.2250581975000428,0.3181395287002462,0.0,0.0,1.0038910505836576,258.0,-0.8177262172888058,0.10777305221246944,1.0,2.0,25.0,32.0,32.0,32.0,64.0,278,32.0,1.9406547769217335e-05,3573.0,258.0,1.0,0,32.0
2098,614041,HP:0003006,"In childhood tumors, including retinoblastoma, osteosarcoma, and neuroblastoma, the RB-E2F1 pathway is inactivated, as a rule.",0,1.3548036122293547,169256.3666666666,118.87491030853865,0.2436752538963897,0.08132866341577015,0.0,0.0,0.9962121212121212,263.0,-0.7566848148170537,0.11375071469411092,1.0,2.0,27.0,38.0,38.0,38.0,76.0,128,37.0,1.9406547769217335e-05,3979.0,265.0,1.0,0,38.0
2099,612424,HP:0000007,"Mutations in EYS are associated with autosomal recessive retinitis pigmentosa (arRP) and autosomal recessive cone-rod dystrophy (arCRD) however, the function of EYS and the molecular mechanisms of how these mutations cause retinal degeneration are still unclear.",1,1.4682135619027408,7034899.17754113,591.6479119779946,0.19451461470664536,0.363961223451824,0.0,0.0,1.0003699593044766,2704.0,-0.5855664614350008,0.019154697716978943,1.0,2.0,21.0,124.0,124.0,124.0,248.0,5160,123.0,1.5011496554636367e-07,70000.0,2704.0,1.0,0,138.0
2100,612424,HP:0000546,"Mutations in EYS are associated with autosomal recessive retinitis pigmentosa (arRP) and autosomal recessive cone-rod dystrophy (arCRD) however, the function of EYS and the molecular mechanisms of how these mutations cause retinal degeneration are still unclear.",0,1.3376631168441575,955197.8888888888,152.34353365738698,0.18016779028081809,0.036571634809453565,0.0,0.0,0.9970930232558141,343.0,-0.5192995190805433,0.2063700707785642,1.0,2.0,1.0,124.0,124.0,125.0,248.0,440,122.0,2.0474601257140515e-05,12246.0,345.0,1.0,0,145.0
2102,612424,HP:0000505,"We constructed an EYS-knockout zebrafish-line by TALEN technology which showed visual impairment at an early age, while the histological and immunofluorescence assays indicated the presence of progressive retinal degeneration with a cone predominately affected pattern.",1,1.4274844266064637,4742910.3870058125,395.6096227446692,0.1617874845634655,0.13291819742239855,0.0,0.0,1.000937207122774,1068.0,-0.6610359528255461,0.07609981431364496,1.0,2.0,1.0,124.0,124.0,124.0,248.0,1888,123.0,1.1197894795778392e-06,43360.0,1068.0,1.0,0,143.0
2111,179035,HP:0002664,"Here, we hypothesize that PYCR1 might be a novel prognostic biomarker and therapeutic target for breast cancer.",0,1.3575580574574715,7334887.157969645,283.1266528542793,0.14584659973811215,0.015183651323034134,0.0,0.0,0.9990029910269193,1002.0,-0.5920422082649268,0.10123216009342492,1.0,2.0,28.0,230.0,230.0,224.0,460.0,1544,228.0,1.67789739321861e-06,50971.0,1004.0,1.0,0,333.0
574,600960,HP:0002664,"In this study, breast cancer tissue samples were obtained from Zhejiang University (ZJU set).",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
2123,179035,HP:0002664,"The prognostic significance and performance of PYCR1 mRNA were validated on 13 worldwide independent microarray data sets, composed of 2500 assessable breast cancer cases.",0,1.3575580574574715,7334887.157969645,283.1266528542793,0.14584659973811215,0.015183651323034134,0.0,0.0,0.9990029910269193,1002.0,-0.5920422082649268,0.10123216009342492,1.0,2.0,28.0,230.0,230.0,224.0,460.0,1544,228.0,1.67789739321861e-06,50971.0,1004.0,1.0,0,333.0
598,600960,HP:0002664,"The prognostic significance and performance of PYCR1 mRNA were validated on 13 worldwide independent microarray data sets, composed of 2500 assessable breast cancer cases.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
2119,179035,HP:0002664,"Our findings revealed that both PYCR1 mRNA and protein expression were significantly associated with tumor size, grade and invasive molecular subtypes of breast cancers.",0,1.3575580574574715,7334887.157969645,283.1266528542793,0.14584659973811215,0.015183651323034134,0.0,0.0,0.9990029910269193,1002.0,-0.5920422082649268,0.10123216009342492,1.0,2.0,28.0,230.0,230.0,224.0,460.0,1544,228.0,1.67789739321861e-06,50971.0,1004.0,1.0,0,333.0
2115,179035,HP:0002664,"Independent and pooled analyses verified that higher PYCR1 mRNA levels were significantly associated with poor survival of breast cancer patients, regardless of estrogen receptor (ER) status.",0,1.3575580574574715,7334887.157969645,283.1266528542793,0.14584659973811215,0.015183651323034134,0.0,0.0,0.9990029910269193,1002.0,-0.5920422082649268,0.10123216009342492,1.0,2.0,28.0,230.0,230.0,224.0,460.0,1544,228.0,1.67789739321861e-06,50971.0,1004.0,1.0,0,333.0
2107,179035,HP:0002664,Further population study also validated that chemotherapy significantly improved survival in early-stage breast cancer patients with low PYCR1 expression levels.,0,1.3575580574574715,7334887.157969645,283.1266528542793,0.14584659973811215,0.015183651323034134,0.0,0.0,0.9990029910269193,1002.0,-0.5920422082649268,0.10123216009342492,1.0,2.0,28.0,230.0,230.0,224.0,460.0,1544,228.0,1.67789739321861e-06,50971.0,1004.0,1.0,0,333.0
2127,179035,HP:0002664,"Therefore, PYCR1 might serve as a prognostic biomaker for either ER-positive or ER-negative breast cancer subtypes and can also be a potential target for breast cancer therapy",0,1.3575580574574715,7334887.157969645,283.1266528542793,0.14584659973811215,0.015183651323034134,0.0,0.0,0.9990029910269193,1002.0,-0.5920422082649268,0.10123216009342492,1.0,2.0,28.0,230.0,230.0,224.0,460.0,1544,228.0,1.67789739321861e-06,50971.0,1004.0,1.0,0,333.0
2131,602023,HP:0001425,"Bartter syndrome type 3 is a clinically heterogeneous hereditary salt-losing tubulopathy caused by mutations of the chloride voltage-gated channel Kb gene (CLCNKB), which encodes the ClC-Kb chloride channel involved in NaCl reabsorption in the renal tubule.",1,1.336650345082932,980701.7748851458,103.1164251390518,0.21496756748220425,0.16310250261711612,0.0,0.0,1.0017636684303348,568.0,-0.2703851267092355,0.08938818093747672,1.0,2.0,12.0,193.0,193.0,2.0,386.0,494,192.0,9.644689633887583e-06,14394.0,568.0,1.0,0,241.0
2132,607672,HP:0001425,"Bartter syndrome type 3 is a clinically heterogeneous hereditary salt-losing tubulopathy caused by mutations of the chloride voltage-gated channel Kb gene (CLCNKB), which encodes the ClC-Kb chloride channel involved in NaCl reabsorption in the renal tubule.",0,1.3227397260273972,722622.7015984015,109.64279461647881,0.21277656991070207,0.10010049877293486,0.0,0.0,0.9974747474747476,395.0,-0.42735754879506255,0.13175838994478792,1.0,2.0,8.0,141.0,141.0,24.0,282.0,496,139.0,1.6259105098855364e-05,10357.0,397.0,1.0,0,163.0
2133,615618,HP:0006785,"Recently, a new type of limb-girdle muscular dystrophy (LGMD type 2Z) has been identified due to a missense mutation in POGLUT1 (protein O-glucosyltransferase-Rumi), an enzyme capable of adding glucose to a distinct serine residue of epidermal growth factor-like repeats containing a C-X-S-X-(P/A)-C consensus sequence such as Notch receptors.",0,1.3031015037593985,9598.833333333334,43.18449612403101,0.323652304411714,0.25392826558429976,0.0,0.0,0.983050847457627,58.0,-0.8506444302249799,0.2915254237288136,1.0,2.0,4.0,16.0,16.0,16.0,32.0,66,15.0,0.0005165289256198346,516.0,60.0,1.0,0,16.0
2134,602690,HP:0002668,Methods of diagnosing malignant pheochromocytoma (PCC) or paraganglioma (PGL) are needed.,1,1.4791825143262842,117396.99615874955,273.5338983050848,0.2851855398126953,0.07083126274117219,0.0,0.0,1.0016447368421053,609.0,-0.7190956228417434,0.027196223316912974,1.0,2.0,31.0,19.0,19.0,19.0,38.0,358,19.0,2.863024327117708e-06,5035.0,609.0,1.0,0,19.0
2136,107323,HP:0001250,"In neonatal seizures, defects in ALDH7A1 and PNPO explain a major fraction of cases.",1,1.4717393594605983,2903699.6602456104,724.767311827957,0.1767521512628261,0.15696290876680252,0.0,0.0,1.0006191950464398,1616.0,-0.7471745118829671,0.03516000980903044,1.0,2.0,1.0,66.0,66.0,66.0,132.0,3100,65.0,4.156965348783942e-07,45881.0,1616.0,1.0,0,63.0
2137,608894,HP:0000657,Biallelic pathogenic variant in AHI1 gene can cause Joubert syndrome-related disorders with oculomotor apraxia characteristics.,1,1.3788090675230054,816419.719047619,161.15645802805108,0.1925461903682085,0.07185263207395827,0.0,0.0,1.0027397260273974,366.0,-0.6654835480954414,0.15745190508271578,1.0,2.0,1.0,85.0,85.0,85.0,170.0,170,85.0,1.2574820180071427e-05,10517.0,366.0,1.0,0,106.0
2138,608894,HP:0000486,"Therefore, we concluded that AHI1 c.3257A&gt;G and NEB c.914 A&gt;G were potential causal variants in this strabismus pedigree.",1,1.3713014688381269,15261415.703752587,406.6790197735051,0.12577229470425896,0.04753115035962213,0.0,0.0,1.0008976660682227,1115.0,-0.6164137649599066,0.13763193275957847,1.0,2.0,1.0,281.0,281.0,281.0,562.0,1668,280.0,1.434257234034924e-06,85477.0,1115.0,1.0,0,304.0
2139,161650,HP:0000486,"Therefore, we concluded that AHI1 c.3257A&gt;G and NEB c.914 A&gt;G were potential causal variants in this strabismus pedigree.",0,1.357938692673406,9654887.118063198,299.0794335215866,0.1380167579851011,0.05594194218627438,0.0,0.0,0.999124343257443,1141.0,-0.5786251206243308,0.10389134808236536,1.0,2.0,6.0,295.0,295.0,121.0,590.0,1670,293.0,1.430828048808406e-06,67805.0,1143.0,1.0,0,343.0
791,171834,HP:0002664,"Oncogenic PIK3CA mutations are found in a significant fraction of human cancers, but therapeutic inhibition of PI3K has only shown limited success in clinical trials.",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
819,171834,HP:0002664,"To understand how mutant PIK3CA contributes to cancer cell proliferation, we used genome scale loss-of-function screening in a large number of genomically annotated cancer cell lines.",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
756,171834,HP:0002664,"As expected, we found that PIK3CA mutant cancer cells require PIK3CA but also require the expression of the TCA cycle enzyme 2-oxoglutarate dehydrogenase (OGDH).",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
2140,613022,HP:0002664,"As expected, we found that PIK3CA mutant cancer cells require PIK3CA but also require the expression of the TCA cycle enzyme 2-oxoglutarate dehydrogenase (OGDH).",0,1.4226877766899368,944483.6554422484,295.0152344522852,0.20323169254737453,0.15427903317111225,0.0,0.0,0.9987966305655838,830.0,-0.7560005486139186,0.048855063408312506,1.0,2.0,39.0,58.0,58.0,57.0,116.0,1544,56.0,1.6778973932186106e-06,16889.0,832.0,1.0,0,54.0
2141,608381,HP:0000546,"In humans, CERKL mutations cause widespread retinal degeneration: early dysfunction and loss of rod and cone photoreceptors in the outer retina and, progressively, death of cells in the inner retina.",0,1.3397505125917581,888201.2235209236,155.9098466221754,0.1796181520804484,-0.011704750684318057,0.0,0.0,0.9970326409495548,336.0,-0.5390555253333134,0.21198180956227064,1.0,2.0,1.0,117.0,117.0,118.0,234.0,440,115.0,2.0474601257140522e-05,12073.0,338.0,1.0,0,142.0
2142,300011,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.3247544388609716,5129675.188388544,203.98634925510675,0.15245516337739515,0.0131616095927979,0.0,0.0,0.9987639060568604,808.0,-0.3189365524102072,0.12665842604037908,1.0,2.0,7.0,332.0,332.0,10.0,664.0,768,330.0,5.5103705173135855e-06,41499.0,810.0,1.0,0,448.0
2143,606978,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.3415334709229048,3908916.251082252,240.348810286221,0.14914481079470573,0.0978231298944326,0.0,0.0,0.9983221476510068,595.0,-0.5149984351662816,0.18617134891459536,1.0,2.0,1.0,213.0,213.0,207.0,426.0,768,211.0,6.746500252993759e-06,33121.0,597.0,1.0,0,338.0
2144,610222,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.3440737121317885,2618603.076984126,205.9896138366776,0.1601727053349763,0.06438285636419955,0.0,0.0,0.9982300884955752,564.0,-0.5757385980659855,0.16033647080896835,1.0,2.0,3.0,178.0,178.0,116.0,356.0,768,176.0,6.746500252993758e-06,25637.0,566.0,1.0,0,221.0
2145,602063,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.3429659498207889,1976971.045490621,188.24432804112686,0.1700310086584898,0.1031946565351776,0.0,0.0,0.9981651376146792,544.0,-0.584752041247536,0.1455455859125584,1.0,2.0,6.0,156.0,156.0,108.0,312.0,768,154.0,6.7465002529937596e-06,21655.0,546.0,1.0,0,203.0
2146,607983,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.3533200979978035,2512349.738453213,217.17688489185443,0.1580329206624428,0.10639800748879588,0.0,0.0,0.9981684981684982,545.0,-0.6206148675379137,0.1676945845135973,1.0,2.0,1.0,161.0,161.0,145.0,322.0,768,159.0,6.7465002529937596e-06,25042.0,547.0,1.0,0,199.0
2147,176876,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.326239271439887,6000200.8866883125,220.60347294252296,0.1482609851065645,0.05748524483991078,0.0,0.0,0.9987834549878344,821.0,-0.3112078892390619,0.13447922117468286,1.0,2.0,6.0,351.0,351.0,9.0,702.0,778,349.0,5.188848127604154e-06,45488.0,823.0,1.0,0,457.0
2149,164757,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3448847893403093,7925441.8446886465,244.2364171310549,0.1468626669603892,0.060585863461271414,0.0,0.0,1.0009505703422052,1053.0,-0.2563451421618408,0.10745868223688247,1.0,2.0,15.0,381.0,381.0,3.0,762.0,798,381.0,2.221032735801493e-06,59519.0,1053.0,1.0,0,410.0
2150,176872,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3339284266448397,6185573.137121213,244.67314444806118,0.14411919900822942,0.01565736556115457,0.0,0.0,1.0013175230566536,760.0,-0.3171554783794008,0.1611712086540462,1.0,2.0,1.0,330.0,330.0,12.0,660.0,766,330.0,6.781684027777778e-06,46485.0,760.0,1.0,0,471.0
2151,190070,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3554603841679134,9396921.799653605,251.2115863151056,0.14908988446937388,-0.002050036713614157,0.0,0.0,1.0008103727714748,1235.0,-0.2763256792169607,0.08710818312456119,1.0,2.0,12.0,383.0,383.0,9.0,766.0,804,383.0,1.3743645282012732e-06,66376.0,1235.0,1.0,0,417.0
2152,601247,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.337455093661791,4334301.801190477,233.54189016463286,0.14887337225637987,0.03889029809504065,0.0,0.0,0.9983948635634028,622.0,-0.4854912797618655,0.17850454788657036,1.0,2.0,1.0,233.0,233.0,132.0,466.0,768,231.0,6.7465002529937596e-06,34697.0,624.0,1.0,0,316.0
2153,602775,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3489329033423476,4019346.453174602,248.56654046997383,0.1472996412464744,0.030412462601434962,0.0,0.0,1.0017182130584192,583.0,-0.5596005154824625,0.1925047007715749,1.0,2.0,2.0,197.0,197.0,199.0,394.0,766,196.0,6.781684027777778e-06,32659.0,583.0,1.0,0,277.0
2154,164790,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3396950135653476,7378032.809815186,240.1075553975913,0.14584526656107855,0.024994471237899826,0.0,0.0,1.0010471204188482,956.0,-0.2447071184990696,0.12074525181274508,1.0,2.0,5.0,379.0,379.0,3.0,758.0,800,379.0,3.0351224368391026e-06,55119.0,956.0,1.0,0,468.0
2155,164760,HP:0000256,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.3340491709732123,5572950.824603177,228.4177329313504,0.14682485847222326,0.05725102649977195,0.0,0.0,1.0013440860215057,745.0,-0.35930706755851993,0.1533845709749585,1.0,2.0,3.0,328.0,328.0,14.0,656.0,766,327.0,6.781684027777778e-06,42509.0,745.0,1.0,0,440.0
2156,300011,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3513917632882595,15468313.577350425,328.3762593921344,0.13235299616010338,0.0582402191266749,0.0,0.0,1.0007733952049498,1294.0,-0.5115253238298739,0.11203233198377664,1.0,2.0,5.0,407.0,407.0,117.0,814.0,1738,406.0,1.3211784912141623e-06,93723.0,1294.0,1.0,0,637.0
2157,606978,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.3876095959201482,10831015.965012766,425.24516902968077,0.13218768895888328,0.07542392162433323,0.0,0.0,0.9990757855822552,1081.0,-0.6555075145243702,0.12495583739970607,1.0,2.0,1.0,213.0,213.0,213.0,426.0,1740,211.0,1.3181465278043237e-06,73212.0,1083.0,1.0,0,257.0
2159,602063,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.3969531940717026,5201727.523822123,340.64133115096234,0.15358915687222147,0.03892380405569873,0.0,0.0,0.9990300678952472,1030.0,-0.6467210445320449,0.0884010406093279,1.0,2.0,6.0,156.0,156.0,153.0,312.0,1740,154.0,1.3181465278043243e-06,47029.0,1032.0,1.0,0,179.0
2160,607983,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.4074959810096623,7302456.458944333,427.09697537967577,0.13878372648734405,0.04672177485765184,0.0,0.0,1.0009708737864076,1031.0,-0.7080775926902634,0.10983398152420593,1.0,2.0,1.0,162.0,162.0,162.0,324.0,1738,161.0,1.3211784912141636e-06,58318.0,1031.0,1.0,0,192.0
2161,176876,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3500188162295654,18241440.933430467,341.915611814346,0.12901841692029498,0.1192936815405198,0.0,0.0,1.0007656967840737,1307.0,-0.4965698135879202,0.11666711581295673,1.0,2.0,4.0,423.0,423.0,124.0,846.0,1738,422.0,1.3211784912141636e-06,99572.0,1307.0,1.0,0,624.0
2162,190020,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3434394647303711,22530276.308585856,352.3218340464992,0.12515357839440094,0.09916418169132456,0.0,0.0,1.0007230657989878,1384.0,-0.4688070727359272,0.11904254385414967,1.0,2.0,2.0,482.0,482.0,97.0,964.0,1738,482.0,1.3211784912141623e-06,113928.0,1384.0,1.0,0,800.0
2163,164757,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3361088292710304,26239304.21154401,341.6737011146798,0.1257567544487958,0.1322566505655957,0.0,0.0,1.0006501950585176,1539.0,-0.3879963301395132,0.10922009546333686,1.0,2.0,9.0,610.0,610.0,36.0,1220.0,1750,610.0,1.321178491214163e-06,129261.0,1539.0,1.0,0,932.0
2164,176872,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3572540715461672,18484060.022247206,381.6807513743349,0.12629368621335724,0.018080248270245312,0.0,0.0,1.0008032128514055,1246.0,-0.5251979914492952,0.12938560018565434,1.0,2.0,1.0,371.0,371.0,201.0,742.0,1738,370.0,1.3211784912141623e-06,100356.0,1246.0,1.0,0,574.0
2166,601247,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3835546562514711,12564742.83278388,405.8806014704537,0.1313132257832096,0.06345496799391942,0.0,0.0,1.000903342366757,1108.0,-0.6349870986754679,0.12405630073147905,1.0,2.0,1.0,238.0,238.0,239.0,476.0,1738,237.0,1.3211784912141631e-06,76081.0,1108.0,1.0,0,300.0
2167,602775,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",0,1.3898202296912523,11044306.523751248,429.6615074798619,0.13117725001929095,0.03130779729516304,0.0,0.0,0.9990654205607478,1069.0,-0.6709549332044007,0.12321264954579965,1.0,2.0,2.0,200.0,200.0,200.0,400.0,1740,198.0,1.3181465278043233e-06,70599.0,1071.0,1.0,0,237.0
2168,164790,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3399266827122192,23938776.790942397,342.22294386639265,0.12565535015297716,0.08283322816338641,0.0,0.0,1.0006939625260236,1442.0,-0.4439037796144261,0.11374151676530687,1.0,2.0,5.0,524.0,524.0,67.0,1048.0,1764,523.0,1.3211784912141631e-06,118173.0,1442.0,1.0,0,794.0
2169,164760,HP:0002650,"Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.",1,1.3593713206855291,16971949.114532687,364.62218591255584,0.12866863225733138,0.0290559576361106,0.0,0.0,1.0008130081300814,1231.0,-0.5376088170876129,0.1230779391465726,1.0,2.0,3.0,359.0,359.0,166.0,718.0,1738,358.0,1.321178491214163e-06,93178.0,1231.0,1.0,0,472.0
2170,172471,HP:0002664,"Screening of breast cancer cell lines showed that the mRNA expression levels for the PHKG2 and DPEP1 were lower in non-tumorigenic mammary epithelial cell MCF10A, but elevated in other cell lines.",0,1.4002900629258082,2830239.6111738333,241.014915693904,0.18257711512012506,0.070159881857729,0.0,0.0,1.0010729613733906,933.0,-0.6178368507138187,0.07421028662903828,1.0,2.0,5.0,158.0,158.0,117.0,316.0,1542,157.0,1.67789739321861e-06,32265.0,933.0,1.0,0,151.0
2174,611192,HP:0100543,"16q24 deletion involving the ANKRD11 gene, ranging from 137 kb to 2 Mb, have been associated with a microdeletion syndrome characterized by variable cognitive impairment, autism spectrum disorder, facial dysmorphisms with dental anomalies, brain abnormalities essentially affecting the corpus callosum and short stature.",0,1.338026768996047,5109560.27395105,198.687517975266,0.16480709484866765,0.05614067678441779,0.0,0.0,0.9988584474885844,875.0,-0.4923002068871222,0.10401274581777854,1.0,2.0,6.0,280.0,280.0,48.0,560.0,1142,278.0,3.056384175265294e-06,39954.0,877.0,1.0,0,344.0
2175,611192,HP:0000717,"16q24 deletion involving the ANKRD11 gene, ranging from 137 kb to 2 Mb, have been associated with a microdeletion syndrome characterized by variable cognitive impairment, autism spectrum disorder, facial dysmorphisms with dental anomalies, brain abnormalities essentially affecting the corpus callosum and short stature.",1,1.3531194971357243,1550723.5444444444,168.12485964518302,0.17314562011529294,0.1754195986660133,0.0,0.0,1.002222222222222,451.0,-0.4690361706448775,0.16358709041635872,1.0,2.0,7.0,146.0,146.0,146.0,292.0,292,146.0,1.0679653124866504e-05,16600.0,451.0,1.0,0,154.0
2176,611192,HP:0000164,"16q24 deletion involving the ANKRD11 gene, ranging from 137 kb to 2 Mb, have been associated with a microdeletion syndrome characterized by variable cognitive impairment, autism spectrum disorder, facial dysmorphisms with dental anomalies, brain abnormalities essentially affecting the corpus callosum and short stature.",1,1.3625570633968498,13738651.847760575,358.21256126415415,0.130774870619142,0.03318924514759785,0.0,0.0,1.000925925925926,1081.0,-0.5605715608086982,0.13435604892589167,1.0,2.0,1.0,304.0,304.0,248.0,608.0,1552,303.0,1.6563723127429687e-06,78429.0,1081.0,1.0,0,428.0
2177,611192,HP:0004322,"16q24 deletion involving the ANKRD11 gene, ranging from 137 kb to 2 Mb, have been associated with a microdeletion syndrome characterized by variable cognitive impairment, autism spectrum disorder, facial dysmorphisms with dental anomalies, brain abnormalities essentially affecting the corpus callosum and short stature.",1,1.3841518186419022,20080730.061168,443.94999561672654,0.12711874028721265,0.13836687183346752,0.0,0.0,1.0007012622720897,1427.0,-0.5969436760349744,0.10463796290927033,1.0,2.0,1.0,304.0,304.0,298.0,608.0,2244,303.0,7.929402939746845e-07,106464.0,1427.0,1.0,0,445.0
2179,611192,HP:0004322,"On the other hand, patients carrying either deletions encompassing solely ANKRD11 or its loss-of-function variants were reported in association with the KBG syndrome, characterized by a very similar phenotype, including mild-to-moderate intellectual disability, short stature and macrodontia of upper incisors, with inter and intrafamilial variability.",1,1.3841518186419022,20080730.061168,443.94999561672654,0.12711874028721265,0.13836687183346752,0.0,0.0,1.0007012622720897,1427.0,-0.5969436760349744,0.10463796290927033,1.0,2.0,1.0,304.0,304.0,298.0,608.0,2244,303.0,7.929402939746845e-07,106464.0,1427.0,1.0,0,445.0
2181,611192,HP:0001249,"On the other hand, patients carrying either deletions encompassing solely ANKRD11 or its loss-of-function variants were reported in association with the KBG syndrome, characterized by a very similar phenotype, including mild-to-moderate intellectual disability, short stature and macrodontia of upper incisors, with inter and intrafamilial variability.",1,1.4059278985661514,25489356.55587433,531.7790548699372,0.12849579660096186,0.0739056387131231,0.0,0.0,1.0005246589716683,1907.0,-0.6035225548122323,0.07497203377846351,1.0,2.0,1.0,304.0,304.0,295.0,608.0,3204,303.0,3.8916426584744994e-07,136252.0,1907.0,1.0,0,403.0
2182,611192,HP:0001627,"By comparing the clinical and genetic features of our patients with those previously reported, we show that the severity of the neurological phenotype and the frequency of congenital heart defects characterize the deletions that, besides ANKRD11, contain ZFPM1, CDH15 and ZNF778 as well.",1,1.3849653036059566,18396892.222125534,419.7532534567527,0.1299173782067305,0.10266215348618664,0.0,0.0,1.0006939625260236,1442.0,-0.5918229076382927,0.09716052864351983,1.0,2.0,2.0,302.0,302.0,296.0,604.0,2274,301.0,7.721745361547563e-07,100946.0,1442.0,1.0,0,425.0
2183,114019,HP:0001627,"By comparing the clinical and genetic features of our patients with those previously reported, we show that the severity of the neurological phenotype and the frequency of congenital heart defects characterize the deletions that, besides ANKRD11, contain ZFPM1, CDH15 and ZNF778 as well.",0,1.4302375010894135,4439306.525301535,376.1735378188214,0.16384195395257198,0.044016245002326704,0.0,0.0,0.999210110584518,1265.0,-0.6948173034651457,0.055252359381604485,1.0,2.0,5.0,126.0,126.0,121.0,252.0,2276,124.0,7.721745361547563e-07,44313.0,1267.0,1.0,0,123.0
2184,611192,HP:0001263,"The single patient not deleted for ANKRD11, whose phenotype is characterized by milder psychomotor delay, cardiac congenital malformation, thrombocytopenia and astigmatism, confirms all this data",1,1.4019171535800443,23394394.865703616,509.2607224488457,0.12861863120826458,0.07553316339923001,0.0,0.0,1.0005546311702718,1804.0,-0.5954453931152361,0.07936021880261156,1.0,2.0,1.0,304.0,304.0,283.0,608.0,2998,303.0,4.4444444444444497e-07,129064.0,1804.0,1.0,0,363.0
2185,616146,HP:0001156,Our findings widen the phenotype spectrum caused by TGDS mutations and underline the phenotypic overlap with Temtamy preaxial brachydactyly syndrome.,0,1.330708940667447,3332308.9619047614,232.7271241830065,0.14749885877389313,0.0968421188962161,0.0,0.0,0.9980430528375732,510.0,-0.4611381829119832,0.2197819838551859,1.0,2.0,3.0,200.0,200.0,194.0,400.0,614,198.0,1.0541406645302749e-05,28751.0,512.0,1.0,0,302.0
33,191170,HP:0002664,"Here, we report that GOF p53 induces tumorigenicity through simultaneous activation of key oncogenic pathways including those controlling putative tumor-initiating cell functions.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
161,191170,HP:0002664,"Thus, therapeutic inhibition of one GOF p53-induced pathway would be insufficient to prevent tumor growth as the oncoprotein activates a multitude of parallel pathways.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
153,191170,HP:0002664,"This discovery suggests enormous selection advantage for cancer cells with GOF p53 to induce oncogenic growth, highlighting the problems of cancer therapy",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
2192,300350,HP:0002664,"Herein, we report that CHRDL1 expression was significantly down-regulated in gastric cancer tissues and associated with poor survival.",0,1.3681494679245652,147140.9307674776,112.75209684392564,0.34330867512702834,0.4213369203784618,0.0,0.0,0.9987760097919216,816.0,-0.5361475834331736,0.016534342052891938,1.0,2.0,149.0,41.0,41.0,31.0,82.0,1544,39.0,1.6778973932186103e-06,5525.0,818.0,1.0,0,32.0
2195,300350,HP:0002664,"In vitro, CHRDL1 knockdown promoted tumor cell proliferation and migration through BMPR II by activating Akt, Erk and b-catenin.",0,1.3681494679245652,147140.9307674776,112.75209684392564,0.34330867512702834,0.4213369203784618,0.0,0.0,0.9987760097919216,816.0,-0.5361475834331736,0.016534342052891938,1.0,2.0,149.0,41.0,41.0,31.0,82.0,1544,39.0,1.6778973932186103e-06,5525.0,818.0,1.0,0,32.0
2189,300350,HP:0002664,"Furthermore, we observed the hypermethylation of the CHRDL1 promoter in gastric cancer, which induced low expression of CHRDL1 and decreased its secretion to the supernatant.",0,1.3681494679245652,147140.9307674776,112.75209684392564,0.34330867512702834,0.4213369203784618,0.0,0.0,0.9987760097919216,816.0,-0.5361475834331736,0.016534342052891938,1.0,2.0,149.0,41.0,41.0,31.0,82.0,1544,39.0,1.6778973932186103e-06,5525.0,818.0,1.0,0,32.0
2186,300350,HP:0002664,"Finally, in vivo experiments confirmed that CHRDL1 acted as a tumor suppressor gene in suppressing tumor growth and metastasis",0,1.3681494679245652,147140.9307674776,112.75209684392564,0.34330867512702834,0.4213369203784618,0.0,0.0,0.9987760097919216,816.0,-0.5361475834331736,0.016534342052891938,1.0,2.0,149.0,41.0,41.0,31.0,82.0,1544,39.0,1.6778973932186103e-06,5525.0,818.0,1.0,0,32.0
2198,606409,HP:0002664,"Moreover, we observed that well-differentiated RT-112 and de-differentiated Cal-29 bladder cancer cells show an inverse expression of tricellulin and Itch.",0,1.3593902648266878,6127323.213671051,265.38211315654667,0.15542181782607156,0.1389030766129514,0.0,0.0,0.9990099009900992,1009.0,-0.5741917084024085,0.09579379302915454,1.0,2.0,21.0,236.0,236.0,182.0,472.0,1544,234.0,1.6778973932186097e-06,48908.0,1011.0,1.0,0,271.0
2199,608053,HP:0002664,"Immunoperoxidase levels in the tumor were positive for factor VIII and CD31 and negative for S100, protein Melan-A, CD34, synaptophysin, chromogranin, desmin, muscle specific actin, ETFA (EMA), KRT20 (CK20), CDX2, TTF1, LNPEP (PLAP), inhibin, ?-fetoprotein, CD30, hepatocyte paraffin, and aberrant expression of cytokeratin 7 and pankeratin.",0,1.3836362542128071,2733857.0880215364,250.60106444832059,0.17160720420719386,0.1617909187244531,0.0,0.0,0.9989094874591058,916.0,-0.6788421808638752,0.0742617657750123,1.0,2.0,27.0,140.0,140.0,107.0,280.0,1550,138.0,1.6778973932186097e-06,31257.0,918.0,1.0,0,131.0
2200,600635,HP:0002664,"Immunoperoxidase levels in the tumor were positive for factor VIII and CD31 and negative for S100, protein Melan-A, CD34, synaptophysin, chromogranin, desmin, muscle specific actin, ETFA (EMA), KRT20 (CK20), CDX2, TTF1, LNPEP (PLAP), inhibin, ?-fetoprotein, CD30, hepatocyte paraffin, and aberrant expression of cytokeratin 7 and pankeratin.",0,1.3794416672335228,5397745.333810635,255.2521983578738,0.15899844853428846,0.2129550782976513,0.0,0.0,1.0010030090270812,998.0,-0.5825651089295633,0.08997533683213971,1.0,2.0,8.0,222.0,222.0,153.0,444.0,1542,221.0,1.677897393218609e-06,44763.0,998.0,1.0,0,241.0
2203,608707,HP:0001360,"We report here that t-butyl alcohol, which is neither a substrate nor an inhibitor of alcohol dehydrogenases or Cyp2E1, is a potent inducer of holoprosencephaly in Cdon mutant mice.",1,1.4144085370115802,859635.4433746813,212.98919888401755,0.200475189740402,0.06719829917225463,0.0,0.0,1.002222222222222,451.0,-0.6909517852527791,0.11676767676767676,1.0,2.0,2.0,65.0,65.0,65.0,130.0,388,65.0,6.67694916838598e-06,11849.0,451.0,1.0,0,65.0
2205,161015,HP:0002352,"The cases with complete clinical data retrieved on literature search at China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform and PubMed (up to August 2016) by using search terms of&quot;NDUFV1&quot; ,&quot;NDUFS1&quot; , or&quot;leukoencephalopathy&quot; , were summarized.",0,1.3345269146017895,1587266.4785714292,172.37843137254902,0.17377538039238505,0.05232719091420858,0.0,0.0,1.0025125628140703,399.0,-0.37089516343712414,0.2164456367048274,1.0,2.0,1.0,178.0,178.0,12.0,356.0,390,177.0,2.3795359904818562e-05,17186.0,399.0,1.0,0,225.0
2206,157655,HP:0002352,"The cases with complete clinical data retrieved on literature search at China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform and PubMed (up to August 2016) by using search terms of&quot;NDUFV1&quot; ,&quot;NDUFS1&quot; , or&quot;leukoencephalopathy&quot; , were summarized.",0,1.3349120274034836,1672810.999206349,174.45100105374078,0.17437678373136756,0.023706679449577158,0.0,0.0,1.0024213075060533,414.0,-0.33276574132678594,0.21048999309868874,1.0,2.0,1.0,188.0,188.0,12.0,376.0,390,187.0,2.0661157024793387e-05,17995.0,414.0,1.0,0,247.0
2207,608730,HP:0000545,"In order to expand the mutation spectrum of the causative genes in Chinese adult population, we investigated three genes, SLC39A5, LEPREL1 and LRPAP1, in a cohort of 187 independent Chinese patients with high myopia.",1,1.4896311671136255,6345.0,244.61419753086415,0.38579212646831706,0.40535157048609705,0.0,0.0,1.0030395136778116,330.0,-0.9387983566396064,0.02654508611955421,1.0,2.0,1.0,6.0,6.0,6.0,12.0,648,5.0,9.467455621301773e-06,1441.0,330.0,1.0,0,5.0
2209,300697,HP:0002664,"The HECT-type ubiquitin ligase HECT, UBA and WWE Domain Containing 1, (HUWE1) regulates key cancer-related pathways, including the Myc oncogene.",0,1.3452493941677022,8415360.613458913,274.2046338875133,0.14496749329028089,0.007506192700240255,0.0,0.0,0.9990347490347492,1035.0,-0.5226146533131448,0.10158312328032676,1.0,2.0,37.0,265.0,265.0,264.0,530.0,1544,263.0,1.67789739321861e-06,54567.0,1037.0,1.0,0,392.0
2252,190080,HP:0002664,"The HECT-type ubiquitin ligase HECT, UBA and WWE Domain Containing 1, (HUWE1) regulates key cancer-related pathways, including the Myc oncogene.",1,1.4396536831054232,1166089.637753825,258.33534370946825,0.21512590240969573,0.06608515489589678,0.0,0.0,1.0011764705882351,851.0,-0.6775154399515846,0.05177023570885463,1.0,2.0,1.0,80.0,80.0,80.0,160.0,1542,79.0,1.6778973932186097e-06,18724.0,851.0,1.0,0,67.0
2259,309550,HP:0000717,"Using the larval startle response to the buzz of a predator (wasp), we examined PPI in wild-type flies and two mutants: an fmr1 mutant, which is implicated in Fragile X syndrome, and a centaurin gamma 1A (CenG1A) mutant, which is associated with GTPase, PH, ArfGAP, and ANK domains and implicated in autism.",1,1.356925052158562,1532898.7568181811,167.9535076795351,0.17542167558653346,0.3505909465737255,0.0,0.0,1.0021052631578946,476.0,-0.4324352392112471,0.15037593984962405,1.0,2.0,15.0,146.0,146.0,146.0,292.0,292,146.0,9.127335456960047e-06,17000.0,476.0,1.0,0,154.0
2260,176941,HP:0000007,"Highlights include the discoveries of (i) a new genetic etiology, autosomal recessive SPPL2a deficiency, (ii) TYK2-deficient patients with a clinical phenotype of MSMD, (iii) an allelic form of partial recessive IFN-yR2 deficiency, and (iv) two forms of syndromic MSMD: RORy/RORyT and JAK1 deficiencies.",1,1.4927252449636987,329412.4712702098,433.04043927648576,0.39717495959927096,0.6809836038179574,0.0,0.0,1.0003837298541831,2607.0,-0.4731290066517009,0.003406320017451097,1.0,2.0,734.0,27.0,27.0,27.0,54.0,5160,26.0,1.5011496554636367e-07,11571.0,2607.0,1.0,0,25.0
2261,600168,HP:0002664,"Moreover, the Kaplan-Meier survival analysis was performed using homologenes (MST1R, PIK3CB and PRKCD) of hub genes in human to evaluate whether exposure to bisphenols may adversely affect breast cancer.",0,1.4864147964145076,105510.60435537703,339.78291180285345,0.32497009705061075,0.15919660044879164,0.0,0.0,1.0012722646310432,787.0,-0.8104257486577393,0.017220029034145837,1.0,2.0,6.0,16.0,16.0,16.0,32.0,1542,15.0,1.67789739321861e-06,5326.0,787.0,1.0,0,16.0
2262,176977,HP:0002664,"Moreover, the Kaplan-Meier survival analysis was performed using homologenes (MST1R, PIK3CB and PRKCD) of hub genes in human to evaluate whether exposure to bisphenols may adversely affect breast cancer.",1,1.3557340062504206,6234793.172881285,210.13919810522754,0.16389791860012173,0.1765062290147129,0.0,0.0,1.000896860986547,1116.0,-0.5267524270214364,0.08050211357024607,1.0,2.0,9.0,303.0,303.0,71.0,606.0,1542,302.0,1.67789739321861e-06,50086.0,1116.0,1.0,0,337.0
2263,612719,HP:0000365,Noise-induced hidden hearing loss (NIHHL) has attracted great attention in hearing research and clinical audiology since the discovery of significant noise-induced synaptic damage in the absence of permanent threshold shifts (PTS) in animal models.,0,1.4298954034528661,4922294.0545891095,424.8037843573162,0.15965689508522313,0.06613490442863475,0.0,0.0,0.9992679355783308,1365.0,-0.7142229499469518,0.05399068826908268,1.0,2.0,17.0,127.0,127.0,125.0,254.0,2476,125.0,6.524672396198986e-07,50409.0,1367.0,1.0,0,137.0
2267,300481,HP:0002664,The impact of NOX2 and ROS on cancer development is only partly explored.,0,1.3653698061919182,2860036.8314133836,226.28979409857325,0.1768268155039901,0.0605547755805711,0.0,0.0,0.9989270386266096,931.0,-0.6460131890411832,0.0704957472549209,1.0,2.0,33.0,145.0,145.0,98.0,290.0,1544,143.0,1.6778973932186103e-06,30650.0,933.0,1.0,0,159.0
2264,300481,HP:0002664,"Recent research published in the Journal of Pathology showed that genetic depletion of any of the NOX2 subunits Cyba, Cybb, Ncf1, Ncf2 and Ncf4 reduced the formation of lung metastases following intravenous injection of murine tumor cells.",0,1.3653698061919182,2860036.8314133836,226.28979409857325,0.1768268155039901,0.0605547755805711,0.0,0.0,0.9989270386266096,931.0,-0.6460131890411832,0.0704957472549209,1.0,2.0,33.0,145.0,145.0,98.0,290.0,1544,143.0,1.6778973932186103e-06,30650.0,933.0,1.0,0,159.0
2273,608508,HP:0002664,"Recent research published in the Journal of Pathology showed that genetic depletion of any of the NOX2 subunits Cyba, Cybb, Ncf1, Ncf2 and Ncf4 reduced the formation of lung metastases following intravenous injection of murine tumor cells.",0,1.3688431234399323,2847224.281027679,235.19373557700402,0.1761643254117228,0.022332784129398417,0.0,0.0,0.9989200863930886,925.0,-0.6538411184800066,0.07189638421159318,1.0,2.0,32.0,141.0,141.0,102.0,282.0,1544,139.0,1.6778973932186097e-06,30858.0,927.0,1.0,0,157.0
2275,601488,HP:0002664,"Recent research published in the Journal of Pathology showed that genetic depletion of any of the NOX2 subunits Cyba, Cybb, Ncf1, Ncf2 and Ncf4 reduced the formation of lung metastases following intravenous injection of murine tumor cells.",0,1.3981918279393073,2835889.3361390163,277.55672356805155,0.17455955398766626,0.2354351327711535,0.0,0.0,0.9988839285714284,895.0,-0.6800772442308232,0.07547479694218824,1.0,2.0,21.0,124.0,124.0,123.0,248.0,1544,122.0,1.6778973932186097e-06,30330.0,897.0,1.0,0,136.0
2270,300481,HP:0002664,"These findings, along with the role of NOX2 in maintaining self-tolerance, imply that NOX2 is a targetable immune checkpoint in cancer.",0,1.3653698061919182,2860036.8314133836,226.28979409857325,0.1768268155039901,0.0605547755805711,0.0,0.0,0.9989270386266096,931.0,-0.6460131890411832,0.0704957472549209,1.0,2.0,33.0,145.0,145.0,98.0,290.0,1544,143.0,1.6778973932186103e-06,30650.0,933.0,1.0,0,159.0
2276,164860,HP:0001425,"Due to the heterogeneity of the studies assessed, no meta-analysis could be performed.",1,1.3654241776951028,294106.18066378066,86.96102162115602,0.26106132616321764,0.07821466403390465,0.0,0.0,1.0029411764705882,341.0,-0.5611466507097432,0.10213903743315507,1.0,2.0,8.0,85.0,85.0,54.0,170.0,494,84.0,1.625910509885536e-05,5921.0,341.0,1.0,0,83.0
293,601231,HP:0002664,"In this study, EPA inhibited the expression of IDO via downregulation of protein kinase B (Akt)/mammalian targets of rapamycin (mTOR) signaling pathway in tumor cells.",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
2277,613534,HP:0001970,"Most instances of renal karyomegaly reported in humans represented cases of the genetic syndrome, karyomegalic interstitial nephritis, known to be caused by a mutation in the FAN1 gene.",1,1.4364245363195518,36848.29913419913,69.6270139042154,0.3602269888517592,0.542870123402176,0.0,0.0,1.0045662100456618,220.0,-0.5284482771509261,0.05952677459526775,1.0,2.0,55.0,23.0,23.0,23.0,46.0,170,23.0,2.550760126517702e-05,1434.0,220.0,1.0,0,23.0
1771,604982,HP:0001022,"Hermansky-Pudlak syndrome (HPS) - characterized by the distinct clinical phenotypes of both oculocutaneous albinism and mild bleeding diathesis-is caused by mutations in genes that have crucial roles in the assembly of cellular organelles (skin melanosomes, platelet delta [dense] granules, lung lamellar bodies, and cytotoxic T-cell lymphocyte granules).",1,1.4175208505761765,17581.58452380952,54.66666666666666,0.3573475676206121,0.20552329952719994,0.0,0.0,1.0081967213114755,123.0,-0.7007423014363683,0.11195521791283487,1.0,2.0,12.0,18.0,18.0,18.0,36.0,66,18.0,8.8999644001424e-05,840.0,123.0,1.0,0,18.0
2278,102578,HP:0002352,Progressive multifocal leukoencephalopathy (PML) is a lethal brain disease caused by uncontrolled replication of JC polyomavirus (JCV).,0,0.9949238578680204,388.03045685279193,2.0,0.7071067811865476,0.7577767276240617,0.0,0.0,0.9949238578680204,196.0,-0.9898477157360408,0.010049735938060812,1.0,2.0,196.0,2.0,2.0,2.0,4.0,392,0.0,2.603082049146189e-05,196.0,198.0,0.0,0,1.0
2294,610206,HP:0002664,"In this study, we aimed to examine the expression of SLC4A11 in ovarian cancer and in normal ovarian tissues, its prognostic value and the possible mechanism of its dysregulation.",0,1.4347451328383982,231695.7917167761,185.8252020353188,0.29323932321792395,0.1195747704968767,0.0,0.0,0.9987669543773121,810.0,-0.6651000194545991,0.023184902176355892,1.0,2.0,34.0,35.0,35.0,30.0,70.0,1544,33.0,1.6778973932186097e-06,7634.0,812.0,1.0,0,29.0
2299,610206,HP:0002664,Results showed that SLC4A11 was upregulated in ovarian cancer compared with normal ovarian epithelial tissues.,0,1.4347451328383982,231695.7917167761,185.8252020353188,0.29323932321792395,0.1195747704968767,0.0,0.0,0.9987669543773121,810.0,-0.6651000194545991,0.023184902176355892,1.0,2.0,34.0,35.0,35.0,30.0,70.0,1544,33.0,1.6778973932186097e-06,7634.0,812.0,1.0,0,29.0
2289,610206,HP:0002664,"In patients with primary serous ovarian cancer in TCGA-OV, the cases with lymphatic invasion (N = 133) had significantly higher SLC4A11 expression than those without lymphatic invasion (N = 77) (p = 0.0069).",0,1.4347451328383982,231695.7917167761,185.8252020353188,0.29323932321792395,0.1195747704968767,0.0,0.0,0.9987669543773121,810.0,-0.6651000194545991,0.023184902176355892,1.0,2.0,34.0,35.0,35.0,30.0,70.0,1544,33.0,1.6778973932186097e-06,7634.0,812.0,1.0,0,29.0
2279,610206,HP:0002664,320 out of 578 (55.4%) ovarian cancer cases had SLC4A11 amplification.,0,1.4347451328383982,231695.7917167761,185.8252020353188,0.29323932321792395,0.1195747704968767,0.0,0.0,0.9987669543773121,810.0,-0.6651000194545991,0.023184902176355892,1.0,2.0,34.0,35.0,35.0,30.0,70.0,1544,33.0,1.6778973932186097e-06,7634.0,812.0,1.0,0,29.0
2304,600956,HP:0002664,Our results indicate that AMHR2-ED vaccination may be particularly useful in providing safe and effective preemptive immunity against EOC in women at high genetic or familial risk who have the greatest need for a preventive vaccine and ultimately in cancer-free postmenopausal women who account for 75% of all EOC cases.,0,1.4441273068501719,226784.54298087198,233.42358781698647,0.2932182538272371,0.12721908674390098,0.0,0.0,0.9987515605493134,800.0,-0.6678190750250678,0.022627575879278085,1.0,2.0,42.0,30.0,30.0,30.0,60.0,1544,28.0,1.6778973932186097e-06,7268.0,802.0,1.0,0,28.0
2305,602238,HP:0001249,Mutations in the RNA exosome gene EXOSC2 cause a distinct syndrome with various tissue-specific phenotypes including retinitis pigmentosa and mild intellectual disability.,0,1.4498345645520514,8484972.31519232,648.7416159190325,0.14957419714808484,-0.02770195362163164,0.0,0.0,1.0005773672055427,1733.0,-0.6787636055676143,0.05234684943409352,1.0,2.0,1.0,131.0,131.0,131.0,262.0,3204,130.0,3.8916426584745004e-07,78561.0,1733.0,1.0,0,126.0
2306,601756,HP:0100774,"Giantin-knockout zebrafish exhibit hyperostosis and ectopic calcium deposits, recapitulating phenotypes of hyperphosphatemic familial tumoral calcinosis, a disease caused by mutations in GALNT3.",0,1.3411441499676795,50065.89761904762,57.14424951267056,0.2698772544014942,0.2465942780680594,0.0,0.0,1.007751937984496,130.0,-0.31232264304261503,0.21514609421586164,1.0,2.0,10.0,51.0,51.0,2.0,102.0,108,50.0,0.00016866250632484398,1804.0,130.0,1.0,0,69.0
2307,601756,HP:0003761,"Giantin-knockout zebrafish exhibit hyperostosis and ectopic calcium deposits, recapitulating phenotypes of hyperphosphatemic familial tumoral calcinosis, a disease caused by mutations in GALNT3.",1,1.4299948240165632,5668.473809523811,46.10167464114833,0.4142704156868761,0.19772754574203968,0.0,0.0,1.0116279069767442,87.0,-0.7610135029374234,0.11841753541833736,1.0,2.0,17.0,11.0,11.0,11.0,22.0,96,11.0,0.00016866250632484398,443.0,87.0,1.0,0,11.0
2308,601548,HP:0000608,"We compared the distribution and localization of UC and esterified cholesterol (EC); the age-related macular degeneration (AMD) associated EFEMP1/Fibulin3 (Fib3); and levels of acyl-coenzyme A (CoA): cholesterol acyltransferases (ACAT) ACAT1, ACAT2 and Apolipoprotein B (ApoB) in ARPE-19 cells cultured in serum-supplemented and serum-free media.",0,1.3447151526129881,11293.597126436782,61.42746913580247,0.29781894400529485,0.19986535695432306,0.0,0.0,0.9897959183673468,97.0,-0.9102622671095782,0.1836734693877551,1.0,2.0,3.0,15.0,15.0,14.0,30.0,164,13.0,0.0001451589490492089,891.0,99.0,1.0,0,20.0
2309,607809,HP:0000608,"We compared the distribution and localization of UC and esterified cholesterol (EC); the age-related macular degeneration (AMD) associated EFEMP1/Fibulin3 (Fib3); and levels of acyl-coenzyme A (CoA): cholesterol acyltransferases (ACAT) ACAT1, ACAT2 and Apolipoprotein B (ApoB) in ARPE-19 cells cultured in serum-supplemented and serum-free media.",0,1.243119783442364,71696.51194638692,43.89231248054777,0.30790067044008945,0.1188457813924591,0.0,0.0,0.9950248756218903,200.0,-0.4032873319268042,0.10930496034678094,1.0,2.0,26.0,64.0,64.0,2.0,128.0,166,62.0,6.944444444444444e-05,2219.0,202.0,1.0,0,61.0
2310,107730,HP:0000608,"We compared the distribution and localization of UC and esterified cholesterol (EC); the age-related macular degeneration (AMD) associated EFEMP1/Fibulin3 (Fib3); and levels of acyl-coenzyme A (CoA): cholesterol acyltransferases (ACAT) ACAT1, ACAT2 and Apolipoprotein B (ApoB) in ARPE-19 cells cultured in serum-supplemented and serum-free media.",0,1.29137136500874,113260.68421115926,55.28173690932312,0.26641886328164033,0.03233786895665081,0.0,0.0,0.995594713656388,226.0,-0.4444308960803684,0.11573537367648196,1.0,2.0,16.0,68.0,68.0,5.0,136.0,290,66.0,4.691311690748733e-05,2995.0,228.0,1.0,0,75.0
2311,607542,HP:0011675,"In conclusion, our results reveal a role for the KCNQ1 potassium channel in the regulation of human growth, and show that growth hormone deficiency associated with maternally inherited gingival fibromatosis is an allelic disorder with cardiac arrhythmia syndromes caused by KCNQ1 mutations",1,1.3378975462854403,1645625.9277777774,141.62795556092257,0.1900966630828403,0.13132763876862974,0.0,0.0,1.0017182130584192,583.0,-0.40415367119508855,0.11857733137639773,1.0,2.0,7.0,216.0,216.0,14.0,432.0,676,215.0,8.701629815264401e-06,20117.0,583.0,1.0,0,269.0
2313,608177,HP:0009733,"RT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma (p &lt; 0.01) and by 3-fold in Grade IV glioma (glioblastoma multiforme, GBM) (p &lt; 0.05), as compared with the para-tumourous tissue.",0,1.3552285088474885,129032.35600804425,86.61705338615356,0.2988673022185353,0.26433088463089177,0.0,0.0,0.9968553459119496,317.0,-0.5753616263081346,0.06204530667770746,1.0,2.0,41.0,39.0,39.0,39.0,78.0,170,38.0,1.2755102040816327e-05,3147.0,319.0,1.0,0,46.0
2314,600853,HP:0009733,"RT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma (p &lt; 0.01) and by 3-fold in Grade IV glioma (glioblastoma multiforme, GBM) (p &lt; 0.05), as compared with the para-tumourous tissue.",0,1.3195090198995725,54231.10952380953,55.05784732100521,0.29473010889739465,0.13382441028199848,0.0,0.0,0.9933333333333334,149.0,-0.61292942507037,0.14578366445916116,1.0,2.0,10.0,39.0,39.0,39.0,78.0,100,38.0,7.971938775510202e-05,1651.0,151.0,1.0,0,48.0
2317,608177,HP:0002664,"RT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma (p &lt; 0.01) and by 3-fold in Grade IV glioma (glioblastoma multiforme, GBM) (p &lt; 0.05), as compared with the para-tumourous tissue.",1,1.3671953875465912,7571634.649574038,252.30185626821753,0.15118185783882274,0.09939107755424499,0.0,0.0,1.0009532888465205,1050.0,-0.5485515347997706,0.0938544645694312,1.0,2.0,3.0,269.0,269.0,125.0,538.0,1542,268.0,1.6778973932186103e-06,51688.0,1050.0,1.0,0,343.0
2319,600853,HP:0002664,"RT-PCR analysis showed that the overall transcriptional activity of the main HS biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma (p &lt; 0.01) and by 3-fold in Grade IV glioma (glioblastoma multiforme, GBM) (p &lt; 0.05), as compared with the para-tumourous tissue.",0,1.3899182804969206,1934265.0362358543,230.154800715112,0.18611998609740954,0.2495883303062277,0.0,0.0,0.9988674971687428,882.0,-0.6531790197234396,0.05898238727497272,1.0,2.0,47.0,112.0,112.0,112.0,224.0,1544,110.0,1.6778973932186103e-06,23020.0,884.0,1.0,0,132.0
2320,609669,HP:0000501,"First, a novel variation c.460-650A&gt;G was found in our study which might cause premature termination of splicing of the conserved domain in WDR36; second, c.1494+1111G&gt;T (rs13178997) had significantly different frequency in our JOAG patients compared to the reference frequency on NCBI; third, a variation c.710+30C&gt;T (rs10038177) was found in our study, which had already been reported to be related to high-pressure glaucoma.",1,1.4912711402073104,3719.0,187.4328947368421,0.4491788770239411,0.5188758425306802,0.0,0.0,1.0032467532467533,309.0,-0.9794234779397007,0.019375446559912586,1.0,2.0,1.0,5.0,5.0,5.0,10.0,608,4.0,1.0749798441279228e-05,922.0,309.0,1.0,0,4.0
2321,600160,HP:0002664,"Although disruption of the CDKN2A (INK4A/ARF) locus has been reported in end-stage disease, information is lacking on the status of this key tumor suppressor gene in pleural lesions preceding mesothelioma.",1,1.3819192877609885,3978882.2976928083,230.5360070919454,0.17439306041142438,0.12633734612896624,0.0,0.0,1.0010121457489878,989.0,-0.5763287178006274,0.0801918266928112,1.0,2.0,4.0,213.0,213.0,104.0,426.0,1542,212.0,1.67789739321861e-06,39179.0,989.0,1.0,0,228.0
2327,600160,HP:0002664,"We show that hypermethylation of p16/Ink4a and p19/Arf in CNT- and asbestos-induced inflammatory lesions precedes mesothelioma; this results in silencing of Cdkn2a (Ink4a/Arf) and loss of p16 and p19 protein, consistent with epigenetic alterations playing a gatekeeper role in cancer.",1,1.3819192877609885,3978882.2976928083,230.5360070919454,0.17439306041142438,0.12633734612896624,0.0,0.0,1.0010121457489878,989.0,-0.5763287178006274,0.0801918266928112,1.0,2.0,4.0,213.0,213.0,104.0,426.0,1542,212.0,1.67789739321861e-06,39179.0,989.0,1.0,0,228.0
657,603113,HP:0002664,"Knockdown of PPP2R1B expression increases AKT phosphorylation, which leads to elevated XIAP expression and enhanced 5-FU resistance; whereas rescue of PPP2R1B expression in miR-587-expressing cells decreases AKT phosphorylation/XIAP expression, re-sensitizing colon cancer cells to 5-FU-induced apoptosis.",1,1.4873012487474293,56683.754180476026,245.41686121919585,0.4091005680924441,0.01853930019144065,0.0,0.0,1.0012738853503185,786.0,-0.7080939589769509,0.011704834605597965,1.0,2.0,5.0,15.0,15.0,15.0,30.0,1542,15.0,1.67789739321861e-06,3611.0,786.0,1.0,0,25.0
2330,300079,HP:0002664,"Knockdown of PPP2R1B expression increases AKT phosphorylation, which leads to elevated XIAP expression and enhanced 5-FU resistance; whereas rescue of PPP2R1B expression in miR-587-expressing cells decreases AKT phosphorylation/XIAP expression, re-sensitizing colon cancer cells to 5-FU-induced apoptosis.",1,1.406634221168284,2214908.756663593,207.984000497486,0.1966682757698364,0.16261722755692914,0.0,0.0,1.0010917030567683,917.0,-0.5998659763136658,0.06079012157548109,1.0,2.0,5.0,141.0,141.0,89.0,282.0,1542,140.0,1.67789739321861e-06,25531.0,917.0,1.0,0,139.0
653,603113,HP:0002664,"Importantly, studies of colorectal cancer specimens indicate that the expression of miR-587 and PPP2R1B positively and inversely correlates with chemoresistance, respectively, in colorectal cancer.",1,1.4873012487474293,56683.754180476026,245.41686121919585,0.4091005680924441,0.01853930019144065,0.0,0.0,1.0012738853503185,786.0,-0.7080939589769509,0.011704834605597965,1.0,2.0,5.0,15.0,15.0,15.0,30.0,1542,15.0,1.67789739321861e-06,3611.0,786.0,1.0,0,25.0
665,603113,HP:0002664,These findings indicate that the miR-587/PPP2R1B/pAKT/XIAP signaling axis has an important role in mediating response to chemotherapy in colorectal cancer.,1,1.4873012487474293,56683.754180476026,245.41686121919585,0.4091005680924441,0.01853930019144065,0.0,0.0,1.0012738853503185,786.0,-0.7080939589769509,0.011704834605597965,1.0,2.0,5.0,15.0,15.0,15.0,30.0,1542,15.0,1.67789739321861e-06,3611.0,786.0,1.0,0,25.0
2332,300079,HP:0002664,These findings indicate that the miR-587/PPP2R1B/pAKT/XIAP signaling axis has an important role in mediating response to chemotherapy in colorectal cancer.,1,1.406634221168284,2214908.756663593,207.984000497486,0.1966682757698364,0.16261722755692914,0.0,0.0,1.0010917030567683,917.0,-0.5998659763136658,0.06079012157548109,1.0,2.0,5.0,141.0,141.0,89.0,282.0,1542,140.0,1.67789739321861e-06,25531.0,917.0,1.0,0,139.0
2334,615068,HP:0001251,"Over the last 5 years, several single gene disorders of the autophagy pathway have emerged: EPG5-associated Vici syndrome, WDR45-associated b-propeller protein-associated neurodegeneration, SNX14-associated autosomal-recessive spinocerebellar ataxia 20, ATG5-associated autosomal-recessive ataxia syndrome, SQSTM1/p62-associated childhood-onset neurodegeneration, and several forms of the hereditary spastic paraplegias.",0,1.3685228639630038,8598149.761979686,301.92288237489123,0.14691971029237838,0.1135796518941587,0.0,0.0,0.9990749306197966,1080.0,-0.581066582427895,0.10492441276903533,1.0,2.0,2.0,251.0,251.0,174.0,502.0,1628,249.0,1.5055139448229141e-06,61362.0,1082.0,1.0,0,269.0
2335,300526,HP:0001251,"Over the last 5 years, several single gene disorders of the autophagy pathway have emerged: EPG5-associated Vici syndrome, WDR45-associated b-propeller protein-associated neurodegeneration, SNX14-associated autosomal-recessive spinocerebellar ataxia 20, ATG5-associated autosomal-recessive ataxia syndrome, SQSTM1/p62-associated childhood-onset neurodegeneration, and several forms of the hereditary spastic paraplegias.",0,1.4280075936960417,2496606.2313588145,354.9176652591268,0.17174371965146668,-0.040396250248275464,0.0,0.0,0.9989023051591658,910.0,-0.700122483456209,0.07581316078340747,1.0,2.0,1.0,97.0,97.0,96.0,194.0,1628,95.0,1.5055139448229141e-06,31494.0,912.0,1.0,0,102.0
2336,616105,HP:0001251,"Over the last 5 years, several single gene disorders of the autophagy pathway have emerged: EPG5-associated Vici syndrome, WDR45-associated b-propeller protein-associated neurodegeneration, SNX14-associated autosomal-recessive spinocerebellar ataxia 20, ATG5-associated autosomal-recessive ataxia syndrome, SQSTM1/p62-associated childhood-onset neurodegeneration, and several forms of the hereditary spastic paraplegias.",1,1.38053623551732,8093049.287370497,324.71516578995585,0.14793249892551286,-0.03285115893557557,0.0,0.0,1.0009551098376313,1048.0,-0.5928213136237607,0.10790007072187348,1.0,2.0,1.0,235.0,235.0,214.0,470.0,1626,234.0,1.5092152684290281e-06,59197.0,1048.0,1.0,0,328.0
2337,604261,HP:0001251,"Over the last 5 years, several single gene disorders of the autophagy pathway have emerged: EPG5-associated Vici syndrome, WDR45-associated b-propeller protein-associated neurodegeneration, SNX14-associated autosomal-recessive spinocerebellar ataxia 20, ATG5-associated autosomal-recessive ataxia syndrome, SQSTM1/p62-associated childhood-onset neurodegeneration, and several forms of the hereditary spastic paraplegias.",0,1.4727106551336575,569148.3636384384,486.0092250922509,0.20828222882845854,0.02570438778504169,0.0,0.0,1.0011820330969268,847.0,-0.8386428295573786,0.04426972125231314,1.0,2.0,1.0,34.0,34.0,34.0,68.0,1626,33.0,1.5092152684290273e-06,15861.0,847.0,1.0,0,33.0
2338,601530,HP:0001251,"Over the last 5 years, several single gene disorders of the autophagy pathway have emerged: EPG5-associated Vici syndrome, WDR45-associated b-propeller protein-associated neurodegeneration, SNX14-associated autosomal-recessive spinocerebellar ataxia 20, ATG5-associated autosomal-recessive ataxia syndrome, SQSTM1/p62-associated childhood-onset neurodegeneration, and several forms of the hereditary spastic paraplegias.",1,1.364755648832075,7043580.63663995,254.25724485257882,0.15502425285411342,0.04137781435987882,0.0,0.0,1.000893655049151,1120.0,-0.5546361028316394,0.09042033703561854,1.0,2.0,8.0,291.0,291.0,96.0,582.0,1626,290.0,1.5092152684290281e-06,56661.0,1120.0,1.0,0,330.0
1658,113705,HP:0002664,"PurposeMonoallelic germ-line mutations in the BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN genes confer high risk of breast cancer.",1,1.342124294666095,14779870.286244314,292.6232998839511,0.14059513390679754,0.0363653511393512,0.0,0.0,1.0008032128514055,1246.0,-0.37767621403519097,0.11088720854525648,1.0,2.0,3.0,471.0,471.0,37.0,942.0,1542,470.0,1.6778973932186097e-06,86008.0,1246.0,1.0,0,633.0
2357,600185,HP:0002664,"PurposeMonoallelic germ-line mutations in the BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN genes confer high risk of breast cancer.",1,1.3416355462103815,14500864.778067766,286.27804058963136,0.14198849810087022,0.09065436525648868,0.0,0.0,1.0007987220447283,1253.0,-0.3695548622099266,0.10824627921741813,1.0,2.0,4.0,477.0,477.0,34.0,954.0,1542,476.0,1.67789739321861e-06,84906.0,1253.0,1.0,0,615.0
2383,610355,HP:0002664,"PurposeMonoallelic germ-line mutations in the BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN genes confer high risk of breast cancer.",1,1.3430869189876868,14665903.757940754,288.6803021880843,0.1417467535489824,0.14445499003691165,0.0,0.0,1.0008116883116882,1233.0,-0.3832445566628932,0.10980108699086802,1.0,2.0,2.0,458.0,458.0,43.0,916.0,1542,457.0,1.6778973932186097e-06,83397.0,1233.0,1.0,0,612.0
2339,600185,HP:0002664,"Biallelic mutations in these genes cause Fanconi anemia (FA), characterized by malformations, bone marrow failure, chromosome fragility, and cancer predisposition (BRCA2/FANCD1 and PALB2/FANCN), or an FA-like disease presenting a phenotype similar to FA but without bone marrow failure (BRCA1/FANCS).",1,1.3416355462103815,14500864.778067766,286.27804058963136,0.14198849810087022,0.09065436525648868,0.0,0.0,1.0007987220447283,1253.0,-0.3695548622099266,0.10824627921741813,1.0,2.0,4.0,477.0,477.0,34.0,954.0,1542,476.0,1.67789739321861e-06,84906.0,1253.0,1.0,0,615.0
2381,610355,HP:0002664,"Biallelic mutations in these genes cause Fanconi anemia (FA), characterized by malformations, bone marrow failure, chromosome fragility, and cancer predisposition (BRCA2/FANCD1 and PALB2/FANCN), or an FA-like disease presenting a phenotype similar to FA but without bone marrow failure (BRCA1/FANCS).",1,1.3430869189876868,14665903.757940754,288.6803021880843,0.1417467535489824,0.14445499003691165,0.0,0.0,1.0008116883116882,1233.0,-0.3832445566628932,0.10980108699086802,1.0,2.0,2.0,458.0,458.0,43.0,916.0,1542,457.0,1.6778973932186097e-06,83397.0,1233.0,1.0,0,612.0
2390,606829,HP:0002664,"FANCM monoallelic mutations have been reported as moderate risk factors for breast cancer, but there are no reports of any clinical phenotype observed in carriers of biallelic mutations.MethodsBreast cancer probands were subjected to mutation analysis by sequencing gene panels or testing DNA damage response genes.ResultsFive cases homozygous for FANCM loss-of-function mutations were identified.",0,1.3621265762760904,2413616.901743359,200.04513618677043,0.18544942053489166,0.21665475310549576,0.0,0.0,0.9989327641408752,936.0,-0.6167799868358901,0.06338106691728125,1.0,2.0,40.0,152.0,152.0,96.0,304.0,1544,150.0,1.6778973932186097e-06,27853.0,938.0,1.0,0,139.0
2405,606829,HP:0002664,"Moreover, our observations support previous findings suggesting that FANCM is a breast cancer-predisposing gene.",0,1.3621265762760904,2413616.901743359,200.04513618677043,0.18544942053489166,0.21665475310549576,0.0,0.0,0.9989327641408752,936.0,-0.6167799868358901,0.06338106691728125,1.0,2.0,40.0,152.0,152.0,96.0,304.0,1544,150.0,1.6778973932186097e-06,27853.0,938.0,1.0,0,139.0
2416,165390,HP:0002664,"The increased RhoA-GTP results from AKT phosphorylating three serines (S298, S329, and S567) in the DLC1 tumor suppressor, a Rho GTPase-activating protein (RhoGAP) associated with focal adhesions.",0,1.3978683131436085,2157606.155043348,229.1092045672004,0.1848188673957168,0.06592376818482969,0.0,0.0,0.9988814317673378,893.0,-0.611879548470754,0.06202742054416158,1.0,2.0,23.0,121.0,121.0,117.0,242.0,1544,119.0,1.67789739321861e-06,24815.0,895.0,1.0,0,117.0
2422,180380,HP:0002664,"The increased RhoA-GTP results from AKT phosphorylating three serines (S298, S329, and S567) in the DLC1 tumor suppressor, a Rho GTPase-activating protein (RhoGAP) associated with focal adhesions.",0,1.3656029541446206,2499829.264422941,200.53807898275682,0.18269083378657847,0.08808076945407306,0.0,0.0,0.9989304812834224,934.0,-0.6348648372529369,0.06318387494858083,1.0,2.0,27.0,140.0,140.0,94.0,280.0,1576,138.0,1.677897393218609e-06,27648.0,936.0,1.0,0,138.0
2414,165390,HP:0002664,"That binding, which interferes with the interaction of RhoA-GTP with the RhoGAP domain, reduces the hydrolysis of RhoA-GTP, the binding of other DLC1 ligands, and the colocalization of DLC1 with focal adhesions and attenuates tumor suppressor activity.",0,1.3978683131436085,2157606.155043348,229.1092045672004,0.1848188673957168,0.06592376818482969,0.0,0.0,0.9988814317673378,893.0,-0.611879548470754,0.06202742054416158,1.0,2.0,23.0,121.0,121.0,117.0,242.0,1544,119.0,1.67789739321861e-06,24815.0,895.0,1.0,0,117.0
2425,150340,HP:0002664,"Thus, the aim of the present study was to elucidate the influence of LMNB1 upregulation on colon cancer cell line after treatment with 5-FU.",0,1.3532048248484854,6776121.672486258,250.70224619738238,0.15231306049935947,0.050402992985762216,0.0,0.0,0.9990347490347492,1035.0,-0.568578163702051,0.09297870676848498,1.0,2.0,15.0,256.0,256.0,125.0,512.0,1544,254.0,1.6778973932186103e-06,49945.0,1037.0,1.0,0,324.0
2446,164840,HP:0003006,"To investigate genetic predispositions for MYCN-amplified neuroblastoma, we performed a meta-analysis of three genome-wide association studies totaling 615 MYCN-amplified high-risk neuroblastoma cases and 1869 MYCN-nonamplified non-high-risk neuroblastoma cases as controls using a fixed-effects model with inverse variance weighting.",0,1.3585645578986312,158772.31998556998,111.13575172130304,0.2582612410847169,0.32192902940968543,0.0,0.0,0.9966777408637876,300.0,-0.6954874948812038,0.08448658995401641,1.0,2.0,35.0,38.0,38.0,38.0,76.0,176,37.0,1.4348025711662073e-05,3840.0,302.0,1.0,0,38.0
2451,164840,HP:0003006,"We identified a novel locus at 3p21.31 indexed by the single nucleotide polymorphism (SNP) rs80059929 (odds ratio [OR] = 2.95, 95% confidence interval [CI] = 2.17 to 4.02, Pmeta = 6.47 x 10-12) associated with MYCN-amplified neuroblastoma, which was replicated in 127 MYCN-amplified cases and 254 non-high-risk controls (OR = 2.30, 95% CI = 1.12 to 4.69, Preplication = .02).",0,1.3585645578986312,158772.31998556998,111.13575172130304,0.2582612410847169,0.32192902940968543,0.0,0.0,0.9966777408637876,300.0,-0.6954874948812038,0.08448658995401641,1.0,2.0,35.0,38.0,38.0,38.0,76.0,176,37.0,1.4348025711662073e-05,3840.0,302.0,1.0,0,38.0
2436,164840,HP:0003006,"Our results indicate that common genetic variation predisposes to different neuroblastoma genotypes, including the likelihood of somatic MYCN-amplification",0,1.3585645578986312,158772.31998556998,111.13575172130304,0.2582612410847169,0.32192902940968543,0.0,0.0,0.9966777408637876,300.0,-0.6954874948812038,0.08448658995401641,1.0,2.0,35.0,38.0,38.0,38.0,76.0,176,37.0,1.4348025711662073e-05,3840.0,302.0,1.0,0,38.0
2456,601239,HP:0030682,DTNA encoding dystrobrevin-a (a-DB) is a putative causal gene associated with left ventricular noncompaction cardiomyopathy (LVNC).,1,1.3798129812981297,4907.5999999999985,30.84090909090909,0.4243898244145562,0.38910233795159865,0.0,0.0,1.0172413793103448,59.0,-0.7005356440703511,0.2016364699006429,1.0,2.0,4.0,15.0,15.0,15.0,30.0,56,15.0,0.0004938271604938272,345.0,59.0,1.0,0,19.0
2457,601239,HP:0001638,"In conclusion, overexpression of the DTNA-p.N49S mutation in a mouse heart can be responsible for the phenotype of deep trabeculation, dilated cardiomyopathy, and cardiac dysfunction, which resembles the phenotype of LVNC",1,1.4408412988656156,142555.47233020814,127.07306711979608,0.3126360836290716,0.028340338989124695,0.0,0.0,1.0021231422505308,472.0,-0.5567246219926939,0.045611572924538483,1.0,2.0,1.0,44.0,44.0,40.0,88.0,856,43.0,5.4335718671383e-06,5070.0,472.0,1.0,0,38.0
2458,615317,HP:0003287,Defects in ISC biogenesis lead to multiple mitochondrial dysfunction syndromes including: ISCA2 with infantile onset leukodystrophy.,0,1.3304816812348892,175175.3892857143,93.16306129137988,0.22230669865870845,-0.03210467388694481,0.0,0.0,0.994047619047619,167.0,-0.6617724774414343,0.24640743871513104,1.0,2.0,2.0,54.0,54.0,54.0,108.0,228,52.0,7.694675284702985e-05,3498.0,169.0,1.0,0,57.0
2459,603220,HP:0002092,"Furthermore, mutations in KCNK3 have been identified as a rare cause of both familial and idiopathic pulmonary arterial hypertension.",1,1.4120689655172414,13982.196527777778,76.02196261682242,0.2929538867166891,0.14522193357082225,0.0,0.0,1.007936507936508,127.0,-0.8324509811711859,0.16010498687664046,1.0,2.0,1.0,20.0,20.0,20.0,40.0,214,19.0,8.573388203017832e-05,1281.0,127.0,1.0,0,24.0
2460,163890,HP:0001300,"We review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).",1,1.3455903849277244,454430.1833333335,113.39205072687906,0.2143750412445194,0.07871553768364241,0.0,0.0,1.003472222222222,289.0,-0.3811381454423558,0.18288638985005767,1.0,2.0,2.0,106.0,106.0,106.0,212.0,212,106.0,2.9536862003780733e-05,7611.0,289.0,1.0,0,126.0
2461,608309,HP:0001300,"We review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).",1,1.3359167991520933,228345.46904761894,94.36988993710692,0.22671302916155,-0.08673039514489503,0.0,0.0,1.0049751243781095,202.0,-0.3899773022410475,0.2341756563716073,1.0,2.0,1.0,87.0,87.0,32.0,174.0,212,86.0,8.734387282732117e-05,4754.0,202.0,1.0,0,112.0
2462,609007,HP:0001300,"We review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).",1,1.3396831461594094,396014.4404761905,109.44095964013495,0.21463274284230105,-0.03971005499085229,0.0,0.0,1.00390625,257.0,-0.34910248641326075,0.20719844357976647,1.0,2.0,1.0,104.0,104.0,22.0,208.0,212,104.0,4.3282548476454294e-05,6816.0,257.0,1.0,0,128.0
2463,606463,HP:0001300,"We review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).",1,1.408916982519147,811410.9480565289,128.97741714732624,0.2393310102746596,0.33154407048115536,0.0,0.0,1.0014619883040936,685.0,-0.3852921006753384,0.04932769880906646,1.0,2.0,83.0,106.0,106.0,106.0,212.0,348,106.0,2.972651605231867e-06,11556.0,685.0,1.0,0,115.0
2464,600225,HP:0001300,"We review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).",1,1.3459915611814346,400601.1571428571,105.7601733809281,0.21641761446545865,0.09134361198602343,0.0,0.0,1.0034482758620689,291.0,-0.304530522119799,0.16890626851522691,1.0,2.0,5.0,106.0,106.0,13.0,212.0,212,106.0,2.8905075731298408e-05,7127.0,291.0,1.0,0,123.0
2465,610513,HP:0001300,"We review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).",1,1.356170856170856,487915.895923521,114.142073859055,0.2167916607606199,0.2814609652083451,0.0,0.0,1.0029498525073746,340.0,-0.4018393934178578,0.14449071664063856,1.0,2.0,6.0,106.0,106.0,106.0,212.0,212,106.0,1.8107741059302852e-05,8327.0,340.0,1.0,0,116.0
2471,300774,HP:0001300,"We review the literature of genetic PD autopsies from cases with molecularly confirmed PD or parkinsonism and summarize main findings on SNCA (n = 25), Parkin (n = 20, 17 bi-allelic and 3 heterozygotes), PINK1 (n = 5, 1 bi-allelic and 4 heterozygotes), DJ-1 (n = 1), LRRK2 (n = 55), GBA (n = 10 Gaucher disease patients with parkinsonism), DNAJC13, GCH1, ATP13A2, PLA2G6 (n = 8 patients, 2 with PD), MPAN (n = 2), FBXO7, RAB39B, and ATXN2 (SCA2), as well as on 22q deletion syndrome (n = 3).",1,1.3530307331045341,338360.30191409896,86.12906004996985,0.23408099020366266,0.1941272764061341,0.0,0.0,1.0030864197530864,325.0,-0.4131301514550687,0.1168471035137702,1.0,2.0,3.0,106.0,106.0,12.0,212.0,212,105.0,2.066115702479339e-05,6152.0,325.0,1.0,0,123.0
1957,605204,HP:0001332,DYT1 is the prototypic hereditary dystonia and is caused by the mutation of the tor1a gene.,1,1.3441858677971743,3650295.9258880005,196.280979751568,0.16365979137147124,0.020350204438969045,0.0,0.0,1.0014285714285711,701.0,-0.5083610177275428,0.13064601589565927,1.0,2.0,3.0,245.0,245.0,56.0,490.0,884,244.0,5.095567365948362e-06,32054.0,701.0,1.0,0,290.0
1985,602662,HP:0001332,Dystonia-4 (DYT4) is another autosomal dominant dystonia that is characterized by onset in the second to third decade of progressive laryngeal dysphonia.,1,1.3709317587013985,2616178.4864898995,237.3883611518984,0.1610990987881749,-0.021579899986396384,0.0,0.0,1.0016891891891893,593.0,-0.6385717455872966,0.15221503122009025,1.0,2.0,2.0,149.0,149.0,127.0,298.0,884,148.0,5.095567365948359e-06,26718.0,593.0,1.0,0,173.0
2472,606990,HP:0002664,"Here, we applied this method to identify differentially expressed proteins (such as coatomer subunit beta 2 [COPB2]) and evaluated the functions and molecular mechanisms of these proteins in prostate cancer (PCA) cell proliferation.",0,1.395971273427921,2482460.1135719,286.12048922991136,0.17109204458641608,0.11414581780228532,0.0,0.0,0.9988623435722412,878.0,-0.6995536032151091,0.07129485986141276,1.0,2.0,40.0,108.0,108.0,108.0,216.0,1544,106.0,1.67789739321861e-06,27574.0,880.0,1.0,0,119.0
2473,601147,HP:0000365,"In four of them otosclerosis was said to be present, one patient had hearing loss due to severe stapes fixation at the age of 6 years, providing evidence that hearing loss in the GDF6-related multiple synostoses syndrome can be present in childhood.",1,1.4079821276036537,10941567.943070792,417.86647803826463,0.14104296334504046,0.05635535262842694,0.0,0.0,1.0006830601092895,1465.0,-0.6514923915705308,0.07501631884220146,1.0,2.0,7.0,221.0,221.0,186.0,442.0,2474,220.0,6.524672396198986e-07,80446.0,1465.0,1.0,0,250.0
1719,131550,HP:0002664,"In this report, we found that both EGFR and Ras signaling can upregulate RNA helicase DDX59 in lung cancer cells.",1,1.4135577242017423,2148700.9990685256,249.19306594831886,0.18304335818682368,0.03828770954761315,0.0,0.0,1.0011111111111108,901.0,-0.6842090355364789,0.06837094586262177,1.0,2.0,6.0,124.0,124.0,94.0,248.0,1542,123.0,1.6778973932186097e-06,27721.0,901.0,1.0,0,105.0
2476,615464,HP:0002664,"In this report, we found that both EGFR and Ras signaling can upregulate RNA helicase DDX59 in lung cancer cells.",0,1.3770259198886117,3668903.0976457763,266.119683348987,0.16338817372289444,0.048072475321173314,0.0,0.0,0.9989094874591058,916.0,-0.6578788430064918,0.07876161490889826,1.0,2.0,38.0,142.0,142.0,136.0,284.0,1544,140.0,1.6778973932186086e-06,33151.0,918.0,1.0,0,171.0
2484,131550,HP:0030078,"Through immunohistochemistry, we found that DDX59 protein expression correlated with Ras and EGFR mutation status in human lung adenocarcinoma.",0,1.4321436588103251,13752.128205128203,50.884615384615394,0.4116440105721133,0.13268454670033908,0.0,0.0,1.0068493150684932,147.0,-0.619390430165819,0.0712887894883981,1.0,2.0,35.0,17.0,17.0,17.0,34.0,230,17.0,5.827166249053085e-05,765.0,147.0,1.0,0,17.0
2487,615464,HP:0030078,"Through immunohistochemistry, we found that DDX59 protein expression correlated with Ras and EGFR mutation status in human lung adenocarcinoma.",0,1.3172975196896672,10798.359702940736,37.0288032454361,0.4249767279403513,-0.030231694000616982,0.0,0.0,0.9938650306748468,162.0,-0.6523111870447591,0.05199760586562921,1.0,2.0,29.0,15.0,15.0,14.0,30.0,120,13.0,4.691311690748734e-05,695.0,164.0,1.0,0,16.0
1709,131550,HP:0002664,"Finally, through a xenograft nude mice model, we demonstrated that DDX59 is pivotal for EGFR mutated lung cancer cell growth in vivo.",1,1.4135577242017423,2148700.9990685256,249.19306594831886,0.18304335818682368,0.03828770954761315,0.0,0.0,1.0011111111111108,901.0,-0.6842090355364789,0.06837094586262177,1.0,2.0,6.0,124.0,124.0,94.0,248.0,1542,123.0,1.6778973932186097e-06,27721.0,901.0,1.0,0,105.0
2474,615464,HP:0002664,"Finally, through a xenograft nude mice model, we demonstrated that DDX59 is pivotal for EGFR mutated lung cancer cell growth in vivo.",0,1.3770259198886117,3668903.0976457763,266.119683348987,0.16338817372289444,0.048072475321173314,0.0,0.0,0.9989094874591058,916.0,-0.6578788430064918,0.07876161490889826,1.0,2.0,38.0,142.0,142.0,136.0,284.0,1544,140.0,1.6778973932186086e-06,33151.0,918.0,1.0,0,171.0
2488,164761,HP:0000843,"4) Multiple endocrine neoplasia type 2A from RET activating mutation rarely presents as familial hyperparathyroidism, because medullary thyroid cancer and pheochromocytoma are more prominent.",1,1.4724365909364103,44461.66472722362,116.24399708949792,0.43325931898482783,0.13080314789707986,0.0,0.0,1.0022123893805308,453.0,-0.4585998904583673,0.020668502998691125,1.0,2.0,133.0,19.0,19.0,19.0,38.0,302,19.0,5.2847139648566525e-06,2116.0,453.0,1.0,0,19.0
1926,164761,HP:0002664,"4) Multiple endocrine neoplasia type 2A from RET activating mutation rarely presents as familial hyperparathyroidism, because medullary thyroid cancer and pheochromocytoma are more prominent.",1,1.3454208312212703,10532873.130266957,248.6928072346046,0.14679757854877915,0.02628547516165559,0.0,0.0,1.0008305647840532,1205.0,-0.4632247979281744,0.09519995588701564,1.0,2.0,7.0,395.0,395.0,52.0,790.0,1542,394.0,1.677897393218609e-06,69059.0,1205.0,1.0,0,548.0
2489,164761,HP:0002666,"4) Multiple endocrine neoplasia type 2A from RET activating mutation rarely presents as familial hyperparathyroidism, because medullary thyroid cancer and pheochromocytoma are more prominent.",1,1.4655664794007488,148961.4624364771,222.36040706605223,0.2531558210998454,0.236278862610364,0.0,0.0,1.0021881838074398,458.0,-0.8040999746000008,0.04832159613197902,1.0,2.0,53.0,24.0,24.0,24.0,48.0,360,24.0,5.2847139648566525e-06,5057.0,458.0,1.0,0,24.0
2490,168450,HP:0003072,"Five of the PHPT syndromes reflect overgrowth of parathyroid tissue; in contrast, familial hypocalciuric hypercalcemia reflects dysregulation of PTH secretion with little or no parathyroid overgrowth.",0,1.308001893939394,24932.781746031742,49.9111111111111,0.2841101545017355,0.05765373717935932,0.0,0.0,0.9882352941176472,84.0,-0.4168391278538978,0.2968536251709986,1.0,2.0,1.0,36.0,36.0,34.0,72.0,92,34.0,0.0004526935264825713,1085.0,86.0,1.0,0,49.0
2491,120070,HP:0009830,"Patients who carry the collagen type IVA3 chain (COL4A3) or COL4A4 mutations usually exhibit Alport Syndrome (AS), thin basement membrane neuropathy or familial hematuria (FH).",0,1.3900207392948638,461389.6953877879,132.19323204419888,0.2615524467911656,0.1427059208247859,0.0,0.0,0.9983974358974358,623.0,-0.6367439196978139,0.04974871794871795,1.0,2.0,12.0,70.0,70.0,51.0,140.0,1108,68.0,3.3791089965397925e-06,9701.0,625.0,1.0,0,64.0
2492,120131,HP:0009830,"Patients who carry the collagen type IVA3 chain (COL4A3) or COL4A4 mutations usually exhibit Alport Syndrome (AS), thin basement membrane neuropathy or familial hematuria (FH).",0,1.4043382228293928,343306.7700432139,139.18974358974359,0.2720923898299178,0.11481711463576345,0.0,0.0,0.9983579638752051,608.0,-0.6475524016981735,0.046149290694231335,1.0,2.0,10.0,57.0,57.0,48.0,114.0,1088,55.0,3.379108996539793e-06,8572.0,610.0,1.0,0,57.0
2493,610550,HP:0002664,"MAT1A reduction is associated with increased oxidative stress, progenitor cell expansion, genomic instability, and other mechanisms implicated in tumorigenesis.",0,1.450279020699189,285200.5772973775,248.1472114137484,0.2556115560454965,0.05215877223862984,0.0,0.0,0.9987623762376238,807.0,-0.8027845893791595,0.028372027561223367,1.0,2.0,20.0,35.0,35.0,28.0,70.0,1544,33.0,1.67789739321861e-06,9273.0,809.0,1.0,0,29.0
2494,108740,HP:0003745,"In Japan, 26 mutations in the ATP2A2 gene in 7 pedigrees and 19 sporadic cases with DD have been reported, among which one pedigree and one sporadic case were accompanied by neuropsychiatric symptoms.",0,1.2686111502512798,110913.06507936507,56.579775280898865,0.2533600535218235,0.1886398824534844,0.0,0.0,0.9945945945945946,184.0,-0.5235118395594373,0.15646614356291774,1.0,2.0,13.0,62.0,62.0,2.0,124.0,192,60.0,0.00010850694444444445,2692.0,186.0,1.0,0,68.0
562,600960,HP:0002664,"In anticipation of the proliferation of time series data sets in the near future, we use the Hopfield model, a recurrent neural network based on spin glasses, to model the dynamics of cell cycle in HeLa (human cervical cancer) and S. cerevisiae cells.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
2495,610330,HP:0000007,Variations in RNASEH2C cause an autosomal recessive form of AGS.,1,1.4389540974129416,17424141.830552127,530.054055304871,0.15869504389331354,0.14755791600213475,0.0,0.0,1.0003512469265894,2848.0,-0.5808202990908313,0.03174221435534349,1.0,2.0,4.0,266.0,266.0,212.0,532.0,5160,265.0,1.5011496554636372e-07,128687.0,2848.0,1.0,0,237.0
1789,608537,HP:0002664,"In support of this view, hypoxia is shown to negatively regulate MHC expression in a HIF-dependent manner as evidenced by (i) lower MHC expression in the hypoxic TME in vivo and in hypoxic 3-dimensional (3D) but not 2-dimensional (2D) tumor cell cultures in vitro; (ii) decreased MHC in human renal cell carcinomas with constitutive expression of HIF due to genetic loss of von Hippel-Lindau (VHL) function as compared with isogenically paired cells with restored VHL function, and iii) increased MHC in tumor cells with siRNA-mediated knockdown of HIF.",1,1.3618496077945474,6027068.07461144,219.1824484467484,0.16311609695858187,0.09506203626881264,0.0,0.0,1.000928505106778,1078.0,-0.5463102846795095,0.08290396432059782,1.0,2.0,3.0,276.0,276.0,77.0,552.0,1542,275.0,1.6778973932186097e-06,48126.0,1078.0,1.0,0,314.0
2497,612048,HP:0004308,"The most important parameters to consider when determining arrhythmic risk include electric instability, including the frequency of premature ventricular contractions and sustained ventricular arrhythmia; proband status; extent of structural disease; cardiac syncope; male sex; the presence of multiple mutations or a mutation in TMEM43; and the patient*s willingness to restrict exercise and to eliminate participation in competitive or endurance exercise",1,1.3511446733260049,169136.65992063488,73.91248235531356,0.28389990651551383,0.08094660371863989,0.0,0.0,1.0038910505836576,258.0,-0.4524960042818068,0.12855548517479565,1.0,2.0,2.0,87.0,87.0,12.0,174.0,174,87.0,3.3802055164954025e-05,4262.0,258.0,1.0,0,99.0
2498,617612,HP:0001425,"Our report of variant in ARMC9 Leading to Joubert syndrome phenotype (JS30), elucidates the genetic heterogeneity of Joubert syndrome, and expands the gene list for ciliopathies",0,1.3194986497277026,1076686.6821428572,119.73871879217276,0.20158597652530968,-0.013193968413715932,0.0,0.0,0.9977272727272726,439.0,-0.3731909568497713,0.13562152133580704,1.0,2.0,7.0,171.0,171.0,5.0,342.0,496,169.0,1.625910509885536e-05,13158.0,441.0,1.0,0,199.0
2499,608771,HP:0001249,"Disruption of MED13L, encoding a component of the Mediator complex, is increasingly recognized as the cause of an intellectual disability syndrome with associated facial dysmorphism.",1,1.4183289704004567,19113949.30546499,559.1615920382922,0.13452461666188326,0.00839743353704378,0.0,0.0,1.0005411255411256,1849.0,-0.6113278534947895,0.07004078488664751,1.0,2.0,3.0,245.0,245.0,244.0,490.0,3204,244.0,3.8916426584744994e-07,119663.0,1849.0,1.0,0,267.0
2500,608771,HP:0001999,"Disruption of MED13L, encoding a component of the Mediator complex, is increasingly recognized as the cause of an intellectual disability syndrome with associated facial dysmorphism.",1,1.3854760194877858,13073297.464495962,424.43538644969414,0.1311276120763601,0.05675914696307083,0.0,0.0,1.000852514919011,1174.0,-0.6194191208722291,0.12022203148350667,1.0,2.0,3.0,245.0,245.0,243.0,490.0,1854,244.0,1.1611920332936979e-06,82779.0,1174.0,1.0,0,295.0
2501,601309,HP:0002671,"Aberrant activation of the Hedgehog pathway represents the molecular driver in basal cell carcinoma pathogenesis, with the majority of BCCs carrying somatic point mutations, mainly ultraviolet (UV)-induced, and/or copy-loss of heterozygosis in the PTCH1 gene.",1,1.4547783476000131,315287.0523112938,169.51799877974375,0.28667216318310323,0.17333852277336906,0.0,0.0,1.0015649452269169,640.0,-0.5749259992129849,0.03396909233176839,1.0,2.0,56.0,44.0,44.0,44.0,88.0,314,44.0,2.8057652865107223e-06,6946.0,640.0,1.0,0,48.0
2502,609332,HP:0011100,"We expand the knowledge about TTC7A deficiency, describing a patient with the mild phenotype of TTC7A deficiency but presenting overlapping features of SD/THE and MIA-CID: intestinal atresia and inflammatory bowel disease evocative of MIA-CID, but also dental abnormalities, huge forehead, liver abnormalities, autoimmune thyroiditis and hypogammaglobulinemia, evocative of SD/THE",1,1.3793604651162792,100806.09166666667,72.46318840579708,0.2667478493062863,0.305162721229911,0.0,0.0,1.0051282051282049,196.0,-0.5362398580864705,0.1334903192046049,1.0,2.0,24.0,46.0,46.0,46.0,92.0,124,46.0,4.385772553835358e-05,2551.0,196.0,1.0,0,46.0
2503,609332,HP:0000164,"We expand the knowledge about TTC7A deficiency, describing a patient with the mild phenotype of TTC7A deficiency but presenting overlapping features of SD/THE and MIA-CID: intestinal atresia and inflammatory bowel disease evocative of MIA-CID, but also dental abnormalities, huge forehead, liver abnormalities, autoimmune thyroiditis and hypogammaglobulinemia, evocative of SD/THE",0,1.4053839412860114,2692051.121590136,255.8671649484536,0.1784452216879238,0.0694328422011846,0.0,0.0,1.0010810810810808,926.0,-0.6120646456595602,0.07509894343587648,1.0,2.0,5.0,140.0,140.0,105.0,280.0,1552,139.0,1.6563723127429697e-06,32163.0,926.0,1.0,0,138.0
2504,609332,HP:0004313,"We expand the knowledge about TTC7A deficiency, describing a patient with the mild phenotype of TTC7A deficiency but presenting overlapping features of SD/THE and MIA-CID: intestinal atresia and inflammatory bowel disease evocative of MIA-CID, but also dental abnormalities, huge forehead, liver abnormalities, autoimmune thyroiditis and hypogammaglobulinemia, evocative of SD/THE",0,1.2981433716742186,434928.13989898993,96.69333333333331,0.21180498620029709,0.1805325718045601,0.0,0.0,0.9966777408637874,300.0,-0.4090610243498566,0.1628567028228202,1.0,2.0,11.0,118.0,118.0,5.0,236.0,302,116.0,4.3282548476454294e-05,7402.0,302.0,1.0,0,131.0
2505,189967,HP:0002664,"Testicular germ cell cancer (TGCC) is derived from germ cell neoplasia in situ (GCNIS), which arises due to niche disturbances affecting the Sertoli cells.",0,1.4222281497536504,97969.88335251069,172.54903287655782,0.3647981539649653,0.4363310199424491,0.0,0.0,0.99874213836478,794.0,-0.6304335172239297,0.014547580670648841,1.0,2.0,87.0,23.0,23.0,21.0,46.0,1544,21.0,1.67789739321861e-06,4603.0,796.0,1.0,0,19.0
2506,607444,HP:0001875,Shwachman-Diamond syndrome (SDS) (OMIM #260400) is a rare inherited bone marrow failure syndrome (IBMFS) that is primarily characterized by neutropenia and exocrine pancreatic insufficiency.,1,1.3466155879893171,1148094.210056447,146.18333333333334,0.1825212438087275,0.11966615215493012,0.0,0.0,1.0022371364653244,448.0,-0.3335855090549108,0.15016778523489932,1.0,2.0,1.0,160.0,160.0,8.0,320.0,320,160.0,1.1973036721303628e-05,15036.0,448.0,1.0,0,206.0
2508,607444,HP:0001875,These 3 patients shared congenital neutropenia linked with various other SDS phenotypes.,1,1.3466155879893171,1148094.210056447,146.18333333333334,0.1825212438087275,0.11966615215493012,0.0,0.0,1.0022371364653244,448.0,-0.3335855090549108,0.15016778523489932,1.0,2.0,1.0,160.0,160.0,8.0,320.0,320,160.0,1.1973036721303628e-05,15036.0,448.0,1.0,0,206.0
2510,604857,HP:0001875,"In conclusion, autosomal dominant mutations in SRP54, a key member of the cotranslation protein-targeting pathway, lead to syndromic neutropenia with a Shwachman-Diamond-like phenotype",1,1.3496430501203478,1156330.4342352094,143.90907258064516,0.18582016881533872,0.09632742725642916,0.0,0.0,1.0021321961620469,470.0,-0.3351559096858868,0.13779431111917614,1.0,2.0,1.0,160.0,160.0,9.0,320.0,320,160.0,1.0339016345984843e-05,15187.0,470.0,1.0,0,202.0
2511,138850,HP:0000135,"Biallelic, partial loss-of-function mutations in GNRHR cause a wide spectrum of reproductive phenotypes from constitutional delay of growth and puberty to complete congenital hypogonadotropic hypogonadism.",1,1.3588838767391844,1763839.9881819396,199.54301289987617,0.16995579192146232,0.03156317913118559,0.0,0.0,1.0020491803278688,489.0,-0.6036273576437191,0.1712678936605317,1.0,2.0,1.0,146.0,146.0,146.0,292.0,686,145.0,8.450513791238506e-06,20435.0,489.0,1.0,0,157.0
2512,608798,HP:0002664,"In conclusion, our findings firstly revealed that GSDME switches chemotherapy drug-induced caspase-3 dependent apoptosis into pyroptosis in gastric cancer cells",0,1.4153137146029984,54716.49350717169,240.1498054474708,0.3658464449605876,0.4358655434557422,0.0,0.0,0.9987244897959182,783.0,-0.7142860843161312,0.011689197972182505,1.0,2.0,123.0,13.0,13.0,13.0,26.0,1544,11.0,1.6778973932186097e-06,3597.0,785.0,1.0,0,13.0
2513,601893,HP:0001298,Trio exome sequencing has been successful in identifying genes with de novo mutations (DNMs) causing epileptic encephalopathy (EE) and other neurodevelopmental disorders.,0,1.2891172261121069,1412756.349206349,123.67640036730947,0.18577181887166072,0.28755738131948977,0.0,0.0,0.9980506822612084,512.0,-0.4087128111365656,0.12166169856114566,1.0,2.0,27.0,197.0,197.0,4.0,394.0,486,195.0,1.3616372326084885e-05,16040.0,514.0,1.0,0,216.0
2515,604237,HP:0000007,Cold-induced sweating syndrome (CISS) is a rare autosomal recessive disease due to mutation in the Cytokine receptor-like factor 1 (CRLF1).,1,1.4500449391188748,13396179.512306988,557.7275879974778,0.1659563868946613,0.061995857571420614,0.0,0.0,1.000358680057389,2789.0,-0.5781303732441619,0.02773500938561154,1.0,2.0,44.0,209.0,209.0,209.0,418.0,5160,208.0,1.5011496554636367e-07,107830.0,2789.0,1.0,0,200.0
2516,602235,HP:0001250,"Using this gene panel, we were able to identify disease-causing variants in 17 out of 87 (19.5%) analyzed patients, all found in known epilepsy-associated genes (KCNQ2, CDKL5, STXBP1, SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2, SYNGAP1, and GRIN1).",1,1.444634701851987,6546663.985802551,507.4264335664336,0.16121325873456538,0.05126153854123573,0.0,0.0,1.0005910165484633,1693.0,-0.6770012052816189,0.0463827553030906,1.0,2.0,2.0,142.0,142.0,135.0,284.0,3100,141.0,4.156965348783941e-07,66433.0,1693.0,1.0,0,141.0
2519,300203,HP:0001250,"Using this gene panel, we were able to identify disease-causing variants in 17 out of 87 (19.5%) analyzed patients, all found in known epilepsy-associated genes (KCNQ2, CDKL5, STXBP1, SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2, SYNGAP1, and GRIN1).",1,1.3978387358386493,23602790.82105435,481.44419833445016,0.13187703661703354,0.0564989490201423,0.0,0.0,1.0005302226935309,1887.0,-0.5761203967910292,0.07489486866943046,1.0,2.0,1.0,335.0,335.0,290.0,670.0,3100,334.0,4.156965348783939e-07,133271.0,1887.0,1.0,0,387.0
2521,602926,HP:0001250,"Using this gene panel, we were able to identify disease-causing variants in 17 out of 87 (19.5%) analyzed patients, all found in known epilepsy-associated genes (KCNQ2, CDKL5, STXBP1, SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2, SYNGAP1, and GRIN1).",1,1.3682673404132604,34449364.62702519,426.8592677183895,0.12812519805737185,0.045692159990592035,0.0,0.0,1.0004768717215071,2098.0,-0.4871897205573442,0.07856291138141419,1.0,2.0,2.0,541.0,541.0,181.0,1082.0,3100,540.0,4.156965348783941e-07,172819.0,2098.0,1.0,0,739.0
2522,182389,HP:0001250,"Using this gene panel, we were able to identify disease-causing variants in 17 out of 87 (19.5%) analyzed patients, all found in known epilepsy-associated genes (KCNQ2, CDKL5, STXBP1, SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2, SYNGAP1, and GRIN1).",1,1.407197460490987,12458784.19595111,398.105833240317,0.1449770079654883,0.08948455818749215,0.0,0.0,1.000544069640914,1839.0,-0.6099803644324051,0.05737848963427514,1.0,2.0,2.0,284.0,284.0,155.0,568.0,3100,283.0,4.156965348783942e-07,96972.0,1839.0,1.0,0,269.0
2523,300460,HP:0001250,"Using this gene panel, we were able to identify disease-causing variants in 17 out of 87 (19.5%) analyzed patients, all found in known epilepsy-associated genes (KCNQ2, CDKL5, STXBP1, SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2, SYNGAP1, and GRIN1).",1,1.4370783456392373,6501240.8072531875,430.37087557603684,0.1649500920550744,0.1465731775605863,0.0,0.0,1.0005824111822947,1718.0,-0.6301383559806428,0.04422799329854234,1.0,2.0,1.0,168.0,168.0,141.0,336.0,3100,167.0,4.156965348783942e-07,65232.0,1718.0,1.0,0,157.0
2524,174763,HP:0001250,"Using this gene panel, we were able to identify disease-causing variants in 17 out of 87 (19.5%) analyzed patients, all found in known epilepsy-associated genes (KCNQ2, CDKL5, STXBP1, SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2, SYNGAP1, and GRIN1).",1,1.3727002491081342,21463561.353017647,352.18093472186945,0.1381998647161225,0.02486841542322867,0.0,0.0,1.0004861448711715,2058.0,-0.5251977613480178,0.06365993859172947,1.0,2.0,7.0,495.0,495.0,126.0,990.0,3100,494.0,4.156965348783942e-07,134746.0,2058.0,1.0,0,604.0
2527,138140,HP:0001250,"Using this gene panel, we were able to identify disease-causing variants in 17 out of 87 (19.5%) analyzed patients, all found in known epilepsy-associated genes (KCNQ2, CDKL5, STXBP1, SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2, SYNGAP1, and GRIN1).",1,1.4093050553419717,14055583.066745827,450.6500358422938,0.14304570831581534,0.022074275539454083,0.0,0.0,1.00054704595186,1829.0,-0.5942424591786458,0.06373848033087158,1.0,2.0,7.0,272.0,272.0,216.0,544.0,3100,271.0,4.156965348783942e-07,106552.0,1829.0,1.0,0,252.0
2529,300776,HP:0001250,"Using this gene panel, we were able to identify disease-causing variants in 17 out of 87 (19.5%) analyzed patients, all found in known epilepsy-associated genes (KCNQ2, CDKL5, STXBP1, SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2, SYNGAP1, and GRIN1).",1,1.4108149740994378,19433002.50583469,511.11940227704,0.13613701793190242,0.06658634547326514,0.0,0.0,1.0005491488193299,1822.0,-0.5873236451297097,0.07129289886077239,1.0,2.0,1.0,272.0,272.0,272.0,544.0,3100,271.0,4.1569653487839437e-07,118270.0,1822.0,1.0,0,282.0
2530,603384,HP:0001250,"Using this gene panel, we were able to identify disease-causing variants in 17 out of 87 (19.5%) analyzed patients, all found in known epilepsy-associated genes (KCNQ2, CDKL5, STXBP1, SCN1A, PCDH19, POLG, SLC2A1, ARX, ALG13, CHD2, SYNGAP1, and GRIN1).",1,1.4103806153957603,20647391.18652147,530.7938780315517,0.1329987609728742,0.025824325347201055,0.0,0.0,1.0005485463521668,1824.0,-0.6062443060445875,0.07433645138628249,1.0,2.0,2.0,273.0,273.0,273.0,546.0,3100,272.0,4.156965348783942e-07,123590.0,1824.0,1.0,0,296.0
2531,170290,HP:0001513,"This mouse model might mimic and explain the pathogenesis of hepatosteatosis occurring in two typical disorders of adipose tissue dysfunction, obesity and lipodystrophy, particularly in lipodystrophic patients with Plin1 mutation",0,1.3852804190289123,395553.9982540673,120.13961038961037,0.2447924644146292,0.013060024755764644,0.0,0.0,0.9976744186046512,429.0,-0.6459693726633556,0.08517779096746345,1.0,2.0,3.0,72.0,72.0,56.0,144.0,706,70.0,8.025102520684701e-06,7893.0,431.0,1.0,0,69.0
2532,125505,HP:0011897,"We investigated which host factors control NETs in vivo and found that two deoxyribonucleases (DNases), DNase1 and DNase1-like 3, degraded NETs in circulation during sterile neutrophilia and septicemia.",0,1.3063178959405377,5283.913419913421,29.424863387978142,0.4318138022155371,0.3338018125026442,0.0,0.0,0.9864864864864864,73.0,-0.6471839002456206,0.1254054054054054,1.0,2.0,11.0,13.0,13.0,13.0,26.0,56,12.0,0.00026014568158168577,348.0,75.0,1.0,0,13.0
2533,606410,HP:0001251,"The ataxia telangiectasia-mutated and Rad3-related (ATR) kinase is a master regulator of DNA damage response and replication stress in humans, but the mechanism of its activation remains unclear.",0,1.3656855599382611,6685104.736803475,242.8272123448508,0.16019853850736485,0.07473967996074285,0.0,0.0,0.9990817263544536,1088.0,-0.5457516497596948,0.0852157943067034,1.0,2.0,3.0,269.0,269.0,111.0,538.0,1632,267.0,1.5055139448229141e-06,50576.0,1090.0,1.0,0,334.0
2537,603248,HP:0002664,We conclude that loss of oncogenic miR-1274a reduced cancer cell proliferation and induced apoptosis in ccRCC through targeting BMPR1B.,1,1.361147393077595,3684985.3411699487,150.0119192096121,0.184141750663458,0.029161707666848214,0.0,0.0,1.0009250693802036,1082.0,-0.5241480417030784,0.056844743947293275,1.0,2.0,10.0,239.0,239.0,44.0,478.0,1542,238.0,1.6778973932186097e-06,33244.0,1082.0,1.0,0,270.0
2538,122500,HP:0001945,"CBG concentration and affinity are affected by a number of common factors including oral contraceptive pills (OCPs), fever and infection, as well as rare mutations in the serine protease inhibitor A6 (SERPINA6) gene, and as such, total cortisol levels might not be the ideal way to assess adrenal function in all clinical circumstances.",0,1.445864908119782,40581.5004939886,123.58984375,0.33655457943847844,-0.0067159986549616395,0.0,0.0,0.9963369963369964,272.0,-0.7759607981234624,0.05622844308975696,1.0,2.0,1.0,17.0,17.0,17.0,34.0,514,15.0,1.5023135628868454e-05,2103.0,274.0,1.0,0,15.0
2539,607182,HP:0002664,"Collectively, our data suggest that FYCO1 regulates MB degradation, and we present the first evidence that cancer invasiveness is a feature that can be modulated by the accumulation of MBs in cancer stem cells.This article has an associated First Person interview with the first author of the paper",0,1.4053439795070242,26996.245856335318,296.9394107837688,0.4182057887546177,0.5667074249653977,0.0,0.0,0.9987163029525032,778.0,-0.7525643678060395,0.009295283236233172,1.0,2.0,154.0,8.0,8.0,8.0,16.0,1544,6.0,1.67789739321861e-06,2824.0,780.0,1.0,0,7.0
2540,604985,HP:0001251,"Moreover, the novel mutation, p.R414C, adds up to the literature for the infantile-onset form of autosomal recessive ataxia associated with SPTBN2.",1,1.436999050265117,2239931.0656666933,384.82441228906686,0.16983040758515788,0.032450748312117306,0.0,0.0,1.0011098779134295,902.0,-0.7504660493945718,0.07596880529394537,1.0,2.0,2.0,88.0,88.0,88.0,176.0,1626,87.0,1.5092152684290268e-06,30870.0,902.0,1.0,0,89.0
2541,615951,HP:0001270,"A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 was previously reported to cause acromelic frontonasal dysostosis (AFND), an autosomal-dominant severe frontonasal and limb malformation syndrome, associated with neurocognitive and motor delay, via a proposed gain-of-function effect.",0,1.35527669543875,6823059.101521517,256.1179450731689,0.14915364629484293,0.1698614080968364,0.0,0.0,1.0011428571428571,876.0,-0.5610760894389586,0.12558382257012393,1.0,2.0,5.0,255.0,255.0,136.0,510.0,1206,254.0,2.741107846147099e-06,48130.0,876.0,1.0,0,343.0
2542,615951,HP:0001249,We present detailed phenotypic information on seven unrelated individuals with a recurrent de novo nonsense variant (c.2737C&gt;T [p.Arg913Ter]) in the penultimate exon of ZSWIM6 who have severe-profound intellectual disability and additional central and peripheral nervous system symptoms but an absence of frontonasal or limb malformations.,1,1.4125331384473037,19959348.53532042,527.958698604766,0.13182846080612198,0.04993777967783348,0.0,0.0,1.0005336179295623,1875.0,-0.635479880830712,0.07009434364994664,1.0,2.0,2.0,269.0,269.0,230.0,538.0,3204,268.0,3.891642658474498e-07,123147.0,1875.0,1.0,0,292.0
2545,604614,HP:0002664,These results indicate that TBX19 may work as an oncogene in colorectal cancer (CRC).,0,1.4249112305178482,706180.1077549986,214.9264353957728,0.2343374003668576,0.19486343916097024,0.0,0.0,0.9988137603795968,842.0,-0.6652985507377295,0.0412794521934189,1.0,2.0,25.0,72.0,72.0,72.0,144.0,1544,70.0,1.67789739321861e-06,14685.0,844.0,1.0,0,68.0
2543,604614,HP:0002664,"Here, we investigated TBX19 mRNA and protein expressions in colon cancer cells or surgically resected CRC.",0,1.4249112305178482,706180.1077549986,214.9264353957728,0.2343374003668576,0.19486343916097024,0.0,0.0,0.9988137603795968,842.0,-0.6652985507377295,0.0412794521934189,1.0,2.0,25.0,72.0,72.0,72.0,144.0,1544,70.0,1.67789739321861e-06,14685.0,844.0,1.0,0,68.0
2556,137290,HP:0002664,"Methods: Ten potentially functional single nucleotide polymorphisms (SNPs) in seven prostate CSC marker genes, TACSTD2, PROM1, ITGA2, POU5F1, EZH2, PSCA, and CD44, were selected for analysis of their association with disease recurrence by Kaplan-Meier analysis and Cox regression in a cohort of 320 patients with localized prostate cancer receiving radical prostatectomy.",0,1.4275991989409729,125722.55083681575,248.7899481193256,0.3232828816680043,0.2520735131704226,0.0,0.0,0.998737373737374,791.0,-0.7159616096733603,0.017839173576878496,1.0,2.0,85.0,21.0,21.0,21.0,42.0,1544,19.0,1.67789739321861e-06,5602.0,793.0,1.0,0,18.0
2564,604365,HP:0002664,"Methods: Ten potentially functional single nucleotide polymorphisms (SNPs) in seven prostate CSC marker genes, TACSTD2, PROM1, ITGA2, POU5F1, EZH2, PSCA, and CD44, were selected for analysis of their association with disease recurrence by Kaplan-Meier analysis and Cox regression in a cohort of 320 patients with localized prostate cancer receiving radical prostatectomy.",0,1.3709112788535172,2386428.8656202042,207.82075398768262,0.1833208203618607,0.15252466058682998,0.0,0.0,0.9989165763813652,922.0,-0.6461356271888048,0.06310825324909831,1.0,2.0,26.0,131.0,131.0,91.0,262.0,1544,129.0,1.67789739321861e-06,26911.0,924.0,1.0,0,128.0
2566,601573,HP:0002664,"Methods: Ten potentially functional single nucleotide polymorphisms (SNPs) in seven prostate CSC marker genes, TACSTD2, PROM1, ITGA2, POU5F1, EZH2, PSCA, and CD44, were selected for analysis of their association with disease recurrence by Kaplan-Meier analysis and Cox regression in a cohort of 320 patients with localized prostate cancer receiving radical prostatectomy.",0,1.3501423663029302,7996754.642513287,245.6594333034021,0.14719100954203887,0.09600053344274788,0.0,0.0,0.9990548204158792,1057.0,-0.5520613057178811,0.09262224411873383,1.0,2.0,16.0,278.0,278.0,117.0,556.0,1544,276.0,1.677897393218609e-06,51888.0,1059.0,1.0,0,337.0
2573,139130,HP:0001513,"The G-protein beta subunit 3 (GNB3) gene has been implicated in obesity risk; however, the molecular mechanism of GNB3-related disease is unknown.",0,1.3883787609334737,226065.6796508316,124.90693181818182,0.2473292001760581,0.06973655398813683,0.0,0.0,0.9975186104218364,402.0,-0.7172823800726104,0.0710389897550549,1.0,2.0,11.0,43.0,43.0,35.0,86.0,716,41.0,8.025102520684701e-06,5783.0,404.0,1.0,0,35.0
2567,139130,HP:0001513,"GNB3 duplication is responsible for a syndromic form of childhood obesity, and an activating DNA sequence variant (C825T) in GNB3 is also associated with obesity.",0,1.3883787609334737,226065.6796508316,124.90693181818182,0.2473292001760581,0.06973655398813683,0.0,0.0,0.9975186104218364,402.0,-0.7172823800726104,0.0710389897550549,1.0,2.0,11.0,43.0,43.0,35.0,86.0,716,41.0,8.025102520684701e-06,5783.0,404.0,1.0,0,35.0
2576,139130,HP:0001513,"To test the hypothesis that GNB3 overexpression causes obesity, we created bacterial artificial chromosome (BAC) transgenic mice that carry an extra copy of the human GNB3 risk allele.",0,1.3883787609334737,226065.6796508316,124.90693181818182,0.2473292001760581,0.06973655398813683,0.0,0.0,0.9975186104218364,402.0,-0.7172823800726104,0.0710389897550549,1.0,2.0,11.0,43.0,43.0,35.0,86.0,716,41.0,8.025102520684701e-06,5783.0,404.0,1.0,0,35.0
2570,139130,HP:0001513,"Taken together, our study provides the first functional link between GNB3 and obesity, and presents insight into novel pathways that could be applied to combat obesity and type 2 diabetes",0,1.3883787609334737,226065.6796508316,124.90693181818182,0.2473292001760581,0.06973655398813683,0.0,0.0,0.9975186104218364,402.0,-0.7172823800726104,0.0710389897550549,1.0,2.0,11.0,43.0,43.0,35.0,86.0,716,41.0,8.025102520684701e-06,5783.0,404.0,1.0,0,35.0
2585,612753,HP:0002664,The present study aimed to investigate the relationship between the expression of collagen and calcium-binding epidermal growth factor domain-containing protein 1 (CCBE1) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) in tumor tissue with the clinical prognosis of lung cancer.,1,1.3563221170316098,10339985.318405043,277.6161666875863,0.14449006938619252,0.08456781575257917,0.0,0.0,1.0009000900090008,1112.0,-0.49355483710535497,0.10625756820286343,1.0,2.0,3.0,335.0,335.0,126.0,670.0,1542,334.0,1.6778973932186103e-06,65637.0,1112.0,1.0,0,470.0
2582,612753,HP:0002664,"In conclusion, the present results suggested that CCBE1 and LYVE1 may have potential as biomarkers for the identification of lung cancer patients at a high risk of LNM",1,1.3563221170316098,10339985.318405043,277.6161666875863,0.14449006938619252,0.08456781575257917,0.0,0.0,1.0009000900090008,1112.0,-0.49355483710535497,0.10625756820286343,1.0,2.0,3.0,335.0,335.0,126.0,670.0,1542,334.0,1.6778973932186103e-06,65637.0,1112.0,1.0,0,470.0
307,601231,HP:0002664,MTORC1/2 inhibition shows antitumor activity in cell culture models of DIPG due to the effect of MTORC2 inhibition on AKT.,0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
2630,164730,HP:0002664,MTORC1/2 inhibition shows antitumor activity in cell culture models of DIPG due to the effect of MTORC2 inhibition on AKT.,1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
2684,165220,HP:0002664,Canonical GLI-dependent Hedgehog signaling is a negative regulator of WNT signaling in normal intestine and intestinal tumors.,1,1.387550981490707,4588366.637610347,249.7119840447373,0.16337642540454422,0.05617857082698744,0.0,0.0,1.001031991744066,970.0,-0.5946728239393734,0.0840445565095273,1.0,2.0,6.0,197.0,197.0,147.0,394.0,1542,196.0,1.6778973932186097e-06,39498.0,970.0,1.0,0,232.0
2685,160775,HP:0040185,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.342857142857143,5404.449206349206,47.39285714285714,0.39262497589542417,0.15207129235188066,0.0,0.0,0.9893617021276596,93.0,-0.8175521977649836,0.10347144456886898,1.0,2.0,15.0,10.0,10.0,10.0,20.0,110,9.0,0.0001384083044982699,462.0,95.0,1.0,0,10.0
2686,159530,HP:0040185,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.3215007215007215,9500.759178338005,65.26118326118326,0.46366577999883896,0.4327403905840279,0.0,0.0,0.995850622406639,240.0,-0.5873897223854653,0.027022392922053426,1.0,2.0,93.0,10.0,10.0,10.0,20.0,226,9.0,1.8579072532699166e-05,788.0,242.0,1.0,0,13.0
2687,165215,HP:0040185,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.3330148112756808,5027.8785484242,36.71857923497268,0.5016206517811016,0.2684822336579358,0.0,0.0,0.9924242424242424,131.0,-0.6077352929870717,0.0480747322852586,1.0,2.0,33.0,10.0,10.0,10.0,20.0,138,9.0,6.609822195782933e-05,422.0,133.0,1.0,0,13.0
2689,610855,HP:0040185,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.2679200940070503,935.0,22.48611111111111,0.39910853975656574,0.3939072521896612,0.0,0.0,0.9615384615384616,25.0,-0.7737089081271783,0.4074074074074074,1.0,2.0,1.0,10.0,10.0,10.0,20.0,30,9.0,0.0034602076124567475,143.0,27.0,1.0,0,13.0
2691,159530,HP:0000365,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.3965365325821857,7783626.215526431,330.8457271642397,0.15352676787252162,0.12997152493428893,0.0,0.0,0.9993192648059904,1468.0,-0.6259462444933312,0.0606437809977633,1.0,2.0,9.0,220.0,220.0,118.0,440.0,2492,218.0,6.514144487633224e-07,65478.0,1470.0,1.0,0,239.0
2692,165215,HP:0000365,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",1,1.441703770546583,4272063.820092323,412.29081463615034,0.17050197248398846,0.07212600862134406,0.0,0.0,1.0007363770250368,1359.0,-0.6498886666896367,0.04961631451697677,1.0,2.0,1.0,116.0,116.0,110.0,232.0,2474,115.0,6.524672396198988e-07,45784.0,1359.0,1.0,0,117.0
2693,151385,HP:0000365,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.397776118852761,3724502.143945797,267.94759560030377,0.1889220743597252,0.15317023309807215,0.0,0.0,0.9992872416250892,1402.0,-0.5894255325022997,0.04073383652856211,1.0,2.0,56.0,155.0,155.0,106.0,310.0,2478,153.0,6.524672396198987e-07,40119.0,1404.0,1.0,0,160.0
2694,160775,HP:0000518,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",1,1.4285942918111498,976771.9042839294,230.00033017829628,0.2033125396120593,0.06370684791472991,0.0,0.0,1.0013661202185793,733.0,-0.6797616564928569,0.06376221680495606,1.0,2.0,4.0,78.0,78.0,66.0,156.0,1298,77.0,2.366863905325444e-06,17106.0,733.0,1.0,0,78.0
2695,159530,HP:0000518,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.3492304762603993,3814187.778472955,206.81033091202585,0.1646124738381448,0.008071736754684575,0.0,0.0,0.9988649262202044,880.0,-0.5862699103790348,0.09207224319920933,1.0,2.0,12.0,211.0,211.0,83.0,422.0,1322,209.0,2.3595980188815043e-06,35772.0,882.0,1.0,0,258.0
2696,165215,HP:0000518,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.3837378869847687,2272728.0278582536,235.21440299072967,0.1768417219228613,0.008338570939472826,0.0,0.0,0.9987046632124352,771.0,-0.6591413428006775,0.08285128260126416,1.0,2.0,18.0,112.0,112.0,106.0,224.0,1300,110.0,2.366863905325444e-06,24721.0,773.0,1.0,0,113.0
2697,610855,HP:0000518,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.436905662994979,81881.9415266647,224.79805469953774,0.3354735050590092,0.17271899953893385,0.0,0.0,0.9984984984984984,665.0,-0.7281733838435815,0.01865733799766784,1.0,2.0,57.0,17.0,17.0,17.0,34.0,1300,15.0,2.366863905325444e-06,4144.0,667.0,1.0,0,16.0
2698,600618,HP:0000518,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.4327050647166812,363938.6490062037,181.1021400445129,0.2672502674706589,0.09497212160200846,0.0,0.0,0.9985611510791368,694.0,-0.6402994159890218,0.03403208467708592,1.0,2.0,25.0,46.0,46.0,46.0,92.0,1298,44.0,2.366863905325444e-06,8231.0,696.0,1.0,0,59.0
2699,157145,HP:0002664,"QM-MSP can be applied to clinical samples of fresh or fixed ductal cells, ductal fluid, nipple fluid, fine needle aspirates, core biopsies, and tumor tissue sections",0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865474,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
2700,308840,HP:0000238,The most common genetic cause is L1CAM-related X-linked hydrocephalus and that explains only 5%-10% of all male cases.,1,1.3494116116601798,2197817.1545005804,196.99312934824002,0.16267645931645322,0.08599463712109932,0.0,0.0,1.0019762845849802,507.0,-0.5564384580496113,0.1750278706800446,1.0,2.0,6.0,162.0,162.0,114.0,324.0,668,161.0,8.910670527957227e-06,22451.0,507.0,1.0,0,212.0
2701,611204,HP:0000238,This suggests that children with CCDC88C-related autosomal recessive hydrocephalus can have normal developmental outcomes under certain circumstances.,1,1.4022579244463742,441056.3330738706,152.97422546211925,0.21333531450231635,0.16077348585638893,0.0,0.0,1.0024875621890548,403.0,-0.7094638218142629,0.10799600014814266,1.0,2.0,4.0,66.0,66.0,51.0,132.0,668,65.0,8.910670527957227e-06,8748.0,403.0,1.0,0,65.0
2703,611204,HP:0000007,This suggests that children with CCDC88C-related autosomal recessive hydrocephalus can have normal developmental outcomes under certain circumstances.,1,1.4815635255145412,2472972.790430817,645.0929558476574,0.215387802836672,0.2570752439027866,0.0,0.0,1.0003776435045315,2649.0,-0.6390897341829634,0.012360589813861242,1.0,2.0,211.0,68.0,68.0,68.0,136.0,5160,67.0,1.5011496554636372e-07,43352.0,2649.0,1.0,0,69.0
2702,611204,HP:0000238,"We recommend CCDC88C analysis in cases of severe non-syndromic congenital hydrocephalus, especially when aqueduct stenosis with or without a medial diverticulum is seen, in order to aid prognosis discussion",1,1.4022579244463742,441056.3330738706,152.97422546211925,0.21333531450231635,0.16077348585638893,0.0,0.0,1.0024875621890548,403.0,-0.7094638218142629,0.10799600014814266,1.0,2.0,4.0,66.0,66.0,51.0,132.0,668,65.0,8.910670527957227e-06,8748.0,403.0,1.0,0,65.0
2706,607145,HP:0100753,The dystrobrevin-binding protein 1 (DTNBP1) gene is a candidate risk factor for schizophrenia and has been associated with cognitive ability in both patient populations and healthy controls.,0,1.2017316017316015,16654.14166666667,30.567629179331302,0.3659919359618594,-0.023096506341365813,0.0,0.0,0.9903846153846154,103.0,-0.4124032888488433,0.15256410256410258,1.0,2.0,16.0,33.0,33.0,2.0,66.0,114,31.0,0.0003077870113881194,833.0,105.0,1.0,0,31.0
2704,607145,HP:0100753,"DTNBP1 encodes dysbindin protein, which is localized to synaptic sites and is reduced in the prefrontal cortex and hippocampus of patients with schizophrenia, indicating a potential role in schizophrenia etiology.",0,1.2017316017316015,16654.14166666667,30.567629179331302,0.3659919359618594,-0.023096506341365813,0.0,0.0,0.9903846153846154,103.0,-0.4124032888488433,0.15256410256410258,1.0,2.0,16.0,33.0,33.0,2.0,66.0,114,31.0,0.0003077870113881194,833.0,105.0,1.0,0,31.0
1848,191160,HP:0002664,The MKK1/2 kinase tumour progression locus 2 (TPL-2) is critical for the production of tumour necrosis factor alpha (TNFa) in innate immune responses and a potential anti-inflammatory drug target.,0,1.4602670579691517,200974.08525960872,239.91050583657588,0.2850613192309647,0.15408425189867206,0.0,0.0,0.9987531172069826,801.0,-0.7836891500894245,0.02382275941528495,1.0,2.0,14.0,31.0,31.0,25.0,62.0,1544,29.0,1.6778973932186097e-06,7671.0,803.0,1.0,0,23.0
2708,191195,HP:0002664,The MKK1/2 kinase tumour progression locus 2 (TPL-2) is critical for the production of tumour necrosis factor alpha (TNFa) in innate immune responses and a potential anti-inflammatory drug target.,1,1.4873012487474293,56683.754180476026,245.41686121919585,0.4091005680924446,0.01853930019144065,0.0,0.0,1.0012738853503185,786.0,-0.7080939589769509,0.011704834605597965,1.0,2.0,5.0,15.0,15.0,15.0,30.0,1542,15.0,1.67789739321861e-06,3611.0,786.0,1.0,0,25.0
2709,609644,HP:0002664,FANCM is a DNA-damage response gene whose heterozygous mutations predispose to breast cancer.,1,1.352582238102203,12017173.424296536,292.6864849433261,0.1406675231511127,0.11309424037472628,0.0,0.0,1.0008787346221442,1139.0,-0.4653114036100979,0.11249809054592642,1.0,2.0,6.0,366.0,366.0,104.0,732.0,1542,365.0,1.6778973932186097e-06,72909.0,1139.0,1.0,0,459.0
2718,251170,HP:0001425,"The aim of this work is to provide supplementary information about MVK variability useful in the molecular diagnosis of MKD, as well as to unravel the presence of novel genes potentially involved as involved in the clinical heterogeneity of MKD phenotype.",0,1.2991255085067417,1297880.6885836385,118.29077767566628,0.2029649451381373,0.16913649002570474,0.0,0.0,0.9982578397212544,573.0,-0.2479158878267781,0.10249962126950464,1.0,2.0,26.0,216.0,216.0,2.0,432.0,496,214.0,9.351999925184e-06,16915.0,575.0,1.0,0,261.0
2719,614452,HP:0100753,"Bidirectional sequencing of exons of ATAD1, the gene encoding Thorase, in a cohort of patients with schizophrenia and healthy controls revealed rare Thorase variants.",0,1.3271855751451551,66401.48095238095,51.348347547974406,0.3109904302484352,0.17700131458792814,0.0,0.0,0.9947643979057592,190.0,-0.5010743896353703,0.11665575916230367,1.0,2.0,7.0,53.0,53.0,21.0,106.0,122,51.0,5.486968449931413e-05,2139.0,192.0,1.0,0,52.0
2728,603287,HP:0002664,"Pyridoxine 5*-phosphate oxidase (PNPO) is an enzyme that converts pyridoxine 5*-phosphate into pyridoxal 5*-phosphate (PLP), an active form of vitamin B6 implicated in several types of cancer.",0,1.3947155307682817,1534982.5648090653,226.0306512003524,0.1896587049494632,0.2009591619123034,0.0,0.0,0.9988610478359908,877.0,-0.7040566175512825,0.056374892777825286,1.0,2.0,33.0,96.0,96.0,69.0,192.0,1544,94.0,1.67789739321861e-06,21754.0,879.0,1.0,0,89.0
2724,603287,HP:0002664,"In the present study, PNPO expression in human ovarian tumour tissue and its association with the clinicopathological features of patients with EOC were examined.",0,1.3947155307682817,1534982.5648090653,226.0306512003524,0.1896587049494632,0.2009591619123034,0.0,0.0,0.9988610478359908,877.0,-0.7040566175512825,0.056374892777825286,1.0,2.0,33.0,96.0,96.0,69.0,192.0,1544,94.0,1.67789739321861e-06,21754.0,879.0,1.0,0,89.0
2732,603287,HP:0002664,Xenografts of PNPO-shRNA-expressing cells into the nude mouse attenuated tumour growth.,0,1.3947155307682817,1534982.5648090653,226.0306512003524,0.1896587049494632,0.2009591619123034,0.0,0.0,0.9988610478359908,877.0,-0.7040566175512825,0.056374892777825286,1.0,2.0,33.0,96.0,96.0,69.0,192.0,1544,94.0,1.67789739321861e-06,21754.0,879.0,1.0,0,89.0
2135,602690,HP:0002668,Phaeochromocytoma and paraganglioma (PHEO/PGL) are rare tumours with an estimated annual incidence of 3 per million.,1,1.4791825143262842,117396.99615874955,273.5338983050848,0.2851855398126953,0.07083126274117219,0.0,0.0,1.0016447368421053,609.0,-0.7190956228417434,0.027196223316912974,1.0,2.0,31.0,19.0,19.0,19.0,38.0,358,19.0,2.863024327117708e-06,5035.0,609.0,1.0,0,19.0
1783,602690,HP:0002664,Phaeochromocytoma and paraganglioma (PHEO/PGL) are rare tumours with an estimated annual incidence of 3 per million.,1,1.3362913929618414,12107845.650814038,238.5258040405373,0.14801864264586315,0.06774311571033638,0.0,0.0,1.000735294117647,1361.0,-0.3764887027914669,0.08614232614427109,1.0,2.0,2.0,521.0,521.0,12.0,1042.0,1542,520.0,1.67789739321861e-06,79723.0,1361.0,1.0,0,697.0
2736,602690,HP:0003745,"It is therefore recommended that, depending on local resources and availability, at least some degree of genetic testing should be offered to all PHEO/PGL patients, including those with clinically sporadic disease.",0,1.3797885687601623,1077107.410432455,156.87966101694917,0.22212529111182225,0.09404290878689787,0.0,0.0,0.998542274052478,685.0,-0.5077675873977929,0.056687927822407815,1.0,2.0,42.0,96.0,96.0,96.0,192.0,368,95.0,2.863024327117708e-06,13358.0,687.0,1.0,0,96.0
2737,151410,HP:0002664,"Integration of the differentially expressed miRNAs with matched mRNA expression profiles identified highly anti-correlated, putative targets, which were significantly enriched in cancer-associated pathways, including phosphatidylinositol (PI)), mitogen-activated protein kinase (MAPK), and B-cell receptor (BCR) signaling.",1,1.3618496077945474,9318176.787612388,278.06558596010933,0.14580752745550246,0.04047526785930392,0.0,0.0,1.000928505106778,1078.0,-0.5175019857743832,0.10517602837539168,1.0,2.0,0.0,302.0,302.0,138.0,604.0,1542,302.0,1.67789739321861e-06,61055.0,1078.0,2.0,0,419.0
2738,610876,HP:0002664,HACE1 is a putative Wilms* tumor susceptibility gene.,1,1.3984175872268259,3944418.7043926087,259.2090371785612,0.16391836717145478,-0.015376232721212559,0.0,0.0,1.001067235859125,938.0,-0.6250773065512586,0.0809665652527119,1.0,2.0,7.0,163.0,163.0,141.0,326.0,1542,162.0,1.677897393218609e-06,35581.0,938.0,1.0,0,202.0
2750,610876,HP:0002664,We investigated the association between five HACE1 gene polymorphisms and Wilms* tumor susceptibility in a Chinese population consisting of 145 patients and 531 controls.,1,1.3984175872268259,3944418.7043926087,259.2090371785612,0.16391836717145478,-0.015376232721212559,0.0,0.0,1.001067235859125,938.0,-0.6250773065512586,0.0809665652527119,1.0,2.0,7.0,163.0,163.0,141.0,326.0,1542,162.0,1.677897393218609e-06,35581.0,938.0,1.0,0,202.0
2746,610876,HP:0002664,We found a significant association between HACE1 rs9404576 polymorphism and decreased Wilms* tumor risk.,1,1.3984175872268259,3944418.7043926087,259.2090371785612,0.16391836717145478,-0.015376232721212559,0.0,0.0,1.001067235859125,938.0,-0.6250773065512586,0.0809665652527119,1.0,2.0,7.0,163.0,163.0,141.0,326.0,1542,162.0,1.677897393218609e-06,35581.0,938.0,1.0,0,202.0
2754,608869,HP:0002664,"In contrast, LRIG2 appears to function as a tumor promoter, while LRIG3 appears to have a function similar to that of LRIG1.",0,1.4351646728695908,606602.5110444266,243.41902909023534,0.2400435667979152,0.21107305419399225,0.0,0.0,0.9987922705314008,827.0,-0.6843382717411691,0.03913393122497858,1.0,2.0,24.0,57.0,57.0,57.0,114.0,1544,55.0,1.6778973932186097e-06,13431.0,829.0,1.0,0,51.0
2755,300180,HP:0004322,"This interval encompasses several genes, especially the short stature homeobox (SHOX) and arylsulfatase (ARSE) genes.",1,1.3949909927942354,11214140.430033192,380.00161541889486,0.13952285926903715,0.05777798571209367,0.0,0.0,1.0007262164124908,1378.0,-0.6267971082130376,0.0834864290284194,1.0,2.0,4.0,245.0,245.0,168.0,490.0,2244,244.0,7.929402939746845e-07,79208.0,1378.0,1.0,0,254.0
2756,608053,HP:0000007,"Neonatal-onset multiple acyl-CoA dehydrogenase deficiency (MADD type I) is an autosomal recessive disorder of the electron transfer flavoprotein function characterized by a severe clinical and biochemical phenotype, including congenital abnormalities with unresponsiveness to riboflavin treatment as distinguishing features.",1,1.4634623016734034,7456412.575170968,588.8287222667736,0.1820505980703256,0.11789884564118162,0.0,0.0,1.0003671071953009,2725.0,-0.6313416473485699,0.021780436217650783,1.0,2.0,16.0,145.0,145.0,143.0,290.0,5160,144.0,1.5011496554636375e-07,80837.0,2725.0,1.0,0,131.0
2757,139250,HP:0004322,Several genetic defects are responsible for impairment of GH and IGF-I actions resulting in short stature that could affect intrauterine growth or be present in the postnatal period.,1,1.4740277705353058,742669.2623465075,457.2549019607843,0.21829494927913945,0.13080848861100744,0.0,0.0,1.0008583690987125,1166.0,-0.7824317291220356,0.028504332334601992,1.0,2.0,4.0,39.0,39.0,36.0,78.0,2244,38.0,7.929402939746845e-07,19360.0,1166.0,1.0,0,38.0
2761,147440,HP:0004322,Gene mutations in the IGF1 and IGF2 genes have been described in patients presenting intrauterine growth retardation and postnatal short stature.,1,1.4198213606020418,8776803.078123385,468.46051535191805,0.14113885496209774,0.02919921663813064,0.0,0.0,1.0007751937984497,1291.0,-0.6868793928008262,0.0826304949591387,1.0,2.0,2.0,168.0,168.0,154.0,336.0,2244,167.0,7.929402939746845e-07,68806.0,1291.0,1.0,0,160.0
2762,147470,HP:0004322,Gene mutations in the IGF1 and IGF2 genes have been described in patients presenting intrauterine growth retardation and postnatal short stature.,1,1.3677442190176632,19358595.938269407,371.54440769733424,0.13088169278731115,0.05834408376042637,0.0,0.0,1.0006570302233904,1523.0,-0.5394574305174078,0.09470294727451094,1.0,2.0,2.0,391.0,391.0,151.0,782.0,2244,391.0,7.929402939746845e-07,109761.0,1523.0,1.0,0,533.0
2763,606416,HP:0003287,"Collectively, our data highlight that, by inhibiting ANT1 and mitochondrial dysfunction, SHP2 orchestrates an intrinsic regulatory loop to limit excessive NLRP3 inflammasome activation",0,1.2947554668360404,347228.5671558019,81.10324483775811,0.2307375107699013,0.29023536360514224,0.0,0.0,0.9976190476190476,419.0,-0.3272305481853678,0.07857708404026692,1.0,2.0,48.0,114.0,114.0,5.0,228.0,244,113.0,1.0610192150579848e-05,6947.0,421.0,1.0,0,145.0
2764,600960,HP:0000135,We performed permutation-based analysis to test for overall enrichment of these 510 genes carrying these 548 variants with genes mutated in Kallmann syndrome and with a control set of genes mutated in hypogonadotrophic hypogonadism without anosmia.,0,1.336457089977603,1589344.6408730156,152.56069832835922,0.17928283473394407,0.1547990058265557,0.0,0.0,0.9980506822612084,512.0,-0.5946129374548002,0.13317556753968796,1.0,2.0,6.0,149.0,149.0,76.0,298.0,688,147.0,8.450513791238506e-06,17558.0,514.0,1.0,0,185.0
2765,154870,HP:0002664,"The expression of uncarboxylated MGP (ucMGP), carboxylated MGP (cMGP), matrix metalloproteinase (MMP)-13, collagen type X, collagen type II, tumor necrosis factor (TNF)-a and interleukin (IL)-1b were detected by ELISA, immunohistochemistry, reverse transcription-quantitative polymerase chain reaction and western blotting.",0,1.3523590893132038,5293478.148117655,247.19586161131724,0.156440283834129,0.14485127782302115,0.0,0.0,0.9989868287740628,986.0,-0.6015220914755985,0.08656666215456807,1.0,2.0,40.0,211.0,211.0,126.0,422.0,1544,209.0,1.67789739321861e-06,42208.0,988.0,1.0,0,267.0
1855,191160,HP:0002664,"The expression of uncarboxylated MGP (ucMGP), carboxylated MGP (cMGP), matrix metalloproteinase (MMP)-13, collagen type X, collagen type II, tumor necrosis factor (TNF)-a and interleukin (IL)-1b were detected by ELISA, immunohistochemistry, reverse transcription-quantitative polymerase chain reaction and western blotting.",0,1.4602670579691517,200974.08525960872,239.91050583657588,0.2850613192309647,0.15408425189867206,0.0,0.0,0.9987531172069826,801.0,-0.7836891500894245,0.02382275941528495,1.0,2.0,14.0,31.0,31.0,25.0,62.0,1544,29.0,1.6778973932186097e-06,7671.0,803.0,1.0,0,23.0
2766,604261,HP:0002664,The effect of Atg5 on exosome production promotes the migration and in vivo metastasis of orthotopic breast cancer cells.,0,1.416338638749705,310409.3699707975,253.597047379263,0.2591307675193178,0.09149255086236656,0.0,0.0,0.998759305210918,805.0,-0.7078344899138966,0.027667340054916504,1.0,2.0,85.0,35.0,35.0,33.0,70.0,1544,33.0,1.6778973932186097e-06,8998.0,807.0,1.0,0,33.0
2767,608025,HP:0000520,"Conclusion: Cases with NBAS gene defects often manifests as short stature, optic nerve atrophy, Pelger-Huet anomaly, skeletal dysplasia, recurrent infections, abnormality of liver enzymes, progeroid appearance, proptosis, hypotonia and immunodeficiency.",1,1.3380074470983565,1235765.7337662338,162.9967390703587,0.16790659961876025,0.11843750597541453,0.0,0.0,1.0026041666666663,385.0,-0.4967936721940914,0.20725108225108224,1.0,2.0,10.0,149.0,149.0,82.0,298.0,444,148.0,2.0108990729755272e-05,15320.0,385.0,1.0,0,247.0
2768,608025,HP:0000648,"Conclusion: Cases with NBAS gene defects often manifests as short stature, optic nerve atrophy, Pelger-Huet anomaly, skeletal dysplasia, recurrent infections, abnormality of liver enzymes, progeroid appearance, proptosis, hypotonia and immunodeficiency.",1,1.3738311735547497,2546910.9556286307,218.12058514408628,0.1685109620803485,0.06004427620920867,0.0,0.0,1.0015060240963856,665.0,-0.6120237627621422,0.12156445330192953,1.0,2.0,3.0,158.0,158.0,102.0,316.0,1004,157.0,3.952428569734674e-06,26839.0,665.0,1.0,0,204.0
2769,608025,HP:0002652,"Conclusion: Cases with NBAS gene defects often manifests as short stature, optic nerve atrophy, Pelger-Huet anomaly, skeletal dysplasia, recurrent infections, abnormality of liver enzymes, progeroid appearance, proptosis, hypotonia and immunodeficiency.",0,1.3113593087928712,816650.1305555556,130.56427614413653,0.1862550971153395,0.006053144956987937,0.0,0.0,0.9970414201183432,337.0,-0.3933500020397218,0.1947426297324187,1.0,2.0,7.0,141.0,141.0,21.0,282.0,350,140.0,3.228305785123967e-05,11157.0,339.0,1.0,0,189.0
899,164870,HP:0002664,"Insertion of a single-chain variable-fragment antibody (scFv) to HER2 (human epidermal growth factor receptor 2) in gD, gH, or gB gives rise to herpes simplex viruses (HSVs) specifically retargeted to HER2-positive cancer cells, hence to highly specific nonattenuated oncolytic agents.",1,1.4721661571960971,183488.34663624788,198.3850960971584,0.3314920934853949,0.09201373930954154,0.0,0.0,1.0012453300124533,804.0,-0.6686948012217765,0.019448213478064226,1.0,2.0,1.0,33.0,33.0,33.0,66.0,1542,33.0,1.6778973932186097e-06,6278.0,804.0,1.0,0,33.0
904,164870,HP:0002664,"Recently, we developed a double-retargeting strategy whereby gH carries the GCN4 peptide for retargeting to the noncancer producer Vero-GCN4R cell line and gD carries the scFv to HER2 for cancer retargeting.",1,1.4721661571960971,183488.34663624788,198.3850960971584,0.3314920934853949,0.09201373930954154,0.0,0.0,1.0012453300124533,804.0,-0.6686948012217765,0.019448213478064226,1.0,2.0,1.0,33.0,33.0,33.0,66.0,1542,33.0,1.6778973932186097e-06,6278.0,804.0,1.0,0,33.0
894,164870,HP:0002664,"Here, we describe a double-retargeting strategy, based on the simultaneous insertion of two ligands in gD, one for retargeting to a producer, universal Vero cell derivative and one for retargeting to the HER2 cancer receptor.",1,1.4721661571960971,183488.34663624788,198.3850960971584,0.3314920934853949,0.09201373930954154,0.0,0.0,1.0012453300124533,804.0,-0.6686948012217765,0.019448213478064226,1.0,2.0,1.0,33.0,33.0,33.0,66.0,1542,33.0,1.6778973932186097e-06,6278.0,804.0,1.0,0,33.0
2770,606597,HP:0002664,"Occurring in the sinonasal area of middle-aged patients, SNS is a locally aggressive tumor harboring in 90% of cases recurrent gene fusions involving the PAX3 gene, in which the chimeric transcription factor induces an aberrant dual myogenic and neural phenotype.",1,1.364808962837165,7439844.299087022,249.5234465883109,0.14993633846416116,0.14315016007653855,0.0,0.0,1.000942507068803,1062.0,-0.548438722735832,0.09356734488126364,1.0,2.0,4.0,280.0,280.0,121.0,560.0,1542,279.0,1.6778973932186103e-06,52715.0,1062.0,1.0,0,387.0
2771,300838,HP:0001249,We report the genetic and functional characterization of 4 FRMPD4 deleterious mutations that cause a new X-linked intellectual disability (ID) syndrome.,1,1.4183289704004567,20565231.844772752,578.7920362704514,0.1336531651755989,0.08017980786780315,0.0,0.0,1.0005411255411256,1849.0,-0.6165286821838176,0.072499701488344,1.0,2.0,1.0,247.0,247.0,247.0,494.0,3204,246.0,3.8916426584745004e-07,123864.0,1849.0,1.0,0,262.0
2772,606158,HP:0002180,Seipinopathy is an autosomal dominant neurodegenerative disease caused by mutations of the Berardinelli-Seip Congenital Lipodystrophy 2 (BSCL2) gene.,0,1.3227600866286997,308974.3297968156,94.69176347929701,0.2589211604506481,0.11999840088035872,0.0,0.0,0.9977578475336324,445.0,-0.4269555971673912,0.0605832606013182,1.0,2.0,69.0,73.0,73.0,73.0,146.0,282,72.0,7.149189281935428e-06,6039.0,447.0,1.0,0,88.0
2783,248610,HP:0002664,Purpose To determine whether the rates and tumor characteristics of screening-detected and interval cancers differ for two-dimensional digital mammography (DM) versus digital breast tomosynthesis (DBT) mammography.,0,1.4151554937699515,942517.1030525952,247.87766536964986,0.21224369875870625,0.004559313476219629,0.0,0.0,0.998819362455726,846.0,-0.7122227313741181,0.04915239134793166,1.0,2.0,26.0,70.0,70.0,64.0,140.0,1554,68.0,1.67789739321861e-06,17652.0,848.0,1.0,0,68.0
2793,248610,HP:0002664,"There were no significant differences in tumor characteristics, including size at pathologic examination, grade, hormone receptor status, and nodal status, between the screening-detected invasive cancers on DM versus DBT (P = .09-.99).",0,1.4151554937699515,942517.1030525952,247.87766536964986,0.21224369875870625,0.004559313476219629,0.0,0.0,0.998819362455726,846.0,-0.7122227313741181,0.04915239134793166,1.0,2.0,26.0,70.0,70.0,64.0,140.0,1554,68.0,1.67789739321861e-06,17652.0,848.0,1.0,0,68.0
2800,601265,HP:0002664,"There were no significant differences in tumor characteristics, including size at pathologic examination, grade, hormone receptor status, and nodal status, between the screening-detected invasive cancers on DM versus DBT (P = .09-.99).",0,1.3553009486897671,9484963.803224552,261.67887651504986,0.14785788912735248,0.11244989016609358,0.0,0.0,1.0008944543828264,1119.0,-0.5053553039056776,0.10030678426463699,1.0,2.0,5.0,334.0,334.0,103.0,668.0,1542,333.0,1.67789739321861e-06,62744.0,1119.0,1.0,0,470.0
2801,600618,HP:0002858,t(12;22)(p13;q12) is a rare but recurrent chromosomal abnormality involving the ETS transcription factor ETV6 and meningioma 1 (MN1) genes.,0,1.3006747638326586,13511.338888888891,32.25454545454545,0.3324155717145164,-0.030691574406825375,0.0,0.0,0.9873417721518988,78.0,-0.5089110498727533,0.2069620253164557,1.0,2.0,2.0,26.0,26.0,4.0,52.0,76,24.0,0.0004725897920604915,654.0,80.0,1.0,0,24.0
2805,613363,HP:0002664,"Nevertheless, little is known about the roles of WDR34 in cancer.",0,1.3533443904940468,8433653.970234584,262.6245938228999,0.14929795796883916,0.039581680168296635,0.0,0.0,0.9990521327014218,1054.0,-0.5397138044771088,0.0987487433577481,1.0,2.0,17.0,278.0,278.0,140.0,556.0,1544,276.0,1.6778973932186103e-06,55007.0,1056.0,1.0,0,354.0
2811,613363,HP:0002664,"oeWDR34 strongly inhibited IL-6 expression, which is closely related to tumoral growth, compared with control cells, suggesting that WDR34 would be a critical molecule for control of tumoral progression.",0,1.3533443904940468,8433653.970234584,262.6245938228999,0.14929795796883916,0.039581680168296635,0.0,0.0,0.9990521327014218,1054.0,-0.5397138044771088,0.0987487433577481,1.0,2.0,17.0,278.0,278.0,140.0,556.0,1544,276.0,1.6778973932186103e-06,55007.0,1056.0,1.0,0,354.0
2802,613363,HP:0002664,"In addition to the in vitro experiments, WDR34 negativity was correlated with tumoral growth of OSCCs.",0,1.3533443904940468,8433653.970234584,262.6245938228999,0.14929795796883916,0.039581680168296635,0.0,0.0,0.9990521327014218,1054.0,-0.5397138044771088,0.0987487433577481,1.0,2.0,17.0,278.0,278.0,140.0,556.0,1544,276.0,1.6778973932186103e-06,55007.0,1056.0,1.0,0,354.0
2808,613363,HP:0002664,Our findings suggested that WDR34 inhibits OSCC progression and might be a potential tumor-suppressor molecule in OSCCs,0,1.3533443904940468,8433653.970234584,262.6245938228999,0.14929795796883916,0.039581680168296635,0.0,0.0,0.9990521327014218,1054.0,-0.5397138044771088,0.0987487433577481,1.0,2.0,17.0,278.0,278.0,140.0,556.0,1544,276.0,1.6778973932186103e-06,55007.0,1056.0,1.0,0,354.0
2816,600726,HP:0000135,"Traditionally, idiopathic hypogonadotropic hypogonadism (IHH) is divided into two major categories: Kallmann syndrome (KS) and normosmic IHH (nIHH).",0,1.2811268715524036,914522.370970792,81.44102307969288,0.2192041215778952,0.13217930558312285,0.0,0.0,0.9983193277310924,594.0,-0.4920177239693226,0.0682871806440697,1.0,2.0,35.0,155.0,155.0,9.0,310.0,688,153.0,8.450513791238506e-06,12108.0,596.0,1.0,0,163.0
2818,600726,HP:0000674,"In a clinical sense, recognizing those IHH genes and associated phenotypes may improve our diagnostic capabilities by enabling us to prioritize the screening of particular gene(s) such as synkinesia (ANOS1), dental agenesis (FGF8/FGFR1) and hearing loss (CHD7).",0,1.3478739316239317,25875.038342213345,68.199203187251,0.3928473287599607,0.35919427439770124,0.0,0.0,0.9962825278810408,268.0,-0.5628283944125396,0.03640368993528845,1.0,2.0,64.0,18.0,18.0,18.0,36.0,150,17.0,1.5747039556563368e-05,1322.0,270.0,1.0,0,24.0
2819,300836,HP:0000674,"In a clinical sense, recognizing those IHH genes and associated phenotypes may improve our diagnostic capabilities by enabling us to prioritize the screening of particular gene(s) such as synkinesia (ANOS1), dental agenesis (FGF8/FGFR1) and hearing loss (CHD7).",0,1.3588850174216027,32448.259307242464,84.52658618032366,0.346569987920688,0.16057936585206842,0.0,0.0,0.9959514170040484,246.0,-0.6470408770634737,0.05067258717513386,1.0,2.0,48.0,18.0,18.0,18.0,36.0,176,17.0,1.8903591682419655e-05,1552.0,248.0,1.0,0,18.0
2820,608892,HP:0000674,"In a clinical sense, recognizing those IHH genes and associated phenotypes may improve our diagnostic capabilities by enabling us to prioritize the screening of particular gene(s) such as synkinesia (ANOS1), dental agenesis (FGF8/FGFR1) and hearing loss (CHD7).",0,1.391392000244828,75549.53752415247,179.93348772579895,0.3666822369448723,0.13456610107137149,0.0,0.0,0.9984686064318532,652.0,-0.561043495598191,0.016850012410376012,1.0,2.0,133.0,18.0,18.0,18.0,36.0,376,17.0,2.4722123333728884e-06,3598.0,654.0,1.0,0,18.0
2821,300836,HP:0000365,"In a clinical sense, recognizing those IHH genes and associated phenotypes may improve our diagnostic capabilities by enabling us to prioritize the screening of particular gene(s) such as synkinesia (ANOS1), dental agenesis (FGF8/FGFR1) and hearing loss (CHD7).",1,1.4077195272123624,10514551.059182666,394.95206391007963,0.1457455667446048,0.025166909718819745,0.0,0.0,1.0006825938566553,1466.0,-0.6279185287354879,0.0710679846719033,1.0,2.0,2.0,228.0,228.0,183.0,456.0,2474,227.0,6.524672396198988e-07,76316.0,1466.0,1.0,0,235.0
2822,608892,HP:0000365,"In a clinical sense, recognizing those IHH genes and associated phenotypes may improve our diagnostic capabilities by enabling us to prioritize the screening of particular gene(s) such as synkinesia (ANOS1), dental agenesis (FGF8/FGFR1) and hearing loss (CHD7).",1,1.3490947939974571,33134128.34251325,373.68503682391366,0.12804512700499648,0.002294051238950011,0.0,0.0,1.0005344735435595,1872.0,-0.4264266238654264,0.08953516790235122,1.0,2.0,1.0,619.0,619.0,90.0,1238.0,2474,618.0,6.524672396198988e-07,156799.0,1872.0,1.0,0,924.0
2823,300371,HP:0012332,"Here, we presented an X-ALD case of a 46-year-old Asian male with severe autonomic dysfunction.",0,1.3030241867662395,286953.5320512821,75.65321930531701,0.25598243278504795,0.266894377795811,0.0,0.0,0.9973753280839894,380.0,-0.36499145761924745,0.08121367028074371,1.0,2.0,37.0,101.0,101.0,14.0,202.0,208,100.0,1.2939288856684434e-05,5910.0,382.0,1.0,0,106.0
2824,614738,HP:0002664,"Although MPC is composed of two subunits, it has been reported that the MPC1 subunit is specifically associated with poor prognosis in several cancers, including colorectal and prostate cancer.",0,1.4054687194812296,1814793.0072595864,294.36199322204084,0.1785931588010571,0.1868699109443116,0.0,0.0,0.9988439306358382,864.0,-0.7220500339563459,0.06708673190137368,1.0,2.0,32.0,92.0,92.0,84.0,184.0,1544,90.0,1.6778973932186103e-06,25127.0,866.0,1.0,0,88.0
2836,614738,HP:0002664,"However, only a few studies have assessed the clinical significance of MPC1 and the molecular mechanisms underlying its influence on cancer progression are not well understood.",0,1.4054687194812296,1814793.0072595864,294.36199322204084,0.1785931588010571,0.1868699109443116,0.0,0.0,0.9988439306358382,864.0,-0.7220500339563459,0.06708673190137368,1.0,2.0,32.0,92.0,92.0,84.0,184.0,1544,90.0,1.6778973932186103e-06,25127.0,866.0,1.0,0,88.0
2842,614738,HP:0002664,Low MPC1 expression correlated with poor ICC prognosis and was correlated with tumor invasion and distant metastasis.,0,1.4054687194812296,1814793.0072595864,294.36199322204084,0.1785931588010571,0.1868699109443116,0.0,0.0,0.9988439306358382,864.0,-0.7220500339563459,0.06708673190137368,1.0,2.0,32.0,92.0,92.0,84.0,184.0,1544,90.0,1.6778973932186103e-06,25127.0,866.0,1.0,0,88.0
2848,614738,HP:0002664,"Therefore, we investigated the impact of altering the MPC1 gene expression on the malignant potential of cancer cells using biliary tract cancer cell lines in vitro.",0,1.4054687194812296,1814793.0072595864,294.36199322204084,0.1785931588010571,0.1868699109443116,0.0,0.0,0.9988439306358382,864.0,-0.7220500339563459,0.06708673190137368,1.0,2.0,32.0,92.0,92.0,84.0,184.0,1544,90.0,1.6778973932186103e-06,25127.0,866.0,1.0,0,88.0
2830,614738,HP:0002664,"Furthermore, the inhibition of MPC1 expression induced EMT in cancer cells, and the overexpression of MPC1 suppressed the migration of tumor cells.",0,1.4054687194812296,1814793.0072595864,294.36199322204084,0.1785931588010571,0.1868699109443116,0.0,0.0,0.9988439306358382,864.0,-0.7220500339563459,0.06708673190137368,1.0,2.0,32.0,92.0,92.0,84.0,184.0,1544,90.0,1.6778973932186103e-06,25127.0,866.0,1.0,0,88.0
2854,614738,HP:0002664,These results indicated that MPC1 could be a novel therapeutic target in some cancers,0,1.4054687194812296,1814793.0072595864,294.36199322204084,0.1785931588010571,0.1868699109443116,0.0,0.0,0.9988439306358382,864.0,-0.7220500339563459,0.06708673190137368,1.0,2.0,32.0,92.0,92.0,84.0,184.0,1544,90.0,1.6778973932186103e-06,25127.0,866.0,1.0,0,88.0
2860,300039,HP:0000365,"Here, we report a novel hemizygous transition c.975G&gt;A (p.Trp325*) in POU3F4 gene (Xq21) found in two deaf half-brothers from one Yakut family (Eastern Siberia, Russia) with identical inner ear abnormalities (&quot;corkscrew&quot; cochlea with an absence of modiolus) specific to X-linked deafness-2 (DFNX2).",1,1.4343372119437898,5005079.344698964,430.42033770936035,0.16028804388214826,0.056715388385209564,0.0,0.0,1.0007256894049346,1379.0,-0.683808467396562,0.0577036219216087,1.0,2.0,2.0,140.0,140.0,136.0,280.0,2474,139.0,6.524672396198987e-07,54826.0,1379.0,1.0,0,124.0
2861,600983,HP:0000365,"Comprehensive clinical evaluation (CT and MR-imaging, audiological and stabilometric examinations) of available members of this family revealed both already known (mixed progressive hearing loss) and additional (enlargement of semicircular canals and postural disorders) clinical DFNX2 features in affected males with c.975G&gt;A (p.Trp325*).",0,1.4405958355270905,454353.92629593477,219.2908423038194,0.29831649161911444,0.33876762591113585,0.0,0.0,0.9992277992277993,1294.0,-0.6194610858455329,0.015651365651365653,1.0,2.0,59.0,52.0,52.0,42.0,104.0,2476,50.0,6.524672396198988e-07,13134.0,1296.0,1.0,0,41.0
1992,606834,HP:0001332,"In 2016, two research groups independently identified microdeletions and pathogenic variants in the lysine-specific histone methyltransferase 2B gene, KMT2B in patients with early-onset progressive dystonia.",1,1.4121998574553318,1204186.8746064436,268.7259211376859,0.17045817767333776,0.10249176005385784,0.0,0.0,1.001930501930502,519.0,-0.7879028526585078,0.13109558774298655,1.0,2.0,1.0,77.0,77.0,77.0,154.0,884,76.0,5.095567365948359e-06,17622.0,519.0,1.0,0,85.0
1995,606834,HP:0001332,KMT2B-dystonia (DYT28) is emerging as an important and frequent cause of childhood-onset progressive generalised dystonia and is estimated to potentially account for up to 10% of early-onset generalised dystonia.,1,1.4121998574553318,1204186.8746064436,268.7259211376859,0.17045817767333776,0.10249176005385784,0.0,0.0,1.001930501930502,519.0,-0.7879028526585078,0.13109558774298655,1.0,2.0,1.0,77.0,77.0,77.0,154.0,884,76.0,5.095567365948359e-06,17622.0,519.0,1.0,0,85.0
1989,606834,HP:0001332,"Herein, we review variants in KMT2B associated with dystonia, as well as the clinical phenotype, treatment and underlying disease mechanisms.",1,1.4121998574553318,1204186.8746064436,268.7259211376859,0.17045817767333776,0.10249176005385784,0.0,0.0,1.001930501930502,519.0,-0.7879028526585078,0.13109558774298655,1.0,2.0,1.0,77.0,77.0,77.0,154.0,884,76.0,5.095567365948359e-06,17622.0,519.0,1.0,0,85.0
2258,309550,HP:0000717,"Fragile X syndrome (FXS), the leading cause of inherited forms of mental retardation and autism, is caused by the transcriptional silencing of fmr1 encoding the fragile X mental retardation protein (FMRP).",1,1.356925052158562,1532898.7568181811,167.9535076795351,0.17542167558653346,0.3505909465737255,0.0,0.0,1.0021052631578946,476.0,-0.4324352392112471,0.15037593984962405,1.0,2.0,15.0,146.0,146.0,146.0,292.0,292,146.0,9.127335456960047e-06,17000.0,476.0,1.0,0,154.0
2862,604579,HP:0002664,"Finally, in colon cancer cells, we prove that the FZD4/PI3K axis elicited by FzM1.8 preserves stemness and promotes proliferation of undifferentiated cells",0,1.4280093850660798,628869.6263006988,206.8401184737789,0.23418361270575305,0.2365305284542201,0.0,0.0,0.99880810488677,838.0,-0.6874625197359543,0.038211589761053405,1.0,2.0,24.0,61.0,61.0,49.0,122.0,1544,59.0,1.6778973932186097e-06,13465.0,840.0,1.0,0,57.0
770,171834,HP:0002664,"Finally, in colon cancer cells, we prove that the FZD4/PI3K axis elicited by FzM1.8 preserves stemness and promotes proliferation of undifferentiated cells",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
2863,121011,HP:0001425,"Fourteen different (half of them novel) non-GJB2 variants causing HL were found in 10 genes (CHD7, HDAC8, MITF, NEFL, OTOF, SF3B4, SLC26A4, TECTA, TMPRSS3, USH2A) among 13 probands, confirming the genetic heterogeneity of hereditary HL.",0,1.3109212158808932,949082.5886002887,105.1329187662016,0.21016357268780134,0.03886380719745931,0.0,0.0,0.9980988593155892,525.0,-0.2992091806469309,0.10111038159897837,1.0,2.0,13.0,192.0,192.0,2.0,384.0,496,191.0,1.2846700325021518e-05,14014.0,527.0,1.0,0,228.0
2864,608892,HP:0001425,"Fourteen different (half of them novel) non-GJB2 variants causing HL were found in 10 genes (CHD7, HDAC8, MITF, NEFL, OTOF, SF3B4, SLC26A4, TECTA, TMPRSS3, USH2A) among 13 probands, confirming the genetic heterogeneity of hereditary HL.",0,1.3489786346581178,2404852.724563924,144.9239822754949,0.2034830001615668,0.017246181634117404,0.0,0.0,0.9988674971687428,882.0,-0.4096048764292031,0.06738135623619602,1.0,2.0,16.0,238.0,238.0,30.0,476.0,526,236.0,2.472212333372889e-06,26298.0,884.0,1.0,0,263.0
2865,300269,HP:0001425,"Fourteen different (half of them novel) non-GJB2 variants causing HL were found in 10 genes (CHD7, HDAC8, MITF, NEFL, OTOF, SF3B4, SLC26A4, TECTA, TMPRSS3, USH2A) among 13 probands, confirming the genetic heterogeneity of hereditary HL.",0,1.3354442255371048,1952190.293518981,132.2174957942802,0.1999059772649726,0.0928935968645345,0.0,0.0,0.998542274052478,685.0,-0.3832563363249497,0.09018379653795393,1.0,2.0,7.0,228.0,228.0,10.0,456.0,496,226.0,5.188848127604155e-06,21251.0,687.0,1.0,0,263.0
2866,156845,HP:0001425,"Fourteen different (half of them novel) non-GJB2 variants causing HL were found in 10 genes (CHD7, HDAC8, MITF, NEFL, OTOF, SF3B4, SLC26A4, TECTA, TMPRSS3, USH2A) among 13 probands, confirming the genetic heterogeneity of hereditary HL.",1,1.3359815387372849,804376.7597680099,105.31645748987854,0.21709144494163046,0.13226188558618324,0.0,0.0,1.0022421524663678,447.0,-0.37035201530291545,0.11676247228659425,1.0,2.0,6.0,171.0,171.0,4.0,342.0,494,170.0,1.625910509885536e-05,11639.0,447.0,1.0,0,184.0
2867,162280,HP:0001425,"Fourteen different (half of them novel) non-GJB2 variants causing HL were found in 10 genes (CHD7, HDAC8, MITF, NEFL, OTOF, SF3B4, SLC26A4, TECTA, TMPRSS3, USH2A) among 13 probands, confirming the genetic heterogeneity of hereditary HL.",1,1.3342342293252545,936743.1894993895,103.59039396452204,0.21852133650464228,0.2280023930249672,0.0,0.0,1.002020202020202,496.0,-0.3439755128094915,0.10463506028022156,1.0,2.0,14.0,179.0,179.0,2.0,358.0,494,178.0,1.6e-05,12845.0,496.0,1.0,0,189.0
2868,605646,HP:0001425,"Fourteen different (half of them novel) non-GJB2 variants causing HL were found in 10 genes (CHD7, HDAC8, MITF, NEFL, OTOF, SF3B4, SLC26A4, TECTA, TMPRSS3, USH2A) among 13 probands, confirming the genetic heterogeneity of hereditary HL.",0,1.3267779831379598,575083.405952381,103.89888417102794,0.21634600241577767,0.1984228300046587,0.0,0.0,0.9973045822102428,370.0,-0.5503224119898319,0.12661217865113178,1.0,2.0,7.0,109.0,109.0,70.0,218.0,506,107.0,1.625910509885536e-05,8737.0,372.0,1.0,0,124.0
2869,602574,HP:0001425,"Fourteen different (half of them novel) non-GJB2 variants causing HL were found in 10 genes (CHD7, HDAC8, MITF, NEFL, OTOF, SF3B4, SLC26A4, TECTA, TMPRSS3, USH2A) among 13 probands, confirming the genetic heterogeneity of hereditary HL.",0,1.4230566766099315,19324.841678477074,90.34311740890688,0.3832659857362351,0.4185833799408353,0.0,0.0,0.9961538461538462,259.0,-0.7090839559415111,0.03743000294724433,1.0,2.0,14.0,12.0,12.0,12.0,24.0,496,10.0,1.6259105098855357e-05,1270.0,261.0,1.0,0,11.0
2870,608400,HP:0001425,"Fourteen different (half of them novel) non-GJB2 variants causing HL were found in 10 genes (CHD7, HDAC8, MITF, NEFL, OTOF, SF3B4, SLC26A4, TECTA, TMPRSS3, USH2A) among 13 probands, confirming the genetic heterogeneity of hereditary HL.",0,1.3141737326907827,743068.1865440116,103.40781401356148,0.21829104167307567,0.1287875730682888,0.0,0.0,0.9975669099756692,410.0,-0.3959357796676429,0.12245765714690665,1.0,2.0,11.0,154.0,154.0,13.0,308.0,496,152.0,1.625910509885536e-05,10368.0,412.0,1.0,0,180.0
2871,300552,HP:0002664,"Misregulation of MID1 expression is associated with various diseases including midline malformation syndromes, cancer and neurodegenerative diseases.",0,1.4006568749611334,3372131.99444069,300.7962397230172,0.16413901749148274,0.1479101295566087,0.0,0.0,0.9988801791713324,892.0,-0.6741359352850601,0.08052188159961521,1.0,2.0,21.0,122.0,122.0,122.0,244.0,1544,120.0,1.6778973932186103e-06,32142.0,894.0,1.0,0,130.0
2872,165240,HP:0000256,"She manifested macrocephaly, preaxial polysyndactyly, psychomotor developmental delay, cerebral cavernous malformations, and glucose intolerance due to a 6.2-Mb deletion of 7p14.1p12.3 which included GLI3, GCK, and CCM2.",1,1.3413813169844346,6953167.5093281735,222.97220570621042,0.14919465879163235,0.09477745193896547,0.0,0.0,1.0010121457489878,989.0,-0.26200551201854755,0.1071032368195904,1.0,2.0,35.0,376.0,376.0,2.0,752.0,766,375.0,2.714079831944176e-06,52327.0,989.0,1.0,0,461.0
2873,607929,HP:0000256,"She manifested macrocephaly, preaxial polysyndactyly, psychomotor developmental delay, cerebral cavernous malformations, and glucose intolerance due to a 6.2-Mb deletion of 7p14.1p12.3 which included GLI3, GCK, and CCM2.",0,1.3847586819797648,574298.0670329671,151.53121591697789,0.21120299867330566,0.003088917104861575,0.0,0.0,0.9978401727861772,462.0,-0.6860844720190076,0.09546994861100767,1.0,2.0,4.0,75.0,75.0,63.0,150.0,768,73.0,6.7465002529937596e-06,10255.0,464.0,1.0,0,77.0
2874,165240,HP:0001263,"She manifested macrocephaly, preaxial polysyndactyly, psychomotor developmental delay, cerebral cavernous malformations, and glucose intolerance due to a 6.2-Mb deletion of 7p14.1p12.3 which included GLI3, GCK, and CCM2.",1,1.3607902914360568,31481292.28177205,355.94524512491273,0.13017297142651568,0.10775570839110184,0.0,0.0,1.0004752851711023,2105.0,-0.4816755306485942,0.06936454033940555,1.0,2.0,25.0,560.0,560.0,114.0,1120.0,2998,559.0,4.444444444444444e-07,153605.0,2105.0,1.0,0,802.0
2875,607929,HP:0001263,"She manifested macrocephaly, preaxial polysyndactyly, psychomotor developmental delay, cerebral cavernous malformations, and glucose intolerance due to a 6.2-Mb deletion of 7p14.1p12.3 which included GLI3, GCK, and CCM2.",0,1.4581713196982655,2319838.375853044,453.4358433048194,0.19683078849008645,0.038180469475677416,0.0,0.0,0.9993666877770742,1578.0,-0.7033216870129599,0.02842369389374785,1.0,2.0,5.0,76.0,76.0,73.0,152.0,3000,74.0,4.43852443918134e-07,35456.0,1580.0,1.0,0,79.0
2876,165230,HP:0000256,"We summarize the phenotypic extent of GLI2/3 syndromes in the literature and determine that these 2 syndromes manifest opposite features to a certain extent, such as midface hypoplasia or macrocephaly, and anterior or posterior side of polydactyly.",0,1.3349904276495126,6393177.085317461,231.71365260409507,0.14741348249977854,0.010510371962970274,0.0,0.0,1.0011933174224343,839.0,-0.3320975079249462,0.13720732432347862,1.0,2.0,6.0,355.0,355.0,2.0,710.0,766,355.0,4.788148375141849e-06,48234.0,839.0,1.0,0,478.0
2877,165230,HP:0011800,"We summarize the phenotypic extent of GLI2/3 syndromes in the literature and determine that these 2 syndromes manifest opposite features to a certain extent, such as midface hypoplasia or macrocephaly, and anterior or posterior side of polydactyly.",1,1.3484591751233592,3322768.7451007324,201.9125,0.15946629471662244,0.09967998518033044,0.0,0.0,1.0014388489208634,696.0,-0.3063126560146606,0.1312701562887621,1.0,2.0,2.0,240.0,240.0,10.0,480.0,480,240.0,4.788148375141851e-06,31749.0,696.0,1.0,0,280.0
2878,165230,HP:0010442,"We summarize the phenotypic extent of GLI2/3 syndromes in the literature and determine that these 2 syndromes manifest opposite features to a certain extent, such as midface hypoplasia or macrocephaly, and anterior or posterior side of polydactyly.",1,1.3536991308979107,3225055.587608225,206.89641744548283,0.15762223274500586,0.12937449100977505,0.0,0.0,1.001494768310912,670.0,-0.3642857622091842,0.13445775606273566,1.0,2.0,3.0,214.0,214.0,214.0,428.0,428,213.0,4.788148375141848e-06,30134.0,670.0,1.0,0,243.0
2879,600040,HP:0002664,"Both in vitro and in vivo antitumor results demonstrated that the sustained-release PTX could induce the microtubules assembly and the over-expression of Bax and Cyclin B1 proteins, resulting in the microtubule dynamics disruption, G2/M phase arrest, and cell apoptosis accordingly.",0,1.45511480176036,618539.5772492185,238.1436677783954,0.2580713024080539,0.08836731037156338,0.0,0.0,1.0012106537530268,827.0,-0.6332279421279401,0.03640159156319262,1.0,2.0,1.0,56.0,56.0,56.0,112.0,1542,56.0,1.67789739321861e-06,12433.0,827.0,1.0,0,68.0
2888,602572,HP:0002664,MATERIAL AND METHODS A total of 63 paired gastric cancer tissues and matched adjacent mucosa were used to measure the ANXA11 levels and its correlation with clinical characteristics.,0,1.4304522677220644,661318.7657481558,208.85347524223698,0.23041572395543874,0.048656366797687166,0.0,0.0,0.998809523809524,839.0,-0.6914807040933326,0.03897004699620634,1.0,2.0,19.0,69.0,69.0,51.0,138.0,1544,67.0,1.6778973932186097e-06,13765.0,841.0,1.0,0,54.0
2896,602572,HP:0002664,RESULTS The expression of ANXA11 in cancer tissues was higher than in adjacent mucosa at mRNA and protein levels.,0,1.4304522677220644,661318.7657481558,208.85347524223698,0.23041572395543874,0.048656366797687166,0.0,0.0,0.998809523809524,839.0,-0.6914807040933326,0.03897004699620634,1.0,2.0,19.0,69.0,69.0,51.0,138.0,1544,67.0,1.6778973932186097e-06,13765.0,841.0,1.0,0,54.0
2880,602572,HP:0002664,"CONCLUSIONS ANXA11 plays a critical role in regulating GC proliferation, migration, and invasion via the AKT/GSK-3b pathway, and can potentially be used as a prognostic factor and therapeutic target for gastric cancer patients",0,1.4304522677220644,661318.7657481558,208.85347524223698,0.23041572395543874,0.048656366797687166,0.0,0.0,0.998809523809524,839.0,-0.6914807040933326,0.03897004699620634,1.0,2.0,19.0,69.0,69.0,51.0,138.0,1544,67.0,1.6778973932186097e-06,13765.0,841.0,1.0,0,54.0
2600,164730,HP:0002664,"CONCLUSIONS ANXA11 plays a critical role in regulating GC proliferation, migration, and invasion via the AKT/GSK-3b pathway, and can potentially be used as a prognostic factor and therapeutic target for gastric cancer patients",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
2900,612386,HP:0002664,FECH and ABCG2) were found to be downregulated in smokers as well as in cancer groups.,0,1.4366672186344318,491554.5122440273,229.9200089793475,0.2497058187742885,0.3084609412417078,0.0,0.0,0.9987864077669902,823.0,-0.6810307201461053,0.0350867902324213,1.0,2.0,26.0,53.0,53.0,53.0,106.0,1544,51.0,1.677897393218609e-06,11926.0,825.0,1.0,0,48.0
2901,603756,HP:0002664,FECH and ABCG2) were found to be downregulated in smokers as well as in cancer groups.,0,0.9987080103359172,1542.0103492884866,2.0,0.7071067811865476,0.8228171589148771,0.0,0.0,0.9987080103359172,773.0,-0.9948520724595946,0.0025773109944152704,1.0,2.0,773.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,773.0,775.0,0.0,0,1.0
105,191170,HP:0002664,The use of low fidelity DNA polymerases in the translesional synthesis (TLS) DNA damage response pathway that repairs lesions caused by cisplatin also presents a mutational carcinogenic burden on cells that needs to be regulated by the tumor suppressor protein p53.,1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
49,191170,HP:0002664,"In this study, the fluorescence lifetime of the metabolic coenzyme NADH reveals that the absence of REV3L can promote the p53-mediated upregulation of oxidative phosphorylation in cisplatin-treated H1299 lung carcinoma cells and increases cancer cell sensitivity to this platinum-based chemotherapy.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
137,191170,HP:0002664,These results demonstrate a previously unrecognized relationship between p53 and REV3L in cancer cell metabolism and may lead to improvements in chemotherapy treatment plans that reduce cisplatin resistance in lung cancer,1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
2902,605907,HP:0100753,"Based upon the development-dependent onsets of these psychotomimetic effects, by using a DNA microarray technique, we identified the WD repeat domain 3 (WDR3) and chitobiosyldiphosphodolichol beta-mannosyltransferase (ALG1) genes as novel candidates for schizophrenia-related molecules, whose mRNAs were up-regulated in the adult (postnatal week seven), but not in the infant (postnatal week one) rats by an indirect dopamine agonist, and phencyclidine, an antagonist of the NMDA receptor.",0,1.3183333333333334,75184.71611721611,50.947571428571436,0.3020633649790098,0.2215959710086677,0.0,0.0,0.9945054945054944,181.0,-0.5439925134540408,0.12454212454212454,1.0,2.0,8.0,48.0,48.0,22.0,96.0,122,46.0,6.298815822625347e-05,2074.0,183.0,1.0,0,52.0
2904,605907,HP:0100753,"To further elucidate the molecular pathophysiology of schizophrenia, we have evaluated the genetic association of WDR3 and ALG1 in schizophrenia.",0,1.3183333333333334,75184.71611721611,50.947571428571436,0.3020633649790098,0.2215959710086677,0.0,0.0,0.9945054945054944,181.0,-0.5439925134540408,0.12454212454212454,1.0,2.0,8.0,48.0,48.0,22.0,96.0,122,46.0,6.298815822625347e-05,2074.0,183.0,1.0,0,52.0
2906,601023,HP:0002145,"Among these genes, mutations in VCP gene involve in inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD), familial amyotrophic lateral sclerosis (ALS), autism spectrum disorders (ASD), and hereditary spastic paraplegia (HSP).",1,1.4635784844367916,98290.11940693119,154.29176470588234,0.3264309447600601,0.3819814954668685,0.0,0.0,1.0022271714922049,450.0,-0.6360853109881619,0.03606038109378867,1.0,2.0,42.0,25.0,25.0,25.0,50.0,330,25.0,5.5103705173135855e-06,3643.0,450.0,1.0,0,32.0
2910,601023,HP:0000717,"Among these genes, mutations in VCP gene involve in inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD), familial amyotrophic lateral sclerosis (ALS), autism spectrum disorders (ASD), and hereditary spastic paraplegia (HSP).",0,1.290541582345572,1002232.3179991513,128.13532634971796,0.1810301623703217,0.3562705174019338,0.0,0.0,0.9982517482517484,571.0,-0.3264492473814269,0.08712578869646932,1.0,2.0,77.0,147.0,147.0,147.0,294.0,366,146.0,5.510370517313584e-06,14278.0,573.0,1.0,0,169.0
1841,191160,HP:0002664,"However, because dicumarol did not affect well-known apoptosis inducers, such as anti-Fas IgG, tumor necrosis factor (TNF)-a, TNF-related apoptosis-inducing ligand, UV-B and H2O2 of HeLa cells at all, we concluded that NQO1-related intracellular reduction of CoQ, or its reduced product, ubiquinol, may participate in the apoptosis induction of HeLa cells",0,1.4602670579691517,200974.08525960872,239.91050583657588,0.2850613192309647,0.15408425189867206,0.0,0.0,0.9987531172069826,801.0,-0.7836891500894245,0.02382275941528495,1.0,2.0,14.0,31.0,31.0,25.0,62.0,1544,29.0,1.6778973932186097e-06,7671.0,803.0,1.0,0,23.0
2911,604831,HP:0000365,This study reports first case of variants in the genes causing EvC syndrome and profound deafness in the same family,0,1.3885215411947591,12774898.150223665,343.73978824216294,0.14358103537880734,0.00871649783470945,0.0,0.0,0.9993446920052425,1525.0,-0.5703798507951655,0.06982999757102604,1.0,2.0,4.0,283.0,283.0,163.0,566.0,2476,281.0,6.514144487633223e-07,81359.0,1527.0,1.0,0,368.0
2912,300658,HP:0000252,"The contiguous deletion of NDP and its neighbouring genes, MAOA/B and EFHC2, reportedly leads to syndromic clinical features such as microcephaly, intellectual disability, and epilepsy.",1,1.3933959050718605,9682756.342256105,390.80428503996217,0.13689431493525825,0.0060862053295719365,0.0,0.0,1.000784929356358,1275.0,-0.6133149141743386,0.0943441992181488,1.0,2.0,5.0,229.0,229.0,174.0,458.0,2066,228.0,9.353172034763872e-07,76624.0,1275.0,1.0,0,265.0
2914,300658,HP:0001249,"The contiguous deletion of NDP and its neighbouring genes, MAOA/B and EFHC2, reportedly leads to syndromic clinical features such as microcephaly, intellectual disability, and epilepsy.",1,1.4194905713795278,14976104.96948907,512.5361479968221,0.1402037175501184,-0.015815459008236932,0.0,0.0,1.0005425935973955,1844.0,-0.6322467939736284,0.06341400833075375,1.0,2.0,4.0,234.0,234.0,200.0,468.0,3204,233.0,3.8916426584745004e-07,107756.0,1844.0,1.0,0,243.0
2915,309850,HP:0001249,"The contiguous deletion of NDP and its neighbouring genes, MAOA/B and EFHC2, reportedly leads to syndromic clinical features such as microcephaly, intellectual disability, and epilepsy.",1,1.4837878252158283,645146.365745386,578.0248373743348,0.2541469814397484,0.12090707130170655,0.0,0.0,1.0006101281269066,1640.0,-0.6887569101249271,0.015964523281596452,1.0,2.0,1.0,38.0,38.0,38.0,76.0,3204,37.0,3.8916426584744994e-07,21456.0,1640.0,1.0,0,35.0
2916,300658,HP:0001250,"The contiguous deletion of NDP and its neighbouring genes, MAOA/B and EFHC2, reportedly leads to syndromic clinical features such as microcephaly, intellectual disability, and epilepsy.",1,1.4176251827054551,13681212.166791147,479.1151586243668,0.14209038513825198,0.04479061157874588,0.0,0.0,1.0005583472920156,1792.0,-0.6219597401793253,0.062495014756321285,1.0,2.0,7.0,231.0,231.0,193.0,462.0,3100,230.0,4.156965348783941e-07,100288.0,1792.0,1.0,0,229.0
2917,309850,HP:0001250,"The contiguous deletion of NDP and its neighbouring genes, MAOA/B and EFHC2, reportedly leads to syndromic clinical features such as microcephaly, intellectual disability, and epilepsy.",0,1.4801387710373533,765662.9385452569,553.1627164685908,0.24547312200558835,0.07795047807647237,0.0,0.0,0.9993706733794839,1588.0,-0.7147142364331275,0.017439867643508238,1.0,2.0,1.0,39.0,39.0,39.0,78.0,3102,37.0,4.151610160484642e-07,22031.0,1590.0,1.0,0,36.0
2918,607805,HP:0000556,"Our data, for the first time, functionally link Jalili syndrome gene CNNM4 to LCA gene IQCB1, providing important insights into the molecular pathogenic mechanism of retinal dystrophy in Jalili syndrome",1,1.4274458497937048,283549.6941331105,192.2028140263906,0.21598404359812973,0.06340636602069145,0.0,0.0,1.002770083102493,362.0,-0.8044443608206004,0.11146141014064677,1.0,2.0,1.0,43.0,43.0,43.0,86.0,638,42.0,9.765625e-06,7283.0,362.0,1.0,0,46.0
2919,609237,HP:0000556,"Our data, for the first time, functionally link Jalili syndrome gene CNNM4 to LCA gene IQCB1, providing important insights into the molecular pathogenic mechanism of retinal dystrophy in Jalili syndrome",1,1.3652516878838652,1380410.2095435928,186.058706184098,0.1810272451496029,0.09501831080827476,0.0,0.0,1.0022779043280179,440.0,-0.6174241659437233,0.16899979291778836,1.0,2.0,1.0,121.0,121.0,121.0,242.0,638,120.0,9.765625e-06,16322.0,440.0,1.0,0,154.0
2920,142461,HP:0012174,"Taken together, the results indicate that increase of HS content and up-regulation of perlecan/HSPG2 expression in glioblastoma tissues contribute to tumour development through the transformation of brain extracellular matrix into tumour microenvironment, and represent negative prognostic factors for glioblastoma progression",0,1.3634020565201461,57615.101682418455,104.62946859903386,0.3696180639256613,0.261184665776464,0.0,0.0,0.9977011494252874,434.0,-0.5177367363832326,0.025224085205103868,1.0,2.0,103.0,21.0,21.0,21.0,42.0,666,20.0,5.806357961968356e-06,2392.0,436.0,1.0,0,25.0
2921,142461,HP:0002664,"Taken together, the results indicate that increase of HS content and up-regulation of perlecan/HSPG2 expression in glioblastoma tissues contribute to tumour development through the transformation of brain extracellular matrix into tumour microenvironment, and represent negative prognostic factors for glioblastoma progression",1,1.3473266468794804,10938709.279540928,252.110518994718,0.14404596620188376,0.017728356455362998,0.0,0.0,1.0008445945945947,1185.0,-0.4541974855159309,0.0968026570874672,1.0,2.0,14.0,396.0,396.0,53.0,792.0,1542,395.0,1.6778973932186097e-06,67909.0,1185.0,1.0,0,571.0
1960,605204,HP:0001332,"This chapter focuses on the current data covering the etiology and epidemiology, clinical presentation, and pathogenesis of four monogenic forms of isolated dystonia: DYT-TOR1A, DYT-THAP1, DYT-GCH1, and DYT-GNAL",1,1.3441858677971743,3650295.9258880005,196.280979751568,0.16365979137147124,0.020350204438969045,0.0,0.0,1.0014285714285711,701.0,-0.5083610177275428,0.13064601589565927,1.0,2.0,3.0,245.0,245.0,56.0,490.0,884,244.0,5.095567365948362e-06,32054.0,701.0,1.0,0,290.0
1970,609520,HP:0001332,"This chapter focuses on the current data covering the etiology and epidemiology, clinical presentation, and pathogenesis of four monogenic forms of isolated dystonia: DYT-TOR1A, DYT-THAP1, DYT-GCH1, and DYT-GNAL",1,1.4478135650774089,240116.1505671264,195.15686274509804,0.2451008234036936,-0.006949444589638083,0.0,0.0,1.0020833333333332,481.0,-0.7518606575889373,0.060585585585585584,1.0,2.0,1.0,39.0,39.0,39.0,78.0,884,38.0,5.095567365948362e-06,6994.0,481.0,1.0,0,38.0
1975,600225,HP:0001332,"This chapter focuses on the current data covering the etiology and epidemiology, clinical presentation, and pathogenesis of four monogenic forms of isolated dystonia: DYT-TOR1A, DYT-THAP1, DYT-GCH1, and DYT-GNAL",1,1.3595311650294468,2574343.2247114,209.8690228690228,0.1662247764459072,0.14841700849448067,0.0,0.0,1.0015974440894568,627.0,-0.5751768970835153,0.13946425750696811,1.0,2.0,4.0,179.0,179.0,112.0,358.0,884,178.0,5.095567365948361e-06,27370.0,627.0,1.0,0,242.0
2210,190080,HP:0002664,"ARID5B also activates the expression of the oncogene MYC Importantly, ARID5B is required for the survival and growth of T-ALL cells, and forced expression of ARID5B in immature thymocytes results in thymus retention, differentiation arrest, radioresistance, and tumor formation in zebrafish.",1,1.4396536831054232,1166089.637753825,258.33534370946825,0.21512590240969573,0.06608515489589678,0.0,0.0,1.0011764705882351,851.0,-0.6775154399515846,0.05177023570885463,1.0,2.0,1.0,80.0,80.0,80.0,160.0,1542,79.0,1.6778973932186097e-06,18724.0,851.0,1.0,0,67.0
1834,191160,HP:0002664,"Furthermore, we found that tumor necrosis factor (TNF) receptor-associated factor 5 (TRAF5) and TGF-b activated kinase 1 (MAP3K7) binding protein 1 (TAB1) were direct targets of miR-873 in CRC cells.",0,1.4602670579691517,200974.08525960872,239.91050583657588,0.2850613192309647,0.15408425189867206,0.0,0.0,0.9987531172069826,801.0,-0.7836891500894245,0.02382275941528495,1.0,2.0,14.0,31.0,31.0,25.0,62.0,1544,29.0,1.6778973932186097e-06,7671.0,803.0,1.0,0,23.0
2923,300560,HP:0002664,PHF8 knockdown inhibits proliferation and promotes the apoptosis of ALL cells in vitro as well as attenuates tumor growth in vivo.,0,1.3922947939955286,2406615.639777693,252.0185573181681,0.17476683636454635,-0.005093522215479257,0.0,0.0,0.9988751406074242,888.0,-0.6374988260500006,0.06644506515337269,1.0,2.0,38.0,118.0,118.0,118.0,236.0,1544,116.0,1.6778973932186103e-06,26286.0,890.0,1.0,0,130.0
2926,123580,HP:0000518,"To investigate the mechanism by which the a-crystallin mutations Cryaa-R49C and Cryab-R120G lead to cataract formation, we determined whether these mutations cause an altered expression of specific transcripts in the lens at an early postnatal age by RNA-seq analysis.",1,1.4648347930684509,308894.8867038237,287.35169491525426,0.25866110695466465,0.12506491493606692,0.0,0.0,1.0014619883040936,685.0,-0.6765876886729213,0.041836342681521324,1.0,2.0,1.0,36.0,36.0,35.0,72.0,1298,35.0,2.3668639053254444e-06,9801.0,685.0,1.0,0,34.0
2931,123590,HP:0000518,"To investigate the mechanism by which the a-crystallin mutations Cryaa-R49C and Cryab-R120G lead to cataract formation, we determined whether these mutations cause an altered expression of specific transcripts in the lens at an early postnatal age by RNA-seq analysis.",1,1.3913006837584865,2426669.337339308,219.17012541202632,0.17585925224135954,0.028714448450859163,0.0,0.0,1.001240694789082,807.0,-0.6405814432874484,0.08563100168808288,1.0,2.0,11.0,146.0,146.0,83.0,292.0,1298,145.0,2.366863905325443e-06,27849.0,807.0,1.0,0,139.0
2930,123590,HP:0000518,"Taken together, these findings offer additional insight into the early transcriptional changes caused by Cryaa and Cryab mutations associated with autosomal dominant human cataracts, and indicate that the transcript levels of certain genes are affected by the expression of mutant a-crystallin in vivo",1,1.3913006837584865,2426669.337339308,219.17012541202632,0.17585925224135954,0.028714448450859163,0.0,0.0,1.001240694789082,807.0,-0.6405814432874484,0.08563100168808288,1.0,2.0,11.0,146.0,146.0,83.0,292.0,1298,145.0,2.366863905325443e-06,27849.0,807.0,1.0,0,139.0
2932,609186,HP:0002664,Our study identifies urine D2HG and tissue D2HGDH expression as biomarkers to identify patients at risk for progressing from colitis to cancer.,0,1.4063362270592743,1810037.807815421,271.42643482490274,0.1811670631726036,0.1869999176002235,0.0,0.0,0.9988479262672808,867.0,-0.7168398813714275,0.06328583625439485,1.0,2.0,30.0,93.0,93.0,80.0,186.0,1544,91.0,1.677897393218609e-06,23868.0,869.0,1.0,0,91.0
2939,602959,HP:0002664,"Higher expression of EEF1A2, EEF1B2, EEF1G, EEF1D, EEF1E1 and EEF2 was observed in most of the cancer types, whereas reverse trend was observed for EEF1A1.",0,1.3611605943863512,5027980.903161693,220.15123436435184,0.16143869167523578,0.2077663017622937,0.0,0.0,0.9990079365079364,1007.0,-0.570480244264796,0.07949289725801123,1.0,2.0,20.0,225.0,225.0,112.0,450.0,1544,223.0,1.677897393218609e-06,40425.0,1009.0,1.0,0,293.0
2945,130610,HP:0002664,"Higher expression of EEF1A2, EEF1B2, EEF1G, EEF1D, EEF1E1 and EEF2 was observed in most of the cancer types, whereas reverse trend was observed for EEF1A1.",0,1.4296393451628853,343083.78647375153,184.37221624306648,0.27195806234387354,0.16165429408569978,0.0,0.0,0.9987789987789988,818.0,-0.6539580209715203,0.026495726495726492,1.0,2.0,41.0,47.0,47.0,38.0,94.0,1544,45.0,1.67789739321861e-06,8897.0,820.0,1.0,0,46.0
2942,602959,HP:0002664,"Overexpression of many factors predicted poor prognosis in breast (EEF1D, EEF1E1, EEF2) and lung cancer (EEF1A2, EEF1B2, EEF1G, EEF1E1).",0,1.3611605943863512,5027980.903161693,220.15123436435184,0.16143869167523578,0.2077663017622937,0.0,0.0,0.9990079365079364,1007.0,-0.570480244264796,0.07949289725801123,1.0,2.0,20.0,225.0,225.0,112.0,450.0,1544,223.0,1.677897393218609e-06,40425.0,1009.0,1.0,0,293.0
2947,130610,HP:0002664,"Overexpression of many factors predicted poor prognosis in breast (EEF1D, EEF1E1, EEF2) and lung cancer (EEF1A2, EEF1B2, EEF1G, EEF1E1).",0,1.4296393451628853,343083.78647375153,184.37221624306648,0.27195806234387354,0.16165429408569978,0.0,0.0,0.9987789987789988,818.0,-0.6539580209715203,0.026495726495726492,1.0,2.0,41.0,47.0,47.0,38.0,94.0,1544,45.0,1.67789739321861e-06,8897.0,820.0,1.0,0,46.0
2949,602117,HP:0000717,"We phenotyped a large population of typical individuals for schizophrenia-spectrum and autism-spectrum traits, and genotyped them for the single-nucleotide polymorphism rs850807, which is putatively functional and linked with MAGEL2 and NDN Genetic variation in rs850807 was strongly and exclusively associated with the ideas of reference subscale of the schizophrenia spectrum, which is best typified as paranoia.",1,1.3578313913424795,1473460.9618076368,166.67987606001302,0.176245015600284,0.06835261161097841,0.0,0.0,1.002079002079002,482.0,-0.4718732808219204,0.14634104260660274,1.0,2.0,0.0,146.0,146.0,146.0,292.0,292,146.0,8.805219734258468e-06,16964.0,482.0,2.0,0,176.0
2950,609102,HP:0002664,"The F-box protein FBXO31 is a tumor suppressor that is encoded in 16q24.3, for which there is loss of heterozygosity in various solid tumors.",0,1.3889219285804053,2407494.8194730105,241.2503242542153,0.17826077958917208,0.22211013658206846,0.0,0.0,0.9988826815642458,894.0,-0.6523048784012888,0.06552523942537909,1.0,2.0,39.0,124.0,124.0,124.0,248.0,1544,122.0,1.67789739321861e-06,26273.0,896.0,1.0,0,148.0
2971,131399,HP:0002664,The use of recombinant human erythropoietin (Epo) has consistently been shown to reduce the need for blood transfusions and to increase hemoglobin levels in lung cancer patients with chemotherapy-induced anemia.,0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865475,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
2956,131399,HP:0002664,"However, clinical and preclinical studies have prompted concerns that Epo and the presence of its receptor, EpoR, in tumor cells may be responsible for adverse effects and, eventually, death.",0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865475,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
2966,131399,HP:0002664,The question has been raised whether Epo promotes tumor growth and inhibits the death of cancer cells.,0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865475,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
2961,131399,HP:0002664,"Since the protein expression of both Epo and EpoR is induced by hypoxia, which is frequently present in lung cancer, the cells were treated with Epo under both normoxic and hypoxic conditions (1% O2).",0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865475,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
2951,131399,HP:0002664,"By using quantitative (real-time) PCR, western blot analysis, and immunocytochemical staining, three non-small cell lung cancer (NSCLC) cell lines (A427, A549 and NCI-H358) were analyzed for the expression of EpoR and its specific downstream signaling pathways [Janus kinase 2 (Jak2)-signal transducer and activator of transcription 5 (STAT5), phosphatidylinositol-3-kinase (PI3K)-Akt, mitogen-activated protein (MAP) kinase].",0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865475,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
2986,147796,HP:0002664,"By using quantitative (real-time) PCR, western blot analysis, and immunocytochemical staining, three non-small cell lung cancer (NSCLC) cell lines (A427, A549 and NCI-H358) were analyzed for the expression of EpoR and its specific downstream signaling pathways [Janus kinase 2 (Jak2)-signal transducer and activator of transcription 5 (STAT5), phosphatidylinositol-3-kinase (PI3K)-Akt, mitogen-activated protein (MAP) kinase].",1,1.3763145095164877,4369421.488381941,218.9158241483917,0.17159428162803164,-0.007808146158270163,0.0,0.0,1.0009910802775024,1010.0,-0.5770386266264725,0.07838365600682963,1.0,2.0,2.0,229.0,229.0,91.0,458.0,1544,229.0,1.6778973932186097e-06,39940.0,1010.0,1.0,0,249.0
2594,164730,HP:0002664,"By using quantitative (real-time) PCR, western blot analysis, and immunocytochemical staining, three non-small cell lung cancer (NSCLC) cell lines (A427, A549 and NCI-H358) were analyzed for the expression of EpoR and its specific downstream signaling pathways [Janus kinase 2 (Jak2)-signal transducer and activator of transcription 5 (STAT5), phosphatidylinositol-3-kinase (PI3K)-Akt, mitogen-activated protein (MAP) kinase].",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
2981,131399,HP:0002664,"While Epo markedly enhanced the proliferation and reduced apoptosis of Epo-dependent UT-7/Epo leukemia cells, it did not affect tumor cell proliferation or the cisplatin-induced apoptosis of NSCLC cells.",0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865475,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
2987,107741,HP:0003287,"Well-established intrinsic mechanisms of cognitive decline include aging, apolipoprotein E (APOE) e4 carrier status, SORL1 mutations, neuroinflammation, mitochondrial dysfunction, amyloid deposition, and demyelination.",0,1.2408334292621157,356630.8946184533,79.67118558965669,0.22624864261380145,0.050789876367523516,0.0,0.0,0.9974747474747476,395.0,-0.31078833876695305,0.08473907844184922,1.0,2.0,85.0,113.0,113.0,4.0,226.0,396,111.0,1.2486109203511094e-05,6661.0,397.0,1.0,0,129.0
2990,182310,HP:0003745,"Somatic mutations in four genes (KCNJ5, ATP1A1, ATP2B3 and CACNA1D), differently implicated in intracellular ion homeostasis, have been identified in nearly 60% of the sporadic APAs.",0,1.290377105554584,93025.12222222224,57.52357606344629,0.2647354198752769,0.015833269023287532,0.0,0.0,0.9940828402366864,168.0,-0.5168293529388095,0.1712495649147233,1.0,2.0,7.0,57.0,57.0,22.0,114.0,192,55.0,0.00010850694444444445,2460.0,170.0,1.0,0,59.0
3004,608305,HP:0002664,We investigated the possible association between chemoresistance and cellular redox state regulation in patients undergoing neoadjuvant chemotherapy (NACT) for breast cancer.,0,1.3667690632195133,4183866.360958761,254.9827703101049,0.16404497182558564,0.03313191085398609,0.0,0.0,0.9989451476793249,947.0,-0.6093297406689304,0.08269197423003563,1.0,2.0,38.0,173.0,173.0,168.0,346.0,1544,171.0,1.6778973932186097e-06,37197.0,949.0,1.0,0,210.0
2996,608305,HP:0002664,"In total, 53 women with primarily inoperable or inflammatory breast cancer who were treated with NACT were included in the study.",0,1.3667690632195133,4183866.360958761,254.9827703101049,0.16404497182558564,0.03313191085398609,0.0,0.0,0.9989451476793249,947.0,-0.6093297406689304,0.08269197423003563,1.0,2.0,38.0,173.0,173.0,168.0,346.0,1544,171.0,1.6778973932186097e-06,37197.0,949.0,1.0,0,210.0
3000,608305,HP:0002664,"Pre-NACT core needle biopsies and postoperative tumor samples were immunohistochemically stained for nuclear factor erythroid 2-related factor 2 (Nrf2), Kelch-like ECH-associated protein 1 (Keap1), thioredoxin (Trx), and peroxiredoxin I (Prx I).",0,1.3667690632195133,4183866.360958761,254.9827703101049,0.16404497182558564,0.03313191085398609,0.0,0.0,0.9989451476793249,947.0,-0.6093297406689304,0.08269197423003563,1.0,2.0,38.0,173.0,173.0,168.0,346.0,1544,171.0,1.6778973932186097e-06,37197.0,949.0,1.0,0,210.0
2992,608305,HP:0002664,"Higher pre-NACT nuclear Prx I expression predicted smaller size of a resected tumor (p = 0.00052; r = -0.550), and higher pre-NACT cytoplasmic Prx I expression predicted a lower amount of evacuated nodal metastasis (p = 0.0024; r = -0.472).",0,1.3667690632195133,4183866.360958761,254.9827703101049,0.16404497182558564,0.03313191085398609,0.0,0.0,0.9989451476793249,947.0,-0.6093297406689304,0.08269197423003563,1.0,2.0,38.0,173.0,173.0,168.0,346.0,1544,171.0,1.6778973932186097e-06,37197.0,949.0,1.0,0,210.0
2799,601265,HP:0002664,"Higher pre-NACT nuclear Prx I expression predicted smaller size of a resected tumor (p = 0.00052; r = -0.550), and higher pre-NACT cytoplasmic Prx I expression predicted a lower amount of evacuated nodal metastasis (p = 0.0024; r = -0.472).",0,1.3553009486897671,9484963.803224552,261.67887651504986,0.14785788912735248,0.11244989016609358,0.0,0.0,1.0008944543828264,1119.0,-0.5053553039056776,0.10030678426463699,1.0,2.0,5.0,334.0,334.0,103.0,668.0,1542,333.0,1.67789739321861e-06,62744.0,1119.0,1.0,0,470.0
3011,606754,HP:0002664,SAMHD1 regulates cellular deoxynucleotide levels and acts as a potential tumor suppressor in other leukemias.,0,1.3684454688256968,7376836.929335822,261.58156240646514,0.1522427845378035,0.022926595403155062,0.0,0.0,1.000958772770853,1044.0,-0.5704155327586572,0.09686543752732137,1.0,2.0,6.0,259.0,259.0,146.0,518.0,1542,258.0,1.67789739321861e-06,52738.0,1044.0,1.0,0,290.0
3017,606754,HP:0002664,"Thus, our study considerably extends the picture of pathways involved in molecular pathogenesis of T-PLL and identifies the tumor suppressor gene SAMHD1 with ~20% of T-PLL affected by destructive lesions likely as major player in T-PLL pathogenesis",0,1.3684454688256968,7376836.929335822,261.58156240646514,0.1522427845378035,0.022926595403155062,0.0,0.0,1.000958772770853,1044.0,-0.5704155327586572,0.09686543752732137,1.0,2.0,6.0,259.0,259.0,146.0,518.0,1542,258.0,1.67789739321861e-06,52738.0,1044.0,1.0,0,290.0
3020,192240,HP:0002120,"These changes were accompanied by cortical atrophy as well as increased expression of angiogenesis-related genes such as Vegfa, Serpine1, and Plau in CD31-positive endothelial cells.",0,0.9961240310077522,510.0232558139535,2.0,0.7071067811865477,0.7773381017611438,0.0,0.0,0.9961240310077522,257.0,-0.992248062015504,0.0076920774595193205,1.0,2.0,257.0,2.0,2.0,2.0,4.0,514,0.0,1.5140274644582053e-05,257.0,259.0,0.0,0,1.0
3021,173360,HP:0002120,"These changes were accompanied by cortical atrophy as well as increased expression of angiogenesis-related genes such as Vegfa, Serpine1, and Plau in CD31-positive endothelial cells.",0,1.2926025756214434,355893.6856136553,103.27370689655173,0.21810324281841406,0.2456552163126821,0.0,0.0,0.9970930232558141,343.0,-0.7038771135140397,0.11659925851027975,1.0,2.0,22.0,64.0,64.0,41.0,128.0,514,62.0,1.5023135628868454e-05,6919.0,345.0,1.0,0,63.0
3022,191342,HP:0002664,"In the present study, the results obtained from our previously published methylation array were analyzed and 10 candidate genes involved in DNA repair [protein phosphatase 4 catalytic subunit (PPP4C)], apoptosis [runt related transcription factor 3 (RUNX3), interferon regulatory factor 4 (IRF4), ubiquitin C-terminal hydrolase L1 (UCHL1) and tumor protein p53 inducible protein 3 (TP53I3)], cell proliferation [cyclin D2 (CCND2) and Ras association domain family member 1 (RASSF1)], drug metabolism [aldehyde dehydrogenase 1 family member A3 (ALDH1A3) and solute carrier family 29 member 1 (SLC29A1)] and angiogenesis [human immunodeficiency virus-1 tat interactive protein 2 (HTATIP2)] were selected for quantification of their methylation levels in 54 CCA and 19 adjacent normal tissues using methylation-sensitive high-resolution melting.",0,1.387293295798144,2276163.362671489,189.02515900176581,0.18929604145319928,0.1451091122642712,0.0,0.0,0.9989339019189766,937.0,-0.5930520654675416,0.060135198039923614,1.0,2.0,10.0,162.0,162.0,94.0,324.0,1544,160.0,1.6778973932186103e-06,26483.0,939.0,1.0,0,167.0
3023,123833,HP:0002664,"In the present study, the results obtained from our previously published methylation array were analyzed and 10 candidate genes involved in DNA repair [protein phosphatase 4 catalytic subunit (PPP4C)], apoptosis [runt related transcription factor 3 (RUNX3), interferon regulatory factor 4 (IRF4), ubiquitin C-terminal hydrolase L1 (UCHL1) and tumor protein p53 inducible protein 3 (TP53I3)], cell proliferation [cyclin D2 (CCND2) and Ras association domain family member 1 (RASSF1)], drug metabolism [aldehyde dehydrogenase 1 family member A3 (ALDH1A3) and solute carrier family 29 member 1 (SLC29A1)] and angiogenesis [human immunodeficiency virus-1 tat interactive protein 2 (HTATIP2)] were selected for quantification of their methylation levels in 54 CCA and 19 adjacent normal tissues using methylation-sensitive high-resolution melting.",0,1.4143727087075266,2495316.127567163,308.24370545683075,0.16941539031594827,0.15258036187246715,0.0,0.0,0.998849252013809,868.0,-0.7182123200056743,0.07209766808195442,1.0,2.0,18.0,98.0,98.0,98.0,196.0,1544,96.0,1.6778973932186103e-06,27254.0,870.0,1.0,0,107.0
3024,600463,HP:0002664,"In the present study, the results obtained from our previously published methylation array were analyzed and 10 candidate genes involved in DNA repair [protein phosphatase 4 catalytic subunit (PPP4C)], apoptosis [runt related transcription factor 3 (RUNX3), interferon regulatory factor 4 (IRF4), ubiquitin C-terminal hydrolase L1 (UCHL1) and tumor protein p53 inducible protein 3 (TP53I3)], cell proliferation [cyclin D2 (CCND2) and Ras association domain family member 1 (RASSF1)], drug metabolism [aldehyde dehydrogenase 1 family member A3 (ALDH1A3) and solute carrier family 29 member 1 (SLC29A1)] and angiogenesis [human immunodeficiency virus-1 tat interactive protein 2 (HTATIP2)] were selected for quantification of their methylation levels in 54 CCA and 19 adjacent normal tissues using methylation-sensitive high-resolution melting.",0,1.4258449037903478,258242.12805337552,284.13715953307394,0.26026385634489657,0.2030532335097854,0.0,0.0,0.99875,799.0,-0.7632434080504382,0.02628589263420724,1.0,2.0,76.0,29.0,29.0,29.0,58.0,1544,27.0,1.6778973932186103e-06,8422.0,801.0,1.0,0,35.0
3025,613018,HP:0002664,"In the present study, the results obtained from our previously published methylation array were analyzed and 10 candidate genes involved in DNA repair [protein phosphatase 4 catalytic subunit (PPP4C)], apoptosis [runt related transcription factor 3 (RUNX3), interferon regulatory factor 4 (IRF4), ubiquitin C-terminal hydrolase L1 (UCHL1) and tumor protein p53 inducible protein 3 (TP53I3)], cell proliferation [cyclin D2 (CCND2) and Ras association domain family member 1 (RASSF1)], drug metabolism [aldehyde dehydrogenase 1 family member A3 (ALDH1A3) and solute carrier family 29 member 1 (SLC29A1)] and angiogenesis [human immunodeficiency virus-1 tat interactive protein 2 (HTATIP2)] were selected for quantification of their methylation levels in 54 CCA and 19 adjacent normal tissues using methylation-sensitive high-resolution melting.",0,1.4058718817521116,1746862.611312963,280.3267185473411,0.18173137938782896,0.03776925723242878,0.0,0.0,0.9988399071925754,861.0,-0.7220471664068914,0.06262081499544297,1.0,2.0,34.0,86.0,86.0,77.0,172.0,1544,84.0,1.67789739321861e-06,23292.0,863.0,1.0,0,74.0
121,191170,HP:0002664,"These effects are cell-type-selective, cell-autonomous, and involve activation of p53 tumour-suppressor protein.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
1968,609520,HP:0001332,"Mutations in THAP1 [THAP (Thanatos-associated protein) domain containing, apoptosis associated protein 1], a ubiquitously expressed transcription factor with DNA binding and protein-interaction domains, cause dystonia, DYT6.",1,1.4478135650774089,240116.1505671264,195.15686274509804,0.2451008234036936,-0.006949444589638083,0.0,0.0,1.0020833333333332,481.0,-0.7518606575889373,0.060585585585585584,1.0,2.0,1.0,39.0,39.0,39.0,78.0,884,38.0,5.095567365948362e-06,6994.0,481.0,1.0,0,38.0
1966,609520,HP:0001332,"However, THAP1 downstream targets in neurons, and the mechanism via which it causes dystonia are largely unknown.",1,1.4478135650774089,240116.1505671264,195.15686274509804,0.2451008234036936,-0.006949444589638083,0.0,0.0,1.0020833333333332,481.0,-0.7518606575889373,0.060585585585585584,1.0,2.0,1.0,39.0,39.0,39.0,78.0,884,38.0,5.095567365948362e-06,6994.0,481.0,1.0,0,38.0
1644,113705,HP:0002664,Missense mutations that disrupt the RING domain of the tumor suppressor gene BRCA1 lead to increased risk of breast and ovarian cancer.,1,1.342124294666095,14779870.286244314,292.6232998839511,0.14059513390679754,0.0363653511393512,0.0,0.0,1.0008032128514055,1246.0,-0.37767621403519097,0.11088720854525648,1.0,2.0,3.0,471.0,471.0,37.0,942.0,1542,470.0,1.6778973932186097e-06,86008.0,1246.0,1.0,0,633.0
1672,113705,HP:0002664,"The BARD1 mutations also caused loss of transcriptional repression of BRCA1-regulated estrogen metabolism genes CYP1A1 and CYP3A4; breast epithelial cells edited to create heterozygous loss of BARD1 showed significantly higher expression of CYP1A1 and CYP3A4 Reintroduction of wild-type BARD1 into these cells restored CYP1A1 and CYP3A4 transcription to normal levels, but introduction of the cancer-predisposing BARD1 RING mutants failed to do so.",1,1.342124294666095,14779870.286244314,292.6232998839511,0.14059513390679754,0.0363653511393512,0.0,0.0,1.0008032128514055,1246.0,-0.37767621403519097,0.11088720854525648,1.0,2.0,3.0,471.0,471.0,37.0,942.0,1542,470.0,1.6778973932186097e-06,86008.0,1246.0,1.0,0,633.0
3026,601593,HP:0002664,"The BARD1 mutations also caused loss of transcriptional repression of BRCA1-regulated estrogen metabolism genes CYP1A1 and CYP3A4; breast epithelial cells edited to create heterozygous loss of BARD1 showed significantly higher expression of CYP1A1 and CYP3A4 Reintroduction of wild-type BARD1 into these cells restored CYP1A1 and CYP3A4 transcription to normal levels, but introduction of the cancer-predisposing BARD1 RING mutants failed to do so.",1,1.4690265087320626,317878.5603318781,229.65134784590043,0.304142381423776,0.1874614328934079,0.0,0.0,1.0012391573729864,808.0,-0.6148112135826345,0.02486902965389476,1.0,2.0,1.0,37.0,37.0,37.0,74.0,1542,37.0,1.67789739321861e-06,8108.0,808.0,1.0,0,45.0
889,164870,HP:0002664,"Doxorubicin and the ERBB2 targeted therapy, trastuzumab, are routinely used in the treatment of HER2+ breast cancer.",1,1.4721661571960971,183488.34663624788,198.3850960971584,0.3314920934853949,0.09201373930954154,0.0,0.0,1.0012453300124533,804.0,-0.6686948012217765,0.019448213478064226,1.0,2.0,1.0,33.0,33.0,33.0,66.0,1542,33.0,1.6778973932186097e-06,6278.0,804.0,1.0,0,33.0
3030,118485,HP:0002664,"Curcumin decreased the expression of steroidogenic acute regulatory proteins, CYP11A1 and HSD3B2 in prostate cancer cell lines, supporting the decrease of testosterone production.",0,1.3757813835372257,2268046.5583602567,185.57915256448632,0.1947972693668962,0.08558020844132906,0.0,0.0,0.9989373007438892,940.0,-0.575672385124728,0.05953597722078197,1.0,2.0,24.0,165.0,165.0,86.0,330.0,1544,163.0,1.67789739321861e-06,26387.0,942.0,1.0,0,156.0
3031,613890,HP:0002664,"Curcumin decreased the expression of steroidogenic acute regulatory proteins, CYP11A1 and HSD3B2 in prostate cancer cell lines, supporting the decrease of testosterone production.",0,1.3836996114618747,2268769.7520865183,180.822395640864,0.19628183113687475,0.12418922505813845,0.0,0.0,0.9989484752891692,950.0,-0.5773817519625694,0.059486255069851286,1.0,2.0,10.0,172.0,172.0,78.0,344.0,1544,170.0,1.6778973932186097e-06,26928.0,952.0,1.0,0,161.0
3032,600450,HP:0002664,"Meanwhile, curcumin treatments considerably increased the expression of AKR1C2 in prostate cancer cell lines, supporting the decrease of dihydrotestosterone.",0,1.4209283531580676,70016.24357830775,239.08541782471744,0.3400346874688863,0.39228925155075456,0.0,0.0,0.9987277353689568,785.0,-0.7351743445065217,0.013078298430927508,1.0,2.0,108.0,15.0,15.0,15.0,30.0,1544,13.0,1.6778973932186097e-06,4045.0,787.0,1.0,0,19.0
3033,609062,HP:0000501,"In addition, these POU6F2 RGCs die early in the DBA/2J model of glaucoma than most RGCs.",0,1.389275749689339,292088.75806423306,107.03987240829346,0.25629734050372843,0.02361537518566988,0.0,0.0,0.9973045822102428,370.0,-0.6102678342788455,0.08790539953047563,1.0,2.0,1.0,67.0,67.0,49.0,134.0,610,65.0,1.0679653124866504e-05,6066.0,372.0,1.0,0,60.0
3034,603474,HP:0000501,"In addition, these POU6F2 RGCs die early in the DBA/2J model of glaucoma than most RGCs.",0,1.3342527481861302,3582732.7175731,187.39682284980742,0.15892729787344018,0.05755843332243407,0.0,0.0,1.001584786053883,632.0,-0.4298031562501937,0.14827779895283758,1.0,2.0,8.0,242.0,242.0,2.0,484.0,608,241.0,9.238643397603495e-06,29566.0,632.0,1.0,0,294.0
3036,602115,HP:0002664,"This study aims to determine the association between FGF10 (rs4415084 C&gt;T), FGFR2 (rs2981582 C&gt;T) and MAP3K1 (rs889312 A&gt;C) gene polymorphisms and breast cancer, to analyse the discriminative ability of each SNP and to test the accuracy of the predictive breast cancer risk model which includes all SNPs.",0,1.352639620441478,7948099.491240703,227.73201881072305,0.15006376111346156,0.13076118941764125,0.0,0.0,0.999089253187614,1097.0,-0.5424314165118554,0.08753942564112764,1.0,2.0,6.0,293.0,293.0,90.0,586.0,1544,292.0,1.67789739321861e-06,52817.0,1099.0,1.0,0,386.0
3043,176943,HP:0002664,"This study aims to determine the association between FGF10 (rs4415084 C&gt;T), FGFR2 (rs2981582 C&gt;T) and MAP3K1 (rs889312 A&gt;C) gene polymorphisms and breast cancer, to analyse the discriminative ability of each SNP and to test the accuracy of the predictive breast cancer risk model which includes all SNPs.",1,1.3342720026288826,16211979.667147012,229.2539594307243,0.14556000393076873,0.00478701158553484,0.0,0.0,1.0006053268765134,1653.0,-0.29974239614532194,0.06907391213275738,1.0,2.0,25.0,637.0,637.0,2.0,1274.0,1542,636.0,1.282562662805298e-06,94312.0,1653.0,1.0,0,710.0
3052,600982,HP:0002664,"This study aims to determine the association between FGF10 (rs4415084 C&gt;T), FGFR2 (rs2981582 C&gt;T) and MAP3K1 (rs889312 A&gt;C) gene polymorphisms and breast cancer, to analyse the discriminative ability of each SNP and to test the accuracy of the predictive breast cancer risk model which includes all SNPs.",1,1.402604812106191,1804110.6806849327,175.89539060161633,0.20860268969819928,0.15241958795445512,0.0,0.0,1.0010799136069115,927.0,-0.5676668316039679,0.053173221870405706,1.0,2.0,2.0,151.0,151.0,72.0,302.0,1542,150.0,1.67789739321861e-06,22822.0,927.0,1.0,0,143.0
3046,176943,HP:0002664,We have revealed significant association of FGFR2 and MAP3K1 polymorphisms with breast cancer.,1,1.3342720026288826,16211979.667147012,229.2539594307243,0.14556000393076873,0.00478701158553484,0.0,0.0,1.0006053268765134,1653.0,-0.29974239614532194,0.06907391213275738,1.0,2.0,25.0,637.0,637.0,2.0,1274.0,1542,636.0,1.282562662805298e-06,94312.0,1653.0,1.0,0,710.0
3055,600982,HP:0002664,We have revealed significant association of FGFR2 and MAP3K1 polymorphisms with breast cancer.,1,1.402604812106191,1804110.6806849327,175.89539060161633,0.20860268969819928,0.15241958795445512,0.0,0.0,1.0010799136069115,927.0,-0.5676668316039679,0.053173221870405706,1.0,2.0,2.0,151.0,151.0,72.0,302.0,1542,150.0,1.67789739321861e-06,22822.0,927.0,1.0,0,143.0
3058,602228,HP:0100753,"A replicative analysis of associations of 15 SNPs located in the regions of 11 genes (TCF4, VRK2, NOTCH4, ZNF804A, AGBL1, RELN, ZFP64P1, KCNB2, CSMD1, CPVL, NRIP1) and three intergenic regions (SLCO6A1/LINCOO491, LOC105376248/LOC105376249, SPA17/NRGN) with schizophrenia was conducted in the Russian population of the Siberian region.",0,1.2996777658431795,3746.3444444444453,16.38888888888889,0.5274233112862988,0.5167807822740722,0.0,0.0,0.9866666666666668,74.0,-0.5669506050128185,0.09473684210526316,1.0,2.0,7.0,15.0,15.0,9.0,30.0,120,13.0,0.0003077870113881194,270.0,76.0,1.0,0,12.0
3059,615496,HP:0100753,"A replicative analysis of associations of 15 SNPs located in the regions of 11 genes (TCF4, VRK2, NOTCH4, ZNF804A, AGBL1, RELN, ZFP64P1, KCNB2, CSMD1, CPVL, NRIP1) and three intergenic regions (SLCO6A1/LINCOO491, LOC105376248/LOC105376249, SPA17/NRGN) with schizophrenia was conducted in the Russian population of the Siberian region.",0,1.3612698412698414,1942.1663419913416,26.42857142857143,0.4873646290421886,0.4811220753287199,0.0,0.0,0.984375,63.0,-0.8198774416602773,0.1033653846153846,1.0,2.0,3.0,8.0,8.0,7.0,16.0,114,6.0,0.0003077870113881194,215.0,65.0,1.0,0,6.0
3060,600514,HP:0100753,"A replicative analysis of associations of 15 SNPs located in the regions of 11 genes (TCF4, VRK2, NOTCH4, ZNF804A, AGBL1, RELN, ZFP64P1, KCNB2, CSMD1, CPVL, NRIP1) and three intergenic regions (SLCO6A1/LINCOO491, LOC105376248/LOC105376249, SPA17/NRGN) with schizophrenia was conducted in the Russian population of the Siberian region.",0,1.3021964982596772,97098.69285714287,58.85185185185186,0.30353969058657393,0.05440377266426714,0.0,0.0,0.9959349593495936,245.0,-0.5234974127568501,0.0889042493663803,1.0,2.0,31.0,57.0,57.0,57.0,114.0,162,55.0,2.770083102493075e-05,2701.0,247.0,1.0,0,55.0
3061,602490,HP:0100753,"A replicative analysis of associations of 15 SNPs located in the regions of 11 genes (TCF4, VRK2, NOTCH4, ZNF804A, AGBL1, RELN, ZFP64P1, KCNB2, CSMD1, CPVL, NRIP1) and three intergenic regions (SLCO6A1/LINCOO491, LOC105376248/LOC105376249, SPA17/NRGN) with schizophrenia was conducted in the Russian population of the Siberian region.",0,1.2216259881137843,3096.057142857143,15.675324675324676,0.5120748097853584,0.4533582314678787,0.0,0.0,0.9873417721518988,78.0,-0.5081980321501655,0.0930379746835443,1.0,2.0,14.0,18.0,18.0,5.0,36.0,114,16.0,0.0003077870113881194,294.0,80.0,1.0,0,15.0
3062,605577,HP:0002664,"Finally, twenty-four important hub genes (RASGRP2, IKZF1, CXCR5, LTB, BLK, LINGO3, CCR6, P2RY10, RHOH, JUP, KRT14, PLA2G3, SPRR1A, KRT78, SFN, CLDN4, IL1RN, PKP3, CBLC, KRT16, TMEM79, KLK8, LYPD3 and LYPD5) were treated as valuable factors involved in the immune response and tumor cell development in tumorigenesis.",0,1.4351650347191196,94198.7657478664,229.63769995676608,0.3476158125245763,0.23373813074352034,0.0,0.0,0.99873417721519,789.0,-0.7235636564311092,0.015340299892781132,1.0,2.0,74.0,19.0,19.0,19.0,38.0,1544,17.0,1.6778973932186097e-06,4793.0,791.0,1.0,0,17.0
3063,603023,HP:0002664,"Finally, twenty-four important hub genes (RASGRP2, IKZF1, CXCR5, LTB, BLK, LINGO3, CCR6, P2RY10, RHOH, JUP, KRT14, PLA2G3, SPRR1A, KRT78, SFN, CLDN4, IL1RN, PKP3, CBLC, KRT16, TMEM79, KLK8, LYPD3 and LYPD5) were treated as valuable factors involved in the immune response and tumor cell development in tumorigenesis.",0,1.38814192113254,3676744.1535371486,252.8137662686167,0.17381240793587585,0.11890131902111956,0.0,0.0,0.9989429175475688,945.0,-0.6125110705277591,0.08159962137025567,1.0,2.0,7.0,173.0,173.0,148.0,346.0,1544,171.0,1.6778973932186103e-06,36551.0,947.0,1.0,0,176.0
3064,191305,HP:0002664,"Finally, twenty-four important hub genes (RASGRP2, IKZF1, CXCR5, LTB, BLK, LINGO3, CCR6, P2RY10, RHOH, JUP, KRT14, PLA2G3, SPRR1A, KRT78, SFN, CLDN4, IL1RN, PKP3, CBLC, KRT16, TMEM79, KLK8, LYPD3 and LYPD5) were treated as valuable factors involved in the immune response and tumor cell development in tumorigenesis.",0,1.4420816267294485,684319.2824718312,201.7761109973377,0.2441303163906248,-0.0006912478643396683,0.0,0.0,1.0011820330969263,847.0,-0.6504631938990005,0.03896103896103896,1.0,2.0,6.0,71.0,71.0,76.0,142.0,1542,70.0,1.6778973932186097e-06,13959.0,847.0,1.0,0,67.0
3068,173325,HP:0002664,"Finally, twenty-four important hub genes (RASGRP2, IKZF1, CXCR5, LTB, BLK, LINGO3, CCR6, P2RY10, RHOH, JUP, KRT14, PLA2G3, SPRR1A, KRT78, SFN, CLDN4, IL1RN, PKP3, CBLC, KRT16, TMEM79, KLK8, LYPD3 and LYPD5) were treated as valuable factors involved in the immune response and tumor cell development in tumorigenesis.",0,1.3697729952596884,2747397.9429770736,194.8954432429721,0.17904393157356854,0.08039346658178244,0.0,0.0,0.9989506820566632,952.0,-0.6066398578819507,0.06429657200806897,1.0,2.0,22.0,168.0,168.0,89.0,336.0,1544,166.0,1.67789739321861e-06,29228.0,954.0,1.0,0,147.0
3069,148066,HP:0002664,"Finally, twenty-four important hub genes (RASGRP2, IKZF1, CXCR5, LTB, BLK, LINGO3, CCR6, P2RY10, RHOH, JUP, KRT14, PLA2G3, SPRR1A, KRT78, SFN, CLDN4, IL1RN, PKP3, CBLC, KRT16, TMEM79, KLK8, LYPD3 and LYPD5) were treated as valuable factors involved in the immune response and tumor cell development in tumorigenesis.",1,1.3743358938333996,4839874.199683868,228.29987870004254,0.16267605756258935,0.03240710120054899,0.0,0.0,1.0009832841691249,1018.0,-0.5898296239272289,0.08250314399800639,1.0,2.0,7.0,227.0,227.0,93.0,454.0,1560,226.0,1.6778973932186097e-06,42708.0,1018.0,1.0,0,238.0
3070,148067,HP:0002664,"Finally, twenty-four important hub genes (RASGRP2, IKZF1, CXCR5, LTB, BLK, LINGO3, CCR6, P2RY10, RHOH, JUP, KRT14, PLA2G3, SPRR1A, KRT78, SFN, CLDN4, IL1RN, PKP3, CBLC, KRT16, TMEM79, KLK8, LYPD3 and LYPD5) were treated as valuable factors involved in the immune response and tumor cell development in tumorigenesis.",1,1.4211218904597709,1903611.5206776243,241.18147996450267,0.1895920076555231,0.05385793112328807,0.0,0.0,1.0011312217194572,885.0,-0.6887717180862317,0.061234245980008685,1.0,2.0,7.0,106.0,106.0,80.0,212.0,1542,105.0,1.6778973932186103e-06,23953.0,885.0,1.0,0,100.0
3082,600725,HP:0002664,"Medulloblastoma (MB) is the most common malignant pediatric brain tumor, and overactivation of the Sonic Hedgehog (Shh) signaling pathway, which requires the primary cilium, causes 30% of MBs.",1,1.3415673643588644,12257345.15556943,249.37693243428313,0.1462616341640359,0.02060471606945835,0.0,0.0,1.0007980845969673,1254.0,-0.4151526290473577,0.09426308279586727,1.0,2.0,13.0,444.0,444.0,30.0,888.0,1560,444.0,1.6778973932186103e-06,74056.0,1254.0,1.0,0,584.0
3091,601309,HP:0002664,"Shh signaling mutations, like those that remove Patched1 (Ptch1) or activate Smoothened (Smo), cause tumors dependent on the presence of cilia.",1,1.3360964844428909,15329627.400801975,258.5786066208793,0.1417913193636364,0.06032979236632585,0.0,0.0,1.000732064421669,1367.0,-0.3552680890708966,0.09309695917468974,1.0,2.0,1.0,535.0,535.0,9.0,1070.0,1542,535.0,1.6778973932186097e-06,86921.0,1367.0,1.0,0,692.0
3079,600725,HP:0002664,"Here, we show that deletion of Arl13b reduced Shh signaling levels in the presence of oncogenic SmoA1, suggesting Arl13b acts downstream of known tumor resistance mechanisms.",1,1.3415673643588644,12257345.15556943,249.37693243428313,0.1462616341640359,0.02060471606945835,0.0,0.0,1.0007980845969673,1254.0,-0.4151526290473577,0.09426308279586727,1.0,2.0,13.0,444.0,444.0,30.0,888.0,1560,444.0,1.6778973932186103e-06,74056.0,1254.0,1.0,0,584.0
3092,608922,HP:0002664,"Here, we show that deletion of Arl13b reduced Shh signaling levels in the presence of oncogenic SmoA1, suggesting Arl13b acts downstream of known tumor resistance mechanisms.",0,1.3626585769442912,6337130.112402875,286.5826657511253,0.1513780071860483,0.0615791832124534,0.0,0.0,0.9989754098360656,975.0,-0.6094419738134146,0.0983333892645603,1.0,2.0,33.0,205.0,205.0,205.0,410.0,1544,203.0,1.6778973932186106e-06,46883.0,977.0,1.0,0,242.0
3094,608922,HP:0002664,"Importantly, loss of Arl13b in a Ptch1-deleted mouse model of MB inhibited tumor formation.",0,1.3626585769442912,6337130.112402875,286.5826657511253,0.1513780071860483,0.0615791832124534,0.0,0.0,0.9989754098360656,975.0,-0.6094419738134146,0.0983333892645603,1.0,2.0,33.0,205.0,205.0,205.0,410.0,1544,203.0,1.6778973932186106e-06,46883.0,977.0,1.0,0,242.0
3096,164017,HP:0001425,"Mechanistically, lncSHGL recruited heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) to enhance the translation efficiency of CALM mRNAs to increase calmodulin (CaM) protein level without affecting their transcription, leading to the activation of the phosphatidyl inositol 3-kinase (PI3K)/Akt pathway and repression of the mTOR/SREBP-1C pathway independent of insulin and calcium in hepatocytes.",0,1.3247575205671318,701870.4514705881,101.12431399010349,0.2166004685123733,0.20984398488275768,0.0,0.0,0.997663551401869,427.0,-0.4078232458044214,0.11707295819445353,1.0,2.0,4.0,156.0,156.0,5.0,312.0,496,154.0,1.625910509885536e-05,10748.0,429.0,1.0,0,173.0
3097,164730,HP:0001425,"Mechanistically, lncSHGL recruited heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) to enhance the translation efficiency of CALM mRNAs to increase calmodulin (CaM) protein level without affecting their transcription, leading to the activation of the phosphatidyl inositol 3-kinase (PI3K)/Akt pathway and repression of the mTOR/SREBP-1C pathway independent of insulin and calcium in hepatocytes.",1,1.3670494295769406,2247116.6624990017,139.6902238628245,0.20991446392370366,0.014602618208014916,0.0,0.0,1.0010799136069115,927.0,-0.35708052366597043,0.058970039678379126,1.0,2.0,15.0,238.0,238.0,14.0,476.0,494,237.0,2.1562830854685934e-06,25310.0,927.0,1.0,0,240.0
3098,601231,HP:0001425,"Mechanistically, lncSHGL recruited heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) to enhance the translation efficiency of CALM mRNAs to increase calmodulin (CaM) protein level without affecting their transcription, leading to the activation of the phosphatidyl inositol 3-kinase (PI3K)/Akt pathway and repression of the mTOR/SREBP-1C pathway independent of insulin and calcium in hepatocytes.",0,1.3242895300031523,1269124.3182748535,118.09687680740312,0.1996836519231132,0.12119147585445945,0.0,0.0,0.9980544747081712,513.0,-0.32105007392468593,0.11621774772392428,1.0,2.0,4.0,203.0,203.0,2.0,406.0,496,201.0,1.4027409558276873e-05,15382.0,515.0,1.0,0,222.0
3099,604214,HP:0001425,"Mechanistically, lncSHGL recruited heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) to enhance the translation efficiency of CALM mRNAs to increase calmodulin (CaM) protein level without affecting their transcription, leading to the activation of the phosphatidyl inositol 3-kinase (PI3K)/Akt pathway and repression of the mTOR/SREBP-1C pathway independent of insulin and calcium in hepatocytes.",1,1.3685542575570775,338844.1488455988,95.34494836919436,0.2448183914924361,0.11813727940609316,0.0,0.0,1.0029850746268656,336.0,-0.6112576237823569,0.11083866382373846,1.0,2.0,2.0,80.0,80.0,50.0,160.0,494,79.0,1.625910509885536e-05,6238.0,336.0,1.0,0,87.0
3101,164730,HP:0003074,Hepatic hnRNPA1 overexpression also activated the CaM/Akt pathway and repressed the mTOR/SREBP-1C pathway to ameliorate hyperglycemia and steatosis in obese mice.,0,1.3374418802095558,162256.78805074046,101.10588235294115,0.3691598066167567,0.03902870030237153,0.0,0.0,0.9986130374479888,720.0,-0.3634313806995057,0.01715069482597654,1.0,2.0,217.0,41.0,41.0,41.0,82.0,514,40.0,2.1562830854685917e-06,4464.0,722.0,1.0,0,46.0
3103,604214,HP:0003074,Hepatic hnRNPA1 overexpression also activated the CaM/Akt pathway and repressed the mTOR/SREBP-1C pathway to ameliorate hyperglycemia and steatosis in obese mice.,0,1.257744455418874,24701.91904761905,37.61994382022472,0.3388540808967961,0.1884201852223764,0.0,0.0,0.9923076923076924,129.0,-0.4402815893177101,0.1305930710510863,1.0,2.0,19.0,40.0,40.0,41.0,80.0,94,38.0,0.00012345679012345677,1112.0,131.0,1.0,0,42.0
3106,613553,HP:0002664,"More importantly, XPNPEP3 expression was upregulated compared to normal samples in published expression data sets from several cancers including CRC.",0,1.4305258874987286,731216.2202578157,240.92195606355384,0.22509098195526486,0.3166113425378479,0.0,0.0,0.998803827751196,835.0,-0.7207792623522241,0.04274207839572865,1.0,2.0,23.0,62.0,62.0,58.0,124.0,1544,60.0,1.67789739321861e-06,14954.0,837.0,1.0,0,60.0
3104,613553,HP:0002664,"Finally, XPNPEP3 expression correlated with poor survival in many cancers.",0,1.4305258874987286,731216.2202578157,240.92195606355384,0.22509098195526486,0.3166113425378479,0.0,0.0,0.998803827751196,835.0,-0.7207792623522241,0.04274207839572865,1.0,2.0,23.0,62.0,62.0,58.0,124.0,1544,60.0,1.67789739321861e-06,14954.0,837.0,1.0,0,60.0
3108,601607,HP:0100008,Peripheral schwannomas were detected in 3 LZTR1-mutant (60%) and 10 SMARCB1-mutant subjects (66.7%).,0,1.4906108961960025,15884.883347475583,203.49367704280155,0.50652818471217,0.3698795588596784,0.0,0.0,1.0019193857965452,522.0,-0.6778216042265213,0.011788411616328752,1.0,2.0,73.0,8.0,8.0,8.0,16.0,426,8.0,3.770383636535018e-06,1603.0,522.0,1.0,0,8.0
3111,600574,HP:0100008,Peripheral schwannomas were detected in 3 LZTR1-mutant (60%) and 10 SMARCB1-mutant subjects (66.7%).,0,1.4828561329091552,10704.57589843759,131.49358974358975,0.4541137640877441,0.20036893284785487,0.0,0.0,1.0035714285714286,281.0,-0.7664583632060709,0.02597864768683274,1.0,2.0,36.0,8.0,8.0,8.0,16.0,286,8.0,1.3319835899621714e-05,1022.0,281.0,1.0,0,8.0
1215,601607,HP:0002664,"Among those with peripheral tumors, the median tumor number was 4 in the LZTR1 group (median total body tumor volume 30 cc) and 10 in the SMARCB1 group (median volume 85cc), (P=.2915 for tumor number and P = .2289 for volume).",1,1.3396459207409952,12225578.24190254,245.38261997405968,0.14557418044513382,0.12700196151807008,0.0,0.0,1.000778816199377,1285.0,-0.4059447124260791,0.09173182055105034,1.0,2.0,2.0,465.0,465.0,24.0,930.0,1542,464.0,1.677897393218609e-06,75676.0,1285.0,1.0,0,609.0
3113,600574,HP:0002664,"Among those with peripheral tumors, the median tumor number was 4 in the LZTR1 group (median total body tumor volume 30 cc) and 10 in the SMARCB1 group (median volume 85cc), (P=.2915 for tumor number and P = .2289 for volume).",0,1.3684454688256968,9134101.014117826,292.1700089793475,0.14494148147191802,0.08559950420896603,0.0,0.0,1.000958772770853,1044.0,-0.5570944844751394,0.10819254802129136,1.0,2.0,7.0,269.0,269.0,213.0,538.0,1542,268.0,1.6778973932186103e-06,58905.0,1044.0,1.0,0,379.0
3109,600574,HP:0100008,"Pain scores correlated with total body tumor volume (rho = 0.32471, P = .0499), but not with number of tumors (rho = 0.23065, P = .1696).We found no significant difference in quantitative tumor burden between mutational groups, but spinal schwannomas were more common in LZTR1-mutant patients.",0,1.4828561329091552,10704.57589843759,131.49358974358975,0.4541137640877441,0.20036893284785487,0.0,0.0,1.0035714285714286,281.0,-0.7664583632060709,0.02597864768683274,1.0,2.0,36.0,8.0,8.0,8.0,16.0,286,8.0,1.3319835899621714e-05,1022.0,281.0,1.0,0,8.0
3114,180380,HP:0100008,"Pain scores correlated with total body tumor volume (rho = 0.32471, P = .0499), but not with number of tumors (rho = 0.23065, P = .1696).We found no significant difference in quantitative tumor burden between mutational groups, but spinal schwannomas were more common in LZTR1-mutant patients.",0,1.3197826139002609,6446.820994794679,53.66717791411043,0.4615718727860506,0.144619812199241,0.0,0.0,0.994186046511628,171.0,-0.6387899177996732,0.03797553434601425,1.0,2.0,61.0,9.0,9.0,9.0,18.0,144,8.0,3.7180249851278996e-05,565.0,173.0,1.0,0,12.0
2418,180380,HP:0002664,"Pain scores correlated with total body tumor volume (rho = 0.32471, P = .0499), but not with number of tumors (rho = 0.23065, P = .1696).We found no significant difference in quantitative tumor burden between mutational groups, but spinal schwannomas were more common in LZTR1-mutant patients.",0,1.3656029541446206,2499829.264422941,200.53807898275682,0.18269083378657847,0.08808076945407306,0.0,0.0,0.9989304812834224,934.0,-0.6348648372529369,0.06318387494858083,1.0,2.0,27.0,140.0,140.0,94.0,280.0,1576,138.0,1.677897393218609e-06,27648.0,936.0,1.0,0,138.0
1235,601607,HP:0002664,"Pain was significantly higher in LZTR1-mutant than in SMARCB1-mutant patients, though spinal tumor location did not significantly correlate with pain.",1,1.3396459207409952,12225578.24190254,245.38261997405968,0.14557418044513382,0.12700196151807008,0.0,0.0,1.000778816199377,1285.0,-0.4059447124260791,0.09173182055105034,1.0,2.0,2.0,465.0,465.0,24.0,930.0,1542,464.0,1.677897393218609e-06,75676.0,1285.0,1.0,0,609.0
3115,606558,HP:0001263,"Taken together, we show here that mutations leading either to BCL11B haploinsufficiency or to a truncated BCL11B protein clinically cause a non-syndromic neurodevelopmental delay.",1,1.4328078467308325,10127823.03128752,533.0266580733671,0.14698042562627006,0.06356930999127226,0.0,0.0,1.0005970149253731,1676.0,-0.6493381485190298,0.060116125814839876,1.0,2.0,2.0,176.0,176.0,176.0,352.0,2998,175.0,4.444444444444444e-07,84382.0,1676.0,1.0,0,176.0
3116,605380,HP:0012418,"We conducted a case-control study within the Hispanic Community Health Study/Study of Latinos to investigate whether sleep disordered breathing, as a model of hypoxemia, is independently associated with elevated cFGF23 levels in the general population and with elevated cFGF23 and iFGF23 levels in patients with chronic kidney disease (CKD), in whom FGF23 cleavage may be impaired.",0,1.283056268865162,15666.473015873014,38.85624438454627,0.3708357311738887,0.19584176994020525,0.0,0.0,0.9921875,127.0,-0.5711940383492998,0.09362887596899223,1.0,2.0,29.0,22.0,22.0,22.0,44.0,92,21.0,8.734387282732117e-05,773.0,129.0,1.0,0,25.0
3125,116806,HP:0002664,"Molecular genetic studies of PCR and direct sequencing showed CTNNB1 mutations in 4 of 7 (4/7) cases, 4 of the four mutation-carrying cases showed diffuse b-catenin nuclear and cytoplasm immunoreactivity and diffuse cyclin D1 nuclear immunoreactivity in the tumor cells.",1,1.3518211230574562,8628385.610725343,244.5227047309904,0.15288895987823498,0.10335671492220867,0.0,0.0,1.0008741258741258,1145.0,-0.4805894159801953,0.09402388005008093,1.0,2.0,4.0,359.0,359.0,79.0,718.0,1542,359.0,1.6778973932186097e-06,61580.0,1145.0,1.0,0,481.0
3121,116806,HP:0002664,"Molecular analyses showed mutations of exon 3 of CTNNB1 in more than half of these tumors, and nuclear accumulation of b-catenin and over expression of cyclin D1 can be useful for the differential diagnosis of SCT, NOS",1,1.3518211230574562,8628385.610725343,244.5227047309904,0.15288895987823498,0.10335671492220867,0.0,0.0,1.0008741258741258,1145.0,-0.4805894159801953,0.09402388005008093,1.0,2.0,4.0,359.0,359.0,79.0,718.0,1542,359.0,1.6778973932186097e-06,61580.0,1145.0,1.0,0,481.0
3139,300037,HP:0002664,GPC3 was positive in yolk sac tumor component.,1,1.3412986642461031,13641671.894191915,268.83984371878967,0.14318359385542614,0.06328425266292867,0.0,0.0,1.0007955449482897,1258.0,-0.3838060772541164,0.1014869987213101,1.0,2.0,1.0,469.0,469.0,33.0,938.0,1542,468.0,1.6778973932186097e-06,80241.0,1258.0,1.0,0,618.0
3141,605207,HP:0002756,"Since excessive ingestion of vitamin A is known to induce spontaneous fractures and as the Vegfa-induced femur angulation in mice appears to be caused by intrauterine fractures, we analyzed bones from a CYP26B1 deficient human and rats with hypervitaminosis A to further explore Vegfa as a mechanistic link for the effect of vitamin A on bone.",0,1.2665286404416838,19546.716666666667,37.517307692307696,0.3184217750007894,-0.0050342023989698725,0.0,0.0,0.9892473118279572,92.0,-0.4390990009281444,0.20475863646762754,1.0,2.0,7.0,34.0,34.0,4.0,68.0,82,32.0,0.00035599857600569594,895.0,94.0,1.0,0,36.0
3142,192240,HP:0002756,"Since excessive ingestion of vitamin A is known to induce spontaneous fractures and as the Vegfa-induced femur angulation in mice appears to be caused by intrauterine fractures, we analyzed bones from a CYP26B1 deficient human and rats with hypervitaminosis A to further explore Vegfa as a mechanistic link for the effect of vitamin A on bone.",0,0.9761904761904762,78.14285714285714,2.0,0.7071067811865476,0.6574545499066383,0.0,0.0,0.9761904761904762,41.0,-0.952380952380952,0.04540420819490587,1.0,2.0,41.0,2.0,2.0,2.0,4.0,82,0.0,0.0005948839976204638,41.0,43.0,0.0,0,1.0
2908,601023,HP:0002145,"In humans, mutations in VCP lead to severe myo- and neuro-degenerative disorders such as inclusion body myopathy with Paget disease of the bone and frontotemporal dementia (IBMPFD), amyotrophic lateral sclerosis (ALS) or and hereditary spastic paraplegia (HSP).",1,1.4635784844367916,98290.11940693119,154.29176470588234,0.3264309447600601,0.3819814954668685,0.0,0.0,1.0022271714922049,450.0,-0.6360853109881619,0.03606038109378867,1.0,2.0,42.0,25.0,25.0,25.0,50.0,330,25.0,5.5103705173135855e-06,3643.0,450.0,1.0,0,32.0
3143,600824,HP:0000007,"By combining meta-analysis results and identification of two unrelated HCM patients with homozygous CSRP3 truncating variants, we suggest that the association of CSRP3 as a validated HCM-causing gene require additional studies and those CSRP3 variants could result in HCM with an autosomal recessive inheritance rather than with an autosomal dominant transmission as usually reported on HCM (OMIM 612124)",0,1.46008653912095,1587412.6069147566,463.1163983303518,0.2796574135854597,0.5054050784774479,0.0,0.0,0.9996220710506424,2645.0,-0.5722510431202116,0.009103704446140629,1.0,2.0,109.0,64.0,64.0,62.0,128.0,5162,62.0,1.5011496554636367e-07,31881.0,2647.0,1.0,0,63.0
3146,107310,HP:0001251,"Mice with a homozygous null mutation in Slc9a1 (Nhe1) exhibited ataxia, recurrent seizures, and selective neuronal cell death.",1,1.467519479165616,816831.8761193509,491.16593165931664,0.1975615265861431,0.014197781668912966,0.0,0.0,1.0011723329425557,854.0,-0.8158061484494928,0.05263417995722495,1.0,2.0,1.0,41.0,41.0,41.0,82.0,1626,40.0,1.5092152684290285e-06,19171.0,854.0,1.0,0,40.0
3148,107310,HP:0001250,"Mice with a homozygous null mutation in Slc9a1 (Nhe1) exhibited ataxia, recurrent seizures, and selective neuronal cell death.",0,1.4788720134423268,1359623.6805694785,729.7291581431945,0.20614543181029465,0.2440269970569068,0.0,0.0,0.9993718592964824,1591.0,-0.7746254305641831,0.024178488172185472,1.0,2.0,1.0,42.0,42.0,42.0,84.0,3102,40.0,4.151610160484642e-07,30659.0,1593.0,1.0,0,53.0
3144,107310,HP:0001251,"In humans, three unrelated patients have been reported: a patient with a homozygous missense mutation in SLC9A1, c.913G&gt;A (p.Gly305Arg), which caused Lichtenstein-Knorr syndrome characterized by cerebellar ataxia and sensorineural hearing loss, a patient with compound heterozygous mutations, c.1351A&gt;C (p.Ile451Leu) and c.1585C&gt;T (p.His529Tyr), which caused a neuromuscular disorder, and a patient with de novo mutation, c.796A&gt;C (p.Asn266His) which associated multiple anomalies.",1,1.467519479165616,816831.8761193509,491.16593165931664,0.1975615265861431,0.014197781668912966,0.0,0.0,1.0011723329425557,854.0,-0.8158061484494928,0.05263417995722495,1.0,2.0,1.0,41.0,41.0,41.0,82.0,1626,40.0,1.5092152684290285e-06,19171.0,854.0,1.0,0,40.0
3149,107310,HP:0000365,"In humans, three unrelated patients have been reported: a patient with a homozygous missense mutation in SLC9A1, c.913G&gt;A (p.Gly305Arg), which caused Lichtenstein-Knorr syndrome characterized by cerebellar ataxia and sensorineural hearing loss, a patient with compound heterozygous mutations, c.1351A&gt;C (p.Ile451Leu) and c.1585C&gt;T (p.His529Tyr), which caused a neuromuscular disorder, and a patient with de novo mutation, c.796A&gt;C (p.Asn266His) which associated multiple anomalies.",0,1.462904081484142,998929.2768494374,521.4198000670386,0.2170259017119628,0.22449890185891253,0.0,0.0,0.9992181391712276,1278.0,-0.7673038595482528,0.02674330531665364,1.0,2.0,29.0,42.0,42.0,42.0,84.0,2476,40.0,6.524672396198987e-07,21891.0,1280.0,1.0,0,50.0
3151,107310,HP:0000365,The main clinical feature was similar to Lichtenstein-Knorr syndrome but deafness may not be an essential phenotypic feature of SLC9A1 mutation.,0,1.462904081484142,998929.2768494374,521.4198000670386,0.2170259017119628,0.22449890185891253,0.0,0.0,0.9992181391712276,1278.0,-0.7673038595482528,0.02674330531665364,1.0,2.0,29.0,42.0,42.0,42.0,84.0,2476,40.0,6.524672396198987e-07,21891.0,1280.0,1.0,0,50.0
2654,164730,HP:0002664,"Taken together, we firstly revealed that quercetin suppressed the progression of breast cancer by inhibiting cell mobility and glycolysis through Akt-mTOR pathway mediated autophagy induction and may provide a potential therapeutic target for breast cancer treatment",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
3153,603026,HP:0002664,Here we show that the transcription factor pleomorphic adenoma gene 1 (PLAG1) is a microRNA target gene that is overexpressed in Wilms tumors with mutations in microRNA processing genes.,1,1.3941237167148521,5398300.320529471,290.62597366838395,0.15636015064578018,0.07121050410229862,0.0,0.0,1.0010537407797682,950.0,-0.6178887773057918,0.0936609173090788,1.0,2.0,1.0,178.0,178.0,173.0,356.0,1542,177.0,1.6778973932186106e-06,42220.0,950.0,1.0,0,174.0
3169,603026,HP:0002664,"Wilms tumors can also overexpress PLAG1 through copy number alterations, and PLAG1 expression correlates with prognosis in Wilms tumors.",1,1.3941237167148521,5398300.320529471,290.62597366838395,0.15636015064578018,0.07121050410229862,0.0,0.0,1.0010537407797682,950.0,-0.6178887773057918,0.0936609173090788,1.0,2.0,1.0,178.0,178.0,173.0,356.0,1542,177.0,1.6778973932186106e-06,42220.0,950.0,1.0,0,174.0
3161,603026,HP:0002664,PLAG1 overexpression accelerates growth of Wilms tumor cells in vitro and induces neoplastic growth in the developing mouse kidney in vivo.,1,1.3941237167148521,5398300.320529471,290.62597366838395,0.15636015064578018,0.07121050410229862,0.0,0.0,1.0010537407797682,950.0,-0.6178887773057918,0.0936609173090788,1.0,2.0,1.0,178.0,178.0,173.0,356.0,1542,177.0,1.6778973932186106e-06,42220.0,950.0,1.0,0,174.0
3157,603026,HP:0002664,"In both settings, PLAG1 transactivates insulin-like growth factor 2 (IGF2), a key Wilms tumor oncogene, and drives mammalian target of rapamycin complex 1 (mTORC1) signaling.",1,1.3941237167148521,5398300.320529471,290.62597366838395,0.15636015064578018,0.07121050410229862,0.0,0.0,1.0010537407797682,950.0,-0.6178887773057918,0.0936609173090788,1.0,2.0,1.0,178.0,178.0,173.0,356.0,1542,177.0,1.6778973932186106e-06,42220.0,950.0,1.0,0,174.0
3173,147470,HP:0002664,"In both settings, PLAG1 transactivates insulin-like growth factor 2 (IGF2), a key Wilms tumor oncogene, and drives mammalian target of rapamycin complex 1 (mTORC1) signaling.",1,1.348682374477382,10579896.297426306,252.1552668264488,0.14689451214354046,0.1508022933308487,0.0,0.0,1.0008539709649873,1172.0,-0.4534080366306401,0.0969359055443992,1.0,2.0,2.0,384.0,384.0,63.0,768.0,1542,383.0,1.6778973932186103e-06,66518.0,1172.0,1.0,0,547.0
3165,603026,HP:0002664,"These data link microRNA impairment to the PLAG1-IGF2 pathway, providing new insight into the manner in which common Wilms tumor mutations drive disease pathogenesis",1,1.3941237167148521,5398300.320529471,290.62597366838395,0.15636015064578018,0.07121050410229862,0.0,0.0,1.0010537407797682,950.0,-0.6178887773057918,0.0936609173090788,1.0,2.0,1.0,178.0,178.0,173.0,356.0,1542,177.0,1.6778973932186106e-06,42220.0,950.0,1.0,0,174.0
3175,147470,HP:0002664,"These data link microRNA impairment to the PLAG1-IGF2 pathway, providing new insight into the manner in which common Wilms tumor mutations drive disease pathogenesis",1,1.348682374477382,10579896.297426306,252.1552668264488,0.14689451214354046,0.1508022933308487,0.0,0.0,1.0008539709649873,1172.0,-0.4534080366306401,0.0969359055443992,1.0,2.0,2.0,384.0,384.0,63.0,768.0,1542,383.0,1.6778973932186103e-06,66518.0,1172.0,1.0,0,547.0
3177,182100,HP:0002664,"A number of studies report that miRNAs are involved in homeostatic maintenance such as cell cycle regulation, cell division and apoptosis, and that aberrant expression of miRNAs is often detected in various types of diseases, including cancer.",0,0.9987080103359172,1542.0103492884866,2.0,0.7071067811865472,0.8228171589148771,0.0,0.0,0.9987080103359172,773.0,-0.9948520724595946,0.0025773109944152704,1.0,2.0,773.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,773.0,775.0,0.0,0,1.0
3187,182100,HP:0002664,"In cancer biology, miRNAs play functional roles in tumor seeding, drug sensitivity, and metastasis.",0,0.9987080103359172,1542.0103492884866,2.0,0.7071067811865472,0.8228171589148771,0.0,0.0,0.9987080103359172,773.0,-0.9948520724595946,0.0025773109944152704,1.0,2.0,773.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,773.0,775.0,0.0,0,1.0
3197,182100,HP:0002664,"MiRNAs are also secreted through the small vesicles called exosomes, which are endosome-derived vesicles from various cell types including immune and tumor cells.",0,0.9987080103359172,1542.0103492884866,2.0,0.7071067811865472,0.8228171589148771,0.0,0.0,0.9987080103359172,773.0,-0.9948520724595946,0.0025773109944152704,1.0,2.0,773.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,773.0,775.0,0.0,0,1.0
3182,182100,HP:0002664,"In addition to cellular miRNAs, secreted miRNAs also play important roles in cancer development and metastasis.",0,0.9987080103359172,1542.0103492884866,2.0,0.7071067811865472,0.8228171589148771,0.0,0.0,0.9987080103359172,773.0,-0.9948520724595946,0.0025773109944152704,1.0,2.0,773.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,773.0,775.0,0.0,0,1.0
3202,182100,HP:0002664,"Therefore, secreted miRNAs in body fluids have been investigated as a promising biomarkers and therapeutic targets for the treatment of cancer patients.",0,0.9987080103359172,1542.0103492884866,2.0,0.7071067811865472,0.8228171589148771,0.0,0.0,0.9987080103359172,773.0,-0.9948520724595946,0.0025773109944152704,1.0,2.0,773.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,773.0,775.0,0.0,0,1.0
3192,182100,HP:0002664,"In this review, we introduce the current knowledge of miRNA functions in cancer development and discuss the clinical applications of se-miRNAs, eg, as diagnostic markers and therapeutic targets",0,0.9987080103359172,1542.0103492884866,2.0,0.7071067811865472,0.8228171589148771,0.0,0.0,0.9987080103359172,773.0,-0.9948520724595946,0.0025773109944152704,1.0,2.0,773.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,773.0,775.0,0.0,0,1.0
3207,604569,HP:0000717,"Consistent with this result, mutations in the CNTNAP2 gene coding for CASPR2 in human have been identified in neurodevelopmental disorders such as autism, intellectual disability, and epilepsy.",0,1.3270696314855417,368536.98293650796,126.45312222024548,0.19093724787412047,-0.11194644172811268,0.0,0.0,0.9955357142857144,223.0,-0.6304460325854833,0.25781746031746033,1.0,2.0,3.0,75.0,75.0,73.0,150.0,294,73.0,4.565376186997809e-05,6497.0,225.0,1.0,0,119.0
3208,604569,HP:0001249,"Consistent with this result, mutations in the CNTNAP2 gene coding for CASPR2 in human have been identified in neurodevelopmental disorders such as autism, intellectual disability, and epilepsy.",1,1.4684118520713167,3854404.5295044114,726.2953775313325,0.166525814741326,0.05779718596257919,0.0,0.0,1.0005959475566149,1679.0,-0.7488465996767643,0.03787940633826963,1.0,2.0,3.0,75.0,75.0,75.0,150.0,3204,74.0,3.8916426584744994e-07,53360.0,1679.0,1.0,0,72.0
3209,604569,HP:0001250,"Consistent with this result, mutations in the CNTNAP2 gene coding for CASPR2 in human have been identified in neurodevelopmental disorders such as autism, intellectual disability, and epilepsy.",1,1.4674726352507934,3958720.1407508887,722.7369836614998,0.16413636503508208,0.06789538035104987,0.0,0.0,1.0006150061500616,1627.0,-0.7647913413216134,0.04008086177973028,1.0,2.0,2.0,76.0,76.0,75.0,152.0,3100,75.0,4.156965348783941e-07,53017.0,1627.0,1.0,0,72.0
3210,601763,HP:0100242,"Kaposi*s sarcoma (KS)-associated herpesvirus (KSHV) vFLIP, a latent gene of KSHV, was first identified as a FLICE-inhibitory protein (FLIP) protecting cells from apoptosis.",0,1.2908347556861033,226024.2845238095,66.88524406627855,0.2563380132737702,0.004769589315010986,0.0,0.0,0.9963099630996308,270.0,-0.510019254001683,0.12380616453223355,1.0,2.0,12.0,82.0,82.0,13.0,164.0,320,80.0,4.162330905306972e-05,4563.0,272.0,1.0,0,82.0
3211,609145,HP:0100242,The vFLIP protein has been shown to activate the NF-kB signaling involved in spindle morphology formation both in HUVECs infected with KSHV and Kaposi*s sarcoma (KS) itself.,0,1.3147840832131354,434477.5195970697,98.43729404923435,0.2040893310803472,0.38804508702427504,0.0,0.0,0.9965397923875432,288.0,-0.36522106598194987,0.17176947858250805,1.0,2.0,5.0,108.0,108.0,4.0,216.0,310,106.0,4.162330905306972e-05,7198.0,290.0,1.0,0,135.0
3214,133450,HP:0100242,"In Ewing sarcoma, the oncogenic fusion protein EWS-FLI1 induces chromatin features typical of active enhancers at GGAA microsatellite repeats, but the function of these sites has not been directly demonstrated.",1,1.3504218148000529,283006.6077380952,95.34740259740259,0.23387161813348506,-0.09176612103245764,0.0,0.0,1.0042918454935623,234.0,-0.5733172943831915,0.18414584938190087,1.0,2.0,1.0,79.0,79.0,64.0,158.0,308,78.0,4.162330905306972e-05,5020.0,234.0,1.0,0,78.0
3212,133450,HP:0100242,"Epigenome silencing of these repeat sites does not affect gene expression in unrelated cells, can prevent the induction of gene expression by EWS-FLI1, and, in the case of a GGAA repeat that controls SOX2 expression from a distance of 470 kb, is sufficient to impair the growth of Ewing sarcoma xenografts.",1,1.3504218148000529,283006.6077380952,95.34740259740259,0.23387161813348506,-0.09176612103245764,0.0,0.0,1.0042918454935623,234.0,-0.5733172943831915,0.18414584938190087,1.0,2.0,1.0,79.0,79.0,64.0,158.0,308,78.0,4.162330905306972e-05,5020.0,234.0,1.0,0,78.0
3218,184429,HP:0100242,"Epigenome silencing of these repeat sites does not affect gene expression in unrelated cells, can prevent the induction of gene expression by EWS-FLI1, and, in the case of a GGAA repeat that controls SOX2 expression from a distance of 470 kb, is sufficient to impair the growth of Ewing sarcoma xenografts.",0,1.31627142263067,891431.6111305363,129.03728354978355,0.18708004323239344,0.04256700372319791,0.0,0.0,0.9974683544303796,394.0,-0.3491817955678653,0.15740953842219665,1.0,2.0,11.0,148.0,148.0,6.0,296.0,310,146.0,1.7217334412286292e-05,12311.0,396.0,1.0,0,172.0
3219,610531,HP:0002664,"Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide; however, the mutational properties of HCC-associated carcinogens remain largely uncharacterized.",0,1.3833646643722706,1282814.8241142896,204.7643664469679,0.2047026621012316,0.10612743961063728,0.0,0.0,0.9988505747126436,869.0,-0.6387722046304269,0.048824841310687934,1.0,2.0,68.0,96.0,96.0,73.0,192.0,1544,94.0,1.67789739321861e-06,18499.0,871.0,1.0,0,89.0
3225,610531,HP:0002664,We hypothesized that mechanisms underlying chemical-induced HCC can be characterized by evaluating the mutational spectra of these tumors.,0,1.3833646643722706,1282814.8241142896,204.7643664469679,0.2047026621012316,0.10612743961063728,0.0,0.0,0.9988505747126436,869.0,-0.6387722046304269,0.048824841310687934,1.0,2.0,68.0,96.0,96.0,73.0,192.0,1544,94.0,1.67789739321861e-06,18499.0,871.0,1.0,0,89.0
3222,610531,HP:0002664,"The MEG tumors clustered closest to Catalogue of Somatic Mutations in Cancer signatures 4 and 24, which are, respectively, associated with benzo(a)pyrene- and aflatoxin-induced HCCs in humans.",0,1.3833646643722706,1282814.8241142896,204.7643664469679,0.2047026621012316,0.10612743961063728,0.0,0.0,0.9988505747126436,869.0,-0.6387722046304269,0.048824841310687934,1.0,2.0,68.0,96.0,96.0,73.0,192.0,1544,94.0,1.67789739321861e-06,18499.0,871.0,1.0,0,89.0
3228,600281,HP:0000121,Analysis of the adult Hnf4a mutant kidney also showed proximal tubule dysgenesis and nephrocalcinosis.,1,1.3898257448004498,191644.87332407926,85.14529624604252,0.2825904367597634,0.2867886207225745,0.0,0.0,1.0030303030303032,331.0,-0.4603125074864651,0.0833104458482102,1.0,2.0,23.0,67.0,67.0,67.0,134.0,182,67.0,1.4239943040227844e-05,4550.0,331.0,1.0,0,69.0
3229,612920,HP:0000007,"With the notable exception of WNT10A (Tooth agenesis, selective, 4, MIM #150400), the genotype-phenotype relationships described in the present cohort represent an expansion of the clinical spectrum associated with these genes: TSPEAR (Deafness, autosomal recessive 98, MIM #614861), LAMB3 (Amelogenesis imperfecta, type IA, MIM #104530; Epidermolysis bullosa, junctional, MIMs #226700 and #226650), and BCOR (Microphthalmia, syndromic 2, MIM #300166).",1,1.4886365081199788,939493.4515087805,611.8483942414175,0.2694708477919026,0.7556162120797061,0.0,0.0,1.0003815337657382,2622.0,-0.6050683254641247,0.007358857971363724,1.0,2.0,508.0,40.0,40.0,40.0,80.0,5160,39.0,1.5011496554636367e-07,25286.0,2622.0,1.0,0,38.0
3230,150310,HP:0000007,"With the notable exception of WNT10A (Tooth agenesis, selective, 4, MIM #150400), the genotype-phenotype relationships described in the present cohort represent an expansion of the clinical spectrum associated with these genes: TSPEAR (Deafness, autosomal recessive 98, MIM #614861), LAMB3 (Amelogenesis imperfecta, type IA, MIM #104530; Epidermolysis bullosa, junctional, MIMs #226700 and #226650), and BCOR (Microphthalmia, syndromic 2, MIM #300166).",1,1.4396704371282674,11536439.68481237,418.63736786469343,0.17948015013569762,0.2419013895257468,0.0,0.0,1.0003517411185368,2844.0,-0.5397324521176794,0.0248002224230758,1.0,2.0,37.0,255.0,255.0,179.0,510.0,5160,254.0,1.5011496554636375e-07,100261.0,2844.0,1.0,0,233.0
3231,300485,HP:0000007,"With the notable exception of WNT10A (Tooth agenesis, selective, 4, MIM #150400), the genotype-phenotype relationships described in the present cohort represent an expansion of the clinical spectrum associated with these genes: TSPEAR (Deafness, autosomal recessive 98, MIM #614861), LAMB3 (Amelogenesis imperfecta, type IA, MIM #104530; Epidermolysis bullosa, junctional, MIMs #226700 and #226650), and BCOR (Microphthalmia, syndromic 2, MIM #300166).",0,1.3884382277852607,35110533.90392102,391.4742306788818,0.14811702521858156,0.07097523482069053,0.0,0.0,0.9996850393700788,3174.0,-0.474760075237533,0.03792736865070708,1.0,2.0,13.0,582.0,582.0,162.0,1164.0,5162,580.0,1.5011496554636354e-07,191226.0,3176.0,1.0,0,705.0
3232,606268,HP:0000007,"With the notable exception of WNT10A (Tooth agenesis, selective, 4, MIM #150400), the genotype-phenotype relationships described in the present cohort represent an expansion of the clinical spectrum associated with these genes: TSPEAR (Deafness, autosomal recessive 98, MIM #614861), LAMB3 (Amelogenesis imperfecta, type IA, MIM #104530; Epidermolysis bullosa, junctional, MIMs #226700 and #226650), and BCOR (Microphthalmia, syndromic 2, MIM #300166).",1,1.4621378005901926,4932403.897747884,411.0940833718364,0.20182439137704333,0.2920947857366084,0.0,0.0,1.0003663003663004,2731.0,-0.5847671656857386,0.015731199107251834,1.0,2.0,93.0,144.0,144.0,109.0,288.0,5160,143.0,1.5011496554636367e-07,58643.0,2731.0,1.0,0,140.0
3233,300429,HP:0000717,"ARHGEF9 alterations, some inherited from unaffected mothers, have been reported in males with autism, seizures and severe neurodevelopmental abnormalities.",0,1.3339231396250422,211158.62698412692,101.56925418569254,0.21155223763359127,0.18383817546106013,0.0,0.0,0.9952380952380954,209.0,-0.6916817773560703,0.20722184608440533,1.0,2.0,3.0,61.0,61.0,50.0,122.0,294,59.0,4.565376186997809e-05,4591.0,211.0,1.0,0,65.0
3237,300429,HP:0001250,"ARHGEF9 alterations, some inherited from unaffected mothers, have been reported in males with autism, seizures and severe neurodevelopmental abnormalities.",1,1.4729281638487586,2253665.891314517,651.1135074244751,0.1805096853050472,0.06087335199151064,0.0,0.0,1.000620347394541,1613.0,-0.7777153644438689,0.030319719278381764,1.0,2.0,1.0,61.0,61.0,61.0,122.0,3100,60.0,4.156965348783943e-07,39418.0,1613.0,1.0,0,55.0
3235,300429,HP:0000717,Our findings highlight the importance of ARHGEF9 integrity and suggest further research on its correlation with autism and neurobehavioral problems,0,1.3339231396250422,211158.62698412692,101.56925418569254,0.21155223763359127,0.18383817546106013,0.0,0.0,0.9952380952380954,209.0,-0.6916817773560703,0.20722184608440533,1.0,2.0,3.0,61.0,61.0,50.0,122.0,294,59.0,4.565376186997809e-05,4591.0,211.0,1.0,0,65.0
3216,133450,HP:0100242,We report a surgical case of 51-year-old woman with myoepithelioma occurring in the posterior mediastinum that harbored the Ewing sarcoma breakpoint region1 (EWSR1) gene rearrangement.,1,1.3504218148000529,283006.6077380952,95.34740259740259,0.23387161813348506,-0.09176612103245764,0.0,0.0,1.0042918454935623,234.0,-0.5733172943831915,0.18414584938190087,1.0,2.0,1.0,79.0,79.0,64.0,158.0,308,78.0,4.162330905306972e-05,5020.0,234.0,1.0,0,78.0
3244,606368,HP:0001513,"Numerous evidence has demonstrated for an association between apoA5 and the increased risk of obesity and metabolic syndrome, but the mechanism remains to be fully elucidated.",0,1.3920881805656171,182329.94788264023,111.84848484848486,0.27137486553246765,0.0038398282251994337,0.0,0.0,0.9975062344139648,400.0,-0.7314869389538282,0.06253024156027841,1.0,2.0,8.0,41.0,41.0,31.0,82.0,706,39.0,8.025102520684701e-06,5040.0,402.0,1.0,0,36.0
3238,606368,HP:0001513,"Furthermore, since adipocytes provide the largest storage depot for TG and play a crucial role in the development of obesity, we could infer that apoA5 also acts as a novel regulator to modulate TG storage in adipocytes.",0,1.3920881805656171,182329.94788264023,111.84848484848486,0.27137486553246765,0.0038398282251994337,0.0,0.0,0.9975062344139648,400.0,-0.7314869389538282,0.06253024156027841,1.0,2.0,8.0,41.0,41.0,31.0,82.0,706,39.0,8.025102520684701e-06,5040.0,402.0,1.0,0,36.0
3247,188450,HP:0001513,"Furthermore, since adipocytes provide the largest storage depot for TG and play a crucial role in the development of obesity, we could infer that apoA5 also acts as a novel regulator to modulate TG storage in adipocytes.",0,1.3692726986682957,800725.0900793652,156.02904749744638,0.199024048401578,0.09244768711383282,0.0,0.0,0.9977375565610859,441.0,-0.6896807973004022,0.1162681429578256,1.0,2.0,5.0,85.0,85.0,73.0,170.0,706,83.0,7.979826997350701e-06,11383.0,443.0,1.0,0,95.0
3241,606368,HP:0001513,"In this review, we focus on the association of gene and protein of apoA5 with obesity and metabolic syndrome, and provide new insights into the physiological role of apoA5 in humans, giving a potential therapeutic target for obesity and associated disorders",0,1.3920881805656171,182329.94788264023,111.84848484848486,0.27137486553246765,0.0038398282251994337,0.0,0.0,0.9975062344139648,400.0,-0.7314869389538282,0.06253024156027841,1.0,2.0,8.0,41.0,41.0,31.0,82.0,706,39.0,8.025102520684701e-06,5040.0,402.0,1.0,0,36.0
3248,300013,HP:0001249,"NAA10-related syndrome is an X-linked condition with a broad spectrum of findings ranging from a severe phenotype in males with p.Ser37Pro in NAA10, originally described as Ogden syndrome, to the milder NAA10-related intellectual disability found with different variants in both males and females.",1,1.3836704894459335,35167684.00222997,484.0492192977956,0.12449813828040335,0.10801697435783404,0.0,0.0,1.0004904364884748,2040.0,-0.5562881715882821,0.08005317870159344,1.0,2.0,2.0,429.0,429.0,240.0,858.0,3204,428.0,3.8916426584745004e-07,166493.0,2040.0,1.0,0,678.0
3249,611720,HP:0002376,"Five individuals who carry IRF2BPL nonsense variants resulting in a premature stop codon display severe neurodevelopmental regression, hypotonia, progressive ataxia, seizures, and a lack of coordination.",0,1.3862368088521566,919232.6036130536,211.9579698651864,0.17272006477492804,0.04670543120710436,0.0,0.0,1.002717391304348,369.0,-0.7730710839132944,0.1920289855072464,1.0,2.0,1.0,78.0,78.0,78.0,156.0,582,77.0,1.1728279226871836e-05,13038.0,369.0,1.0,0,76.0
3250,611720,HP:0003676,"Five individuals who carry IRF2BPL nonsense variants resulting in a premature stop codon display severe neurodevelopmental regression, hypotonia, progressive ataxia, seizures, and a lack of coordination.",0,1.3799038461538462,679394.4967893218,161.74789587003323,0.19495616356401574,0.03375003306685751,0.0,0.0,1.0029498525073746,340.0,-0.692940907409529,0.16869685927468334,1.0,2.0,1.0,78.0,78.0,78.0,156.0,524,77.0,1.4457343607685525e-05,9722.0,340.0,1.0,0,75.0
3251,611720,HP:0001251,"Five individuals who carry IRF2BPL nonsense variants resulting in a premature stop codon display severe neurodevelopmental regression, hypotonia, progressive ataxia, seizures, and a lack of coordination.",0,1.4432865039852136,2541500.0716282767,464.8756741413568,0.16209881297804882,0.09659354927325632,0.0,0.0,1.001123595505618,891.0,-0.7857625271160451,0.0834461973038752,1.0,2.0,1.0,78.0,78.0,78.0,156.0,1626,77.0,1.5092152684290273e-06,33086.0,891.0,1.0,0,77.0
3252,611720,HP:0001250,"Five individuals who carry IRF2BPL nonsense variants resulting in a premature stop codon display severe neurodevelopmental regression, hypotonia, progressive ataxia, seizures, and a lack of coordination.",0,1.4670918035501,4346388.748993514,756.3399834574028,0.1603661498036665,0.06325642123686764,0.0,0.0,1.0006146281499693,1628.0,-0.7732019670361363,0.04241085249075415,1.0,2.0,1.0,78.0,78.0,78.0,156.0,3100,77.0,4.156965348783942e-07,56168.0,1628.0,1.0,0,83.0
73,191170,HP:0002664,Inhibition of p53-MDM2 complex has been emerging as a strategy for antitumoral drug development considering the pro-apoptotic role of functional p53 in tumor cells.,1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
209,164785,HP:0002664,Inhibition of p53-MDM2 complex has been emerging as a strategy for antitumoral drug development considering the pro-apoptotic role of functional p53 in tumor cells.,1,1.391410468595884,3660844.478079444,241.1528468479716,0.1733730375837963,0.17860145508336964,0.0,0.0,1.001044932079415,958.0,-0.6026291737214196,0.07917269302338772,1.0,2.0,2.0,186.0,186.0,112.0,372.0,1542,185.0,1.6778973932186097e-06,36293.0,958.0,1.0,0,185.0
3254,607117,HP:0000252,"Mutations in a number of different genes causative for microcephaly have been identified, e.g., MCPH1, WDR62, and ASPM.",1,1.446917481345746,3456584.1208983106,569.168260587428,0.148131705915047,-0.01942062784803805,0.0,0.0,1.0008904719501337,1124.0,-0.7611540691697282,0.07542234038844857,1.0,2.0,3.0,89.0,89.0,89.0,178.0,2066,88.0,9.35317203476387e-07,47601.0,1124.0,1.0,0,109.0
3257,613583,HP:0000252,"Mutations in a number of different genes causative for microcephaly have been identified, e.g., MCPH1, WDR62, and ASPM.",1,1.4342694660040496,5393701.512815662,536.1105696877008,0.14190795739515186,0.0968985435302059,0.0,0.0,1.000868809730669,1152.0,-0.7251786795337877,0.08628819142774401,1.0,2.0,1.0,119.0,119.0,119.0,238.0,2066,118.0,9.353172034763872e-07,57207.0,1152.0,1.0,0,131.0
3261,605481,HP:0000252,"Mutations in a number of different genes causative for microcephaly have been identified, e.g., MCPH1, WDR62, and ASPM.",1,1.4342694660040496,5562653.248529644,552.2481472743987,0.1413071799331772,0.014248688097506847,0.0,0.0,1.000868809730669,1152.0,-0.718389011847588,0.0888855705183898,1.0,2.0,1.0,119.0,119.0,119.0,238.0,2066,118.0,9.353172034763872e-07,58929.0,1152.0,1.0,0,139.0
3263,108370,HP:0000252,"Recently, mutations in the gene encoding the enzyme asparagine synthetase (ASNS) were associated to microcephaly and so far 24 different mutations in ASNS causing microcephaly have been described.",1,1.4338454621696164,5598173.424938398,557.6367860600194,0.13999306287970215,-0.02641555649885156,0.0,0.0,1.0008680555555556,1153.0,-0.7287985494372742,0.09027175484244004,1.0,2.0,1.0,120.0,120.0,120.0,240.0,2066,119.0,9.353172034763868e-07,59952.0,1153.0,1.0,0,126.0
3264,609377,HP:0002664,"Conclusions: During the natural course of advanced lung cancer, the incidence of anemia is high, especially ACD.",1,1.405810693545157,3822597.442197688,299.22990500227854,0.16475515192964427,0.05582129602081353,0.0,0.0,1.0010893246187365,919.0,-0.6464166262998307,0.08808001498265852,1.0,2.0,1.0,148.0,148.0,148.0,296.0,1542,147.0,1.67789739321861e-06,37154.0,919.0,1.0,0,165.0
3274,607407,HP:0001263,"Using whole-exome sequencing, we identified seven unrelated individuals with global developmental delay, hypotonia, dysmorphic facial features, and an increased frequency of short stature, ataxia, and autism with de novo heterozygous frameshift, nonsense, splice, and missense variants in the Early B-cell Transcription Factor Family Member 3 (EBF3) gene.",1,1.4196275668911686,16539193.032271625,566.849581136687,0.1317321806546134,0.03267849706017684,0.0,0.0,1.0005800464037122,1725.0,-0.6488455958535039,0.07486734590941188,1.0,2.0,1.0,226.0,226.0,226.0,452.0,2998,225.0,4.4444444444444475e-07,111324.0,1725.0,1.0,0,227.0
3277,607407,HP:0004322,"Using whole-exome sequencing, we identified seven unrelated individuals with global developmental delay, hypotonia, dysmorphic facial features, and an increased frequency of short stature, ataxia, and autism with de novo heterozygous frameshift, nonsense, splice, and missense variants in the Early B-cell Transcription Factor Family Member 3 (EBF3) gene.",1,1.402656290595964,12908581.399381073,454.11245721136396,0.13234069971843287,0.03936913737180688,0.0,0.0,1.0007423904974015,1348.0,-0.6537406119364243,0.09409083599338236,1.0,2.0,1.0,226.0,226.0,215.0,452.0,2244,225.0,7.929402939746847e-07,85423.0,1348.0,1.0,0,234.0
3280,607407,HP:0001251,"Using whole-exome sequencing, we identified seven unrelated individuals with global developmental delay, hypotonia, dysmorphic facial features, and an increased frequency of short stature, ataxia, and autism with de novo heterozygous frameshift, nonsense, splice, and missense variants in the Early B-cell Transcription Factor Family Member 3 (EBF3) gene.",1,1.38293381267253,7293964.155466021,313.5920930890725,0.14924523521685573,0.04766073666187312,0.0,0.0,1.0009633911368017,1039.0,-0.5959568467629217,0.10284084481706696,1.0,2.0,1.0,224.0,224.0,187.0,448.0,1626,223.0,1.5092152684290275e-06,55456.0,1039.0,1.0,0,305.0
3282,607407,HP:0000717,"Using whole-exome sequencing, we identified seven unrelated individuals with global developmental delay, hypotonia, dysmorphic facial features, and an increased frequency of short stature, ataxia, and autism with de novo heterozygous frameshift, nonsense, splice, and missense variants in the Early B-cell Transcription Factor Family Member 3 (EBF3) gene.",0,1.324413773236936,1089924.967857143,158.21384410231542,0.16983529921665236,0.16879967582646185,0.0,0.0,0.9973190348525468,372.0,-0.2889756296844705,0.20398273859872976,1.0,2.0,6.0,147.0,147.0,147.0,294.0,294,145.0,1.940654776921733e-05,14228.0,374.0,1.0,0,185.0
3265,607407,HP:0001263,"Haploinsufficiency of EBF3 may affect brain development and function, resulting in developmental delay, intellectual disability, and behavioral differences observed in individuals with a deleterious variant in EBF3",1,1.4196275668911686,16539193.032271625,566.849581136687,0.1317321806546134,0.03267849706017684,0.0,0.0,1.0005800464037122,1725.0,-0.6488455958535039,0.07486734590941188,1.0,2.0,1.0,226.0,226.0,226.0,452.0,2998,225.0,4.4444444444444475e-07,111324.0,1725.0,1.0,0,227.0
3288,607407,HP:0001249,"Haploinsufficiency of EBF3 may affect brain development and function, resulting in developmental delay, intellectual disability, and behavioral differences observed in individuals with a deleterious variant in EBF3",1,1.4233147044975332,17572430.154272385,587.551953862981,0.13233679875660373,0.019169530735568898,0.0,0.0,1.0005473453749316,1828.0,-0.6521585692095052,0.06968772569014024,1.0,2.0,1.0,226.0,226.0,226.0,452.0,3204,225.0,3.891642658474498e-07,116370.0,1828.0,1.0,0,228.0
3318,600259,HP:0002664,"Lynch syndrome (LS) patients with isolated PMS2 loss in the colon cancer, while intact MMR in the prostate cancer, are exceedingly rare.",1,1.3872402977296638,4206211.890374658,241.1820428015564,0.17742948870231876,0.01977480950222539,0.0,0.0,1.0010309278350515,971.0,-0.5551106857517283,0.0813296951808636,1.0,2.0,1.0,200.0,200.0,200.0,400.0,1542,199.0,1.67789739321861e-06,38301.0,971.0,1.0,0,213.0
3313,600259,HP:0002664,"Immunostaining showed that the colon cancer was positive for CDX2, SATB2, had a loss of PMS2 and intact expression of MLH1, MSH2 and MSH6, negative for AMACR, while the prostate cancer was positive for AMACR, had intact expression of PMS2, MLH1, MSH2 and MSH6, and negative for CDX2 and SATB2.",1,1.3872402977296638,4206211.890374658,241.1820428015564,0.17742948870231876,0.01977480950222539,0.0,0.0,1.0010309278350515,971.0,-0.5551106857517283,0.0813296951808636,1.0,2.0,1.0,200.0,200.0,200.0,400.0,1542,199.0,1.67789739321861e-06,38301.0,971.0,1.0,0,213.0
3338,608148,HP:0002664,"Immunostaining showed that the colon cancer was positive for CDX2, SATB2, had a loss of PMS2 and intact expression of MLH1, MSH2 and MSH6, negative for AMACR, while the prostate cancer was positive for AMACR, had intact expression of PMS2, MLH1, MSH2 and MSH6, and negative for CDX2 and SATB2.",0,1.346544906281054,10473441.8775641,255.07825568759412,0.1426592056232719,0.057772763799931875,0.0,0.0,0.999124343257443,1141.0,-0.4862872270624304,0.09869716373019047,1.0,2.0,6.0,365.0,365.0,89.0,730.0,1544,363.0,1.6778973932186097e-06,64415.0,1143.0,1.0,0,513.0
3344,120436,HP:0002664,"Immunostaining showed that the colon cancer was positive for CDX2, SATB2, had a loss of PMS2 and intact expression of MLH1, MSH2 and MSH6, negative for AMACR, while the prostate cancer was positive for AMACR, had intact expression of PMS2, MLH1, MSH2 and MSH6, and negative for CDX2 and SATB2.",1,1.3724379901603143,5818621.47767339,246.4111696040284,0.1639416543826219,-0.008069802038276657,0.0,0.0,1.0009756097560976,1026.0,-0.5524282139315764,0.08979793657585697,1.0,2.0,1.0,250.0,250.0,99.0,500.0,1542,249.0,1.67789739321861e-06,47218.0,1026.0,1.0,0,247.0
3373,609309,HP:0002664,"Immunostaining showed that the colon cancer was positive for CDX2, SATB2, had a loss of PMS2 and intact expression of MLH1, MSH2 and MSH6, negative for AMACR, while the prostate cancer was positive for AMACR, had intact expression of PMS2, MLH1, MSH2 and MSH6, and negative for CDX2 and SATB2.",1,1.3768221907623603,5337536.964099137,247.2793183273408,0.16568705398514247,0.06456760463916675,0.0,0.0,1.0009930486593843,1008.0,-0.5677206892113388,0.0883222206459545,1.0,2.0,1.0,230.0,230.0,119.0,460.0,1542,229.0,1.6778973932186103e-06,44826.0,1008.0,1.0,0,233.0
3393,604489,HP:0002664,"Immunostaining showed that the colon cancer was positive for CDX2, SATB2, had a loss of PMS2 and intact expression of MLH1, MSH2 and MSH6, negative for AMACR, while the prostate cancer was positive for AMACR, had intact expression of PMS2, MLH1, MSH2 and MSH6, and negative for CDX2 and SATB2.",0,1.3928115849274956,3219615.90007383,274.34386365903873,0.17098028776084254,0.18591102919345687,0.0,0.0,0.9989071038251366,914.0,-0.6587398363208193,0.0805736511799938,1.0,2.0,15.0,142.0,142.0,139.0,284.0,1544,140.0,1.6778973932186103e-06,33766.0,916.0,1.0,0,137.0
3328,600259,HP:0002664,"MSI-H phenotype and PMS2 mutation in the colon cancer were confirmed by microsatellite instability (MSI) PCR and next-generation sequencing (NGS), respectively.",1,1.3872402977296638,4206211.890374658,241.1820428015564,0.17742948870231876,0.01977480950222539,0.0,0.0,1.0010309278350515,971.0,-0.5551106857517283,0.0813296951808636,1.0,2.0,1.0,200.0,200.0,200.0,400.0,1542,199.0,1.67789739321861e-06,38301.0,971.0,1.0,0,213.0
3333,600259,HP:0002664,"To the best of our knowledge, this is the first documented case of synchronous colon and prostate cancers, with isolated PMS2 loss present in the colon cancer while intact DNA mismatch repair (MMR) protein expressions present in the prostate cancer, in the English literature.",1,1.3872402977296638,4206211.890374658,241.1820428015564,0.17742948870231876,0.01977480950222539,0.0,0.0,1.0010309278350515,971.0,-0.5551106857517283,0.0813296951808636,1.0,2.0,1.0,200.0,200.0,200.0,400.0,1542,199.0,1.67789739321861e-06,38301.0,971.0,1.0,0,213.0
3397,191311,HP:0002664,The action of the collagen binding receptor tyrosine kinase (RTK) discoidin domain receptor 2 (DDR2) in both tumor and tumor stromal cells has been established as critical for breast cancer metastasis.,0,1.3614966760418832,8070697.19336891,242.18503267726948,0.1496233370980927,0.010437836237240629,0.0,0.0,1.000926784059314,1080.0,-0.5477389283705865,0.09168983626814953,1.0,2.0,10.0,295.0,295.0,116.0,590.0,1542,294.0,1.677897393218611e-06,53424.0,1080.0,1.0,0,384.0
3394,191311,HP:0002664,"By targeting DDR2, WRG-28 inhibits tumor invasion and migration, as well as tumor-supporting roles of the stroma, and inhibits metastatic breast tumor cell colonization in the lungs.",0,1.3614966760418832,8070697.19336891,242.18503267726948,0.1496233370980927,0.010437836237240629,0.0,0.0,1.000926784059314,1080.0,-0.5477389283705865,0.09168983626814953,1.0,2.0,10.0,295.0,295.0,116.0,590.0,1542,294.0,1.677897393218611e-06,53424.0,1080.0,1.0,0,384.0
3400,191311,HP:0002664,"These findings represent an approach to inhibiting tumor-stromal interactions and support the development of allosteric inhibitors of DDR2, such as WRG-28, as a promising approach to antimetastasis treatment",0,1.3614966760418832,8070697.19336891,242.18503267726948,0.1496233370980927,0.010437836237240629,0.0,0.0,1.000926784059314,1080.0,-0.5477389283705865,0.09168983626814953,1.0,2.0,10.0,295.0,295.0,116.0,590.0,1542,294.0,1.677897393218611e-06,53424.0,1080.0,1.0,0,384.0
3403,602228,HP:0003074,"Also the well-known gene variants rs7903146 in TCF7L2, and rs17817449 in FTO, were nominally associated with hyperglycemia (rs7903146), as well as with higher fasting insulin levels (rs17817449).",0,1.3309938588795591,8356.305555555557,38.41111111111111,0.3399121887286092,0.3394483415577648,0.0,0.0,0.9830508474576272,58.0,-0.7135422768959894,0.288135593220339,1.0,2.0,0.0,19.0,19.0,19.0,38.0,62,18.0,0.0005668934240362813,510.0,60.0,5.0,0,25.0
3404,610966,HP:0003074,"Also the well-known gene variants rs7903146 in TCF7L2, and rs17817449 in FTO, were nominally associated with hyperglycemia (rs7903146), as well as with higher fasting insulin levels (rs17817449).",0,1.3525441771343407,66790.28690476192,55.24627329192546,0.3255348063457029,0.14239311038556424,0.0,0.0,0.995049504950495,201.0,-0.5812638357714046,0.09301077891040337,1.0,2.0,10.0,41.0,41.0,41.0,82.0,130,39.0,3.810394756896815e-05,1907.0,203.0,1.0,0,38.0
3405,603060,HP:0000007,Mutations in KIF1C are responsible for autosomal recessive spastic paraplegia type 58 (SPG58) and spastic ataxia 2 (SPAX2).,1,1.4696048890174924,6921436.320612637,675.79387728288,0.17255182504877434,0.3366302991921953,0.0,0.0,1.0003707823507602,2698.0,-0.6620666800353957,0.020959509962611176,1.0,2.0,177.0,118.0,118.0,118.0,236.0,5160,117.0,1.5011496554636367e-07,76256.0,2698.0,1.0,0,118.0
3406,603060,HP:0010550,Mutations in KIF1C are responsible for autosomal recessive spastic paraplegia type 58 (SPG58) and spastic ataxia 2 (SPAX2).,0,1.323433240859942,515217.5564935064,124.64406779661016,0.19211207026296825,-0.02515542857806724,0.0,0.0,0.9962825278810408,268.0,-0.4580152107380003,0.23042819771444306,1.0,2.0,2.0,112.0,112.0,82.0,224.0,302,110.0,4.3282548476454294e-05,8368.0,270.0,1.0,0,142.0
1807,603060,HP:0001251,Mutations in KIF1C are responsible for autosomal recessive spastic paraplegia type 58 (SPG58) and spastic ataxia 2 (SPAX2).,1,1.4221212649558028,3877701.656144328,394.6759126065837,0.15546375313888974,0.05308513808688087,0.0,0.0,1.0010752688172042,931.0,-0.7308934154339733,0.0939422288439994,1.0,2.0,1.0,118.0,118.0,118.0,236.0,1626,117.0,1.5092152684290285e-06,40669.0,931.0,1.0,0,125.0
1811,603060,HP:0001251,We can now report that progressive ataxia of Charolais cattle results from a homozygous single nucleotide polymorphism in the coding region of the KIF1C gene.,1,1.4221212649558028,3877701.656144328,394.6759126065837,0.15546375313888974,0.05308513808688087,0.0,0.0,1.0010752688172042,931.0,-0.7308934154339733,0.0939422288439994,1.0,2.0,1.0,118.0,118.0,118.0,236.0,1626,117.0,1.5092152684290285e-06,40669.0,931.0,1.0,0,125.0
3419,107269,HP:0002664,"The goal of this study was to isolate cancer stem-like cells marked by high expression of CD44, a putative cancer stem cell marker, from primary oral squamous cell carcinomas and identify distinctive gene expression patterns in these cells.",0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865476,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
3427,107269,HP:0030731,"The goal of this study was to isolate cancer stem-like cells marked by high expression of CD44, a putative cancer stem cell marker, from primary oral squamous cell carcinomas and identify distinctive gene expression patterns in these cells.",0,0.9230769230769232,20.46153846153846,2.0,0.7071067811865479,0.6963635963602195,0.0,0.0,0.9230769230769232,12.0,-0.8461538461538458,0.13186813186813187,1.0,2.0,12.0,2.0,2.0,2.0,4.0,24,0.0,0.006944444444444444,12.0,14.0,0.0,0,1.0
3415,107269,HP:0002664,Seventy resected tumours were dissociated into single cells and stained with antibodies to CD44 as well as CD45 and CD31 (together referred as Lineage/Lin).,0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865476,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
3428,124080,HP:0000822,"During drug discovery efforts targeting inhibition of cytochrome P450 11B2 (CYP11B2)-mediated production of aldosterone as a therapeutic approach for the treatment of chronic kidney disease and hypertension, (S)-6-(5-fluoro-4-(1-hydroxyethyl)pyridin-3-yl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (1) was identified as a potent and selective inhibitor of CYP11B2.",1,1.3522498618021006,609226.2396825396,115.40081822202566,0.21093840851567192,0.16795599548892062,0.0,0.0,1.0024752475247525,405.0,-0.5810986553739678,0.125999266593326,1.0,2.0,6.0,117.0,117.0,49.0,234.0,544,116.0,1.3417595835178253e-05,10308.0,405.0,1.0,0,126.0
734,600734,HP:0003745,"Exome analysis of APA has allowed the identification of recurrent somatic mutations in KCNJ5, CACNA1D, ATP1A1, and ATP2B3 in more than 50 % of sporadic cases.",0,1.2704447632711622,144477.20454545456,59.925925925925924,0.249038468443406,0.058829802181857835,0.0,0.0,0.9956709956709956,230.0,-0.4067635559712982,0.129123749813405,1.0,2.0,20.0,74.0,74.0,2.0,148.0,192,73.0,5.406574394463668e-05,3460.0,232.0,1.0,0,83.0
742,114206,HP:0003745,"Exome analysis of APA has allowed the identification of recurrent somatic mutations in KCNJ5, CACNA1D, ATP1A1, and ATP2B3 in more than 50 % of sporadic cases.",0,1.29046319126453,194690.26666666672,73.8835386338186,0.23299679842736384,0.22671571385613884,0.0,0.0,0.9957805907172996,236.0,-0.31189723174840456,0.1530333652448321,1.0,2.0,14.0,88.0,88.0,2.0,176.0,192,87.0,4.959333465582226e-05,4316.0,238.0,1.0,0,105.0
2988,182310,HP:0003745,"Exome analysis of APA has allowed the identification of recurrent somatic mutations in KCNJ5, CACNA1D, ATP1A1, and ATP2B3 in more than 50 % of sporadic cases.",0,1.290377105554584,93025.12222222224,57.52357606344629,0.2647354198752769,0.015833269023287532,0.0,0.0,0.9940828402366864,168.0,-0.5168293529388095,0.1712495649147233,1.0,2.0,7.0,57.0,57.0,22.0,114.0,192,55.0,0.00010850694444444445,2460.0,170.0,1.0,0,59.0
738,300014,HP:0003745,"Exome analysis of APA has allowed the identification of recurrent somatic mutations in KCNJ5, CACNA1D, ATP1A1, and ATP2B3 in more than 50 % of sporadic cases.",0,1.2718270808578058,87161.9142857143,57.30555155010815,0.2638046929237242,-0.057228530812730015,0.0,0.0,0.9940828402366864,168.0,-0.4786106382749185,0.1706230421162548,1.0,2.0,11.0,62.0,62.0,20.0,124.0,192,60.0,0.00010850694444444445,2451.0,170.0,1.0,0,65.0
3129,116806,HP:0002664,"The CTNNB1 mutations were also identified in cortisol-producing adenomas and adrenal cancer, but their role in APA development and the mechanisms specifying the hormonal production or the malignant phenotype remain unknown.",1,1.3518211230574562,8628385.610725343,244.5227047309904,0.15288895987823498,0.10335671492220867,0.0,0.0,1.0008741258741258,1145.0,-0.4805894159801953,0.09402388005008093,1.0,2.0,4.0,359.0,359.0,79.0,718.0,1542,359.0,1.6778973932186097e-06,61580.0,1145.0,1.0,0,481.0
3429,150370,HP:0003745,"Eleven of the 43 kindreds affected by sporadic disease (26%) carry RPSA mutations, whereas 12 of the 13 multiplex kindreds (92%) carry RPSA mutations.",0,1.3039772727272727,13384.930033691799,36.2929061784897,0.3894705661972469,0.2285015670545511,0.0,0.0,0.991596638655462,118.0,-0.6588729873229273,0.10546218487394958,1.0,2.0,9.0,20.0,20.0,19.0,40.0,192,18.0,0.00010850694444444445,753.0,120.0,1.0,0,20.0
3430,600576,HP:0002884,"GATA4, a transcription factor crucial for early liver development, has been implicated in the pathophysiology of hepatoblastoma, an embryonal tumor of childhood.",0,1.3564713287849253,34643.39002648445,133.16647029119682,0.4000318305248183,0.5140050265796537,0.0,0.0,0.9978768577494692,470.0,-0.5511907354663037,0.019144265716650472,1.0,2.0,143.0,14.0,14.0,14.0,28.0,328,13.0,4.767262256631262e-06,2128.0,472.0,1.0,0,14.0
3434,600576,HP:0002884,"However, the molecular and phenotypic consequences of GATA4 expression in hepatoblastoma are not fully understood.",0,1.3564713287849253,34643.39002648445,133.16647029119682,0.4000318305248183,0.5140050265796537,0.0,0.0,0.9978768577494692,470.0,-0.5511907354663037,0.019144265716650472,1.0,2.0,143.0,14.0,14.0,14.0,28.0,328,13.0,4.767262256631262e-06,2128.0,472.0,1.0,0,14.0
3450,600576,HP:0002884,We surveyed GATA4 expression in 24 hepatoblastomas using RNA in situ hybridization and immunohistochemistry.,0,1.3564713287849253,34643.39002648445,133.16647029119682,0.4000318305248183,0.5140050265796537,0.0,0.0,0.9978768577494692,470.0,-0.5511907354663037,0.019144265716650472,1.0,2.0,143.0,14.0,14.0,14.0,28.0,328,13.0,4.767262256631262e-06,2128.0,472.0,1.0,0,14.0
3442,600576,HP:0002884,"RNA interference was used to inhibit GATA4 in human HUH6 hepatoblastoma cells, and changes in cell migration were measured with wound healing and transwell assays.",0,1.3564713287849253,34643.39002648445,133.16647029119682,0.4000318305248183,0.5140050265796537,0.0,0.0,0.9978768577494692,470.0,-0.5511907354663037,0.019144265716650472,1.0,2.0,143.0,14.0,14.0,14.0,28.0,328,13.0,4.767262256631262e-06,2128.0,472.0,1.0,0,14.0
3446,600576,HP:0002884,We found that GATA4 expression was high in most hepatoblastomas but weak or negligible in normal hepatocytes.,0,1.3564713287849253,34643.39002648445,133.16647029119682,0.4000318305248183,0.5140050265796537,0.0,0.0,0.9978768577494692,470.0,-0.5511907354663037,0.019144265716650472,1.0,2.0,143.0,14.0,14.0,14.0,28.0,328,13.0,4.767262256631262e-06,2128.0,472.0,1.0,0,14.0
3438,600576,HP:0002884,"In conclusion, GATA4 is highly expressed in most hepatoblastomas and correlates with a mesenchymal, migratory phenotype of hepatoblastoma cells",0,1.3564713287849253,34643.39002648445,133.16647029119682,0.4000318305248183,0.5140050265796537,0.0,0.0,0.9978768577494692,470.0,-0.5511907354663037,0.019144265716650472,1.0,2.0,143.0,14.0,14.0,14.0,28.0,328,13.0,4.767262256631262e-06,2128.0,472.0,1.0,0,14.0
3454,139320,HP:0008221,"Lately, ARMC5 was linked to the cyclic AMP signaling pathway, which could be implicated in all of mechanisms of cortisol-secreting by macronodules adrenal hyperplasia and the molecular defects in: G protein aberrant receptors; MC2R; GNAS; PRKAR1A; PDE11A; PDE8B.",1,1.4751399395904343,56147.022416773136,130.33132295719844,0.4322193416252491,0.2499413958311393,0.0,0.0,1.00187617260788,534.0,-0.4477879987651132,0.017630401023111354,1.0,2.0,133.0,20.0,20.0,20.0,40.0,662,20.0,3.770383636535017e-06,2509.0,534.0,1.0,0,20.0
3455,615549,HP:0008221,"Lately, ARMC5 was linked to the cyclic AMP signaling pathway, which could be implicated in all of mechanisms of cortisol-secreting by macronodules adrenal hyperplasia and the molecular defects in: G protein aberrant receptors; MC2R; GNAS; PRKAR1A; PDE11A; PDE8B.",1,1.4093307593307594,26581.365476190473,67.87745098039215,0.3322570223704166,0.07972172733110243,0.0,0.0,1.0082644628099175,122.0,-0.7495271511261925,0.15377320146321638,1.0,2.0,2.0,20.0,20.0,20.0,40.0,70,20.0,9.425959091337543e-05,1135.0,122.0,1.0,0,20.0
3456,188830,HP:0008221,"Lately, ARMC5 was linked to the cyclic AMP signaling pathway, which could be implicated in all of mechanisms of cortisol-secreting by macronodules adrenal hyperplasia and the molecular defects in: G protein aberrant receptors; MC2R; GNAS; PRKAR1A; PDE11A; PDE8B.",1,1.4789163427180272,59091.66980193719,140.11300813008128,0.4526151926375922,0.44048569206063376,0.0,0.0,1.001577287066246,635.0,-0.409047580731526,0.013482699520604087,1.0,2.0,204.0,20.0,20.0,20.0,40.0,578,20.0,2.635351661325688e-06,2714.0,635.0,1.0,0,20.0
3457,604961,HP:0008221,"Lately, ARMC5 was linked to the cyclic AMP signaling pathway, which could be implicated in all of mechanisms of cortisol-secreting by macronodules adrenal hyperplasia and the molecular defects in: G protein aberrant receptors; MC2R; GNAS; PRKAR1A; PDE11A; PDE8B.",1,1.4125980564336729,28397.130555555555,66.90370370370371,0.3422295545952788,0.0006555299619737107,0.0,0.0,1.0078740157480317,128.0,-0.7182139430611232,0.1389025590551181,1.0,2.0,1.0,20.0,20.0,20.0,40.0,60,20.0,8.416799932665601e-05,1129.0,128.0,1.0,0,20.0
3458,603390,HP:0008221,"Lately, ARMC5 was linked to the cyclic AMP signaling pathway, which could be implicated in all of mechanisms of cortisol-secreting by macronodules adrenal hyperplasia and the molecular defects in: G protein aberrant receptors; MC2R; GNAS; PRKAR1A; PDE11A; PDE8B.",1,1.4125980564336729,23599.95238095238,60.8,0.34523818708897097,-0.1189055641746972,0.0,0.0,1.0078740157480317,128.0,-0.7176269202491709,0.12623031496062992,1.0,2.0,12.0,20.0,20.0,20.0,40.0,58,20.0,8.416799932665601e-05,1026.0,128.0,1.0,0,20.0
3459,615549,HP:0003745,Around 50 % of patient*s relatives with PMAH and 30 % of apparently sporadic hypercortisolism carried ARMC5 mutations.,0,1.3140435835351092,170609.13333333333,72.62724458204335,0.24418320442651945,0.1366841493137599,0.0,0.0,0.994949494949495,197.0,-0.3271661160253923,0.1863357189990356,1.0,2.0,3.0,81.0,81.0,2.0,162.0,196,79.0,9.425959091337543e-05,3671.0,199.0,1.0,0,94.0
3460,615549,HP:0003118,Around 50 % of patient*s relatives with PMAH and 30 % of apparently sporadic hypercortisolism carried ARMC5 mutations.,0,1.4308449074074074,17098.356132756133,74.24649859943979,0.3408405085271531,0.14726935155604984,0.0,0.0,1.008695652173913,116.0,-0.8616499187245072,0.13703148425787107,1.0,2.0,4.0,14.0,14.0,14.0,28.0,110,14.0,9.425959091337543e-05,914.0,116.0,1.0,0,24.0
3461,603377,HP:0000007,"Sickle cell disease (SCD) is one of the most common autosomal recessive diseases in humans, occurring at a frequency of 1 in 365 African-American and 1 in 50 sub-Saharan African births.",1,1.4770436129647284,2578104.70740925,516.7772921678695,0.2350292422476057,0.3363471880146636,0.0,0.0,1.0003750937734437,2667.0,-0.597906130190344,0.012233935874294784,1.0,2.0,186.0,85.0,85.0,81.0,170.0,5160,84.0,1.501149655463636e-07,43493.0,2667.0,1.0,0,77.0
3462,602054,HP:0001250,We report the case of an infant with a novel heterozygous TBX1 mutation who experienced hypocalcemic seizures.,1,1.3680574879419092,32668201.75509442,388.1317302052785,0.1306817056011416,0.08646644117834815,0.0,0.0,1.0004764173415912,2100.0,-0.4941613846907117,0.07149118627918058,1.0,2.0,6.0,533.0,533.0,140.0,1066.0,3110,533.0,4.15696534878394e-07,157563.0,2100.0,1.0,0,772.0
1724,131550,HP:0002664,"MED1 mediates induction of cell proliferation and migration and the genes associated with it (JUN, FOS, EGFR, VEGF, MMP1, and ERBB4) in breast cancer, which is abrogated when used together with miR-191-inhibition.",1,1.4135577242017423,2148700.9990685256,249.19306594831886,0.18304335818682368,0.03828770954761315,0.0,0.0,1.0011111111111108,901.0,-0.6842090355364789,0.06837094586262177,1.0,2.0,6.0,124.0,124.0,94.0,248.0,1542,123.0,1.6778973932186097e-06,27721.0,901.0,1.0,0,105.0
3463,600543,HP:0002664,"MED1 mediates induction of cell proliferation and migration and the genes associated with it (JUN, FOS, EGFR, VEGF, MMP1, and ERBB4) in breast cancer, which is abrogated when used together with miR-191-inhibition.",0,1.4255613593324041,777540.327635136,201.2754112908731,0.2276485033758965,0.004699987120165061,0.0,0.0,0.9988207547169812,847.0,-0.6761572088469461,0.040649932217703404,1.0,2.0,19.0,77.0,77.0,52.0,154.0,1544,75.0,1.67789739321861e-06,14633.0,849.0,1.0,0,60.0
3464,610812,HP:0000238,"Analysis of Hydin-disrupted spermatozoa in mice is difficult as Hydin-mutant mice (hy3) die within 3 weeks, before sexual maturation, due to hydrocephaly.",0,1.350990846789166,2067208.185103785,201.91616766467064,0.16072436649083602,-0.007601270275992888,0.0,0.0,1.002,501.0,-0.6164938854836458,0.1794810379241517,1.0,2.0,1.0,166.0,166.0,91.0,332.0,668,165.0,8.910670527957227e-06,22480.0,501.0,1.0,0,157.0
2375,600185,HP:0002664,"miR-142-3p overexpression resulted in a strong decline in breast cancer stem cell characteristics with a decrease in CD44, CD133, ALDH1, Bod1, BRCA2, and mammosphere formation as well as reduced survival after irradiation.",1,1.3416355462103815,14500864.778067766,286.27804058963136,0.14198849810087022,0.09065436525648868,0.0,0.0,1.0007987220447283,1253.0,-0.3695548622099266,0.10824627921741813,1.0,2.0,4.0,477.0,477.0,34.0,954.0,1542,476.0,1.67789739321861e-06,84906.0,1253.0,1.0,0,615.0
3465,605283,HP:0000717,"We phenotyped a large population of typical individuals for schizophrenia-spectrum and autism-spectrum traits, and genotyped them for the single-nucleotide polymorphism rs850807, which is putatively functional and linked with MAGEL2 and NDN Genetic variation in rs850807 was strongly and exclusively associated with the ideas of reference subscale of the schizophrenia spectrum, which is best typified as paranoia.",1,1.3714550422844347,2057208.275427205,186.91110192925026,0.1748147903285609,0.01712894280427,0.0,0.0,1.0017361111111112,577.0,-0.5352334725440059,0.12266512613133065,1.0,2.0,10.0,146.0,146.0,146.0,292.0,292,146.0,5.358367626886145e-06,20384.0,577.0,1.0,0,167.0
3466,608226,HP:0100753,"One important line of evidence comes from genetic studies, which have repeatedly detected an association between the neuronal isoform of nitric oxide synthase (nNOS or NOS1) and schizophrenia.",0,1.2294321220701592,8489.436507936507,18.22299651567944,0.4301013435495769,0.1997475790999783,0.0,0.0,0.9897959183673468,97.0,-0.6010487273399954,0.09915481344052772,1.0,2.0,11.0,23.0,23.0,3.0,46.0,118,21.0,0.0002972651605231866,481.0,99.0,1.0,0,21.0
3485,614095,HP:0002664,"PEPCK-M (PCK2), the mitochondrial isoform of phosphoenolpyruvate carboxykinase (PEPCK), has been shown by us and others to be functionally expressed and to mediate gluconeogenesis, the reverse pathway of glycolysis, in different cancer cells.",0,1.4421031060883518,160168.7588703694,239.8708171206225,0.30580860358253903,0.01958354243807805,0.0,0.0,0.9987452948557088,796.0,-0.7577481288878439,0.020616157709203997,1.0,2.0,48.0,25.0,25.0,24.0,50.0,1544,23.0,1.6778973932186097e-06,6556.0,798.0,1.0,0,23.0
3491,614095,HP:0002664,Serine and ribose synthesis have been identified as downstream pathways fed by PEPCK in cancer cells.,0,1.4421031060883518,160168.7588703694,239.8708171206225,0.30580860358253903,0.01958354243807805,0.0,0.0,0.9987452948557088,796.0,-0.7577481288878439,0.020616157709203997,1.0,2.0,48.0,25.0,25.0,24.0,50.0,1544,23.0,1.6778973932186097e-06,6556.0,798.0,1.0,0,23.0
3473,614095,HP:0002664,"Here, we report that PEPCK-M-dependent glycerol phosphate formation from noncarbohydrate precursors (glyceroneogenesis) occurs in starved lung cancer cells and supports de novo glycerophospholipid synthesis.",0,1.4421031060883518,160168.7588703694,239.8708171206225,0.30580860358253903,0.01958354243807805,0.0,0.0,0.9987452948557088,796.0,-0.7577481288878439,0.020616157709203997,1.0,2.0,48.0,25.0,25.0,24.0,50.0,1544,23.0,1.6778973932186097e-06,6556.0,798.0,1.0,0,23.0
3497,614095,HP:0002664,"This pathway is required to maintain levels of GPL, especially phosphatidylethanolamine (PE), as shown by stable shRNA-mediated silencing of PEPCK-M in H23 lung cancer cells.",0,1.4421031060883518,160168.7588703694,239.8708171206225,0.30580860358253903,0.01958354243807805,0.0,0.0,0.9987452948557088,796.0,-0.7577481288878439,0.020616157709203997,1.0,2.0,48.0,25.0,25.0,24.0,50.0,1544,23.0,1.6778973932186097e-06,6556.0,798.0,1.0,0,23.0
3467,614095,HP:0002664,"Furthermore, PEPCK-M silencing abrogated cancer growth in a lung cancer cell xenograft model.",0,1.4421031060883518,160168.7588703694,239.8708171206225,0.30580860358253903,0.01958354243807805,0.0,0.0,0.9987452948557088,796.0,-0.7577481288878439,0.020616157709203997,1.0,2.0,48.0,25.0,25.0,24.0,50.0,1544,23.0,1.6778973932186097e-06,6556.0,798.0,1.0,0,23.0
3479,614095,HP:0002664,"In conclusion, glycerol phosphate formation for de novo GPL synthesis via glyceroneogenesis is a newly characterized anabolic pathway in cancer cells mediated by PEPCK-M under conditions of severe nutrient deprivation",0,1.4421031060883518,160168.7588703694,239.8708171206225,0.30580860358253903,0.01958354243807805,0.0,0.0,0.9987452948557088,796.0,-0.7577481288878439,0.020616157709203997,1.0,2.0,48.0,25.0,25.0,24.0,50.0,1544,23.0,1.6778973932186097e-06,6556.0,798.0,1.0,0,23.0
3503,601199,HP:0001658,"In addition, several studies have demonstrated that CaSR dysfunction may be associated with some fatal vascular diseases, such as pulmonary arterial hypertension, primary hypertension, diabetes, acute myocardial infarction and vascular calcification.",0,1.3218357094879047,158819.22171717172,82.6642259414226,0.27640497789055785,0.3227397282487405,0.0,0.0,0.9965753424657532,291.0,-0.5429781992094416,0.08733461124877273,1.0,2.0,39.0,53.0,53.0,53.0,106.0,144,52.0,1.7361111111111114e-05,3736.0,293.0,1.0,0,56.0
3504,601199,HP:0004934,"In addition, several studies have demonstrated that CaSR dysfunction may be associated with some fatal vascular diseases, such as pulmonary arterial hypertension, primary hypertension, diabetes, acute myocardial infarction and vascular calcification.",0,1.32775641025641,73243.98670995673,79.52705237339491,0.30816630625345565,0.30074822718108474,0.0,0.0,0.9962825278810408,268.0,-0.5926580338786863,0.06259121575106705,1.0,2.0,57.0,30.0,30.0,30.0,60.0,160,29.0,1.736111111111111e-05,2273.0,270.0,1.0,0,38.0
1538,600900,HP:0002664,"These compounds showed excellent anti-tumor activity against A549, Eca-109, HeLa, HepG2 and SGC-7901 cell lines.",0,1.400561161703175,941457.6872488172,204.979171435111,0.21034037305605727,0.11542276431943975,0.0,0.0,0.998833138856476,856.0,-0.7101797965956365,0.04459639932218695,1.0,2.0,41.0,78.0,78.0,53.0,156.0,1544,76.0,1.6778973932186103e-06,16396.0,858.0,1.0,0,67.0
2606,164730,HP:0002664,Compounds exhibit anti-cancer activity via apoptosis and autophagy through inhibition of PI3K/Akt signaling pathway in HeLa cells,1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
3507,606389,HP:0012864,"Some genes, such as GSTM1, DNMT3L, and CYP1A1, have been shown to be potentially associated with oligospermia; some, such as CATSPER1, CRISP2, SEPT4, TCTE3, TEKT4, and DNAH1, with asthenospermia; and still others, such as DPY19L2 and AURKC, with teratospermia.",0,1.2881734853565838,3178.8,26.12980769230769,0.38731006687047137,0.3853193341227519,0.0,0.0,0.9767441860465116,42.0,-0.6234377021493615,0.2970401691331924,1.0,2.0,1.0,17.0,17.0,17.0,34.0,54,15.0,0.0012755102040816323,281.0,44.0,1.0,0,18.0
3508,603332,HP:0012864,"Some genes, such as GSTM1, DNMT3L, and CYP1A1, have been shown to be potentially associated with oligospermia; some, such as CATSPER1, CRISP2, SEPT4, TCTE3, TEKT4, and DNAH1, with asthenospermia; and still others, such as DPY19L2 and AURKC, with teratospermia.",0,1.4233390937019967,11311.85119047619,33.156498673740046,0.531475517719701,0.5927175154876957,0.0,0.0,1.0050251256281406,200.0,-0.4603116851682628,0.037688442211055266,1.0,2.0,14.0,26.0,26.0,6.0,52.0,312,26.0,3.2653061224489787e-05,750.0,200.0,1.0,0,24.0
3509,613893,HP:0012864,"Some genes, such as GSTM1, DNMT3L, and CYP1A1, have been shown to be potentially associated with oligospermia; some, such as CATSPER1, CRISP2, SEPT4, TCTE3, TEKT4, and DNAH1, with asthenospermia; and still others, such as DPY19L2 and AURKC, with teratospermia.",1,1.3787878787878791,1432.1818181818182,27.138461538461538,0.413853977865159,0.4128400885920287,0.0,0.0,1.0285714285714285,36.0,-0.8826779748136725,0.3111111111111111,1.0,2.0,1.0,10.0,10.0,10.0,20.0,52,9.0,0.0013717421124828533,196.0,36.0,1.0,0,9.0
3510,603495,HP:0012864,"Some genes, such as GSTM1, DNMT3L, and CYP1A1, have been shown to be potentially associated with oligospermia; some, such as CATSPER1, CRISP2, SEPT4, TCTE3, TEKT4, and DNAH1, with asthenospermia; and still others, such as DPY19L2 and AURKC, with teratospermia.",0,1.2927387078330477,2274.55,27.87412587412588,0.3847512816045737,0.3832326049452928,0.0,0.0,0.9736842105263156,37.0,-0.8048646985243209,0.319838056680162,1.0,2.0,1.0,12.0,12.0,12.0,24.0,54,10.0,0.0012755102040816323,237.0,39.0,1.0,0,11.0
3511,606389,HP:0000798,"Some genes, such as GSTM1, DNMT3L, and CYP1A1, have been shown to be potentially associated with oligospermia; some, such as CATSPER1, CRISP2, SEPT4, TCTE3, TEKT4, and DNAH1, with asthenospermia; and still others, such as DPY19L2 and AURKC, with teratospermia.",1,1.3512544802867383,2884.4666666666667,28.4375,0.38903331642442507,0.3887625287274021,0.0,0.0,1.0256410256410255,40.0,-0.6728472159926029,0.35,1.0,2.0,1.0,16.0,16.0,16.0,32.0,48,15.0,0.0016,273.0,40.0,1.0,0,19.0
3512,603332,HP:0000798,"Some genes, such as GSTM1, DNMT3L, and CYP1A1, have been shown to be potentially associated with oligospermia; some, such as CATSPER1, CRISP2, SEPT4, TCTE3, TEKT4, and DNAH1, with asthenospermia; and still others, such as DPY19L2 and AURKC, with teratospermia.",0,1.2913974096796184,14388.380867553498,32.67672413793103,0.4719980312115878,-0.0515073521865693,0.0,0.0,0.9949748743718592,198.0,-0.43805889104046136,0.042462311557788936,1.0,2.0,57.0,25.0,25.0,25.0,50.0,196,24.0,3.2653061224489787e-05,845.0,200.0,1.0,0,24.0
3513,613893,HP:0000798,"Some genes, such as GSTM1, DNMT3L, and CYP1A1, have been shown to be potentially associated with oligospermia; some, such as CATSPER1, CRISP2, SEPT4, TCTE3, TEKT4, and DNAH1, with asthenospermia; and still others, such as DPY19L2 and AURKC, with teratospermia.",0,1.2600450016072002,1234.9555555555555,17.725,0.4616747482166095,0.4622680843102257,0.0,0.0,0.9714285714285714,34.0,-0.7368670120606633,0.2301587301587301,1.0,2.0,2.0,10.0,10.0,10.0,20.0,50,8.0,0.0014792899408284025,145.0,36.0,1.0,0,12.0
3514,603495,HP:0000798,"Some genes, such as GSTM1, DNMT3L, and CYP1A1, have been shown to be potentially associated with oligospermia; some, such as CATSPER1, CRISP2, SEPT4, TCTE3, TEKT4, and DNAH1, with asthenospermia; and still others, such as DPY19L2 and AURKC, with teratospermia.",0,1.2865275142314991,2404.916666666667,29.310606060606066,0.3694320698207706,0.3638676158173911,0.0,0.0,0.972222222222222,35.0,-0.865908724034355,0.36186186186186187,1.0,2.0,1.0,12.0,12.0,12.0,24.0,50,10.0,0.0014792899408284025,241.0,37.0,1.0,0,11.0
3515,604687,HP:0001513,"Anthocyanin consumption is linked to benefits in obesity-related metabolic alterations and non-alcoholic fatty liver disease (NAFLD), though the functional role of delphinidin (Dp) is yet to be established.",0,0.997175141242938,702.0169491525422,2.0,0.7071067811865474,0.7979477569470517,0.0,0.0,0.9971751412429378,353.0,-0.9943502824858748,0.005617888119678523,1.0,2.0,353.0,2.0,2.0,2.0,4.0,706,0.0,8.025102520684701e-06,353.0,355.0,0.0,0,1.0
3516,604687,HP:0003074,"Dp did not affect body weight, energy intake, hyperglycemia, insulin resistance, or histological abnormalities elicited by the HFHC diet.",0,0.9761904761904762,78.14285714285714,2.0,0.7071067811865475,0.6574545499066383,0.0,0.0,0.9761904761904762,41.0,-0.952380952380952,0.04540420819490587,1.0,2.0,41.0,2.0,2.0,2.0,4.0,82,0.0,0.0005948839976204638,41.0,43.0,0.0,0,1.0
1567,610966,HP:0001513,Fat mass and obesity-associated protein (FTO) single-nucleotide polymorphisms (SNPs) have been linked to increased body mass and obesity in humans by genome-wide association studies (GWAS) since 2007.,1,1.3551840203056889,2205350.7880762005,190.34733201581028,0.16843673176063007,0.09191852693852773,0.0,0.0,1.001953125,513.0,-0.5941046245150907,0.16011817738791426,1.0,2.0,3.0,159.0,159.0,128.0,318.0,704,158.0,8.025102520684701e-06,21028.0,513.0,1.0,0,202.0
1555,610966,HP:0001513,"Although some recent studies suggest that the obesity-related SNPs in FTO influence obesity susceptibility likely through altering the expression of the adjacent genes such as IRX3 and RPGRIP1L, rather than FTO itself, a solid link between the SNP risk genotype and the increased FTO expression in both human blood cells and fibroblasts has been reported.",1,1.3551840203056889,2205350.7880762005,190.34733201581028,0.16843673176063007,0.09191852693852773,0.0,0.0,1.001953125,513.0,-0.5941046245150907,0.16011817738791426,1.0,2.0,3.0,159.0,159.0,128.0,318.0,704,158.0,8.025102520684701e-06,21028.0,513.0,1.0,0,202.0
1603,610937,HP:0001513,"Although some recent studies suggest that the obesity-related SNPs in FTO influence obesity susceptibility likely through altering the expression of the adjacent genes such as IRX3 and RPGRIP1L, rather than FTO itself, a solid link between the SNP risk genotype and the increased FTO expression in both human blood cells and fibroblasts has been reported.",0,1.3231238044210782,4157055.6676368318,186.81292997543,0.16112279451678652,0.0792281031068982,0.0,0.0,0.9986168741355465,722.0,-0.3510607481652902,0.1301360965284305,1.0,2.0,7.0,289.0,289.0,3.0,578.0,706,287.0,7.265277061340734e-06,34060.0,724.0,1.0,0,350.0
1561,610966,HP:0001513,Epidemiology studies also showed a strong association of FTO SNPs and overweight/obesity with increased risk of various types of cancers.,1,1.3551840203056889,2205350.7880762005,190.34733201581028,0.16843673176063007,0.09191852693852773,0.0,0.0,1.001953125,513.0,-0.5941046245150907,0.16011817738791426,1.0,2.0,3.0,159.0,159.0,128.0,318.0,704,158.0,8.025102520684701e-06,21028.0,513.0,1.0,0,202.0
1597,610966,HP:0001513,"This mini review discusses the roles and underlying molecular mechanisms of FTO in both obesity and cancers, and also summarizes recent advances in the development of FTO inhibitors",1,1.3551840203056889,2205350.7880762005,190.34733201581028,0.16843673176063007,0.09191852693852773,0.0,0.0,1.001953125,513.0,-0.5941046245150907,0.16011817738791426,1.0,2.0,3.0,159.0,159.0,128.0,318.0,704,158.0,8.025102520684701e-06,21028.0,513.0,1.0,0,202.0
3520,164760,HP:0002664,"We found that the human colorectal cancer cell line, HCT-116, displayed reduced expression of Raf1-tr, and reintroduction of Raf1-tr sensitized the cells to bleomycin-induced apoptosis.",1,1.3533679427936751,11525277.26045066,276.92335060300536,0.1430359559485257,0.08758832674956335,0.0,0.0,1.0008833922261484,1133.0,-0.4782514375005684,0.1063766416437177,1.0,2.0,3.0,357.0,357.0,105.0,714.0,1542,356.0,1.67789739321861e-06,68217.0,1133.0,1.0,0,511.0
3518,164760,HP:0002664,"Furthermore, we identified differential Raf1-tr expression in breast cancer cell lines and showed that breast cancer cells with increased Raf1-tr expression become sensitized to bleomycin-induced apoptosis.",1,1.3533679427936751,11525277.26045066,276.92335060300536,0.1430359559485257,0.08758832674956335,0.0,0.0,1.0008833922261484,1133.0,-0.4782514375005684,0.1063766416437177,1.0,2.0,3.0,357.0,357.0,105.0,714.0,1542,356.0,1.67789739321861e-06,68217.0,1133.0,1.0,0,511.0
97,191170,HP:0002664,"The tumour suppressor p53 negatively controls cell cycle progression in response to perturbed ribosome biogenesis in mammalian cells, thus coordinating growth with proliferation.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
203,616404,HP:0002664,"We studied the effect of specific inhibition of rRNA synthesis on cell cycle progression in human cancer cell lines using the small-interfering RNA procedure to silence the POLR1A gene, which encodes the catalytic subunit of RNA polymerase I.",0,1.4035709491839143,3154603.398384072,304.5643074981597,0.16209639772125378,0.21646108517810025,0.0,0.0,0.9988674971687428,882.0,-0.7019512329253574,0.07748164166790507,1.0,2.0,24.0,112.0,112.0,109.0,224.0,1544,110.0,1.677897393218609e-06,30240.0,884.0,1.0,0,133.0
145,191170,HP:0002664,"These results demonstrated the existence of a p53-independent mechanism that links cell growth to cell proliferation in mammalian cells, and suggested that selective targeting of the RNA polymerase I transcription machinery might be advisable to hinder proliferation of p53-deficient cancer cells",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
3522,606557,HP:0002664,"The gene expression levels of Ki-67, BCL11A, FOXC1, HOXD13, PCDHGB7 and her-2 were used as an auxiliary diagnostic index for patients with breast cancer in the early stage.",0,1.4170975762290454,1805113.5738058463,308.26618028534375,0.17583125808347388,0.2507873969832357,0.0,0.0,0.9988262910798122,851.0,-0.7328606410877191,0.06342981688489673,1.0,2.0,29.0,81.0,81.0,81.0,162.0,1544,79.0,1.67789739321861e-06,23049.0,853.0,1.0,0,84.0
3523,601090,HP:0002664,"The gene expression levels of Ki-67, BCL11A, FOXC1, HOXD13, PCDHGB7 and her-2 were used as an auxiliary diagnostic index for patients with breast cancer in the early stage.",0,1.3811197215452533,4216737.962053958,254.1173947647683,0.16053455294406574,0.12268113288655892,0.0,0.0,0.9989451476793249,947.0,-0.6311658660992022,0.08241631208511736,1.0,2.0,13.0,168.0,168.0,143.0,336.0,1544,166.0,1.6778973932186106e-06,37073.0,949.0,1.0,0,166.0
3524,142989,HP:0002664,"The gene expression levels of Ki-67, BCL11A, FOXC1, HOXD13, PCDHGB7 and her-2 were used as an auxiliary diagnostic index for patients with breast cancer in the early stage.",1,1.3532352543159278,6974827.753049483,198.35771939415366,0.15847691524067548,0.024253241866996133,0.0,0.0,1.000882612533098,1134.0,-0.5165784999787962,0.07620510856756811,1.0,2.0,22.0,305.0,305.0,61.0,610.0,1542,304.0,1.6778973932186097e-06,48955.0,1134.0,1.0,0,388.0
3525,600960,HP:0000822,"The present study focuses on replicating the analyses completed by Ji et al to identify effects of rare variants in the population-based Atherosclerosis Risk in Communities (ARIC) study.We attempted to replicate the findings by Ji et al by applying their criteria to identify putative loss-of-function variants with allele frequency &lt;0.001 and complete conservation across a set of orthologs, to exome sequencing data from 7444 European ancestry participants of the ARIC study.Although we failed to replicate the previous findings when applying their methods to the ARIC study data, we observed a similar effect when we restricted analyses to the subset of variants they observed.These results simultaneously support the utility of exome sequencing data for studying extremely rare coding variants in hypertension and underscore the need for improved filtering methods for identifying functional variants in human sequences",0,1.3073046760912117,772375.410064935,99.2410372432997,0.2110501285566736,0.08319550175646896,0.0,0.0,0.9977375565610859,441.0,-0.5183387664629852,0.10803550452999396,1.0,2.0,14.0,140.0,140.0,23.0,280.0,546,138.0,1.3417595835178255e-05,10577.0,443.0,1.0,0,157.0
3527,603381,HP:0002664,"Previously, we demonstrated that a unique category of cancer antigens is selectively presented by tumor cells deficient for the peptide transporter TAP, enabling a specific attack of such tumors without causing immunopathology in mouse models.",0,1.3164151943643017,11815000.236848395,219.29180187455643,0.14503776004066654,0.14961040405428552,0.0,0.0,0.9992319508448542,1301.0,-0.4442300357382053,0.0819920471840359,1.0,2.0,29.0,445.0,445.0,20.0,890.0,1544,443.0,1.677897393218609e-06,69550.0,1303.0,1.0,0,541.0
3528,606989,HP:0002664,"In wild type (WT) mice, we found that ginsenoside Rg3 treatment significantly mitigated pathological damages and reduced myeloperoxidase (MPO) activity as well as the production of pro-inflammatory cytokines tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and interleukin-6 (IL-6); furthermore, the production of anti-inflammatory mediators interleukin-10 (IL-10) and transforming growth factor-b (TGF-b), polarization of M2 macrophages and expression levels of the phosphorylation of phosphatidylinositol 3-hydroxy kinase (PI3K), protein kinase B (PKB, also known as AKT), mammalian target of rapamycin (mTOR) and Mer receptor tyrosine kinase (MerTK) were promoted.",0,1.458702432938241,212186.42112648414,232.1074092088197,0.27986334646349315,-0.0014287629673409158,0.0,0.0,0.9987562189054726,803.0,-0.7978419023669664,0.024328667222891752,1.0,2.0,14.0,32.0,32.0,25.0,64.0,1546,30.0,1.67789739321861e-06,7873.0,805.0,1.0,0,24.0
300,601231,HP:0002664,"In wild type (WT) mice, we found that ginsenoside Rg3 treatment significantly mitigated pathological damages and reduced myeloperoxidase (MPO) activity as well as the production of pro-inflammatory cytokines tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and interleukin-6 (IL-6); furthermore, the production of anti-inflammatory mediators interleukin-10 (IL-10) and transforming growth factor-b (TGF-b), polarization of M2 macrophages and expression levels of the phosphorylation of phosphatidylinositol 3-hydroxy kinase (PI3K), protein kinase B (PKB, also known as AKT), mammalian target of rapamycin (mTOR) and Mer receptor tyrosine kinase (MerTK) were promoted.",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
3529,604705,HP:0002664,"In wild type (WT) mice, we found that ginsenoside Rg3 treatment significantly mitigated pathological damages and reduced myeloperoxidase (MPO) activity as well as the production of pro-inflammatory cytokines tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and interleukin-6 (IL-6); furthermore, the production of anti-inflammatory mediators interleukin-10 (IL-10) and transforming growth factor-b (TGF-b), polarization of M2 macrophages and expression levels of the phosphorylation of phosphatidylinositol 3-hydroxy kinase (PI3K), protein kinase B (PKB, also known as AKT), mammalian target of rapamycin (mTOR) and Mer receptor tyrosine kinase (MerTK) were promoted.",0,1.3949917597509611,2247925.463033656,245.75110355426216,0.18385716949408748,0.0700650544113266,0.0,0.0,0.9988776655443324,890.0,-0.6511105848513898,0.06547286517391153,1.0,2.0,30.0,119.0,119.0,107.0,238.0,1544,117.0,1.67789739321861e-06,26018.0,892.0,1.0,0,128.0
784,171834,HP:0002664,"In wild type (WT) mice, we found that ginsenoside Rg3 treatment significantly mitigated pathological damages and reduced myeloperoxidase (MPO) activity as well as the production of pro-inflammatory cytokines tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and interleukin-6 (IL-6); furthermore, the production of anti-inflammatory mediators interleukin-10 (IL-10) and transforming growth factor-b (TGF-b), polarization of M2 macrophages and expression levels of the phosphorylation of phosphatidylinositol 3-hydroxy kinase (PI3K), protein kinase B (PKB, also known as AKT), mammalian target of rapamycin (mTOR) and Mer receptor tyrosine kinase (MerTK) were promoted.",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
1862,191160,HP:0002664,We studied the expression of TMEM9 and its effect on cytokine secretion in tumor necrosis factor-alpha (TNF-a)-induced LX-2 cells.,0,1.4602670579691517,200974.08525960872,239.91050583657588,0.2850613192309647,0.15408425189867206,0.0,0.0,0.9987531172069826,801.0,-0.7836891500894245,0.02382275941528495,1.0,2.0,14.0,31.0,31.0,25.0,62.0,1544,29.0,1.6778973932186097e-06,7671.0,803.0,1.0,0,23.0
3530,606808,HP:0000365,Myo3a is expressed in cochlear hair cells and retinal cells and is responsible for human recessive hereditary nonsyndromic deafness (DFNB30).,1,1.4936783660063004,112916.09692890749,767.3726758286175,0.29707736493015124,-0.05200268712080945,0.0,0.0,1.000801282051282,1249.0,-0.9087217991893984,0.011701669027529716,1.0,2.0,1.0,12.0,12.0,12.0,24.0,2474,11.0,6.524672396198986e-07,9120.0,1249.0,1.0,0,11.0
3536,606808,HP:0000365,"To investigate the mechanism of DFNB30-type deafness, we established a mouse model of Myo3a kinase domain Y137C mutation by using CRISPR/Cas9 system.",1,1.4936783660063004,112916.09692890749,767.3726758286175,0.29707736493015124,-0.05200268712080945,0.0,0.0,1.000801282051282,1249.0,-0.9087217991893984,0.011701669027529716,1.0,2.0,1.0,12.0,12.0,12.0,24.0,2474,11.0,6.524672396198986e-07,9120.0,1249.0,1.0,0,11.0
3533,606808,HP:0000365,This mouse line is an excellent model for studying DFNB30-type deafness in humans,1,1.4936783660063004,112916.09692890749,767.3726758286175,0.29707736493015124,-0.05200268712080945,0.0,0.0,1.000801282051282,1249.0,-0.9087217991893984,0.011701669027529716,1.0,2.0,1.0,12.0,12.0,12.0,24.0,2474,11.0,6.524672396198986e-07,9120.0,1249.0,1.0,0,11.0
3539,142976,HP:0000968,Pure hair and nail ectodermal dysplasia 9 (ECTD-9) is an autosomal recessive genetic disease caused by mutation of HOXC13 and is characterized by hypotrichosis and nail dystrophy in humans.,1,1.3414634146341464,6892.184523809524,37.642857142857146,0.3335002886257088,0.28430669090753685,0.0,0.0,1.018181818181818,56.0,-0.3633998399272649,0.3422077922077922,1.0,2.0,2.0,24.0,24.0,2.0,48.0,56,23.0,0.0011890606420927464,527.0,56.0,1.0,0,31.0
3540,142976,HP:0000007,Pure hair and nail ectodermal dysplasia 9 (ECTD-9) is an autosomal recessive genetic disease caused by mutation of HOXC13 and is characterized by hypotrichosis and nail dystrophy in humans.,1,1.4924490063048663,501284.8837275211,604.9231450719823,0.3170000854460593,0.6331161925868176,0.0,0.0,1.0003835826620635,2608.0,-0.6315639048286911,0.0049289195441249494,1.0,2.0,624.0,27.0,27.0,27.0,54.0,5160,26.0,1.5011496554636367e-07,16756.0,2608.0,1.0,0,25.0
3541,607212,HP:0000007,"Studies in humans with autosomal recessive CARD9 deficiency have indicated a highly specific role for this molecule in the activation of antifungal immune responses in the central nervous system, the oral mucosa, and the skin.",1,1.4823317586162081,1091371.502461405,376.1397463002114,0.31025188570053264,0.4002684270403496,0.0,0.0,1.0003780718336486,2646.0,-0.5462330855026987,0.006917314289715046,1.0,2.0,180.0,63.0,63.0,60.0,126.0,5160,62.0,1.5011496554636372e-07,24206.0,2646.0,1.0,0,57.0
3542,607212,HP:0002664,"Moreover, CARD9-dependent functions have recently been indicated to modulate the development of autoimmunity, inflammatory bowel diseases, and cancer.",0,1.414178392171886,607908.1148750954,185.25309515387337,0.251484280038842,0.2055722242403008,0.0,0.0,0.9988066825775656,837.0,-0.6402015314162339,0.034072839298972236,1.0,2.0,41.0,63.0,63.0,53.0,126.0,1544,61.0,1.6778973932186097e-06,11978.0,839.0,1.0,0,55.0
3543,601330,HP:0002664,"Because of these wide-ranging roles, dysregulation of the GUCY2C-cGMP signaling axis has been implicated in the pathogenesis of bowel transit disorders, inflammatory bowel disease, and colorectal cancer.",0,1.4497909879570994,165070.97080367256,178.2069886320287,0.31430535488565986,0.10599174217498768,0.0,0.0,0.998759305210918,805.0,-0.7253110912867875,0.02011862702593006,1.0,2.0,18.0,32.0,32.0,24.0,64.0,1544,30.0,1.6778973932186097e-06,6543.0,807.0,1.0,0,24.0
3549,601330,HP:0002664,"In colorectal tumors, endogenous GUCY2C ligand expression is lost by a yet undefined mechanism conserved in mice and humans.",0,1.4497909879570994,165070.97080367256,178.2069886320287,0.31430535488565986,0.10599174217498768,0.0,0.0,0.998759305210918,805.0,-0.7253110912867875,0.02011862702593006,1.0,2.0,18.0,32.0,32.0,24.0,64.0,1544,30.0,1.6778973932186097e-06,6543.0,807.0,1.0,0,24.0
3546,601330,HP:0002664,"Further, reconstitution of GUCY2C signaling through genetic or oral ligand replacement opposes tumorigenesis in mice.",0,1.4497909879570994,165070.97080367256,178.2069886320287,0.31430535488565986,0.10599174217498768,0.0,0.0,0.998759305210918,805.0,-0.7253110912867875,0.02011862702593006,1.0,2.0,18.0,32.0,32.0,24.0,64.0,1544,30.0,1.6778973932186097e-06,6543.0,807.0,1.0,0,24.0
3552,601330,HP:0002664,"Taken together, these findings suggest an intriguing hypothesis that colorectal cancer arises in a microenvironment of functional GUCY2C inactivation, which can be repaired by oral ligand replacement.",0,1.4497909879570994,165070.97080367256,178.2069886320287,0.31430535488565986,0.10599174217498768,0.0,0.0,0.998759305210918,805.0,-0.7253110912867875,0.02011862702593006,1.0,2.0,18.0,32.0,32.0,24.0,64.0,1544,30.0,1.6778973932186097e-06,6543.0,807.0,1.0,0,24.0
3555,300160,HP:0002664,"This review discusses recurrent aberrations in NKTCL detected by NGS, which can be categorized into three main groups, specifically, tumor suppressors (TP53, DDX3X, and MGA), the JAK/STAT cascade, and epigenetic modifiers (KMT2D, BCOR, ARID1A, and EP300).",0,1.371745313669174,3921773.858026288,297.03749557835164,0.16070690493093148,0.3505636557386352,0.0,0.0,0.9988938053097344,903.0,-0.6622374253985246,0.08349630860998386,1.0,2.0,60.0,132.0,132.0,132.0,264.0,1544,130.0,1.67789739321861e-06,34155.0,905.0,1.0,0,129.0
3556,602113,HP:0002664,"This review discusses recurrent aberrations in NKTCL detected by NGS, which can be categorized into three main groups, specifically, tumor suppressors (TP53, DDX3X, and MGA), the JAK/STAT cascade, and epigenetic modifiers (KMT2D, BCOR, ARID1A, and EP300).",0,1.3491255114017005,10777278.22792844,282.1170597260447,0.13996599872040558,0.07257354418709352,0.0,0.0,0.999090909090909,1099.0,-0.5271714774847318,0.10825860787713648,1.0,2.0,9.0,325.0,325.0,144.0,650.0,1544,323.0,1.67789739321861e-06,65556.0,1101.0,1.0,0,460.0
3557,300485,HP:0002664,"This review discusses recurrent aberrations in NKTCL detected by NGS, which can be categorized into three main groups, specifically, tumor suppressors (TP53, DDX3X, and MGA), the JAK/STAT cascade, and epigenetic modifiers (KMT2D, BCOR, ARID1A, and EP300).",0,1.319029944534745,14292560.41171051,257.66888076615703,0.14203425069681447,0.10084419933777866,0.0,0.0,0.9992679355783308,1365.0,-0.3336912635374659,0.09333687494711676,1.0,2.0,24.0,553.0,553.0,8.0,1106.0,1544,551.0,1.6778973932186103e-06,87145.0,1367.0,1.0,0,679.0
1124,603024,HP:0002664,"This review discusses recurrent aberrations in NKTCL detected by NGS, which can be categorized into three main groups, specifically, tumor suppressors (TP53, DDX3X, and MGA), the JAK/STAT cascade, and epigenetic modifiers (KMT2D, BCOR, ARID1A, and EP300).",0,1.3546281035100065,9858656.371040234,272.6693282973591,0.1422430853524375,0.011701026400070123,0.0,0.0,0.999073215940686,1078.0,-0.5409422080924086,0.10384958637970686,1.0,2.0,7.0,296.0,296.0,138.0,592.0,1544,294.0,1.6778973932186103e-06,60509.0,1080.0,1.0,0,396.0
3559,603236,HP:0003074,"This Perspective reviews evidence that 1) the relationship between hyperglycemia and microvascular dysfunction (MVD) is bidirectional and constitutes a vicious cycle; 2) MVD in diabetes affects many, if not all, organs, which may play a role in diabetes-associated comorbidities such as depression and cognitive impairment; and 3) MVD precedes, and contributes to, hyperglycemia in type 2 diabetes (T2D) through impairment of insulin-mediated glucose disposal and, possibly, insulin secretion.",0,1.2358322177599286,2799.471428571428,17.339705882352938,0.4682256661462088,0.4464983121402461,0.0,0.0,0.9827586206896552,57.0,-0.6853057965838183,0.1402688486265342,1.0,2.0,7.0,14.0,14.0,9.0,28.0,82,12.0,0.0005948839976204638,240.0,59.0,1.0,0,12.0
3560,603236,HP:0001513,MVD can be improved through weight loss (in obesity) and through exercise.,0,1.3960212815174646,27298.717908404346,82.78041443850267,0.4014407062720864,0.3055950331026153,0.0,0.0,0.9972972972972972,369.0,-0.6888123043856978,0.02446273767028484,1.0,2.0,47.0,17.0,17.0,15.0,34.0,706,15.0,8.025102520684703e-06,1679.0,371.0,1.0,0,14.0
3561,608896,HP:0001513,"Early postnatal overnutrition in humans is associated with long-term negative outcomes including obesity, increased risk of type-II diabetes, and cardiovascular disease.",0,1.3380074318165884,642155.1545593295,107.46875,0.21625534024984405,0.07111284298467105,0.0,0.0,0.9979209979209979,480.0,-0.6065467000552526,0.08954374099602315,1.0,2.0,11.0,107.0,107.0,45.0,214.0,706,105.0,8.025102520684703e-06,10380.0,482.0,1.0,0,107.0
3562,608896,HP:0001626,"Early postnatal overnutrition in humans is associated with long-term negative outcomes including obesity, increased risk of type-II diabetes, and cardiovascular disease.",1,1.4613357565611569,5259960.863247404,511.31606346785554,0.18778445794008045,0.013350730409024672,0.0,0.0,1.00044286979628,2259.0,-0.6650848655011043,0.02420786296796869,1.0,2.0,6.0,127.0,127.0,121.0,254.0,4262,126.0,2.200014784099349e-07,61740.0,2259.0,1.0,0,137.0
3563,120180,HP:0002664,"This bioinformatics analysis demonstrated that stage-related prognostic DEGs, such as COL3A1, COL1A1, COL1A2, KRAS, and NRAS might play an unfavorable role in the development as well as metastasis of ovarian cancer.",0,1.3296691307778086,11368467.410547387,244.0252207020626,0.14276039480663635,0.031575131495997624,0.0,0.0,0.9991915925626516,1236.0,-0.44514385840826304,0.09329727061275717,1.0,2.0,15.0,420.0,420.0,43.0,840.0,1544,418.0,1.6778973932186103e-06,71438.0,1238.0,1.0,0,606.0
3564,120150,HP:0002664,"This bioinformatics analysis demonstrated that stage-related prognostic DEGs, such as COL3A1, COL1A1, COL1A2, KRAS, and NRAS might play an unfavorable role in the development as well as metastasis of ovarian cancer.",1,1.3435562379965167,10018639.71358437,226.37531572120963,0.14795945247599315,0.029689787626015606,0.0,0.0,1.000815660685155,1227.0,-0.4656096333724264,0.0862380027414708,1.0,2.0,28.0,402.0,402.0,43.0,804.0,1598,402.0,1.6778973932186103e-06,64864.0,1227.0,1.0,0,583.0
3565,120160,HP:0002664,"This bioinformatics analysis demonstrated that stage-related prognostic DEGs, such as COL3A1, COL1A1, COL1A2, KRAS, and NRAS might play an unfavorable role in the development as well as metastasis of ovarian cancer.",0,1.3428623785962983,8631628.059654398,221.71190230298734,0.14878555517530448,0.14844087352755142,0.0,0.0,0.9991266375545852,1144.0,-0.5200734265875349,0.08592789044102518,1.0,2.0,9.0,340.0,340.0,70.0,680.0,1576,338.0,1.6778973932186097e-06,56376.0,1146.0,1.0,0,426.0
2070,190070,HP:0002664,"This bioinformatics analysis demonstrated that stage-related prognostic DEGs, such as COL3A1, COL1A1, COL1A2, KRAS, and NRAS might play an unfavorable role in the development as well as metastasis of ovarian cancer.",1,1.3339771877413191,18178836.290753696,271.2782786211432,0.14438020893870612,0.0522035687829069,0.0,0.0,1.0006165228113442,1623.0,-0.2035822069529308,0.08341633409382543,1.0,2.0,4.0,720.0,720.0,2.0,1440.0,1542,719.0,1.374364528201273e-06,109797.0,1623.0,1.0,0,858.0
3566,164790,HP:0002664,"This bioinformatics analysis demonstrated that stage-related prognostic DEGs, such as COL3A1, COL1A1, COL1A2, KRAS, and NRAS might play an unfavorable role in the development as well as metastasis of ovarian cancer.",1,1.33689469268324,14931785.968068045,272.38494917187853,0.14247327172047747,0.07414697601030018,0.0,0.0,1.0007446016381236,1344.0,-0.3142315149228265,0.09920819593660248,1.0,2.0,4.0,542.0,542.0,15.0,1084.0,1542,541.0,1.6778973932186097e-06,89535.0,1344.0,1.0,0,748.0
3573,182120,HP:0002664,"We found that LGR5 expression in the epithelium and stroma was associated with tumor stage, and by integrating functional experiments with LGR5-sorted cell RNA sequencing data from adenoma and normal organoids, we found correlations between LGR5 and CRC-specific genes, including dickkopf WNT signaling pathway inhibitor 4 (DKK4) and SPARC-related modular calcium binding 2 (SMOC2).",0,1.415274401115109,1303635.1872036636,316.6933144676335,0.19071001043307007,0.04223950800155951,0.0,0.0,0.9988066825775656,837.0,-0.7522995212911145,0.05680418500260283,1.0,2.0,44.0,66.0,66.0,65.0,132.0,1544,64.0,1.67789739321861e-06,19969.0,839.0,1.0,0,62.0
3576,607223,HP:0002664,"We found that LGR5 expression in the epithelium and stroma was associated with tumor stage, and by integrating functional experiments with LGR5-sorted cell RNA sequencing data from adenoma and normal organoids, we found correlations between LGR5 and CRC-specific genes, including dickkopf WNT signaling pathway inhibitor 4 (DKK4) and SPARC-related modular calcium binding 2 (SMOC2).",0,1.409203601822635,159200.27361106474,217.39904885430167,0.2799367754081001,0.3648952265215221,0.0,0.0,0.9987484355444304,798.0,-0.8149573068293925,0.02007822277847309,1.0,2.0,99.0,25.0,25.0,23.0,50.0,1544,23.0,1.6778973932186097e-06,6417.0,800.0,1.0,0,22.0
3577,125240,HP:0002664,"Hexavalent chromium [Cr(VI)] damages DNA and causes cancer, but it is unclear which DNA damage responses (DDRs) most critically protect cells from chromate toxicity.",0,1.4091030918202252,1500649.3252639344,254.09187900087863,0.20285994054141293,0.2626474971640341,0.0,0.0,0.9988439306358382,864.0,-0.6816414875726912,0.05816390553872031,1.0,2.0,26.0,91.0,91.0,88.0,182.0,1544,89.0,1.677897393218609e-06,21785.0,866.0,1.0,0,85.0
3578,614556,HP:0000717,Haploinsufficiency of the chromatin remodeling factor ARID1B leads to autism spectrum disorder and intellectual disability.,0,1.345454330629582,2205220.126082251,188.3477069684336,0.17234355305744795,0.10986320048325716,0.0,0.0,0.99835255354201,606.0,-0.5696522559561967,0.11520202896037456,1.0,2.0,26.0,147.0,147.0,147.0,294.0,334,146.0,4.705417346991594e-06,21258.0,608.0,1.0,0,201.0
3582,614556,HP:0001249,Haploinsufficiency of the chromatin remodeling factor ARID1B leads to autism spectrum disorder and intellectual disability.,1,1.3806643520324569,39630335.25842325,487.1940889106009,0.1232513705156457,0.015245168364198269,0.0,0.0,1.0004852013585637,2062.0,-0.5372077304821901,0.08194020305041529,1.0,2.0,4.0,451.0,451.0,267.0,902.0,3204,450.0,3.8916426584744994e-07,174114.0,2062.0,1.0,0,615.0
3580,614556,HP:0000717,"Several independent research groups, including our own, recently examined the effects of heterozygous deletion of Arid1b in mice and reported severe behavioral abnormalities reminiscent of autism spectrum disorders and intellectual disability as well as marked changes in gene expression and decreased body size.",0,1.345454330629582,2205220.126082251,188.3477069684336,0.17234355305744795,0.10986320048325716,0.0,0.0,0.99835255354201,606.0,-0.5696522559561967,0.11520202896037456,1.0,2.0,26.0,147.0,147.0,147.0,294.0,334,146.0,4.705417346991594e-06,21258.0,608.0,1.0,0,201.0
3584,614556,HP:0001249,"Several independent research groups, including our own, recently examined the effects of heterozygous deletion of Arid1b in mice and reported severe behavioral abnormalities reminiscent of autism spectrum disorders and intellectual disability as well as marked changes in gene expression and decreased body size.",1,1.3806643520324569,39630335.25842325,487.1940889106009,0.1232513705156457,0.015245168364198269,0.0,0.0,1.0004852013585637,2062.0,-0.5372077304821901,0.08194020305041529,1.0,2.0,4.0,451.0,451.0,267.0,902.0,3204,450.0,3.8916426584744994e-07,174114.0,2062.0,1.0,0,615.0
1459,609145,HP:0002664,"The level of gene expression of IRAK1, NF-kB, tumor necrosis factor-a (TNF-a), and interleukin-6 (IL-6) was measured by RT-PCR, and TNF-a, IL-6 levels in the cell supernatant were determined by ELISA.",0,1.3822965008126258,3042852.2095307475,270.7389414793736,0.16620742155098553,0.2396575150870838,0.0,0.0,0.998896247240618,905.0,-0.6703174021911298,0.07687084267324781,1.0,2.0,42.0,135.0,135.0,117.0,270.0,1544,133.0,1.6778973932186086e-06,31584.0,907.0,1.0,0,134.0
1466,609145,HP:0002664,"The protein expression of IRAK1 and downstream molecules tumor necrosis factor receptor-associated factor 6 (TRAF6), inhibitor of nuclear factor kappa-B kinase (IKK), NF-kappa-B inhibitor alpha (IKBa), and NF-kB was detected by Western-blot analysis.",0,1.3822965008126258,3042852.2095307475,270.7389414793736,0.16620742155098553,0.2396575150870838,0.0,0.0,0.998896247240618,905.0,-0.6703174021911298,0.07687084267324781,1.0,2.0,42.0,135.0,135.0,117.0,270.0,1544,133.0,1.6778973932186086e-06,31584.0,907.0,1.0,0,134.0
3586,604860,HP:0002664,MALT1 mediates activation of several immune cell types and is involved in the proliferation and survival of cancer cells.,1,1.4361158276832502,1749545.8978526015,303.8778843543571,0.1915712173917533,0.1094293578411461,0.0,0.0,1.0011682242990654,857.0,-0.6940401828410866,0.06409829987240864,1.0,2.0,5.0,86.0,86.0,86.0,172.0,1542,85.0,1.67789739321861e-06,23511.0,857.0,1.0,0,86.0
1295,605131,HP:0002664,"Homozygous null mutation of tumor suppressor WWOX/Wwox gene leads to severe neural diseases, metabolic disorders and early death in the newborns of humans, mice and rats.",1,1.3555888955907682,8197196.577404298,243.4432423922089,0.15156926192774967,0.17795094962722313,0.0,0.0,1.0008960573476702,1117.0,-0.5011928936683259,0.09327981055245907,1.0,2.0,3.0,335.0,335.0,87.0,670.0,1542,334.0,1.67789739321861e-06,58140.0,1117.0,1.0,0,436.0
3587,605131,HP:0003006,"In vitro analysis revealed that knockdown of WWOX protein in neuroblastoma cells results in aggregation of TRAPPC6AD, TIAF1, amyloid b, and Tau in a sequential manner.",0,1.3649442755825734,197744.21704408425,131.9902359006405,0.25460204338129944,0.01431295060535454,0.0,0.0,0.9973958333333331,383.0,-0.6657021236294574,0.06396103896103895,1.0,2.0,54.0,38.0,38.0,38.0,76.0,196,37.0,8.305027032862993e-06,4728.0,385.0,1.0,0,38.0
3588,104760,HP:0003006,"In vitro analysis revealed that knockdown of WWOX protein in neuroblastoma cells results in aggregation of TRAPPC6AD, TIAF1, amyloid b, and Tau in a sequential manner.",0,1.2953571428571429,61604.035714285725,64.66639158242211,0.27526478026382417,0.3496591590558151,0.0,0.0,0.9940828402366864,168.0,-0.6067425881559054,0.13755656108597286,1.0,2.0,24.0,38.0,38.0,38.0,76.0,122,37.0,5.7392102846648294e-05,1976.0,170.0,1.0,0,48.0
3589,157140,HP:0003006,"In vitro analysis revealed that knockdown of WWOX protein in neuroblastoma cells results in aggregation of TRAPPC6AD, TIAF1, amyloid b, and Tau in a sequential manner.",0,1.2738257626054732,103869.20841543516,76.7085267085267,0.28195867924473245,0.060178907274383936,0.0,0.0,0.9970149253731344,334.0,-0.43980197376047736,0.0496090973702914,1.0,2.0,126.0,38.0,38.0,38.0,76.0,326,37.0,1.1260754020089185e-05,2792.0,336.0,1.0,0,38.0
3590,613354,HP:0000365,"In humans, TPRN mutations cause autosomal recessive nonsyndromic deafness (DFNB79) by an unknown mechanism.",1,1.4896739022460437,312174.9641517,774.8798025783943,0.24705503833750606,0.1138575161800059,0.0,0.0,1.000796812749004,1256.0,-0.8814242134547708,0.018397746593244856,1.0,2.0,1.0,19.0,19.0,19.0,38.0,2474,18.0,6.524672396198988e-07,14500.0,1256.0,1.0,0,18.0
3596,613354,HP:0000365,We observed significant hearing loss and progressive degeneration of stereocilia in the outer hair cells of Tprn-null mice starting from postnatal day 30.,1,1.4896739022460437,312174.9641517,774.8798025783943,0.24705503833750606,0.1138575161800059,0.0,0.0,1.000796812749004,1256.0,-0.8814242134547708,0.018397746593244856,1.0,2.0,1.0,19.0,19.0,19.0,38.0,2474,18.0,6.524672396198988e-07,14500.0,1256.0,1.0,0,18.0
3593,613354,HP:0000365,The generated Tprn-null mice are ideal models of human hereditary deafness DFNB79,1,1.4896739022460437,312174.9641517,774.8798025783943,0.24705503833750606,0.1138575161800059,0.0,0.0,1.000796812749004,1256.0,-0.8814242134547708,0.018397746593244856,1.0,2.0,1.0,19.0,19.0,19.0,38.0,2474,18.0,6.524672396198988e-07,14500.0,1256.0,1.0,0,18.0
3602,164840,HP:0002664,"MYCN activation, often due to genetic amplification, represents the driving oncogenic event for a number of human tumors, conferring bad prognosis and predicting very poor responses even to the most aggressive therapeutic protocols.",1,1.3706173965741355,7309941.283361083,255.55133079847909,0.15145361530517168,0.07542448326775511,0.0,0.0,1.0009680542110355,1034.0,-0.5670642820092309,0.09383759533087044,1.0,2.0,10.0,249.0,249.0,139.0,498.0,1542,248.0,1.677897393218608e-06,50115.0,1034.0,1.0,0,315.0
3608,600814,HP:0003006,"Intriguingly, MRE11 is highly expressed and predicts bad prognosis in MYCN-amplified neuroblastoma.",0,1.3313637562648375,113692.68333333336,85.11418159732766,0.2553737579915079,0.31903224814967623,0.0,0.0,0.9953703703703703,215.0,-0.68173502232518,0.11781020651988396,1.0,2.0,25.0,38.0,38.0,38.0,76.0,118,37.0,3.121001217190474e-05,2761.0,217.0,1.0,0,38.0
2431,164840,HP:0003006,"Intriguingly, MRE11 is highly expressed and predicts bad prognosis in MYCN-amplified neuroblastoma.",0,1.3585645578986312,158772.31998556998,111.13575172130304,0.2582612410847169,0.32192902940968543,0.0,0.0,0.9966777408637876,300.0,-0.6954874948812038,0.08448658995401641,1.0,2.0,35.0,38.0,38.0,38.0,76.0,176,37.0,1.4348025711662073e-05,3840.0,302.0,1.0,0,38.0
2426,164840,HP:0003006,"Encapsulation of mirin in nanoparticles allowed its use on MYCN-amplified neuroblastoma xenografts in vivo, which resulted in a sharp impairment of tumor growth, associated with DDR activation, p53 accumulation, and cell death.",0,1.3585645578986312,158772.31998556998,111.13575172130304,0.2582612410847169,0.32192902940968543,0.0,0.0,0.9966777408637876,300.0,-0.6954874948812038,0.08448658995401641,1.0,2.0,35.0,38.0,38.0,38.0,76.0,176,37.0,1.4348025711662073e-05,3840.0,302.0,1.0,0,38.0
3599,164840,HP:0002664,"Encapsulation of mirin in nanoparticles allowed its use on MYCN-amplified neuroblastoma xenografts in vivo, which resulted in a sharp impairment of tumor growth, associated with DDR activation, p53 accumulation, and cell death.",1,1.3706173965741355,7309941.283361083,255.55133079847909,0.15145361530517168,0.07542448326775511,0.0,0.0,1.0009680542110355,1034.0,-0.5670642820092309,0.09383759533087044,1.0,2.0,10.0,249.0,249.0,139.0,498.0,1542,248.0,1.677897393218608e-06,50115.0,1034.0,1.0,0,315.0
3609,600814,HP:0003006,"Therefore, we propose that MRE11 inhibition might be an effective strategy to treat MYCN-amplified and p53 wild-type neuroblastoma, and suggest that targeting replication stress with appropriate tools should be further exploited to tackle MYCN-driven tumors",0,1.3313637562648375,113692.68333333336,85.11418159732766,0.2553737579915079,0.31903224814967623,0.0,0.0,0.9953703703703703,215.0,-0.68173502232518,0.11781020651988396,1.0,2.0,25.0,38.0,38.0,38.0,76.0,118,37.0,3.121001217190474e-05,2761.0,217.0,1.0,0,38.0
2441,164840,HP:0003006,"Therefore, we propose that MRE11 inhibition might be an effective strategy to treat MYCN-amplified and p53 wild-type neuroblastoma, and suggest that targeting replication stress with appropriate tools should be further exploited to tackle MYCN-driven tumors",0,1.3585645578986312,158772.31998556998,111.13575172130304,0.2582612410847169,0.32192902940968543,0.0,0.0,0.9966777408637876,300.0,-0.6954874948812038,0.08448658995401641,1.0,2.0,35.0,38.0,38.0,38.0,76.0,176,37.0,1.4348025711662073e-05,3840.0,302.0,1.0,0,38.0
3610,191170,HP:0003006,"Therefore, we propose that MRE11 inhibition might be an effective strategy to treat MYCN-amplified and p53 wild-type neuroblastoma, and suggest that targeting replication stress with appropriate tools should be further exploited to tackle MYCN-driven tumors",0,1.3837180470201378,232218.2168123116,151.91163283098766,0.2611029652327526,0.11530815255663088,0.0,0.0,0.9978813559322034,471.0,-0.6290258957567348,0.05000537499552084,1.0,2.0,59.0,38.0,38.0,38.0,76.0,244,37.0,5.2847139648566525e-06,5582.0,473.0,1.0,0,38.0
3613,600814,HP:0002664,"Therefore, we propose that MRE11 inhibition might be an effective strategy to treat MYCN-amplified and p53 wild-type neuroblastoma, and suggest that targeting replication stress with appropriate tools should be further exploited to tackle MYCN-driven tumors",1,1.3944710904152116,3464479.634314876,238.74018129089612,0.16989873399766814,0.01133799162548621,0.0,0.0,1.001054852320675,949.0,-0.6232460551475021,0.07675189962340995,1.0,2.0,5.0,174.0,174.0,108.0,348.0,1542,173.0,1.6778973932186097e-06,34525.0,949.0,1.0,0,185.0
3605,164840,HP:0002664,"Therefore, we propose that MRE11 inhibition might be an effective strategy to treat MYCN-amplified and p53 wild-type neuroblastoma, and suggest that targeting replication stress with appropriate tools should be further exploited to tackle MYCN-driven tumors",1,1.3706173965741355,7309941.283361083,255.55133079847909,0.15145361530517168,0.07542448326775511,0.0,0.0,1.0009680542110355,1034.0,-0.5670642820092309,0.09383759533087044,1.0,2.0,10.0,249.0,249.0,139.0,498.0,1542,248.0,1.677897393218608e-06,50115.0,1034.0,1.0,0,315.0
113,191170,HP:0002664,"Therefore, we propose that MRE11 inhibition might be an effective strategy to treat MYCN-amplified and p53 wild-type neuroblastoma, and suggest that targeting replication stress with appropriate tools should be further exploited to tackle MYCN-driven tumors",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
3615,611549,HP:0001371,"Heterozygous de novo NALCN missense variants in the S5/S6 pore-forming segments lead to congenital contractures of the limbs and face, hypotonia, and developmental delay (CLIFAHDD, OMIM 616266) with some clinical overlap.",1,1.3441757141406678,12324813.431060607,325.9829926273459,0.13410512199608124,0.07937906842852684,0.0,0.0,1.00098814229249,1013.0,-0.4499011685566702,0.14986987346316072,1.0,2.0,2.0,366.0,366.0,127.0,732.0,1280,366.0,2.433794699681904e-06,76820.0,1013.0,1.0,0,611.0
3619,611549,HP:0001263,"Heterozygous de novo NALCN missense variants in the S5/S6 pore-forming segments lead to congenital contractures of the limbs and face, hypotonia, and developmental delay (CLIFAHDD, OMIM 616266) with some clinical overlap.",1,1.3895083639387575,29147098.06012896,512.8717590100282,0.12452788626576015,0.06862711296773227,0.0,0.0,1.0005344735435595,1872.0,-0.5780464038107542,0.08747093514597523,1.0,2.0,3.0,370.0,370.0,318.0,740.0,2998,369.0,4.4444444444444465e-07,153184.0,1872.0,1.0,0,480.0
3617,611549,HP:0001371,"In this study, we present detailed clinical information of 16 novel individuals with biallelic NALCN variants, 1 individual with a heterozygous de novo NALCN missense variant and an interesting clinical phenotype without contractures, and 12 individuals with biallelic UNC80 variants.",1,1.3441757141406678,12324813.431060607,325.9829926273459,0.13410512199608124,0.07937906842852684,0.0,0.0,1.00098814229249,1013.0,-0.4499011685566702,0.14986987346316072,1.0,2.0,2.0,366.0,366.0,127.0,732.0,1280,366.0,2.433794699681904e-06,76820.0,1013.0,1.0,0,611.0
3620,612636,HP:0001371,"In this study, we present detailed clinical information of 16 novel individuals with biallelic NALCN variants, 1 individual with a heterozygous de novo NALCN missense variant and an interesting clinical phenotype without contractures, and 12 individuals with biallelic UNC80 variants.",1,1.3643495167385158,8240179.069999446,329.26396004098365,0.13789518851370558,0.011656263632331692,0.0,0.0,1.0011325028312572,884.0,-0.581367838571074,0.1490317357015112,1.0,2.0,1.0,241.0,241.0,235.0,482.0,1280,240.0,2.433794699681904e-06,58165.0,884.0,1.0,0,396.0
3621,608160,HP:0002664,The tumor samples were divided into three groups depending on the SOX9 expression level.,1,1.3518211230574562,8764479.650612818,230.243658836014,0.1496679375188397,0.017231872860770447,0.0,0.0,1.0008741258741258,1145.0,-0.4873609540337411,0.088533300760375,1.0,2.0,7.0,352.0,352.0,70.0,704.0,1542,351.0,1.6778973932186106e-06,57984.0,1145.0,1.0,0,435.0
3625,131530,HP:0002664,"Stimulation of BxPC-3, Panc-1, and MIA PaCA-2 pancreatic cancer cells with EGF, HGF, FGF-1, FGF-2, FGF-7, and FGF-10 growth factors caused changes in the expression of master genes regulating pancreatic development (SOX9, HNF3b, GATA-4, GATA-6, and HES1).",0,1.4183540398436123,1210345.6075365078,294.30023120735353,0.1921133491501248,0.1846422582674654,0.0,0.0,0.9988109393579072,840.0,-0.7406795875192191,0.05465724832726565,1.0,2.0,38.0,69.0,69.0,70.0,138.0,1544,67.0,1.677897393218609e-06,19352.0,842.0,1.0,0,64.0
3643,147620,HP:0002664,"Stimulation of BxPC-3, Panc-1, and MIA PaCA-2 pancreatic cancer cells with EGF, HGF, FGF-1, FGF-2, FGF-7, and FGF-10 growth factors caused changes in the expression of master genes regulating pancreatic development (SOX9, HNF3b, GATA-4, GATA-6, and HES1).",0,1.3995350101215007,3680346.246413318,262.81069089873785,0.1667454121176664,0.0689327787874495,0.0,0.0,1.0010706638115632,935.0,-0.6770923792463656,0.0813956417684847,1.0,2.0,2.0,159.0,159.0,109.0,318.0,1542,159.0,1.677897393218609e-06,35541.0,935.0,1.0,0,143.0
3646,617209,HP:0002664,"Stimulation of BxPC-3, Panc-1, and MIA PaCA-2 pancreatic cancer cells with EGF, HGF, FGF-1, FGF-2, FGF-7, and FGF-10 growth factors caused changes in the expression of master genes regulating pancreatic development (SOX9, HNF3b, GATA-4, GATA-6, and HES1).",0,1.4189805407040597,440461.7109273413,176.85520022697796,0.2701165340389079,0.10522465462746246,0.0,0.0,0.998803827751196,835.0,-0.6211345850582829,0.03192079253199796,1.0,2.0,35.0,61.0,61.0,58.0,122.0,1544,59.0,1.6778973932186097e-06,11168.0,837.0,1.0,0,54.0
3649,604515,HP:0002664,Human bladder cancer (BCa) is one of the most commonly diagnosed malignancies worldwide.,1,1.4100199029375369,3716627.6337372432,300.73600067670446,0.16690937670490275,0.03184459309160423,0.0,0.0,1.0011013215859033,909.0,-0.6695645543663801,0.08529729624944872,1.0,2.0,5.0,137.0,137.0,138.0,274.0,1542,136.0,1.677897393218609e-06,35201.0,909.0,1.0,0,161.0
3647,604515,HP:0002664,"An increasing number of studies suggest that long-noncoding RNAs (lncRNAs) play important roles in various biological processes and disease pathologies, including cancer.We analyzed the expression profiles of lncRNA, miRNA, and mRNA, along with the clinical information of BCa patients collected from the Cancer Genome Atlas database to identify lncRNA biomarkers for prognosis.",1,1.4100199029375369,3716627.6337372432,300.73600067670446,0.16690937670490275,0.03184459309160423,0.0,0.0,1.0011013215859033,909.0,-0.6695645543663801,0.08529729624944872,1.0,2.0,5.0,137.0,137.0,138.0,274.0,1542,136.0,1.677897393218609e-06,35201.0,909.0,1.0,0,161.0
3651,616086,HP:0002664,"Mutations in SPRTN cause premature ageing and liver cancer in humans and mice; thus, defective DPC repair has great clinical ramifications.",1,1.430484494299693,2099634.1228227653,288.2034695201038,0.18254120232322552,0.12088985950172075,0.0,0.0,1.0011547344110854,867.0,-0.6786542553241516,0.06553883610229855,1.0,2.0,5.0,96.0,96.0,96.0,192.0,1542,95.0,1.677897393218609e-06,24604.0,867.0,1.0,0,93.0
3655,123890,HP:0002664,"On the other hand, growing tumors evade immune surveillance by exploiting co-inhibitory signaling through expression of CTLA4, PD1 and PDL-1.",1,1.3557340062504206,7876492.183733422,245.8980206394857,0.15596580866523213,0.13083347664995296,0.0,0.0,1.000896860986547,1116.0,-0.4961996083568794,0.09420094186476363,1.0,2.0,11.0,327.0,327.0,89.0,654.0,1542,326.0,1.6778973932186103e-06,58609.0,1116.0,1.0,0,427.0
3662,600244,HP:0002664,"On the other hand, growing tumors evade immune surveillance by exploiting co-inhibitory signaling through expression of CTLA4, PD1 and PDL-1.",0,1.4224760788908417,387742.6419946397,219.4438450654404,0.2592635204927137,0.08514585121085216,0.0,0.0,0.9987745098039216,815.0,-0.6786774664518197,0.029597763217894257,1.0,2.0,60.0,45.0,45.0,45.0,90.0,1544,43.0,1.67789739321861e-06,9866.0,817.0,1.0,0,41.0
3652,123890,HP:0002664,"Immune checkpoint blockade (ICB) using anti-CTLA4 and anti-PD1 has drawn considerable attention towards co-signaling receptors in tumor immunology and created renewed interest in studying other co-signaling receptors, which until recently have not been as well studied.",1,1.3557340062504206,7876492.183733422,245.8980206394857,0.15596580866523213,0.13083347664995296,0.0,0.0,1.000896860986547,1116.0,-0.4961996083568794,0.09420094186476363,1.0,2.0,11.0,327.0,327.0,89.0,654.0,1542,326.0,1.6778973932186103e-06,58609.0,1116.0,1.0,0,427.0
3661,600244,HP:0002664,"Immune checkpoint blockade (ICB) using anti-CTLA4 and anti-PD1 has drawn considerable attention towards co-signaling receptors in tumor immunology and created renewed interest in studying other co-signaling receptors, which until recently have not been as well studied.",0,1.4224760788908417,387742.6419946397,219.4438450654404,0.2592635204927137,0.08514585121085216,0.0,0.0,0.9987745098039216,815.0,-0.6786774664518197,0.029597763217894257,1.0,2.0,60.0,45.0,45.0,45.0,90.0,1544,43.0,1.67789739321861e-06,9866.0,817.0,1.0,0,41.0
3663,102565,HP:0003198,"This is an original FLNC mutation in a MFM family with an atypical clinical and histopathological presentation, given the presence of significantly focal lesions and prominent sarcoplasmic masses in muscle biopsies and the constant heart involvement preceding significantly the onset of the myopathy.",1,1.3407119588680874,1038408.682936508,133.35722754217966,0.20124732101556764,0.09357755214009196,0.0,0.0,1.0023419203747073,428.0,-0.4699895372763986,0.1495545973866795,1.0,2.0,3.0,151.0,151.0,51.0,302.0,516,150.0,1.490735081468672e-05,13666.0,428.0,1.0,0,182.0
3665,102565,HP:0003198,"Though a rare etiology, FLNC gene should not be excluded in early-onset arrhythmia, even in the absence of myopathy, which occurs later in the disease course",1,1.3407119588680874,1038408.682936508,133.35722754217966,0.20124732101556764,0.09357755214009196,0.0,0.0,1.0023419203747073,428.0,-0.4699895372763986,0.1495545973866795,1.0,2.0,3.0,151.0,151.0,51.0,302.0,516,150.0,1.490735081468672e-05,13666.0,428.0,1.0,0,182.0
3667,102565,HP:0011675,"Though a rare etiology, FLNC gene should not be excluded in early-onset arrhythmia, even in the absence of myopathy, which occurs later in the disease course",1,1.3507109004739335,1120169.315909091,131.72989906021579,0.2032393690071059,0.21659392912510644,0.0,0.0,1.0019723865877712,508.0,-0.5294728604150586,0.11570299274720836,1.0,2.0,6.0,152.0,152.0,49.0,304.0,676,151.0,8.7016298152644e-06,14900.0,508.0,1.0,0,151.0
3668,608222,HP:0000717,"Transcriptomic analysis revealed significant alterations in a number of genes associated with autism, such as adsl, mbd5, shank3, and tsc1b.",1,1.3350626939928059,667945.0271645023,144.8390660933907,0.17677080266367184,0.11314578586649038,0.0,0.0,1.0035460992907799,283.0,-0.2969355060568074,0.25654712678244745,1.0,2.0,4.0,127.0,127.0,90.0,254.0,292,126.0,4.627701420704336e-05,10237.0,283.0,1.0,0,172.0
3669,611472,HP:0000717,"Transcriptomic analysis revealed significant alterations in a number of genes associated with autism, such as adsl, mbd5, shank3, and tsc1b.",0,1.3441602807197968,1520521.8286796531,173.65782163042442,0.16992559815859992,0.06842565256769816,0.0,0.0,0.9976905311778292,432.0,-0.4472397385958116,0.18118155404902034,1.0,2.0,1.0,147.0,147.0,147.0,294.0,294,146.0,1.2140489747356407e-05,17024.0,434.0,1.0,0,173.0
3670,606230,HP:0000717,"Transcriptomic analysis revealed significant alterations in a number of genes associated with autism, such as adsl, mbd5, shank3, and tsc1b.",1,1.3537304080729475,1594519.2694444444,172.55386354568432,0.17175852216416593,0.01556531656224689,0.0,0.0,1.0022026431718063,455.0,-0.4528223258417512,0.16564844846783172,1.0,2.0,12.0,146.0,146.0,146.0,292.0,292,146.0,1.0405827263267427e-05,17109.0,455.0,1.0,0,155.0
3672,605317,HP:0011098,Heterozygous mutations of the Forkhead-box protein 2 (FOXP2) gene in humans cause childhood apraxia of speech.,0,1.3589600397120871,42293.60833333334,62.872807017543856,0.26361040687773746,0.2552573857730012,0.0,0.0,1.008264462809917,122.0,-0.5426420515780657,0.2228695298740008,1.0,2.0,9.0,38.0,38.0,38.0,76.0,76,38.0,0.0001384083044982699,1645.0,122.0,1.0,0,52.0
2642,164730,HP:0002664,Our results showed that treatment with MEHP enriched the population of cancer-stem-cell (CSC)-like cells and upregulated IL-8 expression by inducing the AKT-b-catenin-TCF4 signaling pathway.,1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
3676,602228,HP:0002664,Our results showed that treatment with MEHP enriched the population of cancer-stem-cell (CSC)-like cells and upregulated IL-8 expression by inducing the AKT-b-catenin-TCF4 signaling pathway.,0,1.4526500317034057,82679.6739006938,209.45503674881112,0.3714071812170805,0.31271604232369743,0.0,0.0,0.99873417721519,789.0,-0.6995600284271578,0.0142040999215862,1.0,2.0,46.0,19.0,19.0,19.0,38.0,1544,18.0,1.67789739321861e-06,4438.0,791.0,1.0,0,26.0
3677,607198,HP:0002664,TDP1 plays an essential role in the resistance of cancer cells to currently used antitumour drugs based on Top1 inhibitors such as topotecan and irinotecan.,0,1.383685476707171,867318.4336948205,179.22529182879376,0.2260490564010369,0.2758447987739598,0.0,0.0,0.9988399071925754,861.0,-0.6167265939870792,0.04071482149626431,1.0,2.0,68.0,87.0,87.0,61.0,174.0,1544,85.0,1.6778973932186103e-06,15144.0,863.0,1.0,0,77.0
3678,105590,HP:0002664,Anaplastic lymphoma kinase (ALK) rearrangements were first implicated as driving mutations in non-small cell lung cancer in 2007.,1,1.4881933376287204,80317.72380628808,355.9190290902353,0.3373768362249434,0.39384005097722136,0.0,0.0,1.0012755102040816,785.0,-0.8104920713322381,0.015904068633822956,1.0,2.0,8.0,14.0,14.0,14.0,28.0,1542,13.0,1.67789739321861e-06,4894.0,785.0,1.0,0,13.0
3684,105590,HP:0002664,"Since then, a number of novel, small-molecule inhibitors directed against the ALK receptor have demonstrated superiority over standard chemotherapies in the treatment of ALK rearrangement-positive lung cancer.",1,1.4881933376287204,80317.72380628808,355.9190290902353,0.3373768362249434,0.39384005097722136,0.0,0.0,1.0012755102040816,785.0,-0.8104920713322381,0.015904068633822956,1.0,2.0,8.0,14.0,14.0,14.0,28.0,1542,13.0,1.67789739321861e-06,4894.0,785.0,1.0,0,13.0
3028,601593,HP:0002664,"The protein product of the breast and ovarian cancer gene, BRCA1, is part of an obligate heterodimer with BARD1.",1,1.4690265087320626,317878.5603318781,229.65134784590043,0.304142381423776,0.1874614328934079,0.0,0.0,1.0012391573729864,808.0,-0.6148112135826345,0.02486902965389476,1.0,2.0,1.0,37.0,37.0,37.0,74.0,1542,37.0,1.67789739321861e-06,8108.0,808.0,1.0,0,45.0
3687,120470,HP:0002664,"The purpose of this study was to conduct a systematic review and meta-analysis of studies investigating the relationship between dietary fiber intake and subsite-specific colon cancer.The PubMed database was searched to identify relevant cohort studies published from inception to August 2016 in order to examine individually the association between dietary fiber intake and the risk of proximal colon cancer (PCC), and that between dietary fiber intake and the risk of distal colon cancer (DCC).",1,1.3695173430983625,6676041.415938074,253.9171022320305,0.15628938827861102,0.03973360344271434,0.0,0.0,1.0009633911368017,1039.0,-0.5336448986884315,0.09364458563054368,1.0,2.0,3.0,260.0,260.0,129.0,520.0,1542,260.0,1.67789739321861e-06,50497.0,1039.0,1.0,0,285.0
3073,148067,HP:0002664,"However, in HaCaT and HEK293T cells that display transformed phenotypes, but do not originate from patient-derived tumors, the ER stress-inducing treatments resulted in an upregulation of FAM129A and HKDC1, but not KRT16 transcripts, By a luciferase reporter approach we identified a highly active ATF4-responsive element within the upstream region of the KRT16 gene.",1,1.4211218904597709,1903611.5206776243,241.18147996450267,0.1895920076555231,0.05385793112328807,0.0,0.0,1.0011312217194572,885.0,-0.6887717180862317,0.061234245980008685,1.0,2.0,7.0,106.0,106.0,80.0,212.0,1542,105.0,1.6778973932186103e-06,23953.0,885.0,1.0,0,100.0
3076,148067,HP:0002664,"The results suggest a conditional regulation of KRT16 gene by ATF4 that may be inhibited in normal cells, but engaged during cancer progression.",1,1.4211218904597709,1903611.5206776243,241.18147996450267,0.1895920076555231,0.05385793112328807,0.0,0.0,1.0011312217194572,885.0,-0.6887717180862317,0.061234245980008685,1.0,2.0,7.0,106.0,106.0,80.0,212.0,1542,105.0,1.6778973932186103e-06,23953.0,885.0,1.0,0,100.0
3688,602208,HP:0001250,"In humans, loss-of-function mutations of KCNJ10, which encodes the inward-rectifying potassium channel KIR4.1, causes seizures and progressive neurological decline.",1,1.4385462290508737,4841465.57498279,401.804100534336,0.17306721927535962,0.10651505227265806,0.0,0.0,1.0005841121495327,1713.0,-0.6580215441729527,0.04041524133754521,1.0,2.0,9.0,150.0,150.0,94.0,300.0,3116,149.0,4.156965348783943e-07,59262.0,1713.0,1.0,0,134.0
3689,602208,HP:0040078,Conditional knockout (cKO) of OL-Kcnj10 resulted in late onset mitochondrial damage and axonal degeneration.,0,1.2710272921193757,19604.6213924964,43.48374233128835,0.4016315486453089,0.4561824594012266,0.0,0.0,0.9945652173913044,183.0,-0.4435303220127725,0.054171562867215035,1.0,2.0,69.0,21.0,21.0,21.0,42.0,178,20.0,3.7180249851278996e-05,922.0,185.0,1.0,0,21.0
3690,605185,HP:0002664,"The tumor-cell activated phenotype of EPC was associated with increased migration and elevated expression of ephrin-B2, and Delta-like 4 ligand (DLL4).",0,1.3694608580432603,6046852.368595295,261.14973093799154,0.15662314653741788,0.02461757576767796,0.0,0.0,0.9990069513406156,1006.0,-0.5784302570889273,0.09394555571318232,1.0,2.0,7.0,234.0,234.0,146.0,468.0,1544,232.0,1.67789739321861e-06,47680.0,1008.0,1.0,0,261.0
3691,600185,HP:0000133,"Drosophila mutants that were null for an orthologue of BRCA2 were sterile, and gonadal dysgenesis was present in both sexes.",0,1.3591699231909449,131858.23289998525,130.90155959364716,0.30866337390891885,0.02678111600099754,0.0,0.0,0.998046875,511.0,-0.5210391799004536,0.03073982699805068,1.0,2.0,117.0,30.0,30.0,30.0,60.0,414,29.0,4.286528726172258e-06,4037.0,513.0,1.0,0,30.0
3692,136350,HP:0002664,"In recent years, high-throughput sequencing has been used to analyze exomes of virtually all human tumors, which allowed to construct phylogenetic trees of clonal cancer evolution with special emphasis on driver mutations in FGFR1-4 genes.",1,1.3338892096087087,17926920.509619627,251.2927140347712,0.143968848359445,0.022238802526675785,0.0,0.0,1.000620732464308,1612.0,-0.2685092163137845,0.07784570408466605,1.0,2.0,7.0,665.0,665.0,2.0,1330.0,1542,664.0,1.410508855174593e-06,101080.0,1612.0,1.0,0,755.0
3694,136350,HP:0002664,"In this review, we discuss current data on the functioning of the FGFR family proteins in both normal and cancer cells, mutations in the FGFR1-4 genes, and mechanisms underlying their oncogenic potential, which might be interesting to a broad range of scientists searching for specific tumor markers and targeted anti-cancer drugs",1,1.3338892096087087,17926920.509619627,251.2927140347712,0.143968848359445,0.022238802526675785,0.0,0.0,1.000620732464308,1612.0,-0.2685092163137845,0.07784570408466605,1.0,2.0,7.0,665.0,665.0,2.0,1330.0,1542,664.0,1.410508855174593e-06,101080.0,1612.0,1.0,0,755.0
3696,613276,HP:0001875,"Loss of function mutations in human Usb1 cause the rare disorder poikiloderma with neutropenia (PN), and result in U6 snRNAs with elongated 3* ends that are aberrantly adenylated.",1,1.3438120646213132,1112919.4332833842,147.53089887640448,0.18323332874550605,0.06826656641310494,0.0,0.0,1.0023474178403755,427.0,-0.3357715748941068,0.16228518652901014,1.0,2.0,1.0,160.0,160.0,7.0,320.0,320,160.0,1.3922922699933172e-05,14760.0,427.0,1.0,0,214.0
3697,606416,HP:0001513,"It was our aim to investigate behavioral and obesity effects evoked by treatment with probiotics via neuroinflammatory factors and namely IL-1b, NLRP3, Caspase-1 and NF-kB levels in the Syrian golden hamster.",0,1.3128544995461016,2909504.727849928,159.12046939988116,0.16737700507218356,0.04448867838106402,0.0,0.0,0.9984825493171472,658.0,-0.4416267357279348,0.12129489124936772,1.0,2.0,14.0,238.0,238.0,11.0,476.0,706,236.0,7.979826997350698e-06,26378.0,660.0,1.0,0,305.0
3698,609145,HP:0001513,"It was our aim to investigate behavioral and obesity effects evoked by treatment with probiotics via neuroinflammatory factors and namely IL-1b, NLRP3, Caspase-1 and NF-kB levels in the Syrian golden hamster.",0,1.3582725326991678,1513985.9682178937,170.95836160108547,0.17640208669047294,0.06512501111728489,0.0,0.0,0.9979466119096508,486.0,-0.6056705020957422,0.1420877234321877,1.0,2.0,1.0,129.0,129.0,109.0,258.0,706,127.0,7.979826997350696e-06,16884.0,488.0,1.0,0,138.0
3699,604619,HP:0009733,Leucine-rich glioma-inactivated protein 1 (LGI1) is a secreted neuronal protein and a Nogo receptor 1 (NgR1) ligand.,0,1.2151775051568776,7871.480555555556,20.49020807833537,0.4052942796334488,0.1562354148233902,0.0,0.0,0.9878048780487804,81.0,-0.5215330237670509,0.13341169556273874,1.0,2.0,12.0,25.0,25.0,3.0,50.0,80,23.0,0.0005165289256198346,454.0,83.0,1.0,0,18.0
3700,604619,HP:0001250,Mutations in LGI1 in humans causes autosomal dominant lateral temporal lobe epilepsy and homozygous deletion of LGI1 in mice results in severe epileptic seizures that cause early postnatal death.,1,1.4811411594667128,444989.4963495896,323.88211552888225,0.3250190083515928,0.056561538584071536,0.0,0.0,1.0006281407035176,1593.0,-0.55711632725934,0.01068667253404499,1.0,2.0,1.0,42.0,42.0,42.0,84.0,3100,41.0,4.156965348783942e-07,13551.0,1593.0,1.0,0,41.0
3701,604619,HP:0002664,RhoA activity is significantly increased in cortical cultures derived from LGI1 null mice and using a reconstituted system; we show directly that LGI1 antagonizes NgR1-tumor necrosis factor receptor orphan Y (TROY) signaling.,0,1.4190301299054615,113799.063077493,102.39652520133923,0.3689361583980906,0.10220939727408104,0.0,0.0,0.9987730061349694,814.0,-0.5847577175818176,0.01474497774569951,1.0,2.0,56.0,39.0,39.0,29.0,78.0,1544,37.0,1.67789739321861e-06,4903.0,816.0,1.0,0,30.0
2412,165390,HP:0002664,RhoA activity is significantly increased in cortical cultures derived from LGI1 null mice and using a reconstituted system; we show directly that LGI1 antagonizes NgR1-tumor necrosis factor receptor orphan Y (TROY) signaling.,0,1.3978683131436085,2157606.155043348,229.1092045672004,0.1848188673957168,0.06592376818482969,0.0,0.0,0.9988814317673378,893.0,-0.611879548470754,0.06202742054416158,1.0,2.0,23.0,121.0,121.0,117.0,242.0,1544,119.0,1.67789739321861e-06,24815.0,895.0,1.0,0,117.0
3712,308840,HP:0002664,L1 cell adhesion molecule (L1CAM) is a member of the immunoglobulin-like cell-adhesion molecule family that was shown to be associated with a worse prognosis in several human cancers.,0,1.3523302977409155,3654825.8435733374,233.868588950616,0.1686814475439899,0.006976185450603328,0.0,0.0,0.9989417989417992,944.0,-0.583935463434677,0.0754074521516382,1.0,2.0,60.0,168.0,168.0,155.0,336.0,1544,166.0,1.6778973932186103e-06,33706.0,946.0,1.0,0,181.0
3729,308840,HP:0012174,We evaluated the presence of L1CAM in cyst fluid and tissue from glioblastomas or brain metastases.The amount of L1CAM in cyst fluid of 9 glioblastomas and 11 brain metastases was assessed using enzyme-linked immunosorbent assay (ELISA).,0,1.3546187363834423,27637.84703727645,58.28236994219653,0.35689779161007623,0.2424920120681438,0.0,0.0,0.9948453608247422,193.0,-0.5925345006762082,0.06354744911445942,1.0,2.0,28.0,21.0,21.0,21.0,42.0,106,20.0,3.302946228035408e-05,1202.0,195.0,1.0,0,22.0
3707,308840,HP:0002664,Corresponding tumor tissue slices were stained immunohistochemically for L1CAM.,0,1.3523302977409155,3654825.8435733374,233.868588950616,0.1686814475439899,0.006976185450603328,0.0,0.0,0.9989417989417992,944.0,-0.583935463434677,0.0754074521516382,1.0,2.0,60.0,168.0,168.0,155.0,336.0,1544,166.0,1.6778973932186103e-06,33706.0,946.0,1.0,0,181.0
3702,308840,HP:0002664,Cerebrospinal fluid of 20 non-tumor patients served as controls.Mean levels of L1CAM in tumor cyst fluid were significantly higher in glioblastoma (6118 + 4095 ng/mL) and metastasis patients (8001 + 6535 ng/mL) than in CSF of control patients (714 + 22 ng/mL).,0,1.3523302977409155,3654825.8435733374,233.868588950616,0.1686814475439899,0.006976185450603328,0.0,0.0,0.9989417989417992,944.0,-0.583935463434677,0.0754074521516382,1.0,2.0,60.0,168.0,168.0,155.0,336.0,1544,166.0,1.6778973932186103e-06,33706.0,946.0,1.0,0,181.0
3727,308840,HP:0012174,Cerebrospinal fluid of 20 non-tumor patients served as controls.Mean levels of L1CAM in tumor cyst fluid were significantly higher in glioblastoma (6118 + 4095 ng/mL) and metastasis patients (8001 + 6535 ng/mL) than in CSF of control patients (714 + 22 ng/mL).,0,1.3546187363834423,27637.84703727645,58.28236994219653,0.35689779161007623,0.2424920120681438,0.0,0.0,0.9948453608247422,193.0,-0.5925345006762082,0.06354744911445942,1.0,2.0,28.0,21.0,21.0,21.0,42.0,106,20.0,3.302946228035408e-05,1202.0,195.0,1.0,0,22.0
3722,308840,HP:0002664,The immunohistochemical expression of L1CAM in corresponding tissue was significantly higher in metastases than in glioblastomas.The present study demonstrates high levels of L1CAM in cyst fluid of glioblastoma and metastatic brain tumors.,0,1.3523302977409155,3654825.8435733374,233.868588950616,0.1686814475439899,0.006976185450603328,0.0,0.0,0.9989417989417992,944.0,-0.583935463434677,0.0754074521516382,1.0,2.0,60.0,168.0,168.0,155.0,336.0,1544,166.0,1.6778973932186103e-06,33706.0,946.0,1.0,0,181.0
3717,308840,HP:0002664,"Soluble L1CAM may represent a motility promoting molecule in cancer progression, a co-factor for development of tumor cysts and a target for new treatment strategies",0,1.3523302977409155,3654825.8435733374,233.868588950616,0.1686814475439899,0.006976185450603328,0.0,0.0,0.9989417989417992,944.0,-0.583935463434677,0.0754074521516382,1.0,2.0,60.0,168.0,168.0,155.0,336.0,1544,166.0,1.6778973932186103e-06,33706.0,946.0,1.0,0,181.0
3780,102582,HP:0002664,"We found that PRMT1 knockout mice showed significantly lower expression of IL10 and IL6 cytokines in the liverand downstream STAT3 activation, which correlated with reduced number of surface tumors, reduced proliferation and reduced number of M2 macrophages in the liver as well as within proliferating nodules.",1,1.3508433607360242,8878616.878968583,248.4226000095069,0.15216571976025756,0.08400986982943877,0.0,0.0,1.0008680555555554,1153.0,-0.4756805464757602,0.09554935193215766,1.0,2.0,7.0,368.0,368.0,71.0,736.0,1542,367.0,1.67789739321861e-06,63457.0,1153.0,1.0,0,460.0
3773,102582,HP:0002664,We found that PRMT1 expression in tumor associated macrophages correlated with STAT3 activation in human HCC specimens.,1,1.3508433607360242,8878616.878968583,248.4226000095069,0.15216571976025756,0.08400986982943877,0.0,0.0,1.0008680555555554,1153.0,-0.4756805464757602,0.09554935193215766,1.0,2.0,7.0,368.0,368.0,71.0,736.0,1542,367.0,1.67789739321861e-06,63457.0,1153.0,1.0,0,460.0
3752,102582,HP:0002664,Taken together these data suggest that the PRMT1-IL6-STAT3 axis is an important mechanism of alcohol-associated tumor progression,1,1.3508433607360242,8878616.878968583,248.4226000095069,0.15216571976025756,0.08400986982943877,0.0,0.0,1.0008680555555554,1153.0,-0.4756805464757602,0.09554935193215766,1.0,2.0,7.0,368.0,368.0,71.0,736.0,1542,367.0,1.67789739321861e-06,63457.0,1153.0,1.0,0,460.0
3787,164160,HP:0001513,"Leptin (LEP) and fat mass and obesity-associated (FTO) alleles are known to influence body fat mass in humans, potentially via effects on appetite.",1,1.3605962219598582,1049944.8940411196,137.60979623824448,0.1987494666178602,0.04026046360047452,0.0,0.0,1.002016129032258,497.0,-0.5716934268958187,0.11465567599143245,1.0,2.0,2.0,129.0,129.0,51.0,258.0,704,128.0,8.025102520684701e-06,14132.0,497.0,1.0,0,132.0
3788,603850,HP:0003287,"DHEA prevents mitochondrial dysfunction by decreasing the activation of DNM1L and MFF, and increasing MFN1 expression.",0,1.3194805194805197,585785.3795815294,113.00017420388822,0.2020849247036625,0.17727224744662334,0.0,0.0,0.997282608695652,367.0,-0.3784376948488823,0.13326263697419582,1.0,2.0,18.0,114.0,114.0,114.0,228.0,228,113.0,1.5378700499807768e-05,9048.0,369.0,1.0,0,142.0
3789,614785,HP:0003287,"DHEA prevents mitochondrial dysfunction by decreasing the activation of DNM1L and MFF, and increasing MFN1 expression.",0,1.3147132537225417,314897.3380952381,97.35695519911505,0.2077689420280636,-0.0697718359777985,0.0,0.0,0.9958677685950412,241.0,-0.3087908864363102,0.2028364452606877,1.0,2.0,4.0,101.0,101.0,6.0,202.0,228,99.0,6.0092542515473815e-05,5964.0,243.0,1.0,0,130.0
433,180069,HP:0000546,"Mutations in RPE65 result in a disrupted chromophore supply, retinal degeneration, and blindness.",0,1.3253582258160417,1303239.9151260508,159.89845751197237,0.17741304443032346,0.09926865126882237,0.0,0.0,0.9973958333333331,383.0,-0.4207411991227773,0.20549242424242425,1.0,2.0,3.0,157.0,157.0,61.0,314.0,440,155.0,2.0474601257140522e-05,15190.0,385.0,1.0,0,184.0
3790,180069,HP:0000618,"Mutations in RPE65 result in a disrupted chromophore supply, retinal degeneration, and blindness.",1,1.340764163372859,1959804.0015873013,207.71363502791644,0.15688138706875684,0.070722760171181,0.0,0.0,1.0024271844660193,413.0,-0.4840022307420997,0.2414020075695245,1.0,2.0,3.0,159.0,159.0,158.0,318.0,498,158.0,1.6e-05,20538.0,413.0,1.0,0,205.0
3791,600957,HP:0008209,"AMH is regarded as a promising predictor for ovarian reserve in humans and non-human primate, and widely used in human medicine to predict ovarian response to gonadotropin, menopause and premature ovarian failure.",0,1.3100417490661391,12897.347985347988,35.46551724137932,0.33845622625668337,0.1375295211931758,0.0,0.0,0.9886363636363636,87.0,-0.6543440523265118,0.1874361593462717,1.0,2.0,2.0,28.0,28.0,12.0,56.0,118,26.0,0.00027777777777777767,734.0,89.0,1.0,0,24.0
3792,605284,HP:0000365,"Conversely, Tsc1 loss led to the early-onset death of cochlear hair cells and consequently accelerated hearing loss.",0,1.3520897239263805,9414457.543196933,271.7520851874329,0.15687622535511775,0.07373731089664452,0.0,0.0,0.9993650793650796,1574.0,-0.5567521126423545,0.058832487309644674,1.0,2.0,54.0,309.0,309.0,99.0,618.0,2516,307.0,6.524672396198987e-07,73017.0,1576.0,1.0,0,310.0
3793,615076,HP:0000602,"Mutations in MGME1-coding gene lead to severe mitochondrial syndromes characterized by external ophthalmoplegia, emaciation, and respiratory failure in humans.",1,1.345314672859423,831926.9206349205,141.5806799607715,0.19782789022153047,0.03180929614434638,0.0,0.0,1.0027624309392265,363.0,-0.5001717854614702,0.1815898817405598,1.0,2.0,1.0,128.0,128.0,125.0,256.0,460,128.0,1.874027848053821e-05,11931.0,363.0,1.0,0,182.0
3794,609007,HP:0003745,"The G2019S mutation in Leucine-Rich Repeat Kinase 2 (LRRK2) is a prevalent cause of late-onset Parkinson*s Disease, producing psychiatric and motor symptoms, including depression, that are indistinguishable from sporadic cases.",0,1.329409394427815,215399.00497835493,76.46023004531196,0.2389572869205501,0.15318947022214352,0.0,0.0,0.9959514170040488,246.0,-0.3720268491648416,0.14979757085020245,1.0,2.0,2.0,90.0,90.0,4.0,180.0,192,89.0,4.3282548476454294e-05,4588.0,248.0,1.0,0,108.0
3658,123890,HP:0002664,"We documented 17 malignancies, which amounts to a cancer prevalence of 12.9% in affected CTLA4 mutation carriers.",1,1.3557340062504206,7876492.183733422,245.8980206394857,0.15596580866523213,0.13083347664995296,0.0,0.0,1.000896860986547,1116.0,-0.4961996083568794,0.09420094186476363,1.0,2.0,11.0,327.0,327.0,89.0,654.0,1542,326.0,1.6778973932186103e-06,58609.0,1116.0,1.0,0,427.0
3795,601421,HP:0000365,"Mutations in the KARS gene, which encodes both the cytosolic and mitochondrial isoform of lysyl-tRNA synthetase, cause predominantly neurological diseases that often involve deafness, but have also been linked to cardiomyopathy, developmental delay and lactic acidosis.",1,1.4742120138814352,972491.1091994748,490.3369206413365,0.21603824751670872,0.007389874539773486,0.0,0.0,1.000778816199377,1285.0,-0.7592792037058504,0.02746402899499376,1.0,2.0,2.0,46.0,46.0,43.0,92.0,2474,45.0,6.524672396198988e-07,22657.0,1285.0,1.0,0,49.0
3796,601421,HP:0001638,"Mutations in the KARS gene, which encodes both the cytosolic and mitochondrial isoform of lysyl-tRNA synthetase, cause predominantly neurological diseases that often involve deafness, but have also been linked to cardiomyopathy, developmental delay and lactic acidosis.",0,1.4150981508346034,347637.1373171491,177.16355140186917,0.2347417922683188,0.07241140935010194,0.0,0.0,0.9979035639413,476.0,-0.7594689787135601,0.07048937308667316,1.0,2.0,10.0,46.0,46.0,43.0,92.0,858,44.0,5.4335718671383015e-06,8036.0,478.0,1.0,0,43.0
3797,601421,HP:0001263,"Mutations in the KARS gene, which encodes both the cytosolic and mitochondrial isoform of lysyl-tRNA synthetase, cause predominantly neurological diseases that often involve deafness, but have also been linked to cardiomyopathy, developmental delay and lactic acidosis.",1,1.4783802823291454,1038983.8757071096,562.4731348676896,0.2213337532252433,0.12136735934447256,0.0,0.0,1.0006468305304008,1547.0,-0.738147365188527,0.021876837111598543,1.0,2.0,2.0,45.0,45.0,43.0,90.0,2998,44.0,4.444444444444443e-07,26161.0,1547.0,1.0,0,46.0
3798,601421,HP:0003128,"Mutations in the KARS gene, which encodes both the cytosolic and mitochondrial isoform of lysyl-tRNA synthetase, cause predominantly neurological diseases that often involve deafness, but have also been linked to cardiomyopathy, developmental delay and lactic acidosis.",0,1.3225126149701327,93082.53995726496,66.25731981981983,0.2719657523946535,0.031061492351174082,0.0,0.0,0.9949238578680202,196.0,-0.6901980159753951,0.1294672614469569,1.0,2.0,7.0,40.0,40.0,28.0,80.0,298,38.0,4.504301608035674e-05,2525.0,198.0,1.0,0,40.0
3799,112262,HP:0002664,"This was confirmed by BMP4 immunoreactivity in tumor cells of metastases with ongoing bone formation, as determined by histological evaluation of van Gieson-stained sections.",0,1.3423888046190733,9852295.206902083,255.74236495496982,0.14692099245942244,0.08129485614387262,0.0,0.0,0.9991126885536824,1126.0,-0.4755124091416698,0.09880779323755404,1.0,2.0,12.0,342.0,342.0,88.0,684.0,1544,340.0,1.67789739321861e-06,62805.0,1128.0,1.0,0,511.0
3008,606754,HP:0002664,Mutations in SAMHD1 are implicated in cancer development and in a severe congenital inflammatory disease known as Aicardi-Goutieres syndrome.,0,1.3684454688256968,7376836.929335822,261.58156240646514,0.1522427845378035,0.022926595403155062,0.0,0.0,1.000958772770853,1044.0,-0.5704155327586572,0.09686543752732137,1.0,2.0,6.0,259.0,259.0,146.0,518.0,1542,258.0,1.67789739321861e-06,52738.0,1044.0,1.0,0,290.0
3014,606754,HP:0002664,The mechanism by which SAMHD1 protects against cancer and chronic inflammation is unknown.,0,1.3684454688256968,7376836.929335822,261.58156240646514,0.1522427845378035,0.022926595403155062,0.0,0.0,1.000958772770853,1044.0,-0.5704155327586572,0.09686543752732137,1.0,2.0,6.0,259.0,259.0,146.0,518.0,1542,258.0,1.67789739321861e-06,52738.0,1044.0,1.0,0,290.0
3800,604161,HP:0000135,"In 2003, inactivating mutations of Kiss1R gene were first associated to lack of pubertal maturation and hypogonadotropic hypogonadism in humans and rodents.",1,1.3403116348749389,3504589.8246818967,218.26048984729198,0.1567730524501417,0.038968382891691904,0.0,0.0,1.0017574692442879,570.0,-0.4892312099888553,0.183849782628804,1.0,2.0,3.0,218.0,218.0,98.0,436.0,686,217.0,8.450513791238506e-06,29814.0,570.0,1.0,0,289.0
3813,611570,HP:0002664,"To search for the underlying molecular mechanism, we turned to examine the impact of CBX3 on the expression of FBP1, a negative regulator of aerobic glycolysis in pancreatic cancer and indicated that CBX3 negatively regulated FBP1 expression.",0,1.4070580617310602,1179108.2608818577,205.14526588845655,0.20831665272809136,0.1711829053616409,0.0,0.0,0.9988584474885844,875.0,-0.6685954345518951,0.050741163055872285,1.0,2.0,24.0,100.0,100.0,68.0,200.0,1544,98.0,1.67789739321861e-06,19491.0,877.0,1.0,0,93.0
3805,611570,HP:0002664,Silencing FBP1 expression attenuated the decrease in glycolytic capacity that caused by CBX3 knockdown in pancreatic cancer cells.,0,1.4070580617310602,1179108.2608818577,205.14526588845655,0.20831665272809136,0.1711829053616409,0.0,0.0,0.9988584474885844,875.0,-0.6685954345518951,0.050741163055872285,1.0,2.0,24.0,100.0,100.0,68.0,200.0,1544,98.0,1.67789739321861e-06,19491.0,877.0,1.0,0,93.0
3809,611570,HP:0002664,"Taken together, these data reveal that CBX3 serves as a positive regulator of aerobic glycolysis via suppressing of the FBP1 in pancreatic cancer cells.",0,1.4070580617310602,1179108.2608818577,205.14526588845655,0.20831665272809136,0.1711829053616409,0.0,0.0,0.9988584474885844,875.0,-0.6685954345518951,0.050741163055872285,1.0,2.0,24.0,100.0,100.0,68.0,200.0,1544,98.0,1.67789739321861e-06,19491.0,877.0,1.0,0,93.0
3801,611570,HP:0002664,Disrupting the CBX3-FBP1 signaling axis would be effective to treat pancreatic cancer and prevent aerobic glycolysis,0,1.4070580617310602,1179108.2608818577,205.14526588845655,0.20831665272809136,0.1711829053616409,0.0,0.0,0.9988584474885844,875.0,-0.6685954345518951,0.050741163055872285,1.0,2.0,24.0,100.0,100.0,68.0,200.0,1544,98.0,1.67789739321861e-06,19491.0,877.0,1.0,0,93.0
3817,603377,HP:0002650,"SCD patients have some degree of (kypho)scoliosis, short stature and suffer from respiratory impairment due to the reduced size of their thoracic cage.",0,1.429772975929978,1079624.1657366958,238.82822110233718,0.21670879298396264,0.08972180383490216,0.0,0.0,0.9989550679205852,956.0,-0.6737395953041231,0.042942563639417716,1.0,2.0,5.0,82.0,82.0,63.0,164.0,1740,80.0,1.3181465278043233e-06,19685.0,958.0,1.0,0,70.0
3818,603377,HP:0004322,"SCD patients have some degree of (kypho)scoliosis, short stature and suffer from respiratory impairment due to the reduced size of their thoracic cage.",0,1.4442075463410058,1373049.7022984328,288.5265843014322,0.21788015811121592,0.10266214560937907,0.0,0.0,0.9991735537190084,1209.0,-0.6590899830886165,0.03322573380376848,1.0,2.0,4.0,85.0,85.0,68.0,170.0,2246,83.0,7.915299958207215e-07,24343.0,1211.0,1.0,0,76.0
3819,603377,HP:0000772,"Therefore, it seems plausible that mutations in DMRT2 are associated with a different (novel) subtype of SCD mainly characterized by severe rib anomalies but lacking clear segmentation defects of the vertebral bodies",0,1.3316885964912282,246802.7689569203,83.01433453157591,0.2524992936733787,0.01449267647876524,0.0,0.0,0.9971181556195964,346.0,-0.6313902138257631,0.09311338567027726,1.0,2.0,10.0,73.0,73.0,34.0,146.0,520,71.0,1.4679761013490698e-05,5622.0,348.0,1.0,0,67.0
501,601728,HP:0002664,"Patients with heritable cancer syndromes characterized by germline PTEN mutations (termed PTEN hamartoma tumor syndrome, PHTS) benefit from PTEN-enabled cancer risk assessment and clinical management.",1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
495,601728,HP:0002664,PTEN-wildtype patients (~50%) remain at increased risk of developing certain cancers.,1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
3820,604933,HP:0002664,"Pathogenic or likely pathogenic cancer susceptibility gene alterations were found in 7 of the 87 (8%) CS/CS-like and BRRS patients and included MUTYH, RET, TSC2, BRCA1, BRCA2, ERCC2 and HRAS.",1,1.4607780900103378,328692.0877861739,202.02796692607004,0.28543136479607306,0.021716481125466584,0.0,0.0,1.0012224938875305,819.0,-0.6557875839410185,0.027253105492714296,1.0,2.0,3.0,47.0,47.0,45.0,94.0,1542,46.0,1.6778973932186103e-06,9129.0,819.0,1.0,0,49.0
1934,164761,HP:0002664,"Pathogenic or likely pathogenic cancer susceptibility gene alterations were found in 7 of the 87 (8%) CS/CS-like and BRRS patients and included MUTYH, RET, TSC2, BRCA1, BRCA2, ERCC2 and HRAS.",1,1.3454208312212703,10532873.130266957,248.6928072346046,0.14679757854877915,0.02628547516165559,0.0,0.0,1.0008305647840532,1205.0,-0.4632247979281744,0.09519995588701564,1.0,2.0,7.0,395.0,395.0,52.0,790.0,1542,394.0,1.677897393218609e-06,69059.0,1205.0,1.0,0,548.0
3821,191092,HP:0002664,"Pathogenic or likely pathogenic cancer susceptibility gene alterations were found in 7 of the 87 (8%) CS/CS-like and BRRS patients and included MUTYH, RET, TSC2, BRCA1, BRCA2, ERCC2 and HRAS.",1,1.35945444387786,5618137.201828054,215.3678800441228,0.16517565239835075,0.05095837144483327,0.0,0.0,1.000916590284143,1092.0,-0.5170170319203347,0.08194082117088533,1.0,2.0,0.0,299.0,299.0,70.0,598.0,1542,299.0,1.6778973932186097e-06,48811.0,1092.0,2.0,0,338.0
1651,113705,HP:0002664,"Pathogenic or likely pathogenic cancer susceptibility gene alterations were found in 7 of the 87 (8%) CS/CS-like and BRRS patients and included MUTYH, RET, TSC2, BRCA1, BRCA2, ERCC2 and HRAS.",1,1.342124294666095,14779870.286244314,292.6232998839511,0.14059513390679754,0.0363653511393512,0.0,0.0,1.0008032128514055,1246.0,-0.37767621403519097,0.11088720854525648,1.0,2.0,3.0,471.0,471.0,37.0,942.0,1542,470.0,1.6778973932186097e-06,86008.0,1246.0,1.0,0,633.0
2345,600185,HP:0002664,"Pathogenic or likely pathogenic cancer susceptibility gene alterations were found in 7 of the 87 (8%) CS/CS-like and BRRS patients and included MUTYH, RET, TSC2, BRCA1, BRCA2, ERCC2 and HRAS.",1,1.3416355462103815,14500864.778067766,286.27804058963136,0.14198849810087022,0.09065436525648868,0.0,0.0,1.0007987220447283,1253.0,-0.3695548622099266,0.10824627921741813,1.0,2.0,4.0,477.0,477.0,34.0,954.0,1542,476.0,1.67789739321861e-06,84906.0,1253.0,1.0,0,615.0
3823,126340,HP:0002664,"Pathogenic or likely pathogenic cancer susceptibility gene alterations were found in 7 of the 87 (8%) CS/CS-like and BRRS patients and included MUTYH, RET, TSC2, BRCA1, BRCA2, ERCC2 and HRAS.",1,1.3385897618281453,14377155.681649394,271.6729331526254,0.14129745822204864,0.059168710782462976,0.0,0.0,1.000766871165644,1305.0,-0.359787523674666,0.1007333756434666,1.0,2.0,3.0,501.0,501.0,22.0,1002.0,1542,500.0,1.6778973932186106e-06,85710.0,1305.0,1.0,0,739.0
3824,190020,HP:0002664,"Pathogenic or likely pathogenic cancer susceptibility gene alterations were found in 7 of the 87 (8%) CS/CS-like and BRRS patients and included MUTYH, RET, TSC2, BRCA1, BRCA2, ERCC2 and HRAS.",1,1.3395898505387556,13489684.110750364,257.11903088914914,0.14214121101440347,0.06291407408994605,0.0,0.0,1.0007782101167315,1286.0,-0.3867350102502192,0.0960817181136574,1.0,2.0,2.0,488.0,488.0,24.0,976.0,1542,487.0,1.67789739321861e-06,79388.0,1286.0,1.0,0,686.0
477,601728,HP:0002664,Our data suggest that only a small subset of PTEN-wildtype CS/CS-like and BRRS patients could be accounted for by germline variants in some of the known cancer-related genes.,1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
3825,613815,HP:0000007,Steroid 21-Hydroxylase deficiency is an inherited autosomal recessive metabolic disorder of the adrenal steroidogenesis caused due to mutations in the CYP21A2 gene in 95% of CAH cases.,1,1.4870334011357358,1018877.9106361964,563.543023255814,0.28842206475838744,-0.00229206522113123,0.0,0.0,1.0003806623524931,2628.0,-0.5901695749263011,0.007693203525732947,1.0,2.0,190.0,48.0,48.0,48.0,96.0,5160,47.0,1.5011496554636372e-07,26556.0,2628.0,1.0,0,47.0
3826,606718,HP:0002652,"Using a targeted sequencing skeletal dysplasia panel, the proband was found to be a compound heterozygote for two mutations in SLC26A2, one novel mutation, p.Ser522Phe and the other, the common mutation, p.Arg279Trp.",1,1.3608676732512954,1962087.4032356527,177.74809778209487,0.1810555276912333,0.07336909572242753,0.0,0.0,1.001669449081803,600.0,-0.4129270722757267,0.12219810795770727,1.0,2.0,19.0,174.0,174.0,174.0,348.0,348,174.0,5.484591041468992e-06,21959.0,600.0,1.0,0,187.0
2049,190070,HP:0002664,"Oncogene-induced senescence appears to decrease the frequency of the multistep progression in KRAS- or BRAF-mutated adenocarcinoma, whose tumor evolution may be associated with epigenetic alterations and kinase-inactive mutations.",1,1.3339771877413191,18178836.290753696,271.2782786211432,0.14438020893870612,0.0522035687829069,0.0,0.0,1.0006165228113442,1623.0,-0.2035822069529308,0.08341633409382543,1.0,2.0,4.0,720.0,720.0,2.0,1440.0,1542,719.0,1.374364528201273e-06,109797.0,1623.0,1.0,0,858.0
242,164757,HP:0002664,"Oncogene-induced senescence appears to decrease the frequency of the multistep progression in KRAS- or BRAF-mutated adenocarcinoma, whose tumor evolution may be associated with epigenetic alterations and kinase-inactive mutations.",1,1.3343717616163435,16381827.818362188,267.1583928605997,0.14243558102353174,0.0178111227871734,0.0,0.0,1.0006944444444446,1441.0,-0.2821765440487228,0.0923076181663968,1.0,2.0,9.0,611.0,611.0,3.0,1222.0,1542,610.0,1.6778973932186103e-06,95771.0,1441.0,1.0,0,790.0
3827,190070,HP:0030078,"This review summarizes the current knowledge of tumorigenesis and tumor progression in early lung adenocarcinoma, with special focus on its clinicopathological characteristics and their associations with driver mutations (EGFR, KRAS, and BRAF) as well as on its molecular pathogenesis and progression",0,1.4868451877999151,53715.9993974927,189.7712648439657,0.4829139799839307,0.2379435284527103,0.0,0.0,1.0011520737327189,869.0,-0.5525676307095275,0.00838667253530463,1.0,2.0,134.0,17.0,17.0,17.0,34.0,738,17.0,1.374364528201273e-06,3163.0,869.0,1.0,0,17.0
3828,164757,HP:0030078,"This review summarizes the current knowledge of tumorigenesis and tumor progression in early lung adenocarcinoma, with special focus on its clinicopathological characteristics and their associations with driver mutations (EGFR, KRAS, and BRAF) as well as on its molecular pathogenesis and progression",0,1.4834810399386047,46371.15012986047,161.16453028972785,0.4598787274228373,0.08242147605854779,0.0,0.0,1.001457725947522,687.0,-0.5837951604010758,0.011339283061945926,1.0,2.0,105.0,17.0,17.0,17.0,34.0,1086,17.0,2.221032735801493e-06,2672.0,687.0,1.0,0,17.0
2481,131550,HP:0030078,"This review summarizes the current knowledge of tumorigenesis and tumor progression in early lung adenocarcinoma, with special focus on its clinicopathological characteristics and their associations with driver mutations (EGFR, KRAS, and BRAF) as well as on its molecular pathogenesis and progression",0,1.4321436588103251,13752.128205128203,50.884615384615394,0.4116440105721133,0.13268454670033908,0.0,0.0,1.0068493150684932,147.0,-0.619390430165819,0.0712887894883981,1.0,2.0,35.0,17.0,17.0,17.0,34.0,230,17.0,5.827166249053085e-05,765.0,147.0,1.0,0,17.0
2077,190070,HP:0002664,"This review summarizes the current knowledge of tumorigenesis and tumor progression in early lung adenocarcinoma, with special focus on its clinicopathological characteristics and their associations with driver mutations (EGFR, KRAS, and BRAF) as well as on its molecular pathogenesis and progression",1,1.3339771877413191,18178836.290753696,271.2782786211432,0.14438020893870612,0.0522035687829069,0.0,0.0,1.0006165228113442,1623.0,-0.2035822069529308,0.08341633409382543,1.0,2.0,4.0,720.0,720.0,2.0,1440.0,1542,719.0,1.374364528201273e-06,109797.0,1623.0,1.0,0,858.0
252,164757,HP:0002664,"This review summarizes the current knowledge of tumorigenesis and tumor progression in early lung adenocarcinoma, with special focus on its clinicopathological characteristics and their associations with driver mutations (EGFR, KRAS, and BRAF) as well as on its molecular pathogenesis and progression",1,1.3343717616163435,16381827.818362188,267.1583928605997,0.14243558102353174,0.0178111227871734,0.0,0.0,1.0006944444444446,1441.0,-0.2821765440487228,0.0923076181663968,1.0,2.0,9.0,611.0,611.0,3.0,1222.0,1542,610.0,1.6778973932186103e-06,95771.0,1441.0,1.0,0,790.0
1734,131550,HP:0002664,"This review summarizes the current knowledge of tumorigenesis and tumor progression in early lung adenocarcinoma, with special focus on its clinicopathological characteristics and their associations with driver mutations (EGFR, KRAS, and BRAF) as well as on its molecular pathogenesis and progression",1,1.4135577242017423,2148700.9990685256,249.19306594831886,0.18304335818682368,0.03828770954761315,0.0,0.0,1.0011111111111108,901.0,-0.6842090355364789,0.06837094586262177,1.0,2.0,6.0,124.0,124.0,94.0,248.0,1542,123.0,1.6778973932186097e-06,27721.0,901.0,1.0,0,105.0
1781,604455,HP:0002668,"Five of the fifteen SDH-deficient GISTs had follow-up data: one patient died 8 months after surgery from unknown cause, four had no recurrences or metastases, and there was no history of paraganglioma and pulmonary chondroma found in patients and their families.",0,1.3196002805049092,19512.302380952387,54.30385241454151,0.3149717259999279,0.19905366377608869,0.0,0.0,0.9914529914529916,116.0,-0.736683234501452,0.13718673040706938,1.0,2.0,16.0,20.0,20.0,20.0,40.0,74,19.0,0.00010412328196584755,947.0,118.0,1.0,0,20.0
3831,300172,HP:0001249,Mutations in CASK cause a wide spectrum of phenotypes in humans ranging from mild X-linked intellectual disability to a severe microcephaly (MC) and pontocerebellar hypoplasia syndrome.,1,1.3940994056335605,32620189.8951711,550.5557580051963,0.12458510793409495,0.058428944877166114,0.0,0.0,1.0005073566717402,1972.0,-0.5778800938497509,0.08515204748776117,1.0,2.0,3.0,366.0,366.0,341.0,732.0,3204,365.0,3.8916426584744994e-07,165485.0,1972.0,1.0,0,387.0
3835,300172,HP:0000252,Mutations in CASK cause a wide spectrum of phenotypes in humans ranging from mild X-linked intellectual disability to a severe microcephaly (MC) and pontocerebellar hypoplasia syndrome.,1,1.3676497130107217,21824970.35294787,439.08860050757437,0.12378933242283365,0.05688395411256428,0.0,0.0,1.0007132667617689,1403.0,-0.5349405737615311,0.12162443835961866,1.0,2.0,4.0,361.0,361.0,291.0,722.0,2066,360.0,9.353172034763868e-07,119618.0,1403.0,1.0,0,462.0
3837,608014,HP:0002664,"In conclusion, we provide evidence that HSPB8 promotes cancer cell growth by activating the ERK-CREB pathway and may serve as a potential prognostic factor in GC patients",0,1.4145400138310429,603979.3820082222,185.06967109975415,0.2367360154694091,0.12275102522707393,0.0,0.0,0.99880810488677,838.0,-0.6775930071067573,0.034403201089732674,1.0,2.0,37.0,63.0,63.0,47.0,126.0,1544,61.0,1.6778973932186097e-06,12123.0,840.0,1.0,0,58.0
3841,600997,HP:0002664,"In conclusion, we provide evidence that HSPB8 promotes cancer cell growth by activating the ERK-CREB pathway and may serve as a potential prognostic factor in GC patients",0,1.4690265087320626,357691.2300742182,297.28916465103237,0.2541462988734713,0.25144426459714403,0.0,0.0,1.0012391573729864,808.0,-0.7632440013769647,0.03219355392788348,1.0,2.0,7.0,35.0,35.0,35.0,70.0,1542,34.0,1.67789739321861e-06,10496.0,808.0,1.0,0,31.0
3847,211100,HP:0002664,Carboxyl terminus of Hsc-70-interacting protein (CHIP) is an E3 ubiquitin ligase that induces the ubiquitination and degradation of numerous tumor-associated proteins and serves as a suppressor or promoter in tumor progression.,0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865482,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
3848,120320,HP:0030731,"Four of the five genes, including AKAP12, SOPB, TCF7L2, COL12A1 and TXNIP were downregulated, and were associated with the OS of patients with breast carcinoma.",0,1.3169086700336698,12626.514156268568,62.1291280148423,0.4736885093404359,0.4590141960443783,0.0,0.0,0.9961089494163424,256.0,-0.5094023169922293,0.0268150695261364,1.0,2.0,100.0,12.0,12.0,12.0,24.0,490,11.0,1.6524555489457333e-05,889.0,258.0,1.0,0,12.0
3849,103850,HP:0005584,"ALDOA has been revealed to be related with many carcinomas, but its expression and function in renal cell carcinoma (RCC) remain unknown.",0,1.26875,59959.48333333334,49.030039675042495,0.2761188386254826,0.10012152597580816,0.0,0.0,0.9931972789115646,146.0,-0.3926177504488205,0.1701599558742416,1.0,2.0,10.0,52.0,52.0,2.0,104.0,158,50.0,0.00015625,1851.0,148.0,1.0,0,61.0
3850,103850,HP:0002664,"Our data revealed that ALDOA functions as a tumor promoter, plays a prominent role in proliferation, migration, and invasion of RCC cells with high expression, and may promote EMT and activate the Wnt/b-catenin signaling pathway",0,1.4219392253689485,1572784.4178430515,306.81045494097754,0.18375678226986325,0.24338055878119594,0.0,0.0,0.99882491186839,850.0,-0.7441107214044678,0.06259413117955677,1.0,2.0,22.0,79.0,79.0,79.0,158.0,1544,77.0,1.6778973932186097e-06,22692.0,852.0,1.0,0,72.0
1744,131550,HP:0002664,We examined differences in the expression levels of EGFR in GC and adjacent non-cancerous tissues.,1,1.4135577242017423,2148700.9990685256,249.19306594831886,0.18304335818682368,0.03828770954761315,0.0,0.0,1.0011111111111108,901.0,-0.6842090355364789,0.06837094586262177,1.0,2.0,6.0,124.0,124.0,94.0,248.0,1542,123.0,1.6778973932186097e-06,27721.0,901.0,1.0,0,105.0
3851,606598,HP:0040078,"Additionally, despite GDAP1 affecting mitochondrial functionality, and hence being of great importance to cellular function, the GDAP1-associated Charcot-Marie-Tooth disease is mainly characterized by axonal degeneration.",0,1.4198663655185393,24293.10248917749,61.036585365853654,0.36118489238490215,0.1601769279726329,0.0,0.0,1.0070422535211268,143.0,-0.6860884042991815,0.10341770905151187,1.0,2.0,14.0,20.0,20.0,20.0,40.0,78,20.0,6.503642039542144e-05,1050.0,143.0,1.0,0,20.0
3852,602194,HP:0000608,"HtrA1 is a serine protease suggested to play a role in the pathogenesis of various diseases, including age-related macular degeneration and osteoarthritis, by modulating extracellular matrix or cell surface proteins.",0,1.2765159095457277,76381.15000000001,49.15154950869237,0.2916153893137641,-0.016948566616773866,0.0,0.0,0.9944444444444444,179.0,-0.442783669138394,0.13934929404542665,1.0,2.0,12.0,61.0,61.0,3.0,122.0,164,59.0,0.00010203040506070808,2270.0,181.0,1.0,0,65.0
3853,125240,HP:0001875,"MDR rectal colonization occurs in 6.5% of haematological inpatients and predicts a 16% probability of MDRrel BSI, particularly during neutropenia, as well as a higher probability of unfavourable outcomes in CR-rel BSIs.",0,1.3260698808234022,318727.63373015873,101.3807123655914,0.22246325681070586,0.11334392422374408,0.0,0.0,0.9960629921259844,253.0,-0.5636450786466535,0.18829705110390613,1.0,2.0,3.0,82.0,82.0,67.0,164.0,322,80.0,3.810394756896815e-05,6098.0,255.0,1.0,0,91.0
996,121011,HP:0000365,"Here we established a mutation detection system based on multiple fluorescent probe technique, which can detect and genotype nine hotspot mutations of four prominent hearing loss-related genes in two reactions on a four-channel real-time PCR instrument, including GJB2 (rs750188782, rs80338943, rs1110333204, and rs80338939), GJB3 (rs74315319), SLC26A4 (rs111033313 and rs121908362), and mtDNA 12S rRNA (rs267606617 and rs267606619).",1,1.395883254657124,11360890.773559922,359.9890516043107,0.1442161069048109,0.0490995817099891,0.0,0.0,1.000660501981506,1515.0,-0.6063388048985573,0.07124963487101682,1.0,2.0,7.0,266.0,266.0,150.0,532.0,2474,265.0,6.524672396198986e-07,81713.0,1515.0,1.0,0,305.0
3854,603324,HP:0000365,"Here we established a mutation detection system based on multiple fluorescent probe technique, which can detect and genotype nine hotspot mutations of four prominent hearing loss-related genes in two reactions on a four-channel real-time PCR instrument, including GJB2 (rs750188782, rs80338943, rs1110333204, and rs80338939), GJB3 (rs74315319), SLC26A4 (rs111033313 and rs121908362), and mtDNA 12S rRNA (rs267606617 and rs267606619).",1,1.43832292578498,6940100.0494014425,523.4543558350355,0.14851335217082265,0.04110556556860274,0.0,0.0,1.0007315288953913,1368.0,-0.7269817689558491,0.06631459164859234,1.0,2.0,2.0,130.0,130.0,128.0,260.0,2474,129.0,6.524672396198984e-07,62006.0,1368.0,1.0,0,125.0
3861,613301,HP:0002664,We aimed to investigate the effect of the AS to FEZF1 gene on non-small cell lung cancer (NSCLC) development.,0,1.381653799901552,4009890.7969294377,267.2045339198105,0.16472928680382126,0.048808509645322594,0.0,0.0,0.9989281886387996,932.0,-0.6303969295897766,0.08320652909841615,1.0,2.0,25.0,161.0,161.0,162.0,322.0,1544,159.0,1.6778973932186097e-06,36254.0,934.0,1.0,0,175.0
3858,613301,HP:0002664,The expression level of lncRNA FEZF-AS1 and FEZF1 was determined by the quantitative Real-time PCR in 160 cases of NSCLC tissues and their adjacent non-tumour tissues.,0,1.381653799901552,4009890.7969294377,267.2045339198105,0.16472928680382126,0.048808509645322594,0.0,0.0,0.9989281886387996,932.0,-0.6303969295897766,0.08320652909841615,1.0,2.0,25.0,161.0,161.0,162.0,322.0,1544,159.0,1.6778973932186097e-06,36254.0,934.0,1.0,0,175.0
3864,601094,HP:0000518,"Monoallelic and biallelic deleterious sequence variants in FOXE3 cause aphakia, cataracts, sclerocornea and microphthalmia in humans.",1,1.3749963850528537,3390425.541297228,215.49908746839802,0.1643839983258576,0.012047089050832387,0.0,0.0,1.0011709601873535,855.0,-0.6202162120886867,0.09229905364504157,1.0,2.0,5.0,181.0,181.0,91.0,362.0,1298,180.0,2.366863905325444e-06,33697.0,855.0,1.0,0,229.0
3868,601094,HP:0000647,"Monoallelic and biallelic deleterious sequence variants in FOXE3 cause aphakia, cataracts, sclerocornea and microphthalmia in humans.",1,1.4118906217308034,107375.91818394023,86.74927840461822,0.2619653809001934,0.3433653756973116,0.0,0.0,1.0041322314049588,243.0,-0.630840265411551,0.09254157739006223,1.0,2.0,49.0,37.0,37.0,37.0,74.0,178,37.0,2.3337767509160075e-05,2721.0,243.0,1.0,0,47.0
3869,601094,HP:0000568,"Monoallelic and biallelic deleterious sequence variants in FOXE3 cause aphakia, cataracts, sclerocornea and microphthalmia in humans.",1,1.33465770907077,1187650.4862914863,140.63525350593312,0.17027510468284832,0.3249473215552108,0.0,0.0,1.0023255813953489,431.0,-0.4966659672912875,0.16321156855339125,1.0,2.0,5.0,154.0,154.0,23.0,308.0,450,153.0,1.957866708434489e-05,15124.0,431.0,1.0,0,209.0
3866,601094,HP:0000518,"Whole genome transcriptome analysis (RNA-Seq) on RNA isolated from wildtype larvae and larvae with eye defects that were putative homozygotes for the foxe3 indel variant found significant dysregulation of genes expressed in the lens and eye whose orthologues are associated with cataracts in human patients, including cryba2a, cryba1l1, mipa and hsf4.",1,1.3749963850528537,3390425.541297228,215.49908746839802,0.1643839983258576,0.012047089050832387,0.0,0.0,1.0011709601873535,855.0,-0.6202162120886867,0.09229905364504157,1.0,2.0,5.0,181.0,181.0,91.0,362.0,1298,180.0,2.366863905325444e-06,33697.0,855.0,1.0,0,229.0
3870,602438,HP:0000518,"Whole genome transcriptome analysis (RNA-Seq) on RNA isolated from wildtype larvae and larvae with eye defects that were putative homozygotes for the foxe3 indel variant found significant dysregulation of genes expressed in the lens and eye whose orthologues are associated with cataracts in human patients, including cryba2a, cryba1l1, mipa and hsf4.",1,1.4860842521911224,31902.0223880597,264.8789346246973,0.33902221772778995,0.1391251970554031,0.0,0.0,1.001510574018127,663.0,-0.9088035064651624,0.016541127257317056,1.0,2.0,1.0,13.0,13.0,13.0,26.0,1298,12.0,2.366863905325444e-06,3630.0,663.0,1.0,0,11.0
3133,116806,HP:0002664,We recently described a novel role for A20 in regulating the wnt-beta-catenin signaling pathway and suppressing colonic tumor development in mice.,1,1.3518211230574562,8628385.610725343,244.5227047309904,0.15288895987823498,0.10335671492220867,0.0,0.0,1.0008741258741258,1145.0,-0.4805894159801953,0.09402388005008093,1.0,2.0,4.0,359.0,359.0,79.0,718.0,1542,359.0,1.6778973932186097e-06,61580.0,1145.0,1.0,0,481.0
3871,608256,HP:0002664,"In this study, we aimed to explore the expression profiles of SCN4B in papillary thyroid cancer (PTC) and its prognostic value in terms of recurrence-free survival (RFS) in classical PTC.",0,1.4412442396313363,153787.1122423285,120.37233030696066,0.33938620803182434,0.3012090933381476,0.0,0.0,0.9987760097919216,816.0,-0.6451549749158879,0.017503957767848858,1.0,2.0,24.0,43.0,43.0,19.0,86.0,1544,41.0,1.67789739321861e-06,5849.0,818.0,1.0,0,32.0
3872,608256,HP:0001428,"In addition, no somatic mutation was found in SCN4B DNA.",0,1.2759889132220092,22230.5631951382,28.51230158730159,0.3861262169208496,0.2504525899797998,0.0,0.0,0.9953271028037384,213.0,-0.6080108609179844,0.050163008041730066,1.0,2.0,26.0,35.0,35.0,11.0,70.0,338,33.0,3.501277966457757e-05,1154.0,215.0,1.0,0,19.0
3875,612778,HP:0002664,"The second most frequently mutated gene, histone methyltransferase SETD2, has known roles in multiple cancers, but has not previously been strongly implicated in osteosarcoma.",1,1.3430869189876868,13127093.0724359,269.85310020718583,0.14231370498978632,0.08691720247752226,0.0,0.0,1.0008116883116882,1233.0,-0.4120926058637731,0.10264006066925777,1.0,2.0,2.0,443.0,443.0,44.0,886.0,1542,442.0,1.6778973932186097e-06,77958.0,1233.0,1.0,0,613.0
3874,612778,HP:0002669,"This study points to the likely importance of histone modifications in osteosarcoma and highlights the strong genetic similarities between human and dog osteosarcoma, suggesting that canine osteosarcoma may serve as an excellent model for developing treatment strategies in both species.Significance: Canine osteosarcoma genomics identify SETD2 as a possible oncogenic driver of osteosarcoma, and findings establish the canine model as a useful comparative model for the corresponding human disease.",0,1.360620492142434,140007.69174837507,143.5772456709957,0.23623370758354784,0.4159245556784684,0.0,0.0,0.997979797979798,494.0,-0.5685566657548863,0.0385386119257087,1.0,2.0,103.0,33.0,33.0,33.0,66.0,486,32.0,4.6648535935699665e-06,4731.0,496.0,1.0,0,33.0
3876,613847,HP:0000568,"We found that Tctn3 KO mice exhibited abnormal global development, including prenatal lethality, microphthalmia, polysyndactyly, and abnormal head, sternum, and neural tube, whereas Tctn3 heterozygous KO mice did not show abnormal development or behaviors.",0,1.3338185648186476,3409463.4662698423,219.0146225614928,0.14945383309834684,0.036387015587735064,0.0,0.0,0.9983844911147012,618.0,-0.3132970512153568,0.16503726093074156,1.0,2.0,7.0,224.0,224.0,226.0,448.0,452,222.0,6.441804736014842e-06,31669.0,620.0,1.0,0,246.0
3877,613847,HP:0000234,"We found that Tctn3 KO mice exhibited abnormal global development, including prenatal lethality, microphthalmia, polysyndactyly, and abnormal head, sternum, and neural tube, whereas Tctn3 heterozygous KO mice did not show abnormal development or behaviors.",1,1.4196086577104652,48963765.73917996,667.954881816642,0.12723075640907652,0.05454258367606744,0.0,0.0,1.0003326679973386,3007.0,-0.5782059913825397,0.05049163395855446,1.0,2.0,4.0,390.0,390.0,340.0,780.0,5228,389.0,1.4623677928117312e-07,228198.0,3007.0,1.0,0,426.0
3878,300377,HP:0003202,"A previous study showed that treatment with resveratrol inhibits muscular atrophy in mdx mice, a model of DMD.",1,1.3418767507002802,3372577.3590048845,194.09303840665137,0.1711904182934408,0.10517439871624744,0.0,0.0,1.0013568521031206,738.0,-0.4486313890943951,0.12469066346023025,1.0,2.0,3.0,266.0,266.0,44.0,532.0,908,265.0,4.830334500664172e-06,33910.0,738.0,1.0,0,379.0
3879,606144,HP:0001513,"Interestingly, RAB23 null allele homozygosity in humans is not lethal, but instead causes the developmental disorder Carpenter*s syndrome (CS), which is characterized by craniofacial malformations, polysyndactyly, obesity and intellectual disability.",1,1.3340501684311838,3570782.132539682,175.03796870785,0.16322014505081514,0.07007422981191093,0.0,0.0,1.0014534883720931,689.0,-0.4212254410699235,0.127147534343673,1.0,2.0,18.0,259.0,259.0,5.0,518.0,704,258.0,8.025102520684701e-06,30136.0,689.0,1.0,0,289.0
3880,606144,HP:0001249,"Interestingly, RAB23 null allele homozygosity in humans is not lethal, but instead causes the developmental disorder Carpenter*s syndrome (CS), which is characterized by craniofacial malformations, polysyndactyly, obesity and intellectual disability.",1,1.3998550639276928,23027197.57027428,456.2095192581973,0.1331711611230086,0.07247766934147519,0.0,0.0,1.0005159958720329,1939.0,-0.5725119183439196,0.06760477324123645,1.0,2.0,5.0,325.0,325.0,253.0,650.0,3204,324.0,3.891642658474498e-07,127022.0,1939.0,1.0,0,432.0
3881,604616,HP:0001249,"Among these genes, it is affirmative that TBR1 is a causative gene for intellectual disability; however, the pathogenic genes of other phenotypes remain unclear.",1,1.442457816518426,10372331.397884576,625.3125568845395,0.14375986983302075,0.027991498586616047,0.0,0.0,1.0005694760820043,1757.0,-0.676765926654528,0.05728663607853,1.0,2.0,5.0,151.0,151.0,150.0,302.0,3204,150.0,3.8916426584745004e-07,88373.0,1757.0,1.0,0,154.0
3885,104150,HP:0002664,"RASSF7 was significantly up-regulated in HCC tissues and cell lines, and correlated with AFP, poor tumor histology and T stage.",0,1.3936926009357131,16591.98454004939,151.78826199740595,0.511950755928789,0.2063200777409981,0.0,0.0,0.9987179487179488,779.0,-0.7352972882800497,0.00645129518368955,1.0,2.0,169.0,7.0,7.0,7.0,14.0,1544,5.0,1.6778973932186097e-06,1965.0,781.0,1.0,0,6.0
3894,606530,HP:0001251,"To date, there are no reports of symptomatic improvement in CTX related ataxia following treatment with Riluzole.",1,1.401643832944441,5114737.13933758,340.7201832497367,0.15566136710539152,0.04794938602965268,0.0,0.0,1.0010214504596526,980.0,-0.6537928346828964,0.0984011173417273,1.0,2.0,2.0,162.0,162.0,142.0,324.0,1626,161.0,1.5092152684290275e-06,47204.0,980.0,1.0,0,166.0
3897,606530,HP:0001251,We report the case of a 45 year old woman diagnosed with CTX-related cerebellar ataxia.,1,1.401643832944441,5114737.13933758,340.7201832497367,0.15566136710539152,0.04794938602965268,0.0,0.0,1.0010214504596526,980.0,-0.6537928346828964,0.0984011173417273,1.0,2.0,2.0,162.0,162.0,142.0,324.0,1626,161.0,1.5092152684290275e-06,47204.0,980.0,1.0,0,166.0
3891,606530,HP:0001251,"Thus, in addition to the standard therapy with CDCA, the addition of Riluzole may have some therapeutic benefits for ataxia caused by CTX.",1,1.401643832944441,5114737.13933758,340.7201832497367,0.15566136710539152,0.04794938602965268,0.0,0.0,1.0010214504596526,980.0,-0.6537928346828964,0.0984011173417273,1.0,2.0,2.0,162.0,162.0,142.0,324.0,1626,161.0,1.5092152684290275e-06,47204.0,980.0,1.0,0,166.0
3900,609591,HP:0002664,"Germline and somatic RIT1 mutations have been identified in Noonan syndrome (NS) and cancer, respectively.",0,1.3625534736587972,8845101.395869628,284.36478362539884,0.14519139363376313,0.11604116959723212,0.0,0.0,0.9990439770554492,1045.0,-0.5526743857447796,0.10615233180113992,1.0,2.0,5.0,272.0,272.0,215.0,544.0,1544,270.0,1.677897393218609e-06,58127.0,1047.0,1.0,0,364.0
3901,138890,HP:0012174,"Although some potential glioblastoma biomarkers have already been identified, there is a lack of cell membrane-bound biomarkers capable of distinguishing brain tissue from glioblastoma and/or glioblastoma stem cells (GSC), which are responsible for the rapid post-operative tumor reoccurrence.",0,1.3230000000000002,22803.26231962482,50.39591836734694,0.37840042852685385,0.10353032284735114,0.0,0.0,0.9940476190476192,167.0,-0.6048384723795468,0.07178078331924485,1.0,2.0,30.0,21.0,21.0,21.0,42.0,236,19.0,4.565376186997809e-05,1019.0,169.0,1.0,0,20.0
1705,138890,HP:0002664,"Although some potential glioblastoma biomarkers have already been identified, there is a lack of cell membrane-bound biomarkers capable of distinguishing brain tissue from glioblastoma and/or glioblastoma stem cells (GSC), which are responsible for the rapid post-operative tumor reoccurrence.",0,1.3814234091422386,3773499.9491447625,262.3012784880489,0.16372186382625006,0.1558280732019673,0.0,0.0,0.9989118607181721,918.0,-0.6628627428106406,0.07819226948005867,1.0,2.0,31.0,145.0,145.0,140.0,290.0,1544,143.0,1.6778973932186097e-06,33055.0,920.0,1.0,0,158.0
3904,608945,HP:0012174,"In addition, FREM2 gene and protein expression levels are higher in GB stem-like cell lines than in conventional glioblastoma cell lines.",0,1.346291869882033,38281.083644133636,71.11946902654867,0.35452486862583205,0.02077058756624236,0.0,0.0,0.9959514170040484,246.0,-0.5724059997684281,0.04949719211179313,1.0,2.0,51.0,21.0,21.0,21.0,42.0,136,20.0,1.9406547769217335e-05,1516.0,248.0,1.0,0,23.0
3902,608945,HP:0012174,FREM2 is thus proposed as a novel GB biomarker and a putative biomarker of glioblastoma stem cells.,0,1.346291869882033,38281.083644133636,71.11946902654867,0.35452486862583205,0.02077058756624236,0.0,0.0,0.9959514170040484,246.0,-0.5724059997684281,0.04949719211179313,1.0,2.0,51.0,21.0,21.0,21.0,42.0,136,20.0,1.9406547769217335e-05,1516.0,248.0,1.0,0,23.0
3906,601639,HP:0008221,"Genomics of tumors identified several new genes - including ZNRF3 in adrenocortical carcinomas, PRKACA in cortisol-producing adrenal adenomas, ARMC5 in primary macronodular adrenal hyperplasia and USP8 in pituitary corticotroph adenomas.",1,1.4360155778618835,31526.896059496063,75.92738095238093,0.3590284238190526,0.3060353914369375,0.0,0.0,1.0053475935828875,188.0,-0.6617224585485397,0.07719877119126181,1.0,2.0,23.0,20.0,20.0,20.0,40.0,126,20.0,3.501277966457757e-05,1357.0,188.0,1.0,0,20.0
3907,603158,HP:0008221,"Genomics of tumors identified several new genes - including ZNRF3 in adrenocortical carcinomas, PRKACA in cortisol-producing adrenal adenomas, ARMC5 in primary macronodular adrenal hyperplasia and USP8 in pituitary corticotroph adenomas.",1,1.4493068987749838,39954.08231225296,96.33185840707964,0.3688382592340976,0.2561974305716697,0.0,0.0,1.0040816326530613,246.0,-0.6356008920130561,0.0587356893977103,1.0,2.0,14.0,20.0,20.0,20.0,40.0,136,20.0,1.940654776921733e-05,1770.0,246.0,1.0,0,20.0
3908,605284,HP:0001250,"Furthermore, in utero CRISPR-Cas9-mediated genome editing of Tsc1 or Tsc2 induced the development of spontaneous behavioral seizures, as well as cytomegalic neurons and cortical dyslamination.",1,1.3978387358386493,11755290.823940035,331.22476500430736,0.15674023893863145,0.19612720072283926,0.0,0.0,1.0005302226935309,1887.0,-0.5465081775938726,0.051526293931633584,1.0,2.0,8.0,313.0,313.0,114.0,626.0,3114,312.0,4.1569653487839437e-07,91688.0,1887.0,1.0,0,309.0
3909,300371,HP:0001425,"X-ALD is clinically heterogeneous, with the cerebral form being the most severe.",0,1.2914543707276387,847704.8482174685,93.19203729958052,0.2176919757196889,0.292544136425386,0.0,0.0,0.998095238095238,524.0,-0.3115493447154236,0.0900307803729857,1.0,2.0,25.0,191.0,191.0,2.0,382.0,496,189.0,1.2939288856684434e-05,12431.0,526.0,1.0,0,209.0
3910,300371,HP:0002180,We show that loss of the Drosophila long-/very-long-chain acyl-CoA synthetase genes bgm and/or dbb is indistinguishable from loss of the Drosophila ABC transporter gene ABCD Shared loss-of-function phenotypes for synthetase and transporter mutants point to a lipid metabolic pathway association with ALD-like neurodegenerative disease in Drosophila; a pathway association that has yet to be established in humans.,1,1.3882412337066277,255687.9857142857,91.06478138788609,0.25138628315238715,0.2234654657150263,0.0,0.0,1.0028735632183907,349.0,-0.4525882729440113,0.08569640681092118,1.0,2.0,42.0,72.0,72.0,72.0,144.0,198,72.0,1.2939288856684434e-05,5204.0,349.0,1.0,0,91.0
3911,303630,HP:0000007,"Mutations in the COL4A5 gene result in X-linked Alport syndrome, homozygous or compound heterozygous mutations in COL4A3 or COL4A4 are responsible for autosomal recessive Alport syndrome, and heterozygous mutations in COL4A3 or COL4A4 cause autosomal dominant Alport syndrome or benign familial hematuria.",0,1.4495201724084097,4781949.518796608,384.1754346130912,0.2196473745688337,0.14634533157999885,0.0,0.0,0.9996363636363635,2749.0,-0.5412420168798515,0.0167518588281947,1.0,2.0,26.0,162.0,162.0,123.0,324.0,5162,160.0,1.5011496554636372e-07,63366.0,2751.0,1.0,0,137.0
3912,123695,HP:0003075,A 17-year-old adolescent boy with a history of hypoproteinemia underwent Ga-NEB PET/MRI to evaluate possible lymphatic disorders suggested by FDG PET/CT imaging.,0,1.2925461990601532,11122.232212885156,38.602040816326536,0.5189056512586503,0.33094355787374763,0.0,0.0,0.9952830188679246,211.0,-0.4243972095755894,0.0319337408096377,1.0,2.0,84.0,16.0,16.0,16.0,32.0,310,15.0,2.5767218944059367e-05,721.0,213.0,1.0,0,16.0
2759,139250,HP:0004322,"Until now, more than 90 GHR mutations relevant to human short stature (Laron syndrome and idiopathic short stature), including deletions, missense, nonsense, frameshift, and splice site mutations, and four GHR defects associated with chicken dwarfism, have been described.",1,1.4740277705353058,742669.2623465075,457.2549019607843,0.21829494927913945,0.13080848861100744,0.0,0.0,1.0008583690987125,1166.0,-0.7824317291220356,0.028504332334601992,1.0,2.0,4.0,39.0,39.0,36.0,78.0,2244,38.0,7.929402939746845e-07,19360.0,1166.0,1.0,0,38.0
3913,600375,HP:0002664,BACKGROUND This case-control study aimed to analyze the association of XRCC2 polymorphisms (rs3218408 and rs3218384) with colorectal cancer (CRC) risk.,1,1.3501369697458,12536042.297456713,285.94927594368005,0.1408780656705339,0.045981924360195436,0.0,0.0,1.0008635578583764,1159.0,-0.4558587453212677,0.1099840401990281,1.0,2.0,7.0,379.0,379.0,84.0,758.0,1542,378.0,1.6778973932186097e-06,73806.0,1159.0,1.0,0,460.0
3914,607057,HP:0002664,"Although the role of USP18 in breast cancer cell lines has been elucidated, the underlying mechanisms and clinical role of USP18 in breast cancer are currently not well understood.",0,1.4120864229784138,1939868.93032196,283.896002829855,0.18542894209862992,0.3726807968957305,0.0,0.0,0.9988518943742823,870.0,-0.6667929300310816,0.06741697300371817,1.0,2.0,20.0,100.0,100.0,100.0,200.0,1544,98.0,1.677897393218609e-06,25602.0,872.0,1.0,0,92.0
3934,607057,HP:0002664,The bioinformatics analysis and experimental results of the present study demonstrated that aberrant promoter methylation led to increased expression of USP18 in breast cancer.,0,1.4120864229784138,1939868.93032196,283.896002829855,0.18542894209862992,0.3726807968957305,0.0,0.0,0.9988518943742823,870.0,-0.6667929300310816,0.06741697300371817,1.0,2.0,20.0,100.0,100.0,100.0,200.0,1544,98.0,1.677897393218609e-06,25602.0,872.0,1.0,0,92.0
3919,607057,HP:0002664,"Furthermore, the Gene Set Enrichment Analysis results demonstrated that USP18 may be negatively associated with apoptosis in patients with breast cancer.",0,1.4120864229784138,1939868.93032196,283.896002829855,0.18542894209862992,0.3726807968957305,0.0,0.0,0.9988518943742823,870.0,-0.6667929300310816,0.06741697300371817,1.0,2.0,20.0,100.0,100.0,100.0,200.0,1544,98.0,1.677897393218609e-06,25602.0,872.0,1.0,0,92.0
550,600960,HP:0002664,"Furthermore, the Gene Set Enrichment Analysis results demonstrated that USP18 may be negatively associated with apoptosis in patients with breast cancer.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
3924,607057,HP:0002664,"In addition, the results indicated that USP18 may promote the epidermal growth factor (EGF)-mediated EGF receptor (EGFR)/AKT/S-phase kinase-associated protein 2 (Skp2) pathway by upregulating EGFR and Skp2 in a AKT/forkhead box O3-dependent manner in breast cancer.",0,1.4120864229784138,1939868.93032196,283.896002829855,0.18542894209862992,0.3726807968957305,0.0,0.0,0.9988518943742823,870.0,-0.6667929300310816,0.06741697300371817,1.0,2.0,20.0,100.0,100.0,100.0,200.0,1544,98.0,1.677897393218609e-06,25602.0,872.0,1.0,0,92.0
2618,164730,HP:0002664,"In addition, the results indicated that USP18 may promote the epidermal growth factor (EGF)-mediated EGF receptor (EGFR)/AKT/S-phase kinase-associated protein 2 (Skp2) pathway by upregulating EGFR and Skp2 in a AKT/forkhead box O3-dependent manner in breast cancer.",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
3944,607057,HP:0002664,"USP18 was also significantly enhanced in patients with human epidermal growth factor receptor 2-positive breast cancer; furthermore, Kaplan-Meier curve demonstrated that combining USP18 and Skp2 expression improved prognostic capability in breast cancer.",0,1.4120864229784138,1939868.93032196,283.896002829855,0.18542894209862992,0.3726807968957305,0.0,0.0,0.9988518943742823,870.0,-0.6667929300310816,0.06741697300371817,1.0,2.0,20.0,100.0,100.0,100.0,200.0,1544,98.0,1.677897393218609e-06,25602.0,872.0,1.0,0,92.0
3929,607057,HP:0002664,"Taken together, these results suggested that USP18 may serve a key role in breast cancer development by upregulating EGFR and subsequently activating the AKT/Skp2 feedback loop pathway.",0,1.4120864229784138,1939868.93032196,283.896002829855,0.18542894209862992,0.3726807968957305,0.0,0.0,0.9988518943742823,870.0,-0.6667929300310816,0.06741697300371817,1.0,2.0,20.0,100.0,100.0,100.0,200.0,1544,98.0,1.677897393218609e-06,25602.0,872.0,1.0,0,92.0
3628,131530,HP:0002664,"Taken together, these results suggested that USP18 may serve a key role in breast cancer development by upregulating EGFR and subsequently activating the AKT/Skp2 feedback loop pathway.",0,1.4183540398436123,1210345.6075365078,294.30023120735353,0.1921133491501248,0.1846422582674654,0.0,0.0,0.9988109393579072,840.0,-0.7406795875192191,0.05465724832726565,1.0,2.0,38.0,69.0,69.0,70.0,138.0,1544,67.0,1.677897393218609e-06,19352.0,842.0,1.0,0,64.0
2648,164730,HP:0002664,"Taken together, these results suggested that USP18 may serve a key role in breast cancer development by upregulating EGFR and subsequently activating the AKT/Skp2 feedback loop pathway.",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
3939,607057,HP:0002664,The role of USP18 in breast cancer provides a novel insight into the clinical application of the USP18/AKT/Skp2 pathway,0,1.4120864229784138,1939868.93032196,283.896002829855,0.18542894209862992,0.3726807968957305,0.0,0.0,0.9988518943742823,870.0,-0.6667929300310816,0.06741697300371817,1.0,2.0,20.0,100.0,100.0,100.0,200.0,1544,98.0,1.677897393218609e-06,25602.0,872.0,1.0,0,92.0
2660,164730,HP:0002664,The role of USP18 in breast cancer provides a novel insight into the clinical application of the USP18/AKT/Skp2 pathway,1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
272,601231,HP:0002664,"Collectively, our findings identified LSD1 as a novel negative regulator of autophagy through the mTOR signaling pathway in ovarian cancer HO8910 cells and indicated that LSD1 may function as a driving factor of ovarian cancer progression via deregulating autophagy",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
3949,134770,HP:0002664,"Given the lack of specific targeted genes and pathways known to be involved in tumour cell dormancy, we proposed enriched candidate genes related to the negative regulation of cell proliferation, signalling pathways regulating pluripotency of stem cells and neuroactive ligand-receptor interaction, and 3 hub genes (FTH1, GRM1 and DDIT3).",0,1.4332630905840806,17625.483739242925,187.526403557532,0.5024554951514111,0.15220006127067612,0.0,0.0,0.9987163029525032,778.0,-0.7679543794276203,0.006797011289950956,1.0,2.0,96.0,8.0,8.0,8.0,16.0,1544,6.0,1.67789739321861e-06,2065.0,780.0,1.0,0,7.0
3950,604473,HP:0002664,"Given the lack of specific targeted genes and pathways known to be involved in tumour cell dormancy, we proposed enriched candidate genes related to the negative regulation of cell proliferation, signalling pathways regulating pluripotency of stem cells and neuroactive ligand-receptor interaction, and 3 hub genes (FTH1, GRM1 and DDIT3).",0,1.407284348864994,1477989.523124289,206.90296172015374,0.20581685863390287,0.06308084751315922,0.0,0.0,0.9988649262202044,880.0,-0.6179719966990695,0.05263035974889388,1.0,2.0,14.0,106.0,106.0,91.0,212.0,1544,104.0,1.6778973932186097e-06,20448.0,882.0,1.0,0,101.0
3951,610000,HP:0002664,BACKGROUND The aim of this study was to investigate the prognostic relevance of CEP55 in lung cancer (LC).,0,1.3536973042156628,7614665.465916688,244.22136664618745,0.15135969844228575,0.03968654263427771,0.0,0.0,0.999053926206244,1056.0,-0.5382513991041921,0.09202847878845324,1.0,2.0,14.0,281.0,281.0,114.0,562.0,1544,279.0,1.6778973932186097e-06,51458.0,1058.0,1.0,0,334.0
3955,605086,HP:0000726,"The triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial innate immune receptor associated with a lethal form of early, progressive dementia, Nasu-Hakola disease, and with an increased risk of Alzheimer*s disease.",1,1.3416952864466678,652224.8162698413,110.95249815407335,0.21597671121797404,0.1247837987613444,0.0,0.0,1.0025575447570334,392.0,-0.33223319258727657,0.13505402160864347,1.0,2.0,1.0,149.0,149.0,7.0,298.0,306,148.0,1.7361111111111108e-05,10350.0,392.0,1.0,0,173.0
3956,605086,HP:0000717,TREM2 protein levels were also negatively correlated with the severity of symptoms in humans affected by autism.,0,1.2719218331282198,641235.4365079366,106.22164268928756,0.1894363427304931,0.2538597797980325,0.0,0.0,0.9974093264248703,385.0,-0.2811693662543941,0.1316222838092943,1.0,2.0,38.0,141.0,141.0,6.0,282.0,294,140.0,1.736111111111111e-05,9831.0,387.0,1.0,0,169.0
3957,612944,HP:0002352,"RNASET2 deficiency in humans is associated with infant cystic leukoencephalopathy, which causes psychomotor impairment, spasticity and epilepsy.",1,1.3645052473763115,594982.7798701298,169.71329284750337,0.17887987430924954,0.05384831820971507,0.0,0.0,1.0037037037037038,271.0,-0.7475843900154892,0.2536832034987017,1.0,2.0,2.0,75.0,75.0,75.0,150.0,390,74.0,2.603082049146189e-05,9281.0,271.0,1.0,0,73.0
3959,612944,HP:0001257,"RNASET2 deficiency in humans is associated with infant cystic leukoencephalopathy, which causes psychomotor impairment, spasticity and epilepsy.",1,1.440622653743772,2293562.4684051857,475.40093708165995,0.15356390027438302,0.036154571869302536,0.0,0.0,1.0012165450121655,823.0,-0.8090578082652086,0.09695109873378804,1.0,2.0,2.0,75.0,75.0,75.0,150.0,1494,74.0,1.787297320483857e-06,32794.0,823.0,1.0,0,73.0
3960,612944,HP:0001250,"RNASET2 deficiency in humans is associated with infant cystic leukoencephalopathy, which causes psychomotor impairment, spasticity and epilepsy.",1,1.4678546276733755,4427624.4807703085,812.1718166383702,0.1551958552294328,0.07279325430086983,0.0,0.0,1.000615384615385,1626.0,-0.7987536266646523,0.04453779922414609,1.0,2.0,1.0,76.0,76.0,75.0,152.0,3100,75.0,4.156965348783943e-07,58840.0,1626.0,1.0,0,74.0
3961,602345,HP:0001251,"Importantly, dysfunction in other family members leads to learning deficits (TRPC1/4/5) and ataxia (TRPC3).",1,1.4781190590393631,288103.4412962201,420.8227415607489,0.2472158277912492,0.1581945535300401,0.0,0.0,1.0011918951132301,840.0,-0.7724809810324287,0.031207787048073105,1.0,2.0,1.0,27.0,27.0,27.0,54.0,1626,26.0,1.5092152684290268e-06,10997.0,840.0,1.0,0,26.0
2517,300203,HP:0001250,"Atypical Rett syndrome is a child neurodevelopmental disorder induced by mutations in CDKL5 gene and characterized by a progressive regression in development with loss of purposeful use of the hands, slowed brain and head growth, problems with walking, seizures, and intellectual disability.",1,1.3978387358386493,23602790.82105435,481.44419833445016,0.13187703661703354,0.0564989490201423,0.0,0.0,1.0005302226935309,1887.0,-0.5761203967910292,0.07489486866943046,1.0,2.0,1.0,335.0,335.0,290.0,670.0,3100,334.0,4.156965348783939e-07,133271.0,1887.0,1.0,0,387.0
3962,300203,HP:0001249,"Atypical Rett syndrome is a child neurodevelopmental disorder induced by mutations in CDKL5 gene and characterized by a progressive regression in development with loss of purposeful use of the hands, slowed brain and head growth, problems with walking, seizures, and intellectual disability.",1,1.3998550639276928,24772214.76040055,509.9108051137858,0.12972924403847005,0.012070010455596471,0.0,0.0,1.0005159958720329,1939.0,-0.5877885749436208,0.07556265903663384,1.0,2.0,1.0,335.0,335.0,291.0,670.0,3204,334.0,3.8916426584745004e-07,141974.0,1939.0,1.0,0,359.0
321,601231,HP:0002664,The mammalian target of rapamycin (mTOR) pathway is overactivated in thyroid cancer (TC).,0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
363,601231,HP:0002664,"We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features.",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
3963,601843,HP:0002664,"We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features.",0,1.4146791046296108,1498953.0261580544,307.2154583930644,0.18683298805400966,0.07976805558513096,0.0,0.0,0.9988207547169812,847.0,-0.7271791490347449,0.06100962286374648,1.0,2.0,37.0,77.0,77.0,77.0,154.0,1544,75.0,1.67789739321861e-06,21962.0,849.0,1.0,0,74.0
3964,601231,HP:0000718,"We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features.",0,1.3178085907748809,1339060.5639971143,138.1691329387298,0.18250400114541016,0.12124744385754455,0.0,0.0,0.9978021978021978,454.0,-0.31842917879161603,0.14895893580104105,1.0,2.0,10.0,180.0,180.0,5.0,360.0,378,178.0,1.4027409558276873e-05,15453.0,456.0,1.0,0,211.0
3965,601843,HP:0000718,"We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features.",0,1.341729903334488,321018.3599206349,104.34434490481523,0.21586118147655706,0.12777724641756955,0.0,0.0,0.9962264150943396,264.0,-0.6580379321295591,0.16464746772591854,1.0,2.0,3.0,74.0,74.0,49.0,148.0,378,72.0,2.770083102493075e-05,5803.0,266.0,1.0,0,79.0
3966,601843,HP:0002895,"We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features.",0,1.3495479982780887,6199.757936507937,40.504784688995215,0.4037003882763836,0.30007902698452593,0.0,0.0,0.9886363636363636,87.0,-0.7870401857563752,0.11670071501532175,1.0,2.0,9.0,12.0,12.0,12.0,24.0,84,11.0,0.00016866250632484398,457.0,89.0,1.0,0,13.0
3967,608968,HP:0100244,The musculo-aponeurotic fibrosarcoma oncogene homolog B (MAFB) significantly enhanced the activation of the TFPI2 promoter via RAR&amp;alpha; while MAFF inhibited it.,0,1.3518424180675837,9573.770483193277,92.42771599657827,0.5187818644004434,0.4679727419887654,0.0,0.0,0.9970760233918128,341.0,-0.5745401296451869,0.016384498661620037,1.0,2.0,114.0,8.0,8.0,8.0,16.0,314,7.0,8.910670527957227e-06,961.0,343.0,1.0,0,8.0
3968,608968,HP:0002664,These results suggest that MAFB and MAFF play critical roles in the antitumor effects of retinoids by regulating the expression of retinoid target genes such as TFPI2 and can be promising for developing therapies to combat HCC invasion,0,1.3413736751449197,8789706.978607502,247.31382759772285,0.14753613176339958,0.1104054913636626,0.0,0.0,0.9990958408679926,1105.0,-0.5041379087595634,0.09519235638408224,1.0,2.0,16.0,322.0,322.0,100.0,644.0,1544,320.0,1.67789739321861e-06,58274.0,1107.0,1.0,0,458.0
3969,611184,HP:0100242,Application of a PIEZO1 agonist Yoda1 effectively induced Ca2+ response and cation channel currents in PIEZO1-expressing HEK (HEK-Piezo1) cells and synovial sarcoma SW982 (SW982) cells.,0,1.2756539111346792,609772.8569985569,109.3215697346132,0.19699441056159545,0.16121656604001233,0.0,0.0,0.9972375690607732,361.0,-0.2491212102691575,0.14973441090969972,1.0,2.0,27.0,137.0,137.0,2.0,274.0,336,135.0,2.3113905325443783e-05,9838.0,363.0,1.0,0,178.0
3973,604373,HP:0002664,BACKGROUND This study aimed to investigate the mechanism of CHEK2 gene dysfunction in drug resistance of triple negative breast cancer (TNBC) cells.,1,1.3907500291201478,3049455.1280453037,216.48240792209663,0.18644085984948167,0.18561350324725764,0.0,0.0,1.0010427528675705,960.0,-0.579863168744912,0.07138512339242266,1.0,2.0,1.0,186.0,186.0,98.0,372.0,1542,185.0,1.67789739321861e-06,32860.0,960.0,1.0,0,173.0
2478,131550,HP:0030078,"In lung adenocarcinoma (LADC), specific thyroxin kinase inhibitors against EGFR mutations and ALK fusions are used as a standard treatment regimen and show significant positive efficacy.",0,1.4321436588103251,13752.128205128203,50.884615384615394,0.4116440105721133,0.13268454670033908,0.0,0.0,1.0068493150684932,147.0,-0.619390430165819,0.0712887894883981,1.0,2.0,35.0,17.0,17.0,17.0,34.0,230,17.0,5.827166249053085e-05,765.0,147.0,1.0,0,17.0
3979,105590,HP:0030078,"In lung adenocarcinoma (LADC), specific thyroxin kinase inhibitors against EGFR mutations and ALK fusions are used as a standard treatment regimen and show significant positive efficacy.",0,1.2200435729847494,1248.8333333333335,15.936974789915965,0.4629195985318881,0.4625564548566653,0.0,0.0,0.96875,31.0,-0.5416689000290573,0.26136363636363635,1.0,2.0,3.0,13.0,13.0,5.0,26.0,36,11.0,0.002770083102493075,138.0,33.0,1.0,0,12.0
3986,610924,HP:0002664,In this study we extend these findings by demonstrating that the mRNA levels of RBCK1 and SHARPIN are also higher in tumors compared to adjacent non-tumor tissue in the same cross sectional study of samples (p &lt; 0.001).,0,1.4286407418534104,1125177.6095683477,294.96480367881145,0.2085195757695738,0.2896448984061758,0.0,0.0,0.9988066825775656,837.0,-0.7078163267761484,0.05304644408475825,1.0,2.0,24.0,67.0,67.0,67.0,134.0,1544,65.0,1.6778973932186103e-06,18648.0,839.0,1.0,0,68.0
3983,610924,HP:0002664,"Furthermore, we investigated whether there is an association between the mRNA and protein expression levels of RBCK1, RNF31 and SHARPIN and clinicopathological parameters including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) status and found that RNF31 protein is significantly higher in ERalpha-negative tumors than ERalpha-positive tumors (p = 0.034).",0,1.4286407418534104,1125177.6095683477,294.96480367881145,0.2085195757695738,0.2896448984061758,0.0,0.0,0.9988066825775656,837.0,-0.7078163267761484,0.05304644408475825,1.0,2.0,24.0,67.0,67.0,67.0,134.0,1544,65.0,1.6778973932186103e-06,18648.0,839.0,1.0,0,68.0
3980,610924,HP:0002664,"Collectively, our findings indicate that up-regulated mRNA expression of RNF31, RBCK1 and SHARPIN could potentially be diagnostic biomarkers of breast cancer and RNF31 might be a drug target for ERalpha-negative breast cancers",0,1.4286407418534104,1125177.6095683477,294.96480367881145,0.2085195757695738,0.2896448984061758,0.0,0.0,0.9988066825775656,837.0,-0.7078163267761484,0.05304644408475825,1.0,2.0,24.0,67.0,67.0,67.0,134.0,1544,65.0,1.6778973932186103e-06,18648.0,839.0,1.0,0,68.0
3989,600582,HP:0001402,"Over-expression of aspartyl (asparagynal)-b-hydroxylase (ASPH) contributes to hepatocellular carcinoma (HCC) invasiveness, but the role of ASPH hydroxylase activity in this process remains to be defined.",0,1.2342410217773474,15292.622835497838,27.38230769230769,0.36454673957175976,0.05207907995630191,0.0,0.0,0.9902912621359224,102.0,-0.5215136511463638,0.13984316654219567,1.0,2.0,11.0,32.0,32.0,2.0,64.0,106,30.0,0.000355998576005696,749.0,104.0,1.0,0,32.0
3990,600582,HP:0002664,"As such, the current study investigated the role of ASPH hydroxylase activity in downstream signalling of HCC tumorgenesis and, specifically, metastasis development.",0,1.40566470965501,678591.6868534653,279.96866407263303,0.21029763628738868,0.25307000792678513,0.0,0.0,0.9987834549878346,821.0,-0.740399919533228,0.041013679110015286,1.0,2.0,80.0,50.0,50.0,49.0,100.0,1544,48.0,1.6778973932186097e-06,13873.0,823.0,1.0,0,49.0
3991,601197,HP:0002090,"Among the 363 outbreaks with a confirmed infectious etiology, 212 (58%) were caused by Cryptosporidium (which causes predominantly gastrointestinal illness), 57 (16%) by Legionella (which causes Legionnaires* disease, a severe pneumonia, and Pontiac fever, a milder illness with flu-like symptoms), and 47 (13%) by Pseudomonas (which causes folliculitis [&quot;hot tub rash&quot;] and otitis externa [&quot;swimmers* ear&quot;]).",0,1.327904058257919,405751.04858670745,92.75621633268692,0.2298738450008013,0.06949888525810388,0.0,0.0,0.9968253968253968,314.0,-0.5205182671645909,0.1410689170182841,1.0,2.0,3.0,108.0,108.0,28.0,216.0,392,106.0,2.603082049146189e-05,7021.0,316.0,1.0,0,111.0
3992,607311,HP:0002664,"Breast cancers may express various profiles of hormone receptors: ER(+)/PgR(+), ER(-)/PgR(-), ER(+)/PgR(-) and ER(-)/PgR(+).",0,1.4399895910212266,35392.56001226505,220.19377431906616,0.4264456575587591,0.34536917171876313,0.0,0.0,0.9987212276214834,781.0,-0.7838782296289327,0.009586709913017348,1.0,2.0,78.0,11.0,11.0,11.0,22.0,1544,9.0,1.67789739321861e-06,2935.0,783.0,1.0,0,10.0
4008,607311,HP:0002664,The existence of the latter profile is a matter of controversy since PgR expressions is induced by ER-dependent pathways in breast cancer cells.,0,1.4399895910212266,35392.56001226505,220.19377431906616,0.4264456575587591,0.34536917171876313,0.0,0.0,0.9987212276214834,781.0,-0.7838782296289327,0.009586709913017348,1.0,2.0,78.0,11.0,11.0,11.0,22.0,1544,9.0,1.67789739321861e-06,2935.0,783.0,1.0,0,10.0
4000,607311,HP:0002664,One of the most extensively propagated hypotheses trying to explain the origin of ER(-)/PgR(+) breast cancers claims that they are technical artifacts dependent on the immunohistochemical procedure.,0,1.4399895910212266,35392.56001226505,220.19377431906616,0.4264456575587591,0.34536917171876313,0.0,0.0,0.9987212276214834,781.0,-0.7838782296289327,0.009586709913017348,1.0,2.0,78.0,11.0,11.0,11.0,22.0,1544,9.0,1.67789739321861e-06,2935.0,783.0,1.0,0,10.0
3996,607311,HP:0002664,"In the following review, we present background theories on the ER(-)/PgR(+) breast cancer origin and their epidemiological and clinicopathological characteristics, including the predictive and prognostic significance of these rare tumors",0,1.4399895910212266,35392.56001226505,220.19377431906616,0.4264456575587591,0.34536917171876313,0.0,0.0,0.9987212276214834,781.0,-0.7838782296289327,0.009586709913017348,1.0,2.0,78.0,11.0,11.0,11.0,22.0,1544,9.0,1.67789739321861e-06,2935.0,783.0,1.0,0,10.0
4012,147650,HP:0006765,"Mutations in IDH1 and IDH2 have recently been observed in multiple tumors, including gliomas, acute myeloid leukemia, myelodysplastic syndromes, and chondrosarcoma.",1,1.4803005123944053,3366.8684210526317,72.38821138211381,0.5595715207328641,0.31676958169839403,0.0,0.0,1.0059171597633136,170.0,-0.6980613827240513,0.02916811695092238,1.0,2.0,55.0,6.0,6.0,6.0,12.0,328,6.0,3.673094582185491e-05,419.0,170.0,1.0,0,6.0
4013,176763,HP:0002664,"Here, we disrupt the peroxiredoxin 1 (PRDX1) and 7,8-dihydro-8-oxoguanine triphosphatase (MTH1) genes in cancer cells and demonstrate that PRDX1 and MTH1 cooperate to prevent accumulation of oxidized guanine in the genome.",0,1.3579659406776678,3445319.712175488,240.27612691925893,0.1667892619208677,0.12353754624149313,0.0,0.0,0.9989484752891692,950.0,-0.6347194994746663,0.07856612676616387,1.0,2.0,33.0,160.0,160.0,118.0,320.0,1544,158.0,1.6778973932186106e-06,35565.0,952.0,1.0,0,165.0
4016,142968,HP:0002664,The HOXB1 gene plays a critical role as an oncogene in diverse tumors.,0,1.3928361536595832,2374107.358823998,281.209783212896,0.17467508152076272,0.07788924458119814,0.0,0.0,0.998859749144812,876.0,-0.6763641200663978,0.06929556393067067,1.0,2.0,45.0,105.0,105.0,103.0,210.0,1544,103.0,1.677897393218609e-06,26679.0,878.0,1.0,0,104.0
4021,142968,HP:0009733,"However, the functional role of HOXB1 and the mechanism regulating HOXB1 expression in glioma are not fully understood.",0,1.3139740093053105,48603.19166666666,51.924561403508775,0.3048085344698052,-0.03271942528929925,0.0,0.0,0.9930555555555556,143.0,-0.6047341169134155,0.1471264367816092,1.0,2.0,10.0,39.0,39.0,39.0,78.0,152,38.0,8.8999644001424e-05,1536.0,145.0,1.0,0,44.0
4018,142968,HP:0009733,"A preliminary bioinformatics analysis showed that HOXB1 is ectopically expressed in glioma, and that HOXB1 is a possible target of miR-3175.",0,1.3139740093053105,48603.19166666666,51.924561403508775,0.3048085344698052,-0.03271942528929925,0.0,0.0,0.9930555555555556,143.0,-0.6047341169134155,0.1471264367816092,1.0,2.0,10.0,39.0,39.0,39.0,78.0,152,38.0,8.8999644001424e-05,1536.0,145.0,1.0,0,44.0
4024,142968,HP:0009733,"In this study, we investigated the function of HOXB1 and the relationship between HOXB1 and miR-3175 in glioma.",0,1.3139740093053105,48603.19166666666,51.924561403508775,0.3048085344698052,-0.03271942528929925,0.0,0.0,0.9930555555555556,143.0,-0.6047341169134155,0.1471264367816092,1.0,2.0,10.0,39.0,39.0,39.0,78.0,152,38.0,8.8999644001424e-05,1536.0,145.0,1.0,0,44.0
4036,142968,HP:0009733,"We show that HOXB1 expression is significantly downregulated in glioma tissues and cell lines, and that its expression may be closely associated with the degree of malignancy.",0,1.3139740093053105,48603.19166666666,51.924561403508775,0.3048085344698052,-0.03271942528929925,0.0,0.0,0.9930555555555556,143.0,-0.6047341169134155,0.1471264367816092,1.0,2.0,10.0,39.0,39.0,39.0,78.0,152,38.0,8.8999644001424e-05,1536.0,145.0,1.0,0,44.0
4030,142968,HP:0009733,"Reduced HOXB1 expression promoted the proliferation and invasion of glioma cells, and inhibited their apoptosis in vitro, and the downregulation of HOXB1 was also associated with worse survival in glioma patients.",0,1.3139740093053105,48603.19166666666,51.924561403508775,0.3048085344698052,-0.03271942528929925,0.0,0.0,0.9930555555555556,143.0,-0.6047341169134155,0.1471264367816092,1.0,2.0,10.0,39.0,39.0,39.0,78.0,152,38.0,8.8999644001424e-05,1536.0,145.0,1.0,0,44.0
4033,142968,HP:0009733,The oncogenicity induced by low HOXB1 expression was prevented by an miR-3175 inhibitor in glioma cells.,0,1.3139740093053105,48603.19166666666,51.924561403508775,0.3048085344698052,-0.03271942528929925,0.0,0.0,0.9930555555555556,143.0,-0.6047341169134155,0.1471264367816092,1.0,2.0,10.0,39.0,39.0,39.0,78.0,152,38.0,8.8999644001424e-05,1536.0,145.0,1.0,0,44.0
4027,142968,HP:0009733,"Our results suggest that HOXB1 functions as a tumor suppressor, regulated by miR-3175 in glioma.",0,1.3139740093053105,48603.19166666666,51.924561403508775,0.3048085344698052,-0.03271942528929925,0.0,0.0,0.9930555555555556,143.0,-0.6047341169134155,0.1471264367816092,1.0,2.0,10.0,39.0,39.0,39.0,78.0,152,38.0,8.8999644001424e-05,1536.0,145.0,1.0,0,44.0
4014,142968,HP:0002664,"Our results suggest that HOXB1 functions as a tumor suppressor, regulated by miR-3175 in glioma.",0,1.3928361536595832,2374107.358823998,281.209783212896,0.17467508152076272,0.07788924458119814,0.0,0.0,0.998859749144812,876.0,-0.6763641200663978,0.06929556393067067,1.0,2.0,45.0,105.0,105.0,103.0,210.0,1544,103.0,1.677897393218609e-06,26679.0,878.0,1.0,0,104.0
4039,605232,HP:0000822,"Variants of WNK1 (lysine deficient protein kinase 1), ADRB2 (b2 adrenergic receptor), NEDD4L (ubiquitin-protein ligase NEDD4-like), KLK1 (kallikrein 1) contribute to hypertension, and AKR1C3 (aldo-keto reductase family1 member C3), is associated with preeclampsia.",1,1.3427323013991541,885632.2474025975,115.61362044817929,0.20315065273993246,0.16503674277512825,0.0,0.0,1.0022779043280179,440.0,-0.5110321624345937,0.12432180575688548,1.0,2.0,10.0,142.0,142.0,38.0,284.0,544,141.0,1.3417595835178253e-05,12007.0,440.0,1.0,0,175.0
4040,109690,HP:0000822,"Variants of WNK1 (lysine deficient protein kinase 1), ADRB2 (b2 adrenergic receptor), NEDD4L (ubiquitin-protein ligase NEDD4-like), KLK1 (kallikrein 1) contribute to hypertension, and AKR1C3 (aldo-keto reductase family1 member C3), is associated with preeclampsia.",0,1.4356405933733791,39821.84937161188,88.81450534759358,0.3582006984339611,0.00583591501639689,0.0,0.0,0.9966101694915256,294.0,-0.7911986572536422,0.047205680256527716,1.0,2.0,2.0,20.0,20.0,17.0,40.0,552,18.0,1.3417595835178253e-05,2061.0,296.0,1.0,0,17.0
4041,606384,HP:0000822,"Variants of WNK1 (lysine deficient protein kinase 1), ADRB2 (b2 adrenergic receptor), NEDD4L (ubiquitin-protein ligase NEDD4-like), KLK1 (kallikrein 1) contribute to hypertension, and AKR1C3 (aldo-keto reductase family1 member C3), is associated with preeclampsia.",0,1.3331000203360652,1324494.6952380952,144.82954125046248,0.1874274467472929,0.14079971176432712,0.0,0.0,0.9976851851851852,431.0,-0.4720695655967361,0.15784577880420836,1.0,2.0,3.0,151.0,151.0,80.0,302.0,546,149.0,1.3319835899621714e-05,14763.0,433.0,1.0,0,208.0
4042,147910,HP:0000822,"Variants of WNK1 (lysine deficient protein kinase 1), ADRB2 (b2 adrenergic receptor), NEDD4L (ubiquitin-protein ligase NEDD4-like), KLK1 (kallikrein 1) contribute to hypertension, and AKR1C3 (aldo-keto reductase family1 member C3), is associated with preeclampsia.",0,0.9963503649635036,542.021897810219,2.0,0.7071067811865475,0.7814718668269909,0.0,0.0,0.9963503649635036,273.0,-0.9927007299270074,0.007246184472461845,1.0,2.0,273.0,2.0,2.0,2.0,4.0,546,0.0,1.3417595835178253e-05,273.0,275.0,0.0,0,1.0
2814,600726,HP:0000135,Idiopathic hypogonadotropic hypogonadism (IHH) is characterized by low levels of gonadotropins and delayed or absent sexual development.,0,1.2811268715524036,914522.370970792,81.44102307969288,0.2192041215778952,0.13217930558312285,0.0,0.0,0.9983193277310924,594.0,-0.4920177239693226,0.0682871806440697,1.0,2.0,35.0,155.0,155.0,9.0,310.0,688,153.0,8.450513791238506e-06,12108.0,596.0,1.0,0,163.0
3283,607407,HP:0001249,"From a GeneMatcher-enabled international collaboration, we identified ten individuals affected by intellectual disability, speech delay, ataxia, and facial dysmorphism and carrying a deleterious EBF3 variant detected by whole-exome sequencing.",1,1.4233147044975332,17572430.154272385,587.551953862981,0.13233679875660373,0.019169530735568898,0.0,0.0,1.0005473453749316,1828.0,-0.6521585692095052,0.06968772569014024,1.0,2.0,1.0,226.0,226.0,226.0,452.0,3204,225.0,3.891642658474498e-07,116370.0,1828.0,1.0,0,228.0
4047,607407,HP:0001999,"From a GeneMatcher-enabled international collaboration, we identified ten individuals affected by intellectual disability, speech delay, ataxia, and facial dysmorphism and carrying a deleterious EBF3 variant detected by whole-exome sequencing.",1,1.390980517969138,11378878.892167553,423.1442086471728,0.1316054584746093,-0.0011549981942023668,0.0,0.0,1.0008680555555556,1153.0,-0.652631422549796,0.11576985159487327,1.0,2.0,1.0,226.0,226.0,217.0,452.0,1854,225.0,1.1611920332936985e-06,76886.0,1153.0,1.0,0,235.0
3298,607407,HP:0001249,Our findings demonstrate that variants disrupting EBF3-mediated transcriptional regulation cause intellectual disability and developmental delay and are present in a0.1% of individuals with unexplained neurodevelopmental disorders,1,1.4233147044975332,17572430.154272385,587.551953862981,0.13233679875660373,0.019169530735568898,0.0,0.0,1.0005473453749316,1828.0,-0.6521585692095052,0.06968772569014024,1.0,2.0,1.0,226.0,226.0,226.0,452.0,3204,225.0,3.891642658474498e-07,116370.0,1828.0,1.0,0,228.0
3271,607407,HP:0001263,Our findings demonstrate that variants disrupting EBF3-mediated transcriptional regulation cause intellectual disability and developmental delay and are present in a0.1% of individuals with unexplained neurodevelopmental disorders,1,1.4196275668911686,16539193.032271625,566.849581136687,0.1317321806546134,0.03267849706017684,0.0,0.0,1.0005800464037122,1725.0,-0.6488455958535039,0.07486734590941188,1.0,2.0,1.0,226.0,226.0,226.0,452.0,2998,225.0,4.4444444444444475e-07,111324.0,1725.0,1.0,0,227.0
1508,610192,HP:0000501,"Single nucleotide polymorphisms in GLIS3 genes have been associated with increased risk of several diseases, including type 1 and type 2 diabetes, glaucoma, and neurological disorders.",1,1.354305451625267,1345151.9264957265,161.60887694588584,0.18110414684125514,0.05526589727613256,0.0,0.0,1.002247191011236,446.0,-0.5800322953441758,0.15762583765808436,1.0,2.0,5.0,134.0,134.0,89.0,268.0,608,133.0,1.0749798441279228e-05,15642.0,446.0,1.0,0,173.0
4048,118502,HP:0001513,"Inactivation of Chrna2 in mice compromised the cold-induced thermogenic response selectively in subcutaneous fat and exacerbated high-fat diet-induced obesity and associated metabolic disorders, indicating that even partial loss of beige fat regulation in vivo had detrimental consequences.",0,1.3729911311397822,212779.33528874887,94.29405594405594,0.2776019320899768,0.2471725183398892,0.0,0.0,0.9976076555023924,417.0,-0.5868965708391399,0.06258921332404563,1.0,2.0,10.0,56.0,56.0,46.0,112.0,706,54.0,8.0251025206847e-06,5481.0,419.0,1.0,0,48.0
4049,601284,HP:0002092,"Mutations in ACVRL1, BMPR2, or ENG are associated with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension in humans [1, 2].",1,1.3490694076668277,386181.4478354978,102.23276579994447,0.2154590065823653,0.13860588324664788,0.0,0.0,1.0032467532467533,309.0,-0.3828642667767488,0.15027529105199008,1.0,2.0,4.0,106.0,106.0,17.0,212.0,214,106.0,2.426654371617851e-05,7151.0,309.0,1.0,0,129.0
4050,600799,HP:0002092,"Mutations in ACVRL1, BMPR2, or ENG are associated with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension in humans [1, 2].",1,1.3424808221160804,86048.54801587302,63.09612817089453,0.2548591267139818,0.1717428693236729,0.0,0.0,1.0056818181818183,177.0,-0.6188379710302107,0.1714175654853621,1.0,2.0,10.0,54.0,54.0,30.0,108.0,214,53.0,8.573388203017832e-05,2670.0,177.0,1.0,0,51.0
4051,131195,HP:0002092,"Mutations in ACVRL1, BMPR2, or ENG are associated with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension in humans [1, 2].",1,1.3636245585696871,479938.27072094573,108.51939337920643,0.2170512315080087,0.15175192619498198,0.0,0.0,1.0026385224274406,380.0,-0.4172178657692711,0.11584502152478822,1.0,2.0,11.0,107.0,107.0,107.0,214.0,272,107.0,1.3319835899621714e-05,8342.0,380.0,1.0,0,126.0
4052,137142,HP:0002664,"Low GABRA5 expression typified hyperproliferative tumors, and loss of taurine signaling correlated with reduced patient survival, suggesting this tumor suppressive mechanism operates in vivo",0,1.3837730925790628,3612368.984636949,245.70856595048767,0.16758906928950126,0.15097966145474429,0.0,0.0,0.9989281886387996,932.0,-0.6244077140814107,0.07663565987546793,1.0,2.0,20.0,160.0,160.0,153.0,320.0,1544,158.0,1.67789739321861e-06,33391.0,934.0,1.0,0,176.0
4053,601623,HP:0003006,"Using human neuroblastoma SH-SY5Y cells in culture, we also observed that human DDI1 is ubiquitinated by UBE3A, without being targeted for degradation.",0,1.3577452591593926,158839.94529914527,112.35582038731644,0.25427859033505457,0.2257166873807904,0.0,0.0,0.9965753424657532,291.0,-0.7032816497600998,0.09011641497966244,1.0,2.0,33.0,38.0,38.0,38.0,76.0,154,37.0,1.5378700499807768e-05,3855.0,293.0,1.0,0,38.0
4056,314310,HP:0002664,Both the primary tumor and the JU-PI cells showed nuclear expression of the TFE3 transcription factor but TFE3-activating chromosomal rearrangements were not found.,1,1.489994604854331,61749.00782632964,339.62159533073935,0.3678870663553596,0.19424813494618126,0.0,0.0,1.0012787723785166,783.0,-0.7388616629527454,0.01310782517238113,1.0,2.0,12.0,12.0,12.0,12.0,24.0,1542,11.0,1.67789739321861e-06,4013.0,783.0,1.0,0,11.0
4055,107400,HP:0100242,"To our knowledge, JU-PI is the first established myxoinflammatory fibroblastic sarcoma cell line.",0,1.3305353550982515,119092.81115779644,70.41034404192298,0.2640850088815324,0.21599077741868056,0.0,0.0,0.9952830188679244,211.0,-0.6653950675292367,0.1353972893967579,1.0,2.0,5.0,52.0,52.0,35.0,104.0,310,50.0,4.162330905306972e-05,3057.0,213.0,1.0,0,47.0
4057,608500,HP:0001250,Homozygous recessive mutations in the PRICKLE1 gene were first described in three consanguineous families with myoclonic epilepsy.,1,1.4741279807059988,1251855.46968504,476.594623655914,0.2371489759227609,0.17010907265482614,0.0,0.0,1.000621504039776,1610.0,-0.6374360633915047,0.021254666105640245,1.0,2.0,1.0,60.0,60.0,60.0,120.0,3100,59.0,4.156965348783942e-07,27530.0,1610.0,1.0,0,55.0
4059,608500,HP:0001250,"We describe a 7-year-old with a novel de novo missense mutation in PRICKLE1 associated with epilepsy, autism spectrum disorder and global developmental delay",1,1.4741279807059988,1251855.46968504,476.594623655914,0.2371489759227609,0.17010907265482614,0.0,0.0,1.000621504039776,1610.0,-0.6374360633915047,0.021254666105640245,1.0,2.0,1.0,60.0,60.0,60.0,120.0,3100,59.0,4.156965348783942e-07,27530.0,1610.0,1.0,0,55.0
4061,608500,HP:0000717,"We describe a 7-year-old with a novel de novo missense mutation in PRICKLE1 associated with epilepsy, autism spectrum disorder and global developmental delay",0,1.3413403497910539,132705.3351731602,75.41689497716895,0.2565225385816892,0.13581066723180898,0.0,0.0,0.9951690821256038,206.0,-0.6210245604598991,0.15458937198067632,1.0,2.0,2.0,59.0,59.0,37.0,118.0,294,57.0,4.565376186997809e-05,3328.0,208.0,1.0,0,52.0
4062,600144,HP:0003745,"Higher gene expression of the inositol 1,4,5-trisphosphate receptor 2 gene (ITPR2), encoding the IP3 receptor 2 (IP3R2), was detected in sporadic ALS patients.",0,1.3317345550862625,3450.920779220779,28.96842105263157,0.4772965981491071,0.3954828873628001,0.0,0.0,0.9905660377358492,105.0,-0.7256913657360587,0.06154117439605007,1.0,2.0,15.0,10.0,10.0,8.0,20.0,192,8.0,0.00010850694444444445,349.0,107.0,1.0,0,8.0
4063,107777,HP:0002664,"They affect AQP2, AQP5 and AQP8, where they are associated with nephrogenic diabetes insipidus, keratoderma and colorectal cancer, respectively.",0,1.4135374535374536,980850.2949219934,217.48172995214455,0.21844754445404585,0.005377154175613186,0.0,0.0,0.9988358556461,858.0,-0.6734523001666932,0.04793025963126405,1.0,2.0,16.0,81.0,81.0,66.0,162.0,1544,79.0,1.67789739321861e-06,17704.0,860.0,1.0,0,76.0
4064,600442,HP:0002664,"They affect AQP2, AQP5 and AQP8, where they are associated with nephrogenic diabetes insipidus, keratoderma and colorectal cancer, respectively.",0,1.4517977501353367,142005.1415904828,244.6725958866037,0.3185561530319537,0.2650060621988091,0.0,0.0,0.9987389659520808,792.0,-0.722491353486321,0.01827387626619572,1.0,2.0,40.0,22.0,22.0,22.0,44.0,1544,20.0,1.6778973932186103e-06,5753.0,794.0,1.0,0,21.0
4071,608750,HP:0002664,RESULTS There was an increased expression of ALG3 in breast cancer tissues compared to normal breast tissues (p&lt;0.05).,0,1.3670282679593666,4914461.559438935,275.9236298885445,0.15525494323200428,0.027112385434254743,0.0,0.0,0.9989462592202318,948.0,-0.6497820828503925,0.08957905828850313,1.0,2.0,37.0,172.0,172.0,154.0,344.0,1544,170.0,1.6778973932186084e-06,40380.0,950.0,1.0,0,183.0
4065,608750,HP:0002664,ALG3 expression was significantly increased in cancer samples with advanced stages (stage III/IV) compared with those in the early stages of disease (stage I/II) (p&lt;0.05).,0,1.3670282679593666,4914461.559438935,275.9236298885445,0.15525494323200428,0.027112385434254743,0.0,0.0,0.9989462592202318,948.0,-0.6497820828503925,0.08957905828850313,1.0,2.0,37.0,172.0,172.0,154.0,344.0,1544,170.0,1.6778973932186084e-06,40380.0,950.0,1.0,0,183.0
4084,606034,HP:0002664,The nucleotide degrading enzyme gene RNASEH2A (ribonuclease H2 subunit A) has been found to be overexpressed in cancers.,0,1.3665847856036455,7418070.764627692,261.14566603195635,0.15255244655505795,0.01770134984954141,0.0,0.0,1.0009505703422057,1053.0,-0.5489900459988296,0.09735176338471647,1.0,2.0,5.0,270.0,270.0,143.0,540.0,1542,269.0,1.67789739321861e-06,53921.0,1053.0,1.0,0,308.0
4078,606034,HP:0002664,Our aim was to understand the role of RNASEH2A in cancer prognostication and to establish a scoring system based on the expressions of genes interacting with RNASEH2A.,0,1.3665847856036455,7418070.764627692,261.14566603195635,0.15255244655505795,0.01770134984954141,0.0,0.0,1.0009505703422057,1053.0,-0.5489900459988296,0.09735176338471647,1.0,2.0,5.0,270.0,270.0,143.0,540.0,1542,269.0,1.67789739321861e-06,53921.0,1053.0,1.0,0,308.0
4087,606034,HP:0002664,We screened the nucleotide degrading enzyme gene expression in RNAseq data of 14 cancer types derived from The Cancer Genome Atlas (TCGA) and found that RNASEH2A overexpression was associated with poor patient survival only in renal cell carcinomas (RCCs).,0,1.3665847856036455,7418070.764627692,261.14566603195635,0.15255244655505795,0.01770134984954141,0.0,0.0,1.0009505703422057,1053.0,-0.5489900459988296,0.09735176338471647,1.0,2.0,5.0,270.0,270.0,143.0,540.0,1542,269.0,1.67789739321861e-06,53921.0,1053.0,1.0,0,308.0
4081,606034,HP:0002664,"The combination of low CD151 expression and high RNASEH2A expression resulted in impaired proliferation in four kidney cancer cell lines, suggesting potential synthetic dosage lethality (SDL) interactions between the two genes.",0,1.3665847856036455,7418070.764627692,261.14566603195635,0.15255244655505795,0.01770134984954141,0.0,0.0,1.0009505703422057,1053.0,-0.5489900459988296,0.09735176338471647,1.0,2.0,5.0,270.0,270.0,143.0,540.0,1542,269.0,1.67789739321861e-06,53921.0,1053.0,1.0,0,308.0
4090,602243,HP:0002664,"The combination of low CD151 expression and high RNASEH2A expression resulted in impaired proliferation in four kidney cancer cell lines, suggesting potential synthetic dosage lethality (SDL) interactions between the two genes.",0,1.4385201670382817,545947.6202894046,280.0014591439689,0.2291791578104163,-0.012206798326586532,0.0,0.0,0.9987804878048779,819.0,-0.7766606542308526,0.039752235524791305,1.0,2.0,25.0,47.0,47.0,44.0,94.0,1544,45.0,1.6778973932186097e-06,13381.0,821.0,1.0,0,41.0
4091,606034,HP:0006770,"A prognostication scoring system was established based on the expression levels of RNASEH2A-, CDK1-, and CD151-related genes, which could effectively predict the overall survival in a TCGA clear cell RCC cohort (n = 533, 995.3 versus 2242.2 days, p &lt; 0.0001), in another clear cell renal cell carcinoma (ccRCC) cohort E-GEOD-22541 (n = 44, 390.0 versus 1889.2 days, p = 0.0007), and in a TCGA papillary RCC (pRCC) cohort (n = 287, 741.6 versus 1623.7 days, p &lt; 0.0001).",0,1.2805306448849032,1159.009756097561,80.27659574468085,0.6824529707378839,0.7249715563218218,0.0,0.0,0.9964788732394366,283.0,-0.7997104132265236,0.00892018779342723,1.0,2.0,205.0,2.0,2.0,2.0,4.0,410,1.0,1.2486109203511094e-05,361.0,285.0,1.0,0,2.0
4092,602243,HP:0006770,"A prognostication scoring system was established based on the expression levels of RNASEH2A-, CDK1-, and CD151-related genes, which could effectively predict the overall survival in a TCGA clear cell RCC cohort (n = 533, 995.3 versus 2242.2 days, p &lt; 0.0001), in another clear cell renal cell carcinoma (ccRCC) cohort E-GEOD-22541 (n = 44, 390.0 versus 1889.2 days, p = 0.0007), and in a TCGA papillary RCC (pRCC) cohort (n = 287, 741.6 versus 1623.7 days, p &lt; 0.0001).",0,1.285861979839752,245.0833333333333,27.52083333333333,0.6403703320172849,0.6192165187514906,0.0,0.0,0.98,49.0,-0.8759432914851821,0.05803921568627453,1.0,2.0,24.0,2.0,2.0,2.0,4.0,96,1.0,0.0004164931278633903,74.0,51.0,1.0,0,2.0
4093,179755,HP:0006770,"A prognostication scoring system was established based on the expression levels of RNASEH2A-, CDK1-, and CD151-related genes, which could effectively predict the overall survival in a TCGA clear cell RCC cohort (n = 533, 995.3 versus 2242.2 days, p &lt; 0.0001), in another clear cell renal cell carcinoma (ccRCC) cohort E-GEOD-22541 (n = 44, 390.0 versus 1889.2 days, p = 0.0007), and in a TCGA papillary RCC (pRCC) cohort (n = 287, 741.6 versus 1623.7 days, p &lt; 0.0001).",0,1.248447204968944,93.33333333333334,13.6875,0.6331727528378785,0.6105415559057561,0.0,0.0,0.9444444444444444,17.0,-0.9557513885872098,0.16374269005847952,1.0,2.0,6.0,2.0,2.0,2.0,4.0,26,1.0,0.0034602076124567475,28.0,19.0,1.0,0,2.0
4094,300747,HP:0002664,"Only minor changes in mRNA transcript levels occurred upon exposure to the compounds confirming that metabolic flux alone can be a key determinant of sialoglycoconjugate display in breast cancer cells; this result complements the well-established role of genetic control (e.g., the transcription of STs) of sialylation abnormalities ubiquitously associated with cancer.",1,1.4277873066020004,1869262.7391977054,283.45515018427915,0.18759935699167046,0.09573451019221194,0.0,0.0,1.0011481056257177,872.0,-0.6862297353146007,0.06665595803621273,1.0,2.0,5.0,101.0,101.0,101.0,202.0,1542,100.0,1.6778973932186097e-06,25313.0,872.0,1.0,0,100.0
4095,608896,HP:0002664,We believe that this strategy combined with multi-dimensional analysis of sialic acid metabolism will ultimately provide novel insights into breast cancer subtypes and provide a foundation for new methods of diagnosis,0,1.3767717688563597,1611387.3493592062,202.84662775616084,0.1932094796161927,0.22190946384700647,0.0,0.0,0.9988888888888888,899.0,-0.6788693002079589,0.056596374398816124,1.0,2.0,43.0,120.0,120.0,66.0,240.0,1544,118.0,1.6778973932186097e-06,22947.0,901.0,1.0,0,112.0
876,604061,HP:0002664,"The positive rate of mSEPT9 in CRC was correlated with tumor size, histological grade, and general histological type (P &lt; 0.05).",0,1.401169031996131,2150343.770653287,278.95674947620466,0.17441469573484886,0.0037803444929031256,0.0,0.0,0.9988584474885844,875.0,-0.7085486973439081,0.0683499684999193,1.0,2.0,24.0,100.0,100.0,99.0,200.0,1544,98.0,1.6778973932186097e-06,26255.0,877.0,1.0,0,96.0
873,604061,HP:0002664,"Beyond CRC, gastric cancer patients also presented a high positive rate of plasma mSEPT9 (70%).",0,1.401169031996131,2150343.770653287,278.95674947620466,0.17441469573484886,0.0037803444929031256,0.0,0.0,0.9988584474885844,875.0,-0.7085486973439081,0.0683499684999193,1.0,2.0,24.0,100.0,100.0,99.0,200.0,1544,98.0,1.6778973932186097e-06,26255.0,877.0,1.0,0,96.0
4114,602460,HP:0000365,Mutations in the POU class 4 transcription factor 3 (POU4F3) are known to cause autosomal dominant nonsyndromic hearing loss linked to the loci of DFNA15.,1,1.4972010306575976,24129.0,919.4381568310428,0.36571261393774496,0.4631941220931329,0.0,0.0,1.000805152979066,1243.0,-0.9400185988274704,0.007112292606713537,1.0,2.0,1.0,6.0,6.0,6.0,12.0,2474,5.0,6.524672396198987e-07,5490.0,1243.0,1.0,0,5.0
4111,602460,HP:0000365,"In this study, we describe a pathogenic missense mutation in POU4F3 in a four-generation Chinese family (6126) with midfrequency, progressive, and postlingual autosomal dominant nonsyndromic hearing loss (ADNSHL).",1,1.4972010306575976,24129.0,919.4381568310428,0.36571261393774496,0.4631941220931329,0.0,0.0,1.000805152979066,1243.0,-0.9400185988274704,0.007112292606713537,1.0,2.0,1.0,6.0,6.0,6.0,12.0,2474,5.0,6.524672396198987e-07,5490.0,1243.0,1.0,0,5.0
4108,602460,HP:0000365,"By combining targeted capture of 129 known deafness genes, next-generation sequencing, and bioinformatic analysis, we identified POU4F3 c.602T&gt;C (p.Leu201Pro) as the disease-causing variant.",1,1.4972010306575976,24129.0,919.4381568310428,0.36571261393774496,0.4631941220931329,0.0,0.0,1.000805152979066,1243.0,-0.9400185988274704,0.007112292606713537,1.0,2.0,1.0,6.0,6.0,6.0,12.0,2474,5.0,6.524672396198987e-07,5490.0,1243.0,1.0,0,5.0
4117,602460,HP:0000365,We conclude that POU4F3 c.602T&gt;C (p.Leu201Pro) is related to midfrequency hearing loss in this family.,1,1.4972010306575976,24129.0,919.4381568310428,0.36571261393774496,0.4631941220931329,0.0,0.0,1.000805152979066,1243.0,-0.9400185988274704,0.007112292606713537,1.0,2.0,1.0,6.0,6.0,6.0,12.0,2474,5.0,6.524672396198987e-07,5490.0,1243.0,1.0,0,5.0
4120,300395,HP:0001249,Previously we implicated four missense variants in the X-linked THOC2 gene in intellectual disability (ID).,1,1.4312143585161603,15830661.39318126,628.5156919235571,0.13443021308604214,-0.01555302900247336,0.0,0.0,1.0005567928730512,1797.0,-0.6850433290100105,0.06770812031435712,1.0,2.0,2.0,194.0,194.0,193.0,388.0,3204,193.0,3.8916426584744994e-07,109261.0,1797.0,1.0,0,182.0
4121,300395,HP:0001298,We present detailed clinical assessment and functional studies on a de novo variant in a female with an epileptic encephalopathy and discuss an additional four families with rare variants in THOC2 with supportive evidence for pathogenicity.,0,1.319199372696905,1316314.4759740257,142.06410256410254,0.17467659756994713,0.2073301679255485,0.0,0.0,0.9977168949771688,437.0,-0.4768227837356231,0.16186642535442736,1.0,2.0,6.0,160.0,160.0,36.0,320.0,486,158.0,1.6796560064498793e-05,15562.0,439.0,1.0,0,192.0
1665,113705,HP:0002664,Some of them were cancer-related according to COSMIC and HGMD databases (no founder mutations in BRCA1 and BRCA2 have been found).,1,1.342124294666095,14779870.286244314,292.6232998839511,0.14059513390679754,0.0363653511393512,0.0,0.0,1.0008032128514055,1246.0,-0.37767621403519097,0.11088720854525648,1.0,2.0,3.0,471.0,471.0,37.0,942.0,1542,470.0,1.6778973932186097e-06,86008.0,1246.0,1.0,0,633.0
2363,600185,HP:0002664,Some of them were cancer-related according to COSMIC and HGMD databases (no founder mutations in BRCA1 and BRCA2 have been found).,1,1.3416355462103815,14500864.778067766,286.27804058963136,0.14198849810087022,0.09065436525648868,0.0,0.0,1.0007987220447283,1253.0,-0.3695548622099266,0.10824627921741813,1.0,2.0,4.0,477.0,477.0,34.0,954.0,1542,476.0,1.67789739321861e-06,84906.0,1253.0,1.0,0,615.0
4124,600960,HP:0001513,"To identify novel susceptibility genes and gene sets for obesity, we conducted a genomewide expression association analysis of obesity via integrating genomewide association study (GWAS) and expression quantitative trait loci (eQTLs) data.",0,1.3469695476495516,1853627.9014400928,160.44222364174288,0.17582016990765326,-0.022241470726693413,0.0,0.0,0.9980842911877392,521.0,-0.5648406095493349,0.1363486516779851,1.0,2.0,1.0,157.0,157.0,82.0,314.0,706,155.0,7.979826997350696e-06,18612.0,523.0,1.0,0,212.0
4122,600960,HP:0001513,The SMR single gene analysis results were further subjected to gene set enrichment analysis (GSEA) for identifying obesity associated gene sets.,0,1.3469695476495516,1853627.9014400928,160.44222364174288,0.17582016990765326,-0.022241470726693413,0.0,0.0,0.9980842911877392,521.0,-0.5648406095493349,0.1363486516779851,1.0,2.0,1.0,157.0,157.0,82.0,314.0,706,155.0,7.979826997350696e-06,18612.0,523.0,1.0,0,212.0
4126,117700,HP:0002664,"In this study, we investigated the anticancer activity of CP-673451, a potent and selective inhibitor of PDGFRb, on NSCLC cell lines (A549 and H358) and the potential mechanism.",0,1.3869148980238446,1495345.4564008447,192.2383114075721,0.2013541174385342,0.2949187137302406,0.0,0.0,0.9988864142538976,897.0,-0.6412461541533414,0.05326383435195255,1.0,2.0,31.0,119.0,119.0,72.0,238.0,1544,117.0,1.677897393218609e-06,21500.0,899.0,1.0,0,104.0
4128,173410,HP:0002664,"In this study, we investigated the anticancer activity of CP-673451, a potent and selective inhibitor of PDGFRb, on NSCLC cell lines (A549 and H358) and the potential mechanism.",1,1.3566208260433492,9637327.304906206,271.71045533326446,0.1459374875667869,0.05786277753633574,0.0,0.0,1.0009017132551847,1110.0,-0.4992168025410438,0.1039472294657146,1.0,2.0,7.0,326.0,326.0,125.0,652.0,1542,325.0,1.6778973932186103e-06,63979.0,1110.0,1.0,0,424.0
4127,117700,HP:0002664,"Specifically, Nrf2 plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and we found that combination of CP-673451 and cisplatin produced a synergistic anticancer effect and substantial ROS production in vitro.",0,1.3869148980238446,1495345.4564008447,192.2383114075721,0.2013541174385342,0.2949187137302406,0.0,0.0,0.9988864142538976,897.0,-0.6412461541533414,0.05326383435195255,1.0,2.0,31.0,119.0,119.0,72.0,238.0,1544,117.0,1.677897393218609e-06,21500.0,899.0,1.0,0,104.0
4129,614917,HP:0000365,"Using whole-exome sequencing, we identified compound heterozygous RMND1 variants in a 4-year-old patient with congenital lactic acidosis, severe myopathy, hearing loss, renal failure, and dysautonomia.",1,1.4394376515503275,4461294.599907747,429.5539548807599,0.1664320528110544,0.08784029718755121,0.0,0.0,1.000733137829912,1365.0,-0.6522525235939406,0.05352389545937933,1.0,2.0,1.0,128.0,128.0,128.0,256.0,2474,127.0,6.524672396198984e-07,49827.0,1365.0,1.0,0,123.0
4130,614917,HP:0000083,"Using whole-exome sequencing, we identified compound heterozygous RMND1 variants in a 4-year-old patient with congenital lactic acidosis, severe myopathy, hearing loss, renal failure, and dysautonomia.",1,1.3604442407227029,695345.5848484847,128.18755056634305,0.2086723577069649,0.20200226400636484,0.0,0.0,1.0022935779816513,437.0,-0.5470780258461444,0.12178531690214768,1.0,2.0,3.0,122.0,122.0,59.0,244.0,618,121.0,1.040582726326743e-05,11602.0,437.0,1.0,0,117.0
4131,614917,HP:0012332,"Using whole-exome sequencing, we identified compound heterozygous RMND1 variants in a 4-year-old patient with congenital lactic acidosis, severe myopathy, hearing loss, renal failure, and dysautonomia.",0,1.3188620823119597,158744.38849206347,65.02389259708738,0.2664375229294505,0.06603321149916333,0.0,0.0,0.9956896551724136,231.0,-0.317106009014828,0.14163090128755365,1.0,2.0,3.0,92.0,92.0,3.0,184.0,208,90.0,6.009254251547383e-05,3828.0,233.0,1.0,0,94.0
4132,602842,HP:0002664,"Conclusions: Two stable multidrug resistant cell lines of pancreatic cancer, JF305/CDDP and PANC-1/GEM, were successfully established.",0,1.3538821191440853,8755603.562589943,257.22554151510155,0.1469199964628819,0.05211063177725015,0.0,0.0,0.999073215940686,1078.0,-0.5125652189676747,0.09802972574056913,1.0,2.0,9.0,304.0,304.0,123.0,608.0,1544,302.0,1.67789739321861e-06,57118.0,1080.0,1.0,0,372.0
4133,123101,HP:0002664,MSX2 might be a new drug resistance related gene in pancreatic cancer cells by up-regulation of MRP2 expression,0,1.4014380448913886,3470895.3339482886,248.45214497222423,0.16512622411118372,0.09615450889208772,0.0,0.0,1.0010764262648009,930.0,-0.6541229992181187,0.0758128175746843,1.0,2.0,9.0,155.0,155.0,116.0,310.0,1542,154.0,1.677897393218609e-06,32750.0,930.0,1.0,0,167.0
4136,607585,HP:0001251,"Western blot was used to analyze the cell cycle-related proteins, serine/threonine kinase ataxia telangiectasia mutant (ATM), ataxia telangiectasia and Rad3-related protein (ATR) and cyclin B1 (CCNB1).",1,1.3840343933043555,4884522.135182295,253.0068814201656,0.16564683663304608,0.05529906972015484,0.0,0.0,1.0009671179883946,1035.0,-0.5972520959401639,0.08245264859510927,1.0,2.0,4.0,206.0,206.0,104.0,412.0,1630,205.0,1.5092152684290275e-06,44120.0,1035.0,1.0,0,234.0
2535,606410,HP:0001251,"Western blot was used to analyze the cell cycle-related proteins, serine/threonine kinase ataxia telangiectasia mutant (ATM), ataxia telangiectasia and Rad3-related protein (ATR) and cyclin B1 (CCNB1).",0,1.3656855599382611,6685104.736803475,242.8272123448508,0.16019853850736485,0.07473967996074285,0.0,0.0,0.9990817263544536,1088.0,-0.5457516497596948,0.0852157943067034,1.0,2.0,3.0,269.0,269.0,111.0,538.0,1632,267.0,1.5055139448229141e-06,50576.0,1090.0,1.0,0,334.0
2778,248610,HP:0002664,"Purpose To compare digital mammography (DM) plus digital breast tomosynthesis (DBT) versus DM alone for breast cancer screening in the Reggio Emilia Tomosynthesis trial, a two-arm test-and-treat randomized controlled trial.",0,1.4151554937699515,942517.1030525952,247.87766536964986,0.21224369875870625,0.004559313476219629,0.0,0.0,0.998819362455726,846.0,-0.7122227313741181,0.04915239134793166,1.0,2.0,26.0,70.0,70.0,64.0,140.0,1554,68.0,1.67789739321861e-06,17652.0,848.0,1.0,0,68.0
2773,248610,HP:0002664,"PPV of the recall was 13.0% and 24.1%, respectively (P = .0002); 72 of 80 cancers found in the DBT+DM arm and with complete DBT imaging were positive at least at one DBT-alone reading.",0,1.4151554937699515,942517.1030525952,247.87766536964986,0.21224369875870625,0.004559313476219629,0.0,0.0,0.998819362455726,846.0,-0.7122227313741181,0.04915239134793166,1.0,2.0,26.0,70.0,70.0,64.0,140.0,1554,68.0,1.67789739321861e-06,17652.0,848.0,1.0,0,68.0
2788,248610,HP:0002664,"The greater detection rate for DM+DBT was stronger for ductal carcinoma in situ (+180%, 95% CI: 1, 665); it was notable for small and medium invasive cancers, but not for large ones (+94 [95% CI: 6, 254]; +122 [95% CI: 18, 316]; -12 [95% CI: -68, 141]; for invasive cancers &lt; 10 mm, 10-19 mm, and G 20 mm, respectively).",0,1.4151554937699515,942517.1030525952,247.87766536964986,0.21224369875870625,0.004559313476219629,0.0,0.0,0.998819362455726,846.0,-0.7122227313741181,0.04915239134793166,1.0,2.0,26.0,70.0,70.0,64.0,140.0,1554,68.0,1.67789739321861e-06,17652.0,848.0,1.0,0,68.0
4138,608171,HP:0001425,"In humans, mutations in the CACNA2D4 gene encoding a2d-4 cause heterogeneous forms of vision impairment in humans, the underlying pathogenic mechanisms of which remain unclear.",0,1.3648893872973795,74564.96788136594,56.86372837688627,0.3296415840278412,0.22086643354176946,0.0,0.0,0.9965753424657532,291.0,-0.6087217515045411,0.05470101454018421,1.0,2.0,19.0,35.0,35.0,24.0,70.0,496,33.0,1.625910509885536e-05,2340.0,293.0,1.0,0,36.0
4144,600724,HP:0002664,Glycoprotein-A repetitions predominant (GARP) is a transmembrane protein that is highly expressed in breast cancer.,0,1.3954549053220018,2242282.4699000414,247.2572160302491,0.18381343264238625,0.08279153050103236,0.0,0.0,0.9988764044943822,889.0,-0.6522397107268361,0.06554433221099888,1.0,2.0,30.0,116.0,116.0,106.0,232.0,1544,114.0,1.6778973932186097e-06,25988.0,891.0,1.0,0,118.0
4152,600724,HP:0002664,"In this investigation, using a large multiethnic cohort (1738 subjects), we aimed to determine whether the magnitude of anti-GARP antibody responsiveness was significantly different in patients with breast cancer from that in matched healthy controls.",0,1.3954549053220018,2242282.4699000414,247.2572160302491,0.18381343264238625,0.08279153050103236,0.0,0.0,0.9988764044943822,889.0,-0.6522397107268361,0.06554433221099888,1.0,2.0,30.0,116.0,116.0,106.0,232.0,1544,114.0,1.6778973932186097e-06,25988.0,891.0,1.0,0,118.0
4148,600724,HP:0002664,"In the two populations with the largest sample size, the probability of breast cancer generally increases as anti-GARP antibody levels increase.",0,1.3954549053220018,2242282.4699000414,247.2572160302491,0.18381343264238625,0.08279153050103236,0.0,0.0,0.9988764044943822,889.0,-0.6522397107268361,0.06554433221099888,1.0,2.0,30.0,116.0,116.0,106.0,232.0,1544,114.0,1.6778973932186097e-06,25988.0,891.0,1.0,0,118.0
4156,600724,HP:0002664,"These results, if confirmed by independent investigations, will aid in devising personalized GARP-based immunotherapeutic strategies against breast cancer and other GARP-overexpressing malignancies",0,1.3954549053220018,2242282.4699000414,247.2572160302491,0.18381343264238625,0.08279153050103236,0.0,0.0,0.9988764044943822,889.0,-0.6522397107268361,0.06554433221099888,1.0,2.0,30.0,116.0,116.0,106.0,232.0,1544,114.0,1.6778973932186097e-06,25988.0,891.0,1.0,0,118.0
4160,608364,HP:0003124,"Similar to the human phenotype, Lima1-deficient mice displayed reduced cholesterol absorption and were resistant to diet-induced hypercholesterolemia.",0,0.9807692307692308,98.1153846153846,2.0,0.7071067811865476,0.6652137815759885,0.0,0.0,0.9807692307692308,51.0,-0.9615384615384612,0.03701015965166909,1.0,2.0,51.0,2.0,2.0,2.0,4.0,102,0.0,0.0003844675124951941,51.0,53.0,0.0,0,1.0
4161,604217,HP:0000007,However autosomal recessive inheritance with mutation in the SLC34A2 gene is suspected,1,1.494114398805474,192419.6607990813,544.5129668780831,0.3971718736141721,0.5315194628920928,0.0,0.0,1.0003844675124949,2602.0,-0.6549055702562983,0.003510149971881565,1.0,2.0,386.0,17.0,17.0,16.0,34.0,5160,16.0,1.5011496554636367e-07,11878.0,2602.0,1.0,0,15.0
4162,151385,HP:0002664,"In this review, we describe the significance and paradoxical requirement of RUNX1 tumor suppressor in hematological malignancies based on recent findings such as &quot;Genetic compensation of RUNX family transcription factors in leukemia,&quot; &quot;RUNX1 inhibition-induced inhibitory effects on leukemia cells through p53 activation&quot; and our novel promising theory &quot;Cluster regulation of RUNX (CROX)&quot; through the RUNX gene switch method using pyrrole-imidazole polyamides as a new technique that could contribute to the next generation of leukemia treatment strategies",1,1.399160527165458,3223742.514817372,242.66176158471882,0.18013254528298778,0.14052515367934554,0.0,0.0,1.0010695187165777,936.0,-0.5984844037051742,0.07537136066547831,1.0,2.0,4.0,160.0,160.0,126.0,320.0,1542,159.0,1.677897393218609e-06,32981.0,936.0,1.0,0,168.0
4163,614260,HP:0100242,"Multiple studies have now demonstrated the ability for superoxide dismutase-1, 43-kDa transactive response (TAR) DNA-binding protein, fused-in sarcoma, and most recently, C9orf72-encoded polypeptides to display properties similar to those of prions.",0,1.3002501860702849,372198.65829170827,69.75714285714285,0.2364010132989049,0.219492849588912,0.0,0.0,0.9973333333333334,374.0,-0.4150220583966129,0.09236879432624114,1.0,2.0,16.0,110.0,110.0,3.0,220.0,330,108.0,2.0474601257140515e-05,6512.0,376.0,1.0,0,123.0
1445,609145,HP:0002664,"In addition, TNFSF15/DR3 signaling pathways in A549 cells include activation of NF-kB during tumor lymphangiogenesis.",0,1.3822965008126258,3042852.2095307475,270.7389414793736,0.16620742155098553,0.2396575150870838,0.0,0.0,0.998896247240618,905.0,-0.6703174021911298,0.07687084267324781,1.0,2.0,42.0,135.0,135.0,117.0,270.0,1544,133.0,1.6778973932186086e-06,31584.0,907.0,1.0,0,134.0
4164,602192,HP:0002745,"Immunohistochemical method was used to examine the immunoexpression of ADAM10 and microvessel density in 80 cases of oral squamous cell carcinoma (OSCC): without metastases - OSCC M(-) (n = 38), and with metastases - OSCC M(+) (n = 42), in 24 cases of oral leukoplakia (OLK), (15 cases with low-grade dysplasia - OLK-LG, and 9 cases with high-grade dysplasia - OLK-HG), and 19 controls.",0,1.2522796352583585,1040.25,23.13636363636364,0.3990307985254764,0.3882089671580097,0.0,0.0,0.96875,31.0,-0.9127337530739976,0.3143939393939394,1.0,2.0,2.0,9.0,9.0,9.0,18.0,46,7.0,0.001890359168241966,166.0,33.0,1.0,0,8.0
4165,602192,HP:0002664,These findings suggest that ADAM10 could potentially contribute to metastases of oral cancer.,0,1.4438335040129555,38040.219837965036,286.16774751405103,0.3866078907245161,0.4927170108318821,0.0,0.0,0.9987195902688859,780.0,-0.8163956398114101,0.010832724783951324,1.0,2.0,69.0,9.0,9.0,9.0,18.0,1544,7.0,1.67789739321861e-06,3308.0,782.0,1.0,0,8.0
4166,610531,HP:0001402,The molecular features of hepatocellular carcinoma arising from non-alcoholic fatty liver disease (NAFLD-HCC) are not well known.,0,1.220656532834567,29072.169624819624,33.848508634222924,0.3407963453746401,0.30507416505669105,0.0,0.0,0.9933774834437086,150.0,-0.4052926121674632,0.10735447891251307,1.0,2.0,27.0,47.0,47.0,3.0,94.0,132,45.0,0.00010203040506070808,1232.0,152.0,1.0,0,47.0
4167,606520,HP:0000007,"Here we describe 4 families with autosomal recessive inherited macrothrombocytopenia with focal myelofibrosis due to germ line loss-of-function mutations in the megakaryocyte-specific immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor G6b-B (G6b, C6orf25, or MPIG6B).",1,1.4935571400562555,334518.31083750556,533.542441860465,0.3777198822327231,0.8448541253490482,0.0,0.0,1.000384172109105,2604.0,-0.5102963826034469,0.0037434650907938564,1.0,2.0,644.0,24.0,24.0,24.0,48.0,5160,23.0,1.5011496554636367e-07,12687.0,2604.0,1.0,0,24.0
4168,606520,HP:0040185,"Here we describe 4 families with autosomal recessive inherited macrothrombocytopenia with focal myelofibrosis due to germ line loss-of-function mutations in the megakaryocyte-specific immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor G6b-B (G6b, C6orf25, or MPIG6B).",0,1.270707070707071,1339.8333333333335,18.652777777777786,0.4686169481695169,0.468938759767275,0.0,0.0,0.9705882352941176,33.0,-0.7023437015289493,0.238655462184874,1.0,2.0,3.0,10.0,10.0,10.0,20.0,36,9.0,0.0016,142.0,35.0,1.0,0,12.0
4169,142968,HP:0030319,"Mutant mice for Hoxb1 were reported to present with facial weakness, resembling MBS.",1,1.3543291113562308,867748.294147519,174.56912235746316,0.17347434422669913,0.01413284538825143,0.0,0.0,1.0030581039755353,328.0,-0.627985040334934,0.2323786081897516,1.0,2.0,3.0,103.0,103.0,102.0,206.0,446,102.0,1.992984693877551e-05,12462.0,328.0,1.0,0,149.0
4171,151443,HP:0006770,"The role of leukemia inhibitory factor receptor (LIFR), which is important in the signal transduction of the interleukin-6 cytokine family, is still undefined in clear cell renal cell carcinoma (ccRCC).",0,1.292807629232529,1284.0103626943005,103.34470989761093,0.6646798098579036,0.6180183181341357,0.0,0.0,0.9966101694915254,294.0,-0.8088481939173299,0.009047182775996336,1.0,2.0,193.0,2.0,2.0,2.0,4.0,586,1.0,1.156925355176084e-05,395.0,296.0,1.0,0,2.0
4176,151443,HP:0002664,Low LIFR expression correlated with a poor prognosis and an aggressive tumor phenotype.,0,1.346206000074814,6997465.662301892,236.38775049468137,0.15290695016799002,0.12460271339467904,0.0,0.0,0.9990610328638498,1064.0,-0.5355598582682272,0.08954187916743739,1.0,2.0,23.0,284.0,284.0,107.0,568.0,1544,282.0,1.6778973932186106e-06,50828.0,1066.0,1.0,0,364.0
4172,151443,HP:0002664,"Conversely, YAP inhibition impaired the LIFR-silencing promotion of cell migration, invasion, and cancer stem cell marker expression.",0,1.346206000074814,6997465.662301892,236.38775049468137,0.15290695016799002,0.12460271339467904,0.0,0.0,0.9990610328638498,1064.0,-0.5355598582682272,0.08954187916743739,1.0,2.0,23.0,284.0,284.0,107.0,568.0,1544,282.0,1.6778973932186106e-06,50828.0,1066.0,1.0,0,364.0
4180,151443,HP:0002664,"Moreover, drug sensitivity analysis and the Cancer Cell Line Encyclopedia database revealed that LIFR-deficient cells had high sensitivity to a YAP inhibitor and to two other anticancer drugs (PHA-665752, PF2341066).",0,1.346206000074814,6997465.662301892,236.38775049468137,0.15290695016799002,0.12460271339467904,0.0,0.0,0.9990610328638498,1064.0,-0.5355598582682272,0.08954187916743739,1.0,2.0,23.0,284.0,284.0,107.0,568.0,1544,282.0,1.6778973932186106e-06,50828.0,1066.0,1.0,0,364.0
4184,151443,HP:0002664,"Our study revealed that LIFR attenuates tumor metastasis by suppressing YAP expression, suggesting that LIFR may serve as a potential target for ccRCC treatment",0,1.346206000074814,6997465.662301892,236.38775049468137,0.15290695016799002,0.12460271339467904,0.0,0.0,0.9990610328638498,1064.0,-0.5355598582682272,0.08954187916743739,1.0,2.0,23.0,284.0,284.0,107.0,568.0,1544,282.0,1.6778973932186106e-06,50828.0,1066.0,1.0,0,364.0
4188,121014,HP:0000007,"However, in recent clinical reports, autosomal recessive ODDD cases due to by GJA1 mutations were also described.",1,1.3953264083359014,33161051.26166827,389.1116232531547,0.14825632555948556,0.08362280995650574,0.0,0.0,1.0003162555344718,3163.0,-0.4842806638204056,0.037002597434800666,1.0,2.0,30.0,552.0,552.0,159.0,1104.0,5160,551.0,1.5011496554636367e-07,185039.0,3163.0,1.0,0,624.0
4189,162030,HP:0002860,Neurotrophins and their receptors might regulate cell survival in head and neck squamous cell carcinoma (HNSCC). mRNA expression of nerve growth factor (NGF) and protein synthesis of high (NTRK1) and low affinity neurotrophin (p75 neurotrophin receptor; NTR) receptors were investigated in normal oral mucosa and in HNSCC.,0,1.2663990969522136,51497.15476190476,52.946505608283005,0.2608422413490337,0.27696162225505816,0.0,0.0,0.9927536231884058,137.0,-0.3587533639346375,0.19403607548743607,1.0,2.0,11.0,54.0,54.0,4.0,108.0,124,52.0,0.00016866250632484398,1861.0,139.0,1.0,0,61.0
4190,191315,HP:0002860,Neurotrophins and their receptors might regulate cell survival in head and neck squamous cell carcinoma (HNSCC). mRNA expression of nerve growth factor (NGF) and protein synthesis of high (NTRK1) and low affinity neurotrophin (p75 neurotrophin receptor; NTR) receptors were investigated in normal oral mucosa and in HNSCC.,0,1.3053136401082734,171081.22879318398,78.24553407336617,0.24926840346361795,0.01838504406643325,0.0,0.0,0.9964912280701754,284.0,-0.575120765074296,0.09657710710342288,1.0,2.0,38.0,61.0,61.0,62.0,122.0,174,59.0,1.992984693877551e-05,3936.0,286.0,1.0,0,63.0
4191,162030,HP:0002664,"p75NTR in HNSCC might be related with NGF-independent therapy resistance, while NTRK1 might transduce a survival signal of NGF and contribute in this way to improved tumor cell survival after cell cycle arrest",0,1.4121229422399848,1264484.137679778,282.15064168202605,0.18907608521135646,0.21226214949079106,0.0,0.0,0.9988207547169812,847.0,-0.7706248776768923,0.05619263506455986,1.0,2.0,39.0,71.0,71.0,63.0,142.0,1544,69.0,1.67789739321861e-06,20228.0,849.0,1.0,0,62.0
2466,603604,HP:0001300,"Mutations in PLA2G6 (PARK14) cause neurodegenerative disorders in humans, including autosomal recessive neuroaxonal dystrophy and early-onset parkinsonism.",1,1.365336496580357,545827.1964285711,118.19216203421922,0.22145931342362074,0.17149294440384394,0.0,0.0,1.0026041666666663,385.0,-0.4481942545330012,0.1228219696969697,1.0,2.0,10.0,106.0,106.0,106.0,212.0,212,106.0,1.2755102040816327e-05,9079.0,385.0,1.0,0,111.0
4192,606879,HP:0002664,"We found that y-OH-PdG and a-methyl-y-OH-PdG are the major adducts formed in tobacco smokers* buccal cells as well as the normal lung tissues of tobacco-smoking lung cancer patients, but not in lung tissues of nonsmokers.",0,1.329984932194877,12168604.029853042,261.40763300483655,0.1397904095635061,0.017904241163758033,0.0,0.0,0.9991666666666668,1199.0,-0.4651798817243722,0.10073966139328336,1.0,2.0,19.0,406.0,406.0,57.0,812.0,1544,404.0,1.6778973932186103e-06,72593.0,1201.0,1.0,0,581.0
4195,601622,HP:0004326,"Serendipitously, we found that overexpression of Twist1 in mouse muscle progenitor cells, either constitutively during development or inducibly in adult animals, caused severe muscle atrophy with features reminiscent of cachexia.",0,1.3389254330711715,313945.3626422189,109.38186954288649,0.2577368069313733,0.18946194848995748,0.0,0.0,0.9978070175438596,455.0,-0.5164787005960018,0.057286268186878576,1.0,2.0,72.0,60.0,60.0,60.0,120.0,262,59.0,6.3448153341496976e-06,5969.0,457.0,1.0,0,60.0
4197,601622,HP:0004326,"Using several genetic mouse models of PDAC, we detected a marked increase in Twist1 expression in muscle undergoing cachexia.",0,1.3389254330711715,313945.3626422189,109.38186954288649,0.2577368069313733,0.18946194848995748,0.0,0.0,0.9978070175438596,455.0,-0.5164787005960018,0.057286268186878576,1.0,2.0,72.0,60.0,60.0,60.0,120.0,262,59.0,6.3448153341496976e-06,5969.0,457.0,1.0,0,60.0
4200,601622,HP:0002664,"In cancer patients, elevated levels of Twist1 are associated with greater degrees of muscle wasting.",1,1.349229806068371,9806976.335756274,235.73846441064342,0.14528346334672976,0.06276688876066062,0.0,0.0,1.0008576329331047,1167.0,-0.4934598634913631,0.09065040471161634,1.0,2.0,8.0,364.0,364.0,60.0,728.0,1542,363.0,1.6778973932186103e-06,61675.0,1167.0,1.0,0,493.0
4193,601622,HP:0004326,"Finally, both genetic and pharmacological inactivation of Twist1 in muscle progenitor cells afforded substantial protection against cancer-mediated cachexia, which translated into meaningful survival benefits, implicating Twist1 as a possible target for attenuating muscle cachexia in cancer patients",0,1.3389254330711715,313945.3626422189,109.38186954288649,0.2577368069313733,0.18946194848995748,0.0,0.0,0.9978070175438596,455.0,-0.5164787005960018,0.057286268186878576,1.0,2.0,72.0,60.0,60.0,60.0,120.0,262,59.0,6.3448153341496976e-06,5969.0,457.0,1.0,0,60.0
4199,601622,HP:0002664,"Finally, both genetic and pharmacological inactivation of Twist1 in muscle progenitor cells afforded substantial protection against cancer-mediated cachexia, which translated into meaningful survival benefits, implicating Twist1 as a possible target for attenuating muscle cachexia in cancer patients",1,1.349229806068371,9806976.335756274,235.73846441064342,0.14528346334672976,0.06276688876066062,0.0,0.0,1.0008576329331047,1167.0,-0.4934598634913631,0.09065040471161634,1.0,2.0,8.0,364.0,364.0,60.0,728.0,1542,363.0,1.6778973932186103e-06,61675.0,1167.0,1.0,0,493.0
4201,164874,HP:0001263,"In this report we describe a female child with global developmental delay, microcephaly and myoclonic seizures harbouring a 5 Mb deletion in 14q12 locus resulting in deletion of single copy of brain specific genes FOXG1, PRKD1 and NOVA1.",0,1.4193776058261411,16157753.73172759,559.1811280942067,0.13323165773290102,0.06579420442947563,0.0,0.0,1.0005797101449274,1726.0,-0.6482225047432046,0.07405242917359396,1.0,2.0,1.0,227.0,227.0,227.0,454.0,2998,226.0,4.4444444444444475e-07,110240.0,1726.0,1.0,0,225.0
4202,164874,HP:0000252,"In this report we describe a female child with global developmental delay, microcephaly and myoclonic seizures harbouring a 5 Mb deletion in 14q12 locus resulting in deletion of single copy of brain specific genes FOXG1, PRKD1 and NOVA1.",1,1.3973531326652235,11073980.563905934,450.79640583220674,0.13111799697481585,0.02038745732435326,0.0,0.0,1.000794281175536,1260.0,-0.632047260601147,0.10577177654222927,1.0,2.0,1.0,227.0,227.0,227.0,454.0,2066,226.0,9.353172034763872e-07,83895.0,1260.0,1.0,0,260.0
4203,605435,HP:0000252,"In this report we describe a female child with global developmental delay, microcephaly and myoclonic seizures harbouring a 5 Mb deletion in 14q12 locus resulting in deletion of single copy of brain specific genes FOXG1, PRKD1 and NOVA1.",1,1.442682939647522,4417406.79667145,566.1380542110358,0.14234412413536796,0.000828414364974008,0.0,0.0,1.0008833922261484,1133.0,-0.7745281409306306,0.08049083236911292,1.0,2.0,1.0,100.0,100.0,100.0,200.0,2066,99.0,9.353172034763868e-07,51617.0,1133.0,1.0,0,119.0
4204,164874,HP:0001250,"In this report we describe a female child with global developmental delay, microcephaly and myoclonic seizures harbouring a 5 Mb deletion in 14q12 locus resulting in deletion of single copy of brain specific genes FOXG1, PRKD1 and NOVA1.",1,1.421248225458752,15735793.221379224,542.3776723035385,0.1358324274072831,0.08624567572854347,0.0,0.0,1.000563063063063,1777.0,-0.6392601054073954,0.06805680187784859,1.0,2.0,1.0,227.0,227.0,227.0,454.0,3100,226.0,4.156965348783941e-07,107392.0,1777.0,1.0,0,254.0
4205,605435,HP:0001250,"In this report we describe a female child with global developmental delay, microcephaly and myoclonic seizures harbouring a 5 Mb deletion in 14q12 locus resulting in deletion of single copy of brain specific genes FOXG1, PRKD1 and NOVA1.",0,1.456195002370463,6406580.995462388,683.1732258064517,0.14858849730370913,0.07492240906695126,0.0,0.0,0.9993943064809206,1650.0,-0.7701970691807505,0.048132102783110385,1.0,2.0,1.0,101.0,101.0,101.0,202.0,3102,99.0,4.151610160484642e-07,65639.0,1652.0,1.0,0,136.0
3674,605317,HP:0011098,"The FoxP2 transcription factor and its target genes have been implicated in developmental brain diseases with a prominent language component, such as developmental verbal dyspraxia and specific language impairment.",0,1.3589600397120871,42293.60833333334,62.872807017543856,0.26361040687773746,0.2552573857730012,0.0,0.0,1.008264462809917,122.0,-0.5426420515780657,0.2228695298740008,1.0,2.0,9.0,38.0,38.0,38.0,76.0,76,38.0,0.0001384083044982699,1645.0,122.0,1.0,0,52.0
2246,190080,HP:0002664,"TUNEL assay was used to detect the effect of each group on the apoptosis of the gastric cancer cells, and Western blot was used to detect the expression of caspase-3, caspase-8, bcl-2, and c-myc, which are the proteins related to apoptosis, after the drug effect in each group.",1,1.4396536831054232,1166089.637753825,258.33534370946825,0.21512590240969573,0.06608515489589678,0.0,0.0,1.0011764705882351,851.0,-0.6775154399515846,0.05177023570885463,1.0,2.0,1.0,80.0,80.0,80.0,160.0,1542,79.0,1.6778973932186097e-06,18724.0,851.0,1.0,0,67.0
1535,600900,HP:0002664,"In conclusion, IL-21 used alone and in combination with 5-Fluorouracil are anti-tumor mechanisms in SGC-7901",0,1.400561161703175,941457.6872488172,204.979171435111,0.21034037305605727,0.11542276431943975,0.0,0.0,0.998833138856476,856.0,-0.7101797965956365,0.04459639932218695,1.0,2.0,41.0,78.0,78.0,53.0,156.0,1544,76.0,1.6778973932186103e-06,16396.0,858.0,1.0,0,67.0
4206,605284,HP:0002664,"The diagnosis is based on genetic criteria, by the identification of inactivating pathogenic mutation of tumor suppressor genes TSC1 and TSC2, and clinical criteria, including cutaneous, renal, pulmonary, cardiac and neurological manifestations.",1,1.3569226781800037,6009995.983633983,215.71345549153855,0.16451859674051014,0.037877207734939716,0.0,0.0,1.000903342366757,1108.0,-0.5033491765785867,0.08248298487798356,1.0,2.0,2.0,313.0,313.0,72.0,626.0,1542,312.0,1.67789739321861e-06,50585.0,1108.0,1.0,0,356.0
3822,191092,HP:0002664,"The diagnosis is based on genetic criteria, by the identification of inactivating pathogenic mutation of tumor suppressor genes TSC1 and TSC2, and clinical criteria, including cutaneous, renal, pulmonary, cardiac and neurological manifestations.",1,1.35945444387786,5618137.201828054,215.3678800441228,0.16517565239835075,0.05095837144483327,0.0,0.0,1.000916590284143,1092.0,-0.5170170319203347,0.08194082117088533,1.0,2.0,0.0,299.0,299.0,70.0,598.0,1542,299.0,1.6778973932186097e-06,48811.0,1092.0,2.0,0,338.0
4207,602869,HP:0001425,We demonstrated that linc-ADAL interacts with heterogeneous nuclear ribonucleoprotein U (hnRNPU) and insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) at distinct subcellular locations to regulate adipocyte differentiation and lipogenesis,0,1.3341241011194307,841278.322852148,115.58583750345764,0.20576117465313887,0.19150838852276547,0.0,0.0,0.9975550122249388,408.0,-0.4026552517214105,0.13690738863378854,1.0,2.0,1.0,155.0,155.0,18.0,310.0,496,153.0,1.625910509885536e-05,11479.0,410.0,1.0,0,179.0
4208,608289,HP:0001425,We demonstrated that linc-ADAL interacts with heterogeneous nuclear ribonucleoprotein U (hnRNPU) and insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) at distinct subcellular locations to regulate adipocyte differentiation and lipogenesis,0,1.4235764235764237,26616.363493190445,71.85605038236619,0.401292521771935,0.14438519337947614,0.0,0.0,0.9962406015037591,265.0,-0.6738828650228714,0.040466334375264,1.0,2.0,12.0,19.0,19.0,19.0,38.0,488,17.0,1.625910509885536e-05,1437.0,267.0,1.0,0,19.0
213,164785,HP:0002664,Ras-association domain family 6 (RASSF6) is a tumor suppressor that interacts with MDM2 and stabilizes p53.,1,1.391410468595884,3660844.478079444,241.1528468479716,0.1733730375837963,0.17860145508336964,0.0,0.0,1.001044932079415,958.0,-0.6026291737214196,0.07917269302338772,1.0,2.0,2.0,186.0,186.0,112.0,372.0,1542,185.0,1.6778973932186097e-06,36293.0,958.0,1.0,0,185.0
89,191170,HP:0002664,Ras-association domain family 6 (RASSF6) is a tumor suppressor that interacts with MDM2 and stabilizes p53.,1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
4209,604011,HP:0002664,These findings support that UNC119 is a regulator of the RASSF6-MDM2-p53 axis and functions as a tumor suppressor,0,1.4289053483903125,1057072.7595678498,272.58946512573317,0.20800757098965966,0.09521188235446924,0.0,0.0,0.99880810488677,838.0,-0.7225643861559699,0.049713377603723255,1.0,2.0,18.0,66.0,66.0,66.0,132.0,1544,64.0,1.67789739321861e-06,17518.0,840.0,1.0,0,64.0
4210,609875,HP:0000717,"We demonstrate the effectiveness of morphometric techniques in measuring changes in the relative size of neuroanatomical subdivisions in atoh7 morphant larvae and in identifying phenotypes in larvae treated with valproic acid, a chemical demonstrated to increase the risk of autism in humans.",0,1.290217955371043,72761.57413419912,49.0806697108067,0.3123541426233922,0.15299675786075342,0.0,0.0,0.9952380952380954,209.0,-0.5648458197394355,0.10295644324080344,1.0,2.0,15.0,50.0,50.0,17.0,100.0,294,48.0,4.627701420704336e-05,2281.0,211.0,1.0,0,43.0
3354,120436,HP:0002664,"Methods: Fourteen haplotype-tagging single nucleotide polymorphisms (htSNPs) of MLH1, MLH3 and MSH2 genes were genotyped by Sequenom MassARRAY method in 146 patients with locally advanced rectal cancer who received preoperative chemoradiotherapy.",1,1.3724379901603143,5818621.47767339,246.4111696040284,0.1639416543826219,-0.008069802038276657,0.0,0.0,1.0009756097560976,1026.0,-0.5524282139315764,0.08979793657585697,1.0,2.0,1.0,250.0,250.0,99.0,500.0,1542,249.0,1.67789739321861e-06,47218.0,1026.0,1.0,0,247.0
4213,604395,HP:0002664,"Methods: Fourteen haplotype-tagging single nucleotide polymorphisms (htSNPs) of MLH1, MLH3 and MSH2 genes were genotyped by Sequenom MassARRAY method in 146 patients with locally advanced rectal cancer who received preoperative chemoradiotherapy.",1,1.391410468595884,3665300.992816173,238.08303682279416,0.17994637579274209,0.017424232260383688,0.0,0.0,1.001044932079415,958.0,-0.5693146103001488,0.07816484621610242,1.0,2.0,2.0,187.0,187.0,187.0,374.0,1542,186.0,1.6778973932186103e-06,35831.0,958.0,1.0,0,188.0
3385,609309,HP:0002664,"Methods: Fourteen haplotype-tagging single nucleotide polymorphisms (htSNPs) of MLH1, MLH3 and MSH2 genes were genotyped by Sequenom MassARRAY method in 146 patients with locally advanced rectal cancer who received preoperative chemoradiotherapy.",1,1.3768221907623603,5337536.964099137,247.2793183273408,0.16568705398514247,0.06456760463916675,0.0,0.0,1.0009930486593843,1008.0,-0.5677206892113388,0.0883222206459545,1.0,2.0,1.0,230.0,230.0,119.0,460.0,1542,229.0,1.6778973932186103e-06,44826.0,1008.0,1.0,0,233.0
3381,609309,HP:0002664,"Meanwhile, MLH3 rs175057 C&gt;T locus was also associated with longer overall survival time in locally advanced rectal cancer (HR=0.44, 95% CI: 0.20-0.96, P=0.038), whereas MSH2 rs3771273 T&gt;A, rs10188090 A&gt;G and rs10191478 T&gt;G loci were associated with shorter overall survival time (HR=1.74, 95% CI: 1.06-2.84, P=0.028; HR=1.64, 95% CI: 1.01-2.66, P=0.046; HR=1.71, 95% CI: 1.01-2.91, P=0.047, respectively).",1,1.3768221907623603,5337536.964099137,247.2793183273408,0.16568705398514247,0.06456760463916675,0.0,0.0,1.0009930486593843,1008.0,-0.5677206892113388,0.0883222206459545,1.0,2.0,1.0,230.0,230.0,119.0,460.0,1542,229.0,1.6778973932186103e-06,44826.0,1008.0,1.0,0,233.0
4211,604395,HP:0002664,"Conclusions: Genetic polymorphisms of MLH3 rs175057 and MSH2 rs13019654 loci can predict the nCRT response, while MLH3 rs175057 as well as MSH2 rs3771273, rs10188090 and rs10191478 may predict prognosis in patients with locally advanced rectal cancer who received preoperative chemoradiotherapy.",1,1.391410468595884,3665300.992816173,238.08303682279416,0.17994637579274209,0.017424232260383688,0.0,0.0,1.001044932079415,958.0,-0.5693146103001488,0.07816484621610242,1.0,2.0,2.0,187.0,187.0,187.0,374.0,1542,186.0,1.6778973932186103e-06,35831.0,958.0,1.0,0,188.0
3369,609309,HP:0002664,"Conclusions: Genetic polymorphisms of MLH3 rs175057 and MSH2 rs13019654 loci can predict the nCRT response, while MLH3 rs175057 as well as MSH2 rs3771273, rs10188090 and rs10191478 may predict prognosis in patients with locally advanced rectal cancer who received preoperative chemoradiotherapy.",1,1.3768221907623603,5337536.964099137,247.2793183273408,0.16568705398514247,0.06456760463916675,0.0,0.0,1.0009930486593843,1008.0,-0.5677206892113388,0.0883222206459545,1.0,2.0,1.0,230.0,230.0,119.0,460.0,1542,229.0,1.6778973932186103e-06,44826.0,1008.0,1.0,0,233.0
4215,167413,HP:0001626,"In T2D patients, PAX4 Arg192His was associated with earlier age at diagnosis, and GLP1R Arg131Gln was associated with decreased risk of cardiovascular disease.",0,1.4660169800178924,2107287.671896684,403.96415215740166,0.2404818563380389,0.19873858056410654,0.0,0.0,0.9995513683266036,2228.0,-0.6462227209444533,0.015901679250483334,1.0,2.0,3.0,96.0,96.0,73.0,192.0,4248,94.0,2.200014784099349e-07,39521.0,2230.0,1.0,0,82.0
4216,100790,HP:0002664,"Moreover, we show that most SCLC tumors can be classified into one of three lineages based on the expression of POU2F3, ASCL1, or NEUROD1.",1,1.418685237095605,2414433.5295363446,274.25879301136797,0.17871843315049465,0.05139823101002758,0.0,0.0,1.001124859392576,890.0,-0.6751095892470718,0.0714677519242679,1.0,2.0,0.0,115.0,115.0,108.0,230.0,1542,115.0,1.6778973932186103e-06,28273.0,890.0,2.0,0,109.0
4217,601724,HP:0002664,"Moreover, we show that most SCLC tumors can be classified into one of three lineages based on the expression of POU2F3, ASCL1, or NEUROD1.",0,1.4372814926581534,769734.1527952289,191.9406614785992,0.2434685741957297,-0.01629306968292657,0.0,0.0,1.0011709601873535,855.0,-0.6369495273390489,0.03982360272265363,1.0,2.0,6.0,78.0,78.0,53.0,156.0,1542,77.0,1.6778973932186097e-06,14539.0,855.0,1.0,0,72.0
4218,607854,HP:0000505,"Permanent visual impairment (bilateral best-corrected visual acuity &lt; 0.3) was found in 7 patients, including patients with a mutation in RAF1, SHOC2, and KRAS.",1,1.4060816407254904,5946832.727257002,322.3760593220339,0.16111342223287775,0.08381918596373578,0.0,0.0,1.0008904719501337,1124.0,-0.6100774386105566,0.07721912898533732,1.0,2.0,6.0,173.0,173.0,147.0,346.0,1888,172.0,1.1197894795778394e-06,48735.0,1124.0,1.0,0,169.0
4219,164760,HP:0000505,"Permanent visual impairment (bilateral best-corrected visual acuity &lt; 0.3) was found in 7 patients, including patients with a mutation in RAF1, SHOC2, and KRAS.",0,1.3594833205894423,12386711.150092393,284.62627586852705,0.14491829754100227,0.052219473003502825,0.0,0.0,0.9992348890589134,1306.0,-0.5108404388872998,0.0880439131563985,1.0,2.0,3.0,357.0,357.0,121.0,714.0,1890,355.0,1.1174233112381495e-06,75258.0,1308.0,1.0,0,485.0
4228,601933,HP:0002664,"The aim of the present study is to evaluate clock (cry1, cry2 and per2) and clock-controlled (vascular endothelial growth factor-a, early growth response protein 1 and estrogen receptor b) gene expression in colorectal cancer and adjacent tissue and identify a possible link between survival of patients and expression of above mentioned genes.",0,1.4564865773864124,26565.67377274186,300.6874189364462,0.41581677756819774,0.2728792363254554,0.0,0.0,0.9987163029525032,778.0,-0.8486287880136307,0.009380863039399627,1.0,2.0,53.0,8.0,8.0,8.0,16.0,1544,6.0,1.67789739321861e-06,2850.0,780.0,1.0,0,7.0
4233,603426,HP:0002664,"The aim of the present study is to evaluate clock (cry1, cry2 and per2) and clock-controlled (vascular endothelial growth factor-a, early growth response protein 1 and estrogen receptor b) gene expression in colorectal cancer and adjacent tissue and identify a possible link between survival of patients and expression of above mentioned genes.",0,1.4513181688398211,37602.256151530666,232.4507133592737,0.4130331869578959,0.336242078413901,0.0,0.0,0.9987212276214834,781.0,-0.7812031296685931,0.00998193713600716,1.0,2.0,54.0,10.0,10.0,10.0,20.0,1544,8.0,1.67789739321861e-06,3056.0,783.0,1.0,0,9.0
4231,603426,HP:0002664,Expression of cry2 and per2 was significantly downregulated in tumor tissue compared to adjacent tissues.,0,1.4513181688398211,37602.256151530666,232.4507133592737,0.4130331869578959,0.336242078413901,0.0,0.0,0.9987212276214834,781.0,-0.7812031296685931,0.00998193713600716,1.0,2.0,54.0,10.0,10.0,10.0,20.0,1544,8.0,1.67789739321861e-06,3056.0,783.0,1.0,0,9.0
4225,601933,HP:0002664,"Moreover, we observed an increase in cry1 expression in female patients with distant metastases in tumor compared to adjacent tissue.",0,1.4564865773864124,26565.67377274186,300.6874189364462,0.41581677756819774,0.2728792363254554,0.0,0.0,0.9987163029525032,778.0,-0.8486287880136307,0.009380863039399627,1.0,2.0,53.0,8.0,8.0,8.0,16.0,1544,6.0,1.67789739321861e-06,2850.0,780.0,1.0,0,7.0
4222,601933,HP:0002664,"Accordingly, women with high expression of cry1 in tumor tissue displayed worse survival, which was not observed in men.",0,1.4564865773864124,26565.67377274186,300.6874189364462,0.41581677756819774,0.2728792363254554,0.0,0.0,0.9987163029525032,778.0,-0.8486287880136307,0.009380863039399627,1.0,2.0,53.0,8.0,8.0,8.0,16.0,1544,6.0,1.67789739321861e-06,2850.0,780.0,1.0,0,7.0
4236,192240,HP:0002664,Low expression of vegf-a in tumor correlated with better survival in men but not in women.,0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865475,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
4237,605158,HP:0002664,"Aberrant PXDN expression has been associated with kidney fibrosis, cancer, congenital eye defects and various cardiovascular disorders.",0,1.3997403179457435,130731.20056390912,175.15492145842342,0.3292517713015852,0.08131963908668151,0.0,0.0,0.9987484355444304,798.0,-0.6507399712618123,0.016630162703379223,1.0,2.0,129.0,28.0,28.0,28.0,56.0,1544,26.0,1.6778973932186097e-06,5315.0,800.0,1.0,0,22.0
4238,189907,HP:0001425,"Humans who carry HNF1B mutations develop heterogeneous renal abnormalities, including multicystic dysplastic kidneys, glomerulocystic kidney disease, renal agenesis, renal hypoplasia, and renal interstitial fibrosis.",0,1.3157107503195449,735402.3909632034,92.85784774436092,0.22014123418167653,0.16382294381441465,0.0,0.0,0.9978813559322036,471.0,-0.3649254203153815,0.09983158347368044,1.0,2.0,8.0,167.0,167.0,2.0,334.0,512,165.0,1.6259105098855357e-05,11144.0,473.0,1.0,0,187.0
4239,189907,HP:0000104,"Humans who carry HNF1B mutations develop heterogeneous renal abnormalities, including multicystic dysplastic kidneys, glomerulocystic kidney disease, renal agenesis, renal hypoplasia, and renal interstitial fibrosis.",1,1.3380625931445604,767353.4644171045,115.8740200348432,0.18859332638300425,0.19263391530990948,0.0,0.0,1.0025839793281657,388.0,-0.3619314475504599,0.14612802685207385,1.0,2.0,11.0,142.0,142.0,3.0,284.0,386,142.0,1.975308641975309e-05,10971.0,388.0,1.0,0,178.0
4240,189907,HP:0000089,"Humans who carry HNF1B mutations develop heterogeneous renal abnormalities, including multicystic dysplastic kidneys, glomerulocystic kidney disease, renal agenesis, renal hypoplasia, and renal interstitial fibrosis.",1,1.3650910270600358,300441.2847529921,99.04744601328905,0.2166315743007612,0.1874910243105079,0.0,0.0,1.0032362459546926,310.0,-0.3825698537929305,0.12851028291053346,1.0,2.0,32.0,86.0,86.0,86.0,172.0,234,86.0,1.975308641975309e-05,6155.0,310.0,1.0,0,106.0
4241,189907,HP:0005576,"Humans who carry HNF1B mutations develop heterogeneous renal abnormalities, including multicystic dysplastic kidneys, glomerulocystic kidney disease, renal agenesis, renal hypoplasia, and renal interstitial fibrosis.",0,1.3375899103359936,17174.67026911261,59.90625,0.4576603593617878,0.436347773660795,0.0,0.0,0.99581589958159,238.0,-0.4848926466144707,0.034902370990237096,1.0,2.0,66.0,15.0,15.0,15.0,30.0,160,14.0,1.975308641975309e-05,1001.0,240.0,1.0,0,15.0
4242,182380,HP:0001638,"Recent studies demonstrated that SGLT1 activation improves ischemia-reperfusion-induced cardiac injury, and increased SGLT1 gene expression is observed in hypertrophic, ischemic, and diabetic cardiomyopathy in human hearts.",0,1.3916140735421942,265049.8685885752,120.69132066799448,0.26492802000801274,0.12886746971749627,0.0,0.0,0.9979591836734696,489.0,-0.6458385844986476,0.056743838064757475,1.0,2.0,15.0,57.0,57.0,42.0,114.0,858,55.0,5.4335718671383e-06,6826.0,491.0,1.0,0,51.0
4243,602118,HP:0000717,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",0,1.3246689593765573,435438.4091269841,127.20221787345078,0.1877563752647549,0.0595586541728127,0.0,0.0,0.9956709956709956,230.0,-0.6330085602222026,0.2577250335871025,1.0,2.0,3.0,82.0,82.0,74.0,164.0,294,80.0,4.565376186997809e-05,6906.0,232.0,1.0,0,103.0
4244,602119,HP:0000717,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",0,1.330192502532928,235372.6404761905,88.91493319803824,0.226480402659008,-0.07725214264909203,0.0,0.0,0.9956140350877192,227.0,-0.5944830220362641,0.1821420363134912,1.0,2.0,2.0,71.0,71.0,46.0,142.0,294,69.0,4.565376186997809e-05,4755.0,229.0,1.0,0,79.0
4245,603277,HP:0000717,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",0,1.3147666800941336,783934.9151515152,133.87527875119466,0.1826601847065301,0.221113535235454,0.0,0.0,0.9968652037617554,318.0,-0.3457688805463041,0.2102664576802508,1.0,2.0,6.0,135.0,135.0,4.0,270.0,294,133.0,3.3412409368839586e-05,10732.0,320.0,1.0,0,170.0
4246,608892,HP:0000717,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",1,1.3948698344737949,2675273.1445085667,205.81805630460576,0.17999159770880668,0.02103675557287892,0.0,0.0,1.0012820512820513,781.0,-0.5549226998059505,0.08021274500147739,1.0,2.0,10.0,146.0,146.0,146.0,292.0,292,146.0,2.472212333372889e-06,24432.0,781.0,1.0,0,150.0
4247,610528,HP:0000717,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",0,1.3622294372294372,263029.80995671,127.95045662100458,0.19633139694372287,0.003720365284652944,0.0,0.0,1.0048780487804878,206.0,-0.7663742359901509,0.25768411082169074,1.0,2.0,3.0,58.0,58.0,58.0,116.0,292,57.0,4.627701420704336e-05,5441.0,206.0,1.0,0,61.0
4248,602118,HP:0001249,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",0,1.4658357959036417,4371752.261961747,719.2512484394507,0.1631221454474062,-0.008159192703094578,0.0,0.0,1.000593471810089,1686.0,-0.7548412507693065,0.040414515067355175,1.0,2.0,1.0,84.0,84.0,84.0,168.0,3204,83.0,3.8916426584744994e-07,57407.0,1686.0,1.0,0,87.0
4249,602119,HP:0001249,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",1,1.4669333266028723,2147163.9182627443,428.55139409072,0.2196678473615733,0.01258995546253342,0.0,0.0,1.0005945303210464,1683.0,-0.6247276378386071,0.023344588078448327,1.0,2.0,1.0,81.0,81.0,81.0,162.0,3204,80.0,3.8916426584744994e-07,33042.0,1683.0,1.0,0,80.0
4250,603277,HP:0001249,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",1,1.437526070824826,12889145.88940261,596.3808611328863,0.1421462420018451,0.05204020479338376,0.0,0.0,1.0005640157924425,1774.0,-0.6528821469144883,0.058901816105416914,1.0,2.0,1.0,172.0,172.0,172.0,344.0,3204,171.0,3.8916426584744994e-07,92632.0,1774.0,1.0,0,183.0
4251,608892,HP:0001249,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",1,1.3618410143668065,43009114.11495271,428.84684400405007,0.12519066184851527,0.06200791233755878,0.0,0.0,1.0004472271914129,2237.0,-0.4746917892698779,0.07797666981478357,1.0,2.0,1.0,623.0,623.0,139.0,1246.0,3204,622.0,3.8916426584744994e-07,195017.0,2237.0,1.0,0,886.0
4253,602119,HP:0001250,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",1,1.4659562295694148,2234912.343398678,438.4538510553564,0.2162483199012014,0.11211074219001388,0.0,0.0,1.0006134969325151,1631.0,-0.6289733901585522,0.025390723444911285,1.0,2.0,1.0,81.0,81.0,81.0,162.0,3100,80.0,4.156965348783941e-07,33751.0,1631.0,1.0,0,86.0
4254,603277,HP:0001250,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",0,1.4334265121458059,11359233.265465427,522.766129032258,0.14742019358377578,0.021928721091134043,0.0,0.0,0.9994196169471852,1722.0,-0.6335450641175416,0.055444087297152084,1.0,2.0,1.0,173.0,173.0,173.0,346.0,3102,171.0,4.1516101604846394e-07,82347.0,1724.0,1.0,0,178.0
4255,608892,HP:0001250,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",1,1.3600699798870566,37108319.28088464,387.61911099822197,0.12993008844601994,0.03544672201996952,0.0,0.0,1.0004578754578757,2185.0,-0.46277140138646505,0.07317876631377776,1.0,2.0,4.0,620.0,620.0,118.0,1240.0,3106,619.0,4.156965348783942e-07,174606.0,2185.0,1.0,0,828.0
4256,610528,HP:0001250,"CHD proteins play an important role in neurodevelopment, as pathogenic variants in CHD1, CHD2, CHD4, CHD7 and CHD8 have been associated with a range of neurological phenotypes, including autism spectrum disorder (ASD), intellectual disability (ID) and epilepsy.",0,1.4741279807059988,2375733.313205896,681.9302150537634,0.18444089280016154,0.014844634170488816,0.0,0.0,1.000621504039776,1610.0,-0.7558231240179427,0.03041200699481565,1.0,2.0,1.0,60.0,60.0,60.0,120.0,3100,59.0,4.156965348783943e-07,39391.0,1610.0,1.0,0,62.0
4257,602119,HP:0001298,"Pathogenic variants in CHD2 are associated with developmental epileptic encephalopathy (DEE) in humans, however little is known about how these variants contribute to this disorder.",1,1.3729310817139881,419993.9295093796,116.79542903785328,0.22645380291112066,0.03270062020988777,0.0,0.0,1.0031055900621118,323.0,-0.6124230512381748,0.13629982885602754,1.0,2.0,1.0,75.0,75.0,70.0,150.0,484,74.0,1.6935087808430286e-05,7088.0,323.0,1.0,0,88.0
4258,168461,HP:0002861,"Moreover, comparison of the porcine results to those reported by human melanoma GWAS indicated shared association signals notably at CDKAL1 and TERT loci but also nearby CCND1, FTO, PLA2G6 and TMEM38B-RAD23B loci.",0,1.3204174430899511,266315.80992063496,96.34649122807018,0.2407475242880196,0.18395168467992729,0.0,0.0,0.9966101694915256,294.0,-0.5722540221833745,0.1173385249656436,1.0,2.0,28.0,67.0,67.0,67.0,134.0,196,66.0,1.9069049026525047e-05,5123.0,296.0,1.0,0,75.0
4260,603604,HP:0002861,"Moreover, comparison of the porcine results to those reported by human melanoma GWAS indicated shared association signals notably at CDKAL1 and TERT loci but also nearby CCND1, FTO, PLA2G6 and TMEM38B-RAD23B loci.",0,1.3196648761866154,242375.6440664408,83.21945259042033,0.25425436424775977,0.2726533092970189,0.0,0.0,0.9971098265895952,345.0,-0.5180946174383853,0.07795972081091436,1.0,2.0,44.0,66.0,66.0,67.0,132.0,192,64.0,1.2755102040816327e-05,4680.0,347.0,1.0,0,69.0
4261,611236,HP:0002861,"Moreover, comparison of the porcine results to those reported by human melanoma GWAS indicated shared association signals notably at CDKAL1 and TERT loci but also nearby CCND1, FTO, PLA2G6 and TMEM38B-RAD23B loci.",0,1.28889669506162,51519.6,54.501748251748246,0.2691454209185337,-0.11879580289448205,0.0,0.0,0.9915966386554622,118.0,-0.40276746536312974,0.2303921568627451,1.0,2.0,5.0,48.0,48.0,41.0,96.0,134,46.0,0.0002227667631989308,1645.0,120.0,1.0,0,56.0
1128,113810,HP:0002664,"Extensive search of the literature revealed a potential key role of genes at the identified porcine loci in tumor invasion (DST, PLEKHA5, CBY1, LIMK2 and ETV5) and immune response modulation (ETV5, HERC3 and DICER1) of the progression phenotypes.",0,1.3963389357853482,2202676.196498029,285.332518065592,0.17459616642363676,0.1091586850513506,0.0,0.0,0.998859749144812,876.0,-0.7133099326630891,0.07028516660909136,1.0,2.0,35.0,102.0,102.0,98.0,204.0,1544,100.0,1.67789739321861e-06,27060.0,878.0,1.0,0,102.0
4262,606241,HP:0002664,"Extensive search of the literature revealed a potential key role of genes at the identified porcine loci in tumor invasion (DST, PLEKHA5, CBY1, LIMK2 and ETV5) and immune response modulation (ETV5, HERC3 and DICER1) of the progression phenotypes.",1,1.4087328518036983,2701795.6544616995,245.8627369815382,0.1765781982299257,0.10090241657496936,0.0,0.0,1.0010976948408343,912.0,-0.6715792366450443,0.07054855855335375,1.0,2.0,11.0,131.0,131.0,101.0,262.0,1542,130.0,1.67789739321861e-06,29307.0,912.0,1.0,0,120.0
4265,607474,HP:0002664,"Among the 44 cases of gastritis/hyperplasia, two cases (4.5%) were diagnosed as HGD and 11 cases (25.0%) were diagnosed as cancer after resection.",0,1.3846757177494156,2584281.2135085333,233.78168100692352,0.1801556426697696,0.005637475038321626,0.0,0.0,0.9989059080962801,913.0,-0.6708356642946588,0.06865157656849732,1.0,2.0,24.0,133.0,133.0,95.0,266.0,1544,131.0,1.6778973932186106e-06,28707.0,915.0,1.0,0,134.0
4263,607474,HP:0002664,"Among the 182 cases of low-grade dysplasia, 33 cases (18.1%) were diagnosed as HGD and nine cases (5.0%) were diagnosed as cancer after resection.",0,1.3846757177494156,2584281.2135085333,233.78168100692352,0.1801556426697696,0.005637475038321626,0.0,0.0,0.9989059080962801,913.0,-0.6708356642946588,0.06865157656849732,1.0,2.0,24.0,133.0,133.0,95.0,266.0,1544,131.0,1.6778973932186106e-06,28707.0,915.0,1.0,0,134.0
4297,607860,HP:0002664,Zyxin regulates YAP activity through the colon cancer oncogene CDK8.,0,1.4068527212636974,1358223.7785376424,256.74811932555116,0.20044559056675704,0.1205930995449105,0.0,0.0,0.9988262910798122,851.0,-0.6786890735043399,0.05315401592831707,1.0,2.0,44.0,79.0,79.0,77.0,158.0,1544,77.0,1.6778973932186103e-06,19315.0,853.0,1.0,0,86.0
4315,603184,HP:0002664,Zyxin regulates YAP activity through the colon cancer oncogene CDK8.,0,1.4011947857247329,3251000.469689542,287.0723776259485,0.1672236298996347,0.1059775114249421,0.0,0.0,0.9988876529477196,898.0,-0.6685211935347839,0.07905574094673093,1.0,2.0,14.0,127.0,127.0,118.0,254.0,1544,125.0,1.6778973932186097e-06,31982.0,900.0,1.0,0,127.0
4303,603184,HP:0002664,"CDK8 knockout phenocopied Zyxin knockdown in colon cancer cells, while ectopic expression of CDK8 substantially restored the tumorigenic defects of Zyxin-depletion cells.",0,1.4011947857247329,3251000.469689542,287.0723776259485,0.1672236298996347,0.1059775114249421,0.0,0.0,0.9988876529477196,898.0,-0.6685211935347839,0.07905574094673093,1.0,2.0,14.0,127.0,127.0,118.0,254.0,1544,125.0,1.6778973932186097e-06,31982.0,900.0,1.0,0,127.0
4267,607860,HP:0002664,Fully activated YAP is required to support the growth in CDK8-knockout colon cancer cells in vitro and in vivo.,0,1.4068527212636974,1358223.7785376424,256.74811932555116,0.20044559056675704,0.1205930995449105,0.0,0.0,0.9988262910798122,851.0,-0.6786890735043399,0.05315401592831707,1.0,2.0,44.0,79.0,79.0,77.0,158.0,1544,77.0,1.6778973932186103e-06,19315.0,853.0,1.0,0,86.0
4307,603184,HP:0002664,Fully activated YAP is required to support the growth in CDK8-knockout colon cancer cells in vitro and in vivo.,0,1.4011947857247329,3251000.469689542,287.0723776259485,0.1672236298996347,0.1059775114249421,0.0,0.0,0.9988876529477196,898.0,-0.6685211935347839,0.07905574094673093,1.0,2.0,14.0,127.0,127.0,118.0,254.0,1544,125.0,1.6778973932186097e-06,31982.0,900.0,1.0,0,127.0
4311,603184,HP:0002664,"Together, these observations suggest that Zyxin promotes colon cancer tumorigenesis in a mitotic-phosphorylation-dependent manner and through CDK8-mediated YAP activation",0,1.4011947857247329,3251000.469689542,287.0723776259485,0.1672236298996347,0.1059775114249421,0.0,0.0,0.9988876529477196,898.0,-0.6685211935347839,0.07905574094673093,1.0,2.0,14.0,127.0,127.0,118.0,254.0,1544,125.0,1.6778973932186097e-06,31982.0,900.0,1.0,0,127.0
4320,607642,HP:0002360,"Smith-Magenis syndrome (SMS), a neurodevelopmental disorder characterized by dysmorphic features, intellectual disability (ID), and sleep disturbances, results from a 17p11.2 microdeletion or a mutation in the RAI1 gene.",1,1.3339082323574791,6744631.927625152,228.1274006129693,0.14943732149269254,0.05799363929802606,0.0,0.0,1.00117508813161,852.0,-0.3316654923133381,0.1339876312319668,1.0,2.0,5.0,366.0,366.0,5.0,732.0,868,365.0,5.284713964856652e-06,48574.0,852.0,1.0,0,447.0
4321,600898,HP:0001249,"SOX11 is a key Transcription Factor (TF) in the regulation of embryonic and adult neurogenesis, whose mutation has recently been linked to an intellectual disability syndrome in humans.",1,1.4067233924055749,26249995.626230586,537.348615310596,0.12690423787491206,0.05366758498040285,0.0,0.0,1.0005257623554151,1903.0,-0.6182614897483025,0.07523623389490168,1.0,2.0,1.0,300.0,300.0,301.0,600.0,3204,299.0,3.891642658474503e-07,136159.0,1903.0,1.0,0,391.0
4324,603639,HP:0002664,"We examined the effects of MEDI3622, a human mAb and potent ADAM17 inhibitor, on NK cell activation by antibody-bound tumor cells.",0,1.3994667594041617,1607504.4904691922,240.24919854146785,0.18932425195126493,0.01636372424015511,0.0,0.0,0.9988610478359908,877.0,-0.7209013586711404,0.05980859384110645,1.0,2.0,29.0,99.0,99.0,73.0,198.0,1544,97.0,1.6778973932186097e-06,23079.0,879.0,1.0,0,95.0
4322,603639,HP:0002664,"These findings support ADAM17 as a dynamic inhibitory checkpoint of the potent activating receptor CD16A, which can be targeted by MEDI3622 to potentially increase the efficacy of anti-tumor therapeutic antibodies",0,1.3994667594041617,1607504.4904691922,240.24919854146785,0.18932425195126493,0.01636372424015511,0.0,0.0,0.9988610478359908,877.0,-0.7209013586711404,0.05980859384110645,1.0,2.0,29.0,99.0,99.0,73.0,198.0,1544,97.0,1.6778973932186097e-06,23079.0,879.0,1.0,0,95.0
3882,104150,HP:0002664,"Although univariate analysis showed that tumor size (P = .012), grade (Z = -2.114, P = .034), and peritumoral enhancement (x = 4.464, P = .035) were associated with MVI, multiple logistic regression analysis showed that capsular invasion (odds ratio [OR] = 23.469, P &lt; .001), margins (OR = 6.751, P &lt; .001), and serum AFP level (OR = 1.001, P = .038) were associated with MVI in HCC (P &lt; .05).",0,1.3936926009357131,16591.98454004939,151.78826199740595,0.511950755928789,0.2063200777409981,0.0,0.0,0.9987179487179488,779.0,-0.7352972882800497,0.00645129518368955,1.0,2.0,169.0,7.0,7.0,7.0,14.0,1544,5.0,1.6778973932186097e-06,1965.0,781.0,1.0,0,6.0
3888,104150,HP:0002664,"Radiographic hepatic capsular invasion and nonsmooth tumor margins identified by preoperative CT images, along with AFP levels greater than 232.2 ng/mL, are important predictors of MVI",0,1.3936926009357131,16591.98454004939,151.78826199740595,0.511950755928789,0.2063200777409981,0.0,0.0,0.9987179487179488,779.0,-0.7352972882800497,0.00645129518368955,1.0,2.0,169.0,7.0,7.0,7.0,14.0,1544,5.0,1.6778973932186097e-06,1965.0,781.0,1.0,0,6.0
4326,600725,HP:0000175,"It is associated with multiple genetic and environmental risk factors, including mutations in the genes encoding signaling molecules in the sonic hedgehog (Shh) pathway, which are risk factors for cleft palate in both humans and mice.",1,1.333857467473322,11899950.599007934,296.8435397577025,0.13220082285615173,0.0218165249962718,0.0,0.0,1.0010131712259374,988.0,-0.33079011633591776,0.15030210550927234,1.0,2.0,10.0,432.0,432.0,17.0,864.0,1028,431.0,3.905700760830508e-06,73284.0,988.0,1.0,0,636.0
4327,603273,HP:0000175,"Collectively, our data illustrate that persistent Hh signaling in the palatal epithelium contributes to the etiology and pathogenesis of submucous cleft palate through its interaction with a p63/Irf6-dependent biological regulatory loop and through a p63-induced cell adhesion network",1,1.3345422985874018,11514710.606715504,264.1052382161293,0.13318201445545652,0.09562462516850843,0.0,0.0,1.0009182736455464,1090.0,-0.3165214882506823,0.12060724004010075,1.0,2.0,16.0,455.0,455.0,2.0,910.0,1010,455.0,2.912089832147141e-06,71581.0,1090.0,1.0,0,639.0
4328,607199,HP:0000175,"Collectively, our data illustrate that persistent Hh signaling in the palatal epithelium contributes to the etiology and pathogenesis of submucous cleft palate through its interaction with a p63/Irf6-dependent biological regulatory loop and through a p63-induced cell adhesion network",1,1.3478802157734906,5870662.852505827,259.06166586918914,0.1381012603148402,0.004333346390871559,0.0,0.0,1.001293661060802,774.0,-0.5906748932204232,0.15199013207376874,1.0,2.0,6.0,249.0,249.0,109.0,498.0,1010,248.0,3.905700760830508e-06,45468.0,774.0,1.0,0,357.0
4329,605219,HP:0002664,"Furthermore, we found increased concentration of cytochrome c, Smac/Diablo and increased caspase-3 and caspase-9 activity, cleavage of PARP as well as activation of DNA repair mechanisms in 1C-treated HCT116 cancer cells.",0,1.4249653836678868,66642.72081087937,231.81285899573842,0.3646611524249747,0.4257136968072651,0.0,0.0,0.9987277353689568,785.0,-0.6781588277445657,0.012754978321386657,1.0,2.0,100.0,15.0,15.0,15.0,30.0,1544,13.0,1.67789739321861e-06,3945.0,787.0,1.0,0,13.0
4365,167411,HP:0000007,A single family with an autosomal recessive form of OFCS and a homozygous missense mutation in PAX1 gene has been described.,1,1.4639070155414968,9029494.088309016,641.7656502412318,0.16957655204604924,0.11370463696859318,0.0,0.0,1.000367376928729,2723.0,-0.6509669432071261,0.023462744093839104,1.0,2.0,55.0,143.0,143.0,143.0,286.0,5160,142.0,1.5011496554636367e-07,86953.0,2723.0,1.0,0,133.0
4367,167411,HP:0000007,"This report provides evidence that bi-allelic null PAX1 mutations may lead to a multi-system autosomal recessive disorders, where SCID might represent the main feature",1,1.4639070155414968,9029494.088309016,641.7656502412318,0.16957655204604924,0.11370463696859318,0.0,0.0,1.000367376928729,2723.0,-0.6509669432071261,0.023462744093839104,1.0,2.0,55.0,143.0,143.0,143.0,286.0,5160,142.0,1.5011496554636367e-07,86953.0,2723.0,1.0,0,133.0
2672,164730,HP:0002664,"To identify the genes that are targets of constitutive PI3K/AKT signalling in lung cancer cells, we performed a comparative transcriptomic analysis of human lung epithelial cells (BEAS-2B) expressing active mutant AKT1 (AKT1-E17K), active mutant PIK3CA (PIK3CA-E545K) or that are silenced for PTEN.",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
513,601728,HP:0002664,"To identify the genes that are targets of constitutive PI3K/AKT signalling in lung cancer cells, we performed a comparative transcriptomic analysis of human lung epithelial cells (BEAS-2B) expressing active mutant AKT1 (AKT1-E17K), active mutant PIK3CA (PIK3CA-E545K) or that are silenced for PTEN.",1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
812,171834,HP:0002664,"To identify the genes that are targets of constitutive PI3K/AKT signalling in lung cancer cells, we performed a comparative transcriptomic analysis of human lung epithelial cells (BEAS-2B) expressing active mutant AKT1 (AKT1-E17K), active mutant PIK3CA (PIK3CA-E545K) or that are silenced for PTEN.",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
2612,164730,HP:0002664,"Expectedly, the analysis of the DEGs common to all three alterations highlighted a group of BioFunctions that included Cell Proliferation of tumor cell lines (14 DEGs), Invasion of cells (10 DEGs) and Migration of tumour cell lines (10 DEGs), with a common core of 5 genes (ATF3, CDKN1A, GDF15, HBEGF and LCN2) that likely represent downstream effectors of the pro-oncogenic activities of PI3K/AKT signalling.",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
763,171834,HP:0002664,"Expectedly, the analysis of the DEGs common to all three alterations highlighted a group of BioFunctions that included Cell Proliferation of tumor cell lines (14 DEGs), Invasion of cells (10 DEGs) and Migration of tumour cell lines (10 DEGs), with a common core of 5 genes (ATF3, CDKN1A, GDF15, HBEGF and LCN2) that likely represent downstream effectors of the pro-oncogenic activities of PI3K/AKT signalling.",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
4369,600528,HP:0002664,"Finally, the simultaneous increase of CPT1A, CACT and CrAT is fundamental for PCCs to sustain FA oxidation in the presence of heavy lipid load on prostate cancer mitochondria.",0,1.4020207635875803,1050589.24189199,205.50320158372585,0.2223483171809912,0.2760233948729109,0.0,0.0,0.9988465974625144,866.0,-0.622647994219124,0.04804426514438793,1.0,2.0,36.0,94.0,94.0,91.0,188.0,1544,92.0,1.6778973932186097e-06,18078.0,868.0,1.0,0,96.0
4370,600184,HP:0002664,"Finally, the simultaneous increase of CPT1A, CACT and CrAT is fundamental for PCCs to sustain FA oxidation in the presence of heavy lipid load on prostate cancer mitochondria.",0,1.4142199194012666,448646.8933780929,232.92147152458438,0.2510292534027018,0.2123015838968912,0.0,0.0,0.9987745098039216,815.0,-0.6540884726478675,0.03128074975400197,1.0,2.0,75.0,45.0,45.0,45.0,90.0,1544,43.0,1.67789739321861e-06,10427.0,817.0,1.0,0,44.0
2395,606829,HP:0002664,"Finally, the simultaneous increase of CPT1A, CACT and CrAT is fundamental for PCCs to sustain FA oxidation in the presence of heavy lipid load on prostate cancer mitochondria.",0,1.3621265762760904,2413616.901743359,200.04513618677043,0.18544942053489166,0.21665475310549576,0.0,0.0,0.9989327641408752,936.0,-0.6167799868358901,0.06338106691728125,1.0,2.0,40.0,152.0,152.0,96.0,304.0,1544,150.0,1.6778973932186097e-06,27853.0,938.0,1.0,0,139.0
3359,120436,HP:0002664,"The DLEC1, TUSC4 and MLH1 expression was analysed in lung tumour tissue samples obtained from 69 patients diagnosed with NSCLC: squamous cell carcinoma (n = 34), adenocarcinoma (n = 24), large cell carcinoma (n = 5), carcinoma adenosquamosum (n = 5).",1,1.3724379901603143,5818621.47767339,246.4111696040284,0.1639416543826219,-0.008069802038276657,0.0,0.0,1.0009756097560976,1026.0,-0.5524282139315764,0.08979793657585697,1.0,2.0,1.0,250.0,250.0,99.0,500.0,1542,249.0,1.67789739321861e-06,47218.0,1026.0,1.0,0,247.0
4371,120436,HP:0002860,"The DLEC1, TUSC4 and MLH1 expression was analysed in lung tumour tissue samples obtained from 69 patients diagnosed with NSCLC: squamous cell carcinoma (n = 34), adenocarcinoma (n = 24), large cell carcinoma (n = 5), carcinoma adenosquamosum (n = 5).",0,1.3607885994054905,184324.15901320905,78.750112504018,0.2684668324718289,0.08143039603299433,0.0,0.0,0.996845425867508,316.0,-0.5292645218930829,0.08122532388945103,1.0,2.0,14.0,62.0,62.0,62.0,124.0,370,60.0,1.52587890625e-05,4094.0,318.0,1.0,0,59.0
4372,120436,HP:0030731,"The DLEC1, TUSC4 and MLH1 expression was analysed in lung tumour tissue samples obtained from 69 patients diagnosed with NSCLC: squamous cell carcinoma (n = 34), adenocarcinoma (n = 24), large cell carcinoma (n = 5), carcinoma adenosquamosum (n = 5).",0,1.4742336661411806,18475.8411840909,124.79714795008913,0.41454164004173294,0.2630503883277857,0.0,0.0,1.0037735849056604,266.0,-0.6997705774828047,0.03733862959285005,1.0,2.0,5.0,11.0,11.0,11.0,22.0,510,11.0,1.5258789062499993e-05,1316.0,266.0,1.0,0,11.0
3339,120436,HP:0002664,"A decreased gene expression (RQ &lt; 0.7) was observed for DLEC1 in 60.9% of tumour samples, for MLH1 in 50.7% and for TUSC4 in 26% of NSCLC samples.",1,1.3724379901603143,5818621.47767339,246.4111696040284,0.1639416543826219,-0.008069802038276657,0.0,0.0,1.0009756097560976,1026.0,-0.5524282139315764,0.08979793657585697,1.0,2.0,1.0,250.0,250.0,99.0,500.0,1542,249.0,1.67789739321861e-06,47218.0,1026.0,1.0,0,247.0
3253,607117,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.446917481345746,3456584.1208983106,569.168260587428,0.148131705915047,-0.01942062784803805,0.0,0.0,1.0008904719501337,1124.0,-0.7611540691697282,0.07542234038844857,1.0,2.0,3.0,89.0,89.0,89.0,178.0,2066,88.0,9.35317203476387e-07,47601.0,1124.0,1.0,0,109.0
3255,613583,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4342694660040496,5393701.512815662,536.1105696877008,0.14190795739515186,0.0968985435302059,0.0,0.0,1.000868809730669,1152.0,-0.7251786795337877,0.08628819142774401,1.0,2.0,1.0,119.0,119.0,119.0,238.0,2066,118.0,9.353172034763872e-07,57207.0,1152.0,1.0,0,131.0
4373,608201,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4431452563962222,4463432.659671985,573.3000479137943,0.14448749362144314,0.032001982837562705,0.0,0.0,1.0008841732979663,1132.0,-0.7494535985021141,0.08090810533846966,1.0,2.0,1.0,99.0,99.0,99.0,198.0,2066,98.0,9.353172034763872e-07,51793.0,1132.0,1.0,0,123.0
3259,605481,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4342694660040496,5562653.248529644,552.2481472743987,0.1413071799331772,0.014248688097506847,0.0,0.0,1.000868809730669,1152.0,-0.718389011847588,0.0888855705183898,1.0,2.0,1.0,119.0,119.0,119.0,238.0,2066,118.0,9.353172034763872e-07,58929.0,1152.0,1.0,0,139.0
4374,609279,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4006947942091874,11724104.927128578,463.399968481956,0.13088149388428466,-0.0019761182219654137,0.0,0.0,1.0008019246190858,1248.0,-0.6359288221542864,0.1059812781444698,1.0,2.0,3.0,213.0,213.0,213.0,426.0,2066,212.0,9.35317203476387e-07,82467.0,1248.0,1.0,0,266.0
4375,181590,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4483665606145069,3531503.031879858,580.2430366100502,0.14903179222245894,0.10609977989085727,0.0,0.0,1.000892857142857,1121.0,-0.7569418619239919,0.07495380400152925,1.0,2.0,1.0,88.0,88.0,88.0,176.0,2066,87.0,9.353172034763868e-07,47053.0,1121.0,1.0,0,108.0
4381,611423,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.446917481345746,3766230.6046776217,579.9176622022703,0.14808628062212087,0.08782731831424101,0.0,0.0,1.0008904719501337,1124.0,-0.7498999694425795,0.07684677861472987,1.0,2.0,1.0,91.0,91.0,91.0,182.0,2066,90.0,9.353172034763868e-07,48500.0,1124.0,1.0,0,115.0
4382,613529,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.3990038044390571,12098557.325574094,457.50157035038313,0.13050741577414834,0.004620934601443437,0.0,0.0,1.0007980845969673,1254.0,-0.6297782933469389,0.1060154194526438,1.0,2.0,2.0,220.0,220.0,220.0,440.0,2066,219.0,9.353172034763872e-07,83289.0,1254.0,1.0,0,263.0
4383,610827,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4454873827359669,3652157.904594018,573.3073675104529,0.1481205119392262,0.10313392234560073,0.0,0.0,1.0008880994671403,1127.0,-0.7450066337145127,0.07785015311244585,1.0,2.0,1.0,94.0,94.0,94.0,188.0,2066,93.0,9.35317203476387e-07,49396.0,1127.0,1.0,0,92.0
4384,602978,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4503287189976752,3163006.224945944,592.5357258101692,0.14927713509190665,0.125594641407462,0.0,0.0,1.0008960573476702,1117.0,-0.7662913316954773,0.07385052768712919,1.0,2.0,1.0,84.0,84.0,84.0,168.0,2066,83.0,9.35317203476387e-07,46030.0,1117.0,1.0,0,105.0
4385,603368,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4493433083956777,3262966.132657367,582.6891645467031,0.14932672691419666,0.053931119514616335,0.0,0.0,1.0008944543828264,1119.0,-0.7614889455793569,0.0739543516524625,1.0,2.0,1.0,86.0,86.0,86.0,172.0,2066,85.0,9.353172034763865e-07,46260.0,1119.0,1.0,0,109.0
4386,117143,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.414097902097902,9781187.922893323,499.1896767149193,0.1329465972223715,0.0681019634918526,0.0,0.0,1.0008305647840532,1205.0,-0.6745629392071387,0.10146675673067644,1.0,2.0,1.0,172.0,172.0,171.0,344.0,2066,171.0,9.353172034763868e-07,73605.0,1205.0,1.0,0,189.0
4387,609321,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4445443808485512,4276756.423120068,573.1410031461762,0.14682034645421774,0.046347770696165136,0.0,0.0,1.000886524822695,1129.0,-0.7431965346340486,0.079061681397584,1.0,2.0,1.0,96.0,96.0,96.0,192.0,2066,95.0,9.353172034763872e-07,50343.0,1129.0,1.0,0,118.0
4388,614397,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4309277252005463,5880203.008624349,539.7906868611414,0.13961234104067582,0.027523599281873267,0.0,0.0,1.000862812769629,1160.0,-0.7173188523413865,0.09081550682812174,1.0,2.0,1.0,127.0,127.0,127.0,254.0,2066,126.0,9.353172034763868e-07,61048.0,1160.0,1.0,0,148.0
4389,616062,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4253467418955397,8278949.663805245,564.3305390208235,0.1330440538172436,0.021347253840949675,0.0,0.0,1.000852514919011,1174.0,-0.7194614884614217,0.10168309972681762,1.0,2.0,1.0,141.0,141.0,141.0,282.0,2066,140.0,9.35317203476387e-07,70014.0,1174.0,1.0,0,164.0
4390,605629,HP:0000252,"Genetic studies on consanguineous families with primary microcephaly have identified 15 (MCPH) causative genes that include MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6, CENPE, SASS6 MFSD2A ANKLE2 and CIT (Khan et al. 2014; Yamamoto et al. 2014; Alakbarzade et al. 2015;Morris-Rosendahl and Kaindl 2015; Basit et al. 2016).",1,1.4317524746719903,6318097.482006498,564.0188654404648,0.13713229442557778,0.013739843694241027,0.0,0.0,1.0008643042350909,1158.0,-0.73186831074238,0.09388224862405453,1.0,2.0,1.0,125.0,125.0,125.0,250.0,2066,124.0,9.35317203476387e-07,62892.0,1158.0,1.0,0,144.0
4391,168461,HP:0002664,"In addition, silencing of CtBP2 markedly increased the apoptosis of PCa cells in vitro, and decreased the expression of IL-8, AT2R, CCND1 and MMP9 which are associated with cancer progression.",1,1.3791735155600702,4535988.085149899,239.63997542494369,0.1700390081304759,0.1560980157708474,0.0,0.0,1.001002004008016,999.0,-0.5641313990479803,0.08458959961965974,1.0,2.0,1.0,224.0,224.0,143.0,448.0,1542,224.0,1.67789739321861e-06,42168.0,999.0,1.0,0,236.0
4392,120361,HP:0002664,"In addition, silencing of CtBP2 markedly increased the apoptosis of PCa cells in vitro, and decreased the expression of IL-8, AT2R, CCND1 and MMP9 which are associated with cancer progression.",0,1.4007585318804,487849.2107265055,197.48134584573128,0.24938651599670825,0.4136712021247838,0.0,0.0,0.9987849331713244,822.0,-0.6379433803860722,0.03000212341775885,1.0,2.0,91.0,52.0,52.0,52.0,104.0,1544,50.0,1.67789739321861e-06,10173.0,824.0,1.0,0,53.0
4393,604305,HP:0002664,"Oral and pharyngeal cancers combined were associated with loci at 6p21.32 (rs3828805, HLA-DQB1), 10q26.13 (rs201982221, LHPP) and 11p15.4 (rs1453414, OR52N2-TRIM5).",0,1.3669907970133703,5499763.868569829,230.3748378728924,0.16295956432887654,0.03331050373060395,0.0,0.0,1.000952380952381,1051.0,-0.5479188929709083,0.08575959403742467,1.0,2.0,7.0,268.0,268.0,91.0,536.0,1546,267.0,1.6778973932186106e-06,47320.0,1051.0,1.0,0,309.0
4397,604349,HP:0002664,"Oral cancer was associated with two new regions, 2p23.3 (rs6547741, GPN1) and 9q34.12 (rs928674, LAMC3), and with known cancer-related loci-9p21.3 (rs8181047, CDKN2B-AS1) and 5p15.33 (rs10462706, CLPTM1L).",0,1.4189426925275983,244552.08585803624,260.33889197702445,0.2690311300992921,0.4343006995810004,0.0,0.0,0.99875,799.0,-0.7500997015381582,0.024279026217228463,1.0,2.0,89.0,29.0,29.0,29.0,58.0,1544,27.0,1.67789739321861e-06,7779.0,801.0,1.0,0,28.0
4395,604305,HP:0002664,"Oropharyngeal cancer associations were limited to the human leukocyte antigen (HLA) region, and classical HLA allele imputation showed a protective association with the class II haplotype HLA-DRB1*1301-HLA-DQA1*0103-HLA-DQB1*0603 (odds ratio (OR) = 0.59, P = 2.7 x 10-9).",0,1.3669907970133703,5499763.868569829,230.3748378728924,0.16295956432887654,0.03331050373060395,0.0,0.0,1.000952380952381,1051.0,-0.5479188929709083,0.08575959403742467,1.0,2.0,7.0,268.0,268.0,91.0,536.0,1546,267.0,1.6778973932186106e-06,47320.0,1051.0,1.0,0,309.0
4399,607223,HP:0030127,"The expression of the ID2, PRELP and SMOC2 genes was compared between the endometrium of women without endometriosis in the proliferative phase of their menstrual cycle and the eutopic and ectopic endometrium of women with endometriosis in the proliferative phase.",0,1.2357954545454546,130.125,14.444444444444445,0.6736565914332397,0.6226530025325223,0.0,0.0,0.9655172413793104,28.0,-0.8453657202883743,0.09195402298850576,1.0,2.0,16.0,2.0,2.0,2.0,4.0,54,1.0,0.0012755102040816323,40.0,30.0,1.0,0,2.0
4398,607223,HP:0030127,"The ID2 gene expression was increased in the most advanced stage of endometriosis and in ovarian endometriomas, the PRELP was more expressed in peritoneal lesions, and the SMOC2 was highly expressed in both peritoneal and endometrioma lesions.",0,1.2357954545454546,130.125,14.444444444444445,0.6736565914332397,0.6226530025325223,0.0,0.0,0.9655172413793104,28.0,-0.8453657202883743,0.09195402298850576,1.0,2.0,16.0,2.0,2.0,2.0,4.0,54,1.0,0.0012755102040816323,40.0,30.0,1.0,0,2.0
4400,615345,HP:0030319,We characterize MYMK-CFZS as a congenital myopathy with marked facial weakness and additional clinical and pathologic features that distinguish it from other congenital neuromuscular syndromes.,1,1.3343951089818509,1875929.9119047616,187.09307807289872,0.16531088228948104,0.2407283048760525,0.0,0.0,1.0021929824561402,457.0,-0.26044019236543337,0.20502706437867094,1.0,2.0,3.0,198.0,198.0,2.0,396.0,446,198.0,1.810774105930285e-05,21363.0,457.0,1.0,0,281.0
3844,600997,HP:0002664,"Initial antitumoral responses are often seen, but drug-resistant clones with reactivation of the MEK-ERK pathway soon appear.",0,1.4690265087320626,357691.2300742182,297.28916465103237,0.2541462988734713,0.25144426459714403,0.0,0.0,1.0012391573729864,808.0,-0.7632440013769647,0.03219355392788348,1.0,2.0,7.0,35.0,35.0,35.0,70.0,1542,34.0,1.67789739321861e-06,10496.0,808.0,1.0,0,31.0
257,164757,HP:0002664,"To elucidate the possible functions of EVs in BRAF-mutant melanoma, we determined the RNA content of the EVs, including apoptotic bodies, microvesicles, and exosomes, released from such cancer cells after vemurafenib treatment.",1,1.3343717616163435,16381827.818362188,267.1583928605997,0.14243558102353174,0.0178111227871734,0.0,0.0,1.0006944444444446,1441.0,-0.2821765440487228,0.0923076181663968,1.0,2.0,9.0,611.0,611.0,3.0,1222.0,1542,610.0,1.6778973932186103e-06,95771.0,1441.0,1.0,0,790.0
2228,190080,HP:0002664,"In DLBCL patients, overexpression of PCYT1A was in parallel with an increase in tumor MYC, as well as a decrease in serum choline metabolite phosphatidylcholine levels and an International Prognostic Index, indicating intermediate-high or high risk.",1,1.4396536831054232,1166089.637753825,258.33534370946825,0.21512590240969573,0.06608515489589678,0.0,0.0,1.0011764705882351,851.0,-0.6775154399515846,0.05177023570885463,1.0,2.0,1.0,80.0,80.0,80.0,160.0,1542,79.0,1.6778973932186097e-06,18724.0,851.0,1.0,0,67.0
4401,123695,HP:0002664,"In DLBCL patients, overexpression of PCYT1A was in parallel with an increase in tumor MYC, as well as a decrease in serum choline metabolite phosphatidylcholine levels and an International Prognostic Index, indicating intermediate-high or high risk.",0,1.3560232837130708,4068277.5597773083,228.92338336112653,0.16399255007187136,0.07497005827026025,0.0,0.0,0.9989669421487604,967.0,-0.6038457339446593,0.07767443645574802,1.0,2.0,47.0,189.0,189.0,117.0,378.0,1544,187.0,1.6778973932186097e-06,36429.0,969.0,1.0,0,230.0
4405,300137,HP:0000821,"Mutations in the immunoglobulin superfamily, member 1 gene (IGSF1/Igsf1) cause an X-linked form of central hypothyroidism.",1,1.4380872191705758,61352.98097572362,114.90342822161007,0.2848440291807156,-0.059584088446629525,0.0,0.0,1.003731343283582,269.0,-0.7888163373516318,0.0774288409254841,1.0,2.0,1.0,26.0,26.0,23.0,52.0,484,25.0,1.6935087808430286e-05,2791.0,269.0,1.0,0,29.0
4406,300646,HP:0003745,"To the best of our knowledge, this is the first report describing sporadic XLID with de novo ZDHHC9 mutation identified by targeted next-generation sequencing",0,1.3269230769230769,410597.03333333327,107.15910157559506,0.2025779003551504,0.16739776660377095,0.0,0.0,0.9960474308300395,252.0,-0.5025374034051948,0.20154990507609474,1.0,2.0,3.0,93.0,93.0,94.0,186.0,192,92.0,4.0057683063611606e-05,6476.0,254.0,1.0,0,112.0
4407,603073,HP:0000480,"We now report that zebrafish with genetic lesions in zebrafish zic2 orthologs, zic2a and zic2b, develop with retinal coloboma and craniofacial anomalies.",0,1.3891686944711674,147911.9523808829,141.3360507246377,0.2694232306622244,0.11650059235172396,0.0,0.0,0.9974937343358397,398.0,-0.7045527173636184,0.05342105263157895,1.0,2.0,46.0,31.0,31.0,31.0,62.0,328,30.0,7.344246884203259e-06,4263.0,400.0,1.0,0,36.0
4408,148043,HP:0001131,"Meesmann epithelial corneal dystrophy (MECD) is a rare autosomal dominant disorder caused by dominant-negative mutations within the KRT3 or KRT12 genes, which encode the cytoskeletal protein keratins K3 and K12, respectively.",1,1.3013565891472871,4562.980158730159,28.38146167557932,0.3726629228207857,0.3484780958256326,0.0,0.0,0.9803921568627452,50.0,-0.7031359370674848,0.2609351432880845,1.0,2.0,1.0,18.0,18.0,15.0,36.0,68,16.0,0.0008163265306122449,346.0,52.0,1.0,0,16.0
4409,601687,HP:0001131,"Meesmann epithelial corneal dystrophy (MECD) is a rare autosomal dominant disorder caused by dominant-negative mutations within the KRT3 or KRT12 genes, which encode the cytoskeletal protein keratins K3 and K12, respectively.",1,1.3452243958573074,6036.125,28.64393939393939,0.3908950855400922,0.35515244334714235,0.0,0.0,1.0178571428571428,57.0,-0.5859842064849959,0.2493734335839599,1.0,2.0,3.0,19.0,19.0,17.0,38.0,66,18.0,0.0008650519031141869,398.0,57.0,1.0,0,22.0
4410,615586,HP:0001513,"Reporting in this issue of Developmental Cell, Kanie et al. (2017) shed light on the mechanism of transport by implicating CEP19, which is associated with an autosomal-recessive obesity syndrome when mutated, in the triggering of intraflagellar transport",1,1.4062957618513174,318595.7287183732,129.89889705882354,0.23656418962926504,0.12765157761091595,0.0,0.0,1.0023866348448691,420.0,-0.6830638720771203,0.08413456074553928,1.0,2.0,1.0,65.0,65.0,39.0,130.0,704,64.0,8.025102520684701e-06,7403.0,420.0,1.0,0,49.0
4411,602302,HP:0002664,"In the present study, a differential cytotoxicity screen of hormone-resistant prostate cancer LNCaP-hr cells and the parental LNCaP-FGC cells against normal MRC5 fibroblast cells, identified a small molecule compound, Aristeromycin (a derivative of 3-deazaneplanocin A (DZNeP)).",0,1.419521493181756,317326.601783806,212.30529781502545,0.2662501690085985,0.4143712056903931,0.0,0.0,0.9987669543773121,810.0,-0.73137403068189,0.02617033037118925,1.0,2.0,63.0,37.0,37.0,36.0,74.0,1544,35.0,1.6778973932186103e-06,8617.0,812.0,1.0,0,36.0
4413,602302,HP:0002664,"To further understand why AHCY inhibitors decreased prostate cancer cell growth, we performed microRNA expression profiling with LNCaP-hr cells.",0,1.419521493181756,317326.601783806,212.30529781502545,0.2662501690085985,0.4143712056903931,0.0,0.0,0.9987669543773121,810.0,-0.73137403068189,0.02617033037118925,1.0,2.0,63.0,37.0,37.0,36.0,74.0,1544,35.0,1.6778973932186103e-06,8617.0,812.0,1.0,0,36.0
4415,180960,HP:0002664,"To further understand why AHCY inhibitors decreased prostate cancer cell growth, we performed microRNA expression profiling with LNCaP-hr cells.",0,1.4054022860307307,3106521.437280782,262.6603643833947,0.16627120731475756,0.11083400617155788,0.0,0.0,1.001088139281828,920.0,-0.6803856532981365,0.07758433079434167,1.0,2.0,9.0,143.0,143.0,104.0,286.0,1542,142.0,1.6778973932186106e-06,32798.0,920.0,1.0,0,132.0
4416,613577,HP:0001250,"Furthermore, with an increasing number of pathogenic mutations leading to epilepsy and hearing loss being discovered in the TLDc protein TBC1D24, understanding the function of this family has important implications for a range of inherited neurological diseases",1,1.3725837501817826,29985195.41064143,409.69650294695487,0.13161738907851156,0.08442516913813516,0.0,0.0,1.0004859086491742,2059.0,-0.5029361300060562,0.07409410721896474,1.0,2.0,11.0,494.0,494.0,164.0,988.0,3100,493.0,4.156965348783941e-07,156984.0,2059.0,1.0,0,643.0
4417,613577,HP:0000365,"Furthermore, with an increasing number of pathogenic mutations leading to epilepsy and hearing loss being discovered in the TLDc protein TBC1D24, understanding the function of this family has important implications for a range of inherited neurological diseases",1,1.359896893969545,23822956.430379923,355.97565565972565,0.13207424040790444,0.10560173078292408,0.0,0.0,1.0005730659025789,1746.0,-0.4905481392901629,0.08426628856132888,1.0,2.0,13.0,487.0,487.0,121.0,974.0,2474,486.0,6.524672396198987e-07,128370.0,1746.0,1.0,0,782.0
4418,601617,HP:0000007,This disorder shows autosomal recessive inheritance and is caused mostly by mutations in the RDH5 gene.,1,1.4810537668882815,1632839.952701566,448.3747243148815,0.2696426519812716,0.4337401581487209,0.0,0.0,1.000377358490566,2651.0,-0.5870210283403589,0.008820309886621637,1.0,2.0,127.0,70.0,70.0,71.0,140.0,5160,70.0,1.5011496554636367e-07,30982.0,2651.0,1.0,0,62.0
4420,606810,HP:0008358,"Depletion of PRODH and GSALDH in humans leads to hyperprolinemia, which is associated with mental disorders such as schizophrenia.",1,1.4635284139100933,1174.2115384615386,39.459375,0.5721886639574274,0.5733579206287269,0.0,0.0,1.0147058823529411,69.0,-0.7492821477674368,0.07800511508951406,1.0,2.0,17.0,5.0,5.0,5.0,10.0,54,5.0,0.00023668639053254438,183.0,69.0,1.0,0,5.0
2017,606810,HP:0100753,"Depletion of PRODH and GSALDH in humans leads to hyperprolinemia, which is associated with mental disorders such as schizophrenia.",1,1.3377541998231657,19801.74761904762,33.984375,0.3673240817292292,-0.022004887483131425,0.0,0.0,1.0084033613445378,120.0,-0.4410723951404332,0.14215686274509806,1.0,2.0,10.0,39.0,39.0,2.0,78.0,112,38.0,0.00023668639053254435,1015.0,120.0,1.0,0,37.0
4421,616144,HP:0000252,Galloway-Mowat syndrome (GMS) is an inherited disorder characterized by microcephaly and nephrosis resulting from mutations in the WDR73 gene.,1,1.3841457228252068,17250738.94134471,468.60249489273895,0.12516663577616818,0.07226692297051178,0.0,0.0,1.0007616146230007,1314.0,-0.6036412292092562,0.12000125196924327,1.0,2.0,1.0,281.0,281.0,281.0,562.0,2066,280.0,9.353172034763868e-07,103518.0,1314.0,1.0,0,321.0
4423,138150,HP:0002664,"Methylation profiling, metabolite assessment and additional analyses were also performed in selected cases.Results: One of the 11 tumors was found to carry a known cancer-predisposing somatic mutation in IDH1 A variant in GOT2, c.357A&gt;T, found in a patient with multiple tumors, was associated with higher tumor mRNA and protein expression levels, increased GOT2 enzymatic activity in lymphoblastic cells, and altered metabolite ratios both in tumors and in GOT2 knockdown HeLa cells transfected with the variant.",0,1.4092547032399416,1862899.1800564053,273.3851864116786,0.1849960315589684,0.0928781027651679,0.0,0.0,0.9988452655889144,865.0,-0.6925672671478209,0.06287242515536305,1.0,2.0,29.0,95.0,95.0,95.0,190.0,1544,93.0,1.6778973932186103e-06,23603.0,867.0,1.0,0,97.0
4424,147700,HP:0001428,"Methylation profiling, metabolite assessment and additional analyses were also performed in selected cases.Results: One of the 11 tumors was found to carry a known cancer-predisposing somatic mutation in IDH1 A variant in GOT2, c.357A&gt;T, found in a patient with multiple tumors, was associated with higher tumor mRNA and protein expression levels, increased GOT2 enzymatic activity in lymphoblastic cells, and altered metabolite ratios both in tumors and in GOT2 knockdown HeLa cells transfected with the variant.",0,1.336461672981638,331469.4535714285,82.08053221288516,0.2390468133136463,0.13613162931303838,0.0,0.0,1.0033003300330037,304.0,-0.3791454678752337,0.1339456314052458,1.0,2.0,0.0,120.0,120.0,4.0,240.0,336,120.0,3.5012779664577565e-05,6169.0,304.0,2.0,0,130.0
4425,138150,HP:0001428,"Methylation profiling, metabolite assessment and additional analyses were also performed in selected cases.Results: One of the 11 tumors was found to carry a known cancer-predisposing somatic mutation in IDH1 A variant in GOT2, c.357A&gt;T, found in a patient with multiple tumors, was associated with higher tumor mRNA and protein expression levels, increased GOT2 enzymatic activity in lymphoblastic cells, and altered metabolite ratios both in tumors and in GOT2 knockdown HeLa cells transfected with the variant.",0,1.2711235392608704,216225.72143870624,67.25113981762918,0.23958108243531984,-0.011899536811286915,0.0,0.0,0.9961977186311788,262.0,-0.4770135774376877,0.12083765410761607,1.0,2.0,24.0,84.0,84.0,18.0,168.0,338,82.0,3.5012779664577565e-05,4195.0,264.0,1.0,0,90.0
4426,602413,HP:0002664,Array methylation-based analysis uncovered a somatic epigenetic mutation in SDHC in a patient with multiple pheochromocytomas and a gastrointestinal stromal tumor.,1,1.3508433607360242,9300702.07784748,250.61098322026882,0.1517624938138286,0.012442826324784929,0.0,0.0,1.0008680555555554,1153.0,-0.4746433411035164,0.09639105714561047,1.0,2.0,1.0,359.0,359.0,80.0,718.0,1542,358.0,1.67789739321861e-06,64016.0,1153.0,1.0,0,441.0
4427,608603,HP:0001371,Biallelic GLDN mutations have recently been identified among infants with lethal congenital contracture syndrome 11 (LCCS11).,0,1.4693488585466608,219512.4511084802,336.8330163043478,0.2537897199888183,-0.0996401217043567,0.0,0.0,0.9984939759036144,663.0,-0.7850745033216159,0.036674517619349575,1.0,2.0,1.0,24.0,24.0,24.0,48.0,1282,22.0,2.42621868964781e-06,8097.0,665.0,1.0,0,23.0
4431,609557,HP:0011968,"PurposePREPL deficiency causes neonatal hypotonia, ptosis, neonatal feeding difficulties, childhood obesity, xerostomia, and growth hormone deficiency.",1,1.4154879930899136,5495967.070648113,415.8927871672746,0.14565068932291875,0.12379397037475312,0.0,0.0,1.0009803921568627,1021.0,-0.7037404579975534,0.0982178179792975,1.0,2.0,2.0,142.0,142.0,142.0,284.0,1756,141.0,1.2942621476209514e-06,51143.0,1021.0,1.0,0,140.0
4435,609557,HP:0001513,"PurposePREPL deficiency causes neonatal hypotonia, ptosis, neonatal feeding difficulties, childhood obesity, xerostomia, and growth hormone deficiency.",0,1.3501445585962355,1831216.9674242425,186.67111013986008,0.17131144528479708,0.07580822397785279,0.0,0.0,0.9979838709677421,495.0,-0.612570707750085,0.15637372622833776,1.0,2.0,3.0,140.0,140.0,107.0,280.0,706,138.0,7.979826997350696e-06,19274.0,497.0,1.0,0,150.0
4437,609557,HP:0000217,"PurposePREPL deficiency causes neonatal hypotonia, ptosis, neonatal feeding difficulties, childhood obesity, xerostomia, and growth hormone deficiency.",0,1.3252443854307363,77159.63333333332,59.99009324009324,0.2946047994647363,0.26282680519737783,0.0,0.0,0.9947916666666666,191.0,-0.5350827876386157,0.1227871329879102,1.0,2.0,12.0,49.0,49.0,49.0,98.0,110,48.0,4.82253086419753e-05,2275.0,193.0,1.0,0,58.0
4438,606521,HP:0002664,We addressed this issue using mouse pancreatic acinar tumor cell line 266-6 and primary PAC of wild-type and transgenic mice carrying the SLC25A19 promoter that were fed alcohol chronically.,0,1.3706262191096843,3873042.6846071742,248.7227552765004,0.1690376513507762,0.1701601686430567,0.0,0.0,0.9989451476793249,947.0,-0.5865539223014401,0.08069786984300596,1.0,2.0,33.0,175.0,175.0,158.0,350.0,1544,173.0,1.6778973932186103e-06,36300.0,949.0,1.0,0,200.0
4439,606521,HP:0001425,"Similarly, chronic alcohol feeding of mice led to a significant inhibition in expression of MTPPT protein, mRNA, heterogeneous nuclear RNA, as well as in activity of SLC25A19 promoter in PAC.",0,1.3145445491457903,802014.219047619,109.77392344497608,0.21351112659167792,-0.0017510831198451653,0.0,0.0,0.997641509433962,423.0,-0.35168789244118626,0.12762486126526082,1.0,2.0,10.0,168.0,168.0,5.0,336.0,496,166.0,1.6259105098855364e-05,11499.0,425.0,1.0,0,200.0
4440,606439,HP:0001257,"Variants in the ATL1 gene have been repeatedly described as the second most frequent cause of hereditary spastic paraplegia (HSP), a motor neuron disease manifested by progressive lower limb spasticity and weakness.",1,1.407282400765184,3229160.3096950264,306.2685982023332,0.16383903500267366,0.04797951822910749,0.0,0.0,1.0011286681715574,887.0,-0.6472648447248389,0.0918967478578209,1.0,2.0,2.0,138.0,138.0,134.0,276.0,1494,137.0,1.787297320483857e-06,36110.0,887.0,1.0,0,151.0
4442,606202,HP:0001022,"Oculocutaneous albinism type 4 (OCA4) in humans and similar phenotypes in many animal species are caused by variants in the SLC45A2 gene, encoding a putative sugar transporter.",1,1.3843684801797465,14336.075,50.7532956685499,0.33434652983253355,0.1988660450648414,0.0,0.0,1.013157894736842,77.0,-0.8013925379040171,0.23923444976076555,1.0,2.0,2.0,18.0,18.0,18.0,36.0,62,18.0,0.00027777777777777783,700.0,77.0,1.0,0,18.0
4441,606202,HP:0001022,"In dog, two independent SLC45A2 variants are known that cause oculocutaneous albinism in Doberman Pinschers and several small dog breeds respectively.",1,1.3843684801797465,14336.075,50.7532956685499,0.33434652983253355,0.1988660450648414,0.0,0.0,1.013157894736842,77.0,-0.8013925379040171,0.23923444976076555,1.0,2.0,2.0,18.0,18.0,18.0,36.0,62,18.0,0.00027777777777777783,700.0,77.0,1.0,0,18.0
4443,606202,HP:0001022,We therefore suggest that SLC45A2:c.1287delC causes the observed oculocutaneous albinism in the affected Bullmastiff,1,1.3843684801797465,14336.075,50.7532956685499,0.33434652983253355,0.1988660450648414,0.0,0.0,1.013157894736842,77.0,-0.8013925379040171,0.23923444976076555,1.0,2.0,2.0,18.0,18.0,18.0,36.0,62,18.0,0.00027777777777777783,700.0,77.0,1.0,0,18.0
4453,610568,HP:0002664,"Zinc finger protein 687 (ZNF687), identified as a C2H2 zinc finger protein, has been found to be mutated and upregulated in giant cell tumor of bone and acute myeloid leukemia, suggesting an oncogenic role for ZNF687 in cancer.",0,1.4479417292964205,405449.4129066839,244.45920429523719,0.2532669808710279,0.13784712594753445,0.0,0.0,0.9987730061349694,814.0,-0.7345812636998991,0.03214543486106099,1.0,2.0,18.0,44.0,44.0,44.0,88.0,1544,42.0,1.67789739321861e-06,10689.0,816.0,1.0,0,37.0
4444,610568,HP:0002664,"However, the clinical significance and precise role of ZNF687 in cancer progression are largely unknown.",0,1.4479417292964205,405449.4129066839,244.45920429523719,0.2532669808710279,0.13784712594753445,0.0,0.0,0.9987730061349694,814.0,-0.7345812636998991,0.03214543486106099,1.0,2.0,18.0,44.0,44.0,44.0,88.0,1544,42.0,1.67789739321861e-06,10689.0,816.0,1.0,0,37.0
4456,610568,HP:0001402,"Herein, we report that ZNF687 was markedly upregulated in hepatocellular carcinoma (HCC) cell lines and HCC tissues, and was significantly correlated with relapse-free survival in HCC.",0,1.2758742493818438,16572.514285714286,33.99239713774597,0.34170052516648064,0.06691911165760299,0.0,0.0,0.9895833333333331,95.0,-0.4860789089313404,0.18213058419243985,1.0,2.0,5.0,34.0,34.0,8.0,68.0,106,32.0,0.000355998576005696,848.0,97.0,1.0,0,35.0
4447,610568,HP:0002664,"Importantly, extreme limiting dilution analysis revealed that even 1 x 102 ZNF687-transduced cells could form tumors in vivo, indicating that ZNF687 contributes to HCC recurrence.",0,1.4479417292964205,405449.4129066839,244.45920429523719,0.2532669808710279,0.13784712594753445,0.0,0.0,0.9987730061349694,814.0,-0.7345812636998991,0.03214543486106099,1.0,2.0,18.0,44.0,44.0,44.0,88.0,1544,42.0,1.67789739321861e-06,10689.0,816.0,1.0,0,37.0
4457,603381,HP:0002650,"FLNB-related disorders are classified as spondylocarpotarsal synostosis (SCT), Larsen syndrome (LS), atelosteogenesis (AO), boomerang dysplasia (BD), and isolated congenital talipes equinovarus, presenting with scoliosis, short-limbed dwarfism, clubfoot, joint dislocation and other unique skeletal abnormalities.",1,1.3424261813931353,18526186.563005056,306.5728814295329,0.13039709400294153,0.0015774961776845522,0.0,0.0,1.0007153075822603,1399.0,-0.4728043882177147,0.1032088115259111,1.0,2.0,16.0,474.0,474.0,73.0,948.0,1738,473.0,1.3211784912141631e-06,100928.0,1399.0,1.0,0,691.0
4459,603381,HP:0002650,"Interventions on FLNB-related diseases require prenatal surveillance by sonography, gene testing in high-risk carriers, and proper orthosis or orthopedic surgeries to correct malformations including scoliosis, cervical spine instability, large joint dislocation, and clubfoot.",1,1.3424261813931353,18526186.563005056,306.5728814295329,0.13039709400294153,0.0015774961776845522,0.0,0.0,1.0007153075822603,1399.0,-0.4728043882177147,0.1032088115259111,1.0,2.0,16.0,474.0,474.0,73.0,948.0,1738,473.0,1.3211784912141631e-06,100928.0,1399.0,1.0,0,691.0
4463,603381,HP:0001762,"Interventions on FLNB-related diseases require prenatal surveillance by sonography, gene testing in high-risk carriers, and proper orthosis or orthopedic surgeries to correct malformations including scoliosis, cervical spine instability, large joint dislocation, and clubfoot.",1,1.3485068608171111,3964759.2257742262,188.84408850278268,0.1634734811565957,0.16634683192591834,0.0,0.0,1.0012391573729864,808.0,-0.3013988485633865,0.10562282994098666,1.0,2.0,21.0,269.0,269.0,4.0,538.0,556,268.0,3.5465897766003107e-06,34436.0,808.0,1.0,0,327.0
4465,608537,HP:0001428,Hemangioblastomas (HBs) are uncommon tumors characterized by the presence of inactivating alterations in the von Hippel-Lindau (VHL) gene in inherited cases and by infrequent somatic mutation in sporadic entities.,0,1.3296191911909288,648600.5862495238,89.35409880564603,0.22106567391234566,0.15221611854466433,0.0,0.0,0.9978991596638654,475.0,-0.4228464864025552,0.08773320649014323,1.0,2.0,9.0,139.0,139.0,5.0,278.0,358,137.0,1.0541406645302749e-05,9960.0,477.0,1.0,0,151.0
4466,608537,HP:0003745,"Genes harboring the most significant mutations include PCDH9, KLHL12, DCAF4L1, and VHL in sporadic HBs, and ZNF814, DLG2, RIMS1, PNN, and MUC7 in familial HBs.",1,1.377286300058577,426082.42583397,100.7997942739585,0.2347659063410987,0.217839072843898,0.0,0.0,1.0024937655860349,402.0,-0.4660899712078853,0.09073088423220556,1.0,2.0,11.0,94.0,94.0,95.0,188.0,214,94.0,1.0541406645302752e-05,7313.0,402.0,1.0,0,100.0
4470,606629,HP:0003745,"Genes harboring the most significant mutations include PCDH9, KLHL12, DCAF4L1, and VHL in sporadic HBs, and ZNF814, DLG2, RIMS1, PNN, and MUC7 in familial HBs.",0,1.2928270042194092,14804.586344537815,39.6311403508772,0.34014698158648865,0.07577640070406133,0.0,0.0,0.9916666666666668,119.0,-0.7814797551458008,0.11570247933884298,1.0,2.0,10.0,20.0,20.0,14.0,40.0,192,18.0,0.00010850694444444445,840.0,121.0,1.0,0,15.0
4471,158375,HP:0003745,"Genes harboring the most significant mutations include PCDH9, KLHL12, DCAF4L1, and VHL in sporadic HBs, and ZNF814, DLG2, RIMS1, PNN, and MUC7 in familial HBs.",0,1.3851135273425008,4441.16847826087,40.55906432748539,0.4372798752476785,0.33333723222531336,0.0,0.0,0.9904761904761906,104.0,-0.7909761772006636,0.07565139263252471,1.0,2.0,6.0,10.0,10.0,10.0,20.0,192,8.0,0.00010850694444444445,421.0,106.0,1.0,0,8.0
4472,614925,HP:0003745,"Five genes, including OTOGL, PLCB4, SCEL, THSD4, and WWOX, have CNVs in the six patients with sporadic HBs, and three genes, including ABCA6, CWC27, and LAMA2, have CNVs in the five patients with familial HBs.",0,1.265158864904196,5850.575757575758,36.690909090909095,0.4035059528775905,0.03616385002143575,0.0,0.0,0.9906542056074766,106.0,-0.7256416992547792,0.07753547940463829,1.0,2.0,33.0,11.0,11.0,11.0,22.0,194,9.0,0.00010850694444444445,448.0,108.0,1.0,0,10.0
4473,600810,HP:0003745,"Five genes, including OTOGL, PLCB4, SCEL, THSD4, and WWOX, have CNVs in the six patients with sporadic HBs, and three genes, including ABCA6, CWC27, and LAMA2, have CNVs in the five patients with familial HBs.",0,1.2825631458094144,227776.26666666663,81.98969607116382,0.2207717540572102,0.3523929760175282,0.0,0.0,0.9957983193277312,237.0,-0.35347996804748105,0.1684188319679336,1.0,2.0,17.0,91.0,91.0,2.0,182.0,192,90.0,4.890214680424472e-05,4790.0,239.0,1.0,0,110.0
4474,605131,HP:0003745,"Five genes, including OTOGL, PLCB4, SCEL, THSD4, and WWOX, have CNVs in the six patients with sporadic HBs, and three genes, including ABCA6, CWC27, and LAMA2, have CNVs in the five patients with familial HBs.",0,1.3512871057513909,742860.1384740259,129.89939154243993,0.21070525495285813,0.31004973665448365,0.0,0.0,0.997737556561086,441.0,-0.5638592638839985,0.10187634699651696,1.0,2.0,21.0,96.0,96.0,96.0,192.0,232,95.0,8.305027032862991e-06,9974.0,443.0,1.0,0,96.0
4475,617170,HP:0003745,"Five genes, including OTOGL, PLCB4, SCEL, THSD4, and WWOX, have CNVs in the six patients with sporadic HBs, and three genes, including ABCA6, CWC27, and LAMA2, have CNVs in the five patients with familial HBs.",0,1.3114922614922615,397288.32251082256,101.84721804511278,0.2110368676629216,0.2232659445702327,0.0,0.0,0.9963099630996308,270.0,-0.4922659432699933,0.17413718254829608,1.0,2.0,11.0,93.0,93.0,96.0,186.0,210,92.0,3.228305785123967e-05,6418.0,272.0,1.0,0,108.0
4476,156225,HP:0003745,"Five genes, including OTOGL, PLCB4, SCEL, THSD4, and WWOX, have CNVs in the six patients with sporadic HBs, and three genes, including ABCA6, CWC27, and LAMA2, have CNVs in the five patients with familial HBs.",0,1.2813805953013575,345097.8523809524,91.91789473684211,0.2218233982433401,0.09118734252836648,0.0,0.0,0.9971098265895952,345.0,-0.3965898232100625,0.10886042211524044,1.0,2.0,44.0,94.0,94.0,95.0,188.0,192,93.0,1.5872763924382153e-05,6535.0,347.0,1.0,0,112.0
4483,602360,HP:0000717,"We sequenced GATM, GAMT and SLC6A8 genes in 166 patients with autism (coding sequence, introns and adjacent untranslated regions).",1,1.33561004784689,230346.0940476191,70.88987585616438,0.22415007997920766,0.11726184233344232,0.0,0.0,1.0036630036630036,274.0,-0.6159244318188295,0.1292746183257132,1.0,2.0,29.0,75.0,75.0,22.0,150.0,292,74.0,4.627701420704336e-05,4835.0,274.0,1.0,0,81.0
4487,601240,HP:0000717,"We sequenced GATM, GAMT and SLC6A8 genes in 166 patients with autism (coding sequence, introns and adjacent untranslated regions).",0,1.3622294372294372,185255.5694444444,95.61598173515982,0.2287071923946101,-0.08353967815578188,0.0,0.0,1.0048780487804878,206.0,-0.6777528845584311,0.19256452758702344,1.0,2.0,2.0,57.0,57.0,54.0,114.0,292,56.0,4.627701420704336e-05,4066.0,206.0,1.0,0,66.0
4490,300036,HP:0000717,"We sequenced GATM, GAMT and SLC6A8 genes in 166 patients with autism (coding sequence, introns and adjacent untranslated regions).",0,1.3138375350140057,804077.7095238095,146.28290320139254,0.16934162522704824,0.11198603153912563,0.0,0.0,0.9969512195121952,327.0,-0.2055839298318841,0.222162502780043,1.0,2.0,7.0,140.0,140.0,6.0,280.0,294,138.0,3.0189590629151068e-05,11987.0,329.0,1.0,0,184.0
4477,602360,HP:0000717,"Nine variants in GATM were shown to have a lower minor allele frequency (MAF) in the autism population than in the 1000 Genomes database, specifically in the East Asian population (Fisher*s exact test).",1,1.33561004784689,230346.0940476191,70.88987585616438,0.22415007997920766,0.11726184233344232,0.0,0.0,1.0036630036630036,274.0,-0.6159244318188295,0.1292746183257132,1.0,2.0,29.0,75.0,75.0,22.0,150.0,292,74.0,4.627701420704336e-05,4835.0,274.0,1.0,0,81.0
4492,177075,HP:0000717,"Nine variants in GATM were shown to have a lower minor allele frequency (MAF) in the autism population than in the 1000 Genomes database, specifically in the East Asian population (Fisher*s exact test).",0,1.3322985969303731,1521228.5573593066,164.46498752680642,0.17411479320283674,0.13039762709803054,0.0,0.0,0.9978260869565216,459.0,-0.4596522070074603,0.1568801282655852,1.0,2.0,12.0,145.0,145.0,147.0,290.0,294,143.0,1.014239928597509e-05,16634.0,461.0,1.0,0,159.0
4486,601240,HP:0000717,"In summary, there were no apparent associations of variants in GAMT and SLC6A8 genes with autism.",0,1.3622294372294372,185255.5694444444,95.61598173515982,0.2287071923946101,-0.08353967815578188,0.0,0.0,1.0048780487804878,206.0,-0.6777528845584311,0.19256452758702344,1.0,2.0,2.0,57.0,57.0,54.0,114.0,292,56.0,4.627701420704336e-05,4066.0,206.0,1.0,0,66.0
4488,300036,HP:0000717,"In summary, there were no apparent associations of variants in GAMT and SLC6A8 genes with autism.",0,1.3138375350140057,804077.7095238095,146.28290320139254,0.16934162522704824,0.11198603153912563,0.0,0.0,0.9969512195121952,327.0,-0.2055839298318841,0.222162502780043,1.0,2.0,7.0,140.0,140.0,6.0,280.0,294,138.0,3.0189590629151068e-05,11987.0,329.0,1.0,0,184.0
4480,602360,HP:0000717,"The data implying there could be a lower association of some specific GATM gene variants with autism is an observation that would need to be corroborated in a larger group of autism patients, and with sub-populations of Asian ethnicities.",1,1.33561004784689,230346.0940476191,70.88987585616438,0.22415007997920766,0.11726184233344232,0.0,0.0,1.0036630036630036,274.0,-0.6159244318188295,0.1292746183257132,1.0,2.0,29.0,75.0,75.0,22.0,150.0,292,74.0,4.627701420704336e-05,4835.0,274.0,1.0,0,81.0
4493,131222,HP:0001298,"Mitochondrial neurogastrointestinal encephalopathy (MNGIE), usually an autosomal-recessive inherited condition, causes gastrointestinal dysmotility, ophthalmoplegia, ptosis, leukoencephalopathy and neuropathy.",0,1.3045952482572198,779813.6296176045,108.89224757455985,0.2014620481111533,0.2359435888316044,0.0,0.0,0.9976580796252928,426.0,-0.4849531006696685,0.12693427301976407,1.0,2.0,13.0,153.0,153.0,23.0,306.0,486,151.0,1.6796560064498793e-05,11599.0,428.0,1.0,0,154.0
4494,131222,HP:0002579,"Mitochondrial neurogastrointestinal encephalopathy (MNGIE), usually an autosomal-recessive inherited condition, causes gastrointestinal dysmotility, ophthalmoplegia, ptosis, leukoencephalopathy and neuropathy.",1,1.3750582968006717,156025.06913919418,80.67028985507247,0.2750634569569569,0.15497931204630694,0.0,0.0,1.0041152263374489,244.0,-0.4764321236365913,0.1231194764892397,1.0,2.0,1.0,60.0,60.0,60.0,120.0,170,60.0,2.921840759678598e-05,3650.0,244.0,1.0,0,68.0
4495,131222,HP:0000602,"Mitochondrial neurogastrointestinal encephalopathy (MNGIE), usually an autosomal-recessive inherited condition, causes gastrointestinal dysmotility, ophthalmoplegia, ptosis, leukoencephalopathy and neuropathy.",1,1.3362552008195865,857434.6599206348,119.60217391304349,0.1991615433141438,0.10853188423330104,0.0,0.0,1.0024213075060533,414.0,-0.503142612782053,0.1430092056473781,1.0,2.0,1.0,149.0,149.0,30.0,298.0,460,148.0,1.874027848053822e-05,12226.0,414.0,1.0,0,190.0
4499,131222,HP:0000508,"Mitochondrial neurogastrointestinal encephalopathy (MNGIE), usually an autosomal-recessive inherited condition, causes gastrointestinal dysmotility, ophthalmoplegia, ptosis, leukoencephalopathy and neuropathy.",1,1.3767290972531143,2818862.156151852,222.07780128392181,0.1667236822713158,0.1318023055375164,0.0,0.0,1.0012836970474968,780.0,-0.6362294596340697,0.10277146901023666,1.0,2.0,1.0,174.0,174.0,92.0,348.0,1192,173.0,2.8057652865107227e-06,31223.0,780.0,1.0,0,175.0
4503,131222,HP:0009830,"Mitochondrial neurogastrointestinal encephalopathy (MNGIE), usually an autosomal-recessive inherited condition, causes gastrointestinal dysmotility, ophthalmoplegia, ptosis, leukoencephalopathy and neuropathy.",1,1.3712350730341174,2433846.0718687717,206.1186744335015,0.1818852697236737,0.031480669340664125,0.0,0.0,1.0013774104683195,727.0,-0.5584316655050511,0.10733949473476796,1.0,2.0,1.0,177.0,177.0,116.0,354.0,1086,176.0,3.379108996539793e-06,28327.0,727.0,1.0,0,190.0
4497,131222,HP:0000602,"The chromosome 22 disorder, due to mutations in the nuclear gene TYMP encoding thymidine phosphorylase (TP), leads to the accumulation of thymidine and deoxyuridine, with mitochondrial dysfunction.This report describes a patient with an MNGIE-like syndrome with a heterozygous TYMP mutation who showed marked, but transient improvement postallogeneic haematopoietic stem cell transplantation (HSCT).The patient, showing ptosis and ophthalmoplegia, was initially managed for myasthenia gravis.",1,1.3362552008195865,857434.6599206348,119.60217391304349,0.1991615433141438,0.10853188423330104,0.0,0.0,1.0024213075060533,414.0,-0.503142612782053,0.1430092056473781,1.0,2.0,1.0,149.0,149.0,30.0,298.0,460,148.0,1.874027848053822e-05,12226.0,414.0,1.0,0,190.0
4501,131222,HP:0000508,"The chromosome 22 disorder, due to mutations in the nuclear gene TYMP encoding thymidine phosphorylase (TP), leads to the accumulation of thymidine and deoxyuridine, with mitochondrial dysfunction.This report describes a patient with an MNGIE-like syndrome with a heterozygous TYMP mutation who showed marked, but transient improvement postallogeneic haematopoietic stem cell transplantation (HSCT).The patient, showing ptosis and ophthalmoplegia, was initially managed for myasthenia gravis.",1,1.3767290972531143,2818862.156151852,222.07780128392181,0.1667236822713158,0.1318023055375164,0.0,0.0,1.0012836970474968,780.0,-0.6362294596340697,0.10277146901023666,1.0,2.0,1.0,174.0,174.0,92.0,348.0,1192,173.0,2.8057652865107227e-06,31223.0,780.0,1.0,0,175.0
4504,131222,HP:0001260,"She developed gastrointestinal symptoms, dysarthria, dysphagia and weakness, and MNGIE was considered due to its low TP levels and improvement after platelet transfusions.",0,1.358416649663334,1929534.0065795318,169.91267501842302,0.1869892693825475,0.13478869170281865,0.0,0.0,0.9984779299847792,656.0,-0.5482102732957465,0.10587870628675056,1.0,2.0,1.0,175.0,175.0,78.0,350.0,946,173.0,4.450853673734622e-06,22886.0,658.0,1.0,0,186.0
4505,131222,HP:0002015,"She developed gastrointestinal symptoms, dysarthria, dysphagia and weakness, and MNGIE was considered due to its low TP levels and improvement after platelet transfusions.",1,1.3542983718410968,1577130.336328949,164.71700702678962,0.18191463134813424,0.12415913434365405,0.0,0.0,1.0017271157167529,580.0,-0.5520921987513393,0.12323863974748375,1.0,2.0,1.0,174.0,174.0,69.0,348.0,792,173.0,6.3448153341496976e-06,20693.0,580.0,1.0,0,203.0
227,609144,HP:0001251,"FLVCR1 encodes for a ubiquitous heme exporter, whose recessive mutations cause posterior column ataxia with retinitis pigmentosa (PCARP).",1,1.4038800339200108,3598751.13586837,288.2122649797927,0.16890308909656404,0.06338047303717034,0.0,0.0,1.001027749229188,974.0,-0.6222014495487379,0.08173877442487196,1.0,2.0,2.0,158.0,158.0,137.0,316.0,1626,157.0,1.5092152684290275e-06,38732.0,974.0,1.0,0,149.0
4506,609144,HP:0003745,"Recently, FLVCR1 recessive mutations were also found in two sporadic children with hereditary sensory-autonomic neuropathy (HSAN).",0,1.2751339997102709,206244.03095238094,74.55704478587774,0.2366974354497788,0.11662240902946595,0.0,0.0,0.9961089494163424,256.0,-0.3003071190444567,0.13847917232226345,1.0,2.0,24.0,93.0,93.0,2.0,186.0,226,91.0,3.810394756896815e-05,4591.0,258.0,1.0,0,105.0
4507,609144,HP:0009830,"Recently, FLVCR1 recessive mutations were also found in two sporadic children with hereditary sensory-autonomic neuropathy (HSAN).",1,1.3792588662878629,2613000.3729651244,226.57360191254017,0.17633199593346122,0.03589194935724377,0.0,0.0,1.0014224751066858,704.0,-0.6038372533311626,0.11370102159575846,1.0,2.0,5.0,157.0,157.0,121.0,314.0,1086,156.0,3.3791089965397912e-06,28136.0,704.0,1.0,0,174.0
4508,616918,HP:0001425,"The 18 new diagnoses made with WGS included structural and non-exonic sequence variants not detectable with whole-exome sequencing, and confirmed recent disease associations with the genes PIGG, RNU4ATAC, TRIO, and UNC13A.ConclusionWGS as a primary clinical test provided a higher diagnostic yield than conventional genetic testing in a clinically heterogeneous cohort",0,1.318258044844732,639634.0577200578,107.26909581646423,0.2130373532631342,0.16138218372303414,0.0,0.0,0.9973890339425588,382.0,-0.475365130792717,0.13015393820713664,1.0,2.0,11.0,128.0,128.0,51.0,256.0,502,126.0,1.625910509885536e-05,9571.0,384.0,1.0,0,138.0
4509,601893,HP:0001425,"The 18 new diagnoses made with WGS included structural and non-exonic sequence variants not detectable with whole-exome sequencing, and confirmed recent disease associations with the genes PIGG, RNU4ATAC, TRIO, and UNC13A.ConclusionWGS as a primary clinical test provided a higher diagnostic yield than conventional genetic testing in a clinically heterogeneous cohort",0,1.3070658568384899,1164683.7793650795,109.09008846903583,0.20571029850449774,0.07193865057749563,0.0,0.0,0.998069498069498,517.0,-0.34382046344492645,0.10661280603477136,1.0,2.0,15.0,191.0,191.0,2.0,382.0,496,189.0,1.3616372326084885e-05,14331.0,519.0,1.0,0,209.0
4510,136440,HP:0000962,"Using whole-exome sequencing in four probands with undiagnosed skin hyperkeratosis/ichthyosis, we identified compound heterozygosity for mutations in KDSR, encoding an enzyme in the de novo synthesis pathway of ceramides.",1,1.3472662592356106,912518.2114357864,146.48162114537442,0.19324429930453169,0.09209239077768323,0.0,0.0,1.002849002849003,352.0,-0.4767145838676342,0.19114219114219114,1.0,2.0,1.0,124.0,124.0,125.0,248.0,454,123.0,1.9236688211757463e-05,11808.0,352.0,1.0,0,149.0
2063,190070,HP:0002664,"The more common member of this family, intraductal papillary mucinous neoplasm, often carries genetic alterations typical of pancreatic infiltrating ductal adenocarcinoma (KRAS, TP53, and CDKN2A) but additionally has mutations in GNAS and RNF43 genes.",1,1.3339771877413191,18178836.290753696,271.2782786211432,0.14438020893870612,0.0522035687829069,0.0,0.0,1.0006165228113442,1623.0,-0.2035822069529308,0.08341633409382543,1.0,2.0,4.0,720.0,720.0,2.0,1440.0,1542,719.0,1.374364528201273e-06,109797.0,1623.0,1.0,0,858.0
2324,600160,HP:0002664,"The more common member of this family, intraductal papillary mucinous neoplasm, often carries genetic alterations typical of pancreatic infiltrating ductal adenocarcinoma (KRAS, TP53, and CDKN2A) but additionally has mutations in GNAS and RNF43 genes.",1,1.3819192877609885,3978882.2976928083,230.5360070919454,0.17439306041142438,0.12633734612896624,0.0,0.0,1.0010121457489878,989.0,-0.5763287178006274,0.0801918266928112,1.0,2.0,4.0,213.0,213.0,104.0,426.0,1542,212.0,1.67789739321861e-06,39179.0,989.0,1.0,0,228.0
4511,139320,HP:0002664,"The more common member of this family, intraductal papillary mucinous neoplasm, often carries genetic alterations typical of pancreatic infiltrating ductal adenocarcinoma (KRAS, TP53, and CDKN2A) but additionally has mutations in GNAS and RNF43 genes.",1,1.3396459207409952,11166241.685427587,237.1952010376135,0.1462259619723506,0.14845988911307284,0.0,0.0,1.000778816199377,1285.0,-0.4214980431467533,0.08867110319163121,1.0,2.0,25.0,452.0,452.0,24.0,904.0,1542,451.0,1.67789739321861e-06,73151.0,1285.0,1.0,0,611.0
4512,605984,HP:0002664,"However, certain chromatin remodeling genes (MLL1, MLL2, MLL3, BAP1, PBRM1, EED, and ATRX) were found to be mutated in 7/22 (32%) of intraductal tubulopapillary neoplasms and 27% harbored phosphatidylinositol 3-kinase (PI3K) pathway (PIK3CA, PIK3CB, INPP4A, and PTEN) mutations.",0,1.3667112840466926,7262236.943050576,272.15156411440125,0.14893828185494967,0.17391844989552135,0.0,0.0,0.9990079365079364,1007.0,-0.5654565005666911,0.09796946528859314,1.0,2.0,11.0,235.0,235.0,234.0,470.0,1544,233.0,1.6778973932186103e-06,49821.0,1009.0,1.0,0,295.0
4513,300032,HP:0002664,"However, certain chromatin remodeling genes (MLL1, MLL2, MLL3, BAP1, PBRM1, EED, and ATRX) were found to be mutated in 7/22 (32%) of intraductal tubulopapillary neoplasms and 27% harbored phosphatidylinositol 3-kinase (PI3K) pathway (PIK3CA, PIK3CB, INPP4A, and PTEN) mutations.",1,1.339989824054622,13476492.553385366,268.768689298079,0.1417504070407192,0.1130870374780097,0.0,0.0,1.0007824726134589,1279.0,-0.36643745056915816,0.10070587717076497,1.0,2.0,11.0,477.0,477.0,24.0,954.0,1542,476.0,1.67789739321861e-06,82305.0,1279.0,1.0,0,679.0
465,601728,HP:0002664,"However, certain chromatin remodeling genes (MLL1, MLL2, MLL3, BAP1, PBRM1, EED, and ATRX) were found to be mutated in 7/22 (32%) of intraductal tubulopapillary neoplasms and 27% harbored phosphatidylinositol 3-kinase (PI3K) pathway (PIK3CA, PIK3CB, INPP4A, and PTEN) mutations.",1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
3037,176943,HP:0002664,"In addition, 4/18 (18%) of intraductal tubulopapillary neoplasms had FGFR2 fusions (FGFR2-CEP55, FGFR2-SASS6, DISP1-FGFR2, FGFR2-TXLNA, and FGFR2-VCL) and 1/18 (5.5%) had STRN-ALK fusion.",1,1.3342720026288826,16211979.667147012,229.2539594307243,0.14556000393076873,0.00478701158553484,0.0,0.0,1.0006053268765134,1653.0,-0.29974239614532194,0.06907391213275738,1.0,2.0,25.0,637.0,637.0,2.0,1274.0,1542,636.0,1.282562662805298e-06,94312.0,1653.0,1.0,0,710.0
3953,610000,HP:0002664,"In addition, 4/18 (18%) of intraductal tubulopapillary neoplasms had FGFR2 fusions (FGFR2-CEP55, FGFR2-SASS6, DISP1-FGFR2, FGFR2-TXLNA, and FGFR2-VCL) and 1/18 (5.5%) had STRN-ALK fusion.",0,1.3536973042156628,7614665.465916688,244.22136664618745,0.15135969844228575,0.03968654263427771,0.0,0.0,0.999053926206244,1056.0,-0.5382513991041921,0.09202847878845324,1.0,2.0,14.0,281.0,281.0,114.0,562.0,1544,279.0,1.6778973932186097e-06,51458.0,1058.0,1.0,0,334.0
4514,609321,HP:0002664,"In addition, 4/18 (18%) of intraductal tubulopapillary neoplasms had FGFR2 fusions (FGFR2-CEP55, FGFR2-SASS6, DISP1-FGFR2, FGFR2-TXLNA, and FGFR2-VCL) and 1/18 (5.5%) had STRN-ALK fusion.",0,1.3998826206731343,2085387.9521441841,280.7036721789883,0.17759307310905628,0.0013716071262560858,0.0,0.0,0.9988479262672808,867.0,-0.6909001253818365,0.06538581875454068,1.0,2.0,43.0,97.0,97.0,97.0,194.0,1544,95.0,1.6778973932186103e-06,24660.0,869.0,1.0,0,108.0
3681,105590,HP:0002664,"In addition, 4/18 (18%) of intraductal tubulopapillary neoplasms had FGFR2 fusions (FGFR2-CEP55, FGFR2-SASS6, DISP1-FGFR2, FGFR2-TXLNA, and FGFR2-VCL) and 1/18 (5.5%) had STRN-ALK fusion.",1,1.4881933376287204,80317.72380628808,355.9190290902353,0.3373768362249434,0.39384005097722136,0.0,0.0,1.0012755102040816,785.0,-0.8104920713322381,0.015904068633822956,1.0,2.0,8.0,14.0,14.0,14.0,28.0,1542,13.0,1.67789739321861e-06,4894.0,785.0,1.0,0,13.0
4517,605632,HP:0003468,"Researchers have identified a subset of Holstein having a range of skeletal deformities, including vertebral anomalies, referred to as complex vertebral malformation due to mutations in the SLC35A3 gene.",0,1.3803385030787974,1596520.4342064366,229.90490104195385,0.16906504234683856,0.017070637832393667,0.0,0.0,0.9978813559322034,471.0,-0.7284906010628139,0.16147382377181352,1.0,2.0,1.0,98.0,98.0,98.0,196.0,750,96.0,7.0733363512901765e-06,18025.0,473.0,1.0,0,108.0
4515,605632,HP:0003468,"Here, we report the first case in humans of SLC35A3-related vertebral anomalies.",0,1.3803385030787974,1596520.4342064366,229.90490104195385,0.16906504234683856,0.017070637832393667,0.0,0.0,0.9978813559322034,471.0,-0.7284906010628139,0.16147382377181352,1.0,2.0,1.0,98.0,98.0,98.0,196.0,750,96.0,7.0733363512901765e-06,18025.0,473.0,1.0,0,108.0
4519,605632,HP:0002652,"Congenital disorders of glycosylation, including SLC35A3-CDG, can present as a wide phenotypic spectrum, including skeletal dysplasia.",0,1.336365377250096,550432.2299422799,128.46024410475175,0.19800140727151416,-0.12802399729822414,0.0,0.0,0.9963235294117648,271.0,-0.59499368878594,0.2194300797241973,1.0,2.0,1.0,94.0,94.0,88.0,188.0,350,92.0,3.228305785123967e-05,8147.0,273.0,1.0,0,103.0
4520,605632,HP:0000717,"Previously reported patients with SLC35A3-CDG have been described with syndromic autism, epilepsy, and arthrogryposis",0,1.3256190084102806,476497.3583333333,120.80610083321564,0.1907875673561252,-0.04893569909445785,0.0,0.0,0.9959016393442623,243.0,-0.5505256828131385,0.2397791903646705,1.0,2.0,2.0,93.0,93.0,82.0,186.0,294,91.0,4.565376186997809e-05,7167.0,245.0,1.0,0,114.0
4521,605632,HP:0001250,"Previously reported patients with SLC35A3-CDG have been described with syndromic autism, epilepsy, and arthrogryposis",1,1.4600708986666522,5423951.53889187,635.0288659793814,0.15971505460795746,0.036689619906013285,0.0,0.0,1.0006075334143378,1647.0,-0.7138446337735952,0.04276710628920656,1.0,2.0,2.0,96.0,96.0,96.0,192.0,3100,95.0,4.1569653487839437e-07,57970.0,1647.0,1.0,0,103.0
4522,614139,HP:0001298,"Here, we report that variants in TRAPPC12 result in progressive childhood encephalopathy.",0,1.345786446611653,1222423.749891775,161.8834590968978,0.1758594088926827,0.12860204872329994,0.0,0.0,1.0026385224274406,380.0,-0.5454110282464464,0.19756978197472566,1.0,2.0,5.0,131.0,131.0,103.0,262.0,484,130.0,1.6935087808430286e-05,14227.0,380.0,1.0,0,152.0
4523,607901,HP:0012174,"In the present study, we hypothesized that FERMT3 would enhance glioblastoma multiforme (GBM) cell survival.",0,1.2779353638688675,11741.709798534795,34.528571428571425,0.36886890358146174,0.05056954454179649,0.0,0.0,0.989010989010989,90.0,-0.6237710737334725,0.14237935977066413,1.0,2.0,13.0,21.0,21.0,21.0,42.0,60,19.0,0.00019837333862328903,596.0,92.0,1.0,0,20.0
4524,173490,HP:0002664,The PDGFRa-LAMB1 pathway supports tumor progression at the invasive front of human HCC through K19 expression,1,1.4241375486668968,1690510.6680563546,241.1264591439689,0.21034111785609624,0.030100933810800524,0.0,0.0,1.001138952164009,879.0,-0.6053612118764925,0.05919441485846672,1.0,2.0,4.0,106.0,106.0,105.0,212.0,1542,105.0,1.67789739321861e-06,22842.0,879.0,1.0,0,103.0
4525,150240,HP:0002664,The PDGFRa-LAMB1 pathway supports tumor progression at the invasive front of human HCC through K19 expression,0,1.3813738308357637,1705171.7459533175,234.83973900844384,0.1907130133926057,0.15082868698841467,0.0,0.0,0.9988505747126436,869.0,-0.6544360594984456,0.055726671681380895,1.0,2.0,67.0,95.0,95.0,94.0,190.0,1544,93.0,1.677897393218609e-06,21114.0,871.0,1.0,0,108.0
3829,300172,HP:0001249,"Loss-of-function mutations of CASK are associated with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH), especially in females.",1,1.3940994056335605,32620189.8951711,550.5557580051963,0.12458510793409495,0.058428944877166114,0.0,0.0,1.0005073566717402,1972.0,-0.5778800938497509,0.08515204748776117,1.0,2.0,3.0,366.0,366.0,341.0,732.0,3204,365.0,3.8916426584744994e-07,165485.0,1972.0,1.0,0,387.0
3833,300172,HP:0000252,"Loss-of-function mutations of CASK are associated with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH), especially in females.",1,1.3676497130107217,21824970.35294787,439.08860050757437,0.12378933242283365,0.05688395411256428,0.0,0.0,1.0007132667617689,1403.0,-0.5349405737615311,0.12162443835961866,1.0,2.0,4.0,361.0,361.0,291.0,722.0,2066,360.0,9.353172034763868e-07,119618.0,1403.0,1.0,0,462.0
4526,300172,HP:0001321,"Loss-of-function mutations of CASK are associated with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH), especially in females.",1,1.3341888466413179,5585423.030952381,242.0653706337917,0.1418241118511549,0.0929176726577787,0.0,0.0,1.0014064697609002,712.0,-0.2634900497360286,0.16996554939237346,1.0,2.0,8.0,311.0,311.0,2.0,622.0,684,310.0,7.2652770613407345e-06,43021.0,712.0,1.0,0,427.0
4527,300172,HP:0001425,"Our results not only identified the etiology of MICPCH in nearly all the investigated patients but also suggest that MICPCH is a genetically heterogeneous condition, in which CASK inactivating mutations appear to account for the majority of cases",0,1.3141424841275728,1625863.5628720957,129.51153299048036,0.19745194562038607,0.141527173272475,0.0,0.0,0.9983818770226538,617.0,-0.3131586675323179,0.10197050258533703,1.0,2.0,17.0,224.0,224.0,2.0,448.0,496,222.0,7.265277061340734e-06,19504.0,619.0,1.0,0,265.0
4534,611731,HP:0002664,Our analyses identified 15 CpG sites within the APC 1A promoter that were significantly hypermethylated and 14 CpG loci within the NFATC1 gene body that were significantly hypomethylated (pLIS &lt; 1 x 10-5 ) in the tumours of active smokers.,1,1.3391008903849515,11574943.624649456,243.44156245977763,0.14922188725133187,0.047377974699447135,0.0,0.0,1.000772797527048,1295.0,-0.3687472023865209,0.0906434807516724,1.0,2.0,7.0,490.0,490.0,21.0,980.0,1542,489.0,1.677897393218609e-06,75947.0,1295.0,1.0,0,662.0
4540,611731,HP:0002664,"The APC 1A promoter was hypermethylated in 7 of 36 tumours from never-smokers (19%), 12 of 47 tumours from former smokers (26%), and 8 of 13 tumours from active smokers (62%).",1,1.3391008903849515,11574943.624649456,243.44156245977763,0.14922188725133187,0.047377974699447135,0.0,0.0,1.000772797527048,1295.0,-0.3687472023865209,0.0906434807516724,1.0,2.0,7.0,490.0,490.0,21.0,980.0,1542,489.0,1.677897393218609e-06,75947.0,1295.0,1.0,0,662.0
4537,611731,HP:0002664,Our findings provide exploratory evidence for hypermethylation of the key tumour suppressor gene APC being implicated in smoking-associated colorectal carcinogenesis.,1,1.3391008903849515,11574943.624649456,243.44156245977763,0.14922188725133187,0.047377974699447135,0.0,0.0,1.000772797527048,1295.0,-0.3687472023865209,0.0906434807516724,1.0,2.0,7.0,490.0,490.0,21.0,980.0,1542,489.0,1.677897393218609e-06,75947.0,1295.0,1.0,0,662.0
4543,300121,HP:0002664,5*-Aza-2*-deoxycytidine (5-Aza-dC) is a demethylating drug that causes genome-wide hypomethylation resulting in the expression of several tumor suppressor genes causing growth arrest of cancer cells.,0,1.3752577667741002,3041321.6932994733,243.0644008576193,0.1714011570686073,0.018221878032652492,0.0,0.0,0.9989118607181721,918.0,-0.6417177764833468,0.07257415905757676,1.0,2.0,38.0,144.0,144.0,119.0,288.0,1544,142.0,1.6778973932186097e-06,30680.0,920.0,1.0,0,153.0
4547,300121,HP:0002664,Induction of p53 by 5-Aza-dC was tested in vitro using cancer cells.,0,1.3752577667741002,3041321.6932994733,243.0644008576193,0.1714011570686073,0.018221878032652492,0.0,0.0,0.9989118607181721,918.0,-0.6417177764833468,0.07257415905757676,1.0,2.0,38.0,144.0,144.0,119.0,288.0,1544,142.0,1.6778973932186097e-06,30680.0,920.0,1.0,0,153.0
65,191170,HP:0002664,Induction of p53 by 5-Aza-dC was tested in vitro using cancer cells.,1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
4545,300121,HP:0002664,Further studies are warranted to dissect these mechanisms and establish 5-Aza-dC as an effective multi-module anticancer reagent,0,1.3752577667741002,3041321.6932994733,243.0644008576193,0.1714011570686073,0.018221878032652492,0.0,0.0,0.9989118607181721,918.0,-0.6417177764833468,0.07257415905757676,1.0,2.0,38.0,144.0,144.0,119.0,288.0,1544,142.0,1.6778973932186097e-06,30680.0,920.0,1.0,0,153.0
4549,605951,HP:0003560,Our findings show that DPM3 mutations may lead to an isolated and mild limb girdle muscular dystrophy phenotype without cardiomyopathy,1,1.3389755405884438,131532.39166666663,75.34333333333333,0.2439758985659789,0.13270826156202925,0.0,0.0,1.0057471264367814,175.0,-0.2534095974908209,0.21208538587848927,1.0,2.0,5.0,71.0,71.0,2.0,142.0,150,70.0,9.802960494069208e-05,3229.0,175.0,1.0,0,88.0
4550,606119,HP:0011496,"Slurp1 expression detected by QPCR, immunoblots and immunofluorescent stain, was significantly decreased in mouse corneas subjected to alkali burn-induced corneal neovascularization (CNV).",0,1.3104073890813128,7496.8,34.080519480519484,0.3806305090135172,0.24415545579655626,0.0,0.0,0.9857142857142857,69.0,-0.7381766824209348,0.17183098591549295,1.0,2.0,7.0,15.0,15.0,15.0,30.0,50,14.0,0.0003188775510204081,427.0,71.0,1.0,0,23.0
1813,191160,HP:0002664,"Addition of exogenous SLURP1 (6XHis-tagged, E. coli expressed and partially purified using Ni-ion columns) significantly suppressed the tumor necrosis factor-a (TNF-a)-stimulated human umbilical cord vascular endothelial cell (HUVEC) tube formation.",0,1.4602670579691517,200974.08525960872,239.91050583657588,0.2850613192309647,0.15408425189867206,0.0,0.0,0.9987531172069826,801.0,-0.7836891500894245,0.02382275941528495,1.0,2.0,14.0,31.0,31.0,25.0,62.0,1544,29.0,1.6778973932186097e-06,7671.0,803.0,1.0,0,23.0
4551,184429,HP:0002664,"Increased RAD6 levels cause histone 2B ubiquitination-mediated epigenetic changes that stimulate transcription of stem cell genes, including ALDH1A1 and SOX2, leading to a cancer stem cell phenotype, which is implicated in disease recurrence and metastasis.",1,1.3760626478711058,7526542.390177959,284.66883916990923,0.14862979817851218,0.05490366024740585,0.0,0.0,1.0009900990099008,1011.0,-0.5819100104631268,0.10204973019557148,1.0,2.0,1.0,239.0,239.0,196.0,478.0,1542,238.0,1.67789739321861e-06,52102.0,1011.0,1.0,0,282.0
4552,601248,HP:0001635,"In human plasma, osmotic shock increased cBIN1 detection by enzyme-linked immunosorbent assay (ELISA), and cBIN1 level decreased in humans with heart failure, a condition with reduced cardiac muscle cBIN1, both of which support cBIN1 release in MPs from human hearts.",0,1.3312811104805882,821565.6341269842,113.55026964560862,0.2103884068878982,0.11308917051855408,0.0,0.0,0.9975786924939468,412.0,-0.31084466365444713,0.1363652314278696,1.0,2.0,1.0,172.0,172.0,3.0,344.0,354,170.0,1.7803414694938486e-05,11658.0,414.0,1.0,0,197.0
4553,607983,HP:0000007,"GO exhibits an autosomal recessive inheritance pattern and is caused by loss-of-function mutations in GORAB, which encodes a protein important for Golgi-related transport.",1,1.4597465838959909,10410246.024369394,603.2649296583405,0.166255804851006,0.4058721524201336,0.0,0.0,1.0003648303538857,2742.0,-0.6302825882230532,0.024469712028837298,1.0,2.0,142.0,162.0,162.0,162.0,324.0,5160,161.0,1.5011496554636372e-07,91955.0,2742.0,1.0,0,163.0
4563,610436,HP:0000252,"Using super-resolution and electron microscopy, we find that the human microcephaly protein, RTTN, is recruited to the proximal end of the procentriole at early S phase, and is located at the inner luminal walls of centrioles.",1,1.3822055990384712,16765168.477193715,447.1843342123709,0.125944886449162,0.06691850871377941,0.0,0.0,1.0007564296520424,1323.0,-0.5993219718585758,0.11578805332857635,1.0,2.0,3.0,286.0,286.0,260.0,572.0,2066,285.0,9.35317203476387e-07,101257.0,1323.0,1.0,0,441.0
4557,610436,HP:0000252,"Interestingly, the naturally occurring microcephaly-associated mutant, RTTN (A578P), shows a low affinity for STIL binding and blocks centriole assembly.",1,1.3822055990384712,16765168.477193715,447.1843342123709,0.125944886449162,0.06691850871377941,0.0,0.0,1.0007564296520424,1323.0,-0.5993219718585758,0.11578805332857635,1.0,2.0,3.0,286.0,286.0,260.0,572.0,2066,285.0,9.35317203476387e-07,101257.0,1323.0,1.0,0,441.0
4379,181590,HP:0000252,"Interestingly, the naturally occurring microcephaly-associated mutant, RTTN (A578P), shows a low affinity for STIL binding and blocks centriole assembly.",1,1.4483665606145069,3531503.031879858,580.2430366100502,0.14903179222245894,0.10609977989085727,0.0,0.0,1.000892857142857,1121.0,-0.7569418619239919,0.07495380400152925,1.0,2.0,1.0,88.0,88.0,88.0,176.0,2066,87.0,9.353172034763868e-07,47053.0,1121.0,1.0,0,108.0
4560,610436,HP:0000252,These findings reveal that RTTN contributes to building full-length centrioles and illuminate the molecular mechanism through which the RTTN (A578P) mutation causes primary microcephaly.Mutations in many centriolar protein-encoding genes cause primary microcephaly.,1,1.3822055990384712,16765168.477193715,447.1843342123709,0.125944886449162,0.06691850871377941,0.0,0.0,1.0007564296520424,1323.0,-0.5993219718585758,0.11578805332857635,1.0,2.0,3.0,286.0,286.0,260.0,572.0,2066,285.0,9.35317203476387e-07,101257.0,1323.0,1.0,0,441.0
4554,610436,HP:0000252,"Here the authors show that human microcephaly protein RTTN directly interacts with STIL and acts downstream of STIL-mediated centriole assembly, contributing to building full-length centrioles",1,1.3822055990384712,16765168.477193715,447.1843342123709,0.125944886449162,0.06691850871377941,0.0,0.0,1.0007564296520424,1323.0,-0.5993219718585758,0.11578805332857635,1.0,2.0,3.0,286.0,286.0,260.0,572.0,2066,285.0,9.35317203476387e-07,101257.0,1323.0,1.0,0,441.0
4377,181590,HP:0000252,"Here the authors show that human microcephaly protein RTTN directly interacts with STIL and acts downstream of STIL-mediated centriole assembly, contributing to building full-length centrioles",1,1.4483665606145069,3531503.031879858,580.2430366100502,0.14903179222245894,0.10609977989085727,0.0,0.0,1.000892857142857,1121.0,-0.7569418619239919,0.07495380400152925,1.0,2.0,1.0,88.0,88.0,88.0,176.0,2066,87.0,9.353172034763868e-07,47053.0,1121.0,1.0,0,108.0
4566,300522,HP:0001249,"Herein we present a case series of six individuals (five males, one female) with intellectual disability and seizures found to have alterations in IQSEC2.",1,1.390367547364261,31681009.03067438,512.5166299758889,0.1259722919942748,0.0583092443159834,0.0,0.0,1.0005015045135406,1995.0,-0.5559157823494709,0.08131713436047491,1.0,2.0,1.0,384.0,384.0,360.0,768.0,3204,383.0,3.8916426584744957e-07,161741.0,1995.0,1.0,0,432.0
4570,300522,HP:0001250,"Herein we present a case series of six individuals (five males, one female) with intellectual disability and seizures found to have alterations in IQSEC2.",1,1.3883355829668014,29189740.485376064,468.9514947057376,0.12953273151893555,0.005990672790454864,0.0,0.0,1.0005149330587024,1943.0,-0.5408155117831377,0.07792688957640859,1.0,2.0,1.0,386.0,386.0,350.0,772.0,3100,385.0,4.156965348783942e-07,147021.0,1943.0,1.0,0,475.0
4568,300522,HP:0001249,"We report these cases to demonstrate the exhaustive work-up prior to finding the changes in IQSEC2 gene, recommend that this gene be considered earlier in the diagnostic evaluation of individuals with global developmental delay, microcephaly, and severe, intractable epilepsy, and support the use of intellectual disability panels including IQSEC2 in the first-line evaluation of these patients",1,1.390367547364261,31681009.03067438,512.5166299758889,0.1259722919942748,0.0583092443159834,0.0,0.0,1.0005015045135406,1995.0,-0.5559157823494709,0.08131713436047491,1.0,2.0,1.0,384.0,384.0,360.0,768.0,3204,383.0,3.8916426584744957e-07,161741.0,1995.0,1.0,0,432.0
4574,300522,HP:0001263,"We report these cases to demonstrate the exhaustive work-up prior to finding the changes in IQSEC2 gene, recommend that this gene be considered earlier in the diagnostic evaluation of individuals with global developmental delay, microcephaly, and severe, intractable epilepsy, and support the use of intellectual disability panels including IQSEC2 in the first-line evaluation of these patients",1,1.3862778071385264,30222079.31455107,493.27589045793036,0.12566339965097148,0.05620603117617097,0.0,0.0,1.000528820729773,1892.0,-0.5530125298390339,0.08585790262766882,1.0,2.0,1.0,385.0,385.0,354.0,770.0,2998,384.0,4.4444444444444454e-07,153590.0,1892.0,1.0,0,450.0
4575,610274,HP:0003155,Hyperphosphatasia with mental retardation syndrome (HPMRS) is caused by mutations in PIGV and includes hyperphosphatasia as a diagnostic hallmark.,1,1.3989955750282643,315202.0370990121,108.00525061986484,0.27005077567299435,0.11232985293610916,0.0,0.0,1.0026809651474529,374.0,-0.5424818923229887,0.08516006938968616,1.0,2.0,6.0,67.0,67.0,67.0,134.0,148,67.0,1.0541406645302749e-05,5940.0,374.0,1.0,0,83.0
4576,612895,HP:0000708,"An accurate spatial and temporal control of NL-NRX signaling is crucial to balance excitatory and inhibitory neurotransmission, and perturbations are linked with neurodevelopmental and psychiatric disorders.",0,1.391085621151158,19568858.840798795,371.663724137931,0.14324002433631236,0.02401074904167873,0.0,0.0,0.9994591671173608,1848.0,-0.5212007616315921,0.0621320509259936,1.0,2.0,2.0,346.0,346.0,180.0,692.0,3002,344.0,4.4326162542265004e-07,106266.0,1850.0,1.0,0,473.0
4577,614603,HP:0001258,We previously described a relatively pure hereditary spastic paraplegia (HSP) phenotype associated with mutations in DDHD1.,1,1.3498627039250524,190449.76388888888,107.14166666666668,0.21008721735585376,-0.0912200953905992,0.0,0.0,1.005464480874317,184.0,-0.6631245304247799,0.2656212877167973,1.0,2.0,2.0,62.0,62.0,61.0,124.0,240,61.0,6.830134553650705e-05,4472.0,184.0,1.0,0,76.0
4578,614603,HP:0000556,"Here we report a complex form of HSP associated with retinal dystrophy and a pattern of neurodegeneration with brain iron accumulation (NBIA) on brain MRI, due to a novel homozygous mutation in DDHD1.",0,1.3851223756803792,230758.61035393176,88.80157719435736,0.2707661515478197,0.1138284543060809,0.0,0.0,0.9973958333333331,383.0,-0.6126673122037749,0.06777597402597403,1.0,2.0,7.0,62.0,62.0,37.0,124.0,640,60.0,9.765625e-06,5010.0,385.0,1.0,0,59.0
4579,614603,HP:0000488,This observation enlarges the clinical spectrum of DDHD1-associated disorders and sheds light on a new aetiology for syndromes associating retinopathy and NBIA.,0,1.268348891969072,56420.25627705628,47.45138888888889,0.29270211033968085,0.16788067143355187,0.0,0.0,0.9935483870967744,154.0,-0.5192492749282119,0.1533498759305211,1.0,2.0,11.0,54.0,54.0,16.0,108.0,188,52.0,0.00012075836251660427,1854.0,156.0,1.0,0,46.0
4580,614783,HP:0004322,"Biallelic loss-of-function mutations affecting POC1A cause SOFT syndrome, an ultra-rare condition characterized by short stature, onychodysplasia, facial dysmorphism and hypotrichosis.",1,1.4194870396874075,8632656.033484679,475.3860962566845,0.13906981216751588,0.05513121771323338,0.0,0.0,1.0007745933384973,1292.0,-0.6987592936225898,0.08415249176844695,1.0,2.0,1.0,170.0,170.0,170.0,340.0,2244,169.0,7.929402939746842e-07,70182.0,1292.0,1.0,0,166.0
4581,614783,HP:0002164,"Biallelic loss-of-function mutations affecting POC1A cause SOFT syndrome, an ultra-rare condition characterized by short stature, onychodysplasia, facial dysmorphism and hypotrichosis.",1,1.3351867865790383,617488.1904761904,122.04597523219816,0.1951857885961564,0.12470949979411552,0.0,0.0,1.0031152647975077,322.0,-0.3011098237991912,0.1895087169365918,1.0,2.0,2.0,137.0,137.0,2.0,274.0,304,136.0,3.419855682090215e-05,9794.0,322.0,1.0,0,166.0
4582,614783,HP:0001999,"Biallelic loss-of-function mutations affecting POC1A cause SOFT syndrome, an ultra-rare condition characterized by short stature, onychodysplasia, facial dysmorphism and hypotrichosis.",1,1.4084407486033084,7349868.458253446,418.8425217336126,0.1390083232337406,0.0350672090991378,0.0,0.0,1.000912408759124,1097.0,-0.7090437813838191,0.10008882885640333,1.0,2.0,1.0,169.0,169.0,168.0,338.0,1854,168.0,1.1611920332936977e-06,60169.0,1097.0,1.0,0,181.0
4583,606489,HP:0001263,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",1,1.4507465322812487,8804494.251543442,724.5808038692462,0.14124536857997616,0.10305817636164052,0.0,0.0,1.0006180469715698,1619.0,-0.7488010542868332,0.061464943108375435,1.0,2.0,1.0,120.0,120.0,120.0,240.0,2998,119.0,4.4444444444444454e-07,80505.0,1619.0,1.0,0,119.0
4584,610826,HP:0001263,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",1,1.4507465322812487,6834797.209463802,651.0651712252612,0.15098851656948284,0.03267360131227433,0.0,0.0,1.0006180469715698,1619.0,-0.7001720037357901,0.055228738458860366,1.0,2.0,1.0,120.0,120.0,120.0,240.0,2998,119.0,4.4444444444444454e-07,72337.0,1619.0,1.0,0,125.0
4585,600354,HP:0001263,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",0,1.455206009256357,2237673.8382324902,440.1009868648064,0.1994214139465695,0.02142107760025461,0.0,0.0,0.9993698802772528,1586.0,-0.6688639828089797,0.029847358655575286,1.0,2.0,5.0,84.0,84.0,70.0,168.0,3000,82.0,4.43852443918134e-07,37610.0,1588.0,1.0,0,81.0
4586,606489,HP:0000365,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",0,1.4328755000413227,6021610.43604108,517.0548167609809,0.15147479861809265,0.17569067614886227,0.0,0.0,0.9992636229749632,1357.0,-0.724670269189787,0.06252756672637877,1.0,2.0,17.0,121.0,121.0,121.0,242.0,2476,119.0,6.524672396198985e-07,57698.0,1359.0,1.0,0,120.0
4587,610826,HP:0000365,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",0,1.430918144166783,5485023.51021099,496.7692939908381,0.1562627483935134,0.08287115677865511,0.0,0.0,0.9992636229749632,1357.0,-0.7102291197261587,0.0601228270375536,1.0,2.0,22.0,121.0,121.0,121.0,242.0,2476,119.0,6.524672396198985e-07,55479.0,1359.0,1.0,0,122.0
4588,600354,HP:0000365,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",0,1.4425803569201674,1872577.1745980445,356.48885419860807,0.20314158731573254,0.13887938988085854,0.0,0.0,0.9992452830188678,1324.0,-0.6695089021376063,0.03430718005634765,1.0,2.0,19.0,84.0,84.0,81.0,168.0,2476,82.0,6.524672396198986e-07,30138.0,1326.0,1.0,0,86.0
4589,606489,HP:0000252,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",1,1.4338454621696164,5871320.500261501,565.2825266214908,0.1378315692698912,0.01844641892234524,0.0,0.0,1.0008680555555556,1153.0,-0.7383868587844377,0.09150946805435096,1.0,2.0,1.0,120.0,120.0,119.0,240.0,2066,119.0,9.35317203476387e-07,60774.0,1153.0,1.0,0,121.0
4590,610826,HP:0000252,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",0,1.4301547572833582,4902137.661145977,489.5415295256535,0.1501148909394723,0.07505136815834154,0.0,0.0,0.9991334488734837,1153.0,-0.6997605132113631,0.08038143254781037,1.0,2.0,1.0,121.0,121.0,121.0,242.0,2068,119.0,9.335107003664032e-07,53569.0,1155.0,1.0,0,115.0
4591,600354,HP:0000252,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",0,1.437292950210883,1415090.8377058955,325.64611498703704,0.19967390166880644,-0.02181641080307202,0.0,0.0,0.9991079393398752,1120.0,-0.6634377119396141,0.04307651209052269,1.0,2.0,6.0,82.0,82.0,68.0,164.0,2068,80.0,9.335107003664028e-07,27090.0,1122.0,1.0,0,74.0
4592,606489,HP:0000648,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",0,1.3867977084320722,2898053.4545557383,293.4644090305445,0.1533580482843105,0.07269250716047823,0.0,0.0,0.9983948635634028,622.0,-0.7225916842796102,0.14842367370457255,1.0,2.0,1.0,121.0,121.0,121.0,242.0,1006,119.0,3.936759889140842e-06,28850.0,624.0,1.0,0,137.0
4593,610826,HP:0000648,"The PCH1sub-types with early death (between ages 1 day and 17 months), seen in patients with p.G31A/EXOSC3 or SLC25A46 mutations have a SMA type 1-like clinical presentation but with global developmental delay, visual and hearing impairment, with or without microcephaly, nystagmus and optic atrophy.",1,1.3926651250180662,2379805.7601093347,278.15501328021253,0.16184313432999026,0.03147803228812033,0.0,0.0,1.001610305958132,622.0,-0.6872530291079639,0.13948563410327705,1.0,2.0,1.0,120.0,120.0,120.0,240.0,1004,119.0,3.952428569734674e-06,26939.0,622.0,1.0,0,146.0
4595,606489,HP:0001251,"Mutations with milder presentation (homozygous p.D132A/EXOSC3 or VRK1) may display additionally signs of upper motor neuron impairment, dystonia or ataxia and die at age between 5 and 18 years.",0,1.4168171712488151,4599717.833989337,416.3988929889299,0.14988916516129086,0.055090393988328594,0.0,0.0,0.9989293361884368,933.0,-0.7422469908942619,0.1013752590777405,1.0,2.0,1.0,121.0,121.0,121.0,242.0,1628,119.0,1.5055139448229141e-06,44265.0,935.0,1.0,0,117.0
4596,602168,HP:0001251,"Mutations with milder presentation (homozygous p.D132A/EXOSC3 or VRK1) may display additionally signs of upper motor neuron impairment, dystonia or ataxia and die at age between 5 and 18 years.",1,1.4398097757832518,2073179.9958569752,392.3619750483218,0.17089183161692933,0.13625237704028642,0.0,0.0,1.0011160714285714,897.0,-0.7647708948455649,0.07433508520465043,1.0,2.0,2.0,83.0,83.0,80.0,166.0,1626,82.0,1.5092152684290281e-06,29872.0,897.0,1.0,0,80.0
4597,606489,HP:0001257,"Other EXOSC3 mutations and EXOSC8 cases are intermediate - SMA type 1-like presentation, spasticity (mostly in EXOSC8) and death between 3 months and 5 years.",1,1.4164086609313402,4289429.86058327,419.5819611780455,0.14500246200460518,0.0011047886172985237,0.0,0.0,1.0011547344110854,867.0,-0.7458145757685052,0.11555601727173685,1.0,2.0,1.0,120.0,120.0,120.0,240.0,1494,119.0,1.787297320483857e-06,43381.0,867.0,1.0,0,124.0
4599,617687,HP:0001249,Here we report three families with homozygous truncating mutations in TBC1D23 who display moderate to severe intellectual disability and microcephaly.,0,1.4524073998647755,9318826.244621372,744.1418501263664,0.14219001923998287,0.023414178167757482,0.0,0.0,1.0005800464037122,1725.0,-0.7417189336769657,0.057166010962036384,1.0,2.0,1.0,123.0,123.0,123.0,246.0,3204,122.0,3.891642658474498e-07,85003.0,1725.0,1.0,0,121.0
4600,617687,HP:0000252,Here we report three families with homozygous truncating mutations in TBC1D23 who display moderate to severe intellectual disability and microcephaly.,0,1.4325842998368303,6243090.25543518,569.2248482988217,0.1364818304058965,-0.022452047166028274,0.0,0.0,1.000865800865801,1156.0,-0.7426155023929749,0.09371770098413697,1.0,2.0,1.0,123.0,123.0,123.0,246.0,2066,122.0,9.353172034763874e-07,62565.0,1156.0,1.0,0,130.0
4603,164730,HP:0009733,"In addition, we found that HCRP1 up-regulation decreased the levels of p-ERK and p-AKT in glioma cells.",0,1.4282355325833591,307804.51916052896,186.9461300309597,0.29482801106164924,0.03779829588816011,0.0,0.0,0.9986091794158553,718.0,-0.538818049792063,0.02848864163189615,1.0,2.0,47.0,39.0,39.0,39.0,78.0,310,38.0,2.1562830854685934e-06,7374.0,720.0,1.0,0,46.0
4607,600997,HP:0009733,We also emphasized that the ERK and AKT signaling pathways were the mechanisms underlying the inhibitory effect of HCRP1 on glioma cells.,0,1.2631724137931033,17687.572222222225,43.50071123755335,0.28989063236004137,0.06707279406921325,0.0,0.0,0.986842105263158,75.0,-0.4805633013584534,0.2915242652084757,1.0,2.0,5.0,28.0,28.0,25.0,56.0,78,26.0,0.000625,853.0,77.0,1.0,0,37.0
4605,164730,HP:0009733,We also emphasized that the ERK and AKT signaling pathways were the mechanisms underlying the inhibitory effect of HCRP1 on glioma cells.,0,1.4282355325833591,307804.51916052896,186.9461300309597,0.29482801106164924,0.03779829588816011,0.0,0.0,0.9986091794158553,718.0,-0.538818049792063,0.02848864163189615,1.0,2.0,47.0,39.0,39.0,39.0,78.0,310,38.0,2.1562830854685934e-06,7374.0,720.0,1.0,0,46.0
4608,601255,HP:0009830,Mutations in the kinesin family member 1A (KIF1A) gene have been associated with a wide range of phenotypes including recessive mutations causing hereditary sensory neuropathy and hereditary spastic paraplegia and de novo dominant mutations causing a more complex neurological disorder affecting both the central and peripheral nervous system.,1,1.3376969882906375,6591790.556168833,227.9517138347052,0.15904236716143416,0.1011509984080574,0.0,0.0,1.0010706638115632,935.0,-0.3896226698563952,0.11884711836846865,1.0,2.0,4.0,363.0,363.0,26.0,726.0,1086,363.0,3.3791089965397925e-06,51894.0,935.0,1.0,0,524.0
4609,601255,HP:0001258,Mutations in the kinesin family member 1A (KIF1A) gene have been associated with a wide range of phenotypes including recessive mutations causing hereditary sensory neuropathy and hereditary spastic paraplegia and de novo dominant mutations causing a more complex neurological disorder affecting both the central and peripheral nervous system.,1,1.3776299581177631,848274.5898617068,138.30748299319728,0.2039208206866369,0.12092892505295555,0.0,0.0,1.0019569471624266,512.0,-0.4339733739769328,0.09713643590998043,1.0,2.0,24.0,120.0,120.0,120.0,240.0,240,120.0,6.47462916561454e-06,12707.0,512.0,1.0,0,120.0
4612,120130,HP:0002664,Collagen type 4 alpha 1 (COL4A1) and collagen type 13 alpha 1 (COL13A1) produced by urothelial cancer cells support the vital oncogenic property of tumor invasion.,0,1.3478609392154903,5596954.7712916015,212.12074127811118,0.16076534470753126,0.07520008162453347,0.0,0.0,0.9990627928772258,1066.0,-0.5121311585471683,0.08055418075109955,1.0,2.0,18.0,286.0,286.0,73.0,572.0,1554,284.0,1.6778973932186097e-06,45898.0,1068.0,1.0,0,358.0
4619,120350,HP:0002664,Collagen type 4 alpha 1 (COL4A1) and collagen type 13 alpha 1 (COL13A1) produced by urothelial cancer cells support the vital oncogenic property of tumor invasion.,0,1.337774430029938,4880387.169680046,202.29726005188067,0.16259778259932373,0.09897594302243401,0.0,0.0,0.9990421455938696,1043.0,-0.575509921662195,0.07574107683000605,1.0,2.0,35.0,246.0,246.0,94.0,492.0,1544,244.0,1.6778973932186103e-06,41316.0,1045.0,1.0,0,286.0
4614,120130,HP:0002664,"We investigated the diagnostic and prognostic capability of COL4A1 and COL13A1 in voided urine and compared the observed values with those of fragments of cytokeratin-19 (CYFRA21-1), nuclear matrix protein 22 (NMP-22), and voided urine cytology in bladder cancer (BCa).",0,1.3478609392154903,5596954.7712916015,212.12074127811118,0.16076534470753126,0.07520008162453347,0.0,0.0,0.9990627928772258,1066.0,-0.5121311585471683,0.08055418075109955,1.0,2.0,18.0,286.0,286.0,73.0,572.0,1554,284.0,1.6778973932186097e-06,45898.0,1068.0,1.0,0,358.0
4622,120350,HP:0002664,"We investigated the diagnostic and prognostic capability of COL4A1 and COL13A1 in voided urine and compared the observed values with those of fragments of cytokeratin-19 (CYFRA21-1), nuclear matrix protein 22 (NMP-22), and voided urine cytology in bladder cancer (BCa).",0,1.337774430029938,4880387.169680046,202.29726005188067,0.16259778259932373,0.09897594302243401,0.0,0.0,0.9990421455938696,1043.0,-0.575509921662195,0.07574107683000605,1.0,2.0,35.0,246.0,246.0,94.0,492.0,1544,244.0,1.6778973932186103e-06,41316.0,1045.0,1.0,0,286.0
4610,120130,HP:0002664,"Among these biomarkers, the optimal cut-off value of COL4A1 + COL13A1 at 1.33 ng/mL resulted in 57.4%, 83.7%, 56.1%, 80.7%, and 91.7% sensitivity for low-grade tumors, high-grade tumors, Ta, T1, and muscle invasive disease, respectively.",0,1.3478609392154903,5596954.7712916015,212.12074127811118,0.16076534470753126,0.07520008162453347,0.0,0.0,0.9990627928772258,1066.0,-0.5121311585471683,0.08055418075109955,1.0,2.0,18.0,286.0,286.0,73.0,572.0,1554,284.0,1.6778973932186097e-06,45898.0,1068.0,1.0,0,358.0
4616,120350,HP:0002664,"Among these biomarkers, the optimal cut-off value of COL4A1 + COL13A1 at 1.33 ng/mL resulted in 57.4%, 83.7%, 56.1%, 80.7%, and 91.7% sensitivity for low-grade tumors, high-grade tumors, Ta, T1, and muscle invasive disease, respectively.",0,1.337774430029938,4880387.169680046,202.29726005188067,0.16259778259932373,0.09897594302243401,0.0,0.0,0.9990421455938696,1043.0,-0.575509921662195,0.07574107683000605,1.0,2.0,35.0,246.0,246.0,94.0,492.0,1544,244.0,1.6778973932186103e-06,41316.0,1045.0,1.0,0,286.0
4625,121015,HP:0000518,"We detected 11 novel mutations in GJA3, GJA8, CRYAA, CRYBB2, CRYGS, CRYGA, GCNT2, CRYGA, and MIP; and three previously reported cataract-causing mutations in GJA8, CRYAA, and CRYBB2 The most commonly mutated genes were those coding for gap junctions and crystallin proteins.",1,1.4925094152809781,19532.716845878138,452.3834745762712,0.3386116006307908,0.3624479260149198,0.0,0.0,1.0015243902439024,657.0,-0.9349015085014424,0.016589635074432937,1.0,2.0,1.0,8.0,8.0,8.0,16.0,1298,7.0,2.366863905325444e-06,3575.0,657.0,1.0,0,7.0
4638,600897,HP:0000518,"We detected 11 novel mutations in GJA3, GJA8, CRYAA, CRYBB2, CRYGS, CRYGA, GCNT2, CRYGA, and MIP; and three previously reported cataract-causing mutations in GJA8, CRYAA, and CRYBB2 The most commonly mutated genes were those coding for gap junctions and crystallin proteins.",1,1.4097327154290509,2467220.003585303,279.6954683734345,0.1669735945376989,0.001018252689578121,0.0,0.0,1.0013071895424837,766.0,-0.6862604246750685,0.09462960118773356,1.0,2.0,1.0,117.0,117.0,117.0,234.0,1298,116.0,2.366863905325444e-06,27726.0,766.0,1.0,0,124.0
2928,123580,HP:0000518,"We detected 11 novel mutations in GJA3, GJA8, CRYAA, CRYBB2, CRYGS, CRYGA, GCNT2, CRYGA, and MIP; and three previously reported cataract-causing mutations in GJA8, CRYAA, and CRYBB2 The most commonly mutated genes were those coding for gap junctions and crystallin proteins.",1,1.4648347930684509,308894.8867038237,287.35169491525426,0.25866110695466465,0.12506491493606692,0.0,0.0,1.0014619883040936,685.0,-0.6765876886729213,0.041836342681521324,1.0,2.0,1.0,36.0,36.0,35.0,72.0,1298,35.0,2.3668639053254444e-06,9801.0,685.0,1.0,0,34.0
4642,123620,HP:0000518,"We detected 11 novel mutations in GJA3, GJA8, CRYAA, CRYBB2, CRYGS, CRYGA, GCNT2, CRYGA, and MIP; and three previously reported cataract-causing mutations in GJA8, CRYAA, and CRYBB2 The most commonly mutated genes were those coding for gap junctions and crystallin proteins.",1,1.46844763018318,179559.72362970907,237.14329738058552,0.2842541737436068,0.06744700078497234,0.0,0.0,1.001470588235294,681.0,-0.6976785112887011,0.03123434395784745,1.0,2.0,3.0,30.0,30.0,28.0,60.0,1298,29.0,2.366863905325443e-06,7232.0,681.0,1.0,0,28.0
4643,600429,HP:0000518,"We detected 11 novel mutations in GJA3, GJA8, CRYAA, CRYBB2, CRYGS, CRYGA, GCNT2, CRYGA, and MIP; and three previously reported cataract-causing mutations in GJA8, CRYAA, and CRYBB2 The most commonly mutated genes were those coding for gap junctions and crystallin proteins.",1,1.4860842521911224,48296.22686944787,338.7239709443099,0.3225977404701797,0.2881500072220806,0.0,0.0,1.001510574018127,663.0,-0.8137782773535479,0.021152593038144842,1.0,2.0,3.0,12.0,12.0,12.0,24.0,1298,11.0,2.366863905325444e-06,4642.0,663.0,1.0,0,11.0
4644,602241,HP:0000518,"We detected 11 novel mutations in GJA3, GJA8, CRYAA, CRYBB2, CRYGS, CRYGA, GCNT2, CRYGA, and MIP; and three previously reported cataract-causing mutations in GJA8, CRYAA, and CRYBB2 The most commonly mutated genes were those coding for gap junctions and crystallin proteins.",1,1.4365559917492847,1456517.9933461288,326.60090309878444,0.17549077441127414,0.11380161338030753,0.0,0.0,1.0013888888888889,721.0,-0.7788008526656846,0.08154954538449684,1.0,2.0,1.0,71.0,71.0,65.0,142.0,1298,70.0,2.366863905325444e-06,21167.0,721.0,1.0,0,73.0
4648,138210,HP:0002664,"Here, we report that in breast cancer tissue samples and breast cancer cell lines, GPT2 expression level was markedly elevated and correlated with the pathological grades of breast cancers.",0,1.3946366644544357,2140987.5495906183,262.91176579581247,0.17804006389245985,0.08682843283585844,0.0,0.0,0.998859749144812,876.0,-0.6924876425912553,0.06490339036319198,1.0,2.0,44.0,106.0,106.0,106.0,212.0,1544,104.0,1.67789739321861e-06,24988.0,878.0,1.0,0,115.0
4645,138210,HP:0002664,GPT2 overexpression increased the subpopulation of breast cancer stem cells in vitro and promoted tumorigenesis in mice.,0,1.3946366644544357,2140987.5495906183,262.91176579581247,0.17804006389245985,0.08682843283585844,0.0,0.0,0.998859749144812,876.0,-0.6924876425912553,0.06490339036319198,1.0,2.0,44.0,106.0,106.0,106.0,212.0,1544,104.0,1.67789739321861e-06,24988.0,878.0,1.0,0,115.0
4651,138210,HP:0002664,"Overall, GPT2 promotes tumorigenesis and stemness of breast cancer cells by activating the Shh signaling, suggesting that GTP2 is a potential target for breast cancer therapy",0,1.3946366644544357,2140987.5495906183,262.91176579581247,0.17804006389245985,0.08682843283585844,0.0,0.0,0.998859749144812,876.0,-0.6924876425912553,0.06490339036319198,1.0,2.0,44.0,106.0,106.0,106.0,212.0,1544,104.0,1.67789739321861e-06,24988.0,878.0,1.0,0,115.0
3085,600725,HP:0002664,"Overall, GPT2 promotes tumorigenesis and stemness of breast cancer cells by activating the Shh signaling, suggesting that GTP2 is a potential target for breast cancer therapy",1,1.3415673643588644,12257345.15556943,249.37693243428313,0.1462616341640359,0.02060471606945835,0.0,0.0,1.0007980845969673,1254.0,-0.4151526290473577,0.09426308279586727,1.0,2.0,13.0,444.0,444.0,30.0,888.0,1560,444.0,1.6778973932186103e-06,74056.0,1254.0,1.0,0,584.0
9,191170,HP:0002664,"Although p53R2 has been linked to human cancer, its role in cervical cancer remains unknown.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
57,191170,HP:0002664,"In this study, we investigated the expression and clinical significance of p53R2 in early-stage cervical cancer.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
185,191170,HP:0002664,"p53R2 expression is significantly upregulated at both mRNA and protein levels in cervical cancer cells and tissues, compared with that in matched normal cervical cells and tissues, respectively.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
193,191170,HP:0002664,"p53R2 overexpression is associated with increased risk of pelvic lymph node metastasis (PLNM, p = 0.001) and cancer relapse (p = 0.009).",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
81,191170,HP:0002664,Patients with high p53R2 expression have a shorter overall survival (OS) and disease-free survival (DFS). p53R2 is an independent factor for predicting OS and DFS of cervical cancer patients.,1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
177,191170,HP:0002664,"We further show that p53R2 is important for oncogenic growth, migration and invasion in cervical cancer cells.",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
41,191170,HP:0002664,"In conclusion, our study demonstrates for the first time that p53R2 protein is overexpressed in early-stage cervical cancer and unravels some unconventional oncogenic functions of p53R2. p53R2 may be a useful prognostic biomarker and therapeutic target for cervical cancer",1,1.3454208312212703,8633395.496864246,230.38088663355396,0.15652290097941474,0.13406706378317107,0.0,0.0,1.0008305647840532,1205.0,-0.4378071388835026,0.08819012696268318,1.0,2.0,8.0,413.0,413.0,46.0,826.0,1542,412.0,1.6778973932186103e-06,63974.0,1205.0,1.0,0,490.0
2222,190080,HP:0002664,Here we show that metabolic reprogramming of colorectal cancer is caused chiefly by aberrant MYC expression.,1,1.4396536831054232,1166089.637753825,258.33534370946825,0.21512590240969573,0.06608515489589678,0.0,0.0,1.0011764705882351,851.0,-0.6775154399515846,0.05177023570885463,1.0,2.0,1.0,80.0,80.0,80.0,160.0,1542,79.0,1.6778973932186097e-06,18724.0,851.0,1.0,0,67.0
2234,190080,HP:0002664,Knockdown of MYC in colorectal cancer cells reset the altered metabolism and suppressed cell growth.,1,1.4396536831054232,1166089.637753825,258.33534370946825,0.21512590240969573,0.06608515489589678,0.0,0.0,1.0011764705882351,851.0,-0.6775154399515846,0.05177023570885463,1.0,2.0,1.0,80.0,80.0,80.0,160.0,1542,79.0,1.6778973932186097e-06,18724.0,851.0,1.0,0,67.0
2240,190080,HP:0002664,"Moreover, inhibition of MYC target pyrimidine synthesis genes such as CAD, UMPS, and CTPS blocked cell growth, and thus are potential targets for colorectal cancer therapy",1,1.4396536831054232,1166089.637753825,258.33534370946825,0.21512590240969573,0.06608515489589678,0.0,0.0,1.0011764705882351,851.0,-0.6775154399515846,0.05177023570885463,1.0,2.0,1.0,80.0,80.0,80.0,160.0,1542,79.0,1.6778973932186097e-06,18724.0,851.0,1.0,0,67.0
4654,123690,HP:0000518,The frequency of CRYGD p.(Tyr56*) in the ExAC dataset was higher than the estimated incidence of congenital cataract in the general population.,1,1.4759973839110532,164528.25586723475,308.89040832049307,0.28387694916729184,0.10346187303105704,0.0,0.0,1.0014880952380951,673.0,-0.7106994518218513,0.03161483761409467,1.0,2.0,1.0,24.0,24.0,24.0,48.0,1298,23.0,2.366863905325444e-06,7149.0,673.0,1.0,0,23.0
4655,606152,HP:0001298,"Herein, we describe the clinical and genetic characterization of 79 patients with inherited thiamine defects causing encephalopathy in childhood, identifying outcome predictors in patients with pathogenic SLC19A3 variants, the most common genetic etiology.",1,1.3351206788100591,1356348.6079365078,150.6781209221401,0.1829531701756322,0.1139370463285043,0.0,0.0,1.002222222222222,451.0,-0.3660759877393244,0.16652377432865234,1.0,2.0,2.0,198.0,198.0,25.0,396.0,484,197.0,1.6935087808430286e-05,16898.0,451.0,1.0,0,253.0
4656,613084,HP:0001513,This study demonstrates that MYT1L variants are associated with syndromic obesity in humans.,1,1.3339652448657189,4437083.52699939,199.2401171774401,0.15637448011259153,0.051557703687293496,0.0,0.0,1.0014204545454546,705.0,-0.3771442075477902,0.14150548033526758,1.0,2.0,1.0,277.0,277.0,2.0,554.0,704,276.0,7.979826997350696e-06,35116.0,705.0,1.0,0,339.0
1820,191160,HP:0002664,"After HDM challenge, these mice also had fewer airway inflammatory cells, reduced interleukin (IL)-5, IL-13, IL-33, tumour necrosis factor (TNF) and CXCL1 levels in the lungs, and reduced IL-5, IL-33 and TNF levels in lung-draining lymph nodes.",0,1.4602670579691517,200974.08525960872,239.91050583657588,0.2850613192309647,0.15408425189867206,0.0,0.0,0.9987531172069826,801.0,-0.7836891500894245,0.02382275941528495,1.0,2.0,14.0,31.0,31.0,25.0,62.0,1544,29.0,1.6778973932186097e-06,7671.0,803.0,1.0,0,23.0
4658,274180,HP:0003330,"TBXAS1 mutations result in Ghosal hematodiaphyseal dysplasia (OMIM 231095), the autosomal recessive syndrome associated with abnormal bone structure and BMF.",1,1.4346358325415918,1159127.9498755718,287.7688329113376,0.19451635001857887,0.07066245138047261,0.0,0.0,1.0014184397163122,706.0,-0.7110648487378108,0.07568360356016314,1.0,2.0,1.0,73.0,73.0,69.0,146.0,1266,72.0,2.4878344893470923e-06,18835.0,706.0,1.0,0,84.0
4659,138492,HP:0000756,"As one of the first findings being confirmed by genome-wide association studies for the phenotype of panic disorder and agoraphobia, allelic variation in a gene coding for the glycine receptor beta subunit (GLRB) has recently been associated with increased neural fear network activation and enhanced acoustic startle reflexes.",0,1.3403451995685003,1323.8061465721041,47.06028368794326,0.5245907228110948,0.4902036908514385,0.0,0.0,0.9897959183673468,97.0,-0.8295955261442827,0.047000618429189865,1.0,2.0,29.0,4.0,4.0,4.0,8.0,188,3.0,0.000110803324099723,228.0,99.0,1.0,0,4.0
4660,606973,HP:0000007,"Mutations affecting human COG1, COG2 and COG4-COG8 cause monogenic forms of inherited, autosomal recessive CDGs.",1,1.435791259927924,22655123.97884842,550.5168536889469,0.1526487183840544,0.024537102246192027,0.0,0.0,1.000349040139616,2866.0,-0.5538457902563968,0.03452306575619071,1.0,2.0,19.0,284.0,284.0,277.0,568.0,5160,283.0,1.5011496554636372e-07,141736.0,2866.0,1.0,0,285.0
4661,606974,HP:0000007,"Mutations affecting human COG1, COG2 and COG4-COG8 cause monogenic forms of inherited, autosomal recessive CDGs.",1,1.4765507029657972,4572940.988579059,726.1930319658568,0.18898564787985184,0.1365136368141142,0.0,0.0,1.0003748125937029,2669.0,-0.6775976385862527,0.017547239868263696,1.0,2.0,128.0,89.0,89.0,89.0,178.0,5160,88.0,1.5011496554636367e-07,62476.0,2669.0,1.0,0,78.0
4662,606976,HP:0000007,"Mutations affecting human COG1, COG2 and COG4-COG8 cause monogenic forms of inherited, autosomal recessive CDGs.",1,1.4351016554465317,18844203.132628128,515.595001336541,0.1572233281283125,0.1823586772527806,0.0,0.0,1.0003485535029626,2870.0,-0.561941386291528,0.03264841153117004,1.0,2.0,86.0,289.0,289.0,263.0,578.0,5160,288.0,1.5011496554636354e-07,134414.0,2870.0,1.0,0,285.0
4663,614194,HP:0000007,"We present a case of type 2 autosomal recessive AOS associated with heterozygous mutations in the dedicator of cytokinesis 6 (DOCK6) gene, with characteristic findings of ACC, TTLD, intracerebral periventricular calcifications, and polymicrogyria",1,1.4373603753167885,19648438.148162868,526.9215319172754,0.15654582426784416,0.11124562398402932,0.0,0.0,1.0003501400560224,2857.0,-0.5554924762581773,0.032307007507238104,1.0,2.0,54.0,277.0,277.0,277.0,554.0,5160,276.0,1.501149655463636e-07,131806.0,2857.0,1.0,0,280.0
4664,614194,HP:0007229,"We present a case of type 2 autosomal recessive AOS associated with heterozygous mutations in the dedicator of cytokinesis 6 (DOCK6) gene, with characteristic findings of ACC, TTLD, intracerebral periventricular calcifications, and polymicrogyria",0,1.3400238438406378,3173.1279581728118,99.37665463297232,0.5852112870629678,0.06426991000260407,0.0,0.0,0.99644128113879,280.0,-0.6782849477209194,0.014361071149138085,1.0,2.0,113.0,4.0,4.0,4.0,8.0,232,3.0,1.2939288856684441e-05,569.0,282.0,1.0,0,4.0
4666,613413,HP:0002145,Single-nucleotide polymorphisms in the TMEM106B gene have been identified as a risk factor in frontotemporal dementia (FTD).,1,1.4167359733862197,55648.407365673535,89.91324324324323,0.2926466069482405,-0.08789352168170947,0.0,0.0,1.005813953488372,173.0,-0.7515494230247107,0.12925124344669986,1.0,2.0,2.0,25.0,25.0,25.0,50.0,244,25.0,4.504301608035674e-05,1923.0,173.0,1.0,0,33.0
4667,138945,HP:0003745,"The major allele of SNP rs3173615 is a risk factor in sporadic FTD, whereas the minor allele seems protective in GRN- and C9orf72-mediated FTD.",0,1.3161154465502292,156113.02445887448,60.83752563226248,0.27035847486471803,0.0325167635562965,0.0,0.0,0.996,249.0,-0.3876059273645393,0.1181195219123506,1.0,2.0,6.0,80.0,80.0,4.0,160.0,192,79.0,4.162330905306971e-05,3706.0,251.0,1.0,0,93.0
4668,614260,HP:0003745,"The major allele of SNP rs3173615 is a risk factor in sporadic FTD, whereas the minor allele seems protective in GRN- and C9orf72-mediated FTD.",0,1.324102008715608,270907.63634920644,79.21267942583732,0.2417058991565683,0.08650197421579893,0.0,0.0,0.9968354430379748,315.0,-0.4119686569813987,0.10857325400311464,1.0,2.0,12.0,91.0,91.0,11.0,182.0,218,90.0,2.0474601257140522e-05,5438.0,317.0,1.0,0,109.0
4675,606097,HP:0000123,Post-infectious glomerulonephritis (PIGN) is one of the most common causes of acute glomerulonephritis in children.,0,1.356922092860752,190726.2072835764,81.85753085570873,0.32075259142127194,0.3273258160580207,0.0,0.0,0.9981916817359856,552.0,-0.3869523973580903,0.03107434995201755,1.0,2.0,82.0,60.0,60.0,60.0,120.0,336,59.0,4.097756068776739e-06,4760.0,554.0,1.0,0,62.0
4669,606097,HP:0000123,"Although post-streptococcal glomerulonephritis (PSGN) is still common, there is a wide spectrum of causative agents of PIGN.",0,1.356922092860752,190726.2072835764,81.85753085570873,0.32075259142127194,0.3273258160580207,0.0,0.0,0.9981916817359856,552.0,-0.3869523973580903,0.03107434995201755,1.0,2.0,82.0,60.0,60.0,60.0,120.0,336,59.0,4.097756068776739e-06,4760.0,554.0,1.0,0,62.0
4678,606097,HP:0000123,The clinical presentation of PIGN varies from a benign asymptomatic condition to rapidly progressive glomerulonephritis requiring dialysis.,0,1.356922092860752,190726.2072835764,81.85753085570873,0.32075259142127194,0.3273258160580207,0.0,0.0,0.9981916817359856,552.0,-0.3869523973580903,0.03107434995201755,1.0,2.0,82.0,60.0,60.0,60.0,120.0,336,59.0,4.097756068776739e-06,4760.0,554.0,1.0,0,62.0
4672,606097,HP:0000123,"IgA-dominant nephritis, endocarditis-associated nephritis and shunt nephritis are special sub-subtypes of PIGN.",0,1.356922092860752,190726.2072835764,81.85753085570873,0.32075259142127194,0.3273258160580207,0.0,0.0,0.9981916817359856,552.0,-0.3869523973580903,0.03107434995201755,1.0,2.0,82.0,60.0,60.0,60.0,120.0,336,59.0,4.097756068776739e-06,4760.0,554.0,1.0,0,62.0
4681,606097,HP:0100584,"IgA-dominant nephritis, endocarditis-associated nephritis and shunt nephritis are special sub-subtypes of PIGN.",0,1.3518949984467226,34312.237048508934,120.97987205492277,0.41363508038370267,0.06987491240277298,0.0,0.0,0.9980276134122288,506.0,-0.4968415904746322,0.015631551973163117,1.0,2.0,165.0,14.0,14.0,14.0,28.0,442,13.0,4.097756068776737e-06,2013.0,508.0,1.0,0,14.0
4682,606060,HP:0004923,"Biallelic DNAJC12 mutations were described in children with hyperphenylalaninemia, neurodevelopmental delay, and dystonia.",0,1.3673890608875128,1507.5995670995676,30.286363636363635,0.4735134175283434,0.4690652748264397,0.0,0.0,0.98,49.0,-0.8502839588984409,0.1380392156862745,1.0,2.0,3.0,6.0,6.0,6.0,12.0,44,5.0,0.0004938271604938272,176.0,51.0,1.0,0,6.0
4683,606060,HP:0012758,"Biallelic DNAJC12 mutations were described in children with hyperphenylalaninemia, neurodevelopmental delay, and dystonia.",1,1.4835763161569613,1764555.4001688631,899.5423031291707,0.19873447699025729,0.21529683944504832,0.0,0.0,1.0005313496280552,1883.0,-0.7940847130106442,0.021815528276660744,1.0,2.0,1.0,44.0,44.0,44.0,88.0,3678,43.0,2.953686200378071e-07,38655.0,1883.0,1.0,0,43.0
4684,606060,HP:0001332,"Biallelic DNAJC12 mutations were described in children with hyperphenylalaninemia, neurodevelopmental delay, and dystonia.",1,1.4423187054126578,515015.76815339294,278.2604895104895,0.2010449332458551,0.07759098808436961,0.0,0.0,1.002061855670103,486.0,-0.8119818797349185,0.09448050570616437,1.0,2.0,1.0,44.0,44.0,44.0,88.0,884,43.0,5.095567365948362e-06,11135.0,486.0,1.0,0,44.0
4687,606060,HP:0001300,We identified DNAJC12 homozygous null variants (c.187A&gt;T;p.K63* and c.79-2A&gt;G;p.V27Wfs*14) in two kindreds with early-onset parkinsonism.,1,1.362655839895013,93963.15555555557,81.59305317324187,0.25167770641530884,-0.00028814554043220253,0.0,0.0,1.0067114093959733,150.0,-0.6952058401957374,0.2270246085011185,1.0,2.0,1.0,44.0,44.0,44.0,88.0,212,43.0,8.734387282732117e-05,2537.0,150.0,1.0,0,52.0
4685,606060,HP:0001300,"Our results suggest that DNAJC12 mutations (absent in 500 early-onset patients with Parkinson*s disease) rarely cause dopa-responsive nonprogressive parkinsonism in adulthood, but broaden the clinical spectrum of DNAJC12 deficiency.",1,1.362655839895013,93963.15555555557,81.59305317324187,0.25167770641530884,-0.00028814554043220253,0.0,0.0,1.0067114093959733,150.0,-0.6952058401957374,0.2270246085011185,1.0,2.0,1.0,44.0,44.0,44.0,88.0,212,43.0,8.734387282732117e-05,2537.0,150.0,1.0,0,52.0
4689,606060,HP:0003680,"Our results suggest that DNAJC12 mutations (absent in 500 early-onset patients with Parkinson*s disease) rarely cause dopa-responsive nonprogressive parkinsonism in adulthood, but broaden the clinical spectrum of DNAJC12 deficiency.",0,1.2954199763393612,7435.684920634922,26.71454545454546,0.3824560463201608,0.2644121131565501,0.0,0.0,0.9857142857142858,69.0,-0.5210514825151374,0.186317907444668,1.0,2.0,3.0,24.0,24.0,26.0,48.0,52,22.0,0.0004938271604938272,463.0,71.0,1.0,0,26.0
4690,615463,HP:0001298,Mutations in SZT2 were first reported in 2013 as a cause of early-onset epileptic encephalopathy.,1,1.3420841625566036,1634786.875252525,194.2568735483174,0.16322301221135815,0.061020346059022526,0.0,0.0,1.0025380710659897,395.0,-0.4793297399074093,0.2340037267878944,1.0,2.0,2.0,152.0,152.0,152.0,304.0,484,151.0,1.6935087808430286e-05,18209.0,395.0,1.0,0,184.0
4691,615463,HP:0001263,"This case suggested a broad phenotypic spectrum arises from SZT2 mutations, forming a continuum from epileptic encephalopathy and severe developmental delay to mild intellectual disability without epilepsy.",1,1.4399894886032891,12268196.265994346,677.6493958935587,0.13652844613521262,-0.0018670955561741684,0.0,0.0,1.0006056935190792,1652.0,-0.7079111395807132,0.0689859986536885,1.0,2.0,1.0,153.0,153.0,153.0,306.0,2998,152.0,4.4444444444444454e-07,94078.0,1652.0,1.0,0,185.0
4694,615463,HP:0001250,"This case suggested a broad phenotypic spectrum arises from SZT2 mutations, forming a continuum from epileptic encephalopathy and severe developmental delay to mild intellectual disability without epilepsy.",1,1.4415463236438413,12261533.543718144,671.9938182584863,0.13835170036148794,0.04032209062699803,0.0,0.0,1.0005875440658047,1703.0,-0.7010937148445229,0.0645698163122657,1.0,2.0,1.0,153.0,153.0,153.0,306.0,3100,152.0,4.15696534878394e-07,93578.0,1703.0,1.0,0,186.0
4692,615463,HP:0001250,"The characteristic thick and short corpus callosum observed in 7/8 cases with epilepsy, including the proband, but not in three non-syndromic cases, appears to be specific, and thus useful for indicating the possibility of SZT2 mutations.",1,1.4415463236438413,12261533.543718144,671.9938182584863,0.13835170036148794,0.04032209062699803,0.0,0.0,1.0005875440658047,1703.0,-0.7010937148445229,0.0645698163122657,1.0,2.0,1.0,153.0,153.0,153.0,306.0,3100,152.0,4.15696534878394e-07,93578.0,1703.0,1.0,0,186.0
4696,601385,HP:0002664,"In this study, we found that tumor suppressor candidate 3 (TUSC3) was downregulated in temozolomide-resistant U87MG cells (U87MG-res cells) and its restoration sensitized U87MG-res cells to temozolomide.",0,1.3934030064022638,1782156.391390605,231.19316821310986,0.18961237794826846,0.26891760340454457,0.0,0.0,0.9988584474885844,875.0,-0.6519693966467417,0.056955269885402185,1.0,2.0,47.0,105.0,105.0,105.0,210.0,1544,103.0,1.6778973932186097e-06,21878.0,877.0,1.0,0,118.0
4698,601385,HP:0002664,"Thus, our data indicate that miR-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting TUSC3 in glioblastoma",0,1.3934030064022638,1782156.391390605,231.19316821310986,0.18961237794826846,0.26891760340454457,0.0,0.0,0.9988584474885844,875.0,-0.6519693966467417,0.056955269885402185,1.0,2.0,47.0,105.0,105.0,105.0,210.0,1544,103.0,1.6778973932186097e-06,21878.0,877.0,1.0,0,118.0
3631,131530,HP:0002664,"Top 10 genes in the brown module, including EGF containing fibulin like extracellular matrix protein 2 (EFEMP2), fibrillin 1 (FBN1) and secreted protein acidic and cysteine rich (SPARC) were also associated with survival time of colon cancer patients.",0,1.4183540398436123,1210345.6075365078,294.30023120735353,0.1921133491501248,0.1846422582674654,0.0,0.0,0.9988109393579072,840.0,-0.7406795875192191,0.05465724832726565,1.0,2.0,38.0,69.0,69.0,70.0,138.0,1544,67.0,1.677897393218609e-06,19352.0,842.0,1.0,0,64.0
4702,604633,HP:0002664,"Top 10 genes in the brown module, including EGF containing fibulin like extracellular matrix protein 2 (EFEMP2), fibrillin 1 (FBN1) and secreted protein acidic and cysteine rich (SPARC) were also associated with survival time of colon cancer patients.",0,1.3651617815542396,7367342.701723278,282.5026611208014,0.14424937596567974,0.10912694474322768,0.0,0.0,0.999003984063745,1003.0,-0.6290676925897041,0.10114170184931914,1.0,2.0,14.0,224.0,224.0,167.0,448.0,1544,222.0,1.6778973932186097e-06,51027.0,1005.0,1.0,0,284.0
4708,134797,HP:0002664,"Top 10 genes in the brown module, including EGF containing fibulin like extracellular matrix protein 2 (EFEMP2), fibrillin 1 (FBN1) and secreted protein acidic and cysteine rich (SPARC) were also associated with survival time of colon cancer patients.",0,1.3175830576105678,13802330.6696414,239.41982453096733,0.14249244734076313,0.05695284521300251,0.0,0.0,0.9992857142857144,1399.0,-0.3535973925392786,0.08521362292240238,1.0,2.0,25.0,544.0,544.0,4.0,1088.0,1544,542.0,1.6778973932186097e-06,83569.0,1401.0,1.0,0,666.0
3570,182120,HP:0002664,"Top 10 genes in the brown module, including EGF containing fibulin like extracellular matrix protein 2 (EFEMP2), fibrillin 1 (FBN1) and secreted protein acidic and cysteine rich (SPARC) were also associated with survival time of colon cancer patients.",0,1.415274401115109,1303635.1872036636,316.6933144676335,0.19071001043307007,0.04223950800155951,0.0,0.0,0.9988066825775656,837.0,-0.7522995212911145,0.05680418500260283,1.0,2.0,44.0,66.0,66.0,65.0,132.0,1544,64.0,1.67789739321861e-06,19969.0,839.0,1.0,0,62.0
4700,604633,HP:0002664,"In conclusion, SERP2, EFEMP2, FBN1, SPARC, and LINC0219 were revealed to be the recurrence-associated molecular and prognostic indicators in colon cancer by WGCNA co-expression network analysis",0,1.3651617815542396,7367342.701723278,282.5026611208014,0.14424937596567974,0.10912694474322768,0.0,0.0,0.999003984063745,1003.0,-0.6290676925897041,0.10114170184931914,1.0,2.0,14.0,224.0,224.0,167.0,448.0,1544,222.0,1.6778973932186097e-06,51027.0,1005.0,1.0,0,284.0
4704,134797,HP:0002664,"In conclusion, SERP2, EFEMP2, FBN1, SPARC, and LINC0219 were revealed to be the recurrence-associated molecular and prognostic indicators in colon cancer by WGCNA co-expression network analysis",0,1.3175830576105678,13802330.6696414,239.41982453096733,0.14249244734076313,0.05695284521300251,0.0,0.0,0.9992857142857144,1399.0,-0.3535973925392786,0.08521362292240238,1.0,2.0,25.0,544.0,544.0,4.0,1088.0,1544,542.0,1.6778973932186097e-06,83569.0,1401.0,1.0,0,666.0
3567,182120,HP:0002664,"In conclusion, SERP2, EFEMP2, FBN1, SPARC, and LINC0219 were revealed to be the recurrence-associated molecular and prognostic indicators in colon cancer by WGCNA co-expression network analysis",0,1.415274401115109,1303635.1872036636,316.6933144676335,0.19071001043307007,0.04223950800155951,0.0,0.0,0.9988066825775656,837.0,-0.7522995212911145,0.05680418500260283,1.0,2.0,44.0,66.0,66.0,65.0,132.0,1544,64.0,1.67789739321861e-06,19969.0,839.0,1.0,0,62.0
4710,612452,HP:0002664,"The present study also identified in tumor and potentially malignant lesions common alterations of chromosomal regions and genes, including FBXL5, UGT2B15, UGT2B28, KANSL1, GSTT1 and DUSP22, being some of these typical aberrations described in oral cancer and others are linked to chemoradioresistance.",0,1.3420532313254572,12680868.262584638,264.1120420931018,0.14187658003348924,0.1404547027421042,0.0,0.0,1.0008025682182986,1247.0,-0.4031461376799857,0.10005264641560292,1.0,2.0,12.0,452.0,452.0,36.0,904.0,1542,451.0,1.67789739321861e-06,77729.0,1247.0,1.0,0,676.0
4712,611654,HP:0002860,"Several putative genes associated with hallmarks of malignancy that may have an important role in predicting the progression of leukoplakia and erythroleukoplakia to squamous cell carcinoma, namely gains in BNIPL, MCL1, STAG2, CSPP1 and ZNRF3 genes were also identified",0,1.3286139758179232,306041.83387112746,106.22101309369185,0.2588438659904284,0.3434234308333512,0.0,0.0,0.9981096408317579,528.0,-0.5238682956647959,0.043877732995684274,1.0,2.0,109.0,59.0,59.0,57.0,118.0,332,57.0,4.565709693914823e-06,6151.0,530.0,1.0,0,64.0
4719,614141,HP:0002664,"To understand the mechanism of TAM-resistance in GPER activated ER+ breast cancer, the function of TRIM2 and Bim inducing cell apoptosis was studied.",0,1.4014911554630831,729124.3928516299,215.17297488503715,0.23223237476113626,0.3909959757399533,0.0,0.0,0.9988066825775656,837.0,-0.6489822189198357,0.03924720018433128,1.0,2.0,71.0,67.0,67.0,66.0,134.0,1544,65.0,1.677897393218609e-06,13797.0,839.0,1.0,0,64.0
4716,614141,HP:0002664,"By using immunohistochemical and western blot analysis, there is an adverse correlation between TRIM2 and Bim in TAM-resistant breast tumor tissues and MCF-7R cells.",0,1.4014911554630831,729124.3928516299,215.17297488503715,0.23223237476113626,0.3909959757399533,0.0,0.0,0.9988066825775656,837.0,-0.6489822189198357,0.03924720018433128,1.0,2.0,71.0,67.0,67.0,66.0,134.0,1544,65.0,1.677897393218609e-06,13797.0,839.0,1.0,0,64.0
4713,614141,HP:0002664,"Activation of GPER and its downstream signaling MAPK/ERK, not PI3K/AKT, led to enhanced TRIM2 protein levels and affected the binding between TRIM2 and Bim which resulted in a reduced Bim in TAM-resistant breast cancer cells.",0,1.4014911554630831,729124.3928516299,215.17297488503715,0.23223237476113626,0.3909959757399533,0.0,0.0,0.9988066825775656,837.0,-0.6489822189198357,0.03924720018433128,1.0,2.0,71.0,67.0,67.0,66.0,134.0,1544,65.0,1.677897393218609e-06,13797.0,839.0,1.0,0,64.0
3838,600997,HP:0002664,"Activation of GPER and its downstream signaling MAPK/ERK, not PI3K/AKT, led to enhanced TRIM2 protein levels and affected the binding between TRIM2 and Bim which resulted in a reduced Bim in TAM-resistant breast cancer cells.",0,1.4690265087320626,357691.2300742182,297.28916465103237,0.2541462988734713,0.25144426459714403,0.0,0.0,1.0012391573729864,808.0,-0.7632440013769647,0.03219355392788348,1.0,2.0,7.0,35.0,35.0,35.0,70.0,1542,34.0,1.67789739321861e-06,10496.0,808.0,1.0,0,31.0
749,171834,HP:0002664,"Activation of GPER and its downstream signaling MAPK/ERK, not PI3K/AKT, led to enhanced TRIM2 protein levels and affected the binding between TRIM2 and Bim which resulted in a reduced Bim in TAM-resistant breast cancer cells.",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
2588,164730,HP:0002664,"Activation of GPER and its downstream signaling MAPK/ERK, not PI3K/AKT, led to enhanced TRIM2 protein levels and affected the binding between TRIM2 and Bim which resulted in a reduced Bim in TAM-resistant breast cancer cells.",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
4722,139320,HP:0000852,"Maternal loss-of-methylation at GNAS exon A/B, observed in pseudohypoparathyroidism type 1b (PHP1B), leads to decreased expression of the stimulatory Gsa.",1,1.4933649920113616,10689.496562065688,226.10894941634243,0.5298348016234911,0.4933346150682988,0.0,0.0,1.001926782273603,520.0,-0.6602645482594451,0.009937750111160515,1.0,2.0,158.0,6.0,6.0,6.0,12.0,1028,6.0,3.770383636535017e-06,1341.0,520.0,1.0,0,6.0
4723,611595,HP:0000453,"Subsequently, we tested a cohort of 19 individuals with (mild) features of BMKS and 17 individuals with isolated choanal atresia for causative variants in TXNL4A by dideoxy-sequence analysis.",1,1.3388862140908362,434304.47420634923,139.6397080291971,0.17977962636486086,0.097785145343672,0.0,0.0,1.0042372881355932,237.0,-0.2266151203986012,0.28863620110133736,1.0,2.0,2.0,100.0,100.0,100.0,200.0,200,100.0,5.250997689561016e-05,8072.0,237.0,1.0,0,137.0
4724,312610,HP:0000546,"Lastly, a syndromic form of PCD with retinal degeneration results in normal ciliary ultrastructure through mutations in the RPGR gene.",1,1.3367126680820949,1245373.0183621934,130.82076017750342,0.18552140307310927,0.1327746768102543,0.0,0.0,1.00199203187251,503.0,-0.30763204361982577,0.12812368814998454,1.0,2.0,37.0,188.0,188.0,2.0,376.0,438,187.0,1.2311480455524776e-05,16176.0,503.0,1.0,0,236.0
4725,117143,HP:0002664,"Notably, genetic deletion or pharmacological inhibition of CENPE significantly decreases tumor growth.",0,1.3589861751152077,5563170.921137048,289.34008988628483,0.15111264353529494,0.05890662845527349,0.0,0.0,0.9989406779661016,943.0,-0.6305605117537002,0.09270693211371177,1.0,2.0,57.0,173.0,173.0,173.0,346.0,1544,171.0,1.6778973932186097e-06,41351.0,945.0,1.0,0,200.0
4726,613009,HP:0002059,"In patients harboring SEPSECS mutations, severe, progressive, cerebello-cerebral atrophy (pontocerebellar hypoplasia type 2D) dominates the phenotype and it is not known whether the disorder is associated with thyroid dysfunction",1,1.3762795340009162,4418889.036956344,295.9529936355779,0.14502551236627634,0.06484975331427091,0.0,0.0,1.0013351134846462,750.0,-0.6413908705153573,0.14304227859368046,1.0,2.0,1.0,176.0,176.0,169.0,352.0,1144,175.0,3.045725476579893e-06,40177.0,750.0,1.0,0,215.0
4727,601570,HP:0000007,Al-Awadi-Raas-Rothschild syndrome (AARRS; OMIM 276820) is a very rare autosomal recessive limb malformation syndrome caused by WNT7A mutations.,1,1.431062075676819,13940836.918366175,354.2481484224559,0.17245229149025168,0.011881620062296748,0.0,0.0,1.00034566194262,2894.0,-0.4955571399736346,0.023688712190686908,1.0,2.0,54.0,304.0,304.0,148.0,608.0,5160,303.0,1.5011496554636367e-07,99165.0,2894.0,1.0,0,345.0
4728,606268,HP:0000668,"Whole exome sequencing of the patient and his parents ruled out mutations in 11 known hypodontia-associated genes including WNT10A, MSX1, EDA, EDAR, EDARADD, PAX9, AXIN2, GREM2, NEMO, KRT17, and TFAP2B.",1,1.3348176877588642,475121.7313492064,104.40999786370436,0.20552763274545965,0.24174154822899416,0.0,0.0,1.00327868852459,306.0,-0.4356044545767129,0.17113468338154933,1.0,2.0,12.0,121.0,121.0,20.0,242.0,310,120.0,4.10913872452334e-05,7986.0,306.0,1.0,0,146.0
4729,142983,HP:0000668,"Whole exome sequencing of the patient and his parents ruled out mutations in 11 known hypodontia-associated genes including WNT10A, MSX1, EDA, EDAR, EDARADD, PAX9, AXIN2, GREM2, NEMO, KRT17, and TFAP2B.",1,1.3369950591619086,679932.7077922077,118.15774193548387,0.200271513368375,0.06849116155985087,0.0,0.0,1.0028248587570625,355.0,-0.3404668786959711,0.16420784594573087,1.0,2.0,5.0,146.0,146.0,5.0,292.0,310,145.0,2.475186257765897e-05,10318.0,355.0,1.0,0,181.0
4730,300451,HP:0000668,"Whole exome sequencing of the patient and his parents ruled out mutations in 11 known hypodontia-associated genes including WNT10A, MSX1, EDA, EDAR, EDARADD, PAX9, AXIN2, GREM2, NEMO, KRT17, and TFAP2B.",1,1.337655177137378,639429.1738095238,112.73504752999844,0.2032991557164618,0.02516614798438168,0.0,0.0,1.002770083102493,362.0,-0.3205697096006208,0.1529208307188442,1.0,2.0,7.0,141.0,141.0,2.0,282.0,310,140.0,2.3113905325443783e-05,9992.0,362.0,1.0,0,159.0
4731,604025,HP:0000668,"Whole exome sequencing of the patient and his parents ruled out mutations in 11 known hypodontia-associated genes including WNT10A, MSX1, EDA, EDAR, EDARADD, PAX9, AXIN2, GREM2, NEMO, KRT17, and TFAP2B.",0,1.3255381152980554,250896.68665413532,88.02222222222224,0.21926707965517067,0.05557996097231233,0.0,0.0,0.9959349593495936,245.0,-0.6220973691354303,0.16928343372502552,1.0,2.0,3.0,70.0,70.0,44.0,140.0,336,68.0,4.056959714390036e-05,5143.0,247.0,1.0,0,69.0
4732,608832,HP:0000668,"Whole exome sequencing of the patient and his parents ruled out mutations in 11 known hypodontia-associated genes including WNT10A, MSX1, EDA, EDAR, EDARADD, PAX9, AXIN2, GREM2, NEMO, KRT17, and TFAP2B.",0,1.4299665551839464,9184.52688172043,136.40806451612906,0.2712437823775249,0.2326950728885616,0.0,0.0,0.994047619047619,167.0,-0.9658908239693668,0.11721611721611724,1.0,2.0,1.0,13.0,13.0,13.0,26.0,312,11.0,4.056959714390036e-05,1664.0,169.0,1.0,0,12.0
4733,148069,HP:0000668,"Whole exome sequencing of the patient and his parents ruled out mutations in 11 known hypodontia-associated genes including WNT10A, MSX1, EDA, EDAR, EDARADD, PAX9, AXIN2, GREM2, NEMO, KRT17, and TFAP2B.",0,1.2932140193885158,410961.8464285713,94.53009147809341,0.21225199182021387,0.06034723045711661,0.0,0.0,0.9965517241379308,289.0,-0.4909408397410692,0.16445076430856734,1.0,2.0,12.0,102.0,102.0,19.0,204.0,312,100.0,4.056959714390037e-05,6939.0,291.0,1.0,0,117.0
4734,601601,HP:0000668,"Whole exome sequencing of the patient and his parents ruled out mutations in 11 known hypodontia-associated genes including WNT10A, MSX1, EDA, EDAR, EDARADD, PAX9, AXIN2, GREM2, NEMO, KRT17, and TFAP2B.",0,1.3168130398115565,779092.4591269841,123.68875234681688,0.1923358981570817,0.02572875263729547,0.0,0.0,0.9971014492753624,344.0,-0.35938963777388044,0.17939180698668006,1.0,2.0,6.0,142.0,142.0,9.0,284.0,312,140.0,2.770083102493076e-05,10707.0,346.0,1.0,0,164.0
4735,601570,HP:0000691,"All lines of evidence suggest that WNT7A has important role in tooth development and its mutation may lead to tooth agenesis, microdontia, and taurodontism.",0,1.3415458328079688,566063.319103119,113.77279161037123,0.21848294888692885,0.07226785160751087,0.0,0.0,0.9975845410628018,413.0,-0.5156633441028341,0.10274140038414528,1.0,2.0,20.0,99.0,99.0,100.0,198.0,238,97.0,1.0078105316200557e-05,8826.0,415.0,1.0,0,123.0
4736,600921,HP:0002664,"In the present study, with the aim of reducing the cost of utilizing growth factors in cancer research, a simple and efficient method for the preparation of recombinant human (rh)FGF9 in Escherichia coli was established.",0,1.3964936966618622,2228585.49256054,220.6136712008661,0.18357467886890194,0.01551698442643496,0.0,0.0,0.9988801791713324,892.0,-0.6414317901679131,0.059513341400051614,1.0,2.0,26.0,117.0,117.0,103.0,234.0,1544,115.0,1.6778973932186097e-06,23756.0,894.0,1.0,0,141.0
4737,600921,HP:0001402,"The FGF9 subfamily, including FGF9, FGF16, and FGF20, in addition to rhFGF16, rhFGF9, and rhFGF20, were shown to stimulate the proliferation and migration of HuH7 human hepatocellular carcinoma (HCC) cells.",0,1.269402985074627,32128.57128851541,32.40972663699937,0.3614016300290117,-0.050984661528819065,0.0,0.0,0.9942528735632185,173.0,-0.5018538316241118,0.08400656814449918,1.0,2.0,21.0,36.0,36.0,11.0,72.0,136,34.0,6.718624025799517e-05,1279.0,175.0,1.0,0,39.0
3066,191305,HP:0002664,"Two pairwise genetic interactions (B cell lymphocyte kinase (BLK) rs13277113,B cell scaffold protein with ankyrin repeats 1 (BANK1) rs3733197and BLK rs13277113 membrane metalloendopeptidase like 1 (MMEL1)/ tumor necrosis factor receptor superfamily member 14 (TNFRSF14) rs3890745) have been demonstrated in determining susceptibility to rheumatoid arthritis (RA) without replication, thus this study was performed to examine whether abovementioned genetic polymorphisms were associated with RA and further tests were performed to see whether aforementioned genetic interactions existed in RA among Chinese population.",0,1.4420816267294485,684319.2824718312,201.7761109973377,0.2441303163906248,-0.0006912478643396683,0.0,0.0,1.0011820330969263,847.0,-0.6504631938990005,0.03896103896103896,1.0,2.0,6.0,71.0,71.0,76.0,142.0,1542,70.0,1.6778973932186097e-06,13959.0,847.0,1.0,0,67.0
4738,602216,HP:0002664,"Hence, we focus on the relationship between YAP/TAZ and serine metabolism to control methylation of DNA or histone in breast cancer with LKB1 deficiency.",1,1.3836372370027596,3743522.1131678782,219.43274478134254,0.17554086748257744,0.01914704282253193,0.0,0.0,1.0010183299389002,983.0,-0.5912721117339543,0.07559675377548672,1.0,2.0,8.0,201.0,201.0,98.0,402.0,1542,200.0,1.6778973932186103e-06,36487.0,983.0,1.0,0,207.0
4273,607860,HP:0002664,"Hence, we focus on the relationship between YAP/TAZ and serine metabolism to control methylation of DNA or histone in breast cancer with LKB1 deficiency.",0,1.4068527212636974,1358223.7785376424,256.74811932555116,0.20044559056675704,0.1205930995449105,0.0,0.0,0.9988262910798122,851.0,-0.6786890735043399,0.05315401592831707,1.0,2.0,44.0,79.0,79.0,77.0,158.0,1544,77.0,1.6778973932186103e-06,19315.0,853.0,1.0,0,86.0
4740,602216,HP:0002664,We hope that our study will stimulate further studies and a new targeted therapy and early medical intervention for YAP/TAZ could be a useful option for breast cancer cases complicated with LKB1 deficiency,1,1.3836372370027596,3743522.1131678782,219.43274478134254,0.17554086748257744,0.01914704282253193,0.0,0.0,1.0010183299389002,983.0,-0.5912721117339543,0.07559675377548672,1.0,2.0,8.0,201.0,201.0,98.0,402.0,1542,200.0,1.6778973932186103e-06,36487.0,983.0,1.0,0,207.0
4291,607860,HP:0002664,We hope that our study will stimulate further studies and a new targeted therapy and early medical intervention for YAP/TAZ could be a useful option for breast cancer cases complicated with LKB1 deficiency,0,1.4068527212636974,1358223.7785376424,256.74811932555116,0.20044559056675704,0.1205930995449105,0.0,0.0,0.9988262910798122,851.0,-0.6786890735043399,0.05315401592831707,1.0,2.0,44.0,79.0,79.0,77.0,158.0,1544,77.0,1.6778973932186103e-06,19315.0,853.0,1.0,0,86.0
4742,300415,HP:0009830,Loss-of-function mutations in MTM1 cause the severe congenital myopathy called myotubular myopathy (or X-linked centronuclear myopathy) while mutations in the MTM1-related protein MTMR2 cause a recessive Charcot-Marie-Tooth peripheral neuropathy.,0,1.3591989987484356,2884272.4453089307,206.1546654389196,0.17419384641860933,0.0842651860752893,0.0,0.0,0.9986187845303868,723.0,-0.5835765282489116,0.10791388835968756,1.0,2.0,6.0,175.0,175.0,106.0,350.0,1088,173.0,3.36671997306624e-06,28322.0,725.0,1.0,0,218.0
4748,300415,HP:0003198,Loss-of-function mutations in MTM1 cause the severe congenital myopathy called myotubular myopathy (or X-linked centronuclear myopathy) while mutations in the MTM1-related protein MTMR2 cause a recessive Charcot-Marie-Tooth peripheral neuropathy.,0,1.319378639901772,1334636.8825396828,142.92583979328163,0.1837555122458715,0.15172179746965972,0.0,0.0,0.9977220956719816,438.0,-0.4405415575588044,0.1592462207496376,1.0,2.0,7.0,168.0,168.0,35.0,336.0,518,166.0,1.4792899408284024e-05,15380.0,440.0,1.0,0,199.0
4754,603557,HP:0003198,Loss-of-function mutations in MTM1 cause the severe congenital myopathy called myotubular myopathy (or X-linked centronuclear myopathy) while mutations in the MTM1-related protein MTMR2 cause a recessive Charcot-Marie-Tooth peripheral neuropathy.,0,1.3776884991305658,369746.8967421468,130.83220805201302,0.21449733542842625,0.050682022195700886,0.0,0.0,0.9968847352024922,320.0,-0.7146633370602486,0.13080242255374314,1.0,2.0,2.0,60.0,60.0,60.0,120.0,518,58.0,1.4792899408284024e-05,6760.0,322.0,1.0,0,57.0
4750,300415,HP:0003198,"Moreover, adeno-associated virus-mediated exogenous expression of several MTMR2 isoforms ameliorates the myopathic phenotype owing to MTM1 loss, with increased muscle force, reduced myofiber atrophy, and reduction of the intracellular disorganization hallmarks associated with myotubular myopathy.",0,1.319378639901772,1334636.8825396828,142.92583979328163,0.1837555122458715,0.15172179746965972,0.0,0.0,0.9977220956719816,438.0,-0.4405415575588044,0.1592462207496376,1.0,2.0,7.0,168.0,168.0,35.0,336.0,518,166.0,1.4792899408284024e-05,15380.0,440.0,1.0,0,199.0
4744,300415,HP:0009830,"They also provide the proof-of-concept that expression of the neuropathy-associated MTMR2 gene improves the MTM1-associated myopathy, thus identifying MTMR2 as a novel therapeutic target for myotubular myopathy",0,1.3591989987484356,2884272.4453089307,206.1546654389196,0.17419384641860933,0.0842651860752893,0.0,0.0,0.9986187845303868,723.0,-0.5835765282489116,0.10791388835968756,1.0,2.0,6.0,175.0,175.0,106.0,350.0,1088,173.0,3.36671997306624e-06,28322.0,725.0,1.0,0,218.0
4747,603557,HP:0009830,"They also provide the proof-of-concept that expression of the neuropathy-associated MTMR2 gene improves the MTM1-associated myopathy, thus identifying MTMR2 as a novel therapeutic target for myotubular myopathy",1,1.4353212875119736,793150.1998774898,242.2623715321096,0.2129646664455065,0.03833510417738703,0.0,0.0,1.0016556291390728,605.0,-0.6825061165330162,0.0737835914837721,1.0,2.0,2.0,61.0,61.0,61.0,122.0,1086,60.0,3.3791089965397925e-06,13481.0,605.0,1.0,0,61.0
4752,300415,HP:0003198,"They also provide the proof-of-concept that expression of the neuropathy-associated MTMR2 gene improves the MTM1-associated myopathy, thus identifying MTMR2 as a novel therapeutic target for myotubular myopathy",0,1.319378639901772,1334636.8825396828,142.92583979328163,0.1837555122458715,0.15172179746965972,0.0,0.0,0.9977220956719816,438.0,-0.4405415575588044,0.1592462207496376,1.0,2.0,7.0,168.0,168.0,35.0,336.0,518,166.0,1.4792899408284024e-05,15380.0,440.0,1.0,0,199.0
4760,603557,HP:0003198,"They also provide the proof-of-concept that expression of the neuropathy-associated MTMR2 gene improves the MTM1-associated myopathy, thus identifying MTMR2 as a novel therapeutic target for myotubular myopathy",0,1.3776884991305658,369746.8967421468,130.83220805201302,0.21449733542842625,0.050682022195700886,0.0,0.0,0.9968847352024922,320.0,-0.7146633370602486,0.13080242255374314,1.0,2.0,2.0,60.0,60.0,60.0,120.0,518,58.0,1.4792899408284024e-05,6760.0,322.0,1.0,0,57.0
223,613900,HP:0001251,"Spinocerebellar ataxia type 35 (SCA35) is a rare autosomal-dominant neurodegenerative disease caused by mutations in the TGM6 gene, which codes for transglutaminase 6 (TG6).",1,1.4438772681720289,1795769.4004353052,386.6604367342375,0.1776976367762186,-0.01800110934048061,0.0,0.0,1.001124859392576,890.0,-0.7437085751561233,0.06874786719075845,1.0,2.0,1.0,77.0,77.0,77.0,154.0,1626,76.0,1.5092152684290275e-06,27197.0,890.0,1.0,0,77.0
4763,613900,HP:0002180,"Spinocerebellar ataxia type 35 (SCA35) is a rare autosomal-dominant neurodegenerative disease caused by mutations in the TGM6 gene, which codes for transglutaminase 6 (TG6).",0,1.313419681177192,102985.76666666666,72.79112554112555,0.2431939213980707,-0.09035946557396103,0.0,0.0,0.9933333333333334,149.0,-0.3099948232099301,0.2457395143487859,1.0,2.0,2.0,66.0,66.0,6.0,132.0,146,64.0,0.0001643655489809336,2783.0,151.0,1.0,0,85.0
4764,610538,HP:0002664,"High UBE2T expression was correlated with higher pathological grade, advanced TNM stage, tumor vascular invasion, and poor overall and disease-free survivals in two independent cohorts containing 827 patients with HCC.",1,1.3533679427936751,12284034.08789544,296.59949409176573,0.14055952578562353,0.0498889284784796,0.0,0.0,1.0008833922261484,1133.0,-0.4663234898167876,0.11393498607468212,1.0,2.0,5.0,362.0,362.0,106.0,724.0,1542,361.0,1.677897393218609e-06,73064.0,1133.0,1.0,0,478.0
4765,605654,HP:0003128,"Biallelic pathogenic variants in FBXL4 are associated with an encephalopathic mtDNA maintenance defect syndrome that is a multisystem disease characterized by lactic acidemia, developmental delay, and hypotonia.",1,1.3378549695740365,611391.7404761905,108.92350264837702,0.2051906922588108,0.1222440062191406,0.0,0.0,1.0028901734104043,347.0,-0.271888205876777,0.15400376472156052,1.0,2.0,17.0,145.0,145.0,2.0,290.0,296,144.0,2.5e-05,9245.0,347.0,1.0,0,168.0
4767,606718,HP:0000365,"A plethora of human diseases are associated with mutations in the genes encoding human SLC26 transporters, including chondrodysplasias with varying severity in SLC26A2 (~50 mutations, 27 point mutations), congenital chloride-losing diarrhea in SLC26A3 (~70 mutations, 31 point mutations) and Pendred Syndrome or deafness autosomal recessive type 4 in SLC26A4 (~500 mutations, 203 point mutations).",1,1.369857374003121,17516331.448788933,312.7328175466164,0.1376757687964383,0.08526575217514612,0.0,0.0,1.0006016847172083,1663.0,-0.5316644559838255,0.07170793796894684,1.0,2.0,12.0,394.0,394.0,116.0,788.0,2474,393.0,6.524672396198986e-07,99097.0,1663.0,1.0,0,541.0
1011,605646,HP:0000365,"A plethora of human diseases are associated with mutations in the genes encoding human SLC26 transporters, including chondrodysplasias with varying severity in SLC26A2 (~50 mutations, 27 point mutations), congenital chloride-losing diarrhea in SLC26A3 (~70 mutations, 31 point mutations) and Pendred Syndrome or deafness autosomal recessive type 4 in SLC26A4 (~500 mutations, 203 point mutations).",1,1.4413226495142712,4479611.427125419,456.96235976102685,0.15949329773347126,0.021256166761706764,0.0,0.0,1.0007358351729212,1360.0,-0.7348599879376381,0.0553207375665498,1.0,2.0,1.0,121.0,121.0,109.0,242.0,2474,120.0,6.524672396198984e-07,51123.0,1360.0,1.0,0,110.0
4768,606718,HP:0000007,"A plethora of human diseases are associated with mutations in the genes encoding human SLC26 transporters, including chondrodysplasias with varying severity in SLC26A2 (~50 mutations, 27 point mutations), congenital chloride-losing diarrhea in SLC26A3 (~70 mutations, 31 point mutations) and Pendred Syndrome or deafness autosomal recessive type 4 in SLC26A4 (~500 mutations, 203 point mutations).",1,1.4142379936010427,20910022.66949551,360.7375040943335,0.16010408598083806,0.059383357648300675,0.0,0.0,1.000332778702163,3006.0,-0.5119606746779461,0.029203047039586937,1.0,2.0,21.0,400.0,400.0,137.0,800.0,5160,399.0,1.5011496554636372e-07,131896.0,3006.0,1.0,0,483.0
4769,126650,HP:0000007,"A plethora of human diseases are associated with mutations in the genes encoding human SLC26 transporters, including chondrodysplasias with varying severity in SLC26A2 (~50 mutations, 27 point mutations), congenital chloride-losing diarrhea in SLC26A3 (~70 mutations, 31 point mutations) and Pendred Syndrome or deafness autosomal recessive type 4 in SLC26A4 (~500 mutations, 203 point mutations).",1,1.4889054719892634,613811.8683680912,460.372282094914,0.3312263099136479,0.5888459872073947,0.0,0.0,1.000381679389313,2621.0,-0.5919547152591825,0.0054113720361961964,1.0,2.0,369.0,41.0,41.0,41.0,82.0,5160,40.0,1.5011496554636367e-07,18580.0,2621.0,1.0,0,41.0
4770,605646,HP:0000007,"A plethora of human diseases are associated with mutations in the genes encoding human SLC26 transporters, including chondrodysplasias with varying severity in SLC26A2 (~50 mutations, 27 point mutations), congenital chloride-losing diarrhea in SLC26A3 (~70 mutations, 31 point mutations) and Pendred Syndrome or deafness autosomal recessive type 4 in SLC26A4 (~500 mutations, 203 point mutations).",1,1.4684443885370235,6020589.913300757,638.4425694838344,0.18280579533481287,0.2699026504527459,0.0,0.0,1.0003700962250186,2703.0,-0.6842496764208129,0.020525758450804312,1.0,2.0,49.0,119.0,119.0,106.0,238.0,5160,118.0,1.5011496554636367e-07,74955.0,2703.0,1.0,0,103.0
4771,138420,HP:0000007,Biallelic mutations in the GPD1 gene cause a rare autosomal recessive inherited disease known as transient infantile hypertriglyceridemia (OMIM #614480).,1,1.4905300418934857,728273.5801457951,628.6135658914733,0.3216430313750411,0.29865391138743586,0.0,0.0,1.0003825554705432,2615.0,-0.5640504427737434,0.006351152274632403,1.0,2.0,265.0,35.0,35.0,35.0,70.0,5160,34.0,1.5011496554636372e-07,21707.0,2615.0,1.0,0,34.0
4772,138420,HP:0002155,Biallelic mutations in the GPD1 gene cause a rare autosomal recessive inherited disease known as transient infantile hypertriglyceridemia (OMIM #614480).,1,1.3547792577699589,34539.80833333333,58.28571428571429,0.2982586841817386,-0.022444400996608646,0.0,0.0,1.0096153846153846,105.0,-0.5850189524907271,0.2490842490842491,1.0,2.0,1.0,35.0,35.0,35.0,70.0,140,34.0,0.00019837333862328903,1360.0,105.0,1.0,0,38.0
4774,133450,HP:0002664,"Many cancer-causing chromosomal translocations result in transactivating protein products encoding FET family (FUS, EWSR1, TAF15) low-complexity (LC) domains fused to a DNA binding domain from one of several transcription factors.",1,1.4396536831054232,1334322.9039242258,271.37352464332037,0.2130728545259895,0.16708468099249316,0.0,0.0,1.0011764705882351,851.0,-0.6715795903248075,0.05438307873090482,1.0,2.0,2.0,80.0,80.0,79.0,160.0,1542,79.0,1.6778973932186103e-06,19669.0,851.0,1.0,0,77.0
4775,601574,HP:0002664,"Many cancer-causing chromosomal translocations result in transactivating protein products encoding FET family (FUS, EWSR1, TAF15) low-complexity (LC) domains fused to a DNA binding domain from one of several transcription factors.",1,1.44331699591497,816161.7180132085,232.5253268833036,0.2184100507469547,0.17583647488397214,0.0,0.0,1.0011848341232228,845.0,-0.6942800669335061,0.04402815558484534,1.0,2.0,1.0,74.0,74.0,55.0,148.0,1542,73.0,1.67789739321861e-06,15700.0,845.0,1.0,0,58.0
4776,609739,HP:0001425,The present study reports a first ILDR1 gene mutation in the UAE population and confirms that the whole-exome sequencing approach is a robust tool for the diagnosis of monogenic diseases with high levels of allelic and locus heterogeneity.,0,1.3630750017345452,27390.172862755524,81.1928137651822,0.38009253963042666,0.28727515201317066,0.0,0.0,0.9962121212121212,263.0,-0.6354675680789831,0.04153802172670097,1.0,2.0,49.0,17.0,17.0,17.0,34.0,496,15.0,1.625910509885536e-05,1453.0,265.0,1.0,0,16.0
4777,300298,HP:0000717,"In humans, mutations in the NMD factor gene, UPF3B, cause intellectual disability (ID) and are strongly associated with autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and schizophrenia (SCZ).",0,1.3439954086756898,1448976.285317461,164.7151886565729,0.17479046403862994,0.147853405416893,0.0,0.0,0.9976851851851852,431.0,-0.4653176137970116,0.17256864254554785,1.0,2.0,1.0,147.0,147.0,147.0,294.0,294,146.0,1.2225536701061176e-05,16140.0,433.0,1.0,0,159.0
4779,606821,HP:0001251,"We reported a milder form of COG5 defect showing Friedreich*s-ataxia-like phenotypes without hypotonia, microcephaly, and short stature that were observed in most patients with COG5 defect",1,1.3845929763781166,8303170.175048483,336.5884322934138,0.1468447137468626,0.037891921151980056,0.0,0.0,1.000968992248062,1033.0,-0.6031753643275748,0.10933571969952798,1.0,2.0,1.0,220.0,220.0,220.0,440.0,1626,219.0,1.5092152684290275e-06,58279.0,1033.0,1.0,0,289.0
4780,606821,HP:0000252,"We reported a milder form of COG5 defect showing Friedreich*s-ataxia-like phenotypes without hypotonia, microcephaly, and short stature that were observed in most patients with COG5 defect",0,1.3992828067685703,12755632.373696364,487.2618498635924,0.12870987780973878,0.12040691796895027,0.0,0.0,1.0007987220447283,1253.0,-0.6391971850701776,0.1126701666798406,1.0,2.0,1.0,220.0,220.0,220.0,440.0,2066,219.0,9.353172034763868e-07,88376.0,1253.0,1.0,0,238.0
4782,300647,HP:0009726,"WTX/AMER1 is an important developmental regulator, mutations in which have been identified in a proportion of patients suffering from the renal neoplasm Wilms* tumor and in the bone malformation syndrome Osteopathia Striata with Cranial Sclerosis (OSCS).",0,1.342668652734904,744148.5396103897,112.1592668946098,0.22025187753640035,0.10143590896018598,0.0,0.0,0.9978540772532188,465.0,-0.537384222531239,0.09087316539688084,1.0,2.0,21.0,110.0,110.0,100.0,220.0,228,108.0,8.025102520684701e-06,9888.0,467.0,1.0,0,120.0
4783,300647,HP:0002664,"WTX/AMER1 is an important developmental regulator, mutations in which have been identified in a proportion of patients suffering from the renal neoplasm Wilms* tumor and in the bone malformation syndrome Osteopathia Striata with Cranial Sclerosis (OSCS).",0,1.3329372325111826,9540409.514716683,250.0810746079472,0.1450232523098349,0.15688929577964333,0.0,0.0,0.9991103202846976,1123.0,-0.4839457120542207,0.09660102807433768,1.0,2.0,31.0,343.0,343.0,94.0,686.0,1544,341.0,1.6778973932186097e-06,61076.0,1125.0,1.0,0,509.0
4784,164860,HP:0002664,The epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) contribute to cancer metastasis of pancreatic ductal adenocarcinoma (PDAC).,1,1.431585086504261,1395307.3315894369,252.0738471727792,0.21043289148276306,0.046553713640460535,0.0,0.0,1.0011574074074074,865.0,-0.6691759975089889,0.0565189466923571,1.0,2.0,2.0,92.0,92.0,77.0,184.0,1542,91.0,1.67789739321861e-06,21120.0,865.0,1.0,0,78.0
2798,601265,HP:0002664,"HCRP1 downregulation was found in 57 of 137 human gastric cancer samples and correlated with advanced TNM stage, positive nodal status, and relapse.",0,1.3553009486897671,9484963.803224552,261.67887651504986,0.14785788912735248,0.11244989016609358,0.0,0.0,1.0008944543828264,1119.0,-0.5053553039056776,0.10030678426463699,1.0,2.0,5.0,334.0,334.0,103.0,668.0,1542,333.0,1.67789739321861e-06,62744.0,1119.0,1.0,0,470.0
4787,612298,HP:0002664,"However, the role of TRIM44 in thyroid cancer has never been revealed.",0,1.4055533423631583,183392.3529666959,170.6911883916991,0.3270433832093521,0.39812445953029263,0.0,0.0,0.9987562189054726,803.0,-0.5656296214179399,0.018497574240598245,1.0,2.0,109.0,33.0,33.0,33.0,66.0,1544,31.0,1.677897393218609e-06,5986.0,805.0,1.0,0,30.0
4785,612298,HP:0002664,"Furthermore, silencing of TRIM44 dramatically down-regulated the expression of b-catenin, cyclin-D1 and c-Myc in PEC cells, and the activator of the Wnt/b-catenin pathway LiCl rescued the anticancer effect of knockdown TRIM44 expression in PTC cells.",0,1.4055533423631583,183392.3529666959,170.6911883916991,0.3270433832093521,0.39812445953029263,0.0,0.0,0.9987562189054726,803.0,-0.5656296214179399,0.018497574240598245,1.0,2.0,109.0,33.0,33.0,33.0,66.0,1544,31.0,1.677897393218609e-06,5986.0,805.0,1.0,0,30.0
4789,600960,HP:0001427,"Through gene set enrichment analysis and bi-clustering, we also found that most of the differential expressed lncRNAs were closely associated with mitochondrial functions (e.g. mitochondrion organization, P=3.21x10-17; mitochondrial ATP synthesis coupled electron transport, P=1.73x10-19 and mitochondrial membrane organization, P=4.04x10-8).",0,1.300944439717519,3977.876190476191,47.73471400394477,0.5458589460085349,0.09732622107121514,0.0,0.0,0.9943181818181818,175.0,-0.5689610893337829,0.02824858757062147,1.0,2.0,82.0,7.0,7.0,7.0,14.0,194,6.0,3.460207612456747e-05,440.0,177.0,1.0,0,7.0
4790,311850,HP:0000365,"Missense variants in PRPS1 are usually associated with disease in male patients, including Arts syndrome, Charcot-Marie-Tooth, and nonsyndromic sensorineural deafness.",1,1.3858356355432848,14253538.581189293,364.9716117963209,0.1396306952461338,0.015719786637472363,0.0,0.0,1.000639795265515,1564.0,-0.5813672103522273,0.07722787020174005,1.0,2.0,13.0,310.0,310.0,172.0,620.0,2474,309.0,6.52467239619899e-07,94393.0,1564.0,1.0,0,369.0
4791,311850,HP:0000546,Our data highlight the unexpected X-linked inheritance of retinal degeneration in females caused by variants in PRPS1 and suggest that tissue-specific skewed X-inactivation or variable levels of pyrophosphate synthetase-1 deficiency are the underlying mechanism(s).,0,1.2966412927350428,1446698.0950216446,134.3428427799422,0.18303057894359887,0.16182403814678467,0.0,0.0,0.9981718464351006,546.0,-0.2630022462163275,0.11945715848890433,1.0,2.0,30.0,210.0,210.0,7.0,420.0,440,208.0,9.295062462819747e-06,17904.0,548.0,1.0,0,219.0
4792,600322,HP:0002664,Samples analyzed were 10 pairs of snap-frozen surgical specimens of cancerous and non-cancerous thymic tissue.,0,1.3552956056051821,4641744.3530955985,222.34089833725776,0.1628095864075481,0.028893508320577733,0.0,0.0,0.9990049751243779,1004.0,-0.5888706987913346,0.07997586619585967,1.0,2.0,20.0,221.0,221.0,112.0,442.0,1544,219.0,1.67789739321861e-06,40429.0,1006.0,1.0,0,251.0
4793,601893,HP:0000252,We performed trio-based whole exome sequencing in seven subjects from five non-consanguineous families who presented with either microcephaly or microlissencephaly.,1,1.3866121000983442,13637010.8811576,411.9415976479869,0.13097742014462682,0.0822021187594225,0.0,0.0,1.000768049155146,1303.0,-0.5935079089459832,0.10395129754919816,1.0,2.0,3.0,262.0,262.0,221.0,524.0,2066,261.0,9.35317203476387e-07,88177.0,1303.0,1.0,0,328.0
4794,601893,HP:0001339,We performed trio-based whole exome sequencing in seven subjects from five non-consanguineous families who presented with either microcephaly or microlissencephaly.,0,1.3235406827029863,927358.963471178,126.00888888888888,0.18970329779057374,0.08840801439205223,0.0,0.0,0.997624703087886,420.0,-0.31694500757550137,0.13934324728979747,1.0,2.0,11.0,150.0,150.0,5.0,300.0,302,148.0,1.3616372326084888e-05,12378.0,422.0,1.0,0,168.0
4795,614218,HP:0001251,"This led to the identification of compound heterozygous mutations in WDR81, a gene previously associated with cerebellar ataxia, intellectual disability and quadrupedal locomotion.",1,1.4069713019589312,5131724.72030625,353.06384005016525,0.15376160560361934,0.012848779149897849,0.0,0.0,1.0010362694300516,966.0,-0.6716947128698669,0.09754020103197844,1.0,2.0,4.0,150.0,150.0,149.0,300.0,1626,149.0,1.5092152684290281e-06,45463.0,966.0,1.0,0,165.0
4796,614218,HP:0001249,"This led to the identification of compound heterozygous mutations in WDR81, a gene previously associated with cerebellar ataxia, intellectual disability and quadrupedal locomotion.",1,1.44305362468196,10623633.710080624,634.9493280458249,0.14366910285443074,0.03963218258078741,0.0,0.0,1.0005701254275945,1755.0,-0.6892314047924837,0.05761547882414472,1.0,2.0,4.0,150.0,150.0,148.0,300.0,3204,149.0,3.891642658474503e-07,88678.0,1755.0,1.0,0,151.0
4797,614218,HP:0000252,"In summary, we highlight the broad phenotypic spectrum of WDR81-related brain malformations, which include microcephaly with moderate to extremely reduced gyration and cerebellar anomalies.",0,1.4134626796012937,7225178.938741276,484.76996374542085,0.1383808741831787,0.08457179838341275,0.0,0.0,0.9991575400168492,1186.0,-0.6864190775561015,0.09292730733337304,1.0,2.0,4.0,151.0,151.0,149.0,302.0,2068,149.0,9.335107003664024e-07,65521.0,1188.0,1.0,0,160.0
4798,603850,HP:0000648,"Using exome sequencing, we identified dominant mutations in DNM1L on chromosome 12p11.21 in three large families with isolated optic atrophy, including the two families that defined the OPA5 locus on chromosome 19q12.1-13.1, the existence of which is denied by the present study.",1,1.3501225861894652,5116158.792726719,251.6343758822976,0.1488285445856126,0.03227482718623953,0.0,0.0,1.0013245033112583,756.0,-0.5454175656884594,0.1487122884473878,1.0,2.0,3.0,250.0,250.0,129.0,500.0,1004,249.0,3.952428569734674e-06,42441.0,756.0,1.0,0,347.0
4799,604392,HP:0000007,"Biallelic mutations in the photoreceptor-expressed aryl hydrocarbon receptor interacting protein-like 1 (AIPL1) are associated with autosomal recessive Leber congenital amaurosis (LCA), the most severe form of inherited retinopathy in early childhood.",1,1.4738721701046722,5460613.793207027,667.9640310077517,0.1860272878225228,0.4178350553804439,0.0,0.0,1.000373273609556,2680.0,-0.6782847082035641,0.017912676260355555,1.0,2.0,138.0,100.0,100.0,100.0,200.0,5160,99.0,1.5011496554636367e-07,64304.0,2680.0,1.0,0,99.0
4800,600960,HP:0001263,"Patients also present a variable set of poorly explained additional clinical features, including ichthyosis, impaired intelligence, developmental delay and anemia.",0,1.4351451287282997,12347673.01712744,607.0434648740186,0.1381842278748342,0.0382077545040978,0.0,0.0,1.000599880023995,1668.0,-0.6889424267728385,0.06631479459503782,1.0,2.0,1.0,169.0,169.0,169.0,338.0,2998,168.0,4.4444444444444454e-07,92196.0,1668.0,1.0,0,185.0
4801,614068,HP:0000546,Our studies identified a novel homozygous mutation in the ciliary protein IFT43 as the underlying cause of recessive inherited retinal degeneration.,0,1.3231890252078309,790833.0263077567,98.29038783885322,0.2133319223951179,0.2626833477640333,0.0,0.0,0.99781181619256,456.0,-0.4092141691051019,0.10908430718660717,1.0,2.0,4.0,165.0,165.0,4.0,330.0,440,163.0,1.7654120471718102e-05,11416.0,458.0,1.0,0,167.0
4805,610681,HP:0002664,"We observed that the alternatively spliced transcripts of a subset of these genes, involved in proliferation and tumor cell migration like REPIN1/AP4, ST3GAL6, TRNAU1AP and PFKM are degraded upon loss of PRMT5.",0,1.4307719599089377,493960.6429781772,190.07129539559014,0.2486127722484784,0.2926196036489038,0.0,0.0,0.998803827751196,835.0,-0.702310790908133,0.03415307574900105,1.0,2.0,18.0,63.0,63.0,42.0,126.0,1544,61.0,1.67789739321861e-06,11949.0,837.0,1.0,0,48.0
4806,602279,HP:0003560,"Although PABPN1 plays a critical role in the regulation of RNA processing, mutation of the gene encoding this ubiquitously expressed RNA binding protein causes a specific form of muscular dystrophy termed oculopharyngeal muscular dystrophy (OPMD).",0,1.301533414708575,123719.30833333336,78.96000000000002,0.23299312200194505,-0.0997387456833686,0.0,0.0,0.9932885906040269,148.0,-0.34885805647182905,0.2680089485458613,1.0,2.0,4.0,68.0,68.0,38.0,136.0,152,66.0,0.00016866250632484398,2995.0,150.0,1.0,0,79.0
4807,164015,HP:0003198,The MATR3 gene is mutated in a form of distal myopathy and amyotrophic lateral sclerosis (ALS).,0,1.3319310032947866,843796.4064990566,120.12906473371592,0.20457755781720147,0.08595355465035202,0.0,0.0,0.9975786924939468,412.0,-0.5094267287192373,0.13807301353358833,1.0,2.0,3.0,137.0,137.0,50.0,274.0,518,135.0,1.4792899408284024e-05,11804.0,414.0,1.0,0,136.0
4811,600722,HP:0002664,"Previously, we reported that human hepatoma cells that harbor OXPHOS defects exhibit high tumor cell invasiveness via elevated claudin-1 (CLN1).",0,1.3865088431178794,1746758.63625366,246.91604155802483,0.1890866956361356,0.3235469560452053,0.0,0.0,0.998849252013809,868.0,-0.6700543704722717,0.05811938679682022,1.0,2.0,61.0,92.0,92.0,89.0,184.0,1544,90.0,1.677897393218609e-06,21970.0,870.0,1.0,0,92.0
4814,600722,HP:0002664,"Specific inhibition of mitoribosomal translation by doxycycline, chloramphenicol, or siRNA-mediated MRPL13 knockdown decreased mitochondrial protein expression, reduced oxygen consumption rate, and increased CLN1-mediated tumor cell invasiveness in SNU387 cells, which have active mitochondria.",0,1.3865088431178794,1746758.63625366,246.91604155802483,0.1890866956361356,0.3235469560452053,0.0,0.0,0.998849252013809,868.0,-0.6700543704722717,0.05811938679682022,1.0,2.0,61.0,92.0,92.0,89.0,184.0,1544,90.0,1.677897393218609e-06,21970.0,870.0,1.0,0,92.0
4817,600722,HP:0001402,A bioinformatic analysis of the open RNA-Seq database from The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) cohort revealed a significant negative correlation between MRPL13 and CLN1 expression.,0,1.267791249341065,44139.48214285714,43.00158604282315,0.3149274610495971,0.20662693568976465,0.0,0.0,0.9933333333333334,149.0,-0.476040167608765,0.13571743929359822,1.0,2.0,14.0,46.0,46.0,22.0,92.0,106,44.0,0.00010412328196584755,1537.0,151.0,1.0,0,48.0
4818,300522,HP:0001298,"Whole exome sequencing identified a truncating pathogenic variant in IQSEC2 at NM_001111125.2: c.2679_2680insA, p.(D894fs*10), a recently identified cause of epileptic encephalopathy in females (MIM 300522).",0,1.319910371318822,2084958.1338023085,145.39011208546253,0.17837253015782714,0.20563375598965225,0.0,0.0,0.9984276729559748,635.0,-0.3300932591976604,0.10915454715993801,1.0,2.0,17.0,235.0,235.0,4.0,470.0,486,233.0,6.441804736014842e-06,22111.0,637.0,1.0,0,276.0
4821,154100,HP:0002664,"We hypothesized that dual inhibition of MDH1 and MDH2 might be a powerful approach to target cancer metabolism and selected methyl-3-(3-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanamido)-benzoate (16c) as the most potent dual inhibitor.",1,1.3750682277898476,4650091.198405121,222.92081286810836,0.17134945381427635,0.0857402099389399,0.0,0.0,1.0009861932938855,1015.0,-0.5454530894457412,0.08028876516940177,1.0,2.0,1.0,233.0,233.0,86.0,466.0,1542,232.0,1.6778973932186103e-06,41317.0,1015.0,1.0,0,229.0
4819,154100,HP:0002664,This finding provides concrete evidence that inhibition of both MDH1 and MDH2 may provide a valuable platform for developing novel therapeutics that target cancer metabolism and tumor growth,1,1.3750682277898476,4650091.198405121,222.92081286810836,0.17134945381427635,0.0857402099389399,0.0,0.0,1.0009861932938855,1015.0,-0.5454530894457412,0.08028876516940177,1.0,2.0,1.0,233.0,233.0,86.0,466.0,1542,232.0,1.6778973932186103e-06,41317.0,1015.0,1.0,0,229.0
4823,305915,HP:0001249,"The most likely causal variant identified was a novel missense variant in the X-linked GRIA3 gene, which has been implicated in intellectual disability.",1,1.428076797705006,14592111.706566373,580.2738967594854,0.13704446149521798,0.02741637706344864,0.0,0.0,1.0005530973451326,1809.0,-0.6523832129342519,0.06504595997397476,1.0,2.0,1.0,207.0,207.0,207.0,414.0,3204,206.0,3.891642658474498e-07,106372.0,1809.0,1.0,0,202.0
4824,615103,HP:0010628,Our findings enlarge the spectrum of tubulinopathies and emphasize that mutations of TUBB6 should be considered in patients with congenital non-progressive facial palsy.,0,1.3929495399428584,237449.6239142393,170.93105899076045,0.1896044654628959,0.04031075311926514,0.0,0.0,1.004016064257028,250.0,-0.8276955674414201,0.21635341365461846,1.0,2.0,2.0,48.0,48.0,48.0,96.0,402,47.0,2.450740123517302e-05,6734.0,250.0,1.0,0,51.0
4825,136351,HP:0001880,FLT3 fusions are associated with myeloid and lymphoid neoplasms with eosinophilia.,0,1.329975256274302,6400.864935064937,33.568627450980394,0.3570829884845877,0.2956374570900545,0.0,0.0,0.9857142857142857,69.0,-0.7374108222288361,0.19678068410462776,1.0,2.0,1.0,17.0,17.0,16.0,34.0,102,16.0,0.000355998576005696,489.0,71.0,1.0,0,20.0
4827,136351,HP:0001880,"We suggest that leukemias and lymphomas with FLT3 fusion genes exhibit similar clinicopathologic features to, and should be included in, the WHO category of &quot;Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2.&quot",0,1.329975256274302,6400.864935064937,33.568627450980394,0.3570829884845877,0.2956374570900545,0.0,0.0,0.9857142857142857,69.0,-0.7374108222288361,0.19678068410462776,1.0,2.0,1.0,17.0,17.0,16.0,34.0,102,16.0,0.000355998576005696,489.0,71.0,1.0,0,20.0
4830,136350,HP:0001880,"We suggest that leukemias and lymphomas with FLT3 fusion genes exhibit similar clinicopathologic features to, and should be included in, the WHO category of &quot;Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2.&quot",0,1.3808630840328835,303184.3978018828,123.18355832225876,0.3401458576093555,0.2976299670820084,0.0,0.0,0.9988801791713326,892.0,-0.3628231554726746,0.01683238511815738,1.0,2.0,154.0,52.0,52.0,52.0,104.0,1226,51.0,1.410508855174593e-06,6719.0,894.0,1.0,0,63.0
4831,605420,HP:0007656,Inactivation of ALX4/Alx4 causes lacrimal gland aplasia in both human and mouse.,0,1.367375509480773,4463.796187683284,152.88888888888889,0.4859568933175461,0.21723541113906866,0.0,0.0,0.9965753424657534,291.0,-0.8266832854091258,0.0172752349338445,1.0,2.0,89.0,4.0,4.0,4.0,8.0,340,3.0,1.1973036721303626e-05,739.0,293.0,1.0,0,4.0
4835,146920,HP:0002664,"In this family, whole-exome sequencing yielded rare, simultaneously heterozygous variants in the Aicardi-Goutieres syndrome (AGS) genes ADAR and RNASEH2B co-segregating with the tumor phenotype.",0,1.3561739316142425,8446978.033387527,247.9284934125196,0.15072613153632422,0.030338738971273305,0.0,0.0,1.0008992805755397,1113.0,-0.5266714050783735,0.09491651961449707,1.0,2.0,13.0,316.0,316.0,101.0,632.0,1542,315.0,1.6778973932186103e-06,58737.0,1113.0,1.0,0,369.0
4844,610326,HP:0002664,"In this family, whole-exome sequencing yielded rare, simultaneously heterozygous variants in the Aicardi-Goutieres syndrome (AGS) genes ADAR and RNASEH2B co-segregating with the tumor phenotype.",0,1.3697350756268474,6845073.774426812,258.5205263848205,0.15345232182524104,0.10682770067919714,0.0,0.0,1.0009643201542913,1038.0,-0.5654051422076939,0.09526145339212157,1.0,2.0,5.0,256.0,256.0,141.0,512.0,1542,255.0,1.677897393218609e-06,51270.0,1038.0,1.0,0,276.0
4850,146920,HP:0009733,"By targeted sequencing, we identified novel ADAR and RNASEH2B variants, and a 3- to 17-fold frequency increase of the AGS mutations ADAR,c.577C&gt;G;p.(P193A) and RNASEH2B,c.529G&gt;A;p.(A177T) in the germline of familial glioma patients as well as in test and validation cohorts of glioblastomas and prostate carcinomas versus ethnicity-matched controls, whereby rare RNASEH2B variants were significantly more frequent in familial glioma patients.",0,1.3464713216614417,169611.95438465357,108.46198830409357,0.2785408423711385,0.21486079232961333,0.0,0.0,0.9973753280839894,380.0,-0.5838167379074777,0.05525552761402207,1.0,2.0,69.0,39.0,39.0,39.0,78.0,498,38.0,8.499859752314087e-06,4021.0,382.0,1.0,0,44.0
4832,146920,HP:0002664,An increased ISG expression was also induced by ADAR and RNASEH2B variants in tumor cells and was blocked by the JAK inhibitor Ruxolitinib.,0,1.3561739316142425,8446978.033387527,247.9284934125196,0.15072613153632422,0.030338738971273305,0.0,0.0,1.0008992805755397,1113.0,-0.5266714050783735,0.09491651961449707,1.0,2.0,13.0,316.0,316.0,101.0,632.0,1542,315.0,1.6778973932186103e-06,58737.0,1113.0,1.0,0,369.0
4841,610326,HP:0002664,An increased ISG expression was also induced by ADAR and RNASEH2B variants in tumor cells and was blocked by the JAK inhibitor Ruxolitinib.,0,1.3697350756268474,6845073.774426812,258.5205263848205,0.15345232182524104,0.10682770067919714,0.0,0.0,1.0009643201542913,1038.0,-0.5654051422076939,0.09526145339212157,1.0,2.0,5.0,256.0,256.0,141.0,512.0,1542,255.0,1.677897393218609e-06,51270.0,1038.0,1.0,0,276.0
4838,146920,HP:0002664,"Our data implicate rare variants in the AGS genes ADAR and RNASEH2B and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis, consistent with a genetic basis underlying inflammation-driven malignant transformation in glioma and prostate carcinoma development",0,1.3561739316142425,8446978.033387527,247.9284934125196,0.15072613153632422,0.030338738971273305,0.0,0.0,1.0008992805755397,1113.0,-0.5266714050783735,0.09491651961449707,1.0,2.0,13.0,316.0,316.0,101.0,632.0,1542,315.0,1.6778973932186103e-06,58737.0,1113.0,1.0,0,369.0
4847,610326,HP:0002664,"Our data implicate rare variants in the AGS genes ADAR and RNASEH2B and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis, consistent with a genetic basis underlying inflammation-driven malignant transformation in glioma and prostate carcinoma development",0,1.3697350756268474,6845073.774426812,258.5205263848205,0.15345232182524104,0.10682770067919714,0.0,0.0,1.0009643201542913,1038.0,-0.5654051422076939,0.09526145339212157,1.0,2.0,5.0,256.0,256.0,141.0,512.0,1542,255.0,1.677897393218609e-06,51270.0,1038.0,1.0,0,276.0
4851,146920,HP:0009733,"Our data implicate rare variants in the AGS genes ADAR and RNASEH2B and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis, consistent with a genetic basis underlying inflammation-driven malignant transformation in glioma and prostate carcinoma development",0,1.3464713216614417,169611.95438465357,108.46198830409357,0.2785408423711385,0.21486079232961333,0.0,0.0,0.9973753280839894,380.0,-0.5838167379074777,0.05525552761402207,1.0,2.0,69.0,39.0,39.0,39.0,78.0,498,38.0,8.499859752314087e-06,4021.0,382.0,1.0,0,44.0
4852,610326,HP:0009733,"Our data implicate rare variants in the AGS genes ADAR and RNASEH2B and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis, consistent with a genetic basis underlying inflammation-driven malignant transformation in glioma and prostate carcinoma development",0,1.3390735985020914,141969.22655816405,93.4458900059137,0.2800585264829587,0.3818233383586305,0.0,0.0,0.9967320261437908,305.0,-0.6045641199290281,0.07125673287773307,1.0,2.0,49.0,39.0,39.0,39.0,78.0,170,38.0,1.3922922699933167e-05,3347.0,307.0,1.0,0,47.0
4853,190315,HP:0001298,"Missense mutations of the human mitochondrial citrate carrier, encoded by the SLC25A1 gene, lead to an autosomal recessive neurometabolic disorder characterised by neonatal-onset encephalopathy with severe muscular weakness, intractable seizures, respiratory distress, and lack of psychomotor development, often resulting in early death.",1,1.3351715035330851,1546463.543650794,138.73005654632448,0.18089097872104348,0.13176386274518814,0.0,0.0,1.0019011406844107,527.0,-0.31923256061982164,0.13099472586777874,1.0,2.0,17.0,227.0,227.0,2.0,454.0,484,226.0,1.2225536701061176e-05,18156.0,527.0,1.0,0,277.0
4854,190315,HP:0001250,"Missense mutations of the human mitochondrial citrate carrier, encoded by the SLC25A1 gene, lead to an autosomal recessive neurometabolic disorder characterised by neonatal-onset encephalopathy with severe muscular weakness, intractable seizures, respiratory distress, and lack of psychomotor development, often resulting in early death.",1,1.4080336136048794,16763802.681232922,464.5758913412564,0.13858979376568578,0.05071304277512136,0.0,0.0,1.000545256270447,1835.0,-0.5992303431612905,0.06646480794202157,1.0,2.0,2.0,279.0,279.0,214.0,558.0,3100,278.0,4.1569653487839437e-07,111840.0,1835.0,1.0,0,294.0
4855,600960,HP:0000007,SPG56 is a rare autosomal recessive early onset complicated form of HSP caused by mutations in CYP2U1.,0,1.4350629738657656,11104649.152978927,584.0362208155589,0.1627053053624527,0.11614850991362102,0.0,0.0,0.9996363636363635,2749.0,-0.6274121045249759,0.025132282475793927,1.0,2.0,117.0,169.0,169.0,170.0,338.0,5162,167.0,1.5011496554636372e-07,95066.0,2751.0,1.0,0,162.0
4856,614780,HP:0000007,Pathogenic sequence variants in the Sorting Nexin 10 (SNX10) gene have been associated with autosomal recessive osteopetrosis (ARO) in human.,1,1.453053263342294,12007786.633319147,587.9924518500759,0.16978881239017912,0.2952110962911938,0.0,0.0,1.000360620266859,2774.0,-0.5997248925241468,0.027584200412308302,1.0,2.0,41.0,194.0,194.0,194.0,388.0,5160,193.0,1.5011496554636354e-07,106093.0,2774.0,1.0,0,184.0
4859,600993,HP:0002664,"Thus, our data indicate that in pancreatic cancer cells, the expression of ENG may be controlled by a pathway mediated by SMAD4.",1,1.3361927954695605,13930500.400868574,255.205350796036,0.14290522615660328,0.0866885436227384,0.0,0.0,1.0007336757153338,1364.0,-0.33425811754301626,0.09202466527390203,1.0,2.0,4.0,552.0,552.0,9.0,1104.0,1542,551.0,1.67789739321861e-06,85543.0,1364.0,1.0,0,725.0
4861,131195,HP:0002664,"In addition, ENG was found to be related to the spheroid-forming ability of cells and to be involved in the invasive capacity of pancreatic cancer cells",1,1.3684454688256968,4984019.097722349,215.51785179800743,0.16147832171855658,0.04777024220024696,0.0,0.0,1.000958772770853,1044.0,-0.6014570610793344,0.07980773116158442,1.0,2.0,14.0,242.0,242.0,91.0,484.0,1542,241.0,1.6778973932186103e-06,43451.0,1044.0,1.0,0,283.0
986,121011,HP:0000365,"Furthermore, 1751 normal Chinese individuals served as controls, and 122 Chinese families segregating with apparent ARNSHL, who had been previously excluded for variants in the common deafness genes GJB2 and SLC26A4, were subjected to screening for candidate mutations.",1,1.395883254657124,11360890.773559922,359.9890516043107,0.1442161069048109,0.0490995817099891,0.0,0.0,1.000660501981506,1515.0,-0.6063388048985573,0.07124963487101682,1.0,2.0,7.0,266.0,266.0,150.0,532.0,2474,265.0,6.524672396198986e-07,81713.0,1515.0,1.0,0,305.0
1023,605646,HP:0000365,"Furthermore, 1751 normal Chinese individuals served as controls, and 122 Chinese families segregating with apparent ARNSHL, who had been previously excluded for variants in the common deafness genes GJB2 and SLC26A4, were subjected to screening for candidate mutations.",1,1.4413226495142712,4479611.427125419,456.96235976102685,0.15949329773347126,0.021256166761706764,0.0,0.0,1.0007358351729212,1360.0,-0.7348599879376381,0.0553207375665498,1.0,2.0,1.0,121.0,121.0,109.0,242.0,2474,120.0,6.524672396198984e-07,51123.0,1360.0,1.0,0,110.0
4865,601513,HP:0002664,"Silencing of FGF12 showed significant inhibition in activity of tumor cell proliferation, colony formation, and cell migration.",0,1.3853180503535287,3605178.2116079233,247.64568077273202,0.16725081438100506,0.002821828313730443,0.0,0.0,0.9989281886387996,932.0,-0.6231569041160526,0.07722779548829385,1.0,2.0,19.0,161.0,161.0,140.0,322.0,1544,159.0,1.6778973932186103e-06,33649.0,934.0,1.0,0,196.0
4867,601513,HP:0002664,"These results indicate that FGF12 has a potential role in ESCC and suggest that cancer genomic datasets with application of in silico approaches are instrumental for biomarker discovery research broadly and specifically, for the identification of FGF12 as a putative biomarker in ESCC",0,1.3853180503535287,3605178.2116079233,247.64568077273202,0.16725081438100506,0.002821828313730443,0.0,0.0,0.9989281886387996,932.0,-0.6231569041160526,0.07722779548829385,1.0,2.0,19.0,161.0,161.0,140.0,322.0,1544,159.0,1.6778973932186103e-06,33649.0,934.0,1.0,0,196.0
4869,176876,HP:0001638,"Result: Three mutant genes (PTPN11 gene in chromosome 12, RIT1 gene in chromosome 1 and RAF1 gene in chromosome 3) in five cases all had been reported to be related to hypertrophic cardiomyopathy.",1,1.333867163164077,5233743.389790767,192.381310544958,0.16350159962463684,0.10306258422915572,0.0,0.0,1.001156069364162,866.0,-0.369375395671157,0.11118824173330308,1.0,2.0,6.0,340.0,340.0,2.0,680.0,866,340.0,5.188848127604154e-06,41645.0,866.0,1.0,0,391.0
4871,164760,HP:0001638,"Result: Three mutant genes (PTPN11 gene in chromosome 12, RIT1 gene in chromosome 1 and RAF1 gene in chromosome 3) in five cases all had been reported to be related to hypertrophic cardiomyopathy.",1,1.3349356407322654,4914967.189266289,205.0106495585274,0.1628998824562806,0.016287050936190414,0.0,0.0,1.0012674271229405,790.0,-0.3733555302468711,0.12901124641029346,1.0,2.0,3.0,317.0,317.0,11.0,634.0,856,316.0,5.4335718671383015e-06,40207.0,790.0,1.0,0,376.0
4872,608517,HP:0001638,"The reported hypertrophic cardiomyopathy relevant genes MYPN, MYH6 and MYBP3 had also been found in case 1 and 2.",1,1.3383064327015202,3784314.0737012993,195.6300391721415,0.16799698863665952,0.09580686275605373,0.0,0.0,1.0013698630136991,731.0,-0.4276495597004163,0.13007514570020426,1.0,2.0,2.0,286.0,286.0,27.0,572.0,856,285.0,5.4335718671383015e-06,34706.0,731.0,1.0,0,347.0
4873,160710,HP:0001638,"The reported hypertrophic cardiomyopathy relevant genes MYPN, MYH6 and MYBP3 had also been found in case 1 and 2.",1,1.3679420224038752,1180834.1623690324,149.47347979123683,0.20676739120830406,0.07366670892095523,0.0,0.0,1.0017211703958693,582.0,-0.5537325916064433,0.1001236167054078,1.0,2.0,4.0,145.0,145.0,66.0,290.0,856,144.0,5.4335718671383015e-06,16928.0,582.0,1.0,0,138.0
4874,182810,HP:0006879,"De novo in-frame deletions and duplications in the SPTAN1 gene, encoding the non-erythrocyte aII spectrin, have been associated with severe West syndrome with hypomyelination and pontocerebellar atrophy.",0,1.3560189573459716,2832.854120879121,43.93137254901961,0.4692601204599631,0.3798134027132088,0.0,0.0,0.9891304347826086,91.0,-0.7573877206236136,0.07620383356708743,1.0,2.0,16.0,7.0,7.0,7.0,14.0,102,6.0,0.0001352082206598161,326.0,93.0,1.0,0,7.0
4875,109690,HP:0002664,"Codeletion of Adrb2 and Cox10, a gene encoding a cytochrome IV oxidase assembly factor, prevented the metabolic shift induced by Adrb2 deletion and rescued prostate cancer progression.",0,1.4642327204034065,106491.52079424838,219.48826789293722,0.3349133810149962,0.08513376503712368,0.0,0.0,0.9987405541561712,793.0,-0.7935956036262927,0.017252031747540517,1.0,2.0,18.0,21.0,21.0,20.0,42.0,1548,19.0,1.6778973932186097e-06,5445.0,795.0,1.0,0,16.0
4876,602125,HP:0002664,"Codeletion of Adrb2 and Cox10, a gene encoding a cytochrome IV oxidase assembly factor, prevented the metabolic shift induced by Adrb2 deletion and rescued prostate cancer progression.",0,1.3834268176526616,1772686.149455565,223.59685285826072,0.19254017893580666,0.12251515392246425,0.0,0.0,0.9988801791713324,892.0,-0.6691075809051565,0.0602949613073094,1.0,2.0,35.0,109.0,109.0,83.0,218.0,1560,107.0,1.67789739321861e-06,24068.0,894.0,1.0,0,97.0
4877,613350,HP:0009830,"By screening a large cohort of 132 patients with early-onset severe sensory, motor and cranial nerve neuropathy we confirmed the strong genetic link between riboflavin transporter mutations and Brown-Vialetto-Van Laere syndrome, identifying 22 pathogenic mutations in SLC52A2 and SLC52A3, 14 of which were novel.",1,1.3887781532772288,2255129.970318115,231.4622067419329,0.17697241200420344,0.13455749979053394,0.0,0.0,1.001470588235294,681.0,-0.643813014435346,0.10999827243672801,1.0,2.0,4.0,135.0,135.0,112.0,270.0,1086,134.0,3.3791089965397938e-06,25469.0,681.0,1.0,0,152.0
2351,600185,HP:0002664,Previous studies have identified a critical role for the tumor suppressors BRCA1 and BRCA2 in preventing the degradation of nascent DNA by the MRE11 nuclease after replication stress.,1,1.3416355462103815,14500864.778067766,286.27804058963136,0.14198849810087022,0.09065436525648868,0.0,0.0,1.0007987220447283,1253.0,-0.3695548622099266,0.10824627921741813,1.0,2.0,4.0,477.0,477.0,34.0,954.0,1542,476.0,1.67789739321861e-06,84906.0,1253.0,1.0,0,615.0
4878,607170,HP:0003745,CRELD1 gene is implicated in causation of sporadic AVSD.,0,1.2492471488799521,84070.10634920634,43.02864372469635,0.2921002409034212,0.3369041310536936,0.0,0.0,0.995,199.0,-0.4664819177661287,0.11124378109452736,1.0,2.0,20.0,63.0,63.0,2.0,126.0,200,61.0,9.0702947845805e-05,2236.0,201.0,1.0,0,58.0
604,600960,HP:0002664,"Through a whole genome sequencing (WGS) analysis of the nine subjects (four lung cancer patients and five normal family members of FLC), we obtained a whole genome dataset of DNA alterations in FLC samples.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
4879,600960,HP:0003745,"Subsequently, the top 12 highly mutated genes were selected for validation by polymerase chain reaction and DNA sequencing in an expanded sample set including FLC, sporadic lung cancer, and healthy population.",0,1.3077441563756291,379032.2954545453,99.39470569915916,0.2100321504717822,0.13025491984110002,0.0,0.0,0.9962264150943396,264.0,-0.4341557315842277,0.17554263016030644,1.0,2.0,11.0,93.0,93.0,94.0,186.0,192,91.0,3.4602076124567484e-05,6187.0,266.0,1.0,0,111.0
586,600960,HP:0002664,"Subsequently, the top 12 highly mutated genes were selected for validation by polymerase chain reaction and DNA sequencing in an expanded sample set including FLC, sporadic lung cancer, and healthy population.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
4880,607295,HP:0002664,"Mutations of the five genes (ARHGEF5, ANKRD20A2, ZNF595, ZNF812, MYO18B) may be potential germline mutations of lung cancer.",0,1.375490201416833,3453650.9587123683,286.35562967080483,0.16125928723152522,0.09238027406470127,0.0,0.0,0.9988864142538976,897.0,-0.6834085530632719,0.07851584661006662,1.0,2.0,58.0,124.0,124.0,122.0,248.0,1544,122.0,1.6778973932186103e-06,31693.0,899.0,1.0,0,136.0
4881,606419,HP:0002664,"In summary, a 15-lncRNA expression signature (BAIAP2-AS1, RP11-203J24.8, LINC01133, RP1-7G5.6, RP11-147L13.15, SERHL, CTC-537E7.3, RP11-440L14.1, RP11-131N11.4, ILF3-AS1, RP11-80H18.4, RP11-1096G20.5, CTD-2192J16.26, RP11-621L6.3, and RP11-571M6.18) were identified and validated which can predict cervical cancer patient survival.",0,1.3965605150389655,2303454.3056277144,234.4405031218894,0.18378842596569464,0.1880749223013835,0.0,0.0,0.9988901220865704,900.0,-0.6426851625179463,0.06542865650632089,1.0,2.0,15.0,125.0,125.0,104.0,250.0,1544,123.0,1.67789739321861e-06,26587.0,902.0,1.0,0,127.0
4882,605789,HP:0002664,"In summary, a 15-lncRNA expression signature (BAIAP2-AS1, RP11-203J24.8, LINC01133, RP1-7G5.6, RP11-147L13.15, SERHL, CTC-537E7.3, RP11-440L14.1, RP11-131N11.4, ILF3-AS1, RP11-80H18.4, RP11-1096G20.5, CTD-2192J16.26, RP11-621L6.3, and RP11-571M6.18) were identified and validated which can predict cervical cancer patient survival.",1,1.382201865853295,7416298.227630701,298.1237605121125,0.14668371674999064,0.04744809775545189,0.0,0.0,1.0010131712259374,988.0,-0.5832484526484379,0.1035403566198639,1.0,2.0,1.0,215.0,215.0,215.0,430.0,1542,214.0,1.67789739321861e-06,50484.0,988.0,1.0,0,255.0
2559,137290,HP:0002664,"Trop2, a transmembrane glycoprotein, has emerged as a biomarker for targeted cancer therapy since it is overexpressed in 80% of triple negative breast cancer (TNBC) patients.",0,1.4275991989409729,125722.55083681575,248.7899481193256,0.3232828816680043,0.2520735131704226,0.0,0.0,0.998737373737374,791.0,-0.7159616096733603,0.017839173576878496,1.0,2.0,85.0,21.0,21.0,21.0,42.0,1544,19.0,1.67789739321861e-06,5602.0,793.0,1.0,0,18.0
2550,137290,HP:0002664,"For the site-specific delivery of the anticancer drug into TNBC, anti-Trop2 antibody-conjugated nanoparticles (ST-NPs) were prepared as the potential nanocarrier, composed of carboxymethyl dextran (CMD) derivatives with bioreducible disulfide bonds.",0,1.4275991989409729,125722.55083681575,248.7899481193256,0.3232828816680043,0.2520735131704226,0.0,0.0,0.998737373737374,791.0,-0.7159616096733603,0.017839173576878496,1.0,2.0,85.0,21.0,21.0,21.0,42.0,1544,19.0,1.67789739321861e-06,5602.0,793.0,1.0,0,18.0
2547,137290,HP:0002664,"Consequently, DOX-ST-NPs exhibited higher toxicity to Trop2-positive MDA-MB-231 cancer cells, compared to DOX-loaded control nanoparticles without the disulfide bond or anti-Trop2 antibody.",0,1.4275991989409729,125722.55083681575,248.7899481193256,0.3232828816680043,0.2520735131704226,0.0,0.0,0.998737373737374,791.0,-0.7159616096733603,0.017839173576878496,1.0,2.0,85.0,21.0,21.0,21.0,42.0,1544,19.0,1.67789739321861e-06,5602.0,793.0,1.0,0,18.0
4883,600734,HP:0000859,"Breakthrough discoveries include the role of somatic variants in the KCNJ5, CACNA1D, ATP1A1, and ATP2B3 genes as causes of aldosterone-producing adenomas (APAs), and the recognition of three novel hyperaldosteronism syndromes with germline variants in the KCNJ5, CACNA1D, and CACNA1H genes.",1,1.4220464656450815,29691.786940836933,68.56296296296297,0.3385044280504176,0.29534704195104466,0.0,0.0,1.0064516129032255,156.0,-0.7042591242433947,0.10306038047973533,1.0,2.0,18.0,21.0,21.0,21.0,42.0,170,21.0,5.406574394463668e-05,1246.0,156.0,1.0,0,21.0
4884,114206,HP:0000859,"Breakthrough discoveries include the role of somatic variants in the KCNJ5, CACNA1D, ATP1A1, and ATP2B3 genes as causes of aldosterone-producing adenomas (APAs), and the recognition of three novel hyperaldosteronism syndromes with germline variants in the KCNJ5, CACNA1D, and CACNA1H genes.",1,1.4243864833611717,29710.788852813846,65.1063829787234,0.3459790775284053,0.3550309172697408,0.0,0.0,1.0062111801242235,162.0,-0.6545313879227813,0.09125067096081588,1.0,2.0,27.0,21.0,21.0,21.0,42.0,282,21.0,4.959333465582227e-05,1190.0,162.0,1.0,0,21.0
4885,182310,HP:0000859,"Breakthrough discoveries include the role of somatic variants in the KCNJ5, CACNA1D, ATP1A1, and ATP2B3 genes as causes of aldosterone-producing adenomas (APAs), and the recognition of three novel hyperaldosteronism syndromes with germline variants in the KCNJ5, CACNA1D, and CACNA1H genes.",0,1.305084745762712,15246.283333333333,39.46510110893672,0.3444021286489154,-0.0051186856364972,0.0,0.0,0.9894736842105264,94.0,-0.6594488712099839,0.15460526315789475,1.0,2.0,10.0,22.0,22.0,22.0,44.0,78,21.0,0.00018261504747991235,705.0,96.0,1.0,0,26.0
4886,300014,HP:0000859,"Breakthrough discoveries include the role of somatic variants in the KCNJ5, CACNA1D, ATP1A1, and ATP2B3 genes as causes of aldosterone-producing adenomas (APAs), and the recognition of three novel hyperaldosteronism syndromes with germline variants in the KCNJ5, CACNA1D, and CACNA1H genes.",0,1.2397798742138364,5175.738744588744,18.862361382909327,0.4802071482542231,0.2659380715438681,0.0,0.0,0.9894736842105264,94.0,-0.4672048803805297,0.08092105263157895,1.0,2.0,22.0,21.0,21.0,22.0,42.0,110,19.0,0.00018261504747991235,369.0,96.0,1.0,0,19.0
4887,607904,HP:0000859,"Breakthrough discoveries include the role of somatic variants in the KCNJ5, CACNA1D, ATP1A1, and ATP2B3 genes as causes of aldosterone-producing adenomas (APAs), and the recognition of three novel hyperaldosteronism syndromes with germline variants in the KCNJ5, CACNA1D, and CACNA1H genes.",0,1.230072463768116,5928.775,21.260952380952386,0.4696940060069642,0.20702249069083267,0.0,0.0,0.9896907216494846,96.0,-0.4419936278276967,0.08668209551861981,1.0,2.0,28.0,22.0,22.0,22.0,44.0,94,21.0,0.00017313019390581717,412.0,98.0,1.0,0,21.0
4888,604831,HP:0010442,"These include the perinatal lethal short-rib polydactyly syndromes (SRPS) and the less severe asphyxiating thoracic dystrophy (ATD), Ellis-van Creveld (EVC) syndrome, and cranioectodermal dysplasia (CED) phenotypes.",1,1.3374674742993644,2153165.2801587298,184.48695482866043,0.16291325065619355,0.11397435359320945,0.0,0.0,1.0019960079840318,502.0,-0.2720511783078989,0.18011785194551136,1.0,2.0,0.0,211.0,211.0,3.0,422.0,428,210.0,1.1973036721303622e-05,22650.0,502.0,2.0,0,266.0
4891,607001,HP:0001249,"Kleefstra syndrome, caused by haploinsufficiency of euchromatin histone methyltransferase 1 (EHMT1), is characterized by intellectual disability (ID), autism spectrum disorder (ASD), characteristic facial dysmorphisms, and other variable clinical features.",1,1.401885650648655,27584242.880467724,540.8531513522207,0.1269570669708781,0.00254769219806545,0.0,0.0,1.0005189413596265,1928.0,-0.5943171920580246,0.07886670528222013,1.0,2.0,1.0,326.0,326.0,325.0,652.0,3204,325.0,3.8916426584745004e-07,146505.0,1928.0,1.0,0,352.0
4895,607001,HP:0000717,"Kleefstra syndrome, caused by haploinsufficiency of euchromatin histone methyltransferase 1 (EHMT1), is characterized by intellectual disability (ID), autism spectrum disorder (ASD), characteristic facial dysmorphisms, and other variable clinical features.",1,1.3563189323239575,1802844.2876984128,179.75191192537184,0.17110436735300438,0.36640734467611297,0.0,0.0,1.0021231422505308,472.0,-0.4870820011620609,0.16306812047932634,1.0,2.0,5.0,146.0,146.0,146.0,292.0,292,146.0,9.351999925184e-06,18126.0,472.0,1.0,0,150.0
4897,160740,HP:0000602,"Mutations in MYH2 are associated with skeletal myopathies, characterized by ophthalmoplegia.",0,1.3894299035118125,320411.11393622716,130.69955784819453,0.2244518703629953,0.1110095254502826,0.0,0.0,1.003472222222222,289.0,-0.6720250657409216,0.1474673202614379,1.0,2.0,1.0,59.0,59.0,59.0,118.0,460,58.0,1.874027848053822e-05,6137.0,289.0,1.0,0,80.0
4898,160720,HP:0002804,Mutations in MYH3 and MYH8 are associated with distal arthrogryposis syndromes.,1,1.3859048032807388,1164655.616733765,158.2431597340607,0.2040005604568233,0.10246222492884836,0.0,0.0,1.0018867924528303,531.0,-0.5411255227713381,0.09938528230821164,1.0,2.0,11.0,112.0,112.0,112.0,224.0,312,112.0,5.668934240362813e-06,13985.0,531.0,1.0,0,127.0
4899,160741,HP:0002804,Mutations in MYH3 and MYH8 are associated with distal arthrogryposis syndromes.,1,1.3356767283349562,287546.80952380947,110.14649791955615,0.20151475751625936,0.022941571486002538,0.0,0.0,1.0046728971962615,215.0,-0.3736709048670946,0.2569006737665725,1.0,2.0,6.0,92.0,92.0,55.0,184.0,224,91.0,7.831466833737959e-05,5910.0,215.0,1.0,0,113.0
4900,160760,HP:0003198,"Mutations in MYH7 are associated with not only skeletal muscle diseases, such as Laing distal myopathy and myosin storage myopathy, but also hypertrophic cardiomyopathy.",1,1.3397850257516704,2265375.8345238105,164.1547965116279,0.18204890223832249,0.09140353560903147,0.0,0.0,1.001560062402496,642.0,-0.22409729841103115,0.12311370959511278,1.0,2.0,16.0,249.0,249.0,2.0,498.0,516,249.0,6.7465002529937596e-06,25332.0,642.0,1.0,0,323.0
4901,612801,HP:0002664,"The purpose of the article is to investigate the role of IARS2 in proliferation, apoptosis, and cell cycle of gastric cancer (GC) cells in vitro.",0,1.3610820039063056,6378875.422866083,264.2296229588976,0.15037900472536536,0.0476818642461558,0.0,0.0,0.999000999000999,1000.0,-0.5995302534875042,0.0943148667699566,1.0,2.0,23.0,227.0,227.0,140.0,454.0,1544,225.0,1.6778973932186103e-06,47299.0,1002.0,1.0,0,253.0
4902,601865,HP:0002664,"In multiple types of tumors, fibrotic collagen is regarded as the *highway* for cancer cell migration, which is mainly modified by lysyl hydroxylase 2 (PLOD2).",0,1.4043503247354383,1931701.401611604,252.2194655263192,0.18986502757904744,0.17855128410347884,0.0,0.0,0.9988545246277206,872.0,-0.6541940165712935,0.060856983336871985,1.0,2.0,27.0,100.0,100.0,100.0,200.0,1544,98.0,1.6778973932186097e-06,23217.0,874.0,1.0,0,108.0
4903,601865,HP:0030078,"Although PLOD2 was confirmed to be related to poor prognosis in lung adenocarcinoma, the regulatory mechanism and function of PLOD2 in human lung adenocarcinoma is poorly understood.",0,1.3421575502571297,8271.45750915751,30.589400116482235,0.4325875994994831,0.23056451038786985,0.0,0.0,0.9915966386554622,118.0,-0.6637497971615667,0.07478991596638655,1.0,2.0,13.0,15.0,15.0,15.0,30.0,96,13.0,9.611687812379853e-05,534.0,120.0,1.0,0,15.0
4904,605294,HP:0002664,"At the suggestive threshold (P &lt; .001), 6 genes were enriched for rare damaging variants (UHMK1, AP1G2, DNTA, CHST6, FGFR3, and EPHA1) and 7 genes had associations with pancreatic cancer risk, based on the sequence-kernel association test.",0,1.4117848304652671,242275.9132242269,162.44676591665257,0.30036498837452863,0.2669736028208424,0.0,0.0,0.9987775061124694,817.0,-0.6375418023767414,0.02323186186266871,1.0,2.0,68.0,43.0,43.0,36.0,86.0,1544,41.0,1.6778973932186097e-06,7782.0,819.0,1.0,0,34.0
4905,134934,HP:0002664,"At the suggestive threshold (P &lt; .001), 6 genes were enriched for rare damaging variants (UHMK1, AP1G2, DNTA, CHST6, FGFR3, and EPHA1) and 7 genes had associations with pancreatic cancer risk, based on the sequence-kernel association test.",1,1.3337185150747015,15604927.954165282,233.33576464169312,0.14426910128279968,0.014585338719835871,0.0,0.0,1.0006317119393555,1584.0,-0.3086138415324786,0.07364867882871673,1.0,2.0,23.0,629.0,629.0,2.0,1258.0,1542,628.0,1.5092152684290275e-06,92336.0,1584.0,1.0,0,705.0
2369,600185,HP:0002664,We confirmed variants in BRCA2 as the most common high-penetrant genetic factor associated with pancreatic cancer and we also identified candidate pancreatic cancer genes.,1,1.3416355462103815,14500864.778067766,286.27804058963136,0.14198849810087022,0.09065436525648868,0.0,0.0,1.0007987220447283,1253.0,-0.3695548622099266,0.10824627921741813,1.0,2.0,4.0,477.0,477.0,34.0,954.0,1542,476.0,1.67789739321861e-06,84906.0,1253.0,1.0,0,615.0
4906,120215,HP:0002664,"miR-25-3p, miR-30a-5p, miR-328 and miR-363-3p directly targeted adhesion-related genes, including COL5A1, COL11A1, ITGA5, MMP16 and THBS2. miR-363-3p and miR-328 inhibited proliferation of renal cancer cells, while miR-25-3p inhibited adhesion, promoted proliferation and migration of renal cancer cells.",0,1.353867516131667,7331447.107800256,243.86071241442696,0.14926804596019885,0.20085884464719966,0.0,0.0,0.9990689013035382,1073.0,-0.5715454137245498,0.09277554025377853,1.0,2.0,8.0,282.0,282.0,113.0,564.0,1544,280.0,1.6778973932186103e-06,53557.0,1075.0,1.0,0,359.0
4907,120280,HP:0002664,"miR-25-3p, miR-30a-5p, miR-328 and miR-363-3p directly targeted adhesion-related genes, including COL5A1, COL11A1, ITGA5, MMP16 and THBS2. miR-363-3p and miR-328 inhibited proliferation of renal cancer cells, while miR-25-3p inhibited adhesion, promoted proliferation and migration of renal cancer cells.",0,1.3255875409605018,8398547.356033918,211.50779173248063,0.15256856480629685,0.10346224779286352,0.0,0.0,0.9991496598639455,1175.0,-0.4626211251579112,0.08194764736820813,1.0,2.0,26.0,365.0,365.0,40.0,730.0,1576,363.0,1.67789739321861e-06,56714.0,1177.0,1.0,0,498.0
4908,188061,HP:0002664,"miR-25-3p, miR-30a-5p, miR-328 and miR-363-3p directly targeted adhesion-related genes, including COL5A1, COL11A1, ITGA5, MMP16 and THBS2. miR-363-3p and miR-328 inhibited proliferation of renal cancer cells, while miR-25-3p inhibited adhesion, promoted proliferation and migration of renal cancer cells.",0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865479,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
4912,607968,HP:0002664,"The analyzed microRNAs, their target genes and TGF-b1 formed a network of strong correlations in tissue samples from renal cancer patients.",0,1.382167461745328,4456380.149059111,290.29824820634065,0.15912584557625145,0.06541130802715996,0.0,0.0,0.9989247311827956,929.0,-0.6350771196323979,0.08947021932711964,1.0,2.0,26.0,159.0,159.0,158.0,318.0,1544,157.0,1.67789739321861e-06,38733.0,931.0,1.0,0,171.0
4915,607968,HP:0002664,The expression signature of microRNAs linked with TGF-b1 levels correlated with poor survival of renal cancer patients.,0,1.382167461745328,4456380.149059111,290.29824820634065,0.15912584557625145,0.06541130802715996,0.0,0.0,0.9989247311827956,929.0,-0.6350771196323979,0.08947021932711964,1.0,2.0,26.0,159.0,159.0,158.0,318.0,1544,157.0,1.67789739321861e-06,38733.0,931.0,1.0,0,171.0
4918,142830,HP:0002352,Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy characterized by dysfunction of the role of glial cells in controlling brain fluid and ion homeostasis.,0,1.2954323929933689,1013696.939484127,109.04481605351171,0.20000989118073806,0.17360289752856467,0.0,0.0,0.99815157116451,540.0,-0.3372799133094123,0.09464501299356802,1.0,2.0,37.0,180.0,180.0,6.0,360.0,392,178.0,8.353102342209896e-06,13876.0,542.0,1.0,0,211.0
4927,605564,HP:0000365,"Defects of CIB2, calcium- and integrin-binding protein 2, have been reported to cause isolated deafness, DFNB48 and Usher syndrome type-IJ, characterized by congenital profound deafness, balance defects and blindness.",1,1.4525391780971713,3553238.953813441,499.8726290260818,0.16904490692238885,0.05588052591153477,0.0,0.0,1.0007513148009015,1332.0,-0.7206961900872911,0.04975035140324397,1.0,2.0,2.0,94.0,94.0,94.0,188.0,2474,93.0,6.524672396198988e-07,44101.0,1332.0,1.0,0,101.0
4935,608896,HP:0000365,"Defects of CIB2, calcium- and integrin-binding protein 2, have been reported to cause isolated deafness, DFNB48 and Usher syndrome type-IJ, characterized by congenital profound deafness, balance defects and blindness.",0,1.4270445289330995,2870984.753039727,316.07689975747775,0.18621974493643287,0.1631972756488952,0.0,0.0,0.9992679355783308,1365.0,-0.6596959718516452,0.0404825734393961,1.0,2.0,18.0,125.0,125.0,90.0,250.0,2476,123.0,6.524672396198988e-07,37797.0,1367.0,1.0,0,123.0
4936,608896,HP:0000618,"Defects of CIB2, calcium- and integrin-binding protein 2, have been reported to cause isolated deafness, DFNB48 and Usher syndrome type-IJ, characterized by congenital profound deafness, balance defects and blindness.",0,1.3130654890133564,452628.32804417796,85.36772088353413,0.2340927272599801,0.12326512913254795,0.0,0.0,0.9973544973544972,377.0,-0.5611278816301113,0.10365623822088202,1.0,2.0,12.0,104.0,104.0,29.0,208.0,500,102.0,1.6e-05,7425.0,379.0,1.0,0,101.0
4919,605564,HP:0000365,"Also, the generated CIB2-/- mice display an early onset profound deafness and have normal balance and retinal functions.",1,1.4525391780971713,3553238.953813441,499.8726290260818,0.16904490692238885,0.05588052591153477,0.0,0.0,1.0007513148009015,1332.0,-0.7206961900872911,0.04975035140324397,1.0,2.0,2.0,94.0,94.0,94.0,188.0,2474,93.0,6.524672396198988e-07,44101.0,1332.0,1.0,0,101.0
4931,605564,HP:0000365,"This essential role of CIB2 in mechanotransduction and cell survival that, we show, is restricted to the cochlea, probably accounts for the presence in CIB2-/- mice and CIB2 patients, unlike in Usher syndrome, of isolated hearing loss without balance and vision deficits",1,1.4525391780971713,3553238.953813441,499.8726290260818,0.16904490692238885,0.05588052591153477,0.0,0.0,1.0007513148009015,1332.0,-0.7206961900872911,0.04975035140324397,1.0,2.0,2.0,94.0,94.0,94.0,188.0,2474,93.0,6.524672396198988e-07,44101.0,1332.0,1.0,0,101.0
4937,126455,HP:0002267,"Prominent examples include mutations in the transporters for dopamine (DAT, SLC6A3), for creatine (CT1, SLC6A8), and for glycine (GlyT2, SLC6A5), which result in infantile dystonia, mental retardation, and hyperekplexia, respectively.",0,1.3124441132637854,15406.841666666665,43.78823529411764,0.3638339333127771,0.0072323469863841425,0.0,0.0,0.9902912621359224,102.0,-0.6809193825303648,0.12957430918595966,1.0,2.0,15.0,18.0,18.0,18.0,36.0,68,17.0,0.0001352082206598161,694.0,104.0,1.0,0,18.0
4938,300036,HP:0002267,"Prominent examples include mutations in the transporters for dopamine (DAT, SLC6A3), for creatine (CT1, SLC6A8), and for glycine (GlyT2, SLC6A5), which result in infantile dystonia, mental retardation, and hyperekplexia, respectively.",0,1.3291620283290468,23527.01309523809,60.94312642183946,0.3840290696559444,0.32965932853353924,0.0,0.0,0.9949748743718594,198.0,-0.5671259364080964,0.05597989949748744,1.0,2.0,48.0,18.0,18.0,18.0,36.0,188,17.0,3.0189590629151068e-05,1114.0,200.0,1.0,0,18.0
4939,163970,HP:0002267,"Prominent examples include mutations in the transporters for dopamine (DAT, SLC6A3), for creatine (CT1, SLC6A8), and for glycine (GlyT2, SLC6A5), which result in infantile dystonia, mental retardation, and hyperekplexia, respectively.",0,1.1363636363636365,219.0,6.436974789915968,0.6004632310439793,0.5979435413963367,0.0,0.0,0.96,24.0,-0.767511400164461,0.14153846153846153,1.0,2.0,5.0,4.0,4.0,3.0,8.0,36,2.0,0.002770083102493075,46.0,26.0,1.0,0,3.0
4923,605564,HP:0000365,CIB2 and GJB2 genes variants contribute significantly in familial cases of prelingual recessive hearing loss (HL).,1,1.4525391780971713,3553238.953813441,499.8726290260818,0.16904490692238885,0.05588052591153477,0.0,0.0,1.0007513148009015,1332.0,-0.7206961900872911,0.04975035140324397,1.0,2.0,2.0,94.0,94.0,94.0,188.0,2474,93.0,6.524672396198988e-07,44101.0,1332.0,1.0,0,101.0
981,121011,HP:0000365,CIB2 and GJB2 genes variants contribute significantly in familial cases of prelingual recessive hearing loss (HL).,1,1.395883254657124,11360890.773559922,359.9890516043107,0.1442161069048109,0.0490995817099891,0.0,0.0,1.000660501981506,1515.0,-0.6063388048985573,0.07124963487101682,1.0,2.0,7.0,266.0,266.0,150.0,532.0,2474,265.0,6.524672396198986e-07,81713.0,1515.0,1.0,0,305.0
4940,604095,HP:0000007,Bardet-Biedl Syndrome (BBS) is a rare multi-systemic disease with autosomal recessive transmission.,1,1.4717208369220942,2798214.159121435,422.6459320105256,0.2279968886188809,0.09744431912791834,0.0,0.0,1.0003720238095235,2689.0,-0.5626059265431222,0.012230438382121164,1.0,2.0,182.0,106.0,106.0,101.0,212.0,5160,105.0,1.5011496554636367e-07,44201.0,2689.0,1.0,0,99.0
4942,611060,HP:0000750,"Type III (simple type) patients with SETBP1 alteration show their major symptom is development delay, in which expressive language delay is the most striking feature.",1,1.3365577125069588,14282987.988488225,269.3660492215858,0.13929277334977375,0.09488290301846096,0.0,0.0,1.000777604976672,1287.0,-0.4056253754646543,0.10270427688779166,1.0,2.0,10.0,488.0,488.0,32.0,976.0,1466,487.0,1.8561278203862235e-06,84992.0,1287.0,1.0,0,642.0
4945,605236,HP:0000822,"This study aims to investigate the association of 2 single nucleotide polymorphisms (SNPs) in CORIN (rs2271037 and rs3749585) with hypertension, as well as their potential interactions with some risk factors of hypertension in a Han population of northeastern China.",0,1.3721146764129577,516497.1075230325,133.8089833759591,0.2172159144324456,0.019721773025446275,0.0,0.0,1.002754820936639,364.0,-0.6227739689025139,0.13923954833045746,1.0,2.0,1.0,87.0,87.0,78.0,174.0,544,86.0,1.3417595835178253e-05,9199.0,364.0,1.0,0,85.0
4944,605236,HP:0000822,Interaction study showed the association between CORIN polymorphisms and hypertension could be changed by overweight (BMI G 25 kg/m2).,0,1.3721146764129577,516497.1075230325,133.8089833759591,0.2172159144324456,0.019721773025446275,0.0,0.0,1.002754820936639,364.0,-0.6227739689025139,0.13923954833045746,1.0,2.0,1.0,87.0,87.0,78.0,174.0,544,86.0,1.3417595835178253e-05,9199.0,364.0,1.0,0,85.0
4943,605236,HP:0000822,"In conclusion, polymorphisms of rs2271037 and rs3749585 in CORIN were significantly associated with hypertension in a Han population of northeastern China.",0,1.3721146764129577,516497.1075230325,133.8089833759591,0.2172159144324456,0.019721773025446275,0.0,0.0,1.002754820936639,364.0,-0.6227739689025139,0.13923954833045746,1.0,2.0,1.0,87.0,87.0,78.0,174.0,544,86.0,1.3417595835178253e-05,9199.0,364.0,1.0,0,85.0
4863,131195,HP:0002664,"Thus, our data indicate that in pancreatic cancer cells, the expression of ENG may be controlled by a pathway mediated by SMAD4.",1,1.3684454688256968,4984019.097722349,215.51785179800743,0.16147832171855658,0.04777024220024696,0.0,0.0,1.000958772770853,1044.0,-0.6014570610793344,0.07980773116158442,1.0,2.0,14.0,242.0,242.0,91.0,484.0,1542,241.0,1.6778973932186103e-06,43451.0,1044.0,1.0,0,283.0
4946,609577,HP:0002664,"Cullin7 (CUL7) is a member of Cullin protein family and exhibits a tumor-promoting role in several types of tumors, including breast, liver and ovarian.",0,1.3592158936800145,5582551.5446855035,239.6620492866407,0.15742867747630998,0.16930684089561573,0.0,0.0,0.9989969909729188,996.0,-0.5598773767290107,0.08520551634864514,1.0,2.0,29.0,224.0,224.0,178.0,448.0,1544,222.0,1.6778973932186103e-06,42390.0,998.0,1.0,0,249.0
4949,609577,HP:0002664,"In the present study, CUL7 expression in EC tissue was revealed to be significantly higher compared with nontumoral tissues, as detected by immunohistochemistry (IHC; P=0.000). x2 analysis confirmed that CUL7 expression was positively associated with invasion depth (P=0.000), lymph node involvement (P=0.033) and advanced clinical stage (P=0.000).",0,1.3592158936800145,5582551.5446855035,239.6620492866407,0.15742867747630998,0.16930684089561573,0.0,0.0,0.9989969909729188,996.0,-0.5598773767290107,0.08520551634864514,1.0,2.0,29.0,224.0,224.0,178.0,448.0,1544,222.0,1.6778973932186103e-06,42390.0,998.0,1.0,0,249.0
4952,609577,HP:0002664,These data may improve our understanding of the role of CUL7 in tumors and provide supporting evidence for the development of novel therapeutic targets for EC,0,1.3592158936800145,5582551.5446855035,239.6620492866407,0.15742867747630998,0.16930684089561573,0.0,0.0,0.9989969909729188,996.0,-0.5598773767290107,0.08520551634864514,1.0,2.0,29.0,224.0,224.0,178.0,448.0,1544,222.0,1.6778973932186103e-06,42390.0,998.0,1.0,0,249.0
4403,123695,HP:0002664,The tumor abnormally accumulated FDGin PET-CT examination(SUVmax 3.3).,0,1.3560232837130708,4068277.5597773083,228.92338336112653,0.16399255007187136,0.07497005827026025,0.0,0.0,0.9989669421487604,967.0,-0.6038457339446593,0.07767443645574802,1.0,2.0,47.0,189.0,189.0,117.0,378.0,1544,187.0,1.6778973932186097e-06,36429.0,969.0,1.0,0,230.0
4956,102579,HP:0002664,"The tumor was diagnosed ACC with immunohistochemistry; positive to ACC phenotype(a1-antitrypsin, a1-antichymotrypsin, BCL10).",0,1.379419855420806,1411774.1267070659,207.44442345711656,0.203525332018984,0.02010068293399404,0.0,0.0,0.998857142857143,874.0,-0.6390386472994743,0.050987606001304635,1.0,2.0,66.0,101.0,101.0,74.0,202.0,1544,99.0,1.67789739321861e-06,19541.0,876.0,1.0,0,96.0
4957,603517,HP:0002664,"The tumor was diagnosed ACC with immunohistochemistry; positive to ACC phenotype(a1-antitrypsin, a1-antichymotrypsin, BCL10).",1,1.4144668655319648,2341283.379367936,260.54129174773016,0.18580371356411665,0.10322893779874226,0.0,0.0,1.0011135857461024,899.0,-0.647578817497391,0.07085576401396255,1.0,2.0,3.0,125.0,125.0,112.0,250.0,1542,124.0,1.67789739321861e-06,28601.0,899.0,1.0,0,116.0
4958,182350,HP:0001251,"Mutations in the ATP1A3 gene, which encodes the alpha3-subunit of sodium-potassium ATPase, are related to a spectrum of neurological diseases including Rapid onset Dystonia-Parkinsonism (RDP), Alternating Hemiplegia of Childhood (AHC) and Cerebellar ataxia, Areflexia, Pes cavus, Optic atrophy and Sensorineural hearing loss (CAPOS) syndrome.",1,1.4118555111202111,3984517.836268032,351.09743267645445,0.15847618676656608,0.04780575053038855,0.0,0.0,1.0010493179433368,954.0,-0.6874231994522098,0.09280634254401306,1.0,2.0,4.0,137.0,137.0,137.0,274.0,1626,136.0,1.5092152684290268e-06,42188.0,954.0,1.0,0,137.0
4962,182350,HP:0000365,"Mutations in the ATP1A3 gene, which encodes the alpha3-subunit of sodium-potassium ATPase, are related to a spectrum of neurological diseases including Rapid onset Dystonia-Parkinsonism (RDP), Alternating Hemiplegia of Childhood (AHC) and Cerebellar ataxia, Areflexia, Pes cavus, Optic atrophy and Sensorineural hearing loss (CAPOS) syndrome.",1,1.4346930728437828,5141631.278809228,422.7456268597671,0.16070766919825766,0.015939685953374298,0.0,0.0,1.0007262164124908,1378.0,-0.6847378622298492,0.056398240637974266,1.0,2.0,4.0,137.0,137.0,137.0,274.0,2474,136.0,6.524672396198987e-07,53508.0,1378.0,1.0,0,150.0
4960,182350,HP:0001251,"Our cases confirm that ATP1A3-related neurological disorders make up a phenotypic continuum rather than overlapping syndromes, in which early onset dystonia, ataxia and paroxysmal episodes with triggering or worsening factors are key diagnostic clues.",1,1.4118555111202111,3984517.836268032,351.09743267645445,0.15847618676656608,0.04780575053038855,0.0,0.0,1.0010493179433368,954.0,-0.6874231994522098,0.09280634254401306,1.0,2.0,4.0,137.0,137.0,137.0,274.0,1626,136.0,1.5092152684290268e-06,42188.0,954.0,1.0,0,137.0
1979,182350,HP:0001332,"Our cases confirm that ATP1A3-related neurological disorders make up a phenotypic continuum rather than overlapping syndromes, in which early onset dystonia, ataxia and paroxysmal episodes with triggering or worsening factors are key diagnostic clues.",1,1.375009138837215,2029170.005620111,216.96221238086068,0.17391535924654716,0.12443608399048756,0.0,0.0,1.0017182130584192,583.0,-0.6119384562462932,0.1367084578522042,1.0,2.0,4.0,137.0,137.0,134.0,274.0,884,136.0,5.095567365948361e-06,23193.0,583.0,1.0,0,162.0
237,164757,HP:0002664,Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor characterized by frequent RAS mutations and an absence of the BRAF V600E mutation commonly seen in classical papillary thyroid carcinoma (cPTC).,1,1.3343717616163435,16381827.818362188,267.1583928605997,0.14243558102353174,0.0178111227871734,0.0,0.0,1.0006944444444446,1441.0,-0.2821765440487228,0.0923076181663968,1.0,2.0,9.0,611.0,611.0,3.0,1222.0,1542,610.0,1.6778973932186103e-06,95771.0,1441.0,1.0,0,790.0
1220,601607,HP:0002664,"Approximately one-third of pediatric malignant rhabdoid tumors are linked to germline SWI/SNF alterations (SMARCB1/INI1, rarely SMARCA4) resulting in occasional familial clustering of these highly aggressive malignancies (so-called rhabdoid tumor predisposition syndrome, RTPS, types 1 and 2, respectively).",1,1.3396459207409952,12225578.24190254,245.38261997405968,0.14557418044513382,0.12700196151807008,0.0,0.0,1.000778816199377,1285.0,-0.4059447124260791,0.09173182055105034,1.0,2.0,2.0,465.0,465.0,24.0,930.0,1542,464.0,1.677897393218609e-06,75676.0,1285.0,1.0,0,609.0
4964,603254,HP:0002664,"Approximately one-third of pediatric malignant rhabdoid tumors are linked to germline SWI/SNF alterations (SMARCB1/INI1, rarely SMARCA4) resulting in occasional familial clustering of these highly aggressive malignancies (so-called rhabdoid tumor predisposition syndrome, RTPS, types 1 and 2, respectively).",0,1.3634839589137742,9600363.765630122,276.83693277274347,0.14358980552268466,0.027061898514284,0.0,0.0,1.0009363295880152,1069.0,-0.546744483496829,0.10423126377341699,1.0,2.0,3.0,288.0,288.0,148.0,576.0,1542,287.0,1.6778973932186103e-06,59500.0,1069.0,1.0,0,386.0
1225,601607,HP:0002664,"However, more recently, inherited SWI/SNF-deficiency has been linked to several benign syndromic tumors including a subset of familial schwannomatosis (linked to SMARCB1) and multiple meningiomas (linked to SMARCE1) as well as others.",1,1.3396459207409952,12225578.24190254,245.38261997405968,0.14557418044513382,0.12700196151807008,0.0,0.0,1.000778816199377,1285.0,-0.4059447124260791,0.09173182055105034,1.0,2.0,2.0,465.0,465.0,24.0,930.0,1542,464.0,1.677897393218609e-06,75676.0,1285.0,1.0,0,609.0
4965,603111,HP:0002664,"However, more recently, inherited SWI/SNF-deficiency has been linked to several benign syndromic tumors including a subset of familial schwannomatosis (linked to SMARCB1) and multiple meningiomas (linked to SMARCE1) as well as others.",0,1.3400484026389383,12405554.731155034,247.94828816798287,0.14507468281911526,0.04419341490577512,0.0,0.0,1.0007830853563038,1278.0,-0.4088970935621737,0.09293960929065212,1.0,2.0,1.0,460.0,460.0,25.0,920.0,1542,459.0,1.6778973932186097e-06,75839.0,1278.0,1.0,0,602.0
4966,608226,HP:0002664,An inverse correlation between the expression levels of human Nanos1 and Nanos3 and E-cadherin was observed in several cancer cell lines.,0,1.4260184297210523,290993.26262636745,183.4548100344816,0.28203002164441165,0.19617842627292728,0.0,0.0,0.998769987699877,812.0,-0.6773804175555341,0.023802400186164027,1.0,2.0,41.0,36.0,36.0,34.0,72.0,1544,34.0,1.6778973932186097e-06,7876.0,814.0,1.0,0,35.0
4967,603811,HP:0002664,"From the integrative analysis of the transcriptome and clinicopathologic data of human multi-stage HCC tissues, we were able to identify barrier-to-autointegration factor 1 (BANF1), procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3) and splicing factor 3b subunit 4 (SF3B4) as early HCC biomarkers which could be detected in precancerous lesions of HCC, with superior capabilities to diagnose eHCC compared to the currently popular HCC diagnostic biomarkers: GPC3, GS, and HSP70.",0,1.3695085854558662,3379301.3090295326,259.0346952010376,0.16600681851475305,0.020141995018481483,0.0,0.0,0.9989082969432316,915.0,-0.6599121431485204,0.07643826222778853,1.0,2.0,57.0,143.0,143.0,121.0,286.0,1544,141.0,1.67789739321861e-06,32103.0,917.0,1.0,0,144.0
4968,604043,HP:0002664,"Never in mitosis gene-A (NIMA)-related expressed kinase 2 (NEK2) has been recently reported to play a role in tumor progression, drug resistance and tumorigenesis.",0,1.401030187377212,2210744.279402738,261.5111661360688,0.1836120864509632,0.04989939829039446,0.0,0.0,0.9988662131519276,881.0,-0.6574062293768927,0.06641705379773652,1.0,2.0,29.0,111.0,111.0,111.0,222.0,1544,109.0,1.67789739321861e-06,25863.0,883.0,1.0,0,116.0
4969,604043,HP:0001402,"However, little is known about the effects of NEK2 in hepatocellular carcinoma (HCC) metastasis and the underlying mechanism.",0,1.3327398908725252,53120.25357142856,44.312587412587405,0.3200479659660393,0.09099620934962473,0.0,0.0,0.9938650306748468,162.0,-0.4860885747756537,0.12389645368846325,1.0,2.0,2.0,48.0,48.0,12.0,96.0,106,46.0,8.116224332440547e-05,1656.0,164.0,1.0,0,56.0
2525,138140,HP:0001250,"Dysfunction of the cerebral glucose transporter GLUT1 (encoded by SLC2A1) is known to result in epilepsy, intellectual disability (ID), and movement disorder.",1,1.4093050553419717,14055583.066745827,450.6500358422938,0.14304570831581534,0.022074275539454083,0.0,0.0,1.00054704595186,1829.0,-0.5942424591786458,0.06373848033087158,1.0,2.0,7.0,272.0,272.0,216.0,544.0,3100,271.0,4.156965348783942e-07,106552.0,1829.0,1.0,0,252.0
4970,138140,HP:0001249,"Dysfunction of the cerebral glucose transporter GLUT1 (encoded by SLC2A1) is known to result in epilepsy, intellectual disability (ID), and movement disorder.",1,1.4112517069360242,14174538.819293804,457.49208650477226,0.14243212625049553,0.08044423131107048,0.0,0.0,1.0005319148936171,1881.0,-0.6051280384959684,0.061481556890291486,1.0,2.0,7.0,270.0,270.0,203.0,540.0,3204,269.0,3.8916426584744994e-07,108708.0,1881.0,1.0,0,273.0
4973,605763,HP:0001250,"Using whole-exome sequencing, we identified rare homozygous missense variants (c.526C&gt;T [p.Arg176Trp] and c.629C&gt;T [p.Ala210Val]) in SLC45A1, encoding another cerebral glucose transporter, in two consanguineous multiplex families with moderate to severe ID, epilepsy, and variable neuropsychiatric features.",1,1.4468507682793397,10497225.79515883,667.1537191650855,0.14247104136447022,0.0628935464078117,0.0,0.0,1.000593471810089,1686.0,-0.7043675706900404,0.0587234372085001,1.0,2.0,1.0,136.0,136.0,136.0,272.0,3100,135.0,4.156965348783941e-07,83414.0,1686.0,1.0,0,155.0
4971,605763,HP:0001250,"All together, our data strongly suggest that recessive mutations in SLC45A1 cause ID and epilepsy.",1,1.4468507682793397,10497225.79515883,667.1537191650855,0.14247104136447022,0.0628935464078117,0.0,0.0,1.000593471810089,1686.0,-0.7043675706900404,0.0587234372085001,1.0,2.0,1.0,136.0,136.0,136.0,272.0,3100,135.0,4.156965348783941e-07,83414.0,1686.0,1.0,0,155.0
2678,164730,HP:0002664,"We find that STX3 promotes the proliferation of breast cancer cells by increasing the activation of the Akt-mTOR signaling, and Akt inhibitor Ipatasertib or MK-2206 represses STX3 effects on the growth of breast cancer cells.",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
356,601231,HP:0002664,"We find that STX3 promotes the proliferation of breast cancer cells by increasing the activation of the Akt-mTOR signaling, and Akt inhibitor Ipatasertib or MK-2206 represses STX3 effects on the growth of breast cancer cells.",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
2666,164730,HP:0002664,"Therefore, STX3 promotes the growth of breast cancer cells by regulating the PTEN-PI3K-Akt-mTOR signaling",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
328,601231,HP:0002664,"Therefore, STX3 promotes the growth of breast cancer cells by regulating the PTEN-PI3K-Akt-mTOR signaling",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
507,601728,HP:0002664,"Therefore, STX3 promotes the growth of breast cancer cells by regulating the PTEN-PI3K-Akt-mTOR signaling",1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
805,171834,HP:0002664,"Therefore, STX3 promotes the growth of breast cancer cells by regulating the PTEN-PI3K-Akt-mTOR signaling",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
4975,164860,HP:0000365,"A dominant substitution (p.Arg544Gln) of METTL13, encoding a predicted methyltransferase, is the DFNM1 suppressor of GAB1-associated deafness.",0,1.4529615617822995,2007297.0308594047,365.0812191472162,0.20264378063304286,0.027411018698344544,0.0,0.0,1.0007518796992478,1331.0,-0.6639956028645883,0.03603373572925552,1.0,2.0,3.0,91.0,91.0,74.0,182.0,2474,90.0,6.524672396198986e-07,31894.0,1331.0,1.0,0,77.0
4981,608528,HP:0000365,"Expression of MET-signaling genes in human lymphoblastoid cells of individuals homozygous for p.Gly116Glu GAB1 revealed dysregulation of HGF, MET, SHP2, and SPRY2, all of which have reported variants associated with deafness.",0,1.4191340361445783,9950390.573251212,459.8436025164505,0.14458817594348322,0.04284587035837363,0.0,0.0,0.9992942836979536,1416.0,-0.647094735338714,0.07267185784544514,1.0,2.0,1.0,180.0,180.0,180.0,360.0,2476,178.0,6.514144487633221e-07,73010.0,1418.0,1.0,0,192.0
4977,164860,HP:0000365,"Expression of MET-signaling genes in human lymphoblastoid cells of individuals homozygous for p.Gly116Glu GAB1 revealed dysregulation of HGF, MET, SHP2, and SPRY2, all of which have reported variants associated with deafness.",0,1.4529615617822995,2007297.0308594047,365.0812191472162,0.20264378063304286,0.027411018698344544,0.0,0.0,1.0007518796992478,1331.0,-0.6639956028645883,0.03603373572925552,1.0,2.0,3.0,91.0,91.0,74.0,182.0,2474,90.0,6.524672396198986e-07,31894.0,1331.0,1.0,0,77.0
4983,147620,HP:0000365,"Expression of MET-signaling genes in human lymphoblastoid cells of individuals homozygous for p.Gly116Glu GAB1 revealed dysregulation of HGF, MET, SHP2, and SPRY2, all of which have reported variants associated with deafness.",0,1.4075104213741776,4903550.867397277,328.2724776702092,0.16788947645192098,0.2150453148174844,0.0,0.0,0.9992867332382313,1401.0,-0.665113614031265,0.04946197418818245,1.0,2.0,37.0,155.0,155.0,106.0,310.0,2486,154.0,6.524672396198984e-07,48646.0,1403.0,1.0,0,139.0
4984,602466,HP:0000365,"Expression of MET-signaling genes in human lymphoblastoid cells of individuals homozygous for p.Gly116Glu GAB1 revealed dysregulation of HGF, MET, SHP2, and SPRY2, all of which have reported variants associated with deafness.",0,1.4460248891562202,325099.3729656713,224.83647368530148,0.3332719589726605,0.2255060058538571,0.0,0.0,0.9992169146436962,1276.0,-0.5910050508676381,0.011888436684669051,1.0,2.0,71.0,38.0,38.0,36.0,76.0,2476,36.0,6.524672396198988e-07,9701.0,1278.0,1.0,0,35.0
4982,608528,HP:0000365,"However, SPRY2 was not dysregulated in normal-hearing humans homozygous for both the GAB1 DFNB26 deafness variant and the dominant METTL13 deafness suppressor, indicating a plausible mechanism of suppression.",0,1.4191340361445783,9950390.573251212,459.8436025164505,0.14458817594348322,0.04284587035837363,0.0,0.0,0.9992942836979536,1416.0,-0.647094735338714,0.07267185784544514,1.0,2.0,1.0,180.0,180.0,180.0,360.0,2476,178.0,6.514144487633221e-07,73010.0,1418.0,1.0,0,192.0
4979,164860,HP:0000365,"However, SPRY2 was not dysregulated in normal-hearing humans homozygous for both the GAB1 DFNB26 deafness variant and the dominant METTL13 deafness suppressor, indicating a plausible mechanism of suppression.",0,1.4529615617822995,2007297.0308594047,365.0812191472162,0.20264378063304286,0.027411018698344544,0.0,0.0,1.0007518796992478,1331.0,-0.6639956028645883,0.03603373572925552,1.0,2.0,3.0,91.0,91.0,74.0,182.0,2474,90.0,6.524672396198986e-07,31894.0,1331.0,1.0,0,77.0
4986,602466,HP:0000365,"However, SPRY2 was not dysregulated in normal-hearing humans homozygous for both the GAB1 DFNB26 deafness variant and the dominant METTL13 deafness suppressor, indicating a plausible mechanism of suppression.",0,1.4460248891562202,325099.3729656713,224.83647368530148,0.3332719589726605,0.2255060058538571,0.0,0.0,0.9992169146436962,1276.0,-0.5910050508676381,0.011888436684669051,1.0,2.0,71.0,38.0,38.0,36.0,76.0,2476,36.0,6.524672396198988e-07,9701.0,1278.0,1.0,0,35.0
4988,602774,HP:0002664,RAD51C and RAD51D have been defined as susceptibility genes for hereditary breast and ovarian cancer syndrome in several studies.,1,1.3495654256832177,12820205.771016564,289.5680636825378,0.14116732754766764,0.06982837343317029,0.0,0.0,1.000859845227859,1164.0,-0.4409432896921249,0.11136325358342716,1.0,2.0,2.0,391.0,391.0,82.0,782.0,1542,390.0,1.6778973932186103e-06,75378.0,1164.0,1.0,0,503.0
4994,602954,HP:0002664,RAD51C and RAD51D have been defined as susceptibility genes for hereditary breast and ovarian cancer syndrome in several studies.,1,1.4713739849617211,248609.3728498354,226.0473411154345,0.310344028142904,0.03111339282097156,0.0,0.0,1.0012437810945274,805.0,-0.6153217517329885,0.022746515867865642,1.0,2.0,4.0,34.0,34.0,34.0,68.0,1542,33.0,1.6778973932186097e-06,7361.0,805.0,1.0,0,44.0
4997,602954,HP:0002664,"The RAD51C pathogenic variant c.404G &gt; A was identified in a breast and ovarian cancer family (0.7%), while the RAD51D pathogenic variant c.694C &gt; T was described in an ovarian cancer family (1.3%).",1,1.4713739849617211,248609.3728498354,226.0473411154345,0.310344028142904,0.03111339282097156,0.0,0.0,1.0012437810945274,805.0,-0.6153217517329885,0.022746515867865642,1.0,2.0,4.0,34.0,34.0,34.0,68.0,1542,33.0,1.6778973932186097e-06,7361.0,805.0,1.0,0,44.0
4990,602774,HP:0002664,These results increase our knowledge about the RAD51C and RAD51D mutation spectrum and support the notion that these genes should be included in the gene panel testing performed on patients with hereditary breast and ovarian cancer syndrome,1,1.3495654256832177,12820205.771016564,289.5680636825378,0.14116732754766764,0.06982837343317029,0.0,0.0,1.000859845227859,1164.0,-0.4409432896921249,0.11136325358342716,1.0,2.0,2.0,391.0,391.0,82.0,782.0,1542,390.0,1.6778973932186103e-06,75378.0,1164.0,1.0,0,503.0
5000,602954,HP:0002664,These results increase our knowledge about the RAD51C and RAD51D mutation spectrum and support the notion that these genes should be included in the gene panel testing performed on patients with hereditary breast and ovarian cancer syndrome,1,1.4713739849617211,248609.3728498354,226.0473411154345,0.310344028142904,0.03111339282097156,0.0,0.0,1.0012437810945274,805.0,-0.6153217517329885,0.022746515867865642,1.0,2.0,4.0,34.0,34.0,34.0,68.0,1542,33.0,1.6778973932186097e-06,7361.0,805.0,1.0,0,44.0
5003,612036,HP:0012469,"The aim of the study was to characterize the PARS2- related phenotype.Three siblings with biallelic PARS2 mutations presented from birth with infantile spasms, secondary microcephaly, and similar facial dysmorphy.",0,1.353714781496872,508921.2404761904,127.32936865115084,0.2049675274577231,0.05598078664561605,0.0,0.0,0.9964285714285714,279.0,-0.6036713137366136,0.18469750889679715,1.0,2.0,2.0,78.0,78.0,78.0,156.0,156,77.0,2.426654371617851e-05,7266.0,281.0,1.0,0,78.0
5004,612036,HP:0000252,"The aim of the study was to characterize the PARS2- related phenotype.Three siblings with biallelic PARS2 mutations presented from birth with infantile spasms, secondary microcephaly, and similar facial dysmorphy.",0,1.4045022465102976,11644893.72424689,493.8319132010008,0.131271626831205,0.009955645136727958,0.0,0.0,1.0008103727714748,1235.0,-0.6389529269910795,0.10949940616408244,1.0,2.0,1.0,202.0,202.0,202.0,404.0,2066,201.0,9.35317203476387e-07,83438.0,1235.0,1.0,0,212.0
5005,603527,HP:0001263,"Biallelic mutations of the gene encoding diphthamide biosynthesis 1 (DPH1, NM_001383.3) cause developmental delay, dysmorphic features, sparse hair, and short stature (MIM *603527).",1,1.4208882254744208,17562248.303878676,565.8447411396436,0.13314896393263792,0.062289316212714385,0.0,0.0,1.0005817335660268,1720.0,-0.6360471051923415,0.07372052437193068,1.0,2.0,1.0,221.0,221.0,221.0,442.0,2998,220.0,4.4444444444444465e-07,108984.0,1720.0,1.0,0,238.0
5006,603527,HP:0008070,"Biallelic mutations of the gene encoding diphthamide biosynthesis 1 (DPH1, NM_001383.3) cause developmental delay, dysmorphic features, sparse hair, and short stature (MIM *603527).",1,1.3371993692790265,2814189.012373737,199.14696647889923,0.15913387218345976,0.08427518872860057,0.0,0.0,1.0019455252918288,515.0,-0.3975212992592292,0.18983038041630465,1.0,2.0,3.0,214.0,214.0,64.0,428.0,588,213.0,1.1490950876185005e-05,25125.0,515.0,1.0,0,295.0
5007,603527,HP:0004322,"Biallelic mutations of the gene encoding diphthamide biosynthesis 1 (DPH1, NM_001383.3) cause developmental delay, dysmorphic features, sparse hair, and short stature (MIM *603527).",1,1.404018916585179,14751147.23706673,480.18524612642256,0.1310929494888204,0.022519011431368988,0.0,0.0,1.0007451564828616,1343.0,-0.6534048059989,0.0983828495272168,1.0,2.0,1.0,221.0,221.0,221.0,442.0,2244,220.0,7.929402939746845e-07,88658.0,1343.0,1.0,0,253.0
5008,607444,HP:0004322,A 7.5 year-old boy born to second-degree cousins presented with severe short stature (height SDS -3.7) and bone age of 6 years.,1,1.3876952979342234,11132908.200462904,351.0076871657754,0.14004414351752878,0.18275906114119167,0.0,0.0,1.0007097232079492,1410.0,-0.6148575432189853,0.0809809280763481,1.0,2.0,1.0,276.0,276.0,137.0,552.0,2244,275.0,7.929402939746847e-07,80442.0,1410.0,1.0,0,274.0
1938,164761,HP:0002664,This study systematically reviewed previous literatures and analyzed the genotype-phenotype relationship between the multiple endocrine neoplasia type 2A (MEN 2A)-cutaneous lichen amyloidosis (CLA) and RET/OSMR/IL31RA mutations.,1,1.3454208312212703,10532873.130266957,248.6928072346046,0.14679757854877915,0.02628547516165559,0.0,0.0,1.0008305647840532,1205.0,-0.4632247979281744,0.09519995588701564,1.0,2.0,7.0,395.0,395.0,52.0,790.0,1542,394.0,1.677897393218609e-06,69059.0,1205.0,1.0,0,548.0
5010,609510,HP:0002664,This study systematically reviewed previous literatures and analyzed the genotype-phenotype relationship between the multiple endocrine neoplasia type 2A (MEN 2A)-cutaneous lichen amyloidosis (CLA) and RET/OSMR/IL31RA mutations.,0,1.464538534079488,34863.588837715906,267.9576307825336,0.40256381871341096,0.3599294633143363,0.0,0.0,0.9987195902688859,780.0,-0.85632686688465,0.010302222542415621,1.0,2.0,36.0,10.0,10.0,10.0,20.0,1544,8.0,1.6778973932186097e-06,3146.0,782.0,1.0,0,8.0
5011,610622,HP:0002664,"However, the role of FUZ in tumor biology remains poorly studied.",1,1.3973180622129413,3914385.3657628205,263.11672388799883,0.16530476628677224,0.03823242863148225,0.0,0.0,1.001063829787234,941.0,-0.6445606656537519,0.08286567029190314,1.0,2.0,4.0,169.0,169.0,126.0,338.0,1542,168.0,1.6778973932186097e-06,36649.0,941.0,1.0,0,192.0
5012,610622,HP:0002664,Our purpose of this study is to discover the physiological effects and mechanism of FUZ in non-small-cell lung cancer (NSCLC) in vitro.,1,1.3973180622129413,3914385.3657628205,263.11672388799883,0.16530476628677224,0.03823242863148225,0.0,0.0,1.001063829787234,941.0,-0.6445606656537519,0.08286567029190314,1.0,2.0,4.0,169.0,169.0,126.0,338.0,1542,168.0,1.6778973932186097e-06,36649.0,941.0,1.0,0,192.0
5013,602591,HP:0002664,"The Kinesin family member 2a (KIF2A), that belongs to the Kinesin-13 microtubule depolymerases, plays an important role in cancer cell proliferation, migration and apoptosis in various types of cancer such as gastric cancer, breast cancer, and squamous cell carcinoma of the oral tongue, but, its role and mechanism in lung adenocarcinoma (LUAD) is largely unknown.",0,1.4287697876708627,999575.9505278631,299.59164448085187,0.1980130732096682,0.13072517456993082,0.0,0.0,0.9987937273823884,828.0,-0.7508326510887379,0.048317758367607946,1.0,2.0,31.0,56.0,56.0,55.0,112.0,1544,54.0,1.6778973932186103e-06,16623.0,830.0,1.0,0,59.0
5014,602591,HP:0030078,"Furthermore, silencing KIF2A inhibited cell proliferation and induced apoptosis in lung adenocarcinoma(LUAD) cells.",0,1.3115709705625185,5200.363095238095,25.59752321981424,0.3991347740321268,0.27531794602241744,0.0,0.0,0.9866666666666668,74.0,-0.7373873475476521,0.1343859649122807,1.0,2.0,6.0,15.0,15.0,11.0,30.0,68,13.0,0.0002972651605231866,383.0,76.0,1.0,0,15.0
5032,177046,HP:0009733,"In this study, we established PSMB8 as a therapeutic target for glioma treatment.",0,1.3354834568852092,149539.0268939394,94.69851074631916,0.2833655195738579,0.4191854502558471,0.0,0.0,0.9971428571428572,349.0,-0.5569765193097984,0.056784696784696775,1.0,2.0,68.0,39.0,39.0,39.0,78.0,292,38.0,1.027284681130835e-05,3488.0,351.0,1.0,0,45.0
5044,164920,HP:0009733,"Then, the role of PSMB8 in migration and proliferation of glioma cells was investigated by conducting wound-healing, trans-well assay, cell counting kit (CCK)-8, flow cytometry assay and colony formation analysis.",0,1.3455882352941178,148573.0969169719,103.083424328456,0.26348357679623363,0.3592074337561161,0.0,0.0,0.9964285714285712,279.0,-0.6831137848187993,0.09143365531265887,1.0,2.0,36.0,39.0,39.0,39.0,78.0,192,38.0,1.7075336384126773e-05,3597.0,281.0,1.0,0,45.0
5036,177046,HP:0009733,"The data showed that interfering PSMB8 may inhibit the migration and proliferation of glioma cells by reducing expression of cyclin A, cyclin B1, cyclin D1, Vimentin, and N-cadherin, and by increasing expression of E-cadherin.",0,1.3354834568852092,149539.0268939394,94.69851074631916,0.2833655195738579,0.4191854502558471,0.0,0.0,0.9971428571428572,349.0,-0.5569765193097984,0.056784696784696775,1.0,2.0,68.0,39.0,39.0,39.0,78.0,292,38.0,1.027284681130835e-05,3488.0,351.0,1.0,0,45.0
5016,177046,HP:0009733,"Additionally, interfering PSMB8 may induce apoptosis of glioma cells by upregulating caspase-3 expression.",0,1.3354834568852092,149539.0268939394,94.69851074631916,0.2833655195738579,0.4191854502558471,0.0,0.0,0.9971428571428572,349.0,-0.5569765193097984,0.056784696784696775,1.0,2.0,68.0,39.0,39.0,39.0,78.0,292,38.0,1.027284681130835e-05,3488.0,351.0,1.0,0,45.0
5024,177046,HP:0009733,"Furthermore, these in vitro findings were validated in vivo and the ERK1/2 and PI3k/AKT signaling pathways were involved in PSMB8-triggered migration and proliferation of glioma cells.",0,1.3354834568852092,149539.0268939394,94.69851074631916,0.2833655195738579,0.4191854502558471,0.0,0.0,0.9971428571428572,349.0,-0.5569765193097984,0.056784696784696775,1.0,2.0,68.0,39.0,39.0,39.0,78.0,292,38.0,1.027284681130835e-05,3488.0,351.0,1.0,0,45.0
5045,171834,HP:0009733,"Furthermore, these in vitro findings were validated in vivo and the ERK1/2 and PI3k/AKT signaling pathways were involved in PSMB8-triggered migration and proliferation of glioma cells.",1,1.466680634261846,309740.3356338503,220.01788031723146,0.289987938030676,0.223308349086544,0.0,0.0,1.0013037809647978,768.0,-0.5705203682142564,0.026982154498044333,1.0,2.0,70.0,38.0,38.0,38.0,76.0,444,38.0,1.8713940575753085e-06,7947.0,768.0,1.0,0,38.0
4601,164730,HP:0009733,"Furthermore, these in vitro findings were validated in vivo and the ERK1/2 and PI3k/AKT signaling pathways were involved in PSMB8-triggered migration and proliferation of glioma cells.",0,1.4282355325833591,307804.51916052896,186.9461300309597,0.29482801106164924,0.03779829588816011,0.0,0.0,0.9986091794158553,718.0,-0.538818049792063,0.02848864163189615,1.0,2.0,47.0,39.0,39.0,39.0,78.0,310,38.0,2.1562830854685934e-06,7374.0,720.0,1.0,0,46.0
5046,177046,HP:0002664,"In an in vivo model, downregulation of PSMB8 suppressed tumor growth.",0,1.3523761050585086,7401297.644652405,251.403163720228,0.14946473815206351,0.24257870141711824,0.0,0.0,0.9990766389658357,1082.0,-0.5465335120099702,0.09600228966278583,1.0,2.0,8.0,301.0,301.0,116.0,602.0,1544,299.0,1.67789739321861e-06,56352.0,1084.0,1.0,0,373.0
5028,177046,HP:0009733,"In conclusion, PSMB8 is closely associated with migration, proliferation, and apoptosis of glioma cells, and might be considered as a novel prognostic indicator in patients with gliomas",0,1.3354834568852092,149539.0268939394,94.69851074631916,0.2833655195738579,0.4191854502558471,0.0,0.0,0.9971428571428572,349.0,-0.5569765193097984,0.056784696784696775,1.0,2.0,68.0,39.0,39.0,39.0,78.0,292,38.0,1.027284681130835e-05,3488.0,351.0,1.0,0,45.0
5047,600856,HP:0002664,"CDKN1C, also known as p57kip2, is considered to be a potential tumor suppressor implicated in several kinds of human cancers.",1,1.3572277044243688,9434274.77177983,263.14736821727934,0.14844267512261738,0.04106640336766694,0.0,0.0,1.0009049773755656,1106.0,-0.4880888203270165,0.10056704278595567,1.0,2.0,1.0,331.0,331.0,99.0,662.0,1542,330.0,1.6778973932186103e-06,61453.0,1106.0,1.0,0,458.0
5052,600856,HP:0002664,"However, the current knowledge of CDKN1C in breast cancer remains obscure.",1,1.3572277044243688,9434274.77177983,263.14736821727934,0.14844267512261738,0.04106640336766694,0.0,0.0,1.0009049773755656,1106.0,-0.4880888203270165,0.10056704278595567,1.0,2.0,1.0,331.0,331.0,99.0,662.0,1542,330.0,1.6778973932186103e-06,61453.0,1106.0,1.0,0,458.0
5062,600856,HP:0002664,"In the present study, we demonstrated that CDKN1C was dramatically downregulated in breast cancer compared with normal tissues by using real-time quantitative polymerase chain reaction, western blot and two public data portals: The Cancer Genome Atlas (TCGA) and Oncomine datasets.",1,1.3572277044243688,9434274.77177983,263.14736821727934,0.14844267512261738,0.04106640336766694,0.0,0.0,1.0009049773755656,1106.0,-0.4880888203270165,0.10056704278595567,1.0,2.0,1.0,331.0,331.0,99.0,662.0,1542,330.0,1.6778973932186103e-06,61453.0,1106.0,1.0,0,458.0
568,600960,HP:0002664,"In the present study, we demonstrated that CDKN1C was dramatically downregulated in breast cancer compared with normal tissues by using real-time quantitative polymerase chain reaction, western blot and two public data portals: The Cancer Genome Atlas (TCGA) and Oncomine datasets.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
5067,600856,HP:0002664,"Moreover, the expression of CDKN1C was correlated with age and tumor size in the TCGA cohort containing 708 cases of breast cancer.",1,1.3572277044243688,9434274.77177983,263.14736821727934,0.14844267512261738,0.04106640336766694,0.0,0.0,1.0009049773755656,1106.0,-0.4880888203270165,0.10056704278595567,1.0,2.0,1.0,331.0,331.0,99.0,662.0,1542,330.0,1.6778973932186103e-06,61453.0,1106.0,1.0,0,458.0
5057,600856,HP:0002664,"In conclusion, our data suggested an essential role of CDKN1C in the tumorgenesis of breast cancer.",1,1.3572277044243688,9434274.77177983,263.14736821727934,0.14844267512261738,0.04106640336766694,0.0,0.0,1.0009049773755656,1106.0,-0.4880888203270165,0.10056704278595567,1.0,2.0,1.0,331.0,331.0,99.0,662.0,1542,330.0,1.6778973932186103e-06,61453.0,1106.0,1.0,0,458.0
5072,600856,HP:0002664,Targeting CDKN1C may be a promising strategy for anticancer therapeutics,1,1.3572277044243688,9434274.77177983,263.14736821727934,0.14844267512261738,0.04106640336766694,0.0,0.0,1.0009049773755656,1106.0,-0.4880888203270165,0.10056704278595567,1.0,2.0,1.0,331.0,331.0,99.0,662.0,1542,330.0,1.6778973932186103e-06,61453.0,1106.0,1.0,0,458.0
5077,609479,HP:0002664,LncRNA MAP3K20 antisense RNA 1 (MLK7-AS1) has been identified as one of gastric cancer-specific lncRNAs.,0,1.3690011668784885,5252491.548528559,251.9081858205001,0.1551390359356155,0.09001477071855715,0.0,0.0,0.9989847715736042,984.0,-0.6214083959604819,0.0879150750095242,1.0,2.0,17.0,211.0,211.0,134.0,422.0,1544,209.0,1.67789739321861e-06,42692.0,986.0,1.0,0,263.0
5078,604149,HP:0001336,We present a case of myoclonus-dystonia syndrome illustrated by three videos in which we found a novel SGCE mutation.,1,1.4242129925452611,165044.84552990587,141.55696408256136,0.2450242623574813,0.06125052770489551,0.0,0.0,1.0029940119760479,335.0,-0.7527396890393763,0.09294843149521853,1.0,2.0,2.0,41.0,41.0,40.0,82.0,586,40.0,1.1569253551760842e-05,5200.0,335.0,1.0,0,39.0
2712,609644,HP:0002664,"Here we report three individuals with biallelic FANCM truncating mutations who developed early-onset cancer and toxicity to chemotherapy but did not present congenital malformations or any hematological phenotype suggestive of FA.MethodsChromosomal breakages, interstrand crosslink sensitivity, and FANCD2 monoubiquitination were assessed in primary fibroblasts.",1,1.352582238102203,12017173.424296536,292.6864849433261,0.1406675231511127,0.11309424037472628,0.0,0.0,1.0008787346221442,1139.0,-0.4653114036100979,0.11249809054592642,1.0,2.0,6.0,366.0,366.0,104.0,732.0,1542,365.0,1.6778973932186097e-06,72909.0,1139.0,1.0,0,459.0
5079,613984,HP:0002664,"Here we report three individuals with biallelic FANCM truncating mutations who developed early-onset cancer and toxicity to chemotherapy but did not present congenital malformations or any hematological phenotype suggestive of FA.MethodsChromosomal breakages, interstrand crosslink sensitivity, and FANCD2 monoubiquitination were assessed in primary fibroblasts.",1,1.3443751049641288,13634066.221587395,277.7363129823827,0.1415596132060388,0.02312098975976063,0.0,0.0,1.0008223684210529,1217.0,-0.4154214980578075,0.10605646974873502,1.0,2.0,5.0,431.0,431.0,44.0,862.0,1542,430.0,1.6778973932186103e-06,78475.0,1217.0,1.0,0,544.0
2715,609644,HP:0002664,Patient-derived cells were genetically complemented upon wild-type FANCM complementary DNA expression.ConclusionLoss-of-function mutations in FANCM cause a cancer predisposition syndrome clinically distinct from bona fide FA.,1,1.352582238102203,12017173.424296536,292.6864849433261,0.1406675231511127,0.11309424037472628,0.0,0.0,1.0008787346221442,1139.0,-0.4653114036100979,0.11249809054592642,1.0,2.0,6.0,366.0,366.0,104.0,732.0,1542,365.0,1.6778973932186097e-06,72909.0,1139.0,1.0,0,459.0
5083,613629,HP:0002664,Piezo2 is needed by brain metastatic cells from breast cancer (MDA-MB-231-BrM2) to probe their physical environment as they anchor and pull on their surroundings or when confronted with confined migration through narrow pores.,1,1.3431640182274327,12464095.01294373,253.58130270010213,0.1419399616640716,0.07992563311111676,0.0,0.0,1.0008123476848092,1232.0,-0.4344990194877429,0.096476837541013,1.0,2.0,19.0,433.0,433.0,41.0,866.0,1542,432.0,1.6778973932186103e-06,73158.0,1232.0,1.0,0,572.0
2410,165390,HP:0002664,"Consequently, hallmarks of cancer invasion and metastasis related to RhoA, actin cytoskeleton, and/or force transmission, such as migration, extracellular matrix degradation, and Serpin B2 secretion, were reduced in cells lacking Piezo2",0,1.3978683131436085,2157606.155043348,229.1092045672004,0.1848188673957168,0.06592376818482969,0.0,0.0,0.9988814317673378,893.0,-0.611879548470754,0.06202742054416158,1.0,2.0,23.0,121.0,121.0,117.0,242.0,1544,119.0,1.67789739321861e-06,24815.0,895.0,1.0,0,117.0
3759,102582,HP:0002664,The activation of signal transducer and activator of transcription 3 (STAT3) by elevated interleukin (IL) levels has been reported to regulate tumorigenesis both in vitro and in vivo.,1,1.3508433607360242,8878616.878968583,248.4226000095069,0.15216571976025756,0.08400986982943877,0.0,0.0,1.0008680555555554,1153.0,-0.4756805464757602,0.09554935193215766,1.0,2.0,7.0,368.0,368.0,71.0,736.0,1542,367.0,1.67789739321861e-06,63457.0,1153.0,1.0,0,460.0
3731,102582,HP:0002664,"However, the clinical implication of p-STAT3 expression in colon cancer is still controversial.",1,1.3508433607360242,8878616.878968583,248.4226000095069,0.15216571976025756,0.08400986982943877,0.0,0.0,1.0008680555555554,1153.0,-0.4756805464757602,0.09554935193215766,1.0,2.0,7.0,368.0,368.0,71.0,736.0,1542,367.0,1.67789739321861e-06,63457.0,1153.0,1.0,0,460.0
3745,102582,HP:0002664,"In this study, we evaluated the effect of STAT3 inactivation on biologic behavior of primary (Caco-2) and metastatic colon cancer cells (LoVo and SNU407) and the relation of p-STAT3 expression with the invasion of colon tumor.",1,1.3508433607360242,8878616.878968583,248.4226000095069,0.15216571976025756,0.08400986982943877,0.0,0.0,1.0008680555555554,1153.0,-0.4756805464757602,0.09554935193215766,1.0,2.0,7.0,368.0,368.0,71.0,736.0,1542,367.0,1.67789739321861e-06,63457.0,1153.0,1.0,0,460.0
3766,102582,HP:0002664,"The immunohistochemical assay using clinical samples of colonic tumors with various invasion depth showed that p-STAT3 expression was inversely associated with tumor invasion (p = 0.001, hazard ratio (HR) = 0.328, 95% confidence interval (95%CI): 0.170-0.632).",1,1.3508433607360242,8878616.878968583,248.4226000095069,0.15216571976025756,0.08400986982943877,0.0,0.0,1.0008680555555554,1153.0,-0.4756805464757602,0.09554935193215766,1.0,2.0,7.0,368.0,368.0,71.0,736.0,1542,367.0,1.67789739321861e-06,63457.0,1153.0,1.0,0,460.0
3738,102582,HP:0002664,"In conclusion, p-STAT3 may participate in the progression of the early stage of colon cancer through the up-regulation of CD133, which in turn induces survivin expression.",1,1.3508433607360242,8878616.878968583,248.4226000095069,0.15216571976025756,0.08400986982943877,0.0,0.0,1.0008680555555554,1153.0,-0.4756805464757602,0.09554935193215766,1.0,2.0,7.0,368.0,368.0,71.0,736.0,1542,367.0,1.67789739321861e-06,63457.0,1153.0,1.0,0,460.0
5084,600702,HP:0001250,Mutations in SCN8A gene have been described in relation to infantile onset epilepsy with movement disorders and developmental delay.,1,1.4255420463817696,14783659.930338308,550.2392626728109,0.13782868567343642,0.015102550640193948,0.0,0.0,1.0005685048322908,1760.0,-0.6604132258189692,0.06574176960049614,1.0,2.0,4.0,206.0,206.0,198.0,412.0,3100,205.0,4.1569653487839437e-07,101763.0,1760.0,1.0,0,203.0
5085,600702,HP:0001263,Mutations in SCN8A gene have been described in relation to infantile onset epilepsy with movement disorders and developmental delay.,1,1.4237265742278349,14935008.965547802,550.2959369738555,0.13606878403127287,0.0147688866629394,0.0,0.0,1.0005854800936769,1709.0,-0.6672824415136661,0.06945047777094128,1.0,2.0,6.0,203.0,203.0,192.0,406.0,2998,202.0,4.4444444444444454e-07,101362.0,1709.0,1.0,0,203.0
5086,606410,HP:0000648,"Mutations in ANTXR1 have been associated with GAPO (growth retardation, alopecia, pseudoanodontia, and optic atrophy) syndrome and infantile hemangioma, however no clinical characteristics associated with these conditions were observed in our study family.",1,1.3467218555393967,4677333.680728732,212.86591814559944,0.15777095285105358,0.05635184124021553,0.0,0.0,1.0012886597938144,777.0,-0.5290332269914493,0.12544945534636254,1.0,2.0,6.0,254.0,254.0,67.0,508.0,1014,254.0,3.952428569734674e-06,37820.0,777.0,1.0,0,305.0
5087,606410,HP:0001028,"Mutations in ANTXR1 have been associated with GAPO (growth retardation, alopecia, pseudoanodontia, and optic atrophy) syndrome and infantile hemangioma, however no clinical characteristics associated with these conditions were observed in our study family.",1,1.3587261131465451,954617.0827380952,142.75164869029277,0.1886082644475326,0.18915368927726176,0.0,0.0,1.0025510204081631,393.0,-0.4845220130521978,0.15302227761333542,1.0,2.0,12.0,118.0,118.0,118.0,236.0,254,118.0,1.312749422390254e-05,11787.0,393.0,1.0,0,137.0
5088,168470,HP:0003006,Models evaluated include a neuroblastoma cell line (SK-N-AS) and immortalized keratinocytes (HaCaT) as a control of high PTHLH production.,0,1.2910572298026897,40527.50833333334,45.324924924924915,0.29760494792142256,0.2280078188187697,0.0,0.0,0.9921875,127.0,-0.5892435533368849,0.1529796511627907,1.0,2.0,12.0,32.0,32.0,38.0,64.0,92,30.0,0.00012075836251660427,1263.0,129.0,1.0,0,42.0
5089,600470,HP:0001363,"Clinical studies have also revealed that ZIC1 gain of function mutations contribute to coronal craniosynostosis, a rare skull malformation.",1,1.336615048890008,825605.4853174603,143.99647593785525,0.1793252047120511,0.1442202524869612,0.0,0.0,1.0030674846625771,327.0,-0.25912663662649177,0.2180259282189828,1.0,2.0,2.0,142.0,142.0,2.0,284.0,290,141.0,2.986055122577563e-05,11621.0,327.0,1.0,0,189.0
5090,148060,HP:0002664,Genomic and transcriptomic analysis of &gt;5000 patients demonstrates that KRT8 mutation and copy number amplification are frequently evident in epithelial-derived cancers.,0,1.4325184275184275,711690.7261927153,270.6326140785285,0.22654869948622586,0.1789963911603671,0.0,0.0,0.9987908101571946,826.0,-0.7352970966389776,0.042692579546583016,1.0,2.0,27.0,55.0,55.0,55.0,110.0,1546,53.0,1.6778973932186097e-06,14617.0,828.0,1.0,0,56.0
924,133430,HP:0002664,Estrogen receptor alpha (ERa) and retinoic acid receptors (RARs) play important and opposite roles in breast cancer growth.,0,1.4122127220908376,2151868.453707986,232.6757750407146,0.1890807510997476,0.016727864277858145,0.0,0.0,1.0011074197120708,904.0,-0.6512926783478565,0.06466400101921814,1.0,2.0,3.0,131.0,131.0,86.0,262.0,1506,130.0,1.6778973932186103e-06,26393.0,904.0,1.0,0,119.0
5091,312820,HP:0100242,Our analyses revealed that the primary tumor and NCC-SS1-C1 cell line harbored the SS18-SSX1 fusion gene typical of synovial sarcoma and similar proteomics profiles.,1,1.475037530312945,4402.600713012478,95.58441558441557,0.4283433966235184,0.4471117051209335,0.0,0.0,1.00625,161.0,-0.901349294999072,0.049689440993788817,1.0,2.0,0.0,7.0,7.0,6.0,14.0,308,6.0,4.162330905306972e-05,640.0,161.0,2.0,0,6.0
5092,312820,HP:0002664,Our analyses revealed that the primary tumor and NCC-SS1-C1 cell line harbored the SS18-SSX1 fusion gene typical of synovial sarcoma and similar proteomics profiles.,1,1.4945996081898718,11419.48385167464,215.22216045951455,0.6197010768977904,0.7154403580757647,0.0,0.0,1.0012870012870012,778.0,-0.5990420932195114,0.004939570492269721,1.0,2.0,404.0,7.0,7.0,6.0,14.0,1542,6.0,1.67789739321861e-06,1493.0,778.0,1.0,0,6.0
5093,194363,HP:0002664,XRCC4 is one of the essential proteins of this pathway and single-nucleotide polymorphisms (SNPs) of this gene are reported to be associated with cancer risks.,1,1.362027453530855,9766838.733910533,288.31111874062213,0.1436789138392778,0.12359113493723295,0.0,0.0,1.0009293680297398,1077.0,-0.5144729464668542,0.10899925098286924,1.0,2.0,5.0,305.0,305.0,167.0,610.0,1542,304.0,1.6778973932186103e-06,63157.0,1077.0,1.0,0,470.0
5094,613932,HP:0001635,"Corresponding implicated genes, such as TNNI3K, ErbB3, MKL2, MTNR1B and PRKD1, may explain the associations between reproductive factors and heart failure.",1,1.404355701588104,44783.52278519033,61.03030303030303,0.3444793513610941,0.09268463369109034,0.0,0.0,1.0047393364928912,212.0,-0.6270409232451121,0.08155235625502996,1.0,2.0,1.0,35.0,35.0,27.0,70.0,352,34.0,3.191930798940279e-05,1824.0,212.0,1.0,0,31.0
5095,190151,HP:0001635,"Corresponding implicated genes, such as TNNI3K, ErbB3, MKL2, MTNR1B and PRKD1, may explain the associations between reproductive factors and heart failure.",0,1.3221822302905657,392467.5773809524,97.97517403767405,0.2275737080184374,0.06565786140880761,0.0,0.0,0.9965277777777776,287.0,-0.4934005961314823,0.1638792772010765,1.0,2.0,4.0,101.0,101.0,41.0,202.0,354,99.0,3.156167150612296e-05,6820.0,289.0,1.0,0,105.0
5096,600804,HP:0001635,"Corresponding implicated genes, such as TNNI3K, ErbB3, MKL2, MTNR1B and PRKD1, may explain the associations between reproductive factors and heart failure.",0,1.42148861753697,21983.74139301544,62.931186868686865,0.3840648006759957,0.08490125405855327,0.0,0.0,0.9948717948717948,194.0,-0.7162128671349879,0.062218733647305076,1.0,2.0,3.0,17.0,17.0,16.0,34.0,354,16.0,3.191930798940279e-05,1189.0,196.0,1.0,0,18.0
5097,605435,HP:0001635,"Corresponding implicated genes, such as TNNI3K, ErbB3, MKL2, MTNR1B and PRKD1, may explain the associations between reproductive factors and heart failure.",0,1.3358253295261169,418352.21190476185,100.08977272727272,0.2166529711161968,0.19661910003040164,0.0,0.0,0.996389891696751,276.0,-0.5537946499502473,0.1696231462483443,1.0,2.0,1.0,90.0,90.0,67.0,180.0,354,88.0,3.191930798940279e-05,6531.0,278.0,1.0,0,110.0
5098,616441,HP:0002860,"This review highlights recent advances in understanding how the OVOL1-OVOL2 axis modulates cell differentiation and proliferation in human keratinocytes, hair follicles, and benign or malignant skin tumors including squamous cell carcinoma and malignant melanoma.",0,1.1522051122919978,19220.33298992674,25.759884281581478,0.3557967523745952,0.2099480555330445,0.0,0.0,0.9923076923076924,129.0,-0.4584477473148848,0.10487375220199648,1.0,2.0,32.0,36.0,36.0,2.0,72.0,176,34.0,0.00021003990758244065,893.0,131.0,1.0,0,37.0
5099,616441,HP:0002861,"This review highlights recent advances in understanding how the OVOL1-OVOL2 axis modulates cell differentiation and proliferation in human keratinocytes, hair follicles, and benign or malignant skin tumors including squamous cell carcinoma and malignant melanoma.",0,1.2187025604695878,35517.74791144529,34.42513368983957,0.3210313194295645,0.22133215383116786,0.0,0.0,0.9925925925925928,134.0,-0.48932210849880003,0.1328976034858388,1.0,2.0,19.0,42.0,42.0,2.0,84.0,166,40.0,0.00021003990758244065,1220.0,136.0,1.0,0,38.0
5100,604202,HP:0009830,"Mutations in SNAP29 gene result in CEDNIK (Cerebral dysgenesis, neuropathy, ichthyosis and palmoplantar keratoderma) syndrome.",1,1.3796396921249874,3494000.52958153,253.80986418047885,0.16553720929554586,0.01095464518175903,0.0,0.0,1.0014245014245016,703.0,-0.6182423248090037,0.12711902185586396,1.0,2.0,1.0,159.0,159.0,158.0,318.0,1086,158.0,3.379108996539792e-06,31367.0,703.0,1.0,0,216.0
5101,604202,HP:0000982,"Mutations in SNAP29 gene result in CEDNIK (Cerebral dysgenesis, neuropathy, ichthyosis and palmoplantar keratoderma) syndrome.",1,1.3357346357346358,363911.13412698405,91.43047445255472,0.2272059626023105,0.23025355665393304,0.0,0.0,1.0033783783783785,297.0,-0.37685618703289264,0.1535171535171535,1.0,2.0,6.0,120.0,120.0,2.0,240.0,274,119.0,3.857875853555032e-05,6748.0,297.0,1.0,0,125.0
5102,612907,HP:0001263,"Mutations in the human TRNT1 gene encoding tRNA nucleotidyltransferase (tRNA-NT), an essential enzyme responsible for addition of the CCA (cytidine-cytidine-adenosine) sequence to the 3*-termini of tRNAs, have been linked to disease phenotypes including congenital sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD) or retinitis pigmentosa with erythrocyte microcytosis.",1,1.4360359780872436,6587677.5264708875,453.36947523248426,0.16244385317591753,-0.020374272963726167,0.0,0.0,1.0006009615384617,1665.0,-0.6482874785225472,0.04891141141141141,1.0,2.0,4.0,160.0,160.0,132.0,320.0,2998,159.0,4.4444444444444454e-07,67756.0,1665.0,1.0,0,133.0
5103,612907,HP:0025066,"Mutations in the human TRNT1 gene encoding tRNA nucleotidyltransferase (tRNA-NT), an essential enzyme responsible for addition of the CCA (cytidine-cytidine-adenosine) sequence to the 3*-termini of tRNAs, have been linked to disease phenotypes including congenital sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD) or retinitis pigmentosa with erythrocyte microcytosis.",1,1.4657928388746804,6077.966192911948,56.19277108433735,0.5348021602554364,-0.07173122260358708,0.0,0.0,1.0057142857142858,176.0,-0.5376171876186144,0.03441558441558441,1.0,2.0,62.0,10.0,10.0,10.0,20.0,150,10.0,3.585643085087311e-05,530.0,176.0,1.0,0,10.0
5104,603073,HP:0002414,"These findings document shared genetic networks between spina bifida risk and bone structure, including PCP components and Zic2.",0,1.3612077083085805,1919916.429761905,192.82273017902816,0.16400269723202526,0.1795173191739528,0.0,0.0,0.998019801980198,504.0,-0.5288382005047135,0.15225609517473487,1.0,2.0,1.0,137.0,137.0,137.0,274.0,274,136.0,7.344246884203259e-06,19453.0,506.0,1.0,0,150.0
5105,607365,HP:0000007,"In the Japanese population, most patients with autosomal recessive woolly hair carry one of two founder mutations in the LIPH gene, c.736T&gt;A (p.Cys246Ser) or c.742C&gt;A (p.His248Asn).",1,1.4849240606146163,1329984.269252138,511.2176079734219,0.27008062715924946,0.006399596870960547,0.0,0.0,1.0003795066413663,2636.0,-0.5925099065458704,0.00806811539535781,1.0,2.0,424.0,56.0,56.0,56.0,112.0,5160,55.0,1.5011496554636372e-07,28020.0,2636.0,1.0,0,50.0
5106,611386,HP:0012758,"A recent syndromic condition with craniofacial dysmorphisms, comprising congenital ocular defect and neurodevelopmental delay named Helsmoortel-Van der Aa Syndrome (HVDAS) (OMIM#615873), has been described and molecularly defined, identifying pathogenic mutations in the ADNP gene (OMIM#611386) as biological cause.",1,1.4085331950618052,31680106.785326313,584.09146112829,0.12733404764387973,-0.006271170312282325,0.0,0.0,1.000460193281178,2174.0,-0.5867930533175761,0.07007427019992371,1.0,2.0,1.0,335.0,335.0,335.0,670.0,3678,334.0,2.9536862003780705e-07,165519.0,2174.0,1.0,0,391.0
5107,611386,HP:0001249,"We report on two children, displaying intellectual disability (ID) and peculiar congenital eyes anomalies, both carrying a de novo nonsense mutation in the ADNP gene.",1,1.4002199529455135,28514396.50442393,537.2290271488997,0.12708856157858914,0.04793729336129049,0.0,0.0,1.00051652892562,1937.0,-0.5875757203637679,0.07938385592442944,1.0,2.0,1.0,335.0,335.0,335.0,670.0,3204,334.0,3.8916426584745004e-07,148846.0,1937.0,1.0,0,425.0
1345,607047,HP:0001251,Spinocerebellar ataxia type 3 (SCA3) is a neurodegenerative disorder caused by a CAG expansion in the ATXN3 gene leading to a polyglutamine expansion in the ataxin-3 protein.,1,1.401643832944441,3824637.9065303686,289.8691178528552,0.1652493812053885,0.05242686260558007,0.0,0.0,1.0010214504596526,980.0,-0.6413500434466297,0.08371516124325114,1.0,2.0,3.0,165.0,165.0,121.0,330.0,1626,164.0,1.5092152684290275e-06,40159.0,980.0,1.0,0,166.0
5108,604975,HP:0001263,"Lamb-Shaffer syndrome (OMIM: 616803) is a neurodevelopmental disorder characterized by developmental delay, mild to moderate intellectual disability, speech delay, and mild characteristic facial appearance caused by SOX5 haploinsufficiency on chromosome 12p12.1.",1,1.4363346941644948,11436843.268992687,604.2028503851053,0.13850291610633672,-0.003899092934346853,0.0,0.0,1.000601322910403,1664.0,-0.6887702956641858,0.06490818261714232,1.0,2.0,1.0,165.0,165.0,164.0,330.0,2998,164.0,4.444444444444443e-07,89808.0,1664.0,1.0,0,160.0
5109,604975,HP:0001249,"Lamb-Shaffer syndrome (OMIM: 616803) is a neurodevelopmental disorder characterized by developmental delay, mild to moderate intellectual disability, speech delay, and mild characteristic facial appearance caused by SOX5 haploinsufficiency on chromosome 12p12.1.",1,1.4395284312382757,12069999.466482222,629.2292815798434,0.13902939210575896,0.0841976997669341,0.0,0.0,1.0005662514156286,1767.0,-0.6910652258098812,0.06032836813840761,1.0,2.0,1.0,165.0,165.0,163.0,330.0,3204,164.0,3.8916426584745004e-07,94128.0,1767.0,1.0,0,166.0
5111,604975,HP:0000750,"Lamb-Shaffer syndrome (OMIM: 616803) is a neurodevelopmental disorder characterized by developmental delay, mild to moderate intellectual disability, speech delay, and mild characteristic facial appearance caused by SOX5 haploinsufficiency on chromosome 12p12.1.",1,1.3960734079354582,5958286.358112883,352.1538054487577,0.1439255496176871,0.02215616854413139,0.0,0.0,1.0011148272017838,898.0,-0.673048012991426,0.1177620030142544,1.0,2.0,2.0,164.0,164.0,157.0,328.0,1466,163.0,1.8561278203862235e-06,47429.0,898.0,1.0,0,211.0
5110,604975,HP:0001249,"This report confirmed that haploinsufficiency of the 2 long forms of SOX5 presents common clinical features, including mild intellectual disability and autistic features, which could be useful for the clinical diagnosis of Lamb-Shaffer syndrome",1,1.4395284312382757,12069999.466482222,629.2292815798434,0.13902939210575896,0.0841976997669341,0.0,0.0,1.0005662514156286,1767.0,-0.6910652258098812,0.06032836813840761,1.0,2.0,1.0,165.0,165.0,163.0,330.0,3204,164.0,3.8916426584745004e-07,94128.0,1767.0,1.0,0,166.0
5112,609118,HP:0002664,"Here, we aimed to figure out the role of PDCD10 in resistance to anti-cancer agents in different cell lines.",1,1.4396536831054232,1436704.7718432825,279.26541828793773,0.1977006652136281,0.10995945920570206,0.0,0.0,1.0011764705882351,851.0,-0.7136439340156319,0.05596460911038916,1.0,2.0,6.0,77.0,77.0,69.0,154.0,1542,76.0,1.6778973932186097e-06,20241.0,851.0,1.0,0,70.0
5114,609118,HP:0002664,We found that PDCD10 expression was cell- and anti-cancer agent-specific; down-regulated in doxorubicin- and docetaxel-resistant MCF7 cells while up-regulated in doxorubicin-resistant HeLa cells.,1,1.4396536831054232,1436704.7718432825,279.26541828793773,0.1977006652136281,0.10995945920570206,0.0,0.0,1.0011764705882351,851.0,-0.7136439340156319,0.05596460911038916,1.0,2.0,6.0,77.0,77.0,69.0,154.0,1542,76.0,1.6778973932186097e-06,20241.0,851.0,1.0,0,70.0
5116,602635,HP:0100660,"Chronic l-DOPA treatment that induces dyskinesia selectively restores spine density and excitability in indirect pathway SPNs (iSPNs), whereas spine loss and hyperexcitability persist in direct pathway SPNs (dSPNs).",1,1.3488333228885965,2307772.1700396826,174.84199456215057,0.1690862437774519,0.2367903308852873,0.0,0.0,1.0017035775127767,588.0,-0.3087012767522288,0.1343450497745947,1.0,2.0,15.0,202.0,202.0,19.0,404.0,404,201.0,6.67694916838598e-06,23185.0,588.0,1.0,0,244.0
5121,602669,HP:0100660,"This indicates that dopamine-mediated synaptic remodeling and plasticity is independent of dopamine innervation during SPN development and that Pitx3-/- mice are a good model because they develop the same pathology described in the toxins-based models and in human postmortem studies of advanced PD.SIGNIFICANCE STATEMENT As the only genetic model of Parkinson*s disease (PD) that develops dyskinesia, Pitx3-/- mice reproduce the behavioral effects seen in humans and are a good system for studying dopamine-induced synaptic remodeling.",0,1.359722281624681,158976.8160714286,109.63598061933851,0.2206102618673972,0.08889938731532812,0.0,0.0,0.996,249.0,-0.8408583872476263,0.1387410358565737,1.0,2.0,5.0,40.0,40.0,27.0,80.0,406,38.0,2.4029219530949632e-05,4353.0,251.0,1.0,0,44.0
5118,602635,HP:0100660,"This indicates that dopamine-mediated synaptic remodeling and plasticity is independent of dopamine innervation during SPN development and that Pitx3-/- mice are a good model because they develop the same pathology described in the toxins-based models and in human postmortem studies of advanced PD.SIGNIFICANCE STATEMENT As the only genetic model of Parkinson*s disease (PD) that develops dyskinesia, Pitx3-/- mice reproduce the behavioral effects seen in humans and are a good system for studying dopamine-induced synaptic remodeling.",1,1.3488333228885965,2307772.1700396826,174.84199456215057,0.1690862437774519,0.2367903308852873,0.0,0.0,1.0017035775127767,588.0,-0.3087012767522288,0.1343450497745947,1.0,2.0,15.0,202.0,202.0,19.0,404.0,404,201.0,6.67694916838598e-06,23185.0,588.0,1.0,0,244.0
5120,602669,HP:0100660,Pitx3-/- mice reproduced the alterations described in patients with advanced PD and in well accepted toxin-based models of PD and dyskinesia.,0,1.359722281624681,158976.8160714286,109.63598061933851,0.2206102618673972,0.08889938731532812,0.0,0.0,0.996,249.0,-0.8408583872476263,0.1387410358565737,1.0,2.0,5.0,40.0,40.0,27.0,80.0,406,38.0,2.4029219530949632e-05,4353.0,251.0,1.0,0,44.0
5122,607604,HP:0000505,"Mutations in the KVS subunit, KV8.2 (KCNV2), lead to severe visual impairment in humans, but the basis of these deficits remains unclear.",0,1.4748484792509446,519979.07996541075,427.39465630885115,0.2381628700435108,0.017566249976521644,0.0,0.0,1.0010214504596529,980.0,-0.7406383652711735,0.03089574951533218,1.0,2.0,1.0,36.0,36.0,36.0,72.0,1888,35.0,1.1197894795778394e-06,14821.0,980.0,1.0,0,34.0
5123,606844,HP:0100753,"Sherlock integrative analysis shows that ALMS1, GLT8D1, and CSNK2B are schizophrenia risk genes, which are validated using independent brain expression quantitative trait loci (eQTL) data and integrative analysis method (SMR).",0,1.3318456274271409,148663.1335809452,72.81406567366284,0.33178549248539063,0.2532020887556511,0.0,0.0,0.997912317327766,478.0,-0.4078773681091098,0.03461203897007655,1.0,2.0,93.0,52.0,52.0,48.0,104.0,264,50.0,5.588808968920633e-06,3979.0,480.0,1.0,0,49.0
5125,609557,HP:0000007,"Prolyl endopeptidase-like (PREPL) deficiency (MIM# 616224) is a rare autosomal recessive inherited congenital myasthenic syndrome characterized by neonatal hypotonia, feeding problems, mild dysmorphism, and neuromuscular symptoms, followed by hyperphagia and obesity in later childhood.",1,1.4639070155414968,9159948.7937877,683.7465251802463,0.16926899232571765,0.16461098885493394,0.0,0.0,1.000367376928729,2723.0,-0.6528853033339088,0.02499755127019595,1.0,2.0,15.0,143.0,143.0,143.0,286.0,5160,142.0,1.5011496554636372e-07,92641.0,2723.0,1.0,0,134.0
4429,609557,HP:0011968,"Prolyl endopeptidase-like (PREPL) deficiency (MIM# 616224) is a rare autosomal recessive inherited congenital myasthenic syndrome characterized by neonatal hypotonia, feeding problems, mild dysmorphism, and neuromuscular symptoms, followed by hyperphagia and obesity in later childhood.",1,1.4154879930899136,5495967.070648113,415.8927871672746,0.14565068932291875,0.12379397037475312,0.0,0.0,1.0009803921568627,1021.0,-0.7037404579975534,0.0982178179792975,1.0,2.0,2.0,142.0,142.0,142.0,284.0,1756,141.0,1.2942621476209514e-06,51143.0,1021.0,1.0,0,140.0
5126,609557,HP:0002591,"Prolyl endopeptidase-like (PREPL) deficiency (MIM# 616224) is a rare autosomal recessive inherited congenital myasthenic syndrome characterized by neonatal hypotonia, feeding problems, mild dysmorphism, and neuromuscular symptoms, followed by hyperphagia and obesity in later childhood.",1,1.3821949556918882,113619.8976190476,86.4935064935065,0.2645763606836465,0.09544151057795894,0.0,0.0,1.0054347826086956,185.0,-0.7009872337474168,0.16498237367802585,1.0,2.0,2.0,42.0,42.0,42.0,84.0,218,42.0,4.82253086419753e-05,2808.0,185.0,1.0,0,42.0
4433,609557,HP:0001513,"Prolyl endopeptidase-like (PREPL) deficiency (MIM# 616224) is a rare autosomal recessive inherited congenital myasthenic syndrome characterized by neonatal hypotonia, feeding problems, mild dysmorphism, and neuromuscular symptoms, followed by hyperphagia and obesity in later childhood.",0,1.3501445585962355,1831216.9674242425,186.67111013986008,0.17131144528479708,0.07580822397785279,0.0,0.0,0.9979838709677421,495.0,-0.612570707750085,0.15637372622833776,1.0,2.0,3.0,140.0,140.0,107.0,280.0,706,138.0,7.979826997350696e-06,19274.0,497.0,1.0,0,150.0
5127,313430,HP:0002669,"However, the expression and precise role of SOX3 in osteosarcoma remain unclear.",0,1.3157851942997456,67642.43650793651,78.73922413793103,0.2577454212100543,0.30339954485412235,0.0,0.0,0.9962264150943396,264.0,-0.549758369776462,0.06871896722939425,1.0,2.0,59.0,33.0,33.0,33.0,66.0,232,32.0,1.841993774061044e-05,2422.0,266.0,1.0,0,42.0
5135,313430,HP:0002669,"To elucidate the cellular and molecular function of SOX3, we examined the consequences of SOX3 knockdown in osteosarcoma cells.",0,1.3157851942997456,67642.43650793651,78.73922413793103,0.2577454212100543,0.30339954485412235,0.0,0.0,0.9962264150943396,264.0,-0.549758369776462,0.06871896722939425,1.0,2.0,59.0,33.0,33.0,33.0,66.0,232,32.0,1.841993774061044e-05,2422.0,266.0,1.0,0,42.0
5139,313430,HP:0002669,"We found that the downregulation of SOX3 inhibited the proliferation, migration and invasion of osteosarcoma cells.",0,1.3157851942997456,67642.43650793651,78.73922413793103,0.2577454212100543,0.30339954485412235,0.0,0.0,0.9962264150943396,264.0,-0.549758369776462,0.06871896722939425,1.0,2.0,59.0,33.0,33.0,33.0,66.0,232,32.0,1.841993774061044e-05,2422.0,266.0,1.0,0,42.0
5131,313430,HP:0002669,"Taken together, our data indicate that SOX3 may serve as an oncogene in osteosarcoma, and SOX3 downregulation may prove to be a novel approach for the inhibition of osteosarcoma progression",0,1.3157851942997456,67642.43650793651,78.73922413793103,0.2577454212100543,0.30339954485412235,0.0,0.0,0.9962264150943396,264.0,-0.549758369776462,0.06871896722939425,1.0,2.0,59.0,33.0,33.0,33.0,66.0,232,32.0,1.841993774061044e-05,2422.0,266.0,1.0,0,42.0
5143,613898,HP:0001425,"Objective Hearing loss (HL) is the most common sensory-neural defect and the most heterogeneous trait in humans, with the involvement of &gt;100 genes, which make a molecular diagnosis problematic.",0,1.3023909985935302,737584.9275946275,97.62760974835278,0.22080699651081032,0.10498052491241372,0.0,0.0,0.9977876106194692,451.0,-0.3628836102949296,0.1087636015550216,1.0,2.0,15.0,163.0,163.0,3.0,326.0,512,161.0,1.6259105098855357e-05,11135.0,453.0,1.0,0,200.0
5144,613898,HP:0000007,Results Clinical evaluations suggested autosomal recessive nonsyndromic HL.,1,1.4510388277209596,10122814.843849067,518.3449156406749,0.1733579927730785,0.046142379701504914,0.0,0.0,1.0003593244699964,2784.0,-0.5954334932984259,0.02529571990864072,1.0,2.0,71.0,202.0,202.0,192.0,404.0,5160,201.0,1.501149655463636e-07,97994.0,2784.0,1.0,0,185.0
1585,610966,HP:0001513,"The fat mass and obesity-associated (FTO) gene is tightly related to body weight and fat mass, and plays a pivotal role in regulating lipid accumulation in hepatocytes.",1,1.3551840203056889,2205350.7880762005,190.34733201581028,0.16843673176063007,0.09191852693852773,0.0,0.0,1.001953125,513.0,-0.5941046245150907,0.16011817738791426,1.0,2.0,3.0,159.0,159.0,128.0,318.0,704,158.0,8.025102520684701e-06,21028.0,513.0,1.0,0,202.0
4626,600897,HP:0000518,"In this study, a novel insert mutation in GJA8 was identified in a Chinese congenital cataract family and cosegregated with the disease in this pedigree.",1,1.4097327154290509,2467220.003585303,279.6954683734345,0.1669735945376989,0.001018252689578121,0.0,0.0,1.0013071895424837,766.0,-0.6862604246750685,0.09462960118773356,1.0,2.0,1.0,117.0,117.0,117.0,234.0,1298,116.0,2.366863905325444e-06,27726.0,766.0,1.0,0,124.0
4634,600897,HP:0000518,"Taken together, these data suggest that the novel insert mutation in the TM2 domain of Cx50 protein, which impairs its trafficking to the cell membrane and gap-junction function, is associated with the cataract formation in this Chinese pedigree",1,1.4097327154290509,2467220.003585303,279.6954683734345,0.1669735945376989,0.001018252689578121,0.0,0.0,1.0013071895424837,766.0,-0.6862604246750685,0.09462960118773356,1.0,2.0,1.0,117.0,117.0,117.0,234.0,1298,116.0,2.366863905325444e-06,27726.0,766.0,1.0,0,124.0
5145,112210,HP:0002664,"Although many new anti-cancer drugs were developed in the last years, it is unclear which of these drugs can be safely combined to improve standard therapy without antagonizing anti-CD20 efficacy.",1,1.4177294790417985,2721310.618275044,277.51238597506733,0.1836244681075819,0.049456943351916687,0.0,0.0,1.0011223344556681,892.0,-0.6407926781130227,0.0730372987473137,1.0,2.0,5.0,121.0,121.0,121.0,242.0,1542,120.0,1.67789739321861e-06,29024.0,892.0,1.0,0,125.0
5146,300192,HP:0100242,"Synovial sarcoma (SS) is genetically characterized by chromosomal translocation, which generates SYT-SSX fusion transcripts.",1,1.475037530312945,4402.600713012478,95.58441558441557,0.428343396623518,0.4471117051209335,0.0,0.0,1.00625,161.0,-0.901349294999072,0.049689440993788817,1.0,2.0,0.0,7.0,7.0,6.0,14.0,308,6.0,4.162330905306972e-05,640.0,161.0,2.0,0,6.0
5147,604934,HP:0000007,Backgorund: Sanjad-Sakati syndrome (SSS) is a rare autosomal recessive disease caused by a deletion mutation (155-166del) in exon 3 of the TBCE gene on chromosome 1q42-43.,1,1.4312270966355116,20555283.12195296,498.1982873913367,0.15427436857932775,0.2866500769666561,0.0,0.0,1.0003457814661134,2893.0,-0.5496329507256154,0.03324306919119408,1.0,2.0,21.0,306.0,306.0,235.0,612.0,5160,305.0,1.5011496554636367e-07,139065.0,2893.0,1.0,0,289.0
5148,606421,HP:0002664,"The promoter methylation levels of ELMO1 and ELMO2 were generally low, whereas ELMO3 methylation levels were high, in the tumor biopsies.",1,1.4177294790417985,2611941.470178554,286.77745977639864,0.17511690649788852,0.1774549439276456,0.0,0.0,1.0011223344556681,892.0,-0.6600114838137101,0.07547573392117488,1.0,2.0,17.0,120.0,120.0,120.0,240.0,1542,119.0,1.6778973932186097e-06,29993.0,892.0,1.0,0,114.0
5149,185535,HP:0002664,"Moreover, immunohistochemistry demonstrates that EpCAM is highly expressed in 80% of H-ChC, implying the stemness of such liver cancer.",1,1.379982198755772,4941394.159715796,247.51439688715956,0.16615344796158885,0.012824122669080257,0.0,0.0,1.0010050251256282,996.0,-0.5693721496286912,0.08700127141732761,1.0,2.0,6.0,219.0,219.0,123.0,438.0,1542,218.0,1.67789739321861e-06,43110.0,996.0,1.0,0,228.0
3634,147620,HP:0002664,"Altogether, these data suggest that Polyphyllin I can inhibit the proliferation of gastric cancer cells by downregulating the expression of FAP and HGF in CAFs in vivo",0,1.3995350101215007,3680346.246413318,262.81069089873785,0.1667454121176664,0.0689327787874495,0.0,0.0,1.0010706638115632,935.0,-0.6770923792463656,0.0813956417684847,1.0,2.0,2.0,159.0,159.0,109.0,318.0,1542,159.0,1.677897393218609e-06,35541.0,935.0,1.0,0,143.0
3637,147620,HP:0002664,"Hepatocyte growth factor (HGF)/c-MET signaling plays an important role in cell proliferation, survival, migration and motility of cancer cells.",0,1.3995350101215007,3680346.246413318,262.81069089873785,0.1667454121176664,0.0689327787874495,0.0,0.0,1.0010706638115632,935.0,-0.6770923792463656,0.0813956417684847,1.0,2.0,2.0,159.0,159.0,109.0,318.0,1542,159.0,1.677897393218609e-06,35541.0,935.0,1.0,0,143.0
5162,605124,HP:0002664,"The scope of the present review is to recapitulate and review the evidence of SPINT2 participation in cancer development and progression, exploring the clinical, biological and functional descriptions of the involvement of this protein in diverse neoplasias.",0,1.4200716845878136,1324344.6782702282,280.6814223390099,0.1951186159072201,0.12013805374203408,0.0,0.0,0.9988221436984688,848.0,-0.7340633360841659,0.05642070255664103,1.0,2.0,27.0,77.0,77.0,77.0,154.0,1544,75.0,1.6778973932186097e-06,20358.0,850.0,1.0,0,69.0
5158,605124,HP:0002664,"Most studies are in agreement as to the belief that, in a large range of human cancers, the SPINT2 gene promoter is frequently methylated, resulting in the epigenetic silence of this gene.",0,1.4200716845878136,1324344.6782702282,280.6814223390099,0.1951186159072201,0.12013805374203408,0.0,0.0,0.9988221436984688,848.0,-0.7340633360841659,0.05642070255664103,1.0,2.0,27.0,77.0,77.0,77.0,154.0,1544,75.0,1.6778973932186097e-06,20358.0,850.0,1.0,0,69.0
5150,605124,HP:0002664,"Functional assays indicate that SPINT2 reactivation ameliorates the malignant phenotype, specifically reducing cell viability, migration and invasion in diverse cancer cell lines.",0,1.4200716845878136,1324344.6782702282,280.6814223390099,0.1951186159072201,0.12013805374203408,0.0,0.0,0.9988221436984688,848.0,-0.7340633360841659,0.05642070255664103,1.0,2.0,27.0,77.0,77.0,77.0,154.0,1544,75.0,1.6778973932186097e-06,20358.0,850.0,1.0,0,69.0
3640,147620,HP:0002664,"In sum, the SPINT2 gene is epigenetically silenced or downregulated in human cancers, altering the balance of HGF activation/inhibition ratio, which contributes to cancer development and progression",0,1.3995350101215007,3680346.246413318,262.81069089873785,0.1667454121176664,0.0689327787874495,0.0,0.0,1.0010706638115632,935.0,-0.6770923792463656,0.0813956417684847,1.0,2.0,2.0,159.0,159.0,109.0,318.0,1542,159.0,1.677897393218609e-06,35541.0,935.0,1.0,0,143.0
5154,605124,HP:0002664,"In sum, the SPINT2 gene is epigenetically silenced or downregulated in human cancers, altering the balance of HGF activation/inhibition ratio, which contributes to cancer development and progression",0,1.4200716845878136,1324344.6782702282,280.6814223390099,0.1951186159072201,0.12013805374203408,0.0,0.0,0.9988221436984688,848.0,-0.7340633360841659,0.05642070255664103,1.0,2.0,27.0,77.0,77.0,77.0,154.0,1544,75.0,1.6778973932186097e-06,20358.0,850.0,1.0,0,69.0
5166,600276,HP:0002352,"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), caused by NOTCH3, primarily affects small cerebral arteries; however, stenosis of major intracranial arteries has occasionally been reported.",1,1.3509627727856226,1519991.1440115438,138.3281264345203,0.18827487963155606,0.4784377662370058,0.0,0.0,1.0017094017094017,586.0,-0.31923510730809085,0.1050027712143753,1.0,2.0,26.0,193.0,193.0,3.0,386.0,390,192.0,6.507705122865472e-06,17998.0,586.0,1.0,0,236.0
5167,613768,HP:0003745,"Recent studies identified a close association between the c.14576G&gt;A (p.R4859K, rs112735431) variant of the ring finger protein 213 (RNF213) gene and sporadic intracranial arterial stenosis (ICAS).",0,1.3117021276595744,54889.57943722943,60.452046783625725,0.2732622613809744,-0.08708629826437934,0.0,0.0,0.9924242424242424,131.0,-0.7382478781729309,0.1887673729778993,1.0,2.0,6.0,32.0,32.0,30.0,64.0,192,30.0,0.00010850694444444445,1657.0,133.0,1.0,0,36.0
5168,613768,HP:0100545,"Recent studies identified a close association between the c.14576G&gt;A (p.R4859K, rs112735431) variant of the ring finger protein 213 (RNF213) gene and sporadic intracranial arterial stenosis (ICAS).",0,1.3271720394616202,47168.39047619048,67.625,0.2606556648312435,0.12544140941373694,0.0,0.0,0.9908256880733946,108.0,-0.6772583375164327,0.2807339449541285,1.0,2.0,1.0,36.0,36.0,37.0,72.0,146,34.0,0.00018261504747991235,1683.0,110.0,1.0,0,48.0
5169,610513,HP:0000717,"At least some P5B isoforms are of vital importance for the nervous system, since ATP13A2 and ATP13A4 are linked to respectively Parkinson disease and autism spectrum disorders",0,1.2966262379564673,697613.9346459094,117.02107481559536,0.1821785315568135,0.010138159004864507,0.0,0.0,0.9973753280839897,380.0,-0.2847799870017669,0.14732517074109192,1.0,2.0,22.0,138.0,138.0,5.0,276.0,304,137.0,1.8107741059302852e-05,10721.0,382.0,1.0,0,181.0
5173,601860,HP:0002664,We previously reported a potential predictive value of HSD17B4 hypermethylation for pathological complete response after preoperative trastuzumab plus chemotherapy in HER2-positive breast cancer.,0,1.3492078920021349,8280920.386788213,271.79534115330364,0.14624716871481316,0.03829366885412477,0.0,0.0,0.9990439770554492,1045.0,-0.5483150683126147,0.10151192243704583,1.0,2.0,22.0,269.0,269.0,183.0,538.0,1544,267.0,1.6778973932186103e-06,55586.0,1047.0,1.0,0,342.0
914,164870,HP:0002664,We previously reported a potential predictive value of HSD17B4 hypermethylation for pathological complete response after preoperative trastuzumab plus chemotherapy in HER2-positive breast cancer.,1,1.4721661571960971,183488.34663624788,198.3850960971584,0.3314920934853949,0.09201373930954154,0.0,0.0,1.0012453300124533,804.0,-0.6686948012217765,0.019448213478064226,1.0,2.0,1.0,33.0,33.0,33.0,66.0,1542,33.0,1.6778973932186097e-06,6278.0,804.0,1.0,0,33.0
5176,601860,HP:0002664,We will prospectively evaluate the predictive performance of HSD17B4 hypermethylation in patients with HER2-positive/HR-negative breast cancer treated with sequential chemo-radiotherapy.,0,1.3492078920021349,8280920.386788213,271.79534115330364,0.14624716871481316,0.03829366885412477,0.0,0.0,0.9990439770554492,1045.0,-0.5483150683126147,0.10151192243704583,1.0,2.0,22.0,269.0,269.0,183.0,538.0,1544,267.0,1.6778973932186103e-06,55586.0,1047.0,1.0,0,342.0
919,164870,HP:0002664,We will prospectively evaluate the predictive performance of HSD17B4 hypermethylation in patients with HER2-positive/HR-negative breast cancer treated with sequential chemo-radiotherapy.,1,1.4721661571960971,183488.34663624788,198.3850960971584,0.3314920934853949,0.09201373930954154,0.0,0.0,1.0012453300124533,804.0,-0.6686948012217765,0.019448213478064226,1.0,2.0,1.0,33.0,33.0,33.0,66.0,1542,33.0,1.6778973932186097e-06,6278.0,804.0,1.0,0,33.0
5170,601860,HP:0002664,"The primary endpoint is the rate of pathological complete response, defined as the absence of invasive and intraductal tumor cells in the breast at surgery, in breast cancer with HSD17B4 hypermethylation.",0,1.3492078920021349,8280920.386788213,271.79534115330364,0.14624716871481316,0.03829366885412477,0.0,0.0,0.9990439770554492,1045.0,-0.5483150683126147,0.10151192243704583,1.0,2.0,22.0,269.0,269.0,183.0,538.0,1544,267.0,1.6778973932186103e-06,55586.0,1047.0,1.0,0,342.0
1609,113705,HP:0002664,BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination.,1,1.342124294666095,14779870.286244314,292.6232998839511,0.14059513390679754,0.0363653511393512,0.0,0.0,1.0008032128514055,1246.0,-0.37767621403519097,0.11088720854525648,1.0,2.0,3.0,471.0,471.0,37.0,942.0,1542,470.0,1.6778973932186097e-06,86008.0,1246.0,1.0,0,633.0
1630,113705,HP:0002664,Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors.,1,1.342124294666095,14779870.286244314,292.6232998839511,0.14059513390679754,0.0363653511393512,0.0,0.0,1.0008032128514055,1246.0,-0.37767621403519097,0.11088720854525648,1.0,2.0,3.0,471.0,471.0,37.0,942.0,1542,470.0,1.6778973932186097e-06,86008.0,1246.0,1.0,0,633.0
1637,113705,HP:0002664,"Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility.",1,1.342124294666095,14779870.286244314,292.6232998839511,0.14059513390679754,0.0363653511393512,0.0,0.0,1.0008032128514055,1246.0,-0.37767621403519097,0.11088720854525648,1.0,2.0,3.0,471.0,471.0,37.0,942.0,1542,470.0,1.6778973932186097e-06,86008.0,1246.0,1.0,0,633.0
5179,607479,HP:0100242,"In addition, the analysis of upstream miRNAs showed that FOXF1 adjacent non-coding developmental regulatory RNA (FENDRR) had common upstream miRNAs, including miR-18b-5p, with another 119 differentially expressed genes, and that FENDRR was co-expressed with adenomatosis polyposis coli downregulated 1 (APCDD1) and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT).",0,1.3623745462310484,43315.107570207576,56.048701298701296,0.3052598027834773,-0.04880880825382072,0.0,0.0,0.9946524064171124,186.0,-0.7438967020366094,0.09204687677779044,1.0,2.0,8.0,29.0,29.0,19.0,58.0,310,27.0,4.162330905306971e-05,1618.0,188.0,1.0,0,26.0
5180,164920,HP:0100242,"In addition, the analysis of upstream miRNAs showed that FOXF1 adjacent non-coding developmental regulatory RNA (FENDRR) had common upstream miRNAs, including miR-18b-5p, with another 119 differentially expressed genes, and that FENDRR was co-expressed with adenomatosis polyposis coli downregulated 1 (APCDD1) and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT).",1,1.3417436086713304,832594.9452380955,129.49197068491674,0.19300928062112155,0.09381159861112977,0.0,0.0,1.0025380710659901,395.0,-0.2508545048551093,0.1563580286577138,1.0,2.0,10.0,154.0,154.0,3.0,308.0,320,154.0,1.7075336384126762e-05,12167.0,395.0,1.0,0,172.0
5209,603464,HP:0002664,The tumor suppressor characteristics of cyclin-dependent kinase 10 (CDK10) in nasopharyngeal carcinoma and breast cancer have been previously demonstrated.,0,1.3647180157971524,5874126.0163119575,287.233075339762,0.1510423678394413,0.09915168399886408,0.0,0.0,0.9989539748953974,955.0,-0.6318637225324562,0.09471281856219096,1.0,2.0,40.0,185.0,185.0,181.0,370.0,1544,183.0,1.6778973932186103e-06,43326.0,957.0,1.0,0,229.0
5199,603464,HP:0002664,"In the present study the expression status of CDK10 and its prognostic significance in gastric cancer was determined, as well as its role in cell proliferation and invasion.",0,1.3647180157971524,5874126.0163119575,287.233075339762,0.1510423678394413,0.09915168399886408,0.0,0.0,0.9989539748953974,955.0,-0.6318637225324562,0.09471281856219096,1.0,2.0,40.0,185.0,185.0,181.0,370.0,1544,183.0,1.6778973932186103e-06,43326.0,957.0,1.0,0,229.0
5184,603464,HP:0002664,Immunoblot analysis revealed that CDK10 protein expression was notably decreased in gastric cancer compared with normal tissues.,0,1.3647180157971524,5874126.0163119575,287.233075339762,0.1510423678394413,0.09915168399886408,0.0,0.0,0.9989539748953974,955.0,-0.6318637225324562,0.09471281856219096,1.0,2.0,40.0,185.0,185.0,181.0,370.0,1544,183.0,1.6778973932186103e-06,43326.0,957.0,1.0,0,229.0
5189,603464,HP:0002664,"Immunohistochemistry demonstrated that the loss of CDK10 expression, which was observed in 50.8% of primary gastric cancer tissues (n=128), significantly correlated with advanced tumor stage (P&lt;0.001), frequent lymph node metastasis (P&lt;0.001), distant metastasis (P=0.013), tumor differentiation (P=0.004) and unfavorable overall survival (P&lt;0.001).",0,1.3647180157971524,5874126.0163119575,287.233075339762,0.1510423678394413,0.09915168399886408,0.0,0.0,0.9989539748953974,955.0,-0.6318637225324562,0.09471281856219096,1.0,2.0,40.0,185.0,185.0,181.0,370.0,1544,183.0,1.6778973932186103e-06,43326.0,957.0,1.0,0,229.0
5204,603464,HP:0002664,Multivariate analysis suggested that CDK10 expression may serve as an independent prognostic predictor (P=0.001) for the progression of gastric cancer.,0,1.3647180157971524,5874126.0163119575,287.233075339762,0.1510423678394413,0.09915168399886408,0.0,0.0,0.9989539748953974,955.0,-0.6318637225324562,0.09471281856219096,1.0,2.0,40.0,185.0,185.0,181.0,370.0,1544,183.0,1.6778973932186103e-06,43326.0,957.0,1.0,0,229.0
5194,603464,HP:0002664,"In addition, ectopic CDK10 expression inhibited gastric cancer cell proliferation, migration and invasion, while knockdown of CDK10 promoted these phenotypes.",0,1.3647180157971524,5874126.0163119575,287.233075339762,0.1510423678394413,0.09915168399886408,0.0,0.0,0.9989539748953974,955.0,-0.6318637225324562,0.09471281856219096,1.0,2.0,40.0,185.0,185.0,181.0,370.0,1544,183.0,1.6778973932186103e-06,43326.0,957.0,1.0,0,229.0
5216,120190,HP:0002664,The present study was aimed to investigate the relationship between the expression of collagen type V alpha 2 chain (COL5A2) and clinical outcomes of patients with bladder cancer.Chi-square test and log-rank-based survival analysis were performed to assess the correlation of COL5A2 expression with clinical characteristics and survivals of patients with bladder cancer using GSE13507.,0,1.3627581430107722,6339372.257324744,241.1870697395989,0.1541536355016478,0.1688053516040565,0.0,0.0,0.9990430622009572,1044.0,-0.580418125929886,0.09014427255345038,1.0,2.0,5.0,257.0,257.0,111.0,514.0,1544,255.0,1.6778973932186097e-06,49267.0,1046.0,1.0,0,293.0
556,600960,HP:0002664,"Gene set enrichment analysis was conducted to study the relevant mechanisms.Bladder cancer patients in COL5A2 low expression group were associated with better invasiveness (P &lt; .0001), tumor grade (P = .001), T staging (P &lt; .0001), N staging (P = .002), cancer specific survival (P &lt; .0001), overall survival (P &lt; .0001), and a trend of better M staging (P = .053) than those in COL5A2 high expression group.COL5A2 might affect the progression of bladder cancer through &quot;Coagulation,&quot; &quot;Hypoxia,&quot; &quot;Apical junction,&quot; &quot;Ultraviolet response,&quot; &quot;Epithelial mesenchymal transition,&quot; &quot;Angiogenesis,&quot; &quot;KRAS (KRAS proto-oncogene, GTPase) signaling,&quot;Complement,&quot;IL2-STAT5-signaling,&quot; &quot;Inflammatory response,&quot; &quot;IL6-JAK-STAT3-signaling,&quot; &quot;Myogenesis,&quot; &quot;TNF a signaling,&quot; &quot;Apoptosis,&quot; and &quot;Hedgehog-signaling.&quot;Our results demonstrated that COL5A2 was correlated with poor clinical outcomes and survivals of patients with bladder cancer, suggesting that it could be regarded as a biomarker of bladder cancer",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
2021,190070,HP:0002664,"Gene set enrichment analysis was conducted to study the relevant mechanisms.Bladder cancer patients in COL5A2 low expression group were associated with better invasiveness (P &lt; .0001), tumor grade (P = .001), T staging (P &lt; .0001), N staging (P = .002), cancer specific survival (P &lt; .0001), overall survival (P &lt; .0001), and a trend of better M staging (P = .053) than those in COL5A2 high expression group.COL5A2 might affect the progression of bladder cancer through &quot;Coagulation,&quot; &quot;Hypoxia,&quot; &quot;Apical junction,&quot; &quot;Ultraviolet response,&quot; &quot;Epithelial mesenchymal transition,&quot; &quot;Angiogenesis,&quot; &quot;KRAS (KRAS proto-oncogene, GTPase) signaling,&quot;Complement,&quot;IL2-STAT5-signaling,&quot; &quot;Inflammatory response,&quot; &quot;IL6-JAK-STAT3-signaling,&quot; &quot;Myogenesis,&quot; &quot;TNF a signaling,&quot; &quot;Apoptosis,&quot; and &quot;Hedgehog-signaling.&quot;Our results demonstrated that COL5A2 was correlated with poor clinical outcomes and survivals of patients with bladder cancer, suggesting that it could be regarded as a biomarker of bladder cancer",1,1.3339771877413191,18178836.290753696,271.2782786211432,0.14438020893870612,0.0522035687829069,0.0,0.0,1.0006165228113442,1623.0,-0.2035822069529308,0.08341633409382543,1.0,2.0,4.0,720.0,720.0,2.0,1440.0,1542,719.0,1.374364528201273e-06,109797.0,1623.0,1.0,0,858.0
5214,120190,HP:0002664,"Gene set enrichment analysis was conducted to study the relevant mechanisms.Bladder cancer patients in COL5A2 low expression group were associated with better invasiveness (P &lt; .0001), tumor grade (P = .001), T staging (P &lt; .0001), N staging (P = .002), cancer specific survival (P &lt; .0001), overall survival (P &lt; .0001), and a trend of better M staging (P = .053) than those in COL5A2 high expression group.COL5A2 might affect the progression of bladder cancer through &quot;Coagulation,&quot; &quot;Hypoxia,&quot; &quot;Apical junction,&quot; &quot;Ultraviolet response,&quot; &quot;Epithelial mesenchymal transition,&quot; &quot;Angiogenesis,&quot; &quot;KRAS (KRAS proto-oncogene, GTPase) signaling,&quot;Complement,&quot;IL2-STAT5-signaling,&quot; &quot;Inflammatory response,&quot; &quot;IL6-JAK-STAT3-signaling,&quot; &quot;Myogenesis,&quot; &quot;TNF a signaling,&quot; &quot;Apoptosis,&quot; and &quot;Hedgehog-signaling.&quot;Our results demonstrated that COL5A2 was correlated with poor clinical outcomes and survivals of patients with bladder cancer, suggesting that it could be regarded as a biomarker of bladder cancer",0,1.3627581430107722,6339372.257324744,241.1870697395989,0.1541536355016478,0.1688053516040565,0.0,0.0,0.9990430622009572,1044.0,-0.580418125929886,0.09014427255345038,1.0,2.0,5.0,257.0,257.0,111.0,514.0,1544,255.0,1.6778973932186097e-06,49267.0,1046.0,1.0,0,293.0
5219,613858,HP:0000540,"We have previously identified a role for the secreted serine protease PRSS56 in ocular size determination and PRSS56 variants have been implicated in the etiology of both hyperopia and myopia, highlighting its importance in refractive development.",1,1.4178973105134474,53817.67784423179,85.84855687606112,0.3072420441771079,-0.003919573227492672,0.0,0.0,1.0045454545454546,221.0,-0.7146815495738073,0.09411764705882353,1.0,2.0,1.0,28.0,28.0,26.0,56.0,380,27.0,2.741152928921905e-05,2288.0,221.0,1.0,0,25.0
5218,613858,HP:0000540,"Here, we use a combination of genetic mouse models to demonstrate that Prss56 mutations leading to reduced ocular size and hyperopia act via a loss of function mechanism.",1,1.4178973105134474,53817.67784423179,85.84855687606112,0.3072420441771079,-0.003919573227492672,0.0,0.0,1.0045454545454546,221.0,-0.7146815495738073,0.09411764705882353,1.0,2.0,1.0,28.0,28.0,26.0,56.0,380,27.0,2.741152928921905e-05,2288.0,221.0,1.0,0,25.0
445,613858,HP:0000545,"Finally, we demonstrate that genetic inactivation of Prss56 rescues axial elongation in a mouse model of myopia caused by a null mutation in Egr1.",0,1.4278465522001595,113951.11678760506,135.63749502190362,0.2797798303701744,-0.048049277364645086,0.0,0.0,0.9971910112359548,355.0,-0.7208163814202093,0.06508670884083971,1.0,2.0,2.0,31.0,31.0,30.0,62.0,650,29.0,9.409462155143213e-06,4136.0,357.0,1.0,0,26.0
448,613858,HP:0000545,"Overall, our findings identify PRSS56 as a potential therapeutic target for modulating ocular growth aimed at preventing or slowing down myopia, which is reaching epidemic proportions",0,1.4278465522001595,113951.11678760506,135.63749502190362,0.2797798303701744,-0.048049277364645086,0.0,0.0,0.9971910112359548,355.0,-0.7208163814202093,0.06508670884083971,1.0,2.0,2.0,31.0,31.0,30.0,62.0,650,29.0,9.409462155143213e-06,4136.0,357.0,1.0,0,26.0
5220,603084,HP:0001257,"Objective: To analyze the clinical and imaging features of hypomyelination with brain stem and spinal cord involvement and leg spasticity (HBSL) due to mutations in DARS, and to identify DARS mutations responsible for HBSL.",1,1.4553307783653766,1336812.2063670792,490.05600178491744,0.1702451275756725,-0.04923606594742514,0.0,0.0,1.00125,801.0,-0.8119641054851945,0.07702559300873907,1.0,2.0,1.0,54.0,54.0,54.0,108.0,1494,53.0,1.787297320483857e-06,24679.0,801.0,1.0,0,53.0
610,600960,HP:0002664,"To comprehensively characterize the mutational landscape of this tumor type, and to identify possible targets of treatment, we conducted the first large exome sequencing study on a population-based set of SBA samples from all three small bowel segments.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
5221,601103,HP:0002664,But the role of MFAP5 in breast cancer remains unclear.,0,1.3908007377432299,3175192.8325402862,228.8390823804636,0.17002320005584834,0.03044180705957828,0.0,0.0,0.9989304812834224,934.0,-0.6530718385240574,0.07188628365098954,1.0,2.0,9.0,153.0,153.0,95.0,306.0,1544,151.0,1.6778973932186103e-06,31456.0,936.0,1.0,0,172.0
5229,601103,HP:0002664,"The present study demonstrated that MFAP5 was up-regulated in breast cancers compared with that in normal breast tissues, and further increased in breast cancer bone metastasis.",0,1.3908007377432299,3175192.8325402862,228.8390823804636,0.17002320005584834,0.03044180705957828,0.0,0.0,0.9989304812834224,934.0,-0.6530718385240574,0.07188628365098954,1.0,2.0,9.0,153.0,153.0,95.0,306.0,1544,151.0,1.6778973932186103e-06,31456.0,936.0,1.0,0,172.0
5225,601103,HP:0002664,"Functionally, MFAP5 overexpression accelerated breast cancer cell proliferation and migration, while an opposite effect was observed when MFAP5 was knocked down.",0,1.3908007377432299,3175192.8325402862,228.8390823804636,0.17002320005584834,0.03044180705957828,0.0,0.0,0.9989304812834224,934.0,-0.6530718385240574,0.07188628365098954,1.0,2.0,9.0,153.0,153.0,95.0,306.0,1544,151.0,1.6778973932186103e-06,31456.0,936.0,1.0,0,172.0
5233,601103,HP:0002664,"These findings may provide a better understanding about the mechanism of breast cancer and suggest that MFAP5 may be a potential prognostic biomarker and therapeutic target for breast cancer, especially for bone metastasis of breast cancer",0,1.3908007377432299,3175192.8325402862,228.8390823804636,0.17002320005584834,0.03044180705957828,0.0,0.0,0.9989304812834224,934.0,-0.6530718385240574,0.07188628365098954,1.0,2.0,9.0,153.0,153.0,95.0,306.0,1544,151.0,1.6778973932186103e-06,31456.0,936.0,1.0,0,172.0
5237,606201,HP:0000365,"A heterozygous mutation in the Wolfram syndrome type 1 gene (WFS1) causes autosomal dominant nonsyndromic hereditary hearing loss, DFNA6/14/38, or Wolfram-like syndrome.",1,1.4053959510956886,10541197.005934788,402.9112857754257,0.14715357081068292,0.014981267276884641,0.0,0.0,1.0006784260515602,1475.0,-0.617029256111068,0.07397833636133662,1.0,2.0,5.0,234.0,234.0,187.0,468.0,2474,233.0,6.524672396198986e-07,80420.0,1475.0,1.0,0,239.0
5239,606201,HP:0000365,"In the present study, WFS1 variants were screened in a large series of Japanese hearing loss (HL) patients to clarify the prevalence and clinical characteristics of DFNA6/14/38 and Wolfram-like syndrome.",1,1.4053959510956886,10541197.005934788,402.9112857754257,0.14715357081068292,0.014981267276884641,0.0,0.0,1.0006784260515602,1475.0,-0.617029256111068,0.07397833636133662,1.0,2.0,5.0,234.0,234.0,187.0,468.0,2474,233.0,6.524672396198986e-07,80420.0,1475.0,1.0,0,239.0
5241,180090,HP:0001427,"One of these two is a novel AMD GWAS locus, near the retinal clusterin-like protein (CLUL1) gene, and the other, near the retinaldehyde binding protein 1 (RLBP1), was recently identified in a joint analysis of nuclear and mitochondrial variants.",0,1.2753100110898277,3401.189724310777,37.56686626746507,0.5862956093749613,0.1896319787101132,0.0,0.0,0.9942528735632185,173.0,-0.5385191726022905,0.024893267651888342,1.0,2.0,101.0,7.0,7.0,7.0,14.0,214,6.0,3.5430839002267575e-05,379.0,175.0,1.0,0,7.0
5242,612392,HP:0000007,Biallelic mutations in NDUFAF6 have been identified as responsible for cases of autosomal recessive Leigh syndrome associated with mitochondrial complex I deficiency.,1,1.441849580355076,13587648.47362874,496.61491325212256,0.16888536401147458,0.0921970178484242,0.0,0.0,1.0003532320734725,2832.0,-0.5725770431785663,0.028440919441134967,1.0,2.0,10.0,250.0,250.0,202.0,500.0,5160,249.0,1.5011496554636367e-07,114011.0,2832.0,1.0,0,228.0
5243,602229,HP:0002664,"Immunohistochemically, the tumor cells were positive for S-100 protein (4/4), SOX10(3/4), Langerin/CD207(4/4), CD1a(3/4), CD68(3/4), CD163(3/4), and INI-1(4/4).",0,1.342624466571835,8446868.024705412,245.41844019624423,0.14981023883479666,0.06486499370895074,0.0,0.0,0.999104744852283,1116.0,-0.515878639981699,0.09470486208426288,1.0,2.0,13.0,326.0,326.0,94.0,652.0,1544,324.0,1.67789739321861e-06,59134.0,1118.0,1.0,0,439.0
5244,604862,HP:0002664,"Immunohistochemically, the tumor cells were positive for S-100 protein (4/4), SOX10(3/4), Langerin/CD207(4/4), CD1a(3/4), CD68(3/4), CD163(3/4), and INI-1(4/4).",0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865477,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
5245,605111,HP:0002664,Objective: To study the effect and mechanism of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo.,0,1.4013316168483727,69438.13644223919,244.7580137113211,0.3643334421373665,0.5469316698628998,0.0,0.0,0.9987277353689568,785.0,-0.6448273939819323,0.013330488116369374,1.0,2.0,149.0,15.0,15.0,15.0,30.0,1544,13.0,1.6778973932186097e-06,4123.0,787.0,1.0,0,14.0
5246,603448,HP:0001251,"To elucidate the influence of cerebellum atrophy and ataxia on the obtained results, the behavioral and neurophysiological findings in reeler mice were reproduced using the Disabled-1 (Dab1) cKO mice, in which the Reelin-Dab1 signal deficiency is confined to the cerebral cortex.",1,1.4493448266393063,1493790.7434525988,398.7957636929309,0.18434439752287435,0.06652087491785931,0.0,0.0,1.0011363636363635,881.0,-0.7417958682841185,0.06455732122587968,1.0,2.0,1.0,68.0,68.0,68.0,136.0,1626,67.0,1.5092152684290275e-06,25025.0,881.0,1.0,0,65.0
5248,603718,HP:0002664,"Here, we identify tumor-associated calcium signal transducer 2 (TACSTD2), one of the most downregulated genes in primary HCC tissue, as a host factor that interacts with CLDN1 and OCLN and regulates their cellular localization.",0,1.413305381857492,1183309.4667782169,228.8369321987999,0.20585694221617035,0.20057583901635875,0.0,0.0,0.9988412514484356,862.0,-0.6690792427645144,0.05183522166430625,1.0,2.0,25.0,92.0,92.0,92.0,184.0,1544,90.0,1.6778973932186103e-06,19325.0,864.0,1.0,0,84.0
5249,602876,HP:0002664,"Here, we identify tumor-associated calcium signal transducer 2 (TACSTD2), one of the most downregulated genes in primary HCC tissue, as a host factor that interacts with CLDN1 and OCLN and regulates their cellular localization.",0,1.3901544315557053,4849420.514901765,306.38938416325993,0.1566291919959497,0.1343580866166212,0.0,0.0,0.9989247311827956,929.0,-0.6454229168578526,0.0943441553191735,1.0,2.0,13.0,159.0,159.0,159.0,318.0,1544,157.0,1.677897393218609e-06,40843.0,931.0,1.0,0,176.0
2553,137290,HP:0002664,"Here, we identify tumor-associated calcium signal transducer 2 (TACSTD2), one of the most downregulated genes in primary HCC tissue, as a host factor that interacts with CLDN1 and OCLN and regulates their cellular localization.",0,1.4275991989409729,125722.55083681575,248.7899481193256,0.3232828816680043,0.2520735131704226,0.0,0.0,0.998737373737374,791.0,-0.7159616096733603,0.017839173576878496,1.0,2.0,85.0,21.0,21.0,21.0,42.0,1544,19.0,1.67789739321861e-06,5602.0,793.0,1.0,0,18.0
5250,300005,HP:0001250,Her epilepsy onset was earlier than is typical for RTT patients.,1,1.3753410218253967,28852959.712532405,418.7840913314748,0.13298510856897924,0.058815669835709995,0.0,0.0,1.0004914004914005,2036.0,-0.4877606645955053,0.07479424414591407,1.0,2.0,7.0,470.0,470.0,182.0,940.0,3100,469.0,4.156965348783941e-07,154946.0,2036.0,1.0,0,632.0
5251,602926,HP:0001298,"STXBP1 mutations cause early infantile epileptic encephalopathy (EIEE), various intractable epilepsies, and neurodevelopmental disorders.",1,1.3565882797511772,2884688.6190438215,172.16467092960124,0.17984375057081964,-0.006108455143493497,0.0,0.0,1.0012674271229405,790.0,-0.3492862079545279,0.09273395260785162,1.0,2.0,14.0,242.0,242.0,19.0,484.0,484,242.0,3.3178390250861803e-06,28901.0,790.0,1.0,0,269.0
5252,607984,HP:0002664,"Additionally, decreased SPRY4-IT1 contributed to tumor suppressive effect through attenuating cell growth, clonogenic ability and facilitating apoptosis via Bcl-2/caspase-3 pathway in PANC1 and Capan-2 cells.",0,1.3723497602285477,5005761.168333627,245.1925502220469,0.16040076590809196,0.1551737392038525,0.0,0.0,0.9989888776541962,988.0,-0.5922517900460946,0.08613945317686471,1.0,2.0,11.0,213.0,213.0,137.0,426.0,1544,211.0,1.6778973932186097e-06,42170.0,990.0,1.0,0,216.0
5254,607984,HP:0002664,"Furthermore, the xenograft study confirmed the tumor proliferation-promoting role of SPRY4-IT1 in PANC1 cells.",0,1.3723497602285477,5005761.168333627,245.1925502220469,0.16040076590809196,0.1551737392038525,0.0,0.0,0.9989888776541962,988.0,-0.5922517900460946,0.08613945317686471,1.0,2.0,11.0,213.0,213.0,137.0,426.0,1544,211.0,1.6778973932186097e-06,42170.0,990.0,1.0,0,216.0
5256,609681,HP:0000365,"The analysis of the two exons of SLITRK6 gene in a Moroccan family allowed us to identify a novel single deleterious mutation c.696delG, p.Trp232Cysfs*10 at homozygous state in the exon 2 of the SLITRK6, a gene reported to cause deafness and myopia in various populations",1,1.4814575486981667,692261.406493969,588.0241095629842,0.22585335057780034,0.1227894025402947,0.0,0.0,1.000787401574803,1271.0,-0.7899879289212983,0.02410898480333546,1.0,2.0,1.0,34.0,34.0,34.0,68.0,2474,33.0,6.52467239619899e-07,19458.0,1271.0,1.0,0,31.0
5257,609681,HP:0000545,"The analysis of the two exons of SLITRK6 gene in a Moroccan family allowed us to identify a novel single deleterious mutation c.696delG, p.Trp232Cysfs*10 at homozygous state in the exon 2 of the SLITRK6, a gene reported to cause deafness and myopia in various populations",1,1.4403846153846154,167347.14621716374,161.45098039215688,0.2551675188000502,0.04344597965434067,0.0,0.0,1.0028011204481793,358.0,-0.751087100235995,0.07774282897516549,1.0,2.0,1.0,34.0,34.0,33.0,68.0,648,33.0,9.467455621301773e-06,4968.0,358.0,1.0,0,36.0
5258,610055,HP:0000752,"In parallel, we recently reported that Cc2d1a-deficient mice present with cognitive and social deficits, hyperactivity and anxiety.",1,1.3783071333234465,2364662.6194444443,254.71148825065274,0.15480821792433738,0.033412613937009415,0.0,0.0,1.002008032128514,499.0,-0.7054074595629739,0.1825176457332336,1.0,2.0,1.0,116.0,116.0,116.0,232.0,766,115.0,6.781684027777778e-06,22678.0,499.0,1.0,0,139.0
5260,610055,HP:0000752,"We generated Cc2d1b knockout (KO), Cc2d1a/1b double heterozygous and double KO mice, then performed behavioral studies to analyze learning and memory, social interactions, anxiety, and hyperactivity.",1,1.3783071333234465,2364662.6194444443,254.71148825065274,0.15480821792433738,0.033412613937009415,0.0,0.0,1.002008032128514,499.0,-0.7054074595629739,0.1825176457332336,1.0,2.0,1.0,116.0,116.0,116.0,232.0,766,115.0,6.781684027777778e-06,22678.0,499.0,1.0,0,139.0
5262,610150,HP:0009830,"Here, we are elucidating the mechanism of a heritable CCT5 subunit mutation that causes profound neuropathy in humans.",1,1.4098405067417872,1152658.0424194152,217.3767429623784,0.2020350308717053,0.06351240799495228,0.0,0.0,1.0015625,641.0,-0.6424188849717305,0.08797776911076444,1.0,2.0,1.0,98.0,98.0,84.0,196.0,1086,97.0,3.379108996539792e-06,18046.0,641.0,1.0,0,82.0
4889,607001,HP:0001249,"Kleefstra syndrome, a disease with intellectual disability, autism spectrum disorders and other developmental defects is caused in humans by haploinsufficiency of EHMT1.",1,1.401885650648655,27584242.880467724,540.8531513522207,0.1269570669708781,0.00254769219806545,0.0,0.0,1.0005189413596265,1928.0,-0.5943171920580246,0.07886670528222013,1.0,2.0,1.0,326.0,326.0,325.0,652.0,3204,325.0,3.8916426584745004e-07,146505.0,1928.0,1.0,0,352.0
4706,134797,HP:0002664,"The subcapsular mass-forming tumor was composed of poorly differentiated tumor cells arranged in small vague glandular or slit-lumen nests, and focally fused or anastomosing large trabecular patterns within the prominent fibrotic stroma.",0,1.3175830576105678,13802330.6696414,239.41982453096733,0.14249244734076313,0.05695284521300251,0.0,0.0,0.9992857142857144,1399.0,-0.3535973925392786,0.08521362292240238,1.0,2.0,25.0,544.0,544.0,4.0,1088.0,1544,542.0,1.6778973932186097e-06,83569.0,1401.0,1.0,0,666.0
5263,109270,HP:0002664,"The tumor cells with immunoreactivity to CK7, CK19, Cam5.2, COX2, EMA, BCL-2, MOC-31 and AE1/AE3, supported a diagnosis of intrahepatic cholangiocarcinoma.",0,1.3557688634192933,2637085.5014916062,191.78058122568092,0.1842070349220632,0.07795776396874363,0.0,0.0,0.9989626556016598,963.0,-0.6352019881674243,0.06479048868058393,1.0,2.0,25.0,165.0,165.0,81.0,330.0,1544,163.0,1.6778973932186097e-06,30136.0,965.0,1.0,0,165.0
971,121011,HP:0000365,"After exclusive analysis of 10 common variations of three hearing loss-related genes, GJB2, mtDNA12srRNA and SLC26A4, a novel truncated variant of SMPX, c.87dupA (p.Gly30Argfs*12) (NCBI ClinVar Submission ID: SUB3136126), was identified by whole-exome sequencing.",1,1.395883254657124,11360890.773559922,359.9890516043107,0.1442161069048109,0.0490995817099891,0.0,0.0,1.000660501981506,1515.0,-0.6063388048985573,0.07124963487101682,1.0,2.0,7.0,266.0,266.0,150.0,532.0,2474,265.0,6.524672396198986e-07,81713.0,1515.0,1.0,0,305.0
1015,605646,HP:0000365,"After exclusive analysis of 10 common variations of three hearing loss-related genes, GJB2, mtDNA12srRNA and SLC26A4, a novel truncated variant of SMPX, c.87dupA (p.Gly30Argfs*12) (NCBI ClinVar Submission ID: SUB3136126), was identified by whole-exome sequencing.",1,1.4413226495142712,4479611.427125419,456.96235976102685,0.15949329773347126,0.021256166761706764,0.0,0.0,1.0007358351729212,1360.0,-0.7348599879376381,0.0553207375665498,1.0,2.0,1.0,121.0,121.0,109.0,242.0,2474,120.0,6.524672396198984e-07,51123.0,1360.0,1.0,0,110.0
1953,300226,HP:0000365,"After exclusive analysis of 10 common variations of three hearing loss-related genes, GJB2, mtDNA12srRNA and SLC26A4, a novel truncated variant of SMPX, c.87dupA (p.Gly30Argfs*12) (NCBI ClinVar Submission ID: SUB3136126), was identified by whole-exome sequencing.",1,1.4908066730810208,158048.05518060905,573.2418089305245,0.3006045477381612,-0.026439552448905168,0.0,0.0,1.0007980845969673,1254.0,-0.8059367870514993,0.01223602429130215,1.0,2.0,1.0,17.0,17.0,17.0,34.0,2474,16.0,6.524672396198987e-07,9613.0,1254.0,1.0,0,15.0
4335,605219,HP:0002664,"In recent years, many studies have shown that Smac/DIABLO is closely related to tumor drug resistance.",0,1.4249653836678868,66642.72081087937,231.81285899573842,0.3646611524249747,0.4257136968072651,0.0,0.0,0.9987277353689568,785.0,-0.6781588277445657,0.012754978321386657,1.0,2.0,100.0,15.0,15.0,15.0,30.0,1544,13.0,1.67789739321861e-06,3945.0,787.0,1.0,0,13.0
4347,605219,HP:0002664,Smac/DIABLO expression is markedly different between drug-resistant and chemo sensitive tumor cells.,0,1.4249653836678868,66642.72081087937,231.81285899573842,0.3646611524249747,0.4257136968072651,0.0,0.0,0.9987277353689568,785.0,-0.6781588277445657,0.012754978321386657,1.0,2.0,100.0,15.0,15.0,15.0,30.0,1544,13.0,1.67789739321861e-06,3945.0,787.0,1.0,0,13.0
4353,605219,HP:0002664,Up-regulation of Smac/DIABLO has been shown to increase tumor cell chemotherapy sensitivity.,0,1.4249653836678868,66642.72081087937,231.81285899573842,0.3646611524249747,0.4257136968072651,0.0,0.0,0.9987277353689568,785.0,-0.6781588277445657,0.012754978321386657,1.0,2.0,100.0,15.0,15.0,15.0,30.0,1544,13.0,1.67789739321861e-06,3945.0,787.0,1.0,0,13.0
4359,605219,HP:0002664,"We found that Smac, combined with DDP greatly inhibited proliferation of subcutaneous xenografts of ovarian cancer cell line SKOV3/DDP without side effects.",0,1.4249653836678868,66642.72081087937,231.81285899573842,0.3646611524249747,0.4257136968072651,0.0,0.0,0.9987277353689568,785.0,-0.6781588277445657,0.012754978321386657,1.0,2.0,100.0,15.0,15.0,15.0,30.0,1544,13.0,1.67789739321861e-06,3945.0,787.0,1.0,0,13.0
5265,300356,HP:0002664,"We found that Smac, combined with DDP greatly inhibited proliferation of subcutaneous xenografts of ovarian cancer cell line SKOV3/DDP without side effects.",0,1.3777785918765733,2136265.6683608405,196.72413125136865,0.19235144856592945,0.32175834507326084,0.0,0.0,0.9989200863930886,925.0,-0.6102518447799006,0.060391285202038215,1.0,2.0,31.0,148.0,148.0,96.0,296.0,1544,146.0,1.6778973932186103e-06,25920.0,927.0,1.0,0,133.0
4341,605219,HP:0002664,"Mechanistic studies showed that Smac can inhibit the expression of Survivin, promote cell apoptosis of drug-resistant ovarian cancer cells and reverse the drug resistance",0,1.4249653836678868,66642.72081087937,231.81285899573842,0.3646611524249747,0.4257136968072651,0.0,0.0,0.9987277353689568,785.0,-0.6781588277445657,0.012754978321386657,1.0,2.0,100.0,15.0,15.0,15.0,30.0,1544,13.0,1.67789739321861e-06,3945.0,787.0,1.0,0,13.0
5266,612373,HP:0001425,"SLC29A3 mutations have been reported as the causal gene in two DOS families, however, genetic heterogeneity has been suggested.",0,1.3238028735267355,1622754.7856134062,122.48253340338516,0.20178224324685493,0.2388941291280283,0.0,0.0,0.998439937597504,640.0,-0.3321955217470978,0.0919221815601596,1.0,2.0,13.0,221.0,221.0,4.0,442.0,512,219.0,6.441804736014842e-06,18914.0,642.0,1.0,0,255.0
5267,603499,HP:0000007,"TNFRSF11A mutations have previously been reported in two autosomal dominant diseases (osteolysis, familial expansile and Paget disease of bone 2, early-onset) and an autosomal recessive disease (osteopetrosis, autosomal recessive 7).",1,1.439132716524706,16219855.193229046,520.8547774584097,0.16057938706513222,0.10627875795556163,0.0,0.0,1.000351370344343,2847.0,-0.5870806975644588,0.03110769161655289,1.0,2.0,8.0,263.0,263.0,208.0,526.0,5160,262.0,1.5011496554636372e-07,126026.0,2847.0,1.0,0,248.0
1001,121011,HP:0000365,"In the present study, we used a custom capture panel (MiamiOtoGenes) to target sequence 180 deafness-associated genes in 5 GJB2 negative deaf probands with autosomal recessive nonsyndromic HL from Iran.",1,1.395883254657124,11360890.773559922,359.9890516043107,0.1442161069048109,0.0490995817099891,0.0,0.0,1.000660501981506,1515.0,-0.6063388048985573,0.07124963487101682,1.0,2.0,7.0,266.0,266.0,150.0,532.0,2474,265.0,6.524672396198986e-07,81713.0,1515.0,1.0,0,305.0
5270,121011,HP:0000007,"In the present study, we used a custom capture panel (MiamiOtoGenes) to target sequence 180 deafness-associated genes in 5 GJB2 negative deaf probands with autosomal recessive nonsyndromic HL from Iran.",1,1.4371848223547383,13847678.02619496,447.4600580001115,0.1681986257336911,0.20630620291213586,0.0,0.0,1.000350017500875,2858.0,-0.5663418099659183,0.0275051541240463,1.0,2.0,17.0,271.0,271.0,162.0,542.0,5160,270.0,1.5011496554636354e-07,112294.0,2858.0,1.0,0,267.0
5272,609761,HP:0000365,"In these 5 families, we detected one reported and six novel mutations in 5 different deafness autosomal recessive (DFNB) genes (TRIOBP, LHFPL5, CDH23, PCDH15, and MYO7A).",1,1.4913764443440591,160906.173735887,648.2780921584479,0.2928962341778909,-0.018930884008525918,0.0,0.0,1.0007987220447283,1253.0,-0.8299221194368974,0.013054930148474331,1.0,2.0,1.0,16.0,16.0,16.0,32.0,2474,15.0,6.524672396198986e-07,10240.0,1253.0,1.0,0,17.0
5273,609427,HP:0000365,"In these 5 families, we detected one reported and six novel mutations in 5 different deafness autosomal recessive (DFNB) genes (TRIOBP, LHFPL5, CDH23, PCDH15, and MYO7A).",1,1.4942596129415908,104137.28730636543,835.4546924377161,0.29702748765235903,-0.034704652142483305,0.0,0.0,1.0008019246190858,1248.0,-0.9110838170590588,0.011706300248802254,1.0,2.0,1.0,11.0,11.0,11.0,22.0,2474,10.0,6.524672396198987e-07,9109.0,1248.0,1.0,0,10.0
5274,605516,HP:0000365,"In these 5 families, we detected one reported and six novel mutations in 5 different deafness autosomal recessive (DFNB) genes (TRIOBP, LHFPL5, CDH23, PCDH15, and MYO7A).",1,1.3843441639620484,12123018.49696314,334.97584671629727,0.1447934283333667,0.019499825224658863,0.0,0.0,1.0006365372374282,1572.0,-0.5712275465153426,0.07151163826544413,1.0,2.0,12.0,317.0,317.0,135.0,634.0,2474,316.0,6.524672396198985e-07,88303.0,1572.0,1.0,0,383.0
5275,605514,HP:0000365,"In these 5 families, we detected one reported and six novel mutations in 5 different deafness autosomal recessive (DFNB) genes (TRIOBP, LHFPL5, CDH23, PCDH15, and MYO7A).",1,1.452118358231438,3588395.347738828,497.8881618835893,0.1690935784411814,0.10384070171526613,0.0,0.0,1.0007507507507507,1333.0,-0.7161599818999996,0.04996181477801883,1.0,2.0,2.0,95.0,95.0,94.0,190.0,2474,94.0,6.524672396198986e-07,44355.0,1333.0,1.0,0,104.0
5276,609427,HP:0000007,"In these 5 families, we detected one reported and six novel mutations in 5 different deafness autosomal recessive (DFNB) genes (TRIOBP, LHFPL5, CDH23, PCDH15, and MYO7A).",1,1.4972178817506734,115986.64332510546,794.0072938689218,0.38854445866312265,0.9271740334367464,0.0,0.0,1.0003861003861003,2591.0,-0.5750340595195119,0.0025919838347472465,1.0,2.0,1389.0,11.0,11.0,11.0,22.0,5160,10.0,1.5011496554636367e-07,8697.0,2591.0,1.0,0,10.0
5277,605516,HP:0000007,"In these 5 families, we detected one reported and six novel mutations in 5 different deafness autosomal recessive (DFNB) genes (TRIOBP, LHFPL5, CDH23, PCDH15, and MYO7A).",1,1.4276608428640485,15646200.600480802,424.3394133981257,0.16574311467352748,0.13986433731791464,0.0,0.0,1.0003431708991075,2915.0,-0.5551610329517521,0.02962383054067958,1.0,2.0,6.0,321.0,321.0,165.0,642.0,5160,320.0,1.5011496554636375e-07,125817.0,2915.0,1.0,0,298.0
5278,605514,HP:0000007,"In these 5 families, we detected one reported and six novel mutations in 5 different deafness autosomal recessive (DFNB) genes (TRIOBP, LHFPL5, CDH23, PCDH15, and MYO7A).",1,1.4748398675789738,4849155.344898755,677.0815891472868,0.19242118377143366,0.2189516031510169,0.0,0.0,1.000373831775701,2676.0,-0.6520230488006948,0.017509185141723598,1.0,2.0,164.0,95.0,95.0,94.0,190.0,5160,94.0,1.5011496554636367e-07,62668.0,2676.0,1.0,0,99.0
5279,276903,HP:0000007,"In these 5 families, we detected one reported and six novel mutations in 5 different deafness autosomal recessive (DFNB) genes (TRIOBP, LHFPL5, CDH23, PCDH15, and MYO7A).",1,1.47195811327023,5177536.48361377,630.9526270456503,0.1903221994711876,0.1790127252054806,0.0,0.0,1.0003721622627466,2688.0,-0.6404418371398037,0.018111066067662645,1.0,2.0,144.0,105.0,105.0,105.0,210.0,5160,104.0,1.5011496554636367e-07,65405.0,2688.0,1.0,0,107.0
1904,109270,HP:0008341,"Primary distal renal tubular acidosis (dRTA) caused by mutations of the SLC4A1 gene, which encodes for erythroid and kidney isoforms of anion exchanger, shows marked difference in inheritance patterns and clinical features in different parts of the world.",1,1.4864599483204133,2437.4367015098724,75.92708333333333,0.6707058791577571,0.5682147029118384,0.0,0.0,1.0051020408163265,197.0,-0.5816153014120314,0.01916502641665804,1.0,2.0,103.0,5.0,5.0,5.0,10.0,384,5.0,2.684635829149776e-05,370.0,197.0,1.0,0,5.0
5286,611731,HP:0030731,"Of the 2 204 genes that were mutated, APC, TTN, TP53, KRAS, OBSCN, SOX9, PCDH17, SIGLEC10, MYH6, and BRD9 were consistent with genes being an early driver of carcinogenesis, in that they were mutated in multiple adenomas and multiple carcinomas.",0,1.486821052924481,24954.171351358185,177.83830673143657,0.4849786287210348,0.25946546982736163,0.0,0.0,1.00187265917603,535.0,-0.5449425873712724,0.013413140116909935,1.0,2.0,131.0,11.0,11.0,11.0,22.0,324,11.0,3.6281179138322e-06,1916.0,535.0,1.0,0,11.0
5289,188840,HP:0030731,"Of the 2 204 genes that were mutated, APC, TTN, TP53, KRAS, OBSCN, SOX9, PCDH17, SIGLEC10, MYH6, and BRD9 were consistent with genes being an early driver of carcinogenesis, in that they were mutated in multiple adenomas and multiple carcinomas.",0,1.3048594058452505,14193.702813852813,68.95924764890283,0.491665900555855,0.5934334667075408,0.0,0.0,0.996978851963746,330.0,-0.4678947584745177,0.018964073817930333,1.0,2.0,157.0,12.0,12.0,12.0,24.0,446,11.0,9.765625e-06,1042.0,332.0,1.0,0,12.0
5290,160710,HP:0030731,"Of the 2 204 genes that were mutated, APC, TTN, TP53, KRAS, OBSCN, SOX9, PCDH17, SIGLEC10, MYH6, and BRD9 were consistent with genes being an early driver of carcinogenesis, in that they were mutated in multiple adenomas and multiple carcinomas.",0,1.2775852721401126,6733.794360902255,37.45454545454546,0.4990387630154274,0.20440204186959848,0.0,0.0,0.993975903614458,165.0,-0.4703929741162534,0.03816463458624919,1.0,2.0,76.0,12.0,12.0,12.0,24.0,254,11.0,4.162330905306972e-05,529.0,167.0,1.0,0,12.0
5291,600960,HP:0030731,Thirty-eight genes were sequenced in a larger independent set of 148 carcinoma/normal tissue pairs to obtain more precise mutation frequencies.,0,1.3281861972718678,10320.91553030303,52.64012910166757,0.4485015865397041,0.2202936751550155,0.0,0.0,0.9944751381215468,180.0,-0.5786422383921991,0.0426810758302471,1.0,2.0,53.0,12.0,12.0,12.0,24.0,160,11.0,3.4602076124567484e-05,703.0,182.0,1.0,0,12.0
5280,611731,HP:0030731,"Eight of the genes, APC, TP53, ATM, CSMD3, LRP1B, RYR2, BIRC6, and MUC17, contained mutations in &gt;20% of the carcinomas.",0,1.486821052924481,24954.171351358185,177.83830673143657,0.4849786287210348,0.25946546982736163,0.0,0.0,1.00187265917603,535.0,-0.5449425873712724,0.013413140116909935,1.0,2.0,131.0,11.0,11.0,11.0,22.0,324,11.0,3.6281179138322e-06,1916.0,535.0,1.0,0,11.0
5293,180902,HP:0030731,"Eight of the genes, APC, TP53, ATM, CSMD3, LRP1B, RYR2, BIRC6, and MUC17, contained mutations in &gt;20% of the carcinomas.",0,1.1796675191815855,1122.8916666666667,12.783549783549786,0.5643469708992249,0.5658655653235934,0.0,0.0,0.9814814814814814,53.0,-0.5223007996318983,0.098989898989899,1.0,2.0,20.0,12.0,12.0,12.0,24.0,60,10.0,0.0005408328826392644,147.0,55.0,1.0,0,12.0
4531,611731,HP:0002664,"Most of the genes that are commonly associated with colon cancer, including APC, TP53, and KRAS, were all classified as being early driver genes being mutated in both adenomas and carcinomas.",1,1.3391008903849515,11574943.624649456,243.44156245977763,0.14922188725133187,0.047377974699447135,0.0,0.0,1.000772797527048,1295.0,-0.3687472023865209,0.0906434807516724,1.0,2.0,7.0,490.0,490.0,21.0,980.0,1542,489.0,1.677897393218609e-06,75947.0,1295.0,1.0,0,662.0
2042,190070,HP:0002664,"Most of the genes that are commonly associated with colon cancer, including APC, TP53, and KRAS, were all classified as being early driver genes being mutated in both adenomas and carcinomas.",1,1.3339771877413191,18178836.290753696,271.2782786211432,0.14438020893870612,0.0522035687829069,0.0,0.0,1.0006165228113442,1623.0,-0.2035822069529308,0.08341633409382543,1.0,2.0,4.0,720.0,720.0,2.0,1440.0,1542,719.0,1.374364528201273e-06,109797.0,1623.0,1.0,0,858.0
5283,611731,HP:0030731,"Most of the genes that are commonly associated with colon cancer, including APC, TP53, and KRAS, were all classified as being early driver genes being mutated in both adenomas and carcinomas.",0,1.486821052924481,24954.171351358185,177.83830673143657,0.4849786287210348,0.25946546982736163,0.0,0.0,1.00187265917603,535.0,-0.5449425873712724,0.013413140116909935,1.0,2.0,131.0,11.0,11.0,11.0,22.0,324,11.0,3.6281179138322e-06,1916.0,535.0,1.0,0,11.0
5294,190070,HP:0030731,"Most of the genes that are commonly associated with colon cancer, including APC, TP53, and KRAS, were all classified as being early driver genes being mutated in both adenomas and carcinomas.",0,1.378978015090394,41263.32811777595,199.5176056338028,0.4831234193143702,0.4116951622974924,0.0,0.0,0.9988425925925926,863.0,-0.5017587060160795,0.008049668165275102,1.0,2.0,238.0,12.0,12.0,12.0,24.0,498,11.0,1.374364528201273e-06,3008.0,865.0,1.0,0,12.0
5298,142958,HP:0002860,Objective: To explore the expression of long noncoding RNA (lncRNA) HOXA11-AS in esophageal squamous cell carcinoma tissues and the relationship of HOXA11-AS level with clinical outcomes.,0,1.2767026049688608,40721.43580586081,37.23567777190199,0.32250575903551204,0.11372342286224645,0.0,0.0,0.9935483870967742,154.0,-0.4718058242704216,0.12009925558312655,1.0,2.0,12.0,47.0,47.0,4.0,94.0,124,45.0,0.00011317338162064282,1452.0,156.0,1.0,0,50.0
5299,142830,HP:0002860,Objective: To explore the expression of long noncoding RNA (lncRNA) HOXA11-AS in esophageal squamous cell carcinoma tissues and the relationship of HOXA11-AS level with clinical outcomes.,0,1.3575033405283174,229349.59256608647,94.2543121881682,0.262013283841347,0.23805385631195344,0.0,0.0,0.9975429975429976,406.0,-0.5516621609688278,0.06248494483788601,1.0,2.0,37.0,61.0,61.0,62.0,122.0,272,59.0,8.353102342209896e-06,5188.0,408.0,1.0,0,58.0
5300,142958,HP:0002664,"Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect the expression level of HOXA11-AS in cell lines HET-1A, EC9706, EC109, and in tumor tissue and paired adjacent tissue samples from 73 ESCC patients who received surgical resection.The correlations of the expression level of HOXA11-AS with clinicopathological features and prognosis were also analyzed.",0,1.4140293083874935,1195001.34707131,204.72423747960337,0.2165166254026998,0.14827270263348885,0.0,0.0,0.9988439306358382,864.0,-0.6127575547211219,0.047225300030703916,1.0,2.0,20.0,91.0,91.0,83.0,182.0,1544,89.0,1.6778973932186097e-06,17688.0,866.0,1.0,0,86.0
5306,142830,HP:0002664,"Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect the expression level of HOXA11-AS in cell lines HET-1A, EC9706, EC109, and in tumor tissue and paired adjacent tissue samples from 73 ESCC patients who received surgical resection.The correlations of the expression level of HOXA11-AS with clinicopathological features and prognosis were also analyzed.",0,1.3477586824203365,7479304.187928737,235.9826086956521,0.155324937708923,0.04255755790290811,0.0,0.0,0.999104744852283,1116.0,-0.5002689703312031,0.09110302160623827,1.0,2.0,8.0,331.0,331.0,86.0,662.0,1544,329.0,1.6778973932186103e-06,56885.0,1118.0,1.0,0,455.0
5302,142958,HP:0002664,"Results: The relative expression levels of HOXA11-AS in tumor tissue and paired adjacent tissue were 0.832+0.387 and 2.486+1.087, respectively, with significant difference (P&lt;0.001).",0,1.4140293083874935,1195001.34707131,204.72423747960337,0.2165166254026998,0.14827270263348885,0.0,0.0,0.9988439306358382,864.0,-0.6127575547211219,0.047225300030703916,1.0,2.0,20.0,91.0,91.0,83.0,182.0,1544,89.0,1.6778973932186097e-06,17688.0,866.0,1.0,0,86.0
5308,142830,HP:0002664,"Results: The relative expression levels of HOXA11-AS in tumor tissue and paired adjacent tissue were 0.832+0.387 and 2.486+1.087, respectively, with significant difference (P&lt;0.001).",0,1.3477586824203365,7479304.187928737,235.9826086956521,0.155324937708923,0.04255755790290811,0.0,0.0,0.999104744852283,1116.0,-0.5002689703312031,0.09110302160623827,1.0,2.0,8.0,331.0,331.0,86.0,662.0,1544,329.0,1.6778973932186103e-06,56885.0,1118.0,1.0,0,455.0
5304,142830,HP:0002664,Conclusions: The expression of HOXA11-AS is upregulated in esophageal cancer cell lines and tissues.,0,1.3477586824203365,7479304.187928737,235.9826086956521,0.155324937708923,0.04255755790290811,0.0,0.0,0.999104744852283,1116.0,-0.5002689703312031,0.09110302160623827,1.0,2.0,8.0,331.0,331.0,86.0,662.0,1544,329.0,1.6778973932186103e-06,56885.0,1118.0,1.0,0,455.0
5310,134790,HP:0002664,"With a feature selection algorithm, we selected a panel of five urinary biomarkers (FTL: Ferritin light chain; MAPK1IP1L: Mitogen-Activated Protein Kinase 1 Interacting Protein 1 Like; FGB: Fibrinogen Beta Chain; RAB33B: RAB33B, Member RAS Oncogene Family; RAB15: RAB15, Member RAS Oncogene Family) and established a combinatorial model that can correctly classify the majority of lung cancer cases both in the training set (n=46) and the test sets (n=14-47 per set) with an AUC ranging from 0.8747 to 0.9853.",0,1.3682143468096024,1923848.9810834872,169.98294344693952,0.1951172570348909,0.04598114374872762,0.0,0.0,0.9989339019189766,937.0,-0.6268162085215989,0.05422908279233681,1.0,2.0,24.0,143.0,143.0,66.0,286.0,1544,141.0,1.67789739321861e-06,23882.0,939.0,1.0,0,140.0
5311,134830,HP:0002664,"With a feature selection algorithm, we selected a panel of five urinary biomarkers (FTL: Ferritin light chain; MAPK1IP1L: Mitogen-Activated Protein Kinase 1 Interacting Protein 1 Like; FGB: Fibrinogen Beta Chain; RAB33B: RAB33B, Member RAS Oncogene Family; RAB15: RAB15, Member RAS Oncogene Family) and established a combinatorial model that can correctly classify the majority of lung cancer cases both in the training set (n=46) and the test sets (n=14-47 per set) with an AUC ranging from 0.8747 to 0.9853.",0,1.430150305900292,1027132.8772534071,292.75409370946824,0.20029776113253056,0.2820998912695132,0.0,0.0,0.998803827751196,835.0,-0.7686033144428118,0.051496858797368136,1.0,2.0,19.0,63.0,63.0,62.0,126.0,1548,61.0,1.6778973932186103e-06,18017.0,837.0,1.0,0,60.0
5312,605950,HP:0002664,"With a feature selection algorithm, we selected a panel of five urinary biomarkers (FTL: Ferritin light chain; MAPK1IP1L: Mitogen-Activated Protein Kinase 1 Interacting Protein 1 Like; FGB: Fibrinogen Beta Chain; RAB33B: RAB33B, Member RAS Oncogene Family; RAB15: RAB15, Member RAS Oncogene Family) and established a combinatorial model that can correctly classify the majority of lung cancer cases both in the training set (n=46) and the test sets (n=14-47 per set) with an AUC ranging from 0.8747 to 0.9853.",0,1.3841562688764724,1056090.7237026398,191.18599221789881,0.2156507558453724,0.3074436049176882,0.0,0.0,0.998833138856476,856.0,-0.6144450266984046,0.041724125738128066,1.0,2.0,82.0,85.0,85.0,78.0,170.0,1544,83.0,1.6778973932186097e-06,15340.0,858.0,1.0,0,78.0
628,600960,HP:0002664,"With a feature selection algorithm, we selected a panel of five urinary biomarkers (FTL: Ferritin light chain; MAPK1IP1L: Mitogen-Activated Protein Kinase 1 Interacting Protein 1 Like; FGB: Fibrinogen Beta Chain; RAB33B: RAB33B, Member RAS Oncogene Family; RAB15: RAB15, Member RAS Oncogene Family) and established a combinatorial model that can correctly classify the majority of lung cancer cases both in the training set (n=46) and the test sets (n=14-47 per set) with an AUC ranging from 0.8747 to 0.9853.",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
592,600960,HP:0002664,"The biomarker panel and the predictive model, when validated by more samples in a multi-center setting, may be used as an auxiliary diagnostic tool along with imaging technology for lung cancer detection",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
5313,604965,HP:0002664,The canonical Hippo tumor suppressor pathway in mammalian cells is primarily composed of the MST1/2-SAV1-LATS1/2-MOB1-YAP/TAZ cascade.,1,1.4667218320883841,348937.3813358515,244.32558365758754,0.28356998477240186,0.3735687866272807,0.0,0.0,1.0012345679012349,811.0,-0.6179403232719333,0.028286979951591545,1.0,2.0,5.0,40.0,40.0,40.0,80.0,1542,39.0,1.6778973932186103e-06,9291.0,811.0,1.0,0,36.0
4279,607860,HP:0002664,The canonical Hippo tumor suppressor pathway in mammalian cells is primarily composed of the MST1/2-SAV1-LATS1/2-MOB1-YAP/TAZ cascade.,0,1.4068527212636974,1358223.7785376424,256.74811932555116,0.20044559056675704,0.1205930995449105,0.0,0.0,0.9988262910798122,851.0,-0.6786890735043399,0.05315401592831707,1.0,2.0,44.0,79.0,79.0,77.0,158.0,1544,77.0,1.6778973932186103e-06,19315.0,853.0,1.0,0,86.0
3035,602115,HP:0002664,"Furthermore, in cultured human BMSCs, TGF-a stimulated production of procancer cytokines including IL-6, VEGF, FGF10, FGF17, and TGF-b1 in a dose-dependent manner.",0,1.352639620441478,7948099.491240703,227.73201881072305,0.15006376111346156,0.13076118941764125,0.0,0.0,0.999089253187614,1097.0,-0.5424314165118554,0.08753942564112764,1.0,2.0,6.0,293.0,293.0,90.0,586.0,1544,292.0,1.67789739321861e-06,52817.0,1099.0,1.0,0,386.0
5314,603725,HP:0002664,"Furthermore, in cultured human BMSCs, TGF-a stimulated production of procancer cytokines including IL-6, VEGF, FGF10, FGF17, and TGF-b1 in a dose-dependent manner.",0,1.3723497602285477,5005761.168333627,245.1925502220469,0.16040076590809202,0.15517373920385094,0.0,0.0,0.9989888776541962,988.0,-0.5922517900460947,0.08613945317686471,1.0,2.0,11.0,213.0,213.0,137.0,426.0,1544,211.0,1.6778973932186097e-06,42170.0,990.0,1.0,0,216.0
4909,607968,HP:0002664,"Furthermore, in cultured human BMSCs, TGF-a stimulated production of procancer cytokines including IL-6, VEGF, FGF10, FGF17, and TGF-b1 in a dose-dependent manner.",0,1.382167461745328,4456380.149059111,290.29824820634065,0.15912584557625145,0.06541130802715996,0.0,0.0,0.9989247311827956,929.0,-0.6350771196323979,0.08947021932711964,1.0,2.0,26.0,159.0,159.0,158.0,318.0,1544,157.0,1.67789739321861e-06,38733.0,931.0,1.0,0,171.0
3349,120436,HP:0002664,"Lynch syndrome, a hereditary cancer syndrome, occurs because of germline mutations in at least one of four DNA mismatch repair genes (MutL Homolog 1 (MLH1), MutS Homolog 2 (MSH2), MutS Homolog 6 (MSH6), and PMS1 Homolog 2 (PMS2)).",1,1.3724379901603143,5818621.47767339,246.4111696040284,0.1639416543826219,-0.008069802038276657,0.0,0.0,1.0009756097560976,1026.0,-0.5524282139315764,0.08979793657585697,1.0,2.0,1.0,250.0,250.0,99.0,500.0,1542,249.0,1.67789739321861e-06,47218.0,1026.0,1.0,0,247.0
3377,609309,HP:0002664,"Lynch syndrome, a hereditary cancer syndrome, occurs because of germline mutations in at least one of four DNA mismatch repair genes (MutL Homolog 1 (MLH1), MutS Homolog 2 (MSH2), MutS Homolog 6 (MSH6), and PMS1 Homolog 2 (PMS2)).",1,1.3768221907623603,5337536.964099137,247.2793183273408,0.16568705398514247,0.06456760463916675,0.0,0.0,1.0009930486593843,1008.0,-0.5677206892113388,0.0883222206459545,1.0,2.0,1.0,230.0,230.0,119.0,460.0,1542,229.0,1.6778973932186103e-06,44826.0,1008.0,1.0,0,233.0
3391,600678,HP:0002664,"Lynch syndrome, a hereditary cancer syndrome, occurs because of germline mutations in at least one of four DNA mismatch repair genes (MutL Homolog 1 (MLH1), MutS Homolog 2 (MSH2), MutS Homolog 6 (MSH6), and PMS1 Homolog 2 (PMS2)).",1,1.3768221907623603,5434927.671252767,247.952322316899,0.16552335810421795,0.08110103513378521,0.0,0.0,1.0009930486593843,1008.0,-0.5593717390308764,0.08856260147223405,1.0,2.0,1.0,236.0,236.0,119.0,472.0,1542,235.0,1.67789739321861e-06,44948.0,1008.0,1.0,0,251.0
3323,600259,HP:0002664,"Lynch syndrome, a hereditary cancer syndrome, occurs because of germline mutations in at least one of four DNA mismatch repair genes (MutL Homolog 1 (MLH1), MutS Homolog 2 (MSH2), MutS Homolog 6 (MSH6), and PMS1 Homolog 2 (PMS2)).",1,1.3872402977296638,4206211.890374658,241.1820428015564,0.17742948870231876,0.01977480950222539,0.0,0.0,1.0010309278350515,971.0,-0.5551106857517283,0.0813296951808636,1.0,2.0,1.0,200.0,200.0,200.0,400.0,1542,199.0,1.67789739321861e-06,38301.0,971.0,1.0,0,213.0
5317,603220,HP:0002664,"TASK-3 potassium channels are believed to promote proliferation and survival of cancer cells, in part, by augmenting their resistance to both hypoxia and serum deprivation.",0,1.4520472018594672,91068.73558437392,184.15570687418938,0.3814288252484451,0.12155656776766265,0.0,0.0,0.998737373737374,791.0,-0.6684919880756613,0.013826792515317106,1.0,2.0,41.0,21.0,21.0,20.0,42.0,1544,19.0,1.6778973932186097e-06,4342.0,793.0,1.0,0,19.0
5319,603220,HP:0002664,"While overexpression of TASK-3 is frequently observed in cancers, the understanding of its role and regulation during tumorigenesis remains incomplete.",0,1.4520472018594672,91068.73558437392,184.15570687418938,0.3814288252484451,0.12155656776766265,0.0,0.0,0.998737373737374,791.0,-0.6684919880756613,0.013826792515317106,1.0,2.0,41.0,21.0,21.0,20.0,42.0,1544,19.0,1.6778973932186097e-06,4342.0,793.0,1.0,0,19.0
5315,603220,HP:0002664,Our observations implicate TASK-3 as a critical factor in cell cycle progression and corroborate its potential as a therapeutic target in breast cancer treatment,0,1.4520472018594672,91068.73558437392,184.15570687418938,0.3814288252484451,0.12155656776766265,0.0,0.0,0.998737373737374,791.0,-0.6684919880756613,0.013826792515317106,1.0,2.0,41.0,21.0,21.0,20.0,42.0,1544,19.0,1.6778973932186097e-06,4342.0,793.0,1.0,0,19.0
5322,600835,HP:0002664,Our data suggest a mechanism whereby CAFs promote tumor cell migration and invasion through CXCL12 secretion to regulate the mDia2-directed cytoskeleton in breast tumor cells,0,1.2467825290491663,2322.002597402597,4.002594033722438,0.7071706999074872,0.8359521385756078,0.0,0.0,0.9987063389391979,772.0,-0.99233106615227,0.00258732212160414,1.0,2.0,770.0,2.0,2.0,2.0,4.0,1540,1.0,1.67789739321861e-06,774.0,774.0,1.0,0,2.0
5323,603470,HP:0002664,"Regarding the important role of arginine (Arg) in the regulation of multiple metabolic and signaling pathways, its deprivation has been proposed as a good strategy for tumor regression in tumors with defected Arg metabolic enzymes like argininosuccinate synthase 1 (ASS1).",0,1.4061234047978832,957413.7358988551,240.82404942316884,0.21322343554999856,0.045920656228996784,0.0,0.0,0.9988207547169812,847.0,-0.7160684398536116,0.0482504389181501,1.0,2.0,40.0,67.0,67.0,61.0,134.0,1544,65.0,1.677897393218609e-06,17369.0,849.0,1.0,0,65.0
5326,191315,HP:0002664,We previously reported that brain-derived neurotrophic factor (BDNF)/neurotrophic receptor tyrosine kinase 2 (NTRK2/TRKB) signaling contributes to induction of malignant phenotype of gallbladder cancer (GBC).,1,1.3576149099201331,4257229.770110128,233.6286576747919,0.16053338380174054,0.00957989121402985,0.0,0.0,0.998994974874372,994.0,-0.6333806699760925,0.08286210167302377,1.0,2.0,21.0,204.0,204.0,104.0,408.0,1544,202.0,1.677897393218609e-06,41059.0,996.0,1.0,0,201.0
5324,191315,HP:0002664,"Recently, pan-TRK inhibitors have been evaluated and their dramatic clinical activity is being shown for a variety of cancer types harboring an NTRK rearrangement in phase I trials.",1,1.3576149099201331,4257229.770110128,233.6286576747919,0.16053338380174054,0.00957989121402985,0.0,0.0,0.998994974874372,994.0,-0.6333806699760925,0.08286210167302377,1.0,2.0,21.0,204.0,204.0,104.0,408.0,1544,202.0,1.677897393218609e-06,41059.0,996.0,1.0,0,201.0
5330,609023,HP:0001251,"Routine gene testing is not necessary to guide treatment for typical forms of paroxysmal kinesigenic dyskinesia (PKD), paroxysmal nonkinesigenic dyskinesia (PNKD), and episodic ataxia type 1 or 2.",0,1.4454898307716193,1180769.288427847,337.7230235938723,0.19342050554426413,0.06913383441111365,0.0,0.0,0.9988636363636364,879.0,-0.7494569822678248,0.05513620885357548,1.0,2.0,1.0,67.0,67.0,62.0,134.0,1628,65.0,1.5055139448229143e-06,21373.0,881.0,1.0,0,61.0
5328,609023,HP:0001251,"Antiepileptic drugs remain the treatment of choice for PKD and episodic ataxia type 1, benzodiazepines are often useful for PNKD, and episodic ataxia type 2 benefits from acetazolamide regardless of the genetic etiology",0,1.4454898307716193,1180769.288427847,337.7230235938723,0.19342050554426413,0.06913383441111365,0.0,0.0,0.9988636363636364,879.0,-0.7494569822678248,0.05513620885357548,1.0,2.0,1.0,67.0,67.0,62.0,134.0,1628,65.0,1.5055139448229143e-06,21373.0,881.0,1.0,0,61.0
5332,607070,HP:0012265,"Zinc finger MYND-type-containing 10 (ZMYND10), a cytoplasmic protein expressed in ciliated cells, causes primary ciliary dyskinesia (PCD) when mutated; however, its function is poorly understood.",1,1.4139029859553878,79200.70238095237,188.73625730994152,0.18832514194075428,-0.09608928653902192,0.0,0.0,1.005,201.0,-0.9968408617216902,0.23965174129353234,1.0,2.0,1.0,30.0,30.0,30.0,60.0,308,30.0,3.3802055164954025e-05,4817.0,201.0,1.0,0,30.0
5333,607070,HP:0000238,"Therefore, in this study, we examined the roles of ZMYND10 using Zmynd10-/-mice exhibiting typical PCD phenotypes, including hydrocephalus and laterality defects.",0,1.3499250183465747,2141882.389798359,196.74256749658574,0.16082477276835633,-0.030332258089145844,0.0,0.0,1.001984126984127,505.0,-0.629486171793485,0.17484677039132485,1.0,2.0,1.0,163.0,163.0,80.0,326.0,668,162.0,8.910670527957227e-06,22251.0,505.0,1.0,0,153.0
5334,300169,HP:0003202,"Importantly, AIF deficiency leads to severe mitochondrial dysfunction, causing muscle atrophy and neurodegeneration in model organisms as well as in humans.",1,1.3359632391191258,4336795.5710317455,199.10816331553173,0.16650110506597599,0.15947519489493675,0.0,0.0,1.001233045622688,812.0,-0.3794359643404665,0.12103891686356928,1.0,2.0,13.0,316.0,316.0,17.0,632.0,908,315.0,4.830334500664172e-06,39854.0,812.0,1.0,0,437.0
5335,176300,HP:0001271,"Mutations in the TTR gene cause TTR tetramer protein to dissociate to monomer, which is the rate-limiting step in familial amyloid polyneuropathy.",1,1.3675748455567875,99748.30476190477,71.93137254901961,0.27556401248169365,0.23019033270580835,0.0,0.0,1.0053763440860215,187.0,-0.5242197850658924,0.15341268472198266,1.0,2.0,10.0,51.0,51.0,51.0,102.0,102,51.0,5.327934359848686e-05,2668.0,187.0,1.0,0,51.0
5336,131240,HP:0000093,"Heterozygous Edn1H/+ females showed no obvious abnormalities before pregnancy, but when mated with wild-type (WT) males developed a full spectrum of preeclampsia-like phenotypes, including increased systolic blood pressure, proteinuria, glomerular endotheliosis, and intrauterine fetal growth restriction.",0,1.2517435089081494,241811.622005772,62.95620297125218,0.24682766988100616,0.07339573005753561,0.0,0.0,0.9965397923875432,288.0,-0.4400752767106663,0.1115857296265362,1.0,2.0,28.0,92.0,92.0,2.0,184.0,294,90.0,4.627701420704336e-05,4676.0,290.0,1.0,0,99.0
5337,614260,HP:0001131,"While these expansions occur in coding and noncoding regions, microsatellite sequence and repeat length diversity is more prominent in introns with eight different trinucleotide to hexanucleotide repeats, causing hereditary diseases such as myotonic dystrophy type 2 (DM2), Fuchs endothelial corneal dystrophy (FECD), and C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD).",0,1.2459447566854012,16111.47381113365,23.431818181818183,0.526459418819384,0.2308930619856535,0.0,0.0,0.9960629921259844,253.0,-0.3784989770459259,0.02680253203643661,1.0,2.0,108.0,28.0,28.0,12.0,56.0,278,26.0,2.0474601257140522e-05,868.0,255.0,1.0,0,23.0
5338,120940,HP:0001131,"While these expansions occur in coding and noncoding regions, microsatellite sequence and repeat length diversity is more prominent in introns with eight different trinucleotide to hexanucleotide repeats, causing hereditary diseases such as myotonic dystrophy type 2 (DM2), Fuchs endothelial corneal dystrophy (FECD), and C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD).",0,0.9581105169340464,168.05882352941177,3.696969696969697,0.7327752937719729,0.6847246437624905,0.0,0.0,0.9767441860465116,42.0,-0.6418918918918923,0.057082452431289635,1.0,2.0,34.0,4.0,4.0,2.0,8.0,68,2.0,0.0008650519031141869,54.0,44.0,1.0,0,3.0
5340,120940,HP:0002145,"While these expansions occur in coding and noncoding regions, microsatellite sequence and repeat length diversity is more prominent in introns with eight different trinucleotide to hexanucleotide repeats, causing hereditary diseases such as myotonic dystrophy type 2 (DM2), Fuchs endothelial corneal dystrophy (FECD), and C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD).",0,0.9333333333333332,189.6923076923077,3.511111111111111,0.7452727688453683,0.6813894889072891,0.0,0.0,0.9714285714285714,34.0,-0.6590250001296956,0.06984126984126984,1.0,2.0,26.0,4.0,4.0,2.0,8.0,52,2.0,0.0014792899408284025,44.0,36.0,1.0,0,3.0
5341,614386,HP:0001250,"For families that PRRT2 mutations were not detected by Sanger sequencing, candidate gene mutations were further screened by next-generation sequencing for epilepsy.",1,1.4207563663083491,8848560.59845867,397.4595238766024,0.15433995105663167,0.0484269368681909,0.0,0.0,1.000562429696288,1779.0,-0.6290519794056838,0.05014255174258361,1.0,2.0,4.0,221.0,221.0,131.0,442.0,3100,220.0,4.156965348783942e-07,79302.0,1779.0,1.0,0,213.0
4096,190090,HP:0002664,"Ablation of SRC-3 or PFKFB4 suppresses breast tumour growth in mice and prevents metastasis to the lung from an orthotopic setting, as does Ser857Ala-mutant SRC-3.",1,1.4426975073862085,1100795.0900881223,261.34194552529186,0.21721520197820027,0.13066453623063334,0.0,0.0,1.001183431952663,846.0,-0.6617598272572203,0.04997552002461986,1.0,2.0,2.0,75.0,75.0,75.0,150.0,1542,74.0,1.6778973932186103e-06,17863.0,846.0,1.0,0,79.0
4102,190090,HP:0002664,"PFKFB4 and phosphorylated SRC-3 levels are increased and correlate in oestrogen receptor-positive tumours, whereas, in patients with the basal subtype, PFKFB4 and SRC-3 drive a common protein signature that correlates with the poor survival of patients with breast cancer.",1,1.4426975073862085,1100795.0900881223,261.34194552529186,0.21721520197820027,0.13066453623063334,0.0,0.0,1.001183431952663,846.0,-0.6617598272572203,0.04997552002461986,1.0,2.0,2.0,75.0,75.0,75.0,150.0,1542,74.0,1.6778973932186103e-06,17863.0,846.0,1.0,0,79.0
4105,190090,HP:0002664,These findings suggest that the Warburg pathway enzyme PFKFB4 acts as a molecular fulcrum that couples sugar metabolism to transcriptional activation by stimulating SRC-3 to promote aggressive metastatic tumours,1,1.4426975073862085,1100795.0900881223,261.34194552529186,0.21721520197820027,0.13066453623063334,0.0,0.0,1.001183431952663,846.0,-0.6617598272572203,0.04997552002461986,1.0,2.0,2.0,75.0,75.0,75.0,150.0,1542,74.0,1.6778973932186103e-06,17863.0,846.0,1.0,0,79.0
5342,609023,HP:0002664,"We previously reported that tyrosine phosphorylation activates and inhibits mitochondrial pyruvate dehydrogenase kinase (PDK) and phosphatase (PDP), respectively, leading to enhanced inhibitory serine phosphorylation of pyruvate dehydrogenase (PDH) and consequently inhibition of pyruvate dehydrogenase complex (PDC) in cancer cells.",0,1.4236510474251185,828352.783275519,252.23151750972764,0.20871005749737567,0.03551464140961946,0.0,0.0,0.9988066825775656,837.0,-0.7486524923001913,0.0456561254590503,1.0,2.0,23.0,63.0,63.0,53.0,126.0,1544,61.0,1.67789739321861e-06,16050.0,839.0,1.0,0,58.0
5343,606933,HP:0002664,"We found that multiple oncogenic tyrosine kinases directly phosphorylated PDP1 at Tyr-94, and Tyr-94 phosphorylation of PDP1 was common in diverse human cancer cells and primary leukemia cells from patients.",1,1.4372814926581534,668533.2814252367,176.6001945525292,0.2526083763771923,0.19765263445695894,0.0,0.0,1.0011709601873535,855.0,-0.5804733607667574,0.0366407822835778,1.0,2.0,3.0,82.0,82.0,60.0,164.0,1542,81.0,1.6778973932186103e-06,13377.0,855.0,1.0,0,68.0
5346,605993,HP:0002664,"We found that multiple oncogenic tyrosine kinases directly phosphorylated PDP1 at Tyr-94, and Tyr-94 phosphorylation of PDP1 was common in diverse human cancer cells and primary leukemia cells from patients.",0,1.4102268580847288,960033.6502128036,229.6921692607004,0.2091197570365685,0.29375068743571386,0.0,0.0,0.9988262910798122,851.0,-0.7127913972321349,0.047757431655191016,1.0,2.0,36.0,74.0,74.0,58.0,148.0,1544,72.0,1.67789739321861e-06,17354.0,853.0,1.0,0,63.0
5344,605993,HP:0002664,"Moreover, expression of a phosphorylation-deficient PDP1 Y94F mutant in cancer cells resulted in increased oxidative phosphorylation, decreased cell proliferation under hypoxia, and reduced tumor growth in mice.",0,1.4102268580847288,960033.6502128036,229.6921692607004,0.2091197570365685,0.29375068743571386,0.0,0.0,0.9988262910798122,851.0,-0.7127913972321349,0.047757431655191016,1.0,2.0,36.0,74.0,74.0,58.0,148.0,1544,72.0,1.67789739321861e-06,17354.0,853.0,1.0,0,63.0
5348,118190,HP:0000501,"BACKGROUND HSP60-related immunological activities are found in normal-pressure glaucoma (NPG) patients, in whom an elevated intraocular pressure (IOP) found in primary open-angle glaucoma (POAG) is not observed.",0,1.3453010773374374,1208485.851722583,157.78344736842104,0.1834890260233525,0.10363276975283647,0.0,0.0,0.9976744186046512,429.0,-0.6397072401119628,0.15354232989801975,1.0,2.0,4.0,115.0,115.0,92.0,230.0,610,113.0,1.0679653124866504e-05,14228.0,431.0,1.0,0,141.0
5349,616658,HP:0001298,"A novel mutation of an essential splice site in the C19orf70 gene encoding QIL1 induces severe mitochondrial encephalopathy, hepatopathy and lactate acidosis consistent with psychomotor retardation.",0,1.3378426897915716,1434190.8373376622,176.71089244307038,0.16921691932627195,0.09812751701940567,0.0,0.0,0.9973821989528796,381.0,-0.52731657448823,0.21606769373778245,1.0,2.0,1.0,140.0,140.0,139.0,280.0,486,138.0,1.6796560064498793e-05,15806.0,383.0,1.0,0,154.0
5375,616661,HP:0002664,"Microrchidia 2 (MORC2) is important in DNA damage repair and lipogenesis, however, the clinical and functional role of MORC2 in liver cancer remains to be fully elucidated.",0,1.3531370232988649,4921242.450273506,219.89691117836384,0.15820907616861998,-0.008171160596404464,0.0,0.0,0.9990147783251232,1014.0,-0.6064828911736247,0.08004732167099803,1.0,2.0,20.0,226.0,226.0,105.0,452.0,1546,224.0,1.67789739321861e-06,41274.0,1016.0,1.0,0,249.0
5380,616661,HP:0002664,The aim the present study was to clarify the role of MORC2 in liver cancer.,0,1.3531370232988649,4921242.450273506,219.89691117836384,0.15820907616861998,-0.008171160596404464,0.0,0.0,0.9990147783251232,1014.0,-0.6064828911736247,0.08004732167099803,1.0,2.0,20.0,226.0,226.0,105.0,452.0,1546,224.0,1.67789739321861e-06,41274.0,1016.0,1.0,0,249.0
5350,616661,HP:0002664,"Expression profile analysis, immunohistochemical staining, reverse transcription-quantitative polymerase chain reaction analysis and western blot analysis were performed to evaluate the levels of MORC2 in liver cancer patient specimens and cell lines; subsequently the expression of MORC2 was suppressed or increased in liver cancer cells and the effects of MORC2 on the cancerous transformation of liver cancer cells were examined in vitro and in vivo.",0,1.3531370232988649,4921242.450273506,219.89691117836384,0.15820907616861998,-0.008171160596404464,0.0,0.0,0.9990147783251232,1014.0,-0.6064828911736247,0.08004732167099803,1.0,2.0,20.0,226.0,226.0,105.0,452.0,1546,224.0,1.67789739321861e-06,41274.0,1016.0,1.0,0,249.0
5370,616661,HP:0002664,"MORC2 was upregulated in liver cancer tissues, and the upregulation was associated with certain clinicopathologic features of patients with liver cancer.",0,1.3531370232988649,4921242.450273506,219.89691117836384,0.15820907616861998,-0.008171160596404464,0.0,0.0,0.9990147783251232,1014.0,-0.6064828911736247,0.08004732167099803,1.0,2.0,20.0,226.0,226.0,105.0,452.0,1546,224.0,1.67789739321861e-06,41274.0,1016.0,1.0,0,249.0
5365,616661,HP:0002664,"MORC2 knockdown caused marked inhibition of liver cancer cell proliferation and clonogenicity, whereas the overexpression of MORC2 substantially promoted liver cancer cell proliferation.",0,1.3531370232988649,4921242.450273506,219.89691117836384,0.15820907616861998,-0.008171160596404464,0.0,0.0,0.9990147783251232,1014.0,-0.6064828911736247,0.08004732167099803,1.0,2.0,20.0,226.0,226.0,105.0,452.0,1546,224.0,1.67789739321861e-06,41274.0,1016.0,1.0,0,249.0
5360,616661,HP:0002664,"In a model of nude mice, the overexpression of MORC2 promoted tumorigenicity and markedly enhanced pulmonary metastasis of liver cancer.",0,1.3531370232988649,4921242.450273506,219.89691117836384,0.15820907616861998,-0.008171160596404464,0.0,0.0,0.9990147783251232,1014.0,-0.6064828911736247,0.08004732167099803,1.0,2.0,20.0,226.0,226.0,105.0,452.0,1546,224.0,1.67789739321861e-06,41274.0,1016.0,1.0,0,249.0
5355,616661,HP:0002664,"For the first time, to the best of our knowledge, the present study confirmed that MORC2 was a novel oncogene in liver cancer.",0,1.3531370232988649,4921242.450273506,219.89691117836384,0.15820907616861998,-0.008171160596404464,0.0,0.0,0.9990147783251232,1014.0,-0.6064828911736247,0.08004732167099803,1.0,2.0,20.0,226.0,226.0,105.0,452.0,1546,224.0,1.67789739321861e-06,41274.0,1016.0,1.0,0,249.0
5385,300084,HP:0002664,"Particularly, NONO expression was statistically higher in tumors with greater tumor invasion depth.",0,1.336969696969697,8232748.074910223,236.5108992519622,0.14719398556953214,0.030176092554861124,0.0,0.0,0.99909338168631,1102.0,-0.5238313675333467,0.09100674051007136,1.0,2.0,26.0,318.0,318.0,101.0,636.0,1544,316.0,1.6778973932186103e-06,55410.0,1104.0,1.0,0,450.0
5387,102560,HP:0000365,"Autosomal dominant missense mutations in ACTG1 are associated with DFNA20/26, a disorder that is typically characterized by post-lingual progressive hearing loss.",1,1.4019196814210404,14512111.312156413,434.70484787825137,0.13465839334974644,0.06170807835582018,0.0,0.0,1.0006720430107527,1489.0,-0.6286207315542441,0.08214902113708414,1.0,2.0,2.0,251.0,251.0,212.0,502.0,2474,250.0,6.524672396198988e-07,91006.0,1489.0,1.0,0,282.0
5406,611966,HP:0002664,"Nevertheless, it is still ambiguous whether NIBP is involved in the chemoresistance of gastric cancer.",0,1.3583838182903232,5325553.608602182,242.8068042580406,0.1578821935947881,0.029625689470903774,0.0,0.0,0.9989888776541962,988.0,-0.5829066247862301,0.08531421392897631,1.0,2.0,34.0,217.0,217.0,142.0,434.0,1544,215.0,1.67789739321861e-06,41766.0,990.0,1.0,0,288.0
5412,611966,HP:0002664,The aim of the present study was to investigate the effect of NIBP on chemotherapy resistance of gastric cancer (GC) and to research the mechanisms of Ginkgo biloba extract 761 (EGb 761R) on reversing chemoresistence which has been confirmed in our previous study.,0,1.3583838182903232,5325553.608602182,242.8068042580406,0.1578821935947881,0.029625689470903774,0.0,0.0,0.9989888776541962,988.0,-0.5829066247862301,0.08531421392897631,1.0,2.0,34.0,217.0,217.0,142.0,434.0,1544,215.0,1.67789739321861e-06,41766.0,990.0,1.0,0,288.0
1452,609145,HP:0002664,"In the present study, the results of immumohistochemisty revealed that the positive staining rates of NIBP, NF-kB p65 and NF-kB p-p65 in gastric cancer tissues were obviously higher than those in normal tissues.",0,1.3822965008126258,3042852.2095307475,270.7389414793736,0.16620742155098553,0.2396575150870838,0.0,0.0,0.998896247240618,905.0,-0.6703174021911298,0.07687084267324781,1.0,2.0,42.0,135.0,135.0,117.0,270.0,1544,133.0,1.6778973932186086e-06,31584.0,907.0,1.0,0,134.0
5427,164014,HP:0002664,"In the present study, the results of immumohistochemisty revealed that the positive staining rates of NIBP, NF-kB p65 and NF-kB p-p65 in gastric cancer tissues were obviously higher than those in normal tissues.",0,1.4361158276832502,1407602.5422335104,267.33912466443456,0.2047993986548798,0.17940532848034033,0.0,0.0,1.0011682242990654,857.0,-0.6830547519604347,0.05639101844076816,1.0,2.0,5.0,83.0,83.0,81.0,166.0,1542,82.0,1.67789739321861e-06,20684.0,857.0,1.0,0,77.0
5394,611966,HP:0002664,"In the present study, the results of immumohistochemisty revealed that the positive staining rates of NIBP, NF-kB p65 and NF-kB p-p65 in gastric cancer tissues were obviously higher than those in normal tissues.",0,1.3583838182903232,5325553.608602182,242.8068042580406,0.1578821935947881,0.029625689470903774,0.0,0.0,0.9989888776541962,988.0,-0.5829066247862301,0.08531421392897631,1.0,2.0,34.0,217.0,217.0,142.0,434.0,1544,215.0,1.67789739321861e-06,41766.0,990.0,1.0,0,288.0
1438,609145,HP:0002664,"Furthermore, a close correlation was found to exist between the expression of NIBP and NF-kB p65 (p-p65) in gastric cancer tissues.",0,1.3822965008126258,3042852.2095307475,270.7389414793736,0.16620742155098553,0.2396575150870838,0.0,0.0,0.998896247240618,905.0,-0.6703174021911298,0.07687084267324781,1.0,2.0,42.0,135.0,135.0,117.0,270.0,1544,133.0,1.6778973932186086e-06,31584.0,907.0,1.0,0,134.0
5400,611966,HP:0002664,"Moreover, the overexpression of NIBP was closely related to tumor differentiation, depth of invasion, clinical stage and lymphatic metastasis in gastric cancer.",0,1.3583838182903232,5325553.608602182,242.8068042580406,0.1578821935947881,0.029625689470903774,0.0,0.0,0.9989888776541962,988.0,-0.5829066247862301,0.08531421392897631,1.0,2.0,34.0,217.0,217.0,142.0,434.0,1544,215.0,1.67789739321861e-06,41766.0,990.0,1.0,0,288.0
1480,609145,HP:0002664,"Western blot analysis, real-time PCR, MTT assay and flow cytometric analysis were performed and the results demonstrated that compared with the gastric cancer SGC-7901 cells, the expression of NIBP, NF-kB p65, NF-kB p-p65 and mesenchymal marker vimentin were significantly increased in gastric cancer multidrug-resistant SGC-7901/CDDP cells, and the epithelial cell marker ZO-1 was significantly decreased.",0,1.3822965008126258,3042852.2095307475,270.7389414793736,0.16620742155098553,0.2396575150870838,0.0,0.0,0.998896247240618,905.0,-0.6703174021911298,0.07687084267324781,1.0,2.0,42.0,135.0,135.0,117.0,270.0,1544,133.0,1.6778973932186086e-06,31584.0,907.0,1.0,0,134.0
5430,164014,HP:0002664,"Western blot analysis, real-time PCR, MTT assay and flow cytometric analysis were performed and the results demonstrated that compared with the gastric cancer SGC-7901 cells, the expression of NIBP, NF-kB p65, NF-kB p-p65 and mesenchymal marker vimentin were significantly increased in gastric cancer multidrug-resistant SGC-7901/CDDP cells, and the epithelial cell marker ZO-1 was significantly decreased.",0,1.4361158276832502,1407602.5422335104,267.33912466443456,0.2047993986548798,0.17940532848034033,0.0,0.0,1.0011682242990654,857.0,-0.6830547519604347,0.05639101844076816,1.0,2.0,5.0,83.0,83.0,81.0,166.0,1542,82.0,1.67789739321861e-06,20684.0,857.0,1.0,0,77.0
1544,600900,HP:0002664,"Western blot analysis, real-time PCR, MTT assay and flow cytometric analysis were performed and the results demonstrated that compared with the gastric cancer SGC-7901 cells, the expression of NIBP, NF-kB p65, NF-kB p-p65 and mesenchymal marker vimentin were significantly increased in gastric cancer multidrug-resistant SGC-7901/CDDP cells, and the epithelial cell marker ZO-1 was significantly decreased.",0,1.400561161703175,941457.6872488172,204.979171435111,0.21034037305605727,0.11542276431943975,0.0,0.0,0.998833138856476,856.0,-0.7101797965956365,0.04459639932218695,1.0,2.0,41.0,78.0,78.0,53.0,156.0,1544,76.0,1.6778973932186103e-06,16396.0,858.0,1.0,0,67.0
5418,611966,HP:0002664,"Western blot analysis, real-time PCR, MTT assay and flow cytometric analysis were performed and the results demonstrated that compared with the gastric cancer SGC-7901 cells, the expression of NIBP, NF-kB p65, NF-kB p-p65 and mesenchymal marker vimentin were significantly increased in gastric cancer multidrug-resistant SGC-7901/CDDP cells, and the epithelial cell marker ZO-1 was significantly decreased.",0,1.3583838182903232,5325553.608602182,242.8068042580406,0.1578821935947881,0.029625689470903774,0.0,0.0,0.9989888776541962,988.0,-0.5829066247862301,0.08531421392897631,1.0,2.0,34.0,217.0,217.0,142.0,434.0,1544,215.0,1.67789739321861e-06,41766.0,990.0,1.0,0,288.0
1431,609145,HP:0002664,"Altogether, these data indicate that the NIBP-regulated NF-kB signaling pathway plays a pivotal role in the chemoresistance of gastric cancer by promoting CD133-induced EMT",0,1.3822965008126258,3042852.2095307475,270.7389414793736,0.16620742155098553,0.2396575150870838,0.0,0.0,0.998896247240618,905.0,-0.6703174021911298,0.07687084267324781,1.0,2.0,42.0,135.0,135.0,117.0,270.0,1544,133.0,1.6778973932186086e-06,31584.0,907.0,1.0,0,134.0
5388,611966,HP:0002664,"Altogether, these data indicate that the NIBP-regulated NF-kB signaling pathway plays a pivotal role in the chemoresistance of gastric cancer by promoting CD133-induced EMT",0,1.3583838182903232,5325553.608602182,242.8068042580406,0.1578821935947881,0.029625689470903774,0.0,0.0,0.9989888776541962,988.0,-0.5829066247862301,0.08531421392897631,1.0,2.0,34.0,217.0,217.0,142.0,434.0,1544,215.0,1.67789739321861e-06,41766.0,990.0,1.0,0,288.0
5433,606441,HP:0001402,The purpose of this study was to detect the expression of high-temperature requirement A2 (HtrA2) and its diagnostic value in the patients with hepatocellular carcinoma (HCC).The relative serum HtrA2 expression at mRNA and protein level was severally detected by quantitative real-time polymerase chain reaction and western blot analysis in 198 HCC patients and 48 healthy controls.,0,1.3124839824486467,94361.32738095237,59.22421328671329,0.30290062478118834,0.10908598823633298,0.0,0.0,0.9956331877729258,228.0,-0.4758488189381319,0.09588000759445604,1.0,2.0,24.0,53.0,53.0,53.0,106.0,138,52.0,3.191930798940279e-05,2525.0,230.0,1.0,0,57.0
5434,606441,HP:0002664,"In addition, the high HtrA2 expression was associated with large tumor size and advanced clinical stage.",0,1.385116142347098,3452113.9366877745,238.5336561136658,0.17063040486396602,-0.025292993119150314,0.0,0.0,0.9989451476793249,947.0,-0.6156938190797916,0.07745217039477488,1.0,2.0,8.0,174.0,174.0,128.0,348.0,1544,172.0,1.6778973932186103e-06,34840.0,949.0,1.0,0,190.0
5435,603634,HP:0002664,"In the PPI network, 2 clusters of VTE genes, including ribosomal protein family genes and NADH family-ubiquinol-cytochrome genes, were identified, such as ribosomal protein L9 (RPL9), RPL5, RPS20, RPL23, and tumor protein p53 (TP53).The nod-like receptor signaling pathway, ribosomal protein family genes, such as RPL9, RPL5, RPS20, and RPL23, and DEG of TP53 may have the potential to be used as targets for diagnosis and treatment of VTE",1,1.3663833537754164,9808266.35702133,293.7044451471862,0.1426330795193488,0.033629786080325325,0.0,0.0,1.0009496676163343,1054.0,-0.5541793742473405,0.10956497294258204,1.0,2.0,1.0,282.0,282.0,211.0,564.0,1542,281.0,1.6778973932186097e-06,60801.0,1054.0,1.0,0,330.0
5442,604214,HP:0002090,"In this study, we investigated the functional significance of the expansion of myeloid-derived suppressor cell (MDSC)-like CD11b+Gr-1+ cells in response to the macrolide antibiotic clarithromycin (CAM) in mouse models of shock and post-influenza pneumococcal pneumonia as well as in humans.",0,1.3146365608610484,260581.6176748689,89.35188706424661,0.2344076009112899,0.08595067038420053,0.0,0.0,0.9964912280701754,284.0,-0.6421753732485248,0.13794626426205372,1.0,2.0,9.0,77.0,77.0,43.0,154.0,392,75.0,2.603082049146189e-05,5622.0,286.0,1.0,0,72.0
5439,604214,HP:0002090,"CAM also improved survival in post-influenza, CAM-resistant pneumococcal pneumonia, with improved lung pathology as well as decreased interferon (IFN)-y and increased IL-10 levels.",0,1.3146365608610484,260581.6176748689,89.35188706424661,0.2344076009112899,0.08595067038420053,0.0,0.0,0.9964912280701754,284.0,-0.6421753732485248,0.13794626426205372,1.0,2.0,9.0,77.0,77.0,43.0,154.0,392,75.0,2.603082049146189e-05,5622.0,286.0,1.0,0,72.0
5436,604214,HP:0002090,Adoptive transfer of CAM-treated CD11b+Gr-1+ cells protected mice from post-influenza pneumococcal pneumonia.,0,1.3146365608610484,260581.6176748689,89.35188706424661,0.2344076009112899,0.08595067038420053,0.0,0.0,0.9964912280701754,284.0,-0.6421753732485248,0.13794626426205372,1.0,2.0,9.0,77.0,77.0,43.0,154.0,392,75.0,2.603082049146189e-05,5622.0,286.0,1.0,0,72.0
856,156845,HP:0000568,"In addition, resorcinol suppressed the expression of melanogenic gene microphthalmia-associated transcriptional factor (MITF) and its downstream target genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2.",0,1.3348988367714958,1528330.9464285714,157.64666666666662,0.1681262711069704,0.023169264425948813,0.0,0.0,1.0023584905660377,425.0,-0.4145555313342822,0.18526082130965602,1.0,2.0,10.0,165.0,165.0,26.0,330.0,450,164.0,1.957866708434489e-05,16692.0,425.0,1.0,0,239.0
5445,115501,HP:0000568,"In addition, resorcinol suppressed the expression of melanogenic gene microphthalmia-associated transcriptional factor (MITF) and its downstream target genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2.",0,1.3643090569561158,181389.34848484845,113.60261437908495,0.23018379851244075,-0.15523107301764374,0.0,0.0,0.9963898916967509,276.0,-0.8159626658926855,0.12767836272498248,1.0,2.0,5.0,42.0,42.0,34.0,84.0,452,40.0,1.9406547769217335e-05,4916.0,278.0,1.0,0,43.0
5264,300356,HP:0002664,"Cisplatin (CDDP) is used in the treatment of non-small cell lung cancer (NSCLC), but due to the development of resistance, the benefit has been limited.",0,1.3777785918765733,2136265.6683608405,196.72413125136865,0.19235144856592945,0.32175834507326084,0.0,0.0,0.9989200863930886,925.0,-0.6102518447799006,0.060391285202038215,1.0,2.0,31.0,148.0,148.0,96.0,296.0,1544,146.0,1.6778973932186103e-06,25920.0,927.0,1.0,0,133.0
5446,607800,HP:0008064,The ichthyosis genetic panel showed mutations in the ABCA12 gene resulting in the lamellar ichthyosis phenotype of ARCI.,1,1.3370813254803977,479941.12857142853,116.88914290837369,0.2046485035938745,0.11561366566686428,0.0,0.0,1.0033333333333334,301.0,-0.26552415610244323,0.19187153931339976,1.0,2.0,3.0,128.0,128.0,2.0,256.0,264,127.0,3.4602076124567484e-05,8663.0,301.0,1.0,0,158.0
5447,612325,HP:0010442,"Several missense mutations in intestinal cell kinase (ICK) gene lead to endocrine-cerebro-osteodysplasia syndrome or short rib-polydactyly syndrome, lethal recessive developmental ciliopathies.",1,1.335239959280319,1402309.726190476,164.13523617075018,0.16451978091659514,0.22415838582727649,0.0,0.0,1.0025125628140703,399.0,-0.4466080933240322,0.20511076686691604,1.0,2.0,5.0,155.0,155.0,57.0,310.0,428,154.0,2.1633315305570567e-05,16286.0,399.0,1.0,0,209.0
4045,607407,HP:0000750,"Pathogenic variants in EBF3 were recently described in three back-to-back publications in association with a novel neurodevelopmental disorder characterized by intellectual disability, speech delay, ataxia, and facial dysmorphisms.",1,1.3766694843617922,8115015.6027380675,334.94779002523273,0.13974540260474227,0.051134823125694916,0.0,0.0,1.0010438413361171,959.0,-0.5997125644460635,0.1259554032667118,1.0,2.0,1.0,226.0,226.0,218.0,452.0,1466,225.0,1.8561278203862235e-06,57859.0,959.0,1.0,0,289.0
3278,607407,HP:0001251,"Pathogenic variants in EBF3 were recently described in three back-to-back publications in association with a novel neurodevelopmental disorder characterized by intellectual disability, speech delay, ataxia, and facial dysmorphisms.",1,1.38293381267253,7293964.155466021,313.5920930890725,0.14924523521685573,0.04766073666187312,0.0,0.0,1.0009633911368017,1039.0,-0.5959568467629217,0.10284084481706696,1.0,2.0,1.0,224.0,224.0,187.0,448.0,1626,223.0,1.5092152684290275e-06,55456.0,1039.0,1.0,0,305.0
5448,120520,HP:0040049,"We present the new observations of postoperative microcystic macular edema (MME) as a mild form of cystoid macular lesions (CMLs) after standard phacoemulsification.To report the incidence, risk factors, and pathophysiology of MME compared to conventional concept of pseudophakic cystoid macular edema (CME), we retrospectively reviewed patients* records.",0,1.2916795545932571,8602.56282051282,28.21266233766233,0.4422930631941387,0.2652985505825043,0.0,0.0,0.9925925925925928,134.0,-0.5299742936090397,0.06710239651416122,1.0,2.0,28.0,23.0,23.0,23.0,46.0,224,21.0,7.831466833737959e-05,616.0,136.0,1.0,0,19.0
5449,120520,HP:0100014,"Pseudophakic MMEs were more likely to have a history of diabetic retinopathy, epiretinal membrane, and eyes were not treated with topical NSAID.This study showed a wide clinical spectrum of CMLs.",0,1.3046938324368138,1572.8753846153845,33.330357142857146,0.6061663886667984,0.6026221292514577,0.0,0.0,0.9914529914529916,116.0,-0.6454809623134736,0.0343328987396784,1.0,2.0,50.0,5.0,5.0,5.0,10.0,224,4.0,7.831466833737959e-05,237.0,118.0,1.0,0,5.0
5450,184600,HP:0002860,"We previously conducted transcriptome analysis of a paired specimen of normal and esophageal squamous cell carcinoma (ESCC) tissues and found that mRNA expression of cystatin A (CSTA), a member of the cystatin superfamily, was perturbed in tumors compared with that in the background mucosa.",0,1.2932380494835454,42574.25476190476,49.163056206089,0.2860288061311489,-0.062200439451301374,0.0,0.0,0.9915254237288136,117.0,-0.3989462014119701,0.21279020082609315,1.0,2.0,4.0,45.0,45.0,5.0,90.0,124,43.0,0.00025195263290501383,1494.0,119.0,1.0,0,57.0
5471,184600,HP:0002664,"We previously conducted transcriptome analysis of a paired specimen of normal and esophageal squamous cell carcinoma (ESCC) tissues and found that mRNA expression of cystatin A (CSTA), a member of the cystatin superfamily, was perturbed in tumors compared with that in the background mucosa.",0,1.418633254511117,476975.8900136986,204.17215582731149,0.25527510279478405,0.4030848741159387,0.0,0.0,0.9987922705314008,827.0,-0.6597011788349869,0.033163755878393736,1.0,2.0,52.0,57.0,57.0,56.0,114.0,1544,55.0,1.67789739321861e-06,11382.0,829.0,1.0,0,51.0
5455,184600,HP:0002664,"However, little is known about the significance of CSTA expression in ESCC.The mRNA expression of CSTA was evaluated by qRT-PCR using 28 paired frozen samples of tumor and nontumor mucosae.",0,1.418633254511117,476975.8900136986,204.17215582731149,0.25527510279478405,0.4030848741159387,0.0,0.0,0.9987922705314008,827.0,-0.6597011788349869,0.033163755878393736,1.0,2.0,52.0,57.0,57.0,56.0,114.0,1544,55.0,1.67789739321861e-06,11382.0,829.0,1.0,0,51.0
5463,184600,HP:0002664,"It was reduced in all ESCC tissue samples compared with normal tissues; however, CSTA expression levels in tumors showed considerable variation.",0,1.418633254511117,476975.8900136986,204.17215582731149,0.25527510279478405,0.4030848741159387,0.0,0.0,0.9987922705314008,827.0,-0.6597011788349869,0.033163755878393736,1.0,2.0,52.0,57.0,57.0,56.0,114.0,1544,55.0,1.67789739321861e-06,11382.0,829.0,1.0,0,51.0
5467,184600,HP:0002664,The expression of CSTA in tumors was significantly associated with pT classification (deeper tumor invasions) (P = .0118) and advanced TNM stages (P = .0497).,0,1.418633254511117,476975.8900136986,204.17215582731149,0.25527510279478405,0.4030848741159387,0.0,0.0,0.9987922705314008,827.0,-0.6597011788349869,0.033163755878393736,1.0,2.0,52.0,57.0,57.0,56.0,114.0,1544,55.0,1.67789739321861e-06,11382.0,829.0,1.0,0,51.0
5459,184600,HP:0002664,"In CSTA-positive tumor samples, CSTA-expressing cancer cells often expressed Ki67, a proliferation marker, which was in sharp contrast to normal mucosa, where Ki67-expressing cells were limited to the basal layer and did not express CSTA.",0,1.418633254511117,476975.8900136986,204.17215582731149,0.25527510279478405,0.4030848741159387,0.0,0.0,0.9987922705314008,827.0,-0.6597011788349869,0.033163755878393736,1.0,2.0,52.0,57.0,57.0,56.0,114.0,1544,55.0,1.67789739321861e-06,11382.0,829.0,1.0,0,51.0
5451,184600,HP:0002664,"Furthermore, CSTA expression was observed in all 22 lymph node metastases analyzed.Relatively high levels of CSTA expression in tumors were correlated with tumor progression and advanced cancer stage, including lymph node metastasis",0,1.418633254511117,476975.8900136986,204.17215582731149,0.25527510279478405,0.4030848741159387,0.0,0.0,0.9987922705314008,827.0,-0.6597011788349869,0.033163755878393736,1.0,2.0,52.0,57.0,57.0,56.0,114.0,1544,55.0,1.67789739321861e-06,11382.0,829.0,1.0,0,51.0
5475,605100,HP:0002664,"PPM1B is a metal-dependent serine/threonine protein phosphatase, with a similar structure and function to the well-known oncogene in breast cancer, PPM1D (WIP1).",1,1.4182060252904582,3131797.70492805,300.69805447470816,0.16877652374264504,0.06321432205475548,0.0,0.0,1.001123595505618,891.0,-0.6560910276266682,0.07875004728937313,1.0,2.0,2.0,120.0,120.0,120.0,240.0,1542,119.0,1.67789739321861e-06,31224.0,891.0,1.0,0,140.0
5478,614041,HP:0002664,"To test if PPM1B can be a drug target in the cellular proliferation and death pathway, the lentiviral PPM1B shRNA was stably expressed in cancer cell lines and its regulatory function in the RB1-E2F1 pathway was examined.",1,1.3797112256908406,7049068.460990399,293.19052948130803,0.14775888586923105,0.1113295334982234,0.0,0.0,1.001004016064257,997.0,-0.593208818239851,0.10320318384873496,1.0,2.0,5.0,217.0,217.0,192.0,434.0,1542,216.0,1.677897393218609e-06,51241.0,997.0,1.0,0,242.0
5476,614041,HP:0002664,Our results suggest that PPM1B plays a negative role in the activation of the p38-RB1-E2F1 pathway and that targeting PPM1B could be useful in certain types of cancer by stimulating chemotherapy-induced cell death,1,1.3797112256908406,7049068.460990399,293.19052948130803,0.14775888586923105,0.1113295334982234,0.0,0.0,1.001004016064257,997.0,-0.593208818239851,0.10320318384873496,1.0,2.0,5.0,217.0,217.0,192.0,434.0,1542,216.0,1.677897393218609e-06,51241.0,997.0,1.0,0,242.0
5480,606526,HP:0002664,Preoperative lymph node (LN) status is important for the treatment of bladder cancer (BCa).,0,1.4211564622088522,296467.11789724487,256.6963801438509,0.2557082249195557,0.4885287962839646,0.0,0.0,0.9987577639751554,804.0,-0.7719049240478243,0.027323027603532512,1.0,2.0,68.0,31.0,31.0,30.0,62.0,1544,29.0,1.6778973932186097e-06,8864.0,806.0,1.0,0,33.0
5487,607803,HP:0100753,"In this study, we examined the potential for genetic susceptibility to schizophrenia of a three-gene cluster region, AS3MT-CNNM2-NT5C2.",0,1.265174094868418,43558.785256410265,45.00916988416989,0.3010180454422867,-0.12969183308235124,0.0,0.0,0.9923664122137404,130.0,-0.4426934503714845,0.1736062919269026,1.0,2.0,11.0,47.0,47.0,3.0,94.0,114,45.0,0.0001777777777777778,1501.0,132.0,1.0,0,46.0
5484,607803,HP:0100753,"Further haplotype and imputation analyses also validated these results, and bioinformatics analyses indicated that CALHM1, which is located approximately 630kb away from CNNM2, might be a susceptible gene for schizophrenia.",0,1.265174094868418,43558.785256410265,45.00916988416989,0.3010180454422867,-0.12969183308235124,0.0,0.0,0.9923664122137404,130.0,-0.4426934503714845,0.1736062919269026,1.0,2.0,11.0,47.0,47.0,3.0,94.0,114,45.0,0.0001777777777777778,1501.0,132.0,1.0,0,46.0
5493,606019,HP:0001257,"Other EXOSC3 mutations and EXOSC8 cases are intermediate - SMA type 1-like presentation, spasticity (mostly in EXOSC8) and death between 3 months and 5 years.",1,1.438764483336893,2254593.388347185,436.64778947011666,0.16214932472359225,0.1010718673784452,0.0,0.0,1.0012121212121212,826.0,-0.7543529836721009,0.09155770782889427,1.0,2.0,1.0,79.0,79.0,79.0,158.0,1494,78.0,1.787297320483857e-06,31196.0,826.0,1.0,0,77.0
5494,601592,HP:0010984,"Since RAPSN-associated limb-girdle type CMS was only manifested in AK9 homozygous variant carriers, the disease phenotype was of digenic inheritance, and was determined by the novel disease modifier AK9 which provides NTPs for N-glycosylation.",0,1.3390229885057472,12308.320380730382,70.49056603773585,0.4756981309768177,0.4556198081942483,0.0,0.0,0.996376811594203,275.0,-0.5506815921231062,0.024459791764767442,1.0,2.0,91.0,11.0,11.0,11.0,22.0,322,10.0,1.4133077053536096e-05,935.0,277.0,1.0,0,11.0
5495,139330,HP:0000007,"Our work confirms that the phenotype and the mode of inheritance associated with GNAT1 variants can vary from autosomal dominant, autosomal recessive congenital stationary night blindness to autosomal recessive rod-cone dystrophy",1,1.4886365081199788,691732.6052648714,420.49756367663343,0.3196711176320266,0.5926850907716702,0.0,0.0,1.0003815337657382,2622.0,-0.4945251877052112,0.00505743232723083,1.0,2.0,781.0,41.0,41.0,41.0,82.0,5160,40.0,1.5011496554636372e-07,17378.0,2622.0,1.0,0,43.0
5496,139330,HP:0000618,"Our work confirms that the phenotype and the mode of inheritance associated with GNAT1 variants can vary from autosomal dominant, autosomal recessive congenital stationary night blindness to autosomal recessive rod-cone dystrophy",0,1.4151663877626657,164381.0645477072,127.35771658060816,0.24183033960803235,0.14561869680086625,0.0,0.0,1.0034482758620689,291.0,-0.7722491329982805,0.10847256783979144,1.0,2.0,2.0,37.0,37.0,31.0,74.0,498,36.0,1.6e-05,4577.0,291.0,1.0,0,36.0
5497,613190,HP:0002664,The most significantly mutated CMG is DNAAF1 with biallelic inactivation and loss of DNAAF1 expression shown in tumours from carriers.,0,1.3708642397032988,2566837.817898849,216.0053589319416,0.1723504537533137,0.11424603340714473,0.0,0.0,0.9989350372736956,938.0,-0.6804477065860286,0.0686878299685043,1.0,2.0,26.0,148.0,148.0,83.0,296.0,1544,146.0,1.6778973932186097e-06,30314.0,940.0,1.0,0,146.0
5498,600509,HP:0001425,Hearing impairment (HI) is genetically heterogeneous which hampers genetic counseling and molecular diagnosis.,1,1.336767814477426,1298148.1116883114,119.0354846391998,0.2052464385015636,-0.0014758178955535653,0.0,0.0,1.0017574692442883,570.0,-0.28151035060217844,0.10274103536521444,1.0,2.0,4.0,214.0,214.0,3.0,428.0,524,213.0,9.525986892242037e-06,16661.0,570.0,1.0,0,264.0
5499,600509,HP:0000007,"In our patient cohort, causative variants in GJB2, USH2A, MYO15A and STRC, and in MYO6 were the leading causes for autosomal recessive and dominant HI, respectively.",1,1.4295894954960584,18270315.432995647,477.8729414164687,0.15513374027321405,0.06282687449691207,0.0,0.0,1.0003445899379737,2903.0,-0.5827249110924341,0.03256665732091591,1.0,2.0,11.0,316.0,316.0,197.0,632.0,5150,315.0,1.5011496554636375e-07,137179.0,2903.0,1.0,0,304.0
5500,606440,HP:0000007,"In our patient cohort, causative variants in GJB2, USH2A, MYO15A and STRC, and in MYO6 were the leading causes for autosomal recessive and dominant HI, respectively.",1,1.4930020126273296,257673.059348019,477.9609123434705,0.3709357899845954,0.3821258504137274,0.0,0.0,1.000383877159309,2606.0,-0.5309623155169568,0.003624589939354479,1.0,2.0,825.0,26.0,26.0,26.0,52.0,5160,25.0,1.5011496554636367e-07,12303.0,2606.0,1.0,0,23.0
5501,608400,HP:0000007,"In our patient cohort, causative variants in GJB2, USH2A, MYO15A and STRC, and in MYO6 were the leading causes for autosomal recessive and dominant HI, respectively.",1,1.4595315458319678,10635560.895282453,595.0667617824703,0.1768170752752477,0.15606921733481804,0.0,0.0,1.00036469730124,2743.0,-0.5901180280845572,0.024259616614454988,1.0,2.0,21.0,163.0,163.0,162.0,326.0,5160,162.0,1.5011496554636367e-07,91232.0,2743.0,1.0,0,160.0
5268,121011,HP:0000007,"In our patient cohort, causative variants in GJB2, USH2A, MYO15A and STRC, and in MYO6 were the leading causes for autosomal recessive and dominant HI, respectively.",1,1.4371848223547383,13847678.02619496,447.4600580001115,0.1681986257336911,0.20630620291213586,0.0,0.0,1.000350017500875,2858.0,-0.5663418099659183,0.0275051541240463,1.0,2.0,17.0,271.0,271.0,162.0,542.0,5160,270.0,1.5011496554636354e-07,112294.0,2858.0,1.0,0,267.0
5502,602666,HP:0000007,"In our patient cohort, causative variants in GJB2, USH2A, MYO15A and STRC, and in MYO6 were the leading causes for autosomal recessive and dominant HI, respectively.",1,1.4969330242916845,114677.01961027794,726.1953488372093,0.3885529646882708,0.9171158603301508,0.0,0.0,1.0003859513701274,2592.0,-0.5772242720394694,0.002583134401608607,1.0,2.0,1389.0,12.0,12.0,12.0,24.0,5160,11.0,1.5011496554636372e-07,8674.0,2592.0,1.0,0,15.0
5503,600970,HP:0000007,"In our patient cohort, causative variants in GJB2, USH2A, MYO15A and STRC, and in MYO6 were the leading causes for autosomal recessive and dominant HI, respectively.",1,1.4927252449636987,442332.49212932686,637.8654608096467,0.3188373289521945,0.6921969942125343,0.0,0.0,1.0003837298541831,2607.0,-0.5986226110187903,0.0050174849518137155,1.0,2.0,599.0,26.0,26.0,26.0,52.0,5160,25.0,1.5011496554636367e-07,17044.0,2607.0,1.0,0,23.0
5504,606412,HP:0000365,"Bartter syndrome type IV, characterized by salt-losing nephropathies and sensorineural deafness, is caused by mutations of BSND or simultaneous mutations of both CLCNKA and CLCNKB.",1,1.4311911222256644,3093865.964074178,313.8896604153394,0.17710185050743155,0.1154837891159762,0.0,0.0,1.0007209805335255,1388.0,-0.6845525153484705,0.04388319699806146,1.0,2.0,2.0,128.0,128.0,79.0,256.0,2474,127.0,6.524672396198986e-07,42241.0,1388.0,1.0,0,114.0
5506,602024,HP:0000365,"Bartter syndrome type IV, characterized by salt-losing nephropathies and sensorineural deafness, is caused by mutations of BSND or simultaneous mutations of both CLCNKA and CLCNKB.",1,1.4368552848387997,2976304.74601728,337.6206952303961,0.1777405358306007,0.10043008050782827,0.0,0.0,1.00072939460248,1372.0,-0.6897306296660745,0.04369350115788735,1.0,2.0,0.0,113.0,113.0,85.0,226.0,2474,113.0,6.524672396198986e-07,41094.0,1372.0,2.0,0,100.0
5507,602023,HP:0000365,"Bartter syndrome type IV, characterized by salt-losing nephropathies and sensorineural deafness, is caused by mutations of BSND or simultaneous mutations of both CLCNKA and CLCNKB.",1,1.3869802751036202,9233485.746950395,293.75356920698,0.14913509931322255,0.011811783313088171,0.0,0.0,1.0006422607578678,1558.0,-0.6143680146466717,0.06172546361910228,1.0,2.0,11.0,281.0,281.0,106.0,562.0,2474,280.0,6.524672396198988e-07,74867.0,1558.0,1.0,0,305.0
991,121011,HP:0000365,GJB2 is the primary causative gene for non-syndromic sensorineural deafness and associated with several syndromic sensorineural deafness.,1,1.395883254657124,11360890.773559922,359.9890516043107,0.1442161069048109,0.0490995817099891,0.0,0.0,1.000660501981506,1515.0,-0.6063388048985573,0.07124963487101682,1.0,2.0,7.0,266.0,266.0,150.0,532.0,2474,265.0,6.524672396198986e-07,81713.0,1515.0,1.0,0,305.0
5505,606412,HP:0000365,"Our results indicated that the homozygous mutation c.22C &gt; T was the key genetic reason for the proband, and a digenic effect of BSND and GJB2 might contributed to sensorineural deafness.",1,1.4311911222256644,3093865.964074178,313.8896604153394,0.17710185050743155,0.1154837891159762,0.0,0.0,1.0007209805335255,1388.0,-0.6845525153484705,0.04388319699806146,1.0,2.0,2.0,128.0,128.0,79.0,256.0,2474,127.0,6.524672396198986e-07,42241.0,1388.0,1.0,0,114.0
5508,616690,HP:0002664,Here we provide structural and biochemical data that Cep104 contains a tubulin-binding TOG (tumor overexpressed gene) domain and a novel C2HC zinc finger array.,0,1.3735969827195418,5524372.155550006,290.24451819638364,0.15429015760541495,0.003732260100904536,0.0,0.0,0.9989384288747346,941.0,-0.6388426787103543,0.09251316550828204,1.0,2.0,33.0,171.0,171.0,171.0,342.0,1544,169.0,1.67789739321861e-06,41090.0,943.0,1.0,0,191.0
5509,615416,HP:0001159,Bhlha9-knockout mice showed syndactyly and poliosis in the limb.,1,1.3469417479745442,1482382.7280219775,152.84481514155104,0.18363787192000566,0.0598247918140441,0.0,0.0,1.001919385796545,522.0,-0.5361835664966462,0.13424669622962032,1.0,2.0,7.0,158.0,158.0,54.0,316.0,674,157.0,8.753194916144391e-06,18255.0,522.0,1.0,0,183.0
5510,604139,HP:0001300,"Mutations in the DNAJB2 gene lead to inherited neuropathies such as Charcot-Marie-Tooth type-2, distal hereditary motor neuropathies, spinal muscular atrophy with parkinsonism and the later stages can resemble amyotrophic lateral sclerosis.",0,1.3511418805651711,66992.88968253968,69.39046121593292,0.2739238939193516,0.07733983192303287,0.0,0.0,0.9930069930069928,142.0,-0.6855020882007421,0.1896853146853147,1.0,2.0,1.0,37.0,37.0,37.0,74.0,214,35.0,8.573388203017832e-05,1953.0,144.0,1.0,0,41.0
5511,608896,HP:0001300,"Mutations in the DNAJB2 gene lead to inherited neuropathies such as Charcot-Marie-Tooth type-2, distal hereditary motor neuropathies, spinal muscular atrophy with parkinsonism and the later stages can resemble amyotrophic lateral sclerosis.",0,1.2923663374541399,123844.3031746032,52.65285966981133,0.2809177155558207,-0.0680008472791501,0.0,0.0,0.9957446808510638,234.0,-0.42760440987648224,0.1143526866209881,1.0,2.0,11.0,83.0,83.0,5.0,166.0,214,81.0,6.009254251547383e-05,3171.0,236.0,1.0,0,82.0
5512,609584,HP:0002352,"Our data provide in vivo evidence that L2hgdh mutation leads to L-2-HG accumulation, leukoencephalopathy, and neurodegeneration in mice, thereby offering new insights into the pathophysiology of L-2-HGA in humans",1,1.3444911297852475,736499.4138888888,144.4871352785146,0.18071193758440304,0.12625420390680192,0.0,0.0,1.0032258064516129,311.0,-0.6095397289613376,0.2180064308681672,1.0,2.0,5.0,103.0,103.0,80.0,206.0,390,102.0,2.603082049146189e-05,10509.0,311.0,1.0,0,120.0
5513,601691,HP:0000007,"In the third family, POD was observed in father and child with early onset cone-rod dystrophy and a novel autosomal recessive p.(W31*) homozygous mutation in ABCA4.",1,1.4603940295746884,7699540.756385315,496.31438496416547,0.1941511093271865,0.046605366416991235,0.0,0.0,1.00036523009496,2739.0,-0.5695867782207132,0.01982376681171862,1.0,2.0,21.0,156.0,156.0,154.0,312.0,5160,155.0,1.501149655463636e-07,74333.0,2739.0,1.0,0,157.0
5514,138492,HP:0002267,"The patient carried GLRB gene mutations found by genetic analysis, and was finally diagnosed with hyperekplexia.",1,1.414887794198139,14810.027272727273,54.04130162703379,0.3795189124746412,0.05028914193477238,0.0,0.0,1.009090909090909,111.0,-0.7038756349166071,0.12743652743652745,1.0,2.0,6.0,17.0,17.0,17.0,34.0,104,17.0,0.000110803324099723,778.0,111.0,1.0,0,17.0
5515,159350,HP:0000007,The deficiency of 3-methycrotonyl-CoA carboxylase (3-MCC; EC 6.4.1.4) is an autosomal recessive organic aciduria that is included in the newborn screening programs of several countries.,0,1.4001734381502848,532264.3033838822,279.4940098661029,0.3731759477880792,0.4991715190086828,0.0,0.0,0.9996190476190476,2624.0,-0.4826380312194902,0.0042444420266202435,1.0,2.0,541.0,42.0,42.0,40.0,84.0,5162,41.0,1.5011496554636367e-07,14629.0,2626.0,1.0,0,45.0
5516,159350,HP:0001992,The deficiency of 3-methycrotonyl-CoA carboxylase (3-MCC; EC 6.4.1.4) is an autosomal recessive organic aciduria that is included in the newborn screening programs of several countries.,0,1.2108281843118784,5231.704021784666,15.805844155844154,0.4551779540383056,0.09404631107917773,0.0,0.0,0.991304347826087,114.0,-0.6097512723345732,0.07301349325337331,1.0,2.0,16.0,18.0,18.0,5.0,36.0,172,16.0,0.0001929012345679012,487.0,116.0,1.0,0,15.0
5517,604174,HP:0002664,The proteomic data suggested that Danu-regulated RPL15 signaling might contribute to the cancer cell killing effect.,1,1.3724379901603143,9002372.918875568,301.336781872282,0.14293373950966584,0.05619312841713218,0.0,0.0,1.0009756097560976,1026.0,-0.5790966737348902,0.10981410164978844,1.0,2.0,1.0,255.0,255.0,255.0,510.0,1542,254.0,1.6778973932186103e-06,57743.0,1026.0,1.0,0,297.0
5518,603617,HP:0000479,"We report the association of many previously unreported variants with retinal disease, as well as new disease phenotypes associated with known genes, including the first association of the SLC24A1 gene with retinitis pigmentosa.",1,1.4699297330250545,326876.8333586687,299.7015158194581,0.2584958820393274,0.23815269579888124,0.0,0.0,1.0012004801920766,834.0,-0.71426557699745,0.030507166895535193,1.0,2.0,1.0,37.0,37.0,37.0,74.0,1594,36.0,1.570341894837344e-06,10597.0,834.0,1.0,0,46.0
5519,616305,HP:0002664,The human tongue cancer cell line CAL27 was used to study the effects of FRMD4A.,0,1.3751974500426951,3040662.646936397,269.719591034371,0.1670954824146219,0.09127863516627087,0.0,0.0,0.9988888888888888,899.0,-0.6605596397104133,0.07470218275989643,1.0,2.0,55.0,126.0,126.0,126.0,252.0,1544,124.0,1.6778973932186103e-06,30288.0,901.0,1.0,0,136.0
5522,616305,HP:0002860,"The results showed FRMD4A overexpression in tongue squamous cell carcinoma, and the positive reaction was predominately located in the cytoplasm.",0,1.293845285149633,101311.9451659452,58.181992827868854,0.260672870670852,0.41040530168260797,0.0,0.0,0.9947368421052633,189.0,-0.5687890289272126,0.13833011848994214,1.0,2.0,15.0,53.0,53.0,46.0,106.0,152,51.0,6.009254251547383e-05,2510.0,191.0,1.0,0,66.0
5520,616305,HP:0002860,The findings of the present study suggest that FRMD4A expression correlates with the development of tongue squamous cell carcinoma.,0,1.293845285149633,101311.9451659452,58.181992827868854,0.260672870670852,0.41040530168260797,0.0,0.0,0.9947368421052633,189.0,-0.5687890289272126,0.13833011848994214,1.0,2.0,15.0,53.0,53.0,46.0,106.0,152,51.0,6.009254251547383e-05,2510.0,191.0,1.0,0,66.0
5524,600179,HP:0000546,"Substitutions of Arg838 in the dimerization domain of a human retinal membrane guanylyl cyclase 1 (RetGC1) linked to autosomal dominant cone-rod degeneration type 6 (CORD6) change RetGC1 regulation in vitro by Ca2+ In addition, we find that R838S substitution makes RetGC1 less sensitive to inhibition by retinal degeneration-3 protein (RD3).",0,1.3372038777678457,905166.582276547,127.27350777896262,0.1922674148998889,0.13250360094019328,0.0,0.0,1.0025974025974025,386.0,-0.4703992669522761,0.1622905591817509,1.0,2.0,11.0,140.0,140.0,40.0,280.0,438,139.0,2.066115702479339e-05,12059.0,386.0,1.0,0,151.0
960,606151,HP:0000007,Bardet-Biedl syndrome (BBS) is an autosomal recessive disorder that is both genetically and clinically heterogeneous.,1,1.4476951697119902,16529860.326488595,570.2214669051879,0.16530792190000526,0.13343289512387654,0.0,0.0,1.0003571428571427,2801.0,-0.5644242727269968,0.029600652828071606,1.0,2.0,19.0,220.0,220.0,219.0,440.0,5160,219.0,1.5011496554636367e-07,116076.0,2801.0,1.0,0,212.0
943,606151,HP:0001425,Bardet-Biedl syndrome (BBS) is an autosomal recessive disorder that is both genetically and clinically heterogeneous.,0,1.3163163281373012,1064593.6309523808,115.29840438199571,0.2067306802427935,0.09903095912423,0.0,0.0,0.997867803837953,468.0,-0.3132181558851957,0.12414825568207595,1.0,2.0,8.0,191.0,191.0,2.0,382.0,496,189.0,1.6259105098855357e-05,13683.0,470.0,1.0,0,221.0
5525,603743,HP:0012592,"The APOL1 G1 polymorphism, an identified risk factor for non-diabetic renal disease, was associated with albuminuria.",0,1.1589285714285715,931.6666666666667,14.178137651821865,0.453389318103632,0.452100581318033,0.0,0.0,0.9696969696969696,32.0,-0.586846162231185,0.22459893048128346,1.0,2.0,8.0,12.0,12.0,5.0,24.0,36,10.0,0.0025,126.0,34.0,1.0,0,12.0
2315,608177,HP:0002664,"In this study, we employed a siRNA knockdown approach for heparan sulphate (EXT1) and heparan/chondroitin/dermatan sulphate-biosynthetic enzymes (b4GalT7) in the aggressive human breast cancer cell line MDA-MB-231 to study the impact on cell behaviour and hyaluronan biosynthesis.",1,1.3671953875465912,7571634.649574038,252.30185626821753,0.15118185783882274,0.09939107755424499,0.0,0.0,1.0009532888465205,1050.0,-0.5485515347997706,0.0938544645694312,1.0,2.0,3.0,269.0,269.0,125.0,538.0,1542,268.0,1.6778973932186103e-06,51688.0,1050.0,1.0,0,343.0
5526,604327,HP:0002664,"In this study, we employed a siRNA knockdown approach for heparan sulphate (EXT1) and heparan/chondroitin/dermatan sulphate-biosynthetic enzymes (b4GalT7) in the aggressive human breast cancer cell line MDA-MB-231 to study the impact on cell behaviour and hyaluronan biosynthesis.",0,1.3512904657966214,6571204.319412572,242.399813229572,0.15196385516535094,0.10564678661621234,0.0,0.0,0.9990215264187868,1021.0,-0.5646358256016002,0.0887704135605152,1.0,2.0,32.0,247.0,247.0,119.0,494.0,1544,245.0,1.677897393218609e-06,46405.0,1023.0,1.0,0,339.0
5527,617220,HP:0003198,"This study establishes PYROXD1 variants as a cause of early-onset myopathy and uses biospecimens and cell lines, yeast, and zebrafish models to elucidate the fundamental role of PYROXD1 in skeletal muscle.",0,1.3318774345327626,1419717.313095238,154.74342920049543,0.18326227185316407,0.058311763496570565,0.0,0.0,0.997663551401869,427.0,-0.4469100621579458,0.1745419689344923,1.0,2.0,2.0,164.0,164.0,70.0,328.0,518,162.0,1.4792899408284024e-05,16024.0,429.0,1.0,0,234.0
5528,617220,HP:0003198,"Zebrafish with ryroxD1 knock-down recapitulate features of PYROXD1 myopathy with sarcomeric disorganization, myofibrillar aggregates, and marked swimming defect.",0,1.3318774345327626,1419717.313095238,154.74342920049543,0.18326227185316407,0.058311763496570565,0.0,0.0,0.997663551401869,427.0,-0.4469100621579458,0.1745419689344923,1.0,2.0,2.0,164.0,164.0,70.0,328.0,518,162.0,1.4792899408284024e-05,16024.0,429.0,1.0,0,234.0
5529,601691,HP:0000608,"In the eyes of Rdh8-/- Abca4-/- mice, a mouse model with defects in retinoid cycle that displays some symbolic characteristics of age-related macular degeneration (AMD), the level of atRAL-dimer was increased compared to wild-type mice, and was even much greater than that of A2E &amp; isomers.",1,1.3512314142905648,265977.6733766234,102.13836477987421,0.2207620290874991,0.1423052966448166,0.0,0.0,1.00418410041841,240.0,-0.4988864715567733,0.19110878661087866,1.0,2.0,4.0,81.0,81.0,81.0,162.0,162,81.0,3.90625e-05,5481.0,240.0,1.0,0,99.0
4528,611731,HP:0002664,"In colorectal cancer, APC-mediated induction of unregulated cell growth involves posttranslational mechanisms that prevent proteasomal degradation of proto-oncogene b-catenin (CTNNB1) and its eventual translocation to the nucleus.",1,1.3391008903849515,11574943.624649456,243.44156245977763,0.14922188725133187,0.047377974699447135,0.0,0.0,1.000772797527048,1295.0,-0.3687472023865209,0.0906434807516724,1.0,2.0,7.0,490.0,490.0,21.0,980.0,1542,489.0,1.677897393218609e-06,75947.0,1295.0,1.0,0,662.0
3117,116806,HP:0002664,"In colorectal cancer, APC-mediated induction of unregulated cell growth involves posttranslational mechanisms that prevent proteasomal degradation of proto-oncogene b-catenin (CTNNB1) and its eventual translocation to the nucleus.",1,1.3518211230574562,8628385.610725343,244.5227047309904,0.15288895987823498,0.10335671492220867,0.0,0.0,1.0008741258741258,1145.0,-0.4805894159801953,0.09402388005008093,1.0,2.0,4.0,359.0,359.0,79.0,718.0,1542,359.0,1.6778973932186097e-06,61580.0,1145.0,1.0,0,481.0
5530,601897,HP:0002664,"Here, we show in colorectal cancer that increased expression of ZNF148, the gene coding for transcription factor ZBP-89, correlated with reduced patient survival.",0,1.3966696402022003,4180050.221168237,296.9839188049305,0.15744208883266486,0.06912149151457997,0.0,0.0,0.9989071038251366,914.0,-0.6781430022198327,0.08709046221394992,1.0,2.0,12.0,144.0,144.0,144.0,288.0,1544,142.0,1.6778973932186097e-06,36497.0,916.0,1.0,0,175.0
5532,601897,HP:0002664,Tissue arrays showed that ZBP-89 protein was overexpressed in the early stages of colorectal cancer.,0,1.3966696402022003,4180050.221168237,296.9839188049305,0.15744208883266486,0.06912149151457997,0.0,0.0,0.9989071038251366,914.0,-0.6781430022198327,0.08709046221394992,1.0,2.0,12.0,144.0,144.0,144.0,288.0,1544,142.0,1.6778973932186097e-06,36497.0,916.0,1.0,0,175.0
5534,612123,HP:0001397,"Moreover, we show that over-expression of PNPLA8 dramatically decreases hepatic steatosis through increased autophagy in hepatocytes of HFD-fed mice.",0,1.304133205628822,112019.55952380953,60.76522569859088,0.2781493984983923,0.11384549422398878,0.0,0.0,0.9946236559139784,185.0,-0.4577800769638451,0.16359036283134956,1.0,2.0,5.0,70.0,70.0,15.0,140.0,214,68.0,8.573388203017832e-05,2845.0,187.0,1.0,0,75.0
5535,615407,HP:0000007,We report a novel ARL2BP splice site mutation after whole-exome sequencing (WES) applied to a Moroccan family including two sisters affected with autosomal recessive rod-cone dystrophy (arRCD).,1,1.4682135619027408,7055595.879807417,604.4951237809453,0.19316778905415533,0.5809931452787571,0.0,0.0,1.0003699593044766,2704.0,-0.5867253763907125,0.0195706282959762,1.0,2.0,21.0,124.0,124.0,124.0,248.0,5160,123.0,1.5011496554636367e-07,71520.0,2704.0,1.0,0,123.0
5536,179615,HP:0002664,"The tumor cells resembled pro-B cells, and were CD19+IgM-IgD-CD93+CD43+CD21-CD23-VpreB+CXCR4+ Consistent with the pro-B-cell stage of B-cell development, microarray analysis revealed enrichment of transcripts, including Rag1, Rag2, CD93, Vpreb1, Vpreb3, and Igll1 We confirmed RAG1 expression in Tg26 tumors, and hypothesized that HIV-1 matrix protein p17 may directly induce RAG1 in B cells.",1,1.377078024841925,5012199.158234822,238.1688155378224,0.16530070525723947,0.025207023642281653,0.0,0.0,1.0009940357852882,1007.0,-0.5821238268500794,0.08496192655388424,1.0,2.0,5.0,220.0,220.0,114.0,440.0,1542,219.0,1.6778973932186103e-06,43035.0,1007.0,1.0,0,226.0
5539,605020,HP:0000563,The aim of this study was to screen the visual system homeobox 1 (VSX1) gene in Turkish patients with keratoconus (KC).,1,1.3357575757575757,141699.6896825397,78.12013862148633,0.2128290428596052,0.2877362217928096,0.0,0.0,1.0049261083743843,204.0,-0.6117031608197327,0.1921182266009852,1.0,2.0,18.0,70.0,70.0,32.0,140.0,212,69.0,8.734387282732117e-05,3978.0,204.0,1.0,0,73.0
5540,600960,HP:0030214,"Kluver-Bucy syndrome (KBS) comprises a set of neurobehavioral symptoms with psychic blindness, hypersexuality, disinhibition, hyperorality, and hypermetamorphosis that were originally observed after bilateral lobectomy in Rhesus monkeys.",0,1.296382189239332,1105.0,46.01479289940829,0.6724762770999959,0.7171868587680963,0.0,0.0,0.994186046511628,171.0,-0.6937474537158063,0.017341040462427744,1.0,2.0,98.0,3.0,3.0,3.0,6.0,244,2.0,3.4602076124567484e-05,258.0,173.0,1.0,0,3.0
798,171834,HP:0002664,Oncogenic mutations in the PI3K/AKT pathway are present in nearly half of human tumors.,1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
2636,164730,HP:0002664,Oncogenic mutations in the PI3K/AKT pathway are present in nearly half of human tumors.,1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
5541,171834,HP:0002860,"We find that lung squamous cell carcinoma (SQCC), which accounts for ~20% of lung cancer, exhibits increased expression of the PI3K subunit PIK3R2, which is at low expression levels in normal tissues.",0,1.387316953618038,375887.2021197393,132.98661576465307,0.2756536133023725,0.10131703787631466,0.0,0.0,0.9987373737373738,791.0,-0.4267531565443305,0.02600086616480059,1.0,2.0,97.0,62.0,62.0,62.0,124.0,324,61.0,1.8713940575753098e-06,8165.0,793.0,1.0,0,62.0
5542,603157,HP:0002860,"We find that lung squamous cell carcinoma (SQCC), which accounts for ~20% of lung cancer, exhibits increased expression of the PI3K subunit PIK3R2, which is at low expression levels in normal tissues.",0,1.3067210567210568,113535.75487012988,61.71697514542569,0.2675800992753125,0.09403286845155033,0.0,0.0,0.9953917050691244,216.0,-0.5703488348172927,0.1196465564621824,1.0,2.0,14.0,56.0,56.0,46.0,112.0,124,54.0,4.1091387245233394e-05,2830.0,218.0,1.0,0,54.0
833,171834,HP:0002664,"We find that lung squamous cell carcinoma (SQCC), which accounts for ~20% of lung cancer, exhibits increased expression of the PI3K subunit PIK3R2, which is at low expression levels in normal tissues.",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
5545,603157,HP:0002664,"We find that lung squamous cell carcinoma (SQCC), which accounts for ~20% of lung cancer, exhibits increased expression of the PI3K subunit PIK3R2, which is at low expression levels in normal tissues.",0,1.3866241349480968,4545275.298909099,284.24383916990917,0.15645454082366428,0.07315355935098944,0.0,0.0,0.9989212513484356,926.0,-0.6547726730255501,0.08683694156158167,1.0,2.0,19.0,155.0,155.0,153.0,310.0,1544,153.0,1.6778973932186103e-06,37351.0,928.0,1.0,0,168.0
5547,603157,HP:0002664,We generated tumor xenografts of SQCC cell lines and examined the consequences of targeting PIK3R2 expression.,0,1.3866241349480968,4545275.298909099,284.24383916990917,0.15645454082366428,0.07315355935098944,0.0,0.0,0.9989212513484356,926.0,-0.6547726730255501,0.08683694156158167,1.0,2.0,19.0,155.0,155.0,153.0,310.0,1544,153.0,1.6778973932186103e-06,37351.0,928.0,1.0,0,168.0
777,171834,HP:0002664,"In tumors with high PIK3R2 expression, and independently of PIK3CA, KRAS, or PTEN mutations, PIK3R2 depletion induced lung SQCC xenograft regression without triggering PI3K/AKT pathway rebound.",1,1.3337404616360629,15332325.655232085,247.31577208037947,0.1456614394042407,0.045038351850683785,0.0,0.0,1.0006666666666666,1501.0,-0.2954567170547207,0.08237708194536976,1.0,2.0,13.0,622.0,622.0,3.0,1244.0,1542,621.0,1.6778973932186097e-06,92736.0,1501.0,1.0,0,799.0
2624,164730,HP:0002664,"In tumors with high PIK3R2 expression, and independently of PIK3CA, KRAS, or PTEN mutations, PIK3R2 depletion induced lung SQCC xenograft regression without triggering PI3K/AKT pathway rebound.",1,1.3342240784702035,14821543.703046473,246.95340276188298,0.14495431677743287,0.09229170384462984,0.0,0.0,1.0006896551724136,1451.0,-0.3195488193133552,0.08482140735283633,1.0,2.0,4.0,593.0,593.0,3.0,1186.0,1542,593.0,1.6778973932186103e-06,89230.0,1451.0,1.0,0,768.0
5543,603157,HP:0002664,"In tumors with high PIK3R2 expression, and independently of PIK3CA, KRAS, or PTEN mutations, PIK3R2 depletion induced lung SQCC xenograft regression without triggering PI3K/AKT pathway rebound.",0,1.3866241349480968,4545275.298909099,284.24383916990917,0.15645454082366428,0.07315355935098944,0.0,0.0,0.9989212513484356,926.0,-0.6547726730255501,0.08683694156158167,1.0,2.0,19.0,155.0,155.0,153.0,310.0,1544,153.0,1.6778973932186103e-06,37351.0,928.0,1.0,0,168.0
2035,190070,HP:0002664,"In tumors with high PIK3R2 expression, and independently of PIK3CA, KRAS, or PTEN mutations, PIK3R2 depletion induced lung SQCC xenograft regression without triggering PI3K/AKT pathway rebound.",1,1.3339771877413191,18178836.290753696,271.2782786211432,0.14438020893870612,0.0522035687829069,0.0,0.0,1.0006165228113442,1623.0,-0.2035822069529308,0.08341633409382543,1.0,2.0,4.0,720.0,720.0,2.0,1440.0,1542,719.0,1.374364528201273e-06,109797.0,1623.0,1.0,0,858.0
5549,616758,HP:0000968,We describe a multigenerational Saudi family with an autosomal dominant form of hypohidrotic ectodermal dysplasia in which positional mapping and exome sequencing identified a novel variant in KDF1 that fully segregates with the phenotype.,0,1.3144031864319672,23171.030952380952,45.85,0.32286843124610737,0.027331416647889656,0.0,0.0,0.98989898989899,98.0,-0.5913031913064017,0.19696969696969696,1.0,2.0,5.0,29.0,29.0,29.0,58.0,66,28.0,0.00019837333862328903,975.0,100.0,1.0,0,35.0
5550,617242,HP:0004756,"A third patient from a consanguineous Sudanese family diagnosed with catecholaminergic polymorphic ventricular tachycardia (CPVT) had a homozygous splice site mutation (c.331+1G&gt;A) in TECRL Analysis of intracellular calcium ([Ca2+]i) dynamics in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) generated from this individual (TECRLHom-hiPSCs), his heterozygous but clinically asymptomatic father (TECRLHet-hiPSCs), and a healthy individual (CTRL-hiPSCs) from the same Sudanese family, revealed smaller [Ca2+]i transient amplitudes as well as elevated diastolic [Ca2+]i in TECRLHom-hiPSC-CMs compared with CTRL-hiPSC-CMs.",1,1.3582417582417583,10989.657936507936,41.766882516188716,0.35263656627330786,0.3789749871749497,0.0,0.0,1.0144927536231885,70.0,-0.6286136501119569,0.2670807453416149,1.0,2.0,1.0,23.0,23.0,23.0,46.0,94,22.0,0.0004340277777777778,645.0,70.0,1.0,0,29.0
5551,606969,HP:0000518,"GEMIN4 was independently mutated in families with a syndrome of cataract, global developmental delay with or without renal involvement.",0,1.4118061195538094,2787453.8377449308,312.7922876583443,0.16219067193597048,0.02636336911711263,0.0,0.0,1.0013140604467805,762.0,-0.6889978380105948,0.10382802018341662,1.0,2.0,1.0,113.0,113.0,113.0,226.0,1298,112.0,2.366863905325444e-06,30104.0,762.0,1.0,0,109.0
5552,610354,HP:0000518,"A founder mutation in RIC1 (KIAA1432) was identified in patients with cataract, brain atrophy, microcephaly with or without cleft lip and palate.",0,1.418363260326478,2382871.5637756907,314.77596912233594,0.16788666080257136,0.06127561688245645,0.0,0.0,1.0013351134846462,750.0,-0.7044880549142849,0.09794748553627056,1.0,2.0,1.0,101.0,101.0,99.0,202.0,1298,100.0,2.3668639053254444e-06,27511.0,750.0,1.0,0,96.0
5553,610354,HP:0000252,"A founder mutation in RIC1 (KIAA1432) was identified in patients with cataract, brain atrophy, microcephaly with or without cleft lip and palate.",0,1.4383640552995391,4226909.075089192,505.7910728149291,0.1536469208036964,0.03322207311721212,0.0,0.0,0.9991189427312775,1134.0,-0.7142381468972314,0.07365669789663089,1.0,2.0,1.0,102.0,102.0,102.0,204.0,2068,100.0,9.335107003664028e-07,47485.0,1136.0,1.0,0,97.0
5554,610354,HP:0410030,"A founder mutation in RIC1 (KIAA1432) was identified in patients with cataract, brain atrophy, microcephaly with or without cleft lip and palate.",0,1.348367394879023,727613.1146103896,158.2345528670514,0.17934898705149827,0.01670545454264891,0.0,0.0,1.0034843205574913,288.0,-0.5945503576299309,0.251088850174216,1.0,2.0,3.0,99.0,99.0,98.0,198.0,374,98.0,2.8293345405160706e-05,10377.0,288.0,1.0,0,135.0
5555,612758,HP:0000518,"For non-syndromic pediatric cataract, we map a novel locus in a multiplex consanguineous family on 4p15.32 where exome sequencing revealed a homozygous truncating mutation in TAPT1.",0,1.3583744076054214,6152781.838799189,265.4341730054592,0.14640650752073028,0.01955430921505561,0.0,0.0,0.9988518943742826,870.0,-0.5950867283404251,0.11665385142038573,1.0,2.0,7.0,212.0,212.0,171.0,424.0,1300,210.0,2.3595980188815043e-06,44300.0,872.0,1.0,0,273.0
4134,607585,HP:0001251,These include an enhancer in an ataxia telangiectasia mutated (ATM) intron that has SNPs in linkage disequilibrium with a metformin treatment response GWAS lead SNP (rs11212617) that showed increased enhancer activity for the associated haplotype.,1,1.3840343933043555,4884522.135182295,253.0068814201656,0.16564683663304608,0.05529906972015484,0.0,0.0,1.0009671179883946,1035.0,-0.5972520959401639,0.08245264859510927,1.0,2.0,4.0,206.0,206.0,104.0,412.0,1630,205.0,1.5092152684290275e-06,44120.0,1035.0,1.0,0,234.0
370,601231,HP:0002664,"We report here that the tumor suppressor ING1b binds rDNA, regulates rDNA chromatin modifications and affects nucleolar localization of mTOR to modulate rRNA levels.",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
5557,610553,HP:0002664,"The ubiquitin-fold modifier 1 (UFM1)-system, a ubiquitin-like protein conjugation system, is involved in the development of breast cancer and several hereditary neurological syndromes.",0,1.4166278528178853,1542975.9087176106,334.1721789883268,0.1831355605437805,0.013209482719906207,0.0,0.0,0.998809523809524,839.0,-0.7429783403803611,0.06114036577770227,1.0,2.0,42.0,69.0,69.0,69.0,138.0,1544,67.0,1.67789739321861e-06,21596.0,841.0,1.0,0,82.0
5558,156540,HP:0002664,"Intriguingly, five CPGs showed concordance between CNL and down-regulation in 50 or more tumor samples: MTAP (216 samples), PTEN (143), MCPH1 (86), SMAD4 (63), and MINPP1 (51), which may represent the recurrent driving force for gene expression change during oncogenesis.",1,1.4321401204861768,1154090.5631268134,226.58265344546254,0.21262931023186127,0.16660789574502252,0.0,0.0,1.0011587485515645,864.0,-0.6720917813616354,0.05043774945281319,1.0,2.0,6.0,86.0,86.0,77.0,172.0,1542,85.0,1.6778973932186097e-06,18804.0,864.0,1.0,0,77.0
471,601728,HP:0002664,"Intriguingly, five CPGs showed concordance between CNL and down-regulation in 50 or more tumor samples: MTAP (216 samples), PTEN (143), MCPH1 (86), SMAD4 (63), and MINPP1 (51), which may represent the recurrent driving force for gene expression change during oncogenesis.",1,1.3343407597332966,15830479.394674528,265.4490341856586,0.14275419633953182,0.03699924186469675,0.0,0.0,1.0006934812760055,1443.0,-0.27905209298652,0.09160873238543142,1.0,2.0,5.0,608.0,608.0,3.0,1216.0,1542,607.0,1.6778973932186103e-06,95310.0,1443.0,1.0,0,802.0
4857,600993,HP:0002664,"Intriguingly, five CPGs showed concordance between CNL and down-regulation in 50 or more tumor samples: MTAP (216 samples), PTEN (143), MCPH1 (86), SMAD4 (63), and MINPP1 (51), which may represent the recurrent driving force for gene expression change during oncogenesis.",1,1.3361927954695605,13930500.400868574,255.205350796036,0.14290522615660328,0.0866885436227384,0.0,0.0,1.0007336757153338,1364.0,-0.33425811754301626,0.09202466527390203,1.0,2.0,4.0,552.0,552.0,9.0,1104.0,1542,551.0,1.67789739321861e-06,85543.0,1364.0,1.0,0,725.0
5560,605391,HP:0002664,"Intriguingly, five CPGs showed concordance between CNL and down-regulation in 50 or more tumor samples: MTAP (216 samples), PTEN (143), MCPH1 (86), SMAD4 (63), and MINPP1 (51), which may represent the recurrent driving force for gene expression change during oncogenesis.",1,1.4503769120050742,879056.7901055687,279.3220925205361,0.21856191061083194,0.084603206830653,0.0,0.0,1.0012004801920769,834.0,-0.7272958707650238,0.04683312173790378,1.0,2.0,1.0,63.0,63.0,63.0,126.0,1542,63.0,1.677897393218609e-06,16268.0,834.0,1.0,0,59.0
5561,615787,HP:0030048,"We report the case of a 10-year-old Spanish girl with mutations in NADK2 Prenatal central nervous system abnormalities showed ventriculomegaly, colpocephaly, and hypoplasia of the corpus callosum.",0,1.3165030005455538,26973.410918003563,61.19656283566058,0.3289511382827379,0.3943351688776719,0.0,0.0,0.9940119760479044,166.0,-0.6461034190532349,0.08283433133732535,1.0,2.0,37.0,20.0,20.0,20.0,40.0,108,19.0,4.565376186997808e-05,1162.0,168.0,1.0,0,20.0
5562,615787,HP:0002079,"We report the case of a 10-year-old Spanish girl with mutations in NADK2 Prenatal central nervous system abnormalities showed ventriculomegaly, colpocephaly, and hypoplasia of the corpus callosum.",1,1.3715884836123893,2160411.5904053883,233.20957072484163,0.15137456774258062,0.151311301950384,0.0,0.0,1.0017211703958693,582.0,-0.7099511162547609,0.15155171495998726,1.0,2.0,15.0,129.0,129.0,94.0,258.0,870,128.0,5.2604999579160005e-06,25623.0,582.0,1.0,0,163.0
5563,146929,HP:0002664,"In A549 lung cancer cells, which endogenously express CXCR1, the depletion of REEP5 and REEP6 significantly reduced growth and invasion by downregulating IL-8-stimulated ERK phosphorylation, actin polymerization and the expression of genes related to metastasis.",0,1.2467825290491663,2322.002597402597,4.002594033722438,0.7071706999074873,0.8359521385756078,0.0,0.0,0.9987063389391979,772.0,-0.99233106615227,0.00258732212160414,1.0,2.0,770.0,2.0,2.0,2.0,4.0,1540,1.0,1.67789739321861e-06,774.0,774.0,1.0,0,2.0
5564,609346,HP:0002664,"In A549 lung cancer cells, which endogenously express CXCR1, the depletion of REEP5 and REEP6 significantly reduced growth and invasion by downregulating IL-8-stimulated ERK phosphorylation, actin polymerization and the expression of genes related to metastasis.",0,1.3962560679334026,2261263.3016735357,246.466439688716,0.18370580851541007,0.045794852831167306,0.0,0.0,0.998878923766816,891.0,-0.6478375029450402,0.06597401814812769,1.0,2.0,29.0,121.0,121.0,107.0,242.0,1544,119.0,1.67789739321861e-06,26276.0,893.0,1.0,0,120.0
5565,609007,HP:0001425,Allelic heterogeneity was observed at LRRK2 while European risk SNPs at 6 other loci including MAPT and GBA-SYT11 were non-polymorphic or very rare in our cohort.,0,1.3231875492513792,494185.75691253186,83.92203126256804,0.2360620039271547,0.008505694549302941,0.0,0.0,0.9974937343358397,398.0,-0.4814526713393171,0.1011904761904762,1.0,2.0,6.0,125.0,125.0,18.0,250.0,496,123.0,1.625910509885536e-05,8075.0,400.0,1.0,0,125.0
5566,157140,HP:0001425,Allelic heterogeneity was observed at LRRK2 while European risk SNPs at 6 other loci including MAPT and GBA-SYT11 were non-polymorphic or very rare in our cohort.,1,1.3354119742405637,751871.7956085416,82.42424242424242,0.2268216800781749,0.17112354591576814,0.0,0.0,1.0018416206261511,544.0,-0.3843882731673001,0.07525593110172246,1.0,2.0,31.0,169.0,169.0,2.0,338.0,554,168.0,1.1260754020089185e-05,11115.0,544.0,1.0,0,182.0
3293,607407,HP:0001249,"Here, we describe three individuals who are affected by global developmental delay, intellectual disability, and expressive speech disorder and carry de novo variants in EBF3.",1,1.4233147044975332,17572430.154272385,587.551953862981,0.13233679875660373,0.019169530735568898,0.0,0.0,1.0005473453749316,1828.0,-0.6521585692095052,0.06968772569014024,1.0,2.0,1.0,226.0,226.0,226.0,452.0,3204,225.0,3.891642658474498e-07,116370.0,1828.0,1.0,0,228.0
5568,600364,HP:0007754,"Genetic screening of patients diagnosed with macular dystrophy disclosed a novel mutation in the GUCA1A gene, namely a c.526C &gt; T substitution leading to the amino acid substitution p.L176F in the guanylate cyclase-activating protein 1 (GCAP1).",0,1.349618320610687,6281.16746031746,28.94772727272727,0.3997646783333039,0.2275823991778225,0.0,0.0,0.9861111111111108,71.0,-0.6119418344636256,0.1541095890410959,1.0,2.0,1.0,17.0,17.0,17.0,34.0,76,16.0,0.0003188775510204081,405.0,73.0,1.0,0,23.0
5569,605490,HP:0000007,"Cerebral, ocular, dental, auricular, skeletal (CODAS) syndrome is a rare autosomal recessive multisystem disorder caused by mutations in LONP1.",1,1.4188710842772168,27764883.83958359,485.21703355228135,0.1484438418815881,0.10591376446826756,0.0,0.0,1.000336473755047,2973.0,-0.5374204792452401,0.037457575786384326,1.0,2.0,12.0,388.0,388.0,271.0,776.0,5160,387.0,1.5011496554636367e-07,165483.0,2973.0,1.0,0,390.0
286,601231,HP:0002664,"Here, we demonstrate that MNK sustains mTORC1 activity following rapamycin treatment and contributes to mTORC1 signaling following T cell activation and growth stimuli in cancer cells.",0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
5570,610350,HP:0002300,Mutations in LINS1 were suspected in this non-syndromic ID case with mutism.,0,1.3400283845489325,136722.81349206352,84.15585721468075,0.2472414099033477,0.09849621993653282,0.0,0.0,0.9940828402366864,168.0,-0.5800674381732657,0.2148277062304212,1.0,2.0,2.0,52.0,52.0,52.0,104.0,110,51.0,7.181844297615628e-05,3086.0,170.0,1.0,0,52.0
5580,611642,HP:0002664,"The expression of hepatocyte cell adhesion molecule (HepaCAM), a novel tumor suppressor, is frequently downregulated or lost in PCa.",0,1.4218679036750594,1051393.658602611,252.46123772466183,0.2066559502511104,0.0805662734604674,0.0,0.0,0.9988123515439432,841.0,-0.6765841303487894,0.047658092492878334,1.0,2.0,22.0,67.0,67.0,67.0,134.0,1544,65.0,1.6778973932186097e-06,16914.0,843.0,1.0,0,75.0
5571,611642,HP:0002664,"Furthermore, the overexpression of HepaCAM induced by transfection with a HepaCAM overexpression vector (Ad-HepaCAM) exerted antitumor effects by decreasing the proliferation, and suppressing the invasion and migration of bicalutamide-resistant (Bica-R) cells and enzalutamide-resistant (Enza-R) cells.",0,1.4218679036750594,1051393.658602611,252.46123772466183,0.2066559502511104,0.0805662734604674,0.0,0.0,0.9988123515439432,841.0,-0.6765841303487894,0.047658092492878334,1.0,2.0,22.0,67.0,67.0,67.0,134.0,1544,65.0,1.6778973932186097e-06,16914.0,843.0,1.0,0,75.0
5574,611642,HP:0002664,"Importantly, we found that the antitumor effects of HepaCAM on the resistant cells were associated with the downregulation of Notch signaling.",0,1.4218679036750594,1051393.658602611,252.46123772466183,0.2066559502511104,0.0805662734604674,0.0,0.0,0.9988123515439432,841.0,-0.6765841303487894,0.047658092492878334,1.0,2.0,22.0,67.0,67.0,67.0,134.0,1544,65.0,1.6778973932186097e-06,16914.0,843.0,1.0,0,75.0
5585,607585,HP:0002664,"We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.",1,1.3808036846385123,5022906.590897991,260.07059978266204,0.1645229560540482,0.06960009981228706,0.0,0.0,1.001008064516129,993.0,-0.5688506603301072,0.09101614527498944,1.0,2.0,2.0,217.0,217.0,167.0,434.0,1542,216.0,1.6778973932186106e-06,44828.0,993.0,1.0,0,244.0
3977,604373,HP:0002664,"We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.",1,1.3907500291201478,3049455.1280453037,216.48240792209663,0.18644085984948167,0.18561350324725764,0.0,0.0,1.0010427528675705,960.0,-0.579863168744912,0.07138512339242266,1.0,2.0,1.0,186.0,186.0,98.0,372.0,1542,185.0,1.67789739321861e-06,32860.0,960.0,1.0,0,173.0
4992,602774,HP:0002664,"We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.",1,1.3495654256832177,12820205.771016564,289.5680636825378,0.14116732754766764,0.06982837343317029,0.0,0.0,1.000859845227859,1164.0,-0.4409432896921249,0.11136325358342716,1.0,2.0,2.0,391.0,391.0,82.0,782.0,1542,390.0,1.6778973932186103e-06,75378.0,1164.0,1.0,0,503.0
5081,613984,HP:0002664,"We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.",1,1.3443751049641288,13634066.221587395,277.7363129823827,0.1415596132060388,0.02312098975976063,0.0,0.0,1.0008223684210529,1217.0,-0.4154214980578075,0.10605646974873502,1.0,2.0,5.0,431.0,431.0,44.0,862.0,1542,430.0,1.6778973932186103e-06,78475.0,1217.0,1.0,0,544.0
5587,611360,HP:0002664,"We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.",1,1.3452416197292556,13554676.38221362,285.6174573709825,0.14121444838110922,0.08941914629284065,0.0,0.0,1.0008291873963515,1207.0,-0.40694479456722427,0.1092933564708905,1.0,2.0,5.0,435.0,435.0,49.0,870.0,1542,434.0,1.6778973932186097e-06,79546.0,1207.0,1.0,0,575.0
5588,607951,HP:0002664,"We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.",1,1.35928994460674,10896855.388275616,293.50859575770755,0.14171968140890848,0.007385459887882827,0.0,0.0,1.000915750915751,1093.0,-0.5087889002621472,0.11171155773168584,1.0,2.0,2.0,318.0,318.0,154.0,636.0,1542,317.0,1.677897393218609e-06,66667.0,1093.0,1.0,0,484.0
5589,603780,HP:0002664,"We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.",1,1.3397023446902216,13036395.691175492,256.32733368223836,0.14286441599117267,0.2096385802778787,0.0,0.0,1.0007794232268123,1284.0,-0.3906226400730149,0.0958605585138026,1.0,2.0,7.0,480.0,480.0,24.0,960.0,1542,479.0,1.67789739321861e-06,78959.0,1284.0,1.0,0,628.0
5590,603550,HP:0002664,"EYA4, one of the four members of the EYA gene family, is associated with several human cancers.",0,1.4435904327570557,242092.5019303901,219.50312463152926,0.300458962707651,0.31528689971602025,0.0,0.0,0.9987577639751554,804.0,-0.6848108191962129,0.02369495861781977,1.0,2.0,32.0,32.0,32.0,32.0,64.0,1544,30.0,1.6778973932186097e-06,7687.0,806.0,1.0,0,31.0
5591,607199,HP:0001425,"Thus, here we report a new candidate gene (NOL4) and a haplotype of IRF6 forVWS, and highlight the genetic heterogeneity of this disorder in the Indian population",0,1.334467822301435,1047939.1552365765,104.329184413708,0.2080617829428328,0.0563125410364023,0.0,0.0,1.0019417475728156,516.0,-0.3240337454976224,0.10110634454730187,1.0,2.0,19.0,194.0,194.0,2.0,388.0,494,193.0,1.3717421124828527e-05,13434.0,516.0,1.0,0,204.0
5592,611507,HP:0003540,"In humans, mutations in CISD2 result in Wolfram syndrome 2, a disease in which the patients display juvenile diabetes, neuropsychiatric disorders and defective platelet aggregation.",1,1.4194317935371936,22498.719246031742,45.97340930674264,0.42842865896321,0.3336728604219709,0.0,0.0,1.0053475935828875,188.0,-0.4684574362851637,0.0585959722380248,1.0,2.0,40.0,26.0,26.0,26.0,52.0,138,26.0,3.763784862057285e-05,1030.0,188.0,1.0,0,29.0
5593,191342,HP:0100242,"This similarity was revealed by the same number of passages, the same germ cell clusters formation and similar level of genes expression of spermatogonial markers including ubiquitin carboxyl-terminal esterase L1 (UCHL1), zinc finger and BTB domain containing 16 (ZBTB16) and glial cell line-derived neurotrophic factor family receptor alpha 1 (GFRA1), as well as germ cell differentiation markers including signal transducer and activator of transcription 3 (STAT3), spermatogenesis and oogenesis specific basic helix-loophelix 2 (SOHLH2), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and synaptonemal complex protein 3 (SYCP3).",0,1.2927763124308689,304152.2832251082,73.41292442497263,0.23302127132870576,0.38431990646377145,0.0,0.0,0.996884735202492,320.0,-0.4363665550031582,0.11658056152164238,1.0,2.0,14.0,105.0,105.0,2.0,210.0,310,103.0,3.58564308508731e-05,6025.0,322.0,1.0,0,116.0
5594,176797,HP:0100242,"This similarity was revealed by the same number of passages, the same germ cell clusters formation and similar level of genes expression of spermatogonial markers including ubiquitin carboxyl-terminal esterase L1 (UCHL1), zinc finger and BTB domain containing 16 (ZBTB16) and glial cell line-derived neurotrophic factor family receptor alpha 1 (GFRA1), as well as germ cell differentiation markers including signal transducer and activator of transcription 3 (STAT3), spermatogenesis and oogenesis specific basic helix-loophelix 2 (SOHLH2), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and synaptonemal complex protein 3 (SYCP3).",0,1.3249367362289006,768464.0206349209,122.61241883116884,0.1917483800872921,0.013998325168982806,0.0,0.0,0.9973614775725594,378.0,-0.257651627780555,0.15810304124427166,1.0,2.0,4.0,144.0,144.0,3.0,288.0,310,142.0,1.975308641975309e-05,11385.0,380.0,1.0,0,164.0
5182,164920,HP:0100242,"This similarity was revealed by the same number of passages, the same germ cell clusters formation and similar level of genes expression of spermatogonial markers including ubiquitin carboxyl-terminal esterase L1 (UCHL1), zinc finger and BTB domain containing 16 (ZBTB16) and glial cell line-derived neurotrophic factor family receptor alpha 1 (GFRA1), as well as germ cell differentiation markers including signal transducer and activator of transcription 3 (STAT3), spermatogenesis and oogenesis specific basic helix-loophelix 2 (SOHLH2), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and synaptonemal complex protein 3 (SYCP3).",1,1.3417436086713304,832594.9452380955,129.49197068491674,0.19300928062112155,0.09381159861112977,0.0,0.0,1.0025380710659901,395.0,-0.2508545048551093,0.1563580286577138,1.0,2.0,10.0,154.0,154.0,3.0,308.0,320,154.0,1.7075336384126762e-05,12167.0,395.0,1.0,0,172.0
5595,604759,HP:0100242,"This similarity was revealed by the same number of passages, the same germ cell clusters formation and similar level of genes expression of spermatogonial markers including ubiquitin carboxyl-terminal esterase L1 (UCHL1), zinc finger and BTB domain containing 16 (ZBTB16) and glial cell line-derived neurotrophic factor family receptor alpha 1 (GFRA1), as well as germ cell differentiation markers including signal transducer and activator of transcription 3 (STAT3), spermatogenesis and oogenesis specific basic helix-loophelix 2 (SOHLH2), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and synaptonemal complex protein 3 (SYCP3).",0,1.3396601294967392,53759.33956214064,56.873113373113355,0.3051615587625788,0.12553607352057514,0.0,0.0,0.9947916666666664,191.0,-0.7162643462318272,0.0986614853195164,1.0,2.0,9.0,30.0,30.0,23.0,60.0,310,28.0,4.162330905306972e-05,1828.0,193.0,1.0,0,30.0
5596,276000,HP:0002664,"To evaluate whether germline variants in genes encoding pancreatic secretory enzymes contribute to pancreatic cancer susceptibility, we sequenced the coding regions of CPB1 and other genes encoding pancreatic secretory enzymes and known pancreatitis susceptibility genes (PRSS1, CPA1, CTRC, and SPINK1) in a hospital series of pancreatic cancer cases and controls.",0,1.436863920580154,953710.2547132358,241.49691958495453,0.22392115134282248,0.21922759262436567,0.0,0.0,0.9988151658767772,843.0,-0.6917293580559583,0.046591323368574564,1.0,2.0,7.0,72.0,72.0,72.0,144.0,1544,71.0,1.67789739321861e-06,16614.0,845.0,1.0,0,65.0
5597,601405,HP:0002664,"To evaluate whether germline variants in genes encoding pancreatic secretory enzymes contribute to pancreatic cancer susceptibility, we sequenced the coding regions of CPB1 and other genes encoding pancreatic secretory enzymes and known pancreatitis susceptibility genes (PRSS1, CPA1, CTRC, and SPINK1) in a hospital series of pancreatic cancer cases and controls.",0,1.436863920580154,953710.2547132357,241.49691958495453,0.2239211513428223,0.21922759262436484,0.0,0.0,0.9988151658767772,843.0,-0.6917293580559584,0.046591323368574564,1.0,2.0,7.0,73.0,73.0,72.0,146.0,1544,71.0,1.67789739321861e-06,16614.0,845.0,1.0,0,65.0
5601,167790,HP:0002664,"To evaluate whether germline variants in genes encoding pancreatic secretory enzymes contribute to pancreatic cancer susceptibility, we sequenced the coding regions of CPB1 and other genes encoding pancreatic secretory enzymes and known pancreatitis susceptibility genes (PRSS1, CPA1, CTRC, and SPINK1) in a hospital series of pancreatic cancer cases and controls.",1,1.4396536831054232,1030012.1486888314,245.03501945525286,0.2207331116132752,0.18358441072633885,0.0,0.0,1.0011764705882351,851.0,-0.6836760981298771,0.049104859335038366,1.0,2.0,8.0,77.0,77.0,74.0,154.0,1542,76.0,1.6778973932186103e-06,17760.0,851.0,1.0,0,70.0
5599,601405,HP:0002664,"Variants in CPB1, CPA1 (encoding carboxypeptidase B1 and A1), and CTRC were evaluated in a second set of cases with familial pancreatic cancer and controls.",0,1.436863920580154,953710.2547132357,241.49691958495453,0.2239211513428223,0.21922759262436484,0.0,0.0,0.9988151658767772,843.0,-0.6917293580559584,0.046591323368574564,1.0,2.0,7.0,73.0,73.0,72.0,146.0,1544,71.0,1.67789739321861e-06,16614.0,845.0,1.0,0,65.0
580,600960,HP:0002664,"More ER stress-inducing CPA1 variants were also found in the combined set of hospital and familial cases with pancreatic cancer than in controls [7/1,546 vs. 1/2,012; P = 0.025; odds ratio, 9.36 (95% CI, 1.15-76.02)].",0,1.3818042268184911,3737346.30175055,234.52734096194138,0.16519411287549554,0.039189680336609765,0.0,0.0,0.9989373007438892,940.0,-0.6397554403433395,0.07484471278916814,1.0,2.0,20.0,163.0,163.0,113.0,326.0,1544,161.0,1.6778973932186103e-06,33172.0,942.0,1.0,0,204.0
5602,603381,HP:0000924,"FLNB-related disorders are classified as spondylocarpotarsal synostosis (SCT), Larsen syndrome (LS), atelosteogenesis (AO), boomerang dysplasia (BD), and isolated congenital talipes equinovarus, presenting with scoliosis, short-limbed dwarfism, clubfoot, joint dislocation and other unique skeletal abnormalities.",1,1.4012504622114357,44259828.66565971,484.2398965660816,0.1339725359500974,0.03824843479751604,0.0,0.0,1.0003213367609254,3113.0,-0.5211849387324266,0.04396357591557752,1.0,2.0,13.0,503.0,503.0,179.0,1006.0,5166,502.0,1.4976660372475533e-07,212952.0,3113.0,1.0,0,581.0
4893,607001,HP:0000717,"Kleefstra syndrome, a disease with intellectual disability, autism spectrum disorders and other developmental defects is caused in humans by haploinsufficiency of EHMT1.",1,1.3563189323239575,1802844.2876984128,179.75191192537184,0.17110436735300438,0.36640734467611297,0.0,0.0,1.0021231422505308,472.0,-0.4870820011620609,0.16306812047932634,1.0,2.0,5.0,146.0,146.0,146.0,292.0,292,146.0,9.351999925184e-06,18126.0,472.0,1.0,0,150.0
5603,608025,HP:0004322,"Conclusion: Cases with NBAS gene defects often manifests as short stature, optic nerve atrophy, Pelger-Huet anomaly, skeletal dysplasia, recurrent infections, abnormality of liver enzymes, progeroid appearance, proptosis, hypotonia and immunodeficiency.",1,1.421854538866987,7102698.478174609,444.95037892457606,0.1466428155170314,0.02892716424596595,0.0,0.0,1.000778816199377,1285.0,-0.6774325604072693,0.0767627913742318,1.0,2.0,5.0,159.0,159.0,150.0,318.0,2244,158.0,7.929402939746845e-07,63327.0,1285.0,1.0,0,146.0
2201,608707,HP:0001360,"We have developed a gene-environment interaction model of holoprosencephaly in mice, in which mutation of the Sonic hedgehog coreceptor, Cdon, synergizes with transient in utero exposure to ethanol.",1,1.4144085370115802,859635.4433746813,212.98919888401755,0.200475189740402,0.06719829917225463,0.0,0.0,1.002222222222222,451.0,-0.6909517852527791,0.11676767676767676,1.0,2.0,2.0,65.0,65.0,65.0,130.0,388,65.0,6.67694916838598e-06,11849.0,451.0,1.0,0,65.0
5604,190090,HP:0003006,"Increased expression of the Src homology 2 B adaptor protein 1 (SH2B1) may stimulate the malignant progression of lung cancer, esophageal cancer and neuroblastoma.",0,1.3141281233386497,40195.89761904762,53.66126126126125,0.2875736018651111,0.05648183294017225,0.0,0.0,0.991150442477876,112.0,-0.530070019679888,0.21611551001397286,1.0,2.0,4.0,36.0,36.0,38.0,72.0,80,35.0,0.00017313019390581717,1392.0,114.0,1.0,0,51.0
5605,600234,HP:0002751,"The created databases include ACAD8 (isobutyryl-CoA dehydrogenase deficiency (IBD)), ACADSB (short-chain acyl-CoA dehydrogenase (SCAD) deficiency), AUH (3-methylglutaconic aciduria (3-MGCA)), DHCR7 (Smith-Lemli-Opitz syndrome), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2 deficiency), HSD17B10 (17-beta-hydroxysteroid dehydrogenase X deficiency), FKBP14 (Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss; EDSKMH) and ROGDI (Kohlschutter-Tonz syndrome).",0,1.4076793147933873,33498.33514735752,66.18237250554324,0.3501157394361713,0.062180364773765325,0.0,0.0,0.9946524064171124,186.0,-0.6888764136791775,0.08140857890544999,1.0,2.0,1.0,23.0,23.0,23.0,46.0,330,21.0,3.673094582185491e-05,1431.0,188.0,1.0,0,20.0
5606,605564,HP:0000618,"Defects of CIB2, calcium- and integrin-binding protein 2, have been reported to cause isolated deafness, DFNB48 and Usher syndrome type-IJ, characterized by congenital profound deafness, balance defects and blindness.",0,1.3524016612995455,674487.6747172584,151.96102303952654,0.1885975960960473,0.021701304883865003,0.0,0.0,0.9971014492753624,344.0,-0.6731652685588346,0.17853732093490826,1.0,2.0,2.0,90.0,90.0,73.0,180.0,500,88.0,1.5872763924382153e-05,10656.0,346.0,1.0,0,99.0
2420,180380,HP:0002664,"That binding, which interferes with the interaction of RhoA-GTP with the RhoGAP domain, reduces the hydrolysis of RhoA-GTP, the binding of other DLC1 ligands, and the colocalization of DLC1 with focal adhesions and attenuates tumor suppressor activity.",0,1.3656029541446206,2499829.264422941,200.53807898275682,0.18269083378657847,0.08808076945407306,0.0,0.0,0.9989304812834224,934.0,-0.6348648372529369,0.06318387494858083,1.0,2.0,27.0,140.0,140.0,94.0,280.0,1576,138.0,1.677897393218609e-06,27648.0,936.0,1.0,0,138.0
267,164757,HP:0002664,We further review the variety of melanocytic tumors associated with such BRAF fusions,1,1.3343717616163435,16381827.818362188,267.1583928605997,0.14243558102353174,0.0178111227871734,0.0,0.0,1.0006944444444446,1441.0,-0.2821765440487228,0.0923076181663968,1.0,2.0,9.0,611.0,611.0,3.0,1222.0,1542,610.0,1.6778973932186103e-06,95771.0,1441.0,1.0,0,790.0
5607,600618,HP:0000365,"In particular, MYH9 mutations result in congenital macrothrombocytopenia and predispose to kidney failure, hearing loss, and cataracts, MPL and MECOM mutations cause congenital thrombocytopenia evolving into bone marrow failure, whereas thrombocytopenias caused by RUNX1, ANKRD26, and ETV6 mutations are characterized by predisposition to hematological malignancies.",0,1.442302085505969,628363.7674147668,287.71799155663336,0.27599355536600834,0.3549434371327357,0.0,0.0,0.9992205767731878,1282.0,-0.6367231612316944,0.016617983066362668,1.0,2.0,79.0,46.0,46.0,46.0,92.0,2466,44.0,6.524672396198986e-07,13688.0,1284.0,1.0,0,52.0
5608,108370,HP:0002664,"In this study, we generated GCN2 inhibitors and demonstrated that inhibition of GCN2 sensitizes cancer cells with low basal-level expression of asparagine synthetase (ASNS) to the antileukemic agent l-asparaginase (ASNase) in vitro and in vivo.",0,1.3879892288773392,2638034.957710676,266.1990272373541,0.17271162240933394,0.35162600432496993,0.0,0.0,0.998878923766816,891.0,-0.6763877817630031,0.07111866585651229,1.0,2.0,41.0,120.0,120.0,117.0,240.0,1544,118.0,1.6778973932186103e-06,28325.0,893.0,1.0,0,132.0
4450,610568,HP:0002664,"ZNF687 overexpression greatly enhanced HCC cell capability for tumorsphere formation, invasion and chemoresistance in vitro, whereas inhibiting ZNF687 reduced these capabilities and inhibited HCC cell tumorigenic capability in vivo.",0,1.4479417292964205,405449.4129066839,244.45920429523719,0.2532669808710279,0.13784712594753445,0.0,0.0,0.9987730061349694,814.0,-0.7345812636998991,0.03214543486106099,1.0,2.0,18.0,44.0,44.0,44.0,88.0,1544,42.0,1.67789739321861e-06,10689.0,816.0,1.0,0,37.0
5609,602037,HP:0002664,"Finally, twenty-four important hub genes (RASGRP2, IKZF1, CXCR5, LTB, BLK, LINGO3, CCR6, P2RY10, RHOH, JUP, KRT14, PLA2G3, SPRR1A, KRT78, SFN, CLDN4, IL1RN, PKP3, CBLC, KRT16, TMEM79, KLK8, LYPD3 and LYPD5) were treated as valuable factors involved in the immune response and tumor cell development in tumorigenesis.",0,1.4713739849617211,448407.9978534386,369.54947737850006,0.23017767213847715,0.3038315442587404,0.0,0.0,1.0012437810945274,805.0,-0.827661485918385,0.03718673712184418,1.0,2.0,5.0,34.0,34.0,34.0,68.0,1542,33.0,1.677897393218609e-06,12034.0,805.0,1.0,0,33.0
5610,608815,HP:0001425,"Our observations strengthen the evidence supporting a role for EFHC1 in JME in a population ethnically and geographically distinct from the one in which the gene was initially identified, and broaden the extent of allelic heterogeneity in the gene",0,1.3693401937046006,82283.6983075549,60.96521523589193,0.3134361152648225,0.19255242697215152,0.0,0.0,0.9966329966329966,296.0,-0.6811105064294373,0.0611709940569001,1.0,2.0,10.0,41.0,41.0,19.0,82.0,496,40.0,1.625910509885536e-05,2707.0,298.0,1.0,0,36.0
342,601231,HP:0002664,These results provide new insights on the biological relevance of the mTOR pathway in breast cancer progression and underscore the need for more genetic epidemiology studies of breast cancer in the African Diaspora,0,1.3699539412139736,8049817.826784328,281.040621982973,0.1469672325960649,0.01957140805944546,0.0,0.0,1.0009652509652511,1037.0,-0.5605804935560739,0.10347080790668063,1.0,2.0,1.0,263.0,263.0,175.0,526.0,1542,262.0,1.67789739321861e-06,55581.0,1037.0,1.0,0,355.0
5612,164005,HP:0003560,"Here, we show that ablating or silencing the transcription factor Nfix ameliorates pathology in several forms of muscular dystrophy.",0,1.3688531991355803,470393.1811070816,112.33405797101447,0.25796271458067144,0.06926084653362842,0.0,0.0,0.9981343283582088,535.0,-0.4878692351452524,0.0531560076711415,1.0,2.0,43.0,76.0,76.0,76.0,152.0,274,75.0,4.705417346991592e-06,7650.0,537.0,1.0,0,87.0
5613,601231,HP:0002895,"We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features.",0,1.3897014604810998,17172.420157293687,86.72829801777168,0.4275054386771317,0.2937713335057244,0.0,0.0,0.9964028776978416,277.0,-0.6625915096903592,0.030220984502720406,1.0,2.0,47.0,12.0,12.0,12.0,24.0,322,11.0,1.4027409558276873e-05,1172.0,279.0,1.0,0,14.0
5386,300084,HP:0002664,"Taken together, our findings suggest that NONO might play an important role in promoting tumorigenesis of ESCC.",0,1.336969696969697,8232748.074910223,236.5108992519622,0.14719398556953214,0.030176092554861124,0.0,0.0,0.99909338168631,1102.0,-0.5238313675333467,0.09100674051007136,1.0,2.0,26.0,318.0,318.0,101.0,636.0,1544,316.0,1.6778973932186103e-06,55410.0,1104.0,1.0,0,450.0
5614,613726,HP:0001251,"Exome and targeted sequencing has recently identified four new genes causing ataxia: TGM6, ANO10, SYT14, and rundataxin.",1,1.4305586791993934,2281186.8592430246,355.7468366762876,0.16890839177433936,0.10010445535449064,0.0,0.0,1.0010952902519168,914.0,-0.7347948863332889,0.07659841674236233,1.0,2.0,2.0,100.0,100.0,100.0,200.0,1626,99.0,1.5092152684290285e-06,31960.0,914.0,1.0,0,101.0
5616,138140,HP:0100022,"Dysfunction of the cerebral glucose transporter GLUT1 (encoded by SLC2A1) is known to result in epilepsy, intellectual disability (ID), and movement disorder.",1,1.4147455597956669,14996471.148345254,467.6569759723881,0.14660545260897784,0.1255784101165891,0.0,0.0,1.0005053057099549,1980.0,-0.5959299634282311,0.05721234579243675,1.0,2.0,8.0,270.0,270.0,220.0,540.0,3402,269.0,3.4520802926259425e-07,112091.0,1980.0,1.0,0,249.0
5617,173490,HP:0001880,"We suggest that leukemias and lymphomas with FLT3 fusion genes exhibit similar clinicopathologic features to, and should be included in, the WHO category of &quot;Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2.&quot",1,1.3558417997097243,85942.61666666668,72.22549019607844,0.2477533322876108,-0.014015292843360096,0.0,0.0,1.0063291139240509,159.0,-0.5133126346613642,0.1991879627418199,1.0,2.0,7.0,51.0,51.0,51.0,102.0,124,51.0,8.416799932665601e-05,2502.0,159.0,1.0,0,69.0
5618,604197,HP:0001627,"Single nucleotide polymorphism in infant genes in the folate (MTHFS rs12438477), homocysteine (TRDMT1 rs6602178 and GNMT rs11752813) and transsulfuration (GSTP1 rs7941395 and MGST1 rs7294985) pathways were also associated with an increased risk of congenital heart defects.Conclusions Common maternal or infant genetic variants in folate, homocysteine, or transsulfuration pathways are associated with an increased risk of certain congenital heart defects among children of women taking SSRIs during cardiogenesis",0,1.4566989597869768,2321420.5166150816,585.6208443271768,0.17012983475267304,0.08974663695591084,0.0,0.0,0.9991652754590984,1197.0,-0.8119710968921918,0.047979604595370935,1.0,2.0,13.0,61.0,61.0,61.0,122.0,2276,59.0,7.721745361547558e-07,34459.0,1199.0,1.0,0,65.0
2284,610206,HP:0002664,"Based on these findings, we infer that high SLC4A11 expression is an independent predictor for poor OS in grade 3/4 serous ovarian cancer.",0,1.4347451328383982,231695.7917167761,185.8252020353188,0.29323932321792395,0.1195747704968767,0.0,0.0,0.9987669543773121,810.0,-0.6651000194545991,0.023184902176355892,1.0,2.0,34.0,35.0,35.0,30.0,70.0,1544,33.0,1.6778973932186097e-06,7634.0,812.0,1.0,0,29.0
5619,300298,HP:0001249,"In humans, mutations in the NMD factor gene, UPF3B, cause intellectual disability (ID) and are strongly associated with autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD) and schizophrenia (SCZ).",1,1.409990497952236,22973402.51841713,531.9904198698995,0.1317577454622618,-0.0005575786221101431,0.0,0.0,1.0005302226935309,1887.0,-0.5948650562049917,0.07233619996392125,1.0,2.0,1.0,285.0,285.0,285.0,570.0,3204,284.0,3.891642658474498e-07,128718.0,1887.0,1.0,0,320.0
5620,609761,HP:0000007,"In these 5 families, we detected one reported and six novel mutations in 5 different deafness autosomal recessive (DFNB) genes (TRIOBP, LHFPL5, CDH23, PCDH15, and MYO7A).",1,1.4957990660641851,192452.08748039792,711.950484496124,0.3875575159578094,0.33946924222283165,0.0,0.0,1.0003853564547207,2596.0,-0.5546355444115497,0.003361032684046302,1.0,2.0,862.0,16.0,16.0,16.0,32.0,5160,15.0,1.5011496554636367e-07,11321.0,2596.0,1.0,0,16.0
3040,176943,HP:0002664,"The Random Forest algorithm selected FGFR2, MAP3K1 and age as important breast cancer predictors.",1,1.3342720026288826,16211979.667147012,229.2539594307243,0.14556000393076873,0.00478701158553484,0.0,0.0,1.0006053268765134,1653.0,-0.29974239614532194,0.06907391213275738,1.0,2.0,25.0,637.0,637.0,2.0,1274.0,1542,636.0,1.282562662805298e-06,94312.0,1653.0,1.0,0,710.0
1729,131550,HP:0002664,Oncogenes EGFR and ras are frequently mutated and activated in human lung cancers.,1,1.4135577242017423,2148700.9990685256,249.19306594831886,0.18304335818682368,0.03828770954761315,0.0,0.0,1.0011111111111108,901.0,-0.6842090355364789,0.06837094586262177,1.0,2.0,6.0,124.0,124.0,94.0,248.0,1542,123.0,1.6778973932186097e-06,27721.0,901.0,1.0,0,105.0
2028,190070,HP:0002664,"In this study, we evaluated the anticancer effect of ONO-7579 using GBC cells with or without KRAS mutant, NOZ, TYGBK-1.",1,1.3339771877413191,18178836.290753696,271.2782786211432,0.14438020893870612,0.0522035687829069,0.0,0.0,1.0006165228113442,1623.0,-0.2035822069529308,0.08341633409382543,1.0,2.0,4.0,720.0,720.0,2.0,1440.0,1542,719.0,1.374364528201273e-06,109797.0,1623.0,1.0,0,858.0
5621,607542,HP:0000169,"In conclusion, our results reveal a role for the KCNQ1 potassium channel in the regulation of human growth, and show that growth hormone deficiency associated with maternally inherited gingival fibromatosis is an allelic disorder with cardiac arrhythmia syndromes caused by KCNQ1 mutations",0,1.329905080242549,26224.471378621376,72.32797118847539,0.3804889882640392,0.2804320133504297,0.0,0.0,0.9961977186311788,262.0,-0.5191816881421841,0.039751123401313516,1.0,2.0,76.0,18.0,18.0,18.0,36.0,194,17.0,1.6524555489457333e-05,1380.0,264.0,1.0,0,18.0
1057,610844,HP:0001258,"Complex recessive spastic paraplegias have in the past been frequently associated with mutations in SPG11 (spatacsin), ZFYVE26/SPG15, SPG7 (paraplegin) and a handful of other rare genes, but many cases remain genetically undefined.",1,1.3532349196243834,686474.1261904761,134.98833333333334,0.1963293848500352,0.11323700453192065,0.0,0.0,1.002710027100271,370.0,-0.3530058694085728,0.16033106277008716,1.0,2.0,3.0,120.0,120.0,120.0,240.0,240,120.0,1.5872763924382153e-05,10945.0,370.0,1.0,0,138.0
4572,300522,HP:0001250,"We report these cases to demonstrate the exhaustive work-up prior to finding the changes in IQSEC2 gene, recommend that this gene be considered earlier in the diagnostic evaluation of individuals with global developmental delay, microcephaly, and severe, intractable epilepsy, and support the use of intellectual disability panels including IQSEC2 in the first-line evaluation of these patients",1,1.3883355829668014,29189740.485376064,468.9514947057376,0.12953273151893555,0.005990672790454864,0.0,0.0,1.0005149330587024,1943.0,-0.5408155117831377,0.07792688957640859,1.0,2.0,1.0,386.0,386.0,350.0,772.0,3100,385.0,4.156965348783942e-07,147021.0,1943.0,1.0,0,475.0
5577,611642,HP:0002664,"In this study, we found that the activities of Notch signaling were elevated, while HepaCAM expression was decreased in CRPC tissues compared with matched primary prostate cancer (PPC) tissues.",0,1.4218679036750594,1051393.658602611,252.46123772466183,0.2066559502511104,0.0805662734604674,0.0,0.0,0.9988123515439432,841.0,-0.6765841303487894,0.047658092492878334,1.0,2.0,22.0,67.0,67.0,67.0,134.0,1544,65.0,1.6778973932186097e-06,16914.0,843.0,1.0,0,75.0
5622,209901,HP:0001425,"Currently, 21 genes (BBS1-21) present on different chromosomes have been mapped: these genes are responsible for BBS phenotypes and they show a great heterogeneity of mutations.The most common genes are BBS1 (locus 11q13) and BBS10.We show here the case of a 50 year old patient with BBS.",0,1.316320620210301,1158794.8102453102,119.10993194934963,0.20145677669793005,0.02633027979261864,0.0,0.0,0.9979296066252588,482.0,-0.30019349243553256,0.1247796998785141,1.0,2.0,8.0,197.0,197.0,2.0,394.0,496,195.0,1.6259105098855364e-05,14585.0,484.0,1.0,0,221.0
5623,102582,HP:0100242,"This similarity was revealed by the same number of passages, the same germ cell clusters formation and similar level of genes expression of spermatogonial markers including ubiquitin carboxyl-terminal esterase L1 (UCHL1), zinc finger and BTB domain containing 16 (ZBTB16) and glial cell line-derived neurotrophic factor family receptor alpha 1 (GFRA1), as well as germ cell differentiation markers including signal transducer and activator of transcription 3 (STAT3), spermatogenesis and oogenesis specific basic helix-loophelix 2 (SOHLH2), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and synaptonemal complex protein 3 (SYCP3).",0,1.3290713414552422,1160523.0488095237,130.38743455497382,0.1944744819148317,0.18447998967875048,0.0,0.0,0.9981378026070764,536.0,-0.3873190390668251,0.10125784857358447,1.0,2.0,24.0,152.0,152.0,153.0,304.0,764,150.0,6.8171437531103245e-06,14627.0,538.0,1.0,0,168.0
2934,609186,HP:0002664,The colonic expression of D2HGDH is decreased in ulcerative colitis (UC) patients at baseline who progress to cancer.,0,1.4063362270592743,1810037.807815421,271.42643482490274,0.1811670631726036,0.1869999176002235,0.0,0.0,0.9988479262672808,867.0,-0.7168398813714275,0.06328583625439485,1.0,2.0,30.0,93.0,93.0,80.0,186.0,1544,91.0,1.677897393218609e-06,23868.0,869.0,1.0,0,91.0
5624,610354,HP:0012444,"A founder mutation in RIC1 (KIAA1432) was identified in patients with cataract, brain atrophy, microcephaly with or without cleft lip and palate.",0,1.4100002047893403,2498167.709793666,301.05452517082693,0.16940413053878645,0.04556460876609235,0.0,0.0,0.9986504723346828,740.0,-0.6986933625998785,0.09756612139928922,1.0,2.0,2.0,101.0,101.0,101.0,202.0,1280,99.0,2.433794699681904e-06,26822.0,742.0,1.0,0,109.0
5296,190070,HP:0030731,"Of the 2 204 genes that were mutated, APC, TTN, TP53, KRAS, OBSCN, SOX9, PCDH17, SIGLEC10, MYH6, and BRD9 were consistent with genes being an early driver of carcinogenesis, in that they were mutated in multiple adenomas and multiple carcinomas.",0,1.378978015090394,41263.32811777595,199.5176056338028,0.4831234193143702,0.4116951622974924,0.0,0.0,0.9988425925925926,863.0,-0.5017587060160795,0.008049668165275102,1.0,2.0,238.0,12.0,12.0,12.0,24.0,498,11.0,1.374364528201273e-06,3008.0,865.0,1.0,0,12.0
4803,614068,HP:0000546,Whole-exome sequencing analysis identified a novel homozygous c.100 G &gt; A change in IFT43 segregating with retinal degeneration and not present in ethnicity-matched controls.,0,1.3231890252078309,790833.0263077567,98.29038783885322,0.2133319223951179,0.2626833477640333,0.0,0.0,0.99781181619256,456.0,-0.4092141691051019,0.10908430718660717,1.0,2.0,4.0,165.0,165.0,4.0,330.0,440,163.0,1.7654120471718102e-05,11416.0,458.0,1.0,0,167.0
649,603113,HP:0002664,A major implication of our study is that inhibition of miR-587 or restoration of PPP2R1B expression may have significant therapeutic potential to overcome drug resistance in colorectal cancer patients and that the combined use of an AKT inhibitor with 5-FU may increase efficacy in colorectal cancer treatment,1,1.4873012487474293,56683.754180476026,245.41686121919585,0.4091005680924441,0.01853930019144065,0.0,0.0,1.0012738853503185,786.0,-0.7080939589769509,0.011704834605597965,1.0,2.0,5.0,15.0,15.0,15.0,30.0,1542,15.0,1.67789739321861e-06,3611.0,786.0,1.0,0,25.0
5625,601528,HP:0002664,"Our data indicate that TNFSF15, a cytokine mainly produced by blood endothelial cells, facilitates tumor lymphangiogenesis by upregulating VEGFC expression in A549 cells, contributing to lymphatic metastasis in tumor-bearing mice.",0,1.4408605886479804,1527241.3071597402,315.34326050084803,0.18871256236303824,0.03223783288049941,0.0,0.0,1.0011792452830188,849.0,-0.7434409044676186,0.06205135897948753,1.0,2.0,1.0,77.0,77.0,75.0,154.0,1542,76.0,1.67789739321861e-06,22337.0,849.0,1.0,0,80.0
5626,158340,HP:0002664,All intraductal tubulopapillary neoplasms revealed the characteristic histologic (cellular intraductal nodules of back-to-back tubular glands lined by predominantly cuboidal cells with atypical nuclei and no obvious intracellular mucin) and immunohistochemical (immunolabeled with MUC1 and MUC6 but were negative for MUC2 and MUC5AC) features.,0,1.4230597525257087,684357.6703770207,182.79610894941638,0.2351582462720065,0.2521698342987163,0.0,0.0,0.9988262910798122,851.0,-0.6684971126506095,0.03840353571212347,1.0,2.0,15.0,76.0,76.0,50.0,152.0,1544,74.0,1.67789739321861e-06,13955.0,853.0,1.0,0,59.0
217,164785,HP:0002664,These findings support that UNC119 is a regulator of the RASSF6-MDM2-p53 axis and functions as a tumor suppressor,1,1.391410468595884,3660844.478079444,241.1528468479716,0.1733730375837963,0.17860145508336964,0.0,0.0,1.001044932079415,958.0,-0.6026291737214196,0.07917269302338772,1.0,2.0,2.0,186.0,186.0,112.0,372.0,1542,185.0,1.6778973932186097e-06,36293.0,958.0,1.0,0,185.0
4074,608750,HP:0002664,"The staining intensity of ALG3 was significantly correlated to the tumor grade (grades 2-3 versus 1, p&lt;0.05).",0,1.3670282679593666,4914461.559438935,275.9236298885445,0.15525494323200428,0.027112385434254743,0.0,0.0,0.9989462592202318,948.0,-0.6497820828503925,0.08957905828850313,1.0,2.0,37.0,172.0,172.0,154.0,344.0,1544,170.0,1.6778973932186084e-06,40380.0,950.0,1.0,0,183.0
5627,120070,HP:0000007,"Mutations in the COL4A5 gene result in X-linked Alport syndrome, homozygous or compound heterozygous mutations in COL4A3 or COL4A4 are responsible for autosomal recessive Alport syndrome, and heterozygous mutations in COL4A3 or COL4A4 cause autosomal dominant Alport syndrome or benign familial hematuria.",1,1.4787833249800368,1516675.5889728847,422.98381782945717,0.28477075721706696,0.3258968169613972,0.0,0.0,1.0003760812335465,2660.0,-0.5512353020836241,0.009280723433254064,1.0,2.0,93.0,74.0,74.0,66.0,148.0,5160,73.0,1.5011496554636372e-07,32821.0,2660.0,1.0,0,62.0
1230,601607,HP:0002664,"In summary, we described four cases of SMARCB1/INI1-deficient sinonasal carcinoma with detailed clinicopathological data indicating that these tumors can be regarded as a distinct entity with aggressive behaviour.",1,1.3396459207409952,12225578.24190254,245.38261997405968,0.14557418044513382,0.12700196151807008,0.0,0.0,1.000778816199377,1285.0,-0.4059447124260791,0.09173182055105034,1.0,2.0,2.0,465.0,465.0,24.0,930.0,1542,464.0,1.677897393218609e-06,75676.0,1285.0,1.0,0,609.0
2884,602572,HP:0002664,"In clinicopathological analysis, we found that increased expression of ANXA11 was significantly associated with tumor size, tumor infiltration, local lymph node metastasis, TNM staging, and vascular invasion.",0,1.4304522677220644,661318.7657481558,208.85347524223698,0.23041572395543874,0.048656366797687166,0.0,0.0,0.998809523809524,839.0,-0.6914807040933326,0.03897004699620634,1.0,2.0,19.0,69.0,69.0,51.0,138.0,1544,67.0,1.6778973932186097e-06,13765.0,841.0,1.0,0,54.0
1591,610966,HP:0001513,The purpose of this review is to present a comprehensive picture of the impact of FTO on obesity susceptibility and to illuminate these new studies of FTO function in adipose tissue,1,1.3551840203056889,2205350.7880762005,190.34733201581028,0.16843673176063007,0.09191852693852773,0.0,0.0,1.001953125,513.0,-0.5941046245150907,0.16011817738791426,1.0,2.0,3.0,159.0,159.0,128.0,318.0,704,158.0,8.025102520684701e-06,21028.0,513.0,1.0,0,202.0
5628,610456,HP:0002664,"Human SAMD9, a tumor suppressor and a restriction factor for poxviruses in cell lines, is antagonized by two classes of poxvirus proteins, represented by vaccinia virus (VACV) K1 and C7.",1,1.3758120959717348,6803939.562590187,282.91295994316806,0.1519537638763528,0.0632704441792858,0.0,0.0,1.0009891196834817,1012.0,-0.5850628871925807,0.1015411501155276,1.0,2.0,7.0,234.0,234.0,186.0,468.0,1542,233.0,1.6778973932186097e-06,51945.0,1012.0,1.0,0,252.0
1384,614901,HP:0002664,"Here we investigated that abnormal branched-chain amino acids catabolism in colorectal cancer is a result of the disease process, with no role in disease initiation; BCKDK is widely expressed in colorectal cancer patients, and those patients that express higher levels of BCKDK have shorter survival times than those with lower levels; BCKDK promotes cell transformation or colorectal cancer ex vivo or in vivo.",0,1.4238984643869208,75944.21407327749,248.1288910505837,0.3353621901125077,0.2231120917922796,0.0,0.0,0.9987309644670048,787.0,-0.7817547415501288,0.014942129406239344,1.0,2.0,95.0,16.0,16.0,16.0,32.0,1544,14.0,1.67789739321861e-06,4645.0,789.0,1.0,0,14.0
5629,601900,HP:0002664,"In the present study, the results obtained from our previously published methylation array were analyzed and 10 candidate genes involved in DNA repair [protein phosphatase 4 catalytic subunit (PPP4C)], apoptosis [runt related transcription factor 3 (RUNX3), interferon regulatory factor 4 (IRF4), ubiquitin C-terminal hydrolase L1 (UCHL1) and tumor protein p53 inducible protein 3 (TP53I3)], cell proliferation [cyclin D2 (CCND2) and Ras association domain family member 1 (RASSF1)], drug metabolism [aldehyde dehydrogenase 1 family member A3 (ALDH1A3) and solute carrier family 29 member 1 (SLC29A1)] and angiogenesis [human immunodeficiency virus-1 tat interactive protein 2 (HTATIP2)] were selected for quantification of their methylation levels in 54 CCA and 19 adjacent normal tissues using methylation-sensitive high-resolution melting.",0,0.998706338939198,1540.0077619663648,2.0,0.7071067811865476,0.8358275756909609,0.0,0.0,0.9987063389391979,772.0,-0.9974126778783974,0.0025806365347266088,1.0,2.0,772.0,2.0,2.0,2.0,4.0,1544,0.0,1.67789739321861e-06,772.0,774.0,0.0,0,1.0
2892,602572,HP:0002664,"Previous studies have shown that ANXA11 participates in many cellular functions and has significant influence on ovarian, breast, liver, and colorectal cancer.",0,1.4304522677220644,661318.7657481558,208.85347524223698,0.23041572395543874,0.048656366797687166,0.0,0.0,0.998809523809524,839.0,-0.6914807040933326,0.03897004699620634,1.0,2.0,19.0,69.0,69.0,51.0,138.0,1544,67.0,1.6778973932186097e-06,13765.0,841.0,1.0,0,54.0
3971,611184,HP:0100242,"Here, we examined the possibility that PIEZO1 is involved in the regulation of synovial sarcoma cell-viability.",0,1.2756539111346792,609772.8569985569,109.3215697346132,0.19699441056159545,0.16121656604001233,0.0,0.0,0.9972375690607732,361.0,-0.2491212102691575,0.14973441090969972,1.0,2.0,27.0,137.0,137.0,2.0,274.0,336,135.0,2.3113905325443783e-05,9838.0,363.0,1.0,0,178.0
5631,191840,HP:0002120,"These changes were accompanied by cortical atrophy as well as increased expression of angiogenesis-related genes such as Vegfa, Serpine1, and Plau in CD31-positive endothelial cells.",0,1.3695400529790989,278305.8698751412,117.89026988636364,0.21701751756323728,-0.047831339054996584,0.0,0.0,0.996904024767802,322.0,-0.7126633785252404,0.1223674655047204,1.0,2.0,3.0,59.0,59.0,39.0,118.0,520,57.0,1.5023135628868454e-05,6403.0,324.0,1.0,0,53.0
5632,300522,HP:0000252,"We report these cases to demonstrate the exhaustive work-up prior to finding the changes in IQSEC2 gene, recommend that this gene be considered earlier in the diagnostic evaluation of individuals with global developmental delay, microcephaly, and severe, intractable epilepsy, and support the use of intellectual disability panels including IQSEC2 in the first-line evaluation of these patients",1,1.3642353488253325,20921262.999740627,402.8898117836584,0.12566345607681606,0.06041217808699401,0.0,0.0,1.0007017543859649,1426.0,-0.5254049016238544,0.11288993873182256,1.0,2.0,1.0,379.0,379.0,191.0,758.0,2066,378.0,9.353172034763874e-07,114699.0,1426.0,1.0,0,510.0
